cah-20210630

0000721371-21-000080.txt : 20210816 0000721371-21-000080.hdr.sgml : 20210816 20210816085000 ACCESSION NUMBER: 0000721371-21-000080 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 130 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210816 DATE AS OF CHANGE: 20210816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CARDINAL HEALTH INC CENTRAL INDEX KEY: 0000721371 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 310958666 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11373 FILM NUMBER: 211174800 BUSINESS ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147573033 MAIL ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: CARDINAL DISTRIBUTION INC DATE OF NAME CHANGE: 19920703 10-K 1 cah-20210630.htm 10-K cah-20210630


Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K


☑			ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended June 30, 2021


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission File Number: 1-11373

Cardinal Health, Inc.

(Exact name of registrant as specified in its charter)


Ohio					31-0958666
(State or other jurisdiction of incorporation or organization)					(IRS Employer Identification No.)

7000 Cardinal Place	,	Dublin	,	Ohio	43017
(Address of principal executive offices)					(Zip Code)

				(614)	757-5000
(Registrant’s telephone number, including area code)


Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common shares (without par value)	CAH	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes þ No o

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No þ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act o

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ

The aggregate market value of voting stock held by non-affiliates on December 31, 2020, was the following: $15,693,865,917.

The number of the registrant’s common shares, without par value, outstanding as of July 31, 2021, was the following: 290,441,408.

Documents Incorporated by Reference:

Portions of the registrant’s Definitive Proxy Statement to be filed for its 2021 Annual Meeting of Shareholders are incorporated by reference into the sections of this Form 10-K addressing the requirements of Part III of Form 10-K.


Cardinal Health Fiscal 2021 Form 10-K

Table of Contents


						Page
			Introduction			2
			Management's Discussion and Analysis of Financial Condition and Results of Operations			3
			Explanation and Reconciliation of Non-GAAP Financial Measures			26

			Quantitative and Qualitative Disclosures about Market Risk			30
			Business			32
			Risk Factors			40
			Properties			47
			Legal Proceedings			48
			Market for Registrant's Common Equity			49
			Reports			51
			Financial Statements and Supplementary Data			56
			Directors, Executive Officers, and Corporate Governance			89

			Exhibits			91
			Form 10-K Cross Reference Index			95
			Signatures			96


1			Cardinal Health \| Fiscal 2021 Form 10-K


Introduction

Introduction

References to Cardinal Health and Fiscal Years

As used in this report, "we," "our," "us," "Cardinal Health" and similar pronouns refer to Cardinal Health, Inc. and its majority-owned subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2022, 2021, 2020, 2019, 2018 and 2017 are to the fiscal years ended June 30, 2022, 2021, 2020, 2019, 2018 and 2017, respectively. Except as otherwise specified, information in this report is provided as of June 30, 2021.

Non-GAAP Financial Measures

In this report, including in the "Fiscal 2021 Overview" section of Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), we use financial measures that are derived from consolidated financial data but are not presented in our financial statements that are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). These measures are considered “non-GAAP financial measures” under the Securities and Exchange Commission (“SEC”) rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the “Explanation and Reconciliation of Non-GAAP Financial Measures” section following MD&A in this report.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Our MD&A within this Form 10-K generally discusses fiscal 2021 and fiscal 2020 items and year-to-year comparisons between fiscal 2021 and fiscal 2020. Fiscal 2019 items and discussions of year-to-year comparisons between fiscal 2020 and fiscal 2019 that are not included in this Form 10-K can be found in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (the "Fiscal 2020 Form 10-K").

Important Information Regarding Forward-Looking Statements

This report (including information incorporated by reference) includes forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in MD&A and Risk Factors, but there are others throughout this report, which may be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “will,” “should,” “could,” “would,” “project,” “continue,” “likely,” and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these risks and uncertainties are described in “Risk Factors” in this report and in Exhibit 99.1 to the Form 10-K included in this report. Forward-looking statements in this report speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.

Available Information

Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports are available free of charge on our website (www.cardinalhealth.com), under the “Investor Relations — Financial Reporting — SEC Filings” caption, as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. The SEC also maintains a website (www.sec.gov) where you can search for annual, quarterly and current reports, proxy and information statements, and other information regarding us and other public companies.


2			Cardinal Health \| Fiscal 2021 Form 10-K


MD&A			About Cardinal Health

Management's Discussion and Analysis of Financial Condition and Results of Operations

About Cardinal Health

Cardinal Health, Inc., an Ohio corporation formed in 1979, is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical.

Pharmaceutical Segment

Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products.

Medical Segment

Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.


			Cardinal Health \| Fiscal 2021 Form 10-K			3


MD&A			Results of Operations

Consolidated Results

Fiscal 2021 Overview

Revenue

Revenue for fiscal 2021 was $162.5 billion, a 6 percent increase from the prior year, primarily due to sales growth from pharmaceutical distribution and specialty solutions customers.

GAAP and Non-GAAP Operating Earnings/(Loss)


(in millions)	2021		2020		Change
GAAP operating earnings/(loss)	$	472	$	(4,098)	N.M.

Surgical gown recall costs/(income)	(28)		85
State opioid assessment related to prior fiscal years	38		3
Restructuring and employee severance	114		122
Amortization and other acquisition-related costs	451		524
Impairments and (gain)/loss on disposal of assets	79		7
Litigation (recoveries)/charges, net	1,129		5,741
Non-GAAP operating earnings	$	2,255	$	2,384	(5)	%

The sum of the components and certain computations may reflect rounding adjustments.

We had GAAP operating earnings of $472 million and a GAAP operating loss of $4.1 billion during fiscal 2021 and 2020, respectively, which includes pre-tax charges of $1.17 billion and $5.63 billion, respectively, recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. See further description of opioid lawsuits in the Significant Developments in Fiscal 2021 and Trends section in this MD&A and Note 7 of the "Notes to Consolidated Financial Statements."

GAAP and Non-GAAP operating earnings during fiscal 2021 were adversely impacted by COVID-19, which includes an inventory reserve recorded to reduce the carrying value of certain Medical segment personal protective equipment, primarily certain categories of gloves, to net realizable value. Personal protective equipment ("PPE") refers to protective clothing, medical and non-medical grade gloves, face shields, face masks and other equipment designed to protect the wearer from injury or the spread of infection or illness. See Significant Developments in Fiscal 2021 and Trends section in this MD&A for additional information. Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19, also had an adverse impact. These factors were partially offset by the beneficial impact of enterprise-wide cost-savings measures, including global manufacturing efficiencies in the Medical segment, and higher contribution from branded pharmaceutical sales mix.

GAAP and Non-GAAP Diluted EPS


($ per share)	2021 (2)		2020 (2) (3)		Change
GAAP diluted EPS (1)	$	2.08	$	(12.61)	N.M.

Surgical gown recall costs/(income)	(0.07)		0.22
State opioid assessment related to prior fiscal years	0.10		0.01
Restructuring and employee severance	0.29		0.31
Amortization and other acquisition-related costs	1.13		1.34
Impairments and (gain)/loss on disposal of assets	0.21		0.02
Litigation (recoveries)/charges, net (4)	1.78		17.84
Loss on early extinguishment of debt	0.04		0.04
(Gain)/loss on sale of equity interest in naviHealth	0.01		(1.68)
Transitional tax benefit, net	—		(0.01)
Non-GAAP diluted EPS (1)	$	5.57	$	5.45	2	%

The sum of the components and certain computations may reflect rounding adjustments.

(1)Diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("diluted EPS" or "diluted loss per share")

(2)The reconciling items are presented within this table net of tax, except for transitional tax benefit, net. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the section titled "Explanation and Reconciliation of Non-GAAP Financial Measures."


4			Cardinal Health \| Fiscal 2021 Form 10-K


MD&A			Results of Operations

(3)For fiscal 2020, GAAP diluted loss per share attributable to Cardinal Health, Inc. and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period. Fiscal 2020 non-GAAP diluted EPS is calculated using a weighted average of 295 million common shares, which includes potentially dilutive shares.

(4)Litigation (recoveries)/charges, net, includes a tax benefit recorded during fiscal 2021 related to a net operating loss carryback. Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-insurance pre-tax loss related to opioid litigation claims versus separate tax adjustments. The tax benefit allocated to the separate tax adjustments of $35 million is included in non-GAAP measures.

The charges we recognized in fiscal 2021 and 2020 for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications had a $(3.21) and $(17.54) per share after-tax impact on GAAP diluted EPS, respectively.

During fiscal 2021, GAAP and non-GAAP diluted EPS were positively impacted by $1.44 and $0.12 per share, respectively, due to a tax benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss, as further described in Significant Developments in Fiscal 2021 and Trends section in this MD&A and Note 7 of the "Notes to Consolidated Financial Statements."

GAAP diluted EPS during fiscal 2020 was favorably impacted by a $1.68 per share gain from the sale of the remainder of our equity interest in naviHealth described further in Note 2 of the "Notes to Consolidated Financial Statements."

Cash and Equivalents

Our cash and equivalents balance was $3.4 billion at June 30, 2021 compared to $2.8 billion at June 30, 2020. The increase in cash during fiscal 2021 was due to net cash provided by operating activities of $2.4 billion, offset by cash deployed of $573 million for dividends, $570 million for debt repayments, $400 million for capital expenditures, and $200 million for share repurchases.


			Cardinal Health \| Fiscal 2021 Form 10-K			5


MD&A			Results of Operations

Significant Developments in Fiscal 2021 and Trends

COVID-19

The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.

COVID-19 had a negative impact on our consolidated operating earnings/(loss) in fiscal 2021 and fiscal 2020. We estimate that the impact on fiscal 2021 operating earnings was approximately $200 million greater than on fiscal 2020 operating earnings, and we estimate that the impact on fiscal 2020 operating earnings/(loss) was approximately $100 million.

Pharmaceutical segment profit has been negatively impacted by COVID-19 largely due to volume declines in our generics program and Nuclear and Precision Health Solutions. While fiscal 2021 volumes within our generics program were lower than levels prior to COVID-19, the impact on Pharmaceutical segment profit improved on a year-over-year basis during the fourth quarter of fiscal 2021. Similarly, in comparison to prior year, the impact of COVID-19 on Nuclear and Precision Health Solutions was positive for Pharmaceutical segment profit during the fourth quarter of fiscal 2021.

Our Medical segment experienced dramatically increased demand for certain personal protective equipment due to COVID-19. Personal protective equipment ("PPE") refers to protective clothing, medical and non-medical grade gloves, face shields, face masks and other equipment designed to protect the wearer from injury or the spread of infection or illness. The peak of this heightened demand was during the second and third quarters of fiscal 2021. This increased demand resulted in higher sales volume for certain products, increased costs to manufacture and source these products and higher inventory levels to meet customer commitments. As a result, we sought out additional sources for these products and to mitigate the impact of these cost increases, we have raised our selling prices for the affected products. During the fourth quarter of fiscal 2021, selling prices and customer demand for certain PPE decreased as compared to the peak, and we expect this decline to continue into fiscal 2022. This resulted in inventory cost above net realizable value, requiring an inventory reserve of $197 million, primarily related to certain categories of gloves, which adversely impacted Medical segment profit. Our estimates for customer demand and selling prices are inherently uncertain and if customer demand or selling prices decline in the future beyond our current assumptions, additional inventory reserves may be required that would adversely impact Medical segment profit. See Critical Accounting Policies and Sensitive Accounting Estimates section in this MD&A for additional information.

During fiscal 2021, COVID-19 benefited Medical segment profit in some ways as well. Higher volumes in our laboratory business and cost savings positively impacted Medical segment profit. Additionally, despite declining customer demand and selling prices in some categories of PPE as described above, Medical segment profit was benefited by pricing actions intended to mitigate the impact of cost increases in certain other PPE categories. In addition, while lower demand for surgical products resulting from reduced elective procedures had an adverse impact on Medical segment profit during the first nine months of fiscal 2021, demand improved during the fourth quarter of fiscal 2021 and was a positive contributor to year-over-year segment profit.

We currently anticipate that the negative impact of the COVID-19 pandemic on operating earnings will be less in fiscal 2022 than it was in fiscal 2021, which includes the inventory reserve of $197 million described above. As a result, in comparison to prior year, we expect the COVID-19 impact for fiscal 2022 will be positive. However, we cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. or global economic consequences on our businesses and results of operations, including whether and when historic economic and operating conditions will resume, or its impact on our business, financial position, results of operations or cash flow. Its impact may be greater or less than we anticipate.

Opioid Lawsuits

In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement (the “Proposed Settlement Agreement”) and settlement process that, if all conditions are satisfied (including Boards of Directors' approval), would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities.

West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups. The settlement process does not contemplate participation by any non-governmental or non-political entities or individuals. In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with the State of New York and its participating subdivisions. If the Proposed Settlement Agreement becomes effective, New York and its participating subdivisions will become a part of it.


6			Cardinal Health \| Fiscal 2021 Form 10-K


MD&A			Results of Operations

The Proposed Settlement Agreement is subject to contingencies and will not become effective unless and until the Boards of Directors of the three distributors each make separate independent determinations that (1) following a sign-on period, a sufficient number of states have agreed to the Proposed Settlement Agreement (the “Settling States”); and, subsequently, (2) following a notice period, that a sufficient number of states and political subdivisions, including those that have not sued, have agreed to the Agreement (or otherwise had their claims foreclosed) to proceed to effectiveness. Prior to the second determination, the Settling States will also have an opportunity to make a determination as to whether a sufficient number of political subdivisions have agreed to the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed with the Proposed Settlement Agreement. This process is currently contemplated to end in February 2022, although it may be extended by agreement. It is possible that a sufficient number of states and subdivisions will not agree to the Proposed Settlement Agreement or that other required contingencies will not be satisfied.

If these conditions are satisfied, the Proposed Settlement Agreement would become effective 60 days after the distributors determine that there is sufficient participation among political subdivisions. During this 60-day period, the Settling States and the distributors would cooperate to obtain consent judgments in each participating state embodying the terms of the Settlement.

The Proposed Settlement Agreement includes a cash component, pursuant to which the Company would pay up to $6.37 billion, the majority of which would be paid over 18 years. The exact payment amount will depend on several factors, including the participation rate of states and political subdivisions, the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., laws barring opioid lawsuits by political subdivisions), and the extent to which political subdivisions in Settling States file additional opioid lawsuits against the Company after the Proposed Settlement Agreement becomes effective.

The Proposed Settlement Agreement also includes injunctive relief terms relating to settling distributors’ controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other national distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.

Additionally, a trial before a judge in West Virginia in the Cabell County and City of Huntington cases concluded in July 2021 and the judge has not yet issued a decision. In addition, a trial in the case brought by the Ohio Attorney General is scheduled to begin in September 2021 and a trial in the case brought by the Washington Attorney General is scheduled to begin in November 2021. The Ohio Attorney General has issued a press release indicating support for the Proposed Settlement Agreement; however, the Washington Attorney General has issued a press release stating that Washington will not agree to the Proposed Settlement Agreement.

In connection with the opioid lawsuits and settlement negotiations, we have recorded total pre-tax charges of $1.17 billion and $5.63 billion in litigation charges/(recoveries), net in the years ended June 30, 2021 and 2020, respectively. In total, we have $6.73 billion accrued at June 30, 2021, of which $405 million is included in other accrued liabilities, as we expect to make our first annual settlement payment into escrow on or before September 30, 2021, and the remainder is included in deferred income taxes and other liabilities in the consolidated balance sheets. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. See Note 7 of the "Notes to Consolidated Financial Statements" for additional information.

Tax Effect of Opioid Litigation Charges

The net tax benefits associated with the opioid litigation charges are $228 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively. The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit may differ materially from these estimates. See Note 8 of the "Notes to Consolidated Financial Statements" for additional information.

Tax Effects of Self-Insurance Pre-Tax Loss

During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.


			Cardinal Health \| Fiscal 2021 Form 10-K			7


MD&A			Results of Operations

Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.

We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021. We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.

We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change. The actual amount or timing of the tax benefit may differ from these expectations. See Note 8 of the "Notes to Consolidated Financial Statements" for additional information.

Cordis Divestiture

On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman & Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and product liability for lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada as described in Note 7 of the “Notes to Consolidated Financial Statements.” The transaction closed on August 2, 2021, and we received proceeds of $927 million, net of cash transferred. In connection with the closing, we entered into a Transition Services Agreement ("TSA") with the buyer to provide support functions for a period of up to twenty-four months following the sale. See Note 2 of the "Notes to Consolidated Financial Statements" for additional information.

During fiscal 2021, we recognized a $60 million pre-tax write-down of the net assets held for sale in impairment and (gain)/loss on disposal of assets in the consolidated statement of earnings/(loss). We recorded a net tax expense of $9 million associated with the impact of the write-down and the required tax adjustments related to held for sale accounting.

In connection with the divestiture, during fiscal 2021 we recognized costs of $28 million associated with exit or disposal activities. We expect to record up to $100 million of additional costs associated with these activities, primarily during fiscal 2022. These costs are recorded in restructuring and employee severance in our consolidated statements of earnings/(loss). We expect these charges to consist of approximately $83 million of professional, project management and other service fees to support the divestiture; $19 million of employee-related costs; and additional expenses from facility exits and other restructuring activities.

We expect the divestiture of the Cordis business will decrease annual Medical segment revenue by approximately $800 million and adversely impact Medical segment profit by approximately $80 million. The divestiture of our Cordis business is subject to risks and uncertainties that may further adversely impact Medical segment profit. For example, the TSA period may be extended beyond our current expectations or could have unintended consequences, and the costs associated with the exit or disposal activities and stranded costs could be greater than anticipated.

Pharmaceutical Segment

The performance of our Pharmaceutical segment generics program adversely impacted the year-over-year comparison of Pharmaceutical segment profit in fiscal 2021 due to volume declines in our generics program, including the impact of COVID-19. The Pharmaceutical segment generics program includes, among other things, the impact of generic pharmaceutical product launches, customer volumes, pricing changes and the Red Oak Sourcing, LLC venture ("Red Oak Sourcing") with CVS Health Corporation ("CVS Health"). In August 2021, we amended our agreement with CVS Health to extend the term of the Red Oak Sourcing agreement through June 2029. The frequency, timing, magnitude and profit impact of generic pharmaceutical customer volumes, pricing changes, customer contract renewals, and branded and generic pharmaceutical manufacturer pricing changes remain uncertain as does their impact on Pharmaceutical segment profit and consolidated operating earnings in fiscal 2022.

Medical Segment

In the fourth quarter of fiscal 2021, our Medical segment experienced increased supply chain costs, primarily related to transportation, labor and commodities. While we are taking actions to mitigate the impact of these and other sourcing cost increases primarily through cost-savings measures, including global manufacturing efficiencies, we expect these increased costs to adversely impact Medical segment profit in fiscal 2022.


8			Cardinal Health \| Fiscal 2021 Form 10-K


MD&A			Results of Operations

Information Technology Investments

Our Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating systems. Within the Medical segment, Cardinal Health at-Home Solutions is also investing in a system transformation. We expect that these investments will result in increased project-related expenses and depreciation related to capital expenditures, which will negatively impact operating earnings and segment profit in fiscal 2022 and beyond.


			Cardinal Health \| Fiscal 2021 Form 10-K			9


MD&A			Results of Operations

Results of Operations

Revenue


	Revenue
(in millions)	2021		2020		Change
Pharmaceutical	$	145,796	$	137,495	6	%
Medical	16,687		15,444		8	%
Total segment revenue	162,483		152,939		6	%
Corporate	(16)		(17)		N.M.
Total revenue	$	162,467	$	152,922	6	%

Fiscal 2021 Compared to Fiscal 2020

Pharmaceutical Segment

Fiscal 2021 Pharmaceutical segment revenue grew by $8.3 billion primarily due to sales growth from pharmaceutical distribution and specialty solutions customers, which together increased revenue by $8.1 billion.

Medical Segment

Fiscal 2021 Medical segment revenue increased primarily within products and distribution, which increased revenue by $1.1 billion, primarily due to a net benefit from COVID-19, including the positive impact of PPE and higher volumes in our laboratory business.

Cost of Products Sold

Cost of products sold for fiscal 2021 increased $9.6 billion (7 percent) due to the factors affecting the changes in revenue and gross margin.


10			Cardinal Health \| Fiscal 2021 Form 10-K


MD&A			Results of Operations

Gross Margin


	Consolidated Gross Margin
(in millions)	2021		2020		Change
Gross margin	$	6,778	$	6,868	(1)	%

Fiscal 2021 Compared to Fiscal 2020

Fiscal 2021 consolidated gross margin decreased primarily due to the adverse impact of COVID-19, which includes an inventory reserve recorded to reduce the carrying value of certain Medical segment PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes in our laboratory business. For additional information regarding inventory reserves, see Significant Developments in Fiscal 2021 and Trends section in this MD&A. Volume declines in our Pharmaceutical segment generics program, which includes the impact of COVID-19, also had an adverse impact. These factors were partially offset by higher contribution from branded pharmaceutical sales mix and the beneficial comparison of the current year insurance recoveries with the prior-year charge in connection with a voluntary recall for certain surgical gowns and a voluntary recall and field actions for surgical procedure packs containing affected gowns (together, the "Recalls").

Gross margin rate declined during fiscal 2021 mainly due to changes in pharmaceutical distribution product sales mix and an inventory reserve recorded to reduce the carrying value of certain Medical segment PPE to net realizable value. While branded pharmaceutical sales contributed positively to gross margin dollars during fiscal 2021, they had a dilutive impact on our overall gross margin rate.


			Cardinal Health \| Fiscal 2021 Form 10-K			11


MD&A			Results of Operations

Distribution, Selling, General and Administrative ("SG&A") Expenses


	SG&A Expenses
(in millions)	2021		2020		Change
SG&A expenses	$	4,533	$	4,572	(1)	%

Fiscal 2021 Compared to Fiscal 2020

Fiscal 2021 SG&A expenses decreased primarily due to the beneficial impact of enterprise-wide cost-savings measures. The year-over-year comparison was also favorably impacted by the $37 million charge in connection with the Recalls recognized during fiscal 2020. These factors were partially offset by information technology investments and the $41 million assessment on prescription opioid medications that were sold or distributed in New York state in calendar years 2017 and 2018. See Note 7 of the "Notes to Consolidated Financial Statements" for additional information on the New York Opioid Stewardship Act.


12			Cardinal Health \| Fiscal 2021 Form 10-K


MD&A			Results of Operations

Segment Profit

We evaluate segment performance based on segment profit, among other measures. See Note 13 of the "Notes to Consolidated Financial Statements" for additional information on segment profit.


	Segment Profit and Operating Earnings
(in millions)	2021		2020		Change
Pharmaceutical	$	1,684	$	1,753	(4)	%
Medical	577		663		(13)	%
Total segment profit	2,261		2,416		(6)	%
Corporate	(1,789)		(6,514)		N.M.
Total consolidated operating earnings/(loss)	$	472	$	(4,098)	N.M.

Fiscal 2021 Compared to Fiscal 2020

Pharmaceutical Segment Profit

Fiscal 2021 Pharmaceutical segment profit was adversely impacted due to volume declines in our generics program, including the impact of COVID-19, partially offset by higher contribution from branded pharmaceutical sales mix.

Pharmaceutical segment financial results do not include the $1.17 billion and $5.63 billion charges associated with the opioid litigation during fiscal 2021 and 2020, respectively. See Significant Developments in Fiscal 2021 and Trends section in this MD&A and Note 7 of the "Notes to Consolidated Financial Statements" for additional information. In addition, Pharmaceutical segment financial results do not include the $41 million assessment on prescription opioid medications that were sold or distributed in New York state in calendar years 2017 and 2018. See Note 7 of the "Notes to Consolidated Financial Statements" for additional information on the New York Opioid Stewardship Act.

Medical Segment Profit

Fiscal 2021 Medical segment profit decreased largely due to the adverse impact of COVID-19, which primarily includes an inventory reserve recorded to reduce the carrying value of certain PPE, primarily certain categories of gloves, to net realizable value, partially offset by higher volumes in our laboratory business. In addition, enterprise-wide cost-savings measures, including global manufacturing efficiencies, had a positive impact on Medical segment profit.

Corporate

The changes in Corporate during fiscal 2021 are due to the factors discussed in the Other Components of Consolidated Operating Earnings/(Loss) section that follows.


			Cardinal Health \| Fiscal 2021 Form 10-K			13


MD&A			Results of Operations

Other Components of Consolidated Operating Earnings/(Loss)

In addition to revenue, gross margin, and SG&A expenses discussed previously, consolidated operating earnings/(loss) were impacted by the following:


(in millions)	2021		2020
Restructuring and employee severance	$	114	$	122
Amortization and other acquisition-related costs	451		524
Impairments and (gain)/loss on disposal of assets, net	79		7
Litigation (recoveries)/charges, net	1,129		5,741

Restructuring and Employee Severance

In fiscal 2021, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of our Cordis business. In fiscal 2020, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures.

Amortization and Other Acquisition-Related Costs

Amortization of acquisition-related intangible assets was $428 million and $512 million for fiscal 2021 and 2020, respectively.

Impairments and (Gain)/Loss on Disposal of Assets, Net

During fiscal 2021, we recognized a $60 million pre-tax write-down of the assets held for sale from the divestiture of our Cordis business. See the Significant Developments in Fiscal 2021 and Trends section in this MD&A and Note 2 of the "Notes to Consolidated Financial Statements" for additional information.

Litigation (Recoveries)/Charges, Net

During fiscal 2021 and 2020, we recognized pre-tax charges of $1.17 billion and $5.63 billion, respectively, associated with certain opioid matters. See Significant Developments in Fiscal 2021 and Trends section in this MD&A and Note 7 of the "Notes to Consolidated Financial Statements" for additional information.

During fiscal 2021 and 2020, we recognized $56 million and $103 million, respectively, of estimated losses and legal defense costs associated with the IVC filter product liability claims.

During fiscal 2021 and 2020, we recognized income of $112 million and $16 million, respectively, for recoveries in class action antitrust lawsuits in which we were a class member.

Other Components of Earnings/(Loss) Before Income Taxes

In addition to the items discussed above, earnings/(loss) before income taxes was impacted by the following:



(in millions)	2021		2020		Change
Other (income)/expense, net	$	(47)	$	(1)	N.M.
Interest expense, net	180		238		(24)	%
Loss on early extinguishment of debt	14		16		N.M.
(Gain)/Loss on sale of equity interest in naviHealth	2		(579)		N.M.

Other (Income)/Expense, Net

During fiscal 2021, other (income)/expense, net was favorable compared to the prior-year period primarily due to an increase in the value of our deferred compensation plan investments, which offsets fluctuations included within SG&A expenses and is discussed further in Note 9 of the "Notes to Consolidated Financial Statements," gains on investments in non-marketable equity securities, and fluctuations in foreign exchange rates.

Interest Expense, Net

Fiscal 2021 interest expense decreased from fiscal 2020 primarily due to lower debt outstanding and lower short-term interest rates.

Loss On Early Extinguishment Of Debt

During fiscal 2021 and 2020, we recognized losses of $14 million and $16 million, respectively, in connection with the redemption and early debt repurchases as described further in Note 6 of the "Notes to Consolidated Financial Statements."

(Gain)/Loss on Sale of Equity Interest in naviHealth

During fiscal 2020, we recognized a pre-tax gain of $579 million from the sale of our equity interest in a partnership that owned naviHealth, as described further in Note 2 of the "Notes to Consolidated Financial Statements."


14			Cardinal Health \| Fiscal 2021 Form 10-K


MD&A			Results of Operations

Provision for Income Taxes

Fluctuations in the effective tax rates are primarily due to the impact of opioid litigation in fiscal 2021 and 2020, as well as the impact of the carryback claim filed in accordance with the CARES Act provision in fiscal year 2021.

A reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate from continuing operations is as follows (see Note 8 of the "Notes to Consolidated Financial Statements" for additional information):


	2021 (1)		2020 (1)
Provision at Federal statutory rate	21.0	%	21.0	%
State and local income taxes, net of federal benefit	3.2		2.5
Tax effect of foreign operations	0.7		—
Nondeductible/nontaxable items (2)	1.6		0.2

Cordis Disposition	7.0		—
Withholding Taxes (2)	9.0		(0.3)
Change in Valuation Allowances	(1.4)		1.5
US Taxes on International Income (2)(3)	(6.7)		0.2
Impact of Resolutions with IRS and other related matters (2)	(13.6)		(0.4)



Opioid litigation	17.7		(23.2)
Loss Carryback Claims	(129.9)		—
Other (2)	1.7		0.6
Effective income tax rate	(89.7)	%	2.1	%

(1) The table represents the following: fiscal 2021 is pretax income with tax benefit and fiscal 2020 is pretax loss with tax benefit.

(2) Certain prior year amounts have been reclassified to conform to current year presentation.

(3) Includes the tax impact of Global Intangible Low-Taxed Income ("GILTI") tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code.

Fiscal 2021

During fiscal 2021 and 2020, the effective tax rate was (89.7) percent and 2.1 percent, respectively. Included in the effective tax rate for fiscal 2021 was a $424 million benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss. Included in both 2021 and 2020 were net tax benefits related to the treatment of the tax impacts of the fiscal 2021 and 2020 opioid litigation charges.

Tax Effects of Self-Insurance Pre-tax Loss

Tax Effect of Opioid Litigation Charges


			Cardinal Health \| Fiscal 2021 Form 10-K			15


MD&A			Results of Operations

Ongoing Audits

We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year. Tax laws are complex and subject to varying interpretations. During fiscal 2021, we resolved all open issues with respect to the Company’s activity within fiscal years 2008 through 2014 with the U.S. Internal Revenue Service ("IRS"). This resolution resulted in an adjustment to our provision for income taxes, including an impact to reserves for later years. New challenges related to future audits may adversely affect our effective tax rate or tax payments.


16			Cardinal Health \| Fiscal 2021 Form 10-K


MD&A			Liquidity and Capital Resources

Liquidity and Capital Resources

We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion; contractual obligations; tax payments; current and projected debt service requirements, early extinguishment of debt, dividends and share repurchases; and potential opioid litigation settlement payments associated with the Proposed Settlement Agreement. If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.

Cash and Equivalents

During fiscal 2020, our cash and equivalents increased due to $2.0 billion of net cash provided by operating activities, which reflects increases to working capital associated with the timing of payments to vendors, and $886 million of net cash proceeds from the sale of investments, substantially all of which was related to the sale of our equity interest in naviHealth, offset by cash deployed of $1.4 billion for debt repayments, $569 million for dividends and $350 million for share repurchases.

Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer payments, inventory purchases, payments to vendors and tax payments in the regular course of business, as well as

fluctuating working capital needs driven by customer and product mix.

The cash and equivalents balance at June 30, 2021 included $523 million of cash and equivalents held by subsidiaries outside of the United States.

In June 2021, we returned $127 million of cash held by foreign subsidiaries to the U.S.

As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment needs. The computation of tax required if those earnings are repatriated is not practicable. For amounts not considered indefinitely reinvested, we have recorded an immaterial amount of income tax expense in our financial statements in fiscal 2021.

Other Financing Arrangements and Financial Instruments

Credit Facilities and Commercial Paper

In addition to cash and equivalents and operating cash flow, other sources of liquidity at June 30, 2021 include a $2.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At June 30, 2021, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility. During fiscal 2021, under our commercial paper program and our committed receivables program, we had maximum combined total daily amounts outstanding of $200 million and an immaterial average combined daily amount outstanding.

Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of June 30, 2021, we were in compliance with this financial covenant.

Long-Term Obligations

At June 30, 2021, we had total long-term obligations, including the current portion and other short-term borrowings of $6.2 billion.

In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.

During fiscal 2021, we also early repurchased $40 million of the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022 with available cash. In connection with the early debt repurchases, we recorded a $1 million loss on early extinguishment of debt.

In June 2020, we redeemed $500 million aggregate principle amount of 4.625% Notes due December 2020 at a redemption


			Cardinal Health \| Fiscal 2021 Form 10-K			17


MD&A			Liquidity and Capital Resources

price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with the redemption, we recorded a $7 million loss on early extinguishment of debt.

During fiscal 2020, we also early repurchased $247 million of the 2.616% Notes due 2022, $11 million of the 3.2% Notes due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the 3.41% Notes due 2027, $6 million of the 4.6% Notes due 2043, $5 million of the 4.9% Notes due 2045, and $35 million of the 4.368% Notes due 2047. In connection with these early debt repurchases, we recognized a $9 million loss on early extinguishment of debt.

The redemption and repurchases were paid for with available cash and other short-term borrowings.

On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on

September 15, 2021 at an expected redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.

Risk Management

We use interest rate swaps, foreign currency contracts and commodity contracts to manage our exposure to cash flow variability. We also use interest rate swaps to protect the value of our debt and use foreign currency forward contracts to protect the value of our existing and forecasted foreign currency assets and liabilities. See the "Quantitative and Qualitative Disclosures About Market Risk" section as well as Note 1 and Note 10 of the “Notes to Consolidated Financial Statements” for information regarding the use of financial instruments and derivatives as well as foreign currency, interest rate and commodity exposures.

Anticipated Capital Resources

Tax Effects of Self-Insurance Pre-tax Loss

In connection with a tax benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss as described further in Significant Developments in Fiscal 2021 and Trends section in this MD&A and Note 8 of the "Notes to Consolidated Financial Statements," we have filed for a U.S. federal income tax refund of $974 million, which we expect to receive within 12 months. Accordingly, we have recorded a current asset for this amount on our consolidated balance sheet at June 30, 2021. We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.

Cordis Divestiture

Capital Deployment

Opioid Settlement Framework

We had $6.73 billion accrued at June 30, 2021 related to certain opioid litigation, including the Proposed Settlement Agreement, as further described within the Significant Developments in Fiscal 2021 and Trends section in this MD&A and Note 7 of the "Notes to Consolidated Financial Statements." We expect the majority of the payment amounts to be spread over 18 years. We currently expect to make our first annual settlement payment under the Proposed Settlement Agreement in the amount of $405 million into escrow on or before September 30, 2021. If the Proposed Settlement Agreement does not become effective, this payment will be returned to us. We expect to make subsequent annual payments beginning in July 2022.

Capital Expenditures

Capital expenditures during fiscal 2021 and 2020 were $400 million and $375 million, respectively.

We expect capital expenditures in fiscal 2022 to be between $400 million and $450 million and to be primarily for information technology and infrastructure projects.


18			Cardinal Health \| Fiscal 2021 Form 10-K


MD&A			Liquidity and Capital Resources

Dividends

During fiscal 2021, we paid quarterly dividends totaling $1.94 per share, an increase of 1 percent from fiscal 2020.

On May 5, 2021, our Board of Directors approved a quarterly dividend of $0.4908 per share, or $1.96 per share on an annualized basis, which was paid on July 15, 2021 to shareholders of record on July 1, 2021.

On August 4, 2021, our Board of Directors approved a quarterly dividend of $0.4908 per share, payable on October 15, 2021 to shareholders of record on October 1, 2021.

Share Repurchases

During fiscal 2021 and 2020, we repurchased $200 million and $350 million, respectively, of our common shares. We funded the repurchases with available cash and short-term borrowings. See Note 11 of the "Notes to Consolidated Financial Statements" for additional information. At June 30, 2021, we had $743 million authorized for share repurchases remaining on a program that expires on December 31, 2021.


			Cardinal Health \| Fiscal 2021 Form 10-K			19


MD&A			Other

Contractual Obligations

At June 30, 2021, our contractual obligations, including estimated payments due by period, were as follows:


(in millions)	2022		2023 to 2024		2025 to 2026		There-after		Total
Long-term debt and short-term borrowings (1)	$	853	$	1,359	$	934	$	3,026	$	6,172
Interest on long-term debt	232		378		286		1,540		2,436
Finance lease obligations (2)	20		34		11		5		70

Operating lease obligations (3)	116		165		115		141		537
Purchase obligations and other payments (4)	715		488		189		273		1,665
Total contractual obligations (5) (6)	$	1,936	$	2,424	$	1,535	$	4,985	$	10,880

(1)Represents maturities of our long-term debt obligations and other short-term borrowings excluding finance lease obligations described below. See Note 6 of the “Notes to Consolidated Financial Statements” for further information.

(2)Represents minimum finance lease obligations included within current portion of long-term obligations and other short-term borrowings and long-term obligations, less current portion in our consolidated balance sheets and further described in Note 5 of the “Notes to Consolidated Financial Statements.”

(3)Represents minimum operating lease obligations included within other accrued liabilities and deferred income taxes and other liabilities in our consolidated balance sheets and further described in Note 5 of the “Notes to Consolidated Financial Statements.”

(4)A purchase obligation is defined as an agreement to purchase goods or services that is legally enforceable and specifies all significant terms, including fixed or minimum quantities to be purchased; fixed, minimum or

variable price provisions; and approximate timing of the transaction. The purchase obligation amounts disclosed above represent estimates of the minimum for which we are obligated and the time period in which cash outflows will occur. Purchase orders and authorizations to purchase that involve no firm commitment from either party are excluded from the above table. In addition, contracts that can be unilaterally canceled with no termination fee or with proper notice are excluded from our total purchase obligations except for the amount of the termination fee or the minimum amount of goods that must be purchased during the requisite notice period. Purchase obligations and other payments also includes quarterly payments to CVS Health Corporation in connection with Red Oak Sourcing, which also reflects the August 2021 amendment to extend the term through June 2029. See Note 7 of the “Notes to Consolidated Financial Statements” for additional information.

(5)Long-term liabilities, such as unrecognized tax benefits, deferred taxes and other tax liabilities, have been excluded from the above table due to the inherent uncertainty of the underlying tax positions or because of the inability to reasonably estimate the timing of any cash outflows. See Note 8 of the "Notes to Consolidated Financial Statements" for further discussion of income taxes.

(6)Total contractual obligations do not include payments that may be made in connection with the opioid litigation, as further described in Significant Developments in Fiscal 2021 and Trends section in this MD&A and Note 7 of the "Notes to Consolidated Financial Statements." In July 2021, we announced that we and two other national distributors have negotiated the Proposed Settlement Agreement and settlement process that, if all conditions are satisfied, would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. The Proposed Settlement Agreement is subject to certain contingencies and includes a cash component, pursuant to which the Company would pay up to approximately $6.37 billion, the majority of which would be paid over 18 years. We currently expect to make our first annual settlement payment of $405 million into escrow on or before September 30, 2021. If the settlement agreement does not become effective, this payment will be returned to us. We expect subsequent annual payments to be made beginning in July 2022.

Off-Balance Sheet Arrangements

We had no significant "off-balance sheet arrangements" at June 30, 2021, as that term is defined in the SEC rules.

Recent Financial Accounting Standards

See Note 1 of the “Notes to Consolidated Financial Statements” for a discussion of recent financial accounting standards.


20			Cardinal Health \| Fiscal 2021 Form 10-K


MD&A			Critical Accounting Policies and Sensitive Accounting Estimates

Critical Accounting Policies and Sensitive Accounting Estimates

Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management’s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ. In this section, we describe the significant policies applied in preparing our consolidated financial statements that management believes are the most dependent on estimates and assumptions. For further discussion of accounting policies for items within this section and of additional accounting policies, see Note 1 of the “Notes to Consolidated Financial Statements.”

The COVID-19 pandemic continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.

Allowance for Doubtful Accounts

The allowance for doubtful accounts includes general and specific reserves. We determine our allowance for doubtful accounts by reviewing accounts receivable aging, historical write-off trends, payment history, industry trends, customer financial strength, customer credit ratings or bankruptcies. We regularly evaluate how changes in economic conditions, including the economic impact of the COVID-19 pandemic, may affect credit risks. See Note 1 of the “Notes to Consolidated Financial Statements” for further information on our policy for Receivables and Allowance for Doubtful Accounts.

A hypothetical 0.1 percent increase or decrease in the reserve as a percentage of trade receivables at June 30, 2021, would result in an increase or decrease in bad debt expense of $9 million. We believe the reserve maintained and expenses recorded in fiscal 2021 are appropriate.

At this time, we are not aware of any analytical findings or customer issues that are likely to lead to a significant future increase in the allowance for doubtful accounts as a percentage of revenue. In addition, the Financial Accounting Standards Board’s

amended accounting guidance that requires entities to measure credit losses on trade and other receivables using an "expected credit loss" model that considers historical experience, current conditions and reasonable and supportable forecasts was effective for us in the first quarter of fiscal 2021. This guidance did not have a material impact on our consolidated financial statements or disclosures. The following table presents information regarding our allowance for doubtful accounts over the past three fiscal years:


(in millions, except percentages)	2021			2020			2019
Allowance for doubtful accounts at beginning of period	$	206		$	193		$	139
Charged to costs and expenses	130			140			141
Reduction to allowance for customer deductions and write-offs	(94)			(127)			(87)
Allowance for doubtful accounts at end of period	$	242		$	206		$	193
Allowance as a percentage of customer receivables	2.7		%	2.5		%	2.3		%
Allowance as a percentage of revenue	0.15		%	0.13		%	0.13		%

The sum of the components may not equal the total due to rounding.

Inventories

LIFO Inventory

A portion of our inventories (50 percent and 56 percent at June 30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These are primarily merchandise inventories at the core pharmaceutical distribution facilities within our Pharmaceutical segment (“distribution facilities”). The LIFO impact on the consolidated statements of earnings/(loss) depends on pharmaceutical manufacturer price appreciation or deflation and our fiscal year-end inventory levels, which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end. Historically, prices for branded pharmaceuticals have generally tended to rise, resulting in an increase in cost of products sold, whereas prices for generic pharmaceuticals generally tend to decline, resulting in a decrease in cost of products sold. See Note 1 of the “Notes to Consolidated Financial Statements” for further information on our policy for Inventories.

Using LIFO, if there is a decrease in inventory levels that have experienced pharmaceutical price appreciation, the result generally will be a decrease in future cost of products sold as our older inventory is held at a lower cost. Conversely, if there is a decrease in inventory levels that have experienced a pharmaceutical price decline, the result generally will be an increase in future cost of products sold as our older inventory is held at a higher cost.


			Cardinal Health \| Fiscal 2021 Form 10-K			21


MD&A			Critical Accounting Policies and Sensitive Accounting Estimates

We believe that the average cost method of inventory valuation provides a reasonable approximation of the current cost of replacing inventory within these distribution facilities. As such, the LIFO reserve is the difference between (a) inventory at the lower of LIFO cost or market and (b) inventory at replacement cost determined using the average cost method of inventory valuation. At June 30, 2021 and 2020, respectively, inventories valued at LIFO cost were $565 million and $411 million higher than the average cost value. We do not record inventories in excess of replacement cost. As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.

FIFO Inventory

Our remaining inventory, including inventory in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out ("FIFO") method, or net realizable value. We reserve for the lower of cost or net realizable value using the estimated selling prices and estimated sales demand in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Due to the unprecedented demand for certain PPE as a result of COVID-19, our Medical segment manufactured and sourced inventory at higher costs than in periods prior to

COVID-19. As selling prices and customer demand have decreased compared to the peak of COVID-19, we recorded a reserve of $197 million, primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value. Our estimates for selling prices and demand are inherently uncertain and if our assumptions decline in the future, additional inventory reserves may be required. For example, a hypothetical 5 percent decline in the estimated selling prices would have decreased the estimated net realizable value of our inventory by approximately $30 million as of June 30, 2021.

Excess and Obsolete Inventory

We reserve for inventory obsolescence using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, age and expiration dates of on-hand inventory and manufacturer return policies. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory which were $185 million and $155 million at June 30, 2021 and 2020, respectively. If actual conditions are less favorable than our assumptions, additional inventory reserves may be required.

Goodwill and Other Indefinite-Lived Intangible Assets

Purchased goodwill and intangible assets with indefinite lives are tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. There is an option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the quantitative goodwill impairment test. We have elected to bypass the qualitative assessment for the annual goodwill impairment test in the current year. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).

We have two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. These operating segments are comprised of divisions (which are components), for which discrete financial information is available. Components are aggregated into reporting units for purposes of goodwill impairment testing to the extent that they share similar economic characteristics. Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health

at-Home Solutions division) (“Medical Unit”); and Cardinal Health at-Home Solutions division.

Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists and, if necessary, the estimation of the fair value of the applicable reporting unit.

Our determination of estimated fair value of our reporting units is based on a combination of the income-based and market-based approaches (using discount rates ranging from 8.5 percent to 11.5 percent). We use discount rates that are commensurate with the risks and uncertainty inherent in the respective reporting units and in our internally-developed forecasts. Under the market-based guideline public company method, we determine fair value by comparing our reporting units to similar businesses or guideline companies whose securities are actively traded in public markets. We also use the market-based guideline transaction method to determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units.

Estimating the fair value of reporting units requires the use of estimates and significant judgments that are based on a number of factors including actual operating results. The use of alternate estimates and assumptions, changes in the industry or peer groups, or changes in weightings assigned to the discounted cash flow method, guideline public company method or guideline transaction method could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment. If a reporting unit fails to achieve expected earnings or


22			Cardinal Health \| Fiscal 2021 Form 10-K


MD&A			Critical Accounting Policies and Sensitive Accounting Estimates

operating cash flow, or otherwise fails to meet current financial plans, or if there were changes to any other key assumptions used in the tests, the reporting unit could incur a goodwill impairment in a future period.

We performed annual impairment testing in fiscal 2021, 2020 and 2019 and concluded that there were no impairments of goodwill as the estimated fair value of each reporting unit exceeded its carrying value.

Medical Unit Goodwill

Due to the planned divestiture of our Cordis business, we allocated $388 million of goodwill from the Medical Unit to the Cordis disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained.

For our annual impairment test in fiscal 2021, the fair value of the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value of $10.2 billion by approximately 3 percent. For this test, we used a discount rate of 8.5 percent and a terminal growth rate of 2 percent. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The goodwill balance for the Medical Unit was $4.1 billion at June 30, 2021.

Additional adverse changes in key assumptions, such as assumptions about the impact of the Cordis divestiture and the COVID-19 pandemic, including estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate; or increases in tax rates, among other things, could result in a goodwill impairment for the Medical Unit. For example, if we were to increase the discount rate by a hypothetical 0.3 percent or decrease the terminal growth rate by a hypothetical 1 percent, the carrying value would have exceeded the fair value for the Medical Unit by approximately 1 percent for fiscal 2021. Additionally, the estimated tax rate used in goodwill impairment

testing is a market-based assumption, which is impacted by the U.S. federal statutory tax rate. If the U.S. federal statutory tax rate were to increase to 28 percent and no other inputs were changed, the carrying value would have exceeded the fair value of the Medical Unit. For any of our other reporting units, the fair value would not have been less than the carrying amount for fiscal 2021 if we increased the discount rate by 1 percent or if the U.S. federal statutory tax rate were to increase to 28 percent.

We also performed goodwill impairment testing during the three months ended March 31, 2021 for the portion of the Medical Unit that would be retained. The carrying value of the Medical Unit that would be retained was $9.3 billion, of which $4.1 billion was goodwill. The fair value of the reporting unit was estimated to exceed its carrying value, using a combination of the income-based approach and the market-based approach, based on assumptions as of March 31, 2021. There have been no known significant changes in the relative fair values for the Medical Unit that would be retained or the Cordis disposal group.

The impairment test for indefinite-lived intangibles other than goodwill (primarily trademarks) involves first assessing qualitative factors to determine if it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount. If so, then a quantitative test is performed to compare the estimated fair value of the indefinite-lived intangible asset to the respective asset's carrying amount. Our qualitative evaluation requires the use of estimates and significant judgments and considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.

See Note 1 of "Notes to Consolidated Financial Statements" for additional information regarding goodwill and other intangible assets.

Loss Contingencies and Self-Insurance

We regularly review contingencies and self-insurance accruals to determine whether our accruals and related disclosures are adequate. Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.

Loss Contingencies

Examples of such contingencies include various lawsuits related to the distribution of prescription opioid pain medications and the Cordis inferior vena cava ("Cordis IVC") filter lawsuits.

In connection with the opioid litigation as described further in the Significant Developments in Fiscal 2021 and Trends section in this MD&A, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively. In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement, subject to certain conditions and contingencies. There is no assurance that the contingencies to the proposed settlement agreement will be satisfied.


			Cardinal Health \| Fiscal 2021 Form 10-K			23


MD&A			Critical Accounting Policies and Sensitive Accounting Estimates

We develop and periodically update reserve estimates for the Cordis IVC claims, including those received to date and expected to be received in the future and related costs. To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs.

Self-Insurance

We self-insure through a wholly-owned insurance subsidiary for employee healthcare, certain product liability matters, auto liability, property and workers' compensation and maintain insurance for losses exceeding certain limits.

Self-insurance accruals include an estimate for expected settlements on pending claims, defense costs, administrative fees, claims adjustment costs and an estimate for claims incurred but not reported. For certain types of exposures, we develop the estimate of expected ultimate costs to settle each claim based on specific information related to each claim if available. Other estimates are based on an assessment of outstanding claims, historical analysis and current payment trends. For claims incurred but not reported, the liabilities are calculated and derived in accordance with generally accepted actuarial practices or using an estimated lag period.

The amount of loss may differ materially from these estimates. See Note 7 of the “Notes to Consolidated Financial Statements” for additional information regarding loss contingencies and product liability lawsuits.

Provision for Income Taxes

We account for income taxes using the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in the respective jurisdictions in which we operate. Our income tax expense, deferred income tax assets and liabilities, and unrecognized tax benefits reflect management’s assessment of estimated future taxes to be paid on items in the consolidated financial statements.

The following table presents information about our tax position at June 30:


(in millions)	2021		2020
Total deferred income tax assets (1)	$	1,808	$	1,412
Valuation allowance for deferred income tax assets (2)	(515)		(470)
Net deferred income tax assets	1,293		942
Total deferred income tax liabilities	(3,225)		(2,161)
Net deferred income tax liability	$	(1,932)	$	(1,219)

(1) Total deferred income tax assets included $805 million and $589 million of loss and tax credit carryforwards at June 30, 2021 and 2020, respectively.

(2) The valuation allowance primarily relates to federal, state and international loss and credit carryforwards for which the ultimate realization of future benefits is uncertain.

Expiring or unusable loss and credit carryforwards and the required valuation allowances are adjusted quarterly when it is more likely than not that at least a portion of the respective deferred tax assets will not be realized. After applying the valuation allowances, we do not anticipate any limitations on our use of any of the other net deferred income tax assets described above. We

operate in a complex multinational tax environment and are subject to tax treaty arrangements and transfer pricing guidelines for intercompany transactions that are subject to interpretation. Uncertainty in a tax position may arise as tax laws are subject to interpretation.

Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.

Tax Effects of Self-Insurance Pre-tax Loss

Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal


24			Cardinal Health \| Fiscal 2021 Form 10-K


MD&A			Critical Accounting Policies and Sensitive Accounting Estimates

statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.

We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheets at June 30, 2021. We also increased our non-current deferred tax liability by approximately $700 million during fiscal 2021 related to this matter.

Tax Effects of Opioid Litigation Charges

In connection with the $1.17 billion and $5.63 billion pre-tax charges for the opioid litigation, during fiscal year 2021 and 2020, respectively we recorded a tax benefit of $228 million and $488 million, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively. The fiscal 2021 net tax benefit and unrecognized tax benefits were primarily due to our assessment of the specific terms of the Proposed Settlement Agreement. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the U.S. tax law governing deductibility was changed by the U.S. Tax Cuts and Jobs Act ("Tax Act"). Further, it is possible that Congress or the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit may differ materially from these estimates. See Note 8 of the “Notes to the Consolidated Financial Statements.”

Our assumptions and estimates around uncertain tax positions require significant judgment; the actual amount of tax benefit related to uncertain tax positions may differ from these estimates. See Note 8 of the “Notes to Consolidated Financial Statements” for additional information regarding unrecognized tax benefits.

We believe that our estimates for the valuation allowances against deferred tax assets and unrecognized tax benefits are appropriate based on current facts and circumstances. The amount we ultimately pay when matters are resolved may differ from the amounts accrued. Changes in our current estimates due to

unanticipated market conditions, tax law changes or other factors could have a material effect on our ability to utilize deferred tax assets. For a further discussion on Provision for Income Taxes, see Note 8 of the “Notes to the Consolidated Financial Statements.”

The calculation of our tax liabilities includes estimates for uncertainties in the application of broad and complex changes to the U.S. tax code as per the Tax Act as enacted by the United States government on December 22, 2017. We have made reasonable estimates and recorded amounts based on management judgment and our current understanding of the Tax Act which is subject to further interpretation by the IRS. See Note 8 of the “Notes to Consolidated Financial Statements” for additional information.


			Cardinal Health \| Fiscal 2021 Form 10-K			25


Explanation and Reconciliation of Non-GAAP Financial Measures

Explanation and Reconciliation of Non-GAAP Financial Measures

This report, including the "Fiscal 2021 Overview" section within MD&A, contains financial measures that are not calculated in accordance with GAAP.

In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.

Exclusions from Non-GAAP Financial Measures

Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors’ assessment of the business for the reasons identified below:

•LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies’ financial results. We did not recognize any LIFO charges or credits during the periods presented.

•Surgical gown recall costs or income includes inventory write-offs and certain remediation and supply disruption costs, net of related insurance recoveries, arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. Income from surgical gown recall costs represents insurance recoveries of these certain costs. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies’ financial results.

•State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.

•Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business.

•Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity’s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions.


26			Cardinal Health \| Fiscal 2021 Form 10-K


Explanation and Reconciliation of Non-GAAP Financial Measures

•Impairments and gain or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.

•Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount. During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss. Some pre-tax amounts, which contributed to this loss, relate to litigation charges. As a result, we allocated substantially all of the tax benefit to litigation charges.

•Loss on early extinguishment of debt is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions.

•(Gain)/Loss on sale of equity interest in naviHealth was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020. The equity interest was retained in connection with the initial sale of our majority interest in naviHealth during fiscal 2019. We exclude this significant gain because gains or losses on investments of this magnitude do not typically occur in the normal course of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results. The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures.

•Transitional tax benefit, net related to the Tax Cuts and Jobs Act is excluded because it results from the one-time impact of a very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial performance. The transitional tax benefit includes the initial estimate and subsequent adjustments for the re-measurement of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings.

The tax effect for each of the items listed above, other than the transitional tax benefit item, is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.

Definitions

Growth rate calculation: growth rates in this report are determined by dividing the difference between current period results and prior period results by prior period results.

Non-GAAP operating earnings: operating earnings/(loss) excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, and (7) litigation (recoveries)/charges, net.

Non-GAAP earnings before income taxes: earnings/(loss) before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt and (9) (gain)/loss on sale of equity interest in naviHealth.

Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings/(loss) attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt and (9) (gain)/loss on sale of equity interest in naviHealth, each net of tax, and (10) transitional tax benefit, net.

Non-GAAP effective tax rate: provision for/(benefit from) income taxes adjusted for (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt and (9) (gain)/loss on sale of equity interest in naviHealth, each net of tax, and (10) transitional tax benefit, net divided by (earnings before income taxes adjusted for the first nine items).

Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.


			Cardinal Health \| Fiscal 2021 Form 10-K			27


Explanation and Reconciliation of Non-GAAP Financial Measures

GAAP to Non-GAAP Reconciliations


(in millions, except per common share amounts)	Operating Earnings/(Loss)		Operating Earnings/(Loss) Growth Rate		Earnings/(Loss) Before Income Taxes		Provision for/(Benefit From) Income Taxes		Net Earnings/(Loss)1		Net Earnings/(Loss)1 Growth Rate		Effective Tax Rate		Diluted EPS1.2		Diluted EPS1 Growth Rate
	Fiscal Year 2021
GAAP	$	472	N.M.		$	323	$	(289)	$	611	N.M.		(89.7)	%	$	2.08	N.M.
Surgical gown recall costs/(income)	(28)				(28)		(7)		(21)						(0.07)
State opioid assessment related to prior fiscal years	38				38		9		29						0.10
Restructuring and employee severance	114				114		27		87						0.29
Amortization and other acquisition-related costs	451				451		118		333						1.13
Impairments and (gain)/loss on disposal of assets	79				79		15		64						0.21
Litigation (recoveries)/charges, net3	1,129				1,129		606		523						1.78
Loss on early extinguishment of debt	—				14		3		11						0.04
Loss on sale of equity interest in naviHealth investment	—				2		1		1						0.01

Non-GAAP	$	2,255	(5)	%	$	2,122	$	483	$	1,637	2	%	22.8	%	$	5.57	2	%

	Fiscal Year 2020
GAAP	$	(4,098)	N.M.		$	(3,772)	$	(79)	$	(3,696)	N.M.		2.1	%	$	(12.61)	N.M.
Surgical gown recall costs/(income)	85				85		22		63						0.22
State opioid assessment related to prior fiscal years	3				3		1		2						0.01
Restructuring and employee severance	122				122		29		93						0.31
Amortization and other acquisition-related costs	524				524		130		394						1.34
Impairments and (gain)/loss on disposal of assets	7				7		2		5						0.02
Litigation (recoveries)/charges, net3	5,741				5,741		514		5,227						17.84
Loss on early extinguishment of debt	—				16		4		12						0.04
Gain on sale of equity interest in naviHealth investment	—				(579)		(86)		(493)						(1.68)

Transitional tax benefit, net4	—				—		2		(2)						(0.01)
Non-GAAP	$	2,384	1	%	$	2,147	$	539	$	1,605	1 %		25.1 %		$	5.45	3	%

	Fiscal Year 2019
GAAP	$	2,060	N.M.		$	1,751	$	386	$	1,363	N.M.		22.1 %		$	4.53	N.M.
Restructuring and employee severance	125				125		32		93						0.31
Amortization and other acquisition-related costs	621				621		148		473						1.57
Impairments and (gain)/loss on disposal of assets5	(488)				(488)		(113)		(375)						(1.25)
Litigation (recoveries)/charges, net	36				36		10		26						0.09

Transitional tax benefit, net4	—				—		(9)		9						0.03
Non-GAAP	$	2,353	(9)	%	$	2,044	$	453	$	1,589	1 %		22.1 %		$	5.28	6 %

1 Attributable to Cardinal Health, Inc.

2 For fiscal 2020, GAAP diluted loss per share attributable to Cardinal Health, Inc. and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period. Fiscal 2020, non-GAAP diluted EPS is calculated using a weighted average of 295 million common shares, which includes potentially dilutive shares.

3 Litigation (recoveries)/charges, net includes pre-tax charges of $1.17 billion and $5.63 billion recorded in fiscal 2021 and 2020, respectively, related to the opioid litigation. The net tax benefits associated with the opioid litigation charges are $228 million and $488 million for fiscal 2021 and 2020, respectively.

Litigation (recoveries)/charges, net, includes a tax benefit recorded during fiscal 2021 related to a net operating loss carryback. Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. The total benefit from the net operating loss carryback was $424 million; however, for purposes of Non-GAAP financial measures, we allocated $389 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-insurance pre-tax loss related to opioid litigation claims versus separate tax adjustments. The tax benefit allocated to the separate tax adjustments of $35


28			Cardinal Health \| Fiscal 2021 Form 10-K


Explanation and Reconciliation of Non-GAAP Financial Measures

million is included in non-GAAP measures.

4 Reflects the net transitional benefit from the remeasurement of our deferred tax assets and liabilities partially offset by the repatriation tax on cash and earnings of foreign subsidiaries. See Note 8 of the "Notes to Consolidated Financial Statements" for more information.

5 During fiscal 2019, we sold our majority interest in naviHealth and recognized a pre-tax gain of $508 million ($378 million after tax).

The sum of the components and certain computations may reflect rounding adjustments.

We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.


			Cardinal Health \| Fiscal 2021 Form 10-K			29


Disclosures about Market Risk

Quantitative and Qualitative Disclosures About Market Risk

We are exposed to cash flow and earnings fluctuations as a result of certain market risks. These market risks primarily relate to foreign exchange, interest rate, and commodity price-related changes. We maintain a hedging program to manage volatility related to some of these market exposures which employs operational, economic, and derivative financial instruments in order to mitigate risk. See Note 1 and Note 10 of the “Notes to Consolidated Financial Statements” for further discussion regarding our use of derivative instruments.

Foreign Exchange Rate Sensitivity

By the nature of our global operations, we are exposed to cash flow and earnings fluctuations resulting from foreign exchange rate variation. These exposures are transactional and translational in nature. The following foreign currencies represent the principal drivers of our foreign exchange exposure: Canadian dollar, euro, Thai baht, Mexican peso, Chinese renminbi, Australian dollar, British pound and Japanese yen.

We apply a Value-At-Risk ("VAR") methodology to our transactional and translational exposures. The VAR model is a risk estimation tool and is not intended to represent actual losses in fair value that could be incurred.

Transactional Exposure

Transactional exposure arises from the purchase and sale of goods and services in currencies other than our functional currency or the functional currency of our subsidiaries. At the end of each fiscal year we perform sensitivity analyses on our

forecasted transactional exposure for the upcoming fiscal year. These analyses include the estimated impact of our hedging program, which is designed to mitigate transactional exposure. Applying a VAR methodology to our transactional exposure and including the impact of our hedging program, the potential maximum loss in earnings for the upcoming fiscal year is estimated to be $16 million, which is based on a one-year horizon and a 95 percent confidence level.

Translational Exposure

We have exposure related to the translation of financial statements of our foreign operations into U.S. dollars, our functional currency. Applying a VAR methodology to our translational exposure, the potential maximum loss in earnings for the upcoming fiscal year is estimated to be $5 million, which is based on a one-year horizon and a 95 percent confidence level.

Interest Rate Sensitivity

We are exposed to changes in interest rates primarily as a result of our borrowing and investing activities to maintain liquidity and fund operations. The nature and amount of our long-term and short-term debt can be expected to fluctuate as a result of business requirements, market conditions and other factors. Our policy is to manage exposures to interest rates using a mix of fixed and floating rate debt as deemed appropriate by management. We utilize interest rate swap instruments to mitigate our exposure to interest rate movements.

As part of our risk management program, we perform an annual sensitivity analysis on our forecasted exposure to interest rates for the upcoming fiscal year. This analysis assumes a hypothetical 50 basis point change in interest rates. At June 30, 2021, the potential increase or decrease in annual interest expense under this analysis as a result of this hypothetical change would be $2 million.

We are also exposed to market risk from changes in interest rates related to our cash and cash equivalents, which includes marketable securities that are carried at fair value in the consolidated balance sheets. The fair value of our cash and cash equivalents is subject to change primarily as a result of changes in market interest rates and investment risk related to the issuers' credit worthiness. At June 30, 2021, a hypothetical increase or decrease of 50 basis points in interest rates would result in a hypothetical $10 million change in the estimated fair value.


30			Cardinal Health \| Fiscal 2021 Form 10-K


Disclosures about Market Risk

Commodity Price Sensitivity

We are directly exposed to market price changes for certain commodities, including oil-based resins, nitrile, cotton, diesel fuel and latex. We typically purchase raw materials at either market prices or prices tied to a commodity index and some finished goods at prices based in part on a commodity price index.

As part of our risk management program, we perform sensitivity analysis on our forecasted direct commodity exposure for the upcoming fiscal year. Our forecasted direct commodity exposure at June 30, 2021 increased approximately $4 million from June 30, 2020. At June 30, 2020, we had hedged a portion of these direct commodity exposures (see Note 10 of the “Notes to Consolidated Financial Statements” for further discussion). There were no outstanding commodity contracts in our hedging program at June 30, 2021.

Our forecasted direct commodity exposures for the upcoming fiscal year is $449 million. The potential gain/loss given a hypothetical 10 percent fluctuation in commodity prices, assuming pricing collectively shifts in the same direction and we are unable to change customer pricing in response to those shifts or otherwise offset, for the upcoming fiscal year is $45 million at June 30, 2021. The hypothetical offsetting impact of hedges in both periods was minimal.


			Cardinal Health \| Fiscal 2021 Form 10-K			31


Business

Business

General

Cardinal Health, Inc. is a global integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency.

Pharmaceutical Segment

In the United States, our Pharmaceutical segment:

•through its Pharmaceutical Distribution division, distributes branded and generic pharmaceutical and over-the-counter healthcare and consumer products to retailers (including chain and independent drug stores and pharmacy departments of supermarkets and mass merchandisers), hospitals and other healthcare providers. This division:

▪maintains prime vendor relationships that streamline the purchasing process resulting in greater efficiency and lower costs for our retail, hospital and other healthcare provider customers;

▪provides services to pharmaceutical manufacturers, including distribution, inventory management, data reporting, new product launch support and chargeback administration;

▪through the Outcomes service offering, connects pharmacists, payers and pharmaceutical companies and delivers health solutions for personalized medication therapy management, digital patient engagement and telepharmacy;

•provides pharmacy management services to hospitals and operates a limited number of pharmacies, including in community health centers; and

•repackages generic pharmaceuticals and over-the-counter healthcare products;

•through its Specialty Solutions division, distributes specialty pharmaceutical products to hospitals and other healthcare providers and provides consulting, patient support and other services for specialty pharmaceutical products to pharmaceutical manufacturers and healthcare providers; and

•through its Nuclear and Precision Health Solutions division, operates nuclear pharmacies and manufacturing facilities, which manufacture, prepare and deliver radiopharmaceuticals for use in nuclear imaging and other procedures in hospitals and physician offices. This division also contract manufactures a radiopharmaceutical treatment (Xofigo) and holds the North American rights to manufacture and distribute Lymphoseek, a radiopharmaceutical diagnostic imaging agent.

See Note 13 of the “Notes to Consolidated Financial Statements” for Pharmaceutical segment revenue, profit and assets for fiscal 2021, 2020 and 2019.

Pharmaceutical Distribution

Our Pharmaceutical Distribution division’s gross margin includes margin from our generic pharmaceutical program, from distribution services agreements with branded pharmaceutical manufacturers and from over-the-counter healthcare and consumer products. It also includes manufacturer cash discounts.

Margin from our generic pharmaceutical program includes price discounts and rebates from manufacturers and may in limited instances include price appreciation. Our earnings on generic pharmaceuticals are generally highest during the period immediately following the initial launch of a product, because generic pharmaceutical selling prices are generally highest during that period and tend to decline over time.

Margin from distribution services agreements with branded pharmaceutical manufacturers is derived from compensation we receive for providing a range of distribution and related services to manufacturers. Our compensation typically is a percentage of the wholesale acquisition cost that is set by manufacturers. In addition, under a limited number of agreements, branded pharmaceutical price appreciation, which is determined by the manufacturers, also serves as part of our compensation.

Sourcing Venture with CVS Health Corporation

Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health negotiates generic pharmaceutical supply contracts on behalf of both companies. In August 2021, we amended our agreement with CVS Health to extend the term of Red Oak Sourcing through June 2029.

Specialty Pharmaceutical Products and Services

We refer to products and services offered by our Specialty Solutions division as “specialty pharmaceutical products and services.” The Specialty Solutions division distributes oncology, rheumatology, urology, nephrology and other pharmaceutical products ("specialty pharmaceutical products") and human-derived plasma products to hospitals, dialysis clinics, physician offices and other healthcare providers; provides consulting, patient support, logistics, group purchasing and other services to pharmaceutical manufacturers and healthcare providers primarily supporting the development, marketing and distribution of specialty pharmaceutical products; and provides specialty pharmacy services. Our use of the terminology "specialty pharmaceutical products and services" may not be comparable to the terminology used by other industry participants.


32			Cardinal Health \| Fiscal 2021 Form 10-K


Business

Medical Segment

Our Medical segment manufactures and sources Cardinal Health branded general and specialty medical, surgical and laboratory products and devices. These products include exam and surgical gloves; needle, syringe and sharps disposal; compression; incontinence; nutritional delivery; wound care; single-use surgical drapes, gowns and apparel; fluid suction and collection systems; urology; operating room supply; and electrode product lines. Our Cardinal Health Brand products are sold directly or through third-party distributors in the United States, Canada, Europe, Asia and other markets. These products are generally higher-margin products.

The Medical segment also distributes a broad range of medical, surgical and laboratory products known as national brand products

and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada and this segment also assembles and sells sterile and non-sterile procedure kits.

Through Cardinal Health at-Home Solutions, this segment also distributes medical products to patients' homes in the United States.

The Medical segment, through its Wavemark division, also provides an automated technology platform for inventory management.

Acquisitions and Divestitures

Acquisitions

We have acquired a number of businesses over the years that have enhanced our core strategic areas of Cardinal Health Brand medical products, generic pharmaceutical distribution and services, specialty pharmaceutical products and services, international and post-acute care. We expect to continue to pursue additional acquisitions in the future.

During the last five fiscal years, we completed several acquisitions. In July 2017, we acquired the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses (the "Patient Recovery Business") from Medtronic plc for $6.1 billion in cash. We also completed several smaller acquisitions during the last five fiscal years, including, in fiscal 2017, the acquisition of the North American rights to Lymphoseek, a radiopharmaceutical diagnostic imaging agent, from Navidea Biopharmaceuticals, Inc.

Date

Company

Location

Lines

of Business

Acquisition

Price

(in billions)

07/17

Patient Recovery Business of Medtronic, plc

Mansfield, MA

Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency

$6.1

Divestitures

Over the past five fiscal years, we have also completed several divestitures.

On August 2, 2021, we completed the divestiture of our Cordis business to Hellman & Freidman ("H&F") for net proceeds of $927 million in cash, subject to customary purchase price adjustments. We have retained certain working capital accounts and product liability for lawsuits related to inferior vena cava filters in the U.S. and Canada, as described in Note 7 of the Notes to the Consolidated Financial Statements. We acquired the Cordis business from Johnson & Johnson for $1.9 billion in October 2015. This divestiture also includes Access Closure, Inc., a manufacturer and distributor of extravascular closure devices, that we acquired for approximately $320 million in May 2014.

In August 2018, we completed the sale of our equity interest in naviHealth, Inc. to investor entities controlled by Clayton, Dubilier & Rice, LLC ("CD&R") for proceeds of $737 million (after adjusting for certain fees and expenses) and a noncontrolling equity interest in a partnership that owned naviHealth. In May 2020, we sold the remainder of our equity interest in naviHealth.

We had acquired our equity interest in naviHealth through a series of transactions beginning in fiscal 2016, when we acquired a majority equity interest.

In February 2018, we completed the sale of our pharmaceutical and medical products distribution business in China to Shanghai Pharmaceuticals Holding Co., Ltd. for proceeds of $861 million (after adjusting for third party indebtedness and preliminary transaction adjustments).


			Cardinal Health \| Fiscal 2021 Form 10-K			33


Business

Customers

Our largest customers, CVS and OptumRx, accounted for 26 percent and 15 percent of our fiscal 2021 revenue, respectively. In the aggregate, our five largest customers, including CVS and OptumRx, accounted for 50 percent of our fiscal 2021 revenue.

In August 2021, we extended our pharmaceutical distribution agreements with CVS through June 2027.

We have agreements with group purchasing organizations (“GPOs”) that act as agents to negotiate vendor contracts on

behalf of their members. Our two largest GPO relationships in terms of revenue are with Vizient, Inc. and Premier, Inc. Sales to members of these two GPOs, under numerous contracts across our businesses, collectively accounted for 15 percent of our revenue in fiscal 2021.

Suppliers

We rely on many different suppliers. Products obtained from our five largest suppliers accounted for an aggregate of 30 percent of our revenue during fiscal 2021, and our largest supplier’s products accounted for approximately 7 percent of revenue.

Competition

We operate in a highly competitive environment in the distribution of pharmaceuticals and consumer healthcare products. We also operate in a highly competitive environment in the manufacturing and distribution of medical devices and surgical products. We compete on many levels, including price, service offerings, support services, customer service, breadth of product lines and product quality and efficacy.

In the Pharmaceutical segment, we compete with wholesale distributors with national reach, including McKesson Corporation and AmerisourceBergen Corporation, regional wholesale distributors, self-warehousing chains, specialty distributors, third-party logistics companies, companies that provide specialty pharmaceutical services and nuclear pharmacies, among others.

In addition, the Pharmaceutical segment has experienced competition from a number of organizations offering generic pharmaceuticals, including telemarketers. We also compete with manufacturers that sell their products directly.

In the Medical segment, we compete with many diversified healthcare companies and national medical product distributors, such as Medline Industries, Inc., Owens & Minor, Inc. and Becton, Dickinson and Company, as well as regional medical product distributors and companies that are focused on specific product categories. We also compete with companies that distribute medical products to patients' homes and third-party logistics companies.

Human Capital Management

Employees

We, through our employees, improve the lives of people every day by solving complex healthcare problems. As of June 30, 2021, we had approximately 47,300 employees globally, approximately 18,300 of whom are based outside the United States. Approximately 98% of our workforce is full time employees. Approximately 29,000 of our employees worked in our distribution centers, manufacturing facilities and pharmacies, and 18,300 worked in other functions, including finance, information technology, human resources and sales.

Approximately 3,230 employees were primarily associated with our Cordis business and were transferred in the divestiture in August 2021. Most of these employees are based outside the United States.

Additionally, we have engaged global professional services firms to perform certain business processes on our behalf, including within finance, information technology and human resources.

Diversity, Equity & Inclusion

At Cardinal Health, we are focused on building a diverse workforce and an inclusive workplace that values the unique perspectives and contributions of all of our employees.

We promote a culture of diversity, equity and inclusion through, for example, seven Employee Resource Groups (ERGs), including groups focused on various racial and ethnic groups, members of the LGBTQ community, employees with disabilities, veterans and women. They are designed to foster an inclusive and engaged workforce and develop future leaders. In addition, we have manager and broad-based unconscious bias and racial equity training courses. Our work is led by our senior executives with advice from a Diversity and Inclusion Steering Council which consists of senior leaders from across the company. Additionally, in December 2019, we created a new African American and Black Racial Equity Cabinet to provide guidance to our senior executives in addressing racism and social injustice.


34			Cardinal Health \| Fiscal 2021 Form 10-K


Business

We also monitor pay equity. We define pay equity as equal pay for people of all gender identities and ethnicities who are performing substantially similar work. We have a pay equity committee, which guides the ongoing analysis and benchmarking, in regular consultation with an independent third-party, to review and help inform our salary and compensation practices.

We have established long-range aspirational representation goals for specific under-represented groups in our manager-and-above level employee population.

Employee Health & Safety

The health, safety and security of our employees is an priority for us. We employ systems designed to continually monitor our facilities and work environment to promote employee safety and identify and prevent or mitigate any potential risks. This includes procedures and equipment for security. We routinely assess facilities to closely monitor adherence to established security and safety standards. Our employees receive specialized training related to their role, work setting, and equipment used in their work environment. As our processes evolve, we update relevant safety training modules, which may include new employee training programs.

COVID-19 Response

Protecting the health and safety of our employees and their families has been a priority throughout the COVID-19 pandemic.

In March, 2020, all employees who could work remotely began working from home. We expanded our technology infrastructure to help employees perform their duties remotely and continue to support customers, patients and our frontline colleagues. Many of these employees continue to work remotely.

Because Cardinal Health is part of a critical infrastructure industry, more than 30,000 of our employees have continued to report to work in distribution centers, supply chain operations, manufacturing sites, pharmacies and other clinical sites.

To help prevent the spread of COVID-19 and protect the safety of our frontline employees, all of our facilities are thoroughly cleaned regularly and we implemented safety measures, including mask and social distancing requirements, in accordance with the U.S.

Centers for Disease Control and Prevention and the World Health Organization guidelines. We also educated employees on how they can help keep themselves and their families safe and have training programs to help employees stay safe in their jobs. Our safety measures have helped us to avoid a wide spread outbreak of COVID-19 among our employees. Since June 2021, we have provided clinics for employees, contractors and their families and friends to receive a COVID-19 vaccine.

Talent Retention & Culture

Talent Development and Learning

Cardinal Health’s talent development strategy is a segmented, multi-pronged approach to build capabilities, skills and competencies of leaders and employees throughout the enterprise ensuring employees capabilities connect to business needs and outcomes. This segmented approach includes broad based employee skill development and learning, manager capabilities and development, differentiated diverse talent development and executive development.

Culture

Cardinal Health’s culture is rooted in our values and behaviors and aligned to the company’s strategic framework. Providing a positive work environment supports our ability to attract, retain and develop our employees and enables business performance. We reinforce, monitor and assess our culture through a variety of programs and processes which include performance management, talent/succession planning, employee engagement surveys and other listening strategies.

Intellectual Property

We rely on a combination of trade secret, patent, copyright and trademark laws, nondisclosure and other contractual provisions, and technical measures to protect our products, services and intangible assets. We hold patents, and continue to pursue patent protection throughout the world, relating to the manufacture, operation and use of various medical and surgical products, to certain distribution and logistics systems, to the production and distribution of our nuclear pharmacy products and to other service offerings. We also operate under licenses for certain proprietary technologies, and in certain instances we license our technologies to third parties.

We believe that we have taken all necessary steps to protect our proprietary rights, but no assurance can be given that we will be able to successfully enforce or protect our rights in the event that they are infringed upon by a third party. While all of these proprietary rights are important to our operations, we do not consider any particular patent, trademark, license, franchise or concession to be material to our overall business.


			Cardinal Health \| Fiscal 2021 Form 10-K			35


Business

Regulatory Matters

Our business is highly regulated in the United States, at both the federal and state level, and in foreign countries. Depending upon the specific business, we may be subject to regulation by government entities including:

•the U.S. Drug Enforcement Administration (the “DEA”);

•certain agencies within the U.S. Department of Health and Human Services, including the U.S. Food and Drug Administration (the “FDA”), the Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights;

•state health departments, insurance departments, Medicaid departments or other comparable state agencies;

•state boards of pharmacy and other controlled substance authorities;

•the U.S. Nuclear Regulatory Commission (the “NRC”);

•the U.S. Federal Trade Commission (the "FTC");

•U.S. Customs and Border Protection; and

•agencies comparable to those listed above in markets outside the United States.

These regulatory agencies have a variety of civil, administrative and criminal sanctions at their disposal for failure to comply with applicable legal or regulatory requirements. They can suspend our ability to manufacture and distribute products, require us to initiate product recalls, seize products or impose criminal, civil and administrative sanctions.

Distribution

State Boards of Pharmacy, FDA, DEA and various other state authorities regulate the marketing, purchase, storage and distribution of pharmaceutical and medical products under various federal and state statutes including the federal Prescription Drug Marketing Act of 1987, Drug Quality and Security Act of 2013 (the “DQSA”), and Controlled Substances Act (the "CSA"). The CSA governs the sale, packaging, storage and distribution of controlled substances. Wholesale distributors of controlled substances must hold valid DEA registrations and state-level licenses, meet various security and operating standards including effective anti-diversion programs, and comply with the CSA. They must also comply with state requirements relating to controlled substances that differ from state to state.

The Proposed Settlement Agreement, as described in the Significant Developments in Fiscal 2021 and Trends section in MD&A and Note 7 of the Notes to Consolidated Financial Statements, if it becomes effective, also includes injunctive relief terms related to settling distributors' controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period

of five years. In addition, the settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting and will fund the clearinghouse for ten years.

Manufacturing, Sourcing and Marketing

We sell our manufactured products in the United States, Canada, Europe, Asia, Latin America and other markets. The FDA and other governmental agencies in the United States, as well as foreign governmental agencies, administer requirements that cover the design, testing, safety, effectiveness, manufacturing (including good manufacturing practices), quality systems, labeling, promotion and advertising (including restrictions on promoting or advertising a product other than for the product's cleared or approved uses), distribution, importation and post-market surveillance for most of our manufactured products. We are also subject to these requirements when we source certain Medical segment products from third-party manufacturers.

We need specific approval or clearance from, and registrations with, regulatory authorities before we can market and sell some products in the United States and certain other countries, including countries in the European Union ("EU").

In the United States, authorization to commercially market a medical device is generally received in one of two ways. The first, known as pre-market notification or the 510(k) process, requires us to demonstrate that a medical device is substantially equivalent to a legally marketed medical device. The second more rigorous process, known as pre-market approval (“PMA”), requires us to independently demonstrate that a medical device is safe and effective. Many of our Medical segment branded products are cleared through the 510(k) process and certain products must be approved through the PMA process.

In the EU, we are required to obtain CE Mark Certification in order to market medical devices. In 2017, EU regulatory bodies finalized a new Medical Device Regulation ("MDR") became effective in May 2021. Under the MDR, medical devices marketed in the EU require significant pre-market and post-market requirements.

It can be costly and time-consuming to obtain regulatory approvals, clearances and registrations of medical devices, and they might not be granted on a timely basis, if at all. Even after we obtain approval or clearance to market a product or obtain product registrations, the product and our manufacturing processes are subject to continued regulatory oversight, including periodic inspection of manufacturing facilities by FDA and other regulatory authorities both in the United States and internationally.

From time to time, we may determine that products we manufacture or market do not meet our specifications, regulatory requirements or published standards. When we or a regulatory agency identify a quality or regulatory issue, we investigate and take appropriate corrective action, which may include recalling the product, correcting the product at the customer location, revising product labeling and notifying customers. For example, in January 2020, we issued a voluntary recall for certain surgical gowns and


36			Cardinal Health \| Fiscal 2021 Form 10-K


Business

two voluntary field actions for certain Presource Procedure Packs because one of our FDA-registered suppliers in China had shifted production of some gowns to unapproved sites.

Any adverse regulatory action, depending on its magnitude, may limit our ability to effectively manufacture, source, market and sell our products, limit our ability to obtain future premarket approvals or result in a substantial modification to our business practices and operations. For additional information, please see our Risk Factor entitled "Our business is subject to rigorous quality regulatory and licensing requirements."

Privacy and Data Protection

We are subject to various and evolving privacy laws and regulations in many jurisdictions. Because we collect, handle and maintain patient-identifiable health information, we are subject to laws that require specified privacy and security measures and that regulate the use and disclosure of such information, including the U.S. Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), as augmented by the Health Information Technology for Economic and Clinical Health Act as well as state laws, in the United States.

We also collect, handle, and maintain other sensitive personal and financial information. Within the U.S., these activities are regulated by certain federal and state laws. For example, the new California Consumer Privacy Act became effective in January 2020 and grants specified rights to consumers over the use of their personal information, including increased transparency. Other states have adopted or are considering adopting similar or different comprehensive privacy laws. Internationally, we are also subject to privacy and data protection laws that require significant compliance efforts, including the EU's General Data Protection Regulation (GDPR), Canada's Personal Information Protection and Electronic Documents Act (PIPEDA) and Japan's Act on the Protection of Personal Information (APPI), among many others.

Nuclear Pharmacies and Related Businesses

Our nuclear pharmacies and radiopharmaceutical manufacturing facilities (including for Xofigo) require licenses or permits and must abide by regulations issued by the NRC, applicable state boards of pharmacy and the radiologic health agency or department of health of each state in which we operate, including pharmacy sterile compounding standards and practices. In addition, our radiopharmaceutical manufacturing facilities also must comply with FDA regulations, including good manufacturing practices.

Product Tracing and Supply Chain Integrity

Title II of the DQSA, known as the Drug Supply Chain Security Act or "Track and Trace," establishes a phased-in national system for tracing pharmaceutical products through the pharmaceutical distribution supply chain to detect, prevent and rapidly respond to the introduction of drugs that may be counterfeit, diverted, stolen, adulterated, subject of a fraudulent transaction or otherwise unfit for distribution. The first phase of implementation began in 2015, and upon full implementation in 2023, we and other supply chain stakeholders will participate in an electronic, interoperable, prescription drug tracing system. In addition, the FDA also has issued regulations requiring most medical device labeling to bear a unique device identifier. The MDR, described above, also introduces a new unique device identifier requirement.


			Cardinal Health \| Fiscal 2021 Form 10-K			37


Business

Government Healthcare Programs

We are subject to U.S. federal healthcare fraud and abuse laws. These laws generally prohibit persons from soliciting, offering, receiving or paying any compensation in order to induce someone to order, recommend or purchase products or services that are in any way paid for by Medicare, Medicaid or other federally-funded healthcare programs. They also prohibit submitting any fraudulent claim for payment by the federal government. There are similar state healthcare fraud and abuse laws that apply to Medicaid and other state-funded healthcare programs. Violations of these laws may result in criminal or civil penalties, as well as breach of contract claims and qui tam actions (false claims cases initiated by private parties purporting to act on behalf of federal or state governments).

Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program. These businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements. Other businesses within each segment manufacture pharmaceutical or medical products or repackage pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs. Failure to comply with applicable eligibility requirements, standards and regulations could result in civil or criminal sanctions, including the loss of our ability to participate in Medicare, Medicaid and other federal and state healthcare programs. For example, the United States Attorney’s Office for the District of Massachusetts has been conducting an investigation related to discounts and rebates offered or provided to certain Specialty Solutions customers as a result of qui tam actions. For more information on this investigation, see Note 7 to the Consolidated Financial Statements.

Our U.S. federal and state government contracts are subject to specific procurement requirements. Failure to comply with applicable rules or regulations or with contractual or other requirements may result in monetary damages and criminal or civil penalties as well as termination of our government contracts or our suspension or debarment from government contract work.

Environmental, Health and Safety Laws

In the United States and other countries, we are subject to various federal, state and local environmental laws, including laws regulating the production or use of hazardous substances, as well as laws relating to safe working conditions and laboratory practices.

Antitrust Laws

The U.S. federal government, most U.S. states and many foreign countries have laws that prohibit certain types of conduct deemed to be anti-competitive. Violations of these laws can result in various sanctions, including criminal and civil penalties. Private plaintiffs also could bring civil lawsuits against us in the United States for alleged antitrust law violations, including claims for treble damages.

Laws Relating to Foreign Trade and Operations

U.S. and foreign laws require us to abide by standards relating to the import and export of finished goods, raw materials and supplies and the handling of information. We also must comply with various export control and trade embargo laws, which may require licenses or other authorizations for transactions within some countries or with some counterparties.

Similarly, we are subject to U.S. and foreign laws concerning the conduct of our foreign operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and other foreign anti-bribery laws. Among other things, these laws generally prohibit companies and their intermediaries from offering, promising or making payments to officials of foreign governments for the purpose of obtaining or retaining business. For example, in February 2020, we paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that our internal controls were not sufficient to detect improper payments made by employees of our former China distribution business.


38			Cardinal Health \| Fiscal 2021 Form 10-K


Business

Other Information

Although our agreements with manufacturers sometimes require us to maintain inventory levels within specified ranges, our distribution businesses are generally not required by our customers to maintain particular inventory levels other than as needed to meet service level requirements. Certain customer contracts require us to maintain sufficient inventory to meet emergency demands, but we do not believe those requirements materially affect inventory levels.

Our customer return policies generally require that the product be physically returned, subject to restocking fees. We only allow customers to return product for credit that can be added back to inventory and resold at full value, or that can be returned to vendors for credit.

We offer market payment terms to our customers.


			Cardinal Health \| Fiscal 2021 Form 10-K			39


Risk Factors

Risk Factors

The risks described below could materially and adversely affect our results of operations, financial condition, liquidity or cash flows. These are not the only risks we face. Our businesses also could be affected by risks we do not currently consider material to our operations or of which we are not presently aware.

COVID-19 Risks

We have been and expect to continue to be negatively affected by the ongoing COVID-19 pandemic.

See the description of the actual and possible effects of the COVID-19 pandemic and resulting disruptions on our business and operations discussed above in “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” In addition to the adverse impacts and uncertainties from the COVID-19 pandemic identified there, we continue to face additional possible adverse impacts, including those described below.

During the COVID-19 pandemic, our Medical segment experienced dramatically increased demand for and industry shortages of certain PPE, such as masks, gowns and gloves. This increased demand resulted in increased costs to manufacture and source these products, and ultimately, higher inventory levels. As a result, we have sought additional sources for these products and to mitigate the cost increases, we have raised our selling prices for affected products. During the fourth quarter of fiscal year 2021, selling prices and customer demand for certain PPE declined, which we expect to continue into fiscal year 2022. This has resulted in inventory reserves. Our estimates for demand and selling prices are inherently uncertain and if demand or selling prices or other market dynamics decline in the future beyond our current assumptions, additional inventory reserves may be required, which would adversely impact Medical segment profit.

Additionally, pricing actions have mitigated the impact of the increased costs to manufacture and source PPE, as a result of the decreased demand and selling price, we may not be successful at continuing to mitigate the impact of these increased costs in the future.

Within our Pharmaceutical segment, COVID-19-related volume declines have negatively impacted our Pharmaceutical segment generics program, but are expected to moderate in fiscal year 2022. If demand for these products does not return to pre-COVID-19 levels, or returns more slowly than anticipated, the negative impact could be more prolonged or significant than we currently expect.

Federal, state and local government policies and initiatives designed to reduce the transmission of COVID-19 also resulted in the cancellation or deferral of many elective medical procedures and some of our customers closing or severely curtailing their operations. While lower demand for surgical products resulting from reduced elective procedures had an adverse impact on Medical segment profit during the first nine months of fiscal 2021, demand improved during the fourth quarter of fiscal 2021. If

governmental policies designed to reduce the transmission of COVID-19 return and demand for these procedures does not increase or decreases further, we could have less sales of the affected products and services than we currently expect. Additionally, sustained changes in the manner in which patients access healthcare may result in shifts in consumer preferences that may not be favorable to us.

We cannot estimate the continued length or severity of the COVID-19 pandemic or the related consequences on the U.S. and global economy and our business and operations, including whether and when normal economic and operating conditions will resume or the extent to which further disruption may impact our business, financial position, results of operations or cash flow. The COVID-19 pandemic has also heightened other risks, including risks associated with competitive pressures, supplier relationships, international operations, regulatory and licensing, changes to the U.S. healthcare environment, cyber security, and access to capital markets.

Legal, Regulatory & Compliance Risks

The public health crisis involving the abuse of prescription opioid pain medication and our efforts to resolve related claims could have additional or unexpected material negative effects on our business.

Our Pharmaceutical segment distributes prescription opioid pain medications. In recent years, the abuse of prescription opioid pain medication has become a public health crisis.

A significant number of states, counties, municipalities and other public plaintiffs, have filed lawsuits against pharmaceutical manufacturers, pharmaceutical wholesale distributors (including us), retail chains and others relating to the manufacturing, marketing or distribution of prescription opioid pain medications. In July 2021, we announced that, as a result of the previously disclosed settlement framework, we and two other national distributors have negotiated a proposed settlement agreement and settlement process that, if all conditions are satisfied (including the approval of the Board of Directors), would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities (the “Proposed Settlement Agreement”). This Proposed Settlement Agreement is subject to contingencies and there is no assurance that a sufficient number of states and subdivisions will agree to the proposed settlement agreement or that the required contingencies will be satisfied. It is possible that we may fail to reach a final settlement. For more information on the proposed settlement and other opioid-related litigation matters, see Note 7 to the Consolidated Financial Statements.

A trial in the case brought by the Ohio Attorney General is scheduled to begin in September 2021 and a trial in the case brought by the Washington Attorney General is scheduled to begin in November 2021. The Ohio Attorney General has issued a press released indicating support for the Proposed Settlement Agreement; however, the Washington Attorney General has issued


40			Cardinal Health \| Fiscal 2021 Form 10-K


Risk Factors

a press release stating that Washington will not agree to the Proposed Settlement Agreement. These public announcements are not binding and there is no assurance that any state that has made a public announcement of support for the Proposed Settlement Agreement will ultimately execute the Proposed Settlement Agreement. It is also possible that, even if the Proposed Settlement Agreement becomes effective, we could have trials for lawsuits brought by other states or subdivisions as well. West Virginia subdivisions and Native American Tribes are not a part of this settlement process and we are involved in separate negotiations with these groups.

In addition to the claims addressed by the Proposed Settlement Agreement, we are also being sued by private plaintiffs, such as unions, other health and welfare funds, hospital systems, other healthcare providers and individuals alleging personal injury for the same activities and could be named as a defendant in additional lawsuits.

We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances.

The defense and resolution of current and future lawsuits and investigations are subject to uncertainty and could have a material adverse effect on our results of operations, financial condition, cash flows, liquidity, or our ability to pay dividends or repurchase our shares, beyond the amounts accrued. In addition, they could have adverse reputational or operational effects on our business.

Other legislative, regulatory or industry measures related to the public health crisis involving the abuse of prescription opioid pain medication and the distribution of these medications could affect our business in ways that we may not be able to predict. For example, several states have now adopted or proposed taxes or other fees on the sale of opioids. These laws and proposals vary in the tax amounts imposed and the means of calculation. Liabilities for taxes or assessments under any such laws could have an adverse impact on our results of operations unless we are able to mitigate them through operational changes or commercial arrangements where permitted.

Ongoing unfavorable publicity regarding the abuse or misuse of prescription opioid pain medications and the role of wholesale distributors in the supply chain of such prescription medications, as well as the continued proliferation of the opioid lawsuits, investigations, regulations and legislative actions, and unfavorable publicity in relation to those lawsuits could have a material adverse effect on our reputation or results of operations.

Our business is subject to other rigorous quality, regulatory and licensing requirements.

As described in greater detail in the "Business" section, products that we manufacture, source, distribute or market must comply with quality and regulatory requirements. Noncompliance or

concerns over noncompliance, including noncompliance by third-party contract manufacturers, may result in suspension of our ability to distribute, import, manufacture or source products, as well as product bans, recalls, safety alerts or seizures, or criminal or civil sanctions, which, in turn, could result in product liability claims and lawsuits, including class actions. In addition, it can be costly and time-consuming to obtain regulatory approvals or product registrations to market a medical device or other product, and such approvals or registrations might not be granted on a timely basis, if at all.

Also as described in greater detail in the "Business" section, our business is highly regulated in the United States, at both the federal and state level, and in foreign countries. If we fail to comply with regulatory requirements, or if allegations are made that we fail to comply, our results of operations and financial condition could be adversely affected.

To lawfully operate our businesses, we are required to obtain and hold permits, product registrations, licenses and other regulatory approvals from, and to comply with operating and security standards of, numerous governmental bodies. For example, as a wholesale distributor of controlled substances, we must hold valid DEA registrations and state-level licenses, meet various security and operating standards, and comply with the CSA. Failure to maintain or renew necessary permits, product registrations, licenses or approvals, or to comply with required standards, could have an adverse effect on our results of operations and financial condition.

We collect, handle and maintain patient-identifiable health information and other sensitive personal and financial information which are subject to federal, state and foreign laws that regulate the use and disclosure of such information. Regulations currently in place continue to evolve, and new laws in this area could further restrict our ability to collect, handle and maintain personal or patient information, or could require us to incur additional compliance costs, either of which could have an adverse impact on our results of operations. Violations of federal, state or foreign laws concerning privacy and data protection could subject us to civil or criminal penalties, breach of contract claims, costs for remediation and harm to our reputation.

We are required to comply with laws relating to healthcare fraud and abuse. The requirements of these laws are complex and subject to varying interpretations. From time to time, regulatory authorities investigate our policies or practices, and may challenge them. We are periodically subject to federal or state government investigations or qui tam actions (false claims cases initiated by private parties purporting to act on behalf of federal or state governments), which could result in civil or criminal sanctions, including the loss of licenses or the ability to participate in Medicare, Medicaid and other federal and state healthcare programs or other remedial measures. For example, the United States Attorney’s Office for the District of Massachusetts and the Department of Health and Human Services, Officer of Inspector General have been conducting an investigation related to discounts and rebates offered or provided to certain Specialty


			Cardinal Health \| Fiscal 2021 Form 10-K			41


Risk Factors

Solutions customers as a result of qui tam actions. For more information on this investigation, see Note 7 to the Consolidated Financial Statements.

Some businesses within each of our segments are Medicare-certified suppliers or participate in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program. In addition, some businesses manufacture pharmaceutical or medical products or repackage pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs. Failure to comply with applicable eligibility requirements, standards and regulations could result in civil or criminal sanctions, including the loss of our ability to participate in Medicare, Medicaid and other federal and state healthcare programs.

Industry participants, including us, rely on ethylene oxide (“EtO”) to sterilize certain medical products that we manufacture or distribute. Regulatory actions have been taken by certain environmental regulatory authorities to reduce EtO emissions during the sterilization and distribution process. If such measures become more widespread, we could experience increased costs to comply with reduced emissions standards and it is possible that we and other industry participants may be unable to effectively sterilize medical products, possibly resulting in industry-wide supply shortages or a reduction in surgical or medical procedures. Such increased costs or industry-wide reductions in surgical and medical procedures would have a negative impact on our Medical segment profit. It is also possible that these regulatory actions could adversely impact our ability to procure products to distribute, resulting in increased costs or industry supply disruptions.

Our government contracts are subject to specific procurement requirements. Failure to comply with applicable rules or regulations or with contractual or other requirements may result in monetary damages and criminal or civil penalties as well as termination of our government contracts or our suspension or debarment from government contract work.

Our global operations (including transition services in connection with divestitures) are subject to the U.S. Foreign Corrupt Practices Act ("FCPA"), the U.K. Bribery Act and similar anti-bribery laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws. If we fail to comply, or are alleged to fail to comply, with any of these laws, we could be subject to investigations or suffer civil or criminal sanctions. For example, in February 2020, we paid approximately $8.4 million to the Securities and Exchange Commission to settle charges that our internal controls were not sufficient to detect improper payments made by employees of our former China distribution business.

We could be subject to adverse changes in the tax laws or

challenges to our tax positions.

We are a large multinational corporation with operations in the United States and many foreign countries. As a result, we are subject to the tax laws of many jurisdictions.

From time to time, proposals are made in the United States and other jurisdictions in which we operate that could adversely affect our tax positions, effective tax rate or tax payments. Specific

initiatives that may impact us include possible increases in U.S. or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation at the U.S. state level on the basis of gross revenues, recommendations of the recently completed base erosion and profit shifting project undertaken by the Organization for Economic Cooperation and Development and the European Commission’s investigation into illegal state aid.

Additionally, in connection with the $5.63 billion pre-tax charge for the opioid litigation taken in the fiscal year ended June 30, 2020, and the additional $1.17 billion pre-tax charge recorded in fiscal year 2021, we recorded net tax benefits of $488 million and $228 million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment.

The U.S. tax law governing deductibility was changed by the Tax Act and the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits, or tax law could change again. The actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. See Note 7 of the "Notes to Consolidated Financial Statements" for more information regarding these matters.

In fiscal year 2021, our provision for income taxes reflects a $424 million benefit from the tax benefits of a net operating loss carryback under the CARES Act. Also as a result of this net operating loss carryback, we have filed for a U.S. federal income tax refund of $974 million. In connection with this net operating loss carryback, certain industry participants, including us, received a letter from the U.S. House of Representatives’ Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including our use of the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act. We have responded to the letter. Additionally, legislation has been proposed that would retroactively repeal the net operating loss carryback provision of the CARES Act. If these initiatives are successful, our effective tax rate could be adversely impacted.

We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions for the periods from 2011 to 2014. During fiscal year 2021, we resolved all open matters with the IRS for fiscal years 2008 to 2014, which also impacted reserves for later years. This resolution has resulted in an adjustment to our provision for income taxes. Proposed adjustments in future audits may adversely affect our effective tax rate or tax payments.


42			Cardinal Health \| Fiscal 2021 Form 10-K


Risk Factors

Changes to the U.S. healthcare environment may not be favorable to us.

Over a number of years, the U.S. healthcare industry has undergone significant changes designed to increase access to medical care, improve safety and patient outcomes, contain costs and increase efficiencies. These changes include a general decline in Medicare and Medicaid reimbursement levels, efforts by healthcare insurance companies to limit or reduce payments to pharmacies and providers, the basis for payments beginning to transition from a fee-for-service model to value-based payments and risk-sharing models, and the industry shifting away from traditional healthcare venues like hospitals and into clinics, physician offices and patients’ homes.

We expect the U.S. healthcare industry to continue to change significantly in the future. Possible changes include further reduction or limitations on governmental funding at the state or federal level, efforts by healthcare insurance companies to further limit payments for products and services or changes in legislation or regulations governing prescription pharmaceutical pricing, healthcare services or mandated benefits. These possible changes, and the uncertainty surrounding these possible changes, may adversely affect us.

Legal proceedings could adversely impact our cash flows or results of operations.

Due to the nature of our business, which includes the distribution of controlled substances and other pharmaceutical products and the sourcing, marketing and manufacturing of medical products, we regularly become involved in disputes, litigation and regulatory matters. Litigation is inherently unpredictable and the unfavorable outcome of legal proceedings could adversely affect our results of operations or financial condition.

For example, we are subject to a number of lawsuits and investigations related to the national health crisis involving the abuse of opioid pain medication as described above in the Risk Factor titled "The public health crisis involving the abuse of prescription opioid pain medication and our efforts to resolve related claims could have additional or unexpected material negative effects on our business" and in Note 7 to the "Notes to Consolidated Financial Statements."

Additionally, some of the products that we distribute or manufacture have been and may in the future be alleged to cause personal injury, subjecting us to product liability claims. For example, we are a defendant in product liability lawsuits that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava (IVC) filter products and in lawsuits alleging impurities in the active pharmaceutical ingredients in certain pharmaceutical products. In addition, product liability insurance for these types of claims is becoming more limited and may not be available to us at amounts that we historically have obtained or that we would like to obtain. It is possible that a settlement of or judgment for a product liability claim may not be covered by insurance or exceed available insurance recoveries. If this happens, and if any such settlement or judgment is in excess

of any prior accruals, our results of operations and financial condition could be adversely affected.

We also operate in an industry characterized by extensive intellectual property litigation. Patent litigation can result in significant damage awards and injunctions that could prevent the manufacture and sale of affected products or force us to make royalty payments in order to continue selling the affected products.

Business & Operational Risks

Our business and operations depend on the proper functioning of information systems, business processes, critical facilities and distribution networks.

We rely on our and third-party service providers' information systems for a wide variety of critical operations, including to obtain, rapidly process, analyze and manage data to:

•facilitate the purchase and distribution of inventory items from numerous distribution centers;

•receive, process and ship orders on a timely basis;

•manage accurate billing and collections for thousands of customers;

•process payments to suppliers;

•facilitate manufacturing and assembly of medical products; and

•generate financial information.

Our business also depends on the proper functioning of our and our suppliers' business processes, critical facilities, including our national logistics center, and our distribution networks. Our results of operations could be adversely affected if our or a service provider's business processes, information systems, critical facilities or distribution networks are disrupted (including disruption of access), are damaged or fail, whether due to physical disruptions, such as fire, natural disaster, pandemic (as they have been by the COVID-19 pandemic, as discussed above) or power outage, or due to cyber-security incidents, ransomware or other actions of third parties, including labor strikes or shortages, political unrest and terrorist attacks. Manufacturing disruptions also can occur due to regulatory action, production quality deviations, safety issues or raw material shortages or defects, or because a key product or component is manufactured at a single manufacturing facility with limited alternate facilities.

From time to time, our businesses perform business process improvements or infrastructure modernizations or use service providers for key systems and processes, such as receiving and processing customer orders, customer service and accounts payable. For example, our Pharmaceutical segment is currently engaged in a multi-year project to implement a replacement of certain finance and operating information systems and we recently transitioned certain finance processes to a third-party service provider. If any of these initiatives are not successfully or efficiently implemented or maintained, they could adversely affect our business and our internal control over financial reporting.


			Cardinal Health \| Fiscal 2021 Form 10-K			43


Risk Factors

Our business and results of operations could be adversely affected if we experience a cyber-attack or other systems breach.

Our business relies on the secure transmission, storage and hosting of patient-identifiable health information, financial information and other sensitive protected information relating to our customers, company, workforce and individuals with whom we and our customers conduct business. We have programs in place to detect, contain and respond to information security incidents. However, because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems change frequently and may be difficult to detect for long periods of time, we may be unable to anticipate these techniques or to implement adequate preventative measures. In addition, hardware, software or applications developed internally or procured from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security.

Unauthorized parties have gained access and will continue to attempt to gain access to our or a service provider's systems or facilities through fraud, trickery or other forms of deception. We have been the target of cyber attacks, including, in prior fiscal years, incidents where certain customer account information was accessed. Although we do not believe these incidents had a material impact on us, similar incidents or events in the future may negatively impact our business, reputation or financial results.

Any compromise of our or a service provider's information systems, including unauthorized access to or use or disclosure of sensitive information, could adversely impact our operations, results of operations or our ability to satisfy legal or regulatory requirements, including the EU general data protection regulation (GDPR) and those related to patient-identifiable health information and other sensitive personal and financial information as further described in the Risk Factor titled “Our business is subject to rigorous regulatory and licensing requirements,” above.

In addition, insurance for losses arising from cyber-attacks or other breaches is becoming more costly and limited and may not be available to us at amounts that we historically have obtained or that we would like to obtain. It is possible that we could incur losses that may not be covered by insurance or that would exceed available insurance recoveries. If this happens, our results of operations and financial condition could be adversely affected.

Our sales and credit concentration is significant.

CVS is a large customer that generates a significant amount of our revenue. CVS accounted for 26 percent of our fiscal 2021 revenue and 24 percent of our gross trade receivable balance at June 30, 2021. If CVS terminates the agreements due to an alleged default by us, defaults in payment or significantly reduces its purchases from us, our results of operations and financial condition could be adversely affected.

Our results of operations could be adversely impacted if we fail to manage and complete divestitures.

We regularly evaluate our portfolio of businesses to determine whether an asset or business may no longer help us meet our objectives or whether there may be a more advantaged owner for

that business. For example, we recently completed the divestiture of our Cordis business, and in the past few years, we have also divested our pharmaceutical and medical products distribution business in China and our ownership interest in naviHealth, Inc. When we decide to sell assets or a business, we may encounter difficulty finding buyers or alternative exit strategies, which could delay the achievement of our strategic objectives. We could also incur higher costs or charges than planned or incur unexpected charges and could experience greater dis-synergies than expected, which could have a negative impact on our results of operations.

Our ability to manage and complete acquisitions could impact our strategic objectives and financial condition.

An important element of our growth strategy has been to acquire other businesses that expand or complement our existing businesses. Completion of acquisitions and the integration of acquired businesses involve a number of risks, including the following: we may overpay for a business or fail to realize the synergies and other benefits we expect from the acquisition; our management’s attention may be diverted to integration efforts; we may fail to retain key personnel of the acquired business; future developments may impair the value of our purchased goodwill or intangible assets; we may face difficulties or delays establishing, integrating or combining operations and systems, including manufacturing facilities; we may assume liabilities related to legal proceedings involving the acquired business; we may face challenges retaining the customers of the acquired business; or we may encounter unforeseen internal control, regulatory or compliance issues.

Our goodwill may be impaired, which would require us to record a significant charge to earnings in accordance with generally accepted accounting principles.

U.S. GAAP requires us to test our goodwill for impairment on an annual basis, or more frequently if indicators for potential impairment exist. For our annual impairment test in fiscal 2021, the fair value of the Medical Unit (which includes the Cordis disposal group) exceeded its carrying value by approximately three percent. This testing involves estimates and significant judgments by management. Additional adverse changes in key assumptions, including current assumptions about the impact of the Cordis divestiture and the COVID-19 pandemic, including estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate or increases in tax rates, among other things, could result in a goodwill impairment in our Medical Unit. For example, if we were to increase the discount rate by a hypothetical 0.5 percent, the carrying value of our Medical Unit would have exceeded the fair value by approximately one percent in fiscal 2021.

It is also possible that we may record significant charges related to other reporting units. Any charge or charges could adversely affect our results of operations. See "Critical Accounting Policies and Sensitive Accounting Estimates" in MD&A above for more information regarding goodwill impairment testing.


44			Cardinal Health \| Fiscal 2021 Form 10-K


Risk Factors

Industry & Economic Risks

We could continue to suffer the adverse effects of competitive pressures.

As described in greater detail in the "Business" section, we operate in markets that are highly competitive and dynamic. In addition, competitive pressures in our pharmaceutical and medical segments may be increased by COVID-19, new business models, new entrants, new regulations, changes in consumer demand or general competitive dynamics. Our businesses face continued pricing pressure from these factors, which adversely affects our margins. If we are unable to offset margin reductions caused by these pricing pressures through steps such as sourcing or cost control measures, additional service offerings and sales of higher margin products, our results of operations could continue to be adversely affected.

Our Pharmaceutical segment’s profit margin could be adversely affected by changes in industry or market dynamics that we are not able to accurately predict.

In fiscal year 2021, our Pharmaceutical segment’s generics program was negatively impacted by volume declines. As has been the case for several years, the frequency, timing, magnitude and profit impact of generic pharmaceutical customer purchase volumes, pricing changes, customer contract renewals, generic pharmaceutical launches, and generic pharmaceutical manufacturer pricing changes remain uncertain as does their impact on Pharmaceutical segment profit and consolidated operating earnings. These factors have contributed to declines in some prior years and have more than offset the benefits from sourcing generic pharmaceuticals through our Red Oak Sourcing venture with CVS. If performance of our generic pharmaceutical program declines in future fiscal years and we are unable to offset the decline, our Pharmaceutical segment profit and consolidated operating earnings will be adversely affected.

With respect to branded pharmaceutical products, compensation under our contractual arrangements with manufacturers for the purchase of branded pharmaceutical products is generally based on the wholesale acquisition cost set by the manufacturer. Sales prices of branded pharmaceutical products to our customers generally are a percentage discount from wholesale acquisition cost.

Also, almost all of our distribution services agreements with branded pharmaceutical manufacturers provide that we receive fees from the manufacturers to compensate us for services we provide them. However, under certain agreements, branded pharmaceutical price appreciation, which is determined by the manufacturers also serves as a part of our compensation. In recent years, manufacturers have increased prices less than in prior years. If manufacturers, in the aggregate, change their historical approach to setting and increasing wholesale acquisition cost, decide to reduce prices, not to increase prices or to implement only small increases and we are unable to negotiate alternative ways to be compensated by manufacturers or customers for the value of our services, our margins could be adversely affected.

We depend on direct and indirect suppliers to make their products and raw materials available to us and are subject to fluctuations in costs, availability and regulatory risks associated with these products and raw materials.

We depend on others to manufacture some products that we market and distribute. Our operations are also dependent on various components, compounds, raw materials and energy supplied by others. We purchase many of these components, raw materials and energy, and source certain products from numerous suppliers in various countries. In some instances, for reasons of quality assurance, cost effectiveness, or availability, we procure certain components and raw materials from a sole supplier. Our supplier relationships could be interrupted, become less favorable to us or be terminated and the supply of these components, compounds, raw materials or products could be interrupted or become insufficient. These supply interruptions or other disruptions in manufacturing processes could be caused by events beyond our control, including natural disasters, supplier facility shut-downs, defective raw materials, the impact of epidemics or pandemics, such as COVID-19, and actions by U.S. or international governments, including export restrictions or tariffs.

In addition, due to the stringent regulatory requirements regarding the manufacture and sourcing of our products, we may not be able to quickly establish additional or replacement sources for certain components, materials or products. A sustained supply reduction or interruption, and an inability to develop alternative and additional sources for such supply, could result in lost sales, increased cost, damage to our reputation, and may have an adverse effect on our business.

Our manufacturing businesses use oil-based resins, pulp, cotton, latex and other commodities as raw materials in many products. Prices of oil and gas also affect our distribution and transportation costs. Prices of these commodities are volatile and can fluctuate significantly, causing our costs to produce and distribute our products to fluctuate. Beginning in the fourth quarter of fiscal year 2021, we have experienced higher supply chain costs, primarily related to the sourcing of certain components, compounds, raw materials and commodities. Due to competitive dynamics and contractual limitations, we may be unable to pass along cost increases through higher prices. If we cannot fully offset cost increases through other cost reductions, or recover these costs through price increases or surcharges, our results of operations could continue to be adversely affected.

Consolidation in the U.S. healthcare industry may negatively impact our results of operations.

In recent years, U.S. healthcare industry participants, including distributors, manufacturers, suppliers, healthcare providers, insurers and pharmacy chains, have consolidated or formed strategic alliances. Consolidations create larger enterprises with greater negotiating power, and also could result in the possible loss of a customer where the combined enterprise selects one distributor from two incumbents. If this consolidation trend continues, it could adversely affect our results of operations.


			Cardinal Health \| Fiscal 2021 Form 10-K			45


Risk Factors

Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency risks, could disrupt our global operations or negatively impact our financial results.

We conduct our operations in various regions of the world outside of the United States, including Europe, Asia and Latin America. Global developments can affect our business in many ways. Our global operations are affected by local economic environments, including inflation, recession and competition. Additionally, divergent or unfamiliar regulatory systems and labor markets can increase the risks and burdens of operating in numerous countries.

Our foreign operations expose us to a number of risks related to trade protection laws, tariffs, excise or other border taxes on goods sourced from certain countries or on the importation or exportation of products or raw materials. Changes or uncertainty in U.S. or international trade policies or tariffs could impact our global operations, as well as our customers and suppliers. We may be required to spend more money to source certain products or materials that we need or to manufacture certain of our products. This could adversely impact our business and results of operations.

In addition, we conduct our business in U.S. dollars and various functional currencies of our foreign subsidiaries. Changes in foreign currency exchange rates could adversely affect our financial results, which are reported in U.S. dollars. We may not be able to hedge to protect us against these exposures, and any hedges may not successfully mitigate these exposures.


46			Cardinal Health \| Fiscal 2021 Form 10-K


Properties and Legal Proceedings

Properties

In the United States, at June 30, 2021, the Pharmaceutical segment operated one national logistics center; a number of primary pharmaceutical and specialty distribution facilities as well as nuclear pharmacy and radiopharmaceutical manufacturing facilities. The Medical segment operated medical-surgical distribution, assembly, manufacturing and other operating facilities in the United States.

At June 30, 2021, our Medical segment also operated manufacturing facilities in Canada, Costa Rica, the Dominican Republic, Germany, Ireland, Japan, Malaysia, Malta, Mexico and Thailand.

Our principal executive offices are headquartered in an owned building located at 7000 Cardinal Place in Dublin, Ohio.

We consider our operating properties to be in satisfactory condition and adequate to meet our present needs. However, we regularly evaluate operating properties and may make further additions and improvements or consolidate locations as we seek opportunities to expand or enhance the efficiency of our business.


			Cardinal Health \| Fiscal 2021 Form 10-K			47


Properties and Legal Proceedings

Legal Proceedings

In addition to the proceedings described below, the legal proceedings described in Note 7 of the "Notes to Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.

In June 2019, Melissa Cohen, a purported shareholder, filed an action on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In December 2019 and January 2020, similar complaints were filed in the U.S. District Court for the Southern District of Ohio by purported shareholders, Stanley M. Malone and Michael Splaine, respectively. In January, 2020, the court consolidated the derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. The amended consolidated derivative complaint seeks, among other things, unspecified money damages against the defendants and an award of attorneys' fees. In February 2021, the court granted in part and denied in part defendants' motion to dismiss. The court dismissed the claim with respect to executive compensation but declined to dismiss the failure to monitor claim.


48			Cardinal Health \| Fiscal 2021 Form 10-K


Market for Registrant's Common Equity

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Our common shares are listed on the New York Stock Exchange under the symbol “CAH.”

At July 31, 2021 there were approximately 7,102 shareholders of record of our common shares.

We anticipate that we will continue to pay quarterly cash dividends in the future. The payment and amount of future dividends remain, however, within the discretion of our Board of Directors and will depend upon our future earnings, financial condition, capital requirements and other factors.

Issuer Purchases of Equity Securities




Period	Total Number of Shares Purchased (1)	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Programs (2)	Approximate Dollar Value of Shares That May Yet be Purchased Under the Programs (2) (in millions)
April 2021	1,311	$	60.84	—	$	743
May 2021	101	56.34		—	743
June 2021	304	57.03		—	743
Total	1,716	$	59.90	—	$	743

(1)Reflects 1,311, 101 and 304 common shares purchased in April, May and June 2021, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.

(2)On November 7, 2018, our Board of Directors approved a $1.0 billion share repurchase program that expires on December 31, 2021. As of June 30, 2021, we have $743 million authorized for share repurchases remaining under this program.


			Cardinal Health \| Fiscal 2021 Form 10-K			49


Market for Registrant's Common Equity

Five Year Performance Graph

The following line graph compares the cumulative total return of our common shares with the cumulative total return of the Standard & Poor’s Composite—500 Stock Index (the "S&P 500 Index") and the Standard & Poor's Composite—500 Healthcare Index (the "S&P 500 Healthcare Index"). The line graph assumes, in each case, an initial investment of $100 invested at the closing price on June 30, 2016, and is based on the market prices at the end of each fiscal year through and including June 30, 2021, and reinvestment of dividends. The S&P 500 Index and S&P 500 Healthcare Index investments are weighted on the basis of market capitalization at the beginning of each period.


	June 30
	2016		2017		2018		2019		2020		2021
Cardinal Health, Inc.	$	100.00	$	102.25	$	66.12	$	66.34	$	76.43	$	86.65
S&P 500 Index	100.00		117.89		134.82		148.86		160.01		225.25
S&P 500 Healthcare Index	100.00		112.47		120.46		136.11		150.95		193.09


50			Cardinal Health \| Fiscal 2021 Form 10-K


Reports

Management Reports

Evaluation of Disclosure Controls and Procedures

We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of June 30, 2021. Based on this evaluation, our principal executive officer and principal financial officer has concluded that our disclosure controls and procedures were effective as of June 30, 2021 to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.

Management’s Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act. Our internal control system is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, controls deemed effective now may become inadequate in the future because of changes in conditions, or because compliance with policies or procedures has deteriorated or been circumvented.

Management assessed the effectiveness of our internal control over financial reporting as of June 30, 2021. In making this assessment, management used the criteria established in the Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the “COSO criteria”). Based on management’s assessment and the COSO criteria, management believes that our internal control over financial reporting was effective as of June 30, 2021.

Our independent registered public accounting firm, Ernst & Young LLP, has issued a report on our internal control over financial reporting. Ernst & Young LLP’s report appears following this "Management Reports" section and expresses an unqualified opinion on the effectiveness of our internal control over financial reporting.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Pharmaceutical Segment Information Technology Initiative

The Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating information systems. During the fiscal year ended June 30, 2021, we transitioned selected processes to the new systems and expect that we will transition additional processes to the new systems throughout fiscal year 2022. If these new systems are not effectively implemented, or fail to operate as intended, it could adversely affect internal control over financial reporting.


			Cardinal Health \| Fiscal 2021 Form 10-K			51


Reports

Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting

The Shareholders and the Board of Directors of Cardinal Health, Inc.

Opinion on Internal Control over Financial Reporting

We have audited Cardinal Health, Inc. and subsidiaries’ internal control over financial reporting as of June 30, 2021, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Cardinal Health, Inc. and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of June 30, 2021, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of June 30, 2021 and 2020, the related consolidated statements of earnings/(loss), comprehensive income/(loss), shareholders' equity and cash flows for each of the three years in the period ended June 30, 2021, and the related notes and the financial statement schedule listed in the Index at Item 15(a)(2) and our report dated August 16, 2021 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying “Management’s Report on Internal Control Over Financial Reporting.” Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.


/s/ Ernst & Young LLP

Grandview Heights, Ohio
August 16, 2021


52			Cardinal Health \| Fiscal 2021 Form 10-K


Reports

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of Cardinal Health, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Cardinal Health, Inc. and subsidiaries (the Company) as of June 30, 2021 and 2020, the related consolidated statements of earnings/(loss), comprehensive income/(loss), shareholders' equity and cash flows for each of the three years in the period ended June 30, 2021, and the related notes and the financial statement schedule listed in the Index at Item 15(a)(2) (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at June 30, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2021, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of June 30, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated August 16, 2021 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.


			Medical Unit Goodwill
Description of the Matter			At June 30, 2021, goodwill related to the Company’s Medical segment, including the Medical Unit was $5.3 billion. As discussed in Note 1 to the consolidated financial statements, goodwill is tested for impairment at least annually at the reporting unit level. Auditing management’s goodwill impairment test for the Medical Unit was challenging because there is significant judgement required in determining the fair value of the reporting unit. In particular, the fair value estimate was sensitive to significant judgmental assumptions including the revenue growth rate, gross margin, distribution, selling, general and administrative expenses, and company specific risk premium, which are affected by expectations about future market or economic conditions.


			Cardinal Health \| Fiscal 2021 Form 10-K			53


Reports


How We Addressed the Matter in Our Audit			We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s goodwill impairment review process. For example, we tested controls over management’s review of significant judgmental assumptions, including the revenue growth rate, gross margin, distribution, selling, general and administrative expenses, and company specific risk premium, among other assumptions. To test the estimated fair value of the Company’s Medical Unit, we performed audit procedures that included, among others, evaluating methodologies used, involving our valuation specialists in testing the significant assumptions described above and testing the underlying data used by the Company in its analysis for completeness and accuracy. We compared the significant assumptions used by management to current industry and economic trends, recent historical performance, changes to the reporting unit’s business model, customer base or product mix and other relevant factors. We assessed the historical accuracy of management’s estimates and performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the reporting unit that would result from changes in the assumptions. We evaluated the incorporation of the applicable assumptions into the model and tested the model’s computational accuracy. In addition, we inspected the Company’s reconciliation of the fair value of all reporting units to the market capitalization of the Company and assessed the result.
			Product Liability Lawsuits
Description of the Matter			As described in Note 1 and Note 7 to the consolidated financial statements, the Company is a defendant in various product liability claims in which individuals seek damages associated with the use of Cordis OptEase and TrapEase inferior vena cava (IVC) filter products. The Company accrues for losses and defense costs related to product liability at the time a loss is probable and the amount of loss can be reasonably estimated. The methodology used by the Company to project future Cordis IVC claim costs is based largely on recent experience, including claim filing rates, indemnity severity by claim type, sales data, implant and injury to report lag patterns, and defense costs. The Company periodically reviews such estimates and records adjustments for changes in reserves in the period in which the change in estimate occurs. At June 30, 2021, the Company’s product liability reserve balance related to the Cordis IVC lawsuits totaled $524 million, net of estimated insurance recoveries. The Company believes there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, the Company has accrued the minimum amount in the range. The Company estimates the high end of the range to be approximately $1.03 billion net of estimated insurance recoveries. Auditing management’s accounting for and disclosure of loss contingencies related to the Cordis IVC product liability lawsuits was challenging due to the significant judgment required to develop the key assumptions utilized in the model and the nature of information available given the early stages of these lawsuits and the limited claims history.
How We Addressed the Matter in Our Audit			We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over management’s evaluation of the product liability litigation reserve. For example, we tested controls over management’s review of the model used to estimate the product liability reserve amount and the significant assumptions as described above used within the model. We also tested management’s controls over the completeness and accuracy of the data used in the model. To test management’s assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable, we evaluated, for example, claims data of the Company, we evaluated the legal letters obtained from internal and external legal counsel, and we discussed with internal and external legal counsel of the plaintiffs’ claims. Among other procedures we performed to test the measurement of the product liability litigation reserve, we evaluated the method of measuring the reserve for claims including analyses to determine the range of possible losses, obtained and performed audit procedures relative to the analysis, tested the accuracy and completeness of the data, and evaluated new or contrary information affecting the estimate. In addition, we involved internal actuarial specialists to assist with our procedures related to the measurement of the product liability reserve. We have also assessed the adequacy of the Company’s disclosures included in Note 7 in relation to these matters.
			Uncertain Tax Positions
Description of the Matter			As described in Note 8 to the consolidated financial statements, the Company’s unrecognized tax benefits related to its uncertain tax positions were approximately $932 million at June 30, 2021. Uncertain tax positions may arise as tax laws are subject to interpretation. The Company uses significant judgment in (1) determining if the tax position is more likely than not to be sustained upon examination, based on the technical merits of the position and (2) measuring the amount of tax benefit that qualifies for recognition. Auditing management's estimate of the amount of tax benefit related to the Company's uncertain tax positions that qualified for recognition was challenging because management's estimate required significant judgment in evaluating the technical merits of the positions, including interpretations of applicable tax laws and regulations.


54			Cardinal Health \| Fiscal 2021 Form 10-K


Reports


How We Addressed the Matter in Our Audit			We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company’s process to assess the technical merits of its uncertain tax positions, including the Company’s assessment as to whether a tax position is more likely than not to be sustained and management’s process to measure the benefit of its tax positions. We involved our international tax, transfer pricing, and national tax professionals in assessing the technical merits of certain of the Company’s tax positions. Depending on the nature of the specific tax position and, where applicable, developments with the relevant tax authorities relating thereto, our procedures included obtaining and examining the Company’s analysis. For example, we evaluated the underlying facts upon which the tax positions are based, and, where applicable, obtained the Company’s correspondence with local tax authorities. We used our knowledge of international and local income tax laws, as well as historical settlement activity, where applicable, with local income tax authorities, to evaluate the Company’s accounting for its uncertain tax positions. We evaluated developments in the applicable tax jurisdictions to assess potential effects on the Company’s positions. We analyzed the Company’s assumptions and data used to evaluate the appropriateness of the Company’s measurement of tax benefits. We have also evaluated the Company’s income tax disclosures in relation to these matters.
			Opioid Lawsuits
Description of the Matter			As discussed in Note 7 to the consolidated financial statements, the Company is a defendant in numerous lawsuits brought by certain state governments, Native American tribes, and other political subdivisions related to opioid matters. The Company accrues for losses related to legal matters at the time a loss is probable and the amount of loss can be reasonably estimated. In July 2021, the Company negotiated a global proposed settlement agreement (the “Proposed Settlement Agreement”), however, the Proposed Settlement Agreement is subject to contingencies. In addition, the Native American tribes and certain other sub-divisions are not included within the Proposed Settlement Agreement and are negotiated separately. The Company has accrued $6.73 billion pretax under the cash component of the Proposed Settlement Agreement and for negotiations with Native American tribes and other sub-divisions as of June 30, 2021. The Company is unable to reasonably estimate the liability associated with other plaintiffs that are not subject to the Proposed Settlement Agreement or other ongoing negotiations. Additionally, management is unable to estimate the range of possible loss associated with these matters. Auditing the Company’s accounting for, and disclosure of, loss contingencies related to the opioid lawsuits was challenging due to the significant judgment required to evaluate management’s assessment of the likelihood of a loss being incurred and management’s determination of whether a reasonable estimate of the range of loss can be made.
How We Addressed the Matter in Our Audit			We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the identification and evaluation of this legal contingency. For example, we tested controls over management’s review of the assessment of the probability of occurrence of a loss and whether the loss was reasonably estimable and whether the assessment considered all relevant facts. To test the Company’s assessment of the probability of a loss and whether the loss was reasonably estimable, among other procedures, we read the Proposed Settlement Agreement, requested and received internal and external legal counsel confirmation letters, met with internal counsel to discuss the status of the proceedings and negotiations of the Proposed Settlement Agreement and negotiations with other plaintiffs, and evaluated the reasonableness of management’s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable. We also assessed the adequacy and the sufficiency of the Company’s disclosures included in Note 7 in relation to these matters.


/s/ Ernst & Young LLP
We have served as the Company's auditor since 2002.
Grandview Heights, Ohio
August 16, 2021


			Cardinal Health \| Fiscal 2021 Form 10-K			55


Financial Statements

Financial Statements and Supplementary Data


			Page

Consolidated Financial Statements and Schedule:
Consolidated Statements of Earnings/(Loss) for the Fiscal Years Ended June 30, 2021, 2020 and 2019			57
Consolidated Statements of Comprehensive Income/(Loss) for the Fiscal Years Ended June 30, 2021, 2020 and 2019			58
Consolidated Balance Sheets at June 30, 2021 and 2020			59
Consolidated Statements of Shareholders’ Equity for the Fiscal Years Ended June 30, 2021, 2020, and 2019			60
Consolidated Statements of Cash Flows for the Fiscal Years Ended June 30, 2021, 2020 and 2019			61
Notes to Consolidated Financial Statements			62


56			Cardinal Health \| Fiscal 2021 Form 10-K


Financial Statements

Consolidated Statements of Earnings/(Loss)


(in millions, except per common share amounts)	2021		2020		2019
Revenue	$	162,467	$	152,922	$	145,534
Cost of products sold	155,689		146,054		138,700
Gross margin	6,778		6,868		6,834

Operating expenses:
Distribution, selling, general and administrative expenses	4,533		4,572		4,480
Restructuring and employee severance	114		122		125
Amortization and other acquisition-related costs	451		524		621
Impairments and (gain)/loss on disposal of assets, net	79		7		(488)
Litigation (recoveries)/charges, net	1,129		5,741		36
Operating earnings/(loss)	472		(4,098)		2,060

Other (income)/expense, net	(47)		(1)		15
Interest expense, net	180		238		294
Loss on early extinguishment of debt	14		16		—
(Gain)/Loss on sale of equity interest in naviHealth	2		(579)		—
Earnings/(loss) before income taxes	323		(3,772)		1,751

Provision for/(benefit from) income taxes	(289)		(79)		386
Net earnings/(loss)	612		(3,693)		1,365

Less: Net earnings attributable to noncontrolling interests	(1)		(3)		(2)
Net earnings/(loss) attributable to Cardinal Health, Inc.	$	611	$	(3,696)	$	1,363

Earnings/(loss) per common share attributable to Cardinal Health, Inc.
Basic	$	2.09	$	(12.61)	$	4.55
Diluted	2.08		(12.61)		4.53

Weighted-average number of common shares outstanding:
Basic	292		293		300
Diluted	294		293		301

The accompanying notes are an integral part of these consolidated statements.


			Cardinal Health \| Fiscal 2021 Form 10-K			57


Financial Statements

Consolidated Statements of Comprehensive Income/(Loss)


(in millions)	2021		2020		2019
Net earnings/(loss)	$	612	$	(3,693)	$	1,365

Other comprehensive income/(loss):
Foreign currency translation adjustments and other	46		3		18

Net unrealized gain/(loss) on derivative instruments, net of tax	24		(28)		(5)
Total other comprehensive income/(loss), net of tax	70		(25)		13

Total comprehensive income/(loss)	682		(3,718)		1,378

Less: comprehensive income attributable to noncontrolling interests	(1)		(3)		(2)
Total comprehensive income/(loss) attributable to Cardinal Health, Inc.	$	681	$	(3,721)	$	1,376

The accompanying notes are an integral part of these consolidated statements.


58			Cardinal Health \| Fiscal 2021 Form 10-K


Financial Statements

Consolidated Balance Sheets


	June 30
(in millions)	2021		2020
Assets
Current assets:
Cash and equivalents	$	3,407	$	2,771
Trade receivables, net	9,103		8,264
Inventories, net	14,594		13,198
Prepaid expenses and other	2,843		1,707
Assets held for sale	1,101		—
Total current assets	31,048		25,940

Property and equipment, net	2,360		2,366
Goodwill and other intangibles, net	10,094		11,275
Other assets	951		1,185
Total assets	$	44,453	$	40,766

Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable	$	23,700	$	21,374
Current portion of long-term obligations and other short-term borrowings	871		10
Other accrued liabilities	2,957		2,231
Liabilities related to assets held for sale	96		—
Total current liabilities	27,624		23,615

Long-term obligations, less current portion	5,365		6,765
Deferred income taxes and other liabilities	9,670		8,594



Shareholders’ equity:
Preferred shares, without par value:
Authorized—500 thousand shares, Issued—none	—		—
Common shares, without par value:
Authorized—755 million shares, Issued— 327 million shares at June 30, 2021 and 2020	2,806		2,789
Retained earnings	1,205		1,170
Common shares in treasury, at cost: 36 million shares and 34 million shares at June 30, 2021 and 2020, respectively	(2,186)		(2,066)
Accumulated other comprehensive loss	(34)		(104)
Total Cardinal Health, Inc. shareholders' equity	1,791		1,789
Noncontrolling interests	3		3
Total shareholders’ equity	1,794		1,792
Total liabilities and shareholders’ equity	$	44,453	$	40,766

The accompanying notes are an integral part of these consolidated statements.


			Cardinal Health \| Fiscal 2021 Form 10-K			59


Financial Statements

Consolidated Statements of Shareholders' Equity


	Common Shares					Treasury Shares			Accumulated Other Comprehensive Loss		Noncontrolling Interests		Total Shareholders’ Equity
(in millions)	Shares Issued	Amount		Retained Earnings		Shares	Amount
Balance at June 30, 2018	327	$	2,730	$	4,645	(18)	$	(1,224)	$	(92)	$	—	$	6,059
Net earnings				1,363							2		1,365
Other comprehensive income, net of tax									13				13

Employee stock plans activity, net of shares withheld for employee taxes	—	33				1	34						67
Share repurchase program activity						(11)	(600)						(600)
Dividends declared				(575)									(575)
Other		—		1		—					—		1

Balance at June 30, 2019	327	2,763		5,434		(28)	(1,790)		(79)		2		6,330
Net earnings/(loss)				(3,696)							3		(3,693)
Other comprehensive loss, net of tax									(25)				(25)

Employee stock plans activity, net of shares withheld for employee taxes	—	26				—	74						100
Share repurchase program activity						(7)	(350)						(350)
Dividends declared				(570)									(570)
Other		—		2		—					(2)		—

Balance at June 30, 2020	327	2,789		1,170		(35)	(2,066)		(104)		3		1,792
Net earnings/(loss)				611							1		612
Other comprehensive income, net of tax									70				70

Employee stock plans activity, net of shares withheld for employee taxes	—	17				3	80						97
Share repurchase program activity						(4)	(200)						(200)
Dividends declared				(576)									(576)
Other											(1)		(1)

Balance at June 30, 2021	327	$	2,806	$	1,205	(36)	$	(2,186)	$	(34)	$	3	$	1,794

The accompanying notes are an integral part of these consolidated statements.


60			Cardinal Health \| Fiscal 2021 Form 10-K


Financial Statements

Consolidated Statements of Cash Flows


(in millions)	2021		2020		2019
Cash flows from operating activities:
Net earnings/(loss)	$	612	$	(3,693)	$	1,365
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:
Depreciation and amortization	783		913		1,000
Impairments and loss on sale of other investments	—		—		3
(Gain)/Loss on sale of equity interest in naviHealth	2		(579)		—
Impairments and (gain)/loss on disposal of assets, net	79		7		(488)
Loss on early extinguishment of debt	14		16		—
Share-based compensation	89		90		82
Provision for/(benefit from) deferred income taxes	496		(961)		(83)
Provision for bad debts	65		106		88

Change in operating assets and liabilities, net of effects from acquisitions and divestitures:
(Increase)/decrease in trade receivables	(904)		82		(751)
Increase in inventories	(1,584)		(409)		(551)
Increase/(decrease) in accounts payable	2,325		(162)		1,864
Other accrued liabilities and operating items, net	452		6,550		193
Net cash provided by operating activities	2,429		1,960		2,722
Cash flows from investing activities:
Acquisition of subsidiaries, net of cash acquired	(3)		—		(82)
Additions to property and equipment	(400)		(375)		(328)
Purchase of other investments	(22)		(20)		(18)
Proceeds from sale of investments	47		886		3


Proceeds from divestitures, net of cash sold, and disposal of property and equipment	—		2		763
Net cash provided by/(used in) investing activities	(378)		493		338
Cash flows from financing activities:

Net change in short-term borrowings	—		(2)		—

Proceeds from interest rate swap terminations	18		112		—

Reduction of long-term obligations	(570)		(1,399)		(1,102)
Net tax proceeds/(withholding) from share-based compensation	8		8		(14)

Dividends on common shares	(573)		(569)		(577)
Purchase of treasury shares	(200)		(350)		(600)
Net cash used in financing activities	(1,317)		(2,200)		(2,293)
Effect of exchange rates changes on cash and equivalents	11		(13)		1
Cash reclassified to assets held for sale	(109)		—		—
Net increase in cash and equivalents	636		240		768
Cash and equivalents at beginning of period	2,771		2,531		1,763
Cash and equivalents at end of period	$	3,407	$	2,771	$	2,531
Supplemental Information:
Cash payments for interest	$	182	$	226	$	285
Cash payments for income taxes	273		368		311

The accompanying notes are an integral part of these consolidated statements.


			Cardinal Health \| Fiscal 2021 Form 10-K			61


Notes to Financial Statements

Notes to Consolidated Financial Statements

1. Basis of Presentation and Summary of Significant Accounting Policies

Cardinal Health, Inc. is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. References to “we”, “our” and similar pronouns in these consolidated financial statements are to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context otherwise requires.

Our fiscal year ends on June 30. References to fiscal 2021, 2020 and 2019 in these consolidated financial statements are to the fiscal years ended June 30, 2021, 2020 and 2019, respectively.

Basis of Presentation

Our consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.

Use of Estimates

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates, judgments and assumptions are used in the accounting and disclosure related to, among other items, allowance for doubtful accounts, inventory valuation and reserves, goodwill and other intangible asset impairment, loss contingencies (including product liability and self-insurance accruals), and income taxes. Actual amounts could ultimately differ from these estimated amounts.

Cash Equivalents

We consider liquid investments purchased with an initial maturity of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.

Receivables and Allowance for Doubtful Accounts

Trade receivables are presented net of an allowance for doubtful accounts of $242 million and $206 million at June 30, 2021 and 2020, respectively. An account is considered past due on the first

day after its due date. In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account is considered past due. We regularly monitor past due accounts and establish appropriate reserves to cover potential losses, and consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts.

We provide financing to various customers. Such financing arrangements range from 1 year to 5 years at interest rates that are generally subject to fluctuation. Interest income on these arrangements is recognized as it is earned. The financings may be collateralized, guaranteed by third parties or unsecured. Finance notes, net and related accrued interest were $63 million (current portion $7 million) and $104 million (current portion $12 million) at June 30, 2021 and 2020, respectively, and are included in other assets (current portion is included in prepaid expenses and other) in the consolidated balance sheets. Finance notes receivable allowance for doubtful accounts were $12 million and $27 million at June 30, 2021 and 2020, respectively. We estimate an allowance for these financing receivables based on historical collection rates and the credit worthiness of the customer. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts.

Concentrations of Credit Risk

We maintain cash depository accounts with major banks, and we invest in high quality, short-term liquid instruments, and in marketable securities. Our short-term liquid instruments mature within three months and we have not historically incurred any related losses.

Our trade receivables and finance notes and related accrued interest are exposed to a concentration of credit risk with certain large customers and with customers in the retail and healthcare sectors. Credit risk can be affected by changes in reimbursement and other economic pressures impacting the healthcare industry. With respect to customers in the retail and healthcare sectors, such credit risk is limited due to supporting collateral and the diversity of the customer base, including its wide geographic dispersion. We perform regular credit evaluations of our customers’ financial conditions and maintain reserves for losses through the established allowance for doubtful accounts. Historically, such losses have been within our expectations. Refer to the "Receivables and Allowance for Doubtful Accounts" section within this Note for additional information on the accounting treatment of reserves for allowance for doubtful accounts.


62			Cardinal Health \| Fiscal 2021 Form 10-K


Notes to Financial Statements

Major Customers

CVS Health Corporation ("CVS") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables. These customers are primarily serviced through our Pharmaceutical segment.

In August 2021, we extended our pharmaceutical distribution agreements with CVS through June 2027.

The following table summarizes historical percent of revenue and gross trade receivables from CVS and OptumRx:


	Percent of Revenue						Percent of Gross Trade Receivables at June 30
	2021		2020		2019		2021		2020
CVS	26	%	26	%	26	%	24	%	26	%
OptumRx	15	%	14	%	13	%	3	%	6	%

We have entered into agreements with group purchasing organizations (“GPOs”) which act as purchasing agents that negotiate vendor contracts on behalf of their members. Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue. Sales to members of these two GPOs collectively accounted for 15 percent, 16 percent and 22 percent of revenue for fiscal 2021, 2020 and 2019, respectively. Our trade receivable balances are with individual members of the GPO, and therefore no significant concentration of credit risk exists with these types of arrangements.

Inventories

A portion of our inventories (50 percent and 56 percent at June 30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These inventories are included within the core pharmaceutical distribution facilities of our Pharmaceutical segment (“distribution facilities”) and are primarily merchandise inventories. The LIFO method presumes that the most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue. We believe that the average cost method of inventory valuation provides a reasonable approximation of the current cost of replacing inventory within the distribution facilities. As such, the LIFO reserve is the difference between (a) inventory at the lower of LIFO cost or market and (b) inventory at replacement cost determined using the average cost method of inventory valuation.

At June 30, 2021 and 2020, respectively, inventories valued at LIFO cost were $565 million and $411 million higher than the average cost value. We do not record inventories in excess of replacement cost. As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.

Our remaining inventory, including inventory in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value. Net realizable value is defined as the estimated selling prices and estimated sales demand in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Due to the unprecedented demand for

certain personal protective equipment as a result of COVID-19, our Medical segment manufactured and sourced inventory at higher costs than in periods prior to COVID-19. Personal protective equipment ("PPE") refers to protective clothing, medical and non-medical grade gloves, face shields, face masks and other equipment designed to protect the wearer from injury or the spread of infection or illness. As selling prices and customer demand have decreased compared to the peak of COVID-19, we recorded a reserve of $197 million, primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value.

Cash Discounts

Manufacturer cash discounts are recorded as a component of inventory cost and recognized as a reduction of cost of products sold as inventory is sold.

Property and Equipment

Property and equipment are carried at cost less accumulated depreciation. Property and equipment held for sale are recorded at the lower of cost less accumulated depreciation before the decision to dispose of the asset was made or fair value less cost to sell. When certain events or changes in operating conditions occur, an impairment assessment may be performed on the recoverability of the carrying amounts.

Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which are depreciated over the terms of their respective leases. We generally use the following range of useful lives for our property and equipment categories: buildings and improvements—3 to 39 years; machinery and equipment—3 to 20 years; and furniture and fixtures—3 to 7 years. We recorded depreciation and amortization expense of $377 million, $405 million and $455 million for fiscal 2021, 2020 and 2019, respectively.

The following table presents the components of property and equipment, net at June 30:


(in millions)	2021		2020
Land, building and improvements	$	2,359	$	2,185
Machinery and equipment	3,093		3,008
Furniture and fixtures	136		138
Total property and equipment, at cost	5,588		5,331
Accumulated depreciation and amortization	(3,228)		(2,965)
Property and equipment, net	$	2,360	$	2,366

Repairs and maintenance expenditures are expensed as incurred. Interest on long-term projects is capitalized using a rate that approximates the weighted-average interest rate on long-term


			Cardinal Health \| Fiscal 2021 Form 10-K			63


Notes to Financial Statements

obligations, which was 3 percent at June 30, 2021. The amount of capitalized interest was immaterial for all periods presented.

Goodwill and Other Intangible Assets

Purchased goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment annually or when indicators of impairment exist.

Purchased goodwill is tested for impairment at least annually. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. There is an option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the quantitative goodwill impairment test. We have elected to bypass the qualitative assessment for our annual goodwill impairment test in the current year. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount.

Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit.

We have two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. These operating segments are comprised of divisions (components), for which discrete financial information is available. Components are aggregated into reporting units for purposes of goodwill impairment testing to the extent that they share similar economic characteristics. Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (“Medical Unit”); and Cardinal Health at-Home Solutions division.

Fair value can be determined using market, income or cost-based approaches. Our determination of estimated fair value of the reporting units is based on a combination of the income-based and market-based approaches. Under the income-based approach, we use a discounted cash flow model in which cash flows anticipated over several future periods, plus a terminal value at the end of that time horizon, are discounted to their present value using an appropriate risk-adjusted rate of return. We use our internal forecasts to estimate future cash flows, which we believe are consistent with those of a market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit. Actual results may differ materially from those used in our forecasts. We use discount rates that are commensurate with the risks and uncertainty inherent in the respective reporting units and in our internally-developed forecasts. Discount rates used in our reporting unit valuations ranged from 8.5 percent to 11.5 percent. Under the market-based guideline public company method, we determine fair value by comparing our reporting units to similar businesses or guideline companies whose securities are actively traded in public markets. We also use the guideline transaction method to

determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units. To further confirm fair value, we compare the aggregate fair value of our reporting units to our total market capitalization. Estimating the fair value of reporting units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results. The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment.

The impairment test for indefinite-lived intangibles other than goodwill involves first assessing qualitative factors to determine if it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount. If so, then a quantitative test is performed to compare the estimated fair value of the indefinite-lived intangible asset to the respective asset's carrying amount. Our qualitative evaluation requires the use of estimates and significant judgments and considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.

Intangible assets with finite lives, primarily customer relationships; trademarks, trade names and patents; and developed technology, are amortized using a combination of straight-line and accelerated methods based on the expected cash flows from the asset over their estimated useful lives. We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group. Actual results may differ materially from those used in our forecasts.

Assets Held for Sale

We classify assets and liabilities (the “disposal group”) as held for sale when management commits to a plan to sell the disposal group in its present condition and at a price that is reasonable in relation to its current fair value. We also consider whether an active program to locate a buyer has been initiated and if it is probable that the sale will occur within one year without significant changes to the plan to sell. Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization.


64			Cardinal Health \| Fiscal 2021 Form 10-K


Notes to Financial Statements

lawsuits related to inferior vena cava filters in the U.S. and Canada as described in Note 7 of the “Notes to Consolidated Financial Statements.” The transaction closed on August 2, 2021. See Note 2 for additional information.

Investments

Investments in non-marketable equity securities are accounted for under the fair value, equity or net asset value method of accounting and are included in other assets in the consolidated balance sheets. For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which we can exercise significant influence but do not control, we use the equity method of accounting. Our share of the earnings and losses are recorded in other (income)/expense, net in the consolidated statements of earnings/(loss). We monitor our investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.

Vendor Reserves

In the ordinary course of business, our vendors may dispute deductions taken against payments otherwise due to them or assert other disputes. These disputes are researched and resolved based upon the findings of the research performed. At any given time, there are outstanding items in various stages of research and resolution. In determining appropriate reserves for areas of exposure with our vendors, we assess historical experience and current outstanding claims. We have established various levels of reserves based on the type of claim and status of review. Though the claim types are relatively consistent, we periodically refine our methodology by updating the reserve estimate percentages to reflect actual historical experience. The ultimate outcome of certain claims may be different than our original estimate and may require an adjustment. Adjustments to vendor reserves are included in cost of products sold. In addition, the reserve balance will fluctuate due to variations of outstanding claims from period-to-period, timing of settlements and specific vendor issues, such as bankruptcies. Vendor reserves were $77 million at both June 30, 2021 and 2020, excluding third-party returns. See Third-Party Returns section within this Note for a description of third-party returns.

Distribution Services Agreement and Other Vendor Fees

Our Pharmaceutical segment recognizes fees received from distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors’ inventory when those fees have been earned and we are entitled to payment. Since the benefit provided to a vendor is related to the purchase and distribution of the vendor’s inventory, we recognize the fees as a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold.

Loss Contingencies and Self-Insurance

Loss Contingencies

We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.

In connection with the opioid litigation as described further in the Note 7, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020 respectively which were retained at Corporate. In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement, subject to certain conditions and contingencies. There is no assurance that the contingencies to the proposed settlement agreement will be satisfied.

We develop and periodically update reserve estimates for the Cordis inferior vena cava ("Cordis IVC") claims, including those received to date and expected to be received in the future and related costs. To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated indemnity severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs.

Self-Insurance

We also self-insure for employee healthcare, general liability, certain product liability matters, auto liability, property and workers' compensation. Self-insurance accruals include an estimate for expected settlements or pending claims, defense costs, administrative fees, claim adjustment costs and an estimate for claims incurred but not reported.

Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies and other liabilities is highly subjective and requires judgments about future events. We regularly review contingencies and our self-insurance accruals to determine whether our accruals and related disclosures are adequate. Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.

The amount of ultimate loss may differ materially from these estimates. We recognize these estimated loss contingencies, income from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss). See Note 7 for additional information regarding loss contingencies and product liability lawsuits.

Guarantees

In the ordinary course of business, we agree to indemnify certain other parties under acquisition and disposition agreements, customer agreements, intellectual property licensing agreements, and other agreements. Such indemnification obligations vary in scope and, when defined, in duration. In many cases, a maximum obligation is not explicitly stated, and therefore the overall maximum amount of the liability under such indemnification obligations cannot be reasonably estimated. Where appropriate, such indemnification obligations are recorded as a liability. Historically, we have not, individually or in the aggregate, made


			Cardinal Health \| Fiscal 2021 Form 10-K			65


Notes to Financial Statements

payments under these indemnification obligations in any material amounts. In certain circumstances, we believe that existing insurance arrangements, subject to the general deduction and exclusion provisions, would cover portions of the liability that may arise from these indemnification obligations. In addition, we believe that the likelihood of a material liability being triggered under these indemnification obligations is not probable.

From time to time we enter into agreements that obligate us to make fixed payments upon the occurrence of certain events. Such obligations primarily relate to obligations arising under acquisition transactions, where we have agreed to make payments based upon the achievement of certain financial performance measures by the acquired business. Generally, the obligation is capped at an explicit amount. There were no material obligations at June 30, 2021.

Income Taxes

We account for income taxes using the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in the respective jurisdictions in which we operate. We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized. The realizability of deferred tax assets depends on our ability to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence.

Deferred taxes for non-U.S. liabilities are not provided on the unremitted earnings of subsidiaries outside of the United States when it is expected that these earnings are indefinitely reinvested.

We operate in a complex multinational tax environment and are subject to tax treaty arrangements and transfer pricing guidelines for intercompany transactions that are subject to interpretation. Uncertainty in a tax position may arise as tax laws are subject to interpretation.

Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.

See Note 8 for additional information regarding income taxes.

Other Accrued Liabilities

Other accrued liabilities represent various current obligations, including certain accrued operating expenses and taxes payable.

Noncontrolling Interests

Noncontrolling interests represent the portion of net earnings, comprehensive income and net assets that is not attributable to Cardinal Health, Inc.

Share-Based Compensation

Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value of the awards. The fair value of restricted share units and performance share units is determined by the grant date market price of our common shares. The fair value of stock options is determined on the grant date using a lattice valuation model. The compensation expense associated with nonvested performance share units is dependent on our periodic assessment of the probability of the targets being achieved and our estimate, which may vary over time, of the number of shares that ultimately will be issued. The compensation expense recognized for share-based awards is net of estimated forfeitures and is recognized ratably over the service period of the awards. All income tax effects of share-based awards are recognized in the consolidated statements of earnings/(loss) as awards vest or are settled. We classify share-based compensation expense in distribution, selling, general and administrative ("SG&A") expenses to correspond with the same line item as the majority of the cash compensation paid to employees. If awards are modified in connection with a restructuring activity, the incremental share-based compensation expense is classified in restructuring and employee severance. See Note 14 for additional information regarding share-based compensation.

Dividends

We paid cash dividends per common share of $1.94, $1.92 and $1.91 in fiscal 2021, 2020 and 2019, respectively.

Revenue Recognition

We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers.

Revenue in both segments is primarily related to the distribution of pharmaceutical and medical products, which include both manufactured and sourced products, and we recognize at a point in time when title transfers to customers and we have no further obligation to provide services related to such merchandise. Service revenues are recognized over the period that services are provided to the customer. Revenues derived from services are not material for either segment for all periods presented.

We are generally the principal in a transaction, therefore our revenue is primarily recorded on a gross basis. When we are a principal in a transaction, we have determined that we control the ability to direct the use of the product or service prior to transfer to a customer, are primarily responsible for fulfilling the promise to provide the product or service to our customer, have discretion in establishing prices, and ultimately control the transfer of the product or services provided to the customer.

Sales Returns and Allowances

Revenue is recorded net of sales returns and allowances. Revenues are measured based on the amount of consideration that we expect to receive, reduced by estimates for return allowances, discounts, rebates and other variable consideration. Sales returns are recorded based on estimates using historical


66			Cardinal Health \| Fiscal 2021 Form 10-K


Notes to Financial Statements

data. Our customer return policies generally require that the product be physically returned, subject to restocking fees. We only allow customers to return products for credit in a condition suitable to be added back to inventory and resold at full value (“merchantable product”) or returned to vendors for credit. Product returns are generally consistent throughout the year and typically are not specific to any particular product or customer.

We accrue for estimated sales returns and allowances at the time of sale based upon historical customer return trends, margin rates and processing costs. Our accrual for sales returns is reflected as a reduction of revenue and cost of products sold for the sales price and cost, respectively. At June 30, 2021 and 2020, the accrual for estimated sales returns and allowances was $689 million and $495 million, respectively, which is reflected in trade receivables, net and inventories, net in the consolidated balance sheets. Sales returns and allowances were $2.6 billion, $2.3 billion and $2.2 billion, for fiscal 2021, 2020 and 2019, respectively, and the net impact on net earnings/(loss) in the consolidated statements of earnings/(loss) was immaterial in fiscal 2021, 2020 and 2019.

Third-Party Returns

We generally do not accept non-merchantable pharmaceutical product returns from our customers, so many of our customers return non-merchantable pharmaceutical products to the manufacturer through third parties. Since our customers generally do not have a direct relationship with manufacturers, our vendors pass the value of such returns to us (usually in the form of an accounts payable deduction). We, in turn, pass the value received to our customer. In certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor. Although we believe we have satisfactory protections, we could be subject to claims from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict with our contractual terms with our customers. We have maintained reserves for some of these situations based on their nature and our historical experience with their resolution.

Shipping and Handling

Shipping and handling costs are primarily included in SG&A expenses in our consolidated statements of earnings/(loss) and include all delivery expenses as well as all costs to prepare the product for shipment to the end customer. Shipping and handling costs were $634 million, $620 million and $622 million, for fiscal 2021, 2020 and 2019, respectively.

Restructuring and Employee Severance

Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance (including rationalizing headcount or other significant changes in personnel) and realigning operations (including realignment of the management structure in response to changing market conditions). Also included within restructuring and employee severance are

employee severance costs that are not incurred in connection with a restructuring activity. See Note 3 for additional information regarding our restructuring activities.

Amortization and Other Acquisition-Related Costs

We classify certain costs incurred in connection with acquisitions as amortization and other acquisition-related costs in our consolidated statements of earnings/(loss). These costs consist of amortization of acquisition-related intangible assets, transaction costs, integration costs and changes in the fair value of contingent consideration obligations. Transaction costs are incurred during the initial evaluation of a potential acquisition and primarily relate to costs to analyze, negotiate and consummate the transaction as well as due diligence activities. Integration costs relate to activities required to combine the operations of an acquired enterprise into our operations and, in the case of the Cordis and Patient Recovery businesses, to stand-up the systems and processes needed to support an expanded geographic footprint. We record changes in the fair value of contingent consideration obligations relating to acquisitions as income or expense in amortization and other acquisition-related costs. See Note 4 for additional information regarding amortization of acquisition-related intangible assets.

Translation of Foreign Currencies

Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign subsidiaries into U.S. dollars are accumulated in shareholders’ equity through accumulated and other comprehensive loss ("AOCI") utilizing period-end exchange rates. Revenues and expenses of these foreign subsidiaries are translated using average exchange rates during the year.

The foreign currency translation gains/(losses) included in AOCI at June 30, 2021 and 2020 are presented in Note 11. Foreign currency transaction gains and losses for the period are included in the consolidated statements of earnings/(loss) in the respective financial statement line item.

Interest Rate, Currency and Commodity Risk

All derivative instruments are recognized at fair value on the consolidated balance sheets and all changes in fair value are recognized in net earnings or shareholders’ equity through AOCI, net of tax.

For contracts that qualify for hedge accounting treatment, the hedge contracts must be effective at reducing the risk associated with the exposure being hedged and must be designated as a hedge at the inception of the contract. Hedge effectiveness is assessed periodically. Any contract not designated as a hedge, or so designated but ineffective, is adjusted to fair value and recognized immediately in net earnings. If a fair value or cash flow hedge ceases to qualify for hedge accounting treatment, the contract continues to be carried on the balance sheet at fair value until settled and future adjustments to the contract’s fair value are recognized immediately in net earnings. If a forecasted transaction is probable not to occur, amounts previously deferred in AOCI are recognized immediately in net earnings. Interest payments


			Cardinal Health \| Fiscal 2021 Form 10-K			67


Notes to Financial Statements

received from the cross currency swap are excluded from the net investment hedge effectiveness assessment and are recorded in interest expense, net in the consolidated statements of earnings/(loss).

See Note 10 for additional information regarding our derivative instruments, including the accounting treatment for instruments designated as fair value, cash flow, net investment and economic hedges.

Fair Value Measurements

Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are:

Level 1 - Observable prices in active markets for identical assets and liabilities.

Level 2 - Observable inputs other than quoted prices in active markets for identical assets and liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.

See Note 9 for additional information regarding fair value measurements.

Recently Adopted Financial Accounting Standards

Financial Instruments - Credit Losses

In June 2016, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our consolidated financial statements.

Recently Issued Financial Accounting Standards Not Yet Adopted

We address the adoption impacts of recently issued accounting standards by the FASB on the our consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2020 Form 10-K. There were no accounting

standards issued in fiscal 2021 that will have a material impact on our consolidated financial statements.

2. Divestitures and Acquisitions

Divestitures

Cordis Assets Held for Sale

On March 12, 2021, we signed a definitive agreement with Hellman & Friedman to sell our Cordis business for gross proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and certain liabilities. The transaction closed on August 2, 2021 and we received proceeds of $927 million, net of cash transferred. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in Note 7.

Upon signing the agreement, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale. In connection with the divestiture, we allocated $388 million of goodwill from the Medical Unit (within our Medical Segment) to the Cordis disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained. We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations.

At June 30, 2021, the book value of the disposal group exceeded its fair value less costs to sell. Accordingly, we recognized a $60 million pre-tax write-down on the disposal group in impairments and (gain)/loss on disposal of assets in our consolidated statement of earnings/(loss). This write-down includes a $3 million loss related to currency translation adjustments in accumulated other comprehensive loss. We recorded a net tax expense of $9 million associated with the impact of the write-down and the required tax adjustments related to held for sale accounting.

The following table presents information related to the assets and liabilities that were classified as held for sale at June 30, 2021 related to the Cordis divestiture in the consolidated balance sheets:


(in millions)	June 30, 2021
Cash and equivalents	$	109
Inventories, net	164
Property and equipment, net	90
Goodwill and other intangibles, net	778
Other assets	10
Write-down of assets held for sale	(60)
Total assets held for sale	$	1,091

Other accrued liabilities	$	61
Deferred income taxes and other liabilities	34
Total liabilities related to assets held for sale	$	95


68			Cardinal Health \| Fiscal 2021 Form 10-K


Notes to Financial Statements

naviHealth

In August 2018, we sold our majority ownership interest in naviHealth, which operated within our Medical segment in exchange for cash proceeds of $737 million (after adjusting for certain fees and expenses) and a noncontrolling equity interest in a partnership that owned naviHealth. We also had certain call rights to reacquire naviHealth.

As a result of this divestiture, during the fiscal year ended June 30, 2019, we recognized a pre-tax gain of $508 million in impairments and (gain)/loss on disposal of assets in our consolidated statements of earnings/(loss). This gain included our initial recognition of an equity method investment for $358 million and the derecognition of redeemable noncontrolling interests of $12 million. The fiscal 2019 tax expense as a result of this transaction was $130 million. We determined that the sale of the naviHealth business did not meet the criteria to be classified as discontinued operations.

In May 2020 we sold the remainder of our noncontrolling equity interest in a partnership that owned naviHealth. We recognized a pre-tax gain of $579 million from this disposal in gain on sale of equity interest in naviHealth in our consolidated statements of earnings/(loss) during fiscal year 2020.

Our proportionate share of naviHealth’s results, which was recorded in other (income)/expense, net in the consolidated statements of earnings/(loss), was income of $2 million and a loss of $10 million during fiscal 2020 and 2019, respectively.

Acquisitions

We did not complete any acquisitions during fiscal 2020. While we completed several small acquisitions during fiscal 2021 and 2019, the pro forma results of operations and the results of operations for acquired businesses since the acquisition dates have not been separately disclosed because the effects were not significant compared to the consolidated financial statements, individually or in the aggregate. The cash paid for these acquisitions, net of cash acquired was $3 million and $82 million for fiscal 2021 and 2019, respectively.

3. Restructuring and Employee Severance

The following tables summarize restructuring and employee severance costs:


(in millions)	2021		2020		2019
Employee-related costs	$	53	$	66	$	95
Facility exit and other costs	61		56		30
Total restructuring and employee severance	$	114	$	122	$	125

Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of professional, project management and other service fees to support divestitures, vendor transition fees, accelerated depreciation, lease costs associated with vacant facilities, equipment relocation costs, project consulting fees, costs

associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.

In fiscal 2021, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of our Cordis business. In fiscal 2020 and 2019, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures.

The following table summarizes activity related to liabilities associated with restructuring and employee severance:


(in millions)	Employee- Related Costs		Facility Exit and Other Costs		Total
Balance at June 30, 2019	$	64	$	8	$	72
Additions	85		24		109
Payments and other adjustments	(81)		(4)		(85)
Balance at June 30, 2020	68		28		96
Additions	49		26		75
Payments and other adjustments	(64)		(28)		(92)
Balance at June 30, 2021	$	53	$	26	$	79

4. Goodwill and Other Intangible Assets

Goodwill

The following table summarizes the changes in the carrying amount of goodwill by segment and in total:


(in millions)	Pharmaceutical (1)		Medical (2)		Total
Balance at June 30, 2019	$	2,663	$	5,715	$	8,378
Goodwill acquired, net of purchase price adjustments	(5)		—		(5)
Foreign currency translation adjustments and other	(1)		(15)		(16)



Balance at June 30, 2020	2,657		5,700		8,357
Goodwill acquired, net of purchase price adjustments	2		—		2
Foreign currency translation adjustments and other	—		18		18
Cordis goodwill reclassified to assets held for sale	—		(388)		(388)
Balance at June 30, 2021	$	2,659	$	5,330	$	7,989

(1) At June 30, 2021 and 2020, the Pharmaceutical segment accumulated goodwill impairment loss was $829 million.

(2) At June 30, 2021 and 2020, the Medical segment accumulated goodwill impairment loss was $1.4 billion.

In connection with the divestiture of our Cordis business, during fiscal 2021 we allocated and reclassified $388 million of goodwill from the Medical Unit (within our Medical Segment) to the Cordis disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained, discussed further in Note 2.


			Cardinal Health \| Fiscal 2021 Form 10-K			69


Notes to Financial Statements

Other Intangible Assets

The following tables summarize other intangible assets by class at June 30:


	2021
(in millions)	Gross Intangible		Accumulated Amortization		Net Intangible		Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents	$	12	$	—	$	12	N/A
Total indefinite-life intangibles	12		—		12		N/A
Definite-life intangibles:
Customer relationships	3,330		1,989		1,341		11
Trademarks, trade names and patents	551		328		223		9
Developed technology and other	1,035		506		529		10
Total definite-life intangibles	4,916		2,823		2,093		10
Total other intangible assets	$	4,928	$	2,823	$	2,105	N/A


	2020
(in millions)	Gross Intangible		Accumulated Amortization		Net Intangible
Indefinite-life intangibles:
IPR&D, trademarks and other	$	23	$	—	$	23
Total indefinite-life intangibles	23		—		23
Definite-life intangibles:
Customer relationships	3,554		1,828		1,726
Trademarks, trade names and patents	673		341		332
Developed technology and other	1,604		767		837
Total definite-life intangibles	5,831		2,936		2,895
Total other intangible assets	$	5,854	$	2,936	$	2,918

Total amortization of intangible assets was $428 million, $512 million and $531 million for fiscal 2021, 2020 and 2019, respectively. The estimated annual amortization for intangible assets for fiscal 2022 through 2026 is as follows: $315 million, $287 million, $264 million, $238 million and $212 million.


70			Cardinal Health \| Fiscal 2021 Form 10-K


Notes to Financial Statements

5. Leases

Our operating leases are primarily for corporate offices, distribution facilities, vehicles, and equipment. We determine if an arrangement is a lease at its inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of the asset. Our lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.

Beginning July 1, 2019, operating lease right-of-use assets and corresponding operating lease liabilities are recognized in our consolidated balance sheets at lease commencement date based on the present value of lease payments over the lease term. Operating lease expense for operating lease assets is recognized on a straight-line basis over the lease term. As most of our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. We use the implicit rate if it is readily determinable.

Our lease agreements contain lease components and non-lease components. For all asset classes, we have elected to account for both of these components as a single lease component. We also, from time to time, sublease portions of our real estate property, resulting in sublease income. Sublease income and the related assets and cash flows are not material to the consolidated financial statements at or for the fiscal years ended June 30, 2021 and 2020.

We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. Short-term lease expense recognized in fiscal 2021 and 2020 was not material. In addition, upon adoption of the new lease standard, we elected the package of three practical expedients permitted under the transition guidance, which include the carry forward of our leases without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs.

Our leases have remaining lease terms from less than 1 year up to approximately 21 years. Our lease terms may include options to extend or terminate the lease when it is reasonably certain and there is a significant economic incentive to exercise that option.

The following table summarizes the components of lease cost:



(in millions)	2021		2020
Operating lease cost	$	119	$	134

Finance lease cost	16		13



Variable lease cost	24		17

Total lease cost	$	159	$	164

Variable lease cost primarily includes payments for property taxes, maintenance and insurance. Our rental expense relating to operating leases was $153 million in fiscal 2019.

The following table summarizes supplemental balance sheet and other information related to leases at June 30:


(in millions)	2021			2020
Operating Leases
Operating lease right-of-use assets	$	460		$	426

Current portion of operating lease liabilities	105			104
Long-term operating lease liabilities	374			341
Total operating lease liabilities	479			445

Finance Leases
Finance lease right-of-use assets	63			33

Current portion of finance lease liabilities	19			9
Long-term finance lease liabilities	45			25
Total finance lease liabilities	$	64		$	34

Weighted-average remaining lease term (years)
Operating leases	6.5 years			6.4 years
Finance leases	4.2 years			4.3 years

Weighted-average discount rate
Operating leases	2.9		%	2.9		%
Finance leases	1.5		%	2.4		%

Operating leases are included in other assets, other accrued liabilities, and deferred income taxes and other liabilities in our consolidated balance sheet. Finance leases are included in property and equipment, net, current portion of long-term obligations and other short-term borrowings, and long-term obligations, less current portion in our consolidated balance sheet.

The following tables summarizes supplemental cash flow information related to leases:



(in millions)	2021		2020
Cash paid for lease liabilities:
Operating cash flows paid for operating leases	$	115	$	125

Financing cash flows paid for finance leases	15		7
Non-cash right-of-use assets obtained in exchange for lease obligations:
New operating leases	138		150
New finance leases	45		40
Amended lease standard adoption impact as of July 1, 2019 (1)	—		400

(1)Includes the effect of $22 million from reclassifying deferred rent as an offset to the lease right-of-use asset in accordance with the transition guidance.


			Cardinal Health \| Fiscal 2021 Form 10-K			71


Notes to Financial Statements

Future lease payments under non-cancellable leases as of June 30, 2021 were as follows:


(in millions)	Operating Leases		Finance Leases		Total

2022	$	116	$	20	$	136
2023	93		20		113
2024	72		14		86
2025	65		8		73
2026	50		3		53
Thereafter	141		5		146
Total future lease payments	537		70		607
Less: leases not yet commenced (1)	3		—		3
Less: imputed interest	55		6		61
Total lease liabilities	$	479	$	64	$	543

(1)As of June 30, 2021, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the consolidated balance sheet.

6. Long-Term Obligations and Other Short-Term Borrowings

The following table summarizes long-term obligations and other short-term borrowings at June 30:


(in millions) (1)	2021		2020


2.616% Notes due 2022	$	572	$	834
3.2% Notes due 2022	—		236
Floating Rate Notes due 2022	281		321
3.2% Notes due 2023	564		576
3.079% Notes due 2024	794		809
3.5% Notes due 2024	410		413
3.75% Notes due 2025	524		529
3.41% Notes due 2027	1,216		1,215
4.6% Notes due 2043	341		340
4.5% Notes due 2044	342		342
4.9% Notes due 2045	441		441
4.368% Notes due 2047	560		560
7.0% Debentures due 2026	124		124
Other Obligations	67		35
Total	6,236		6,775
Less: current portion of long-term obligations and other short-term borrowings	871		10
Long-term obligations, less current portion	$	5,365	$	6,765

(1) Maturities are presented on a calendar year basis.

Maturities of existing long-term obligations and other short-term borrowings for fiscal 2022 through 2026 and thereafter are as follows: $872 million, $584 million, $808 million, $418 million, $525 million and $3.0 billion.

Long-Term Debt

All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. The 7.0% Debentures represent unsecured obligations of Allegiance Corporation (a wholly-owned subsidiary), which Cardinal Health, Inc. has guaranteed. None of these obligations are subject to a sinking fund and the Allegiance obligations are not redeemable prior to maturity. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $23.7 billion and $21.4 billion at June 30, 2021 and 2020, respectively.

During fiscal 2020, we redeemed $500 million aggregate principle amount of 4.625% Notes due December 2020 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with the redemption, we recorded a $7 million loss on early extinguishment of debt. We also early repurchased $247 million of the 2.616% Notes due 2022, $11 million of the 3.2% Notes due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the 3.41% Notes due 2027, $6 million of the 4.6% Notes due 2043, $5 million of the 4.9% Notes due 2045, and $35 million of the 4.368% Notes due 2047. In connection with the early debt repurchases, we recognized a $9 million loss on early extinguishment of debt. We also repaid the full principal of the $450 million 2.4% Notes due 2019 as they became due.

During fiscal 2019, we repurchased $67 million of the 2.616% Notes due 2022, $1 million of the 3.2% Notes due 2022, 8 million of the Floating Rate Notes due 2022, and $24 million of the 3.41% Notes due 2027 for a total of $100 million. The loss on early extinguishment of debt in connection with these early repurchases was immaterial. We also repaid the full principal of the $1.0 billion 1.948% Notes due 2019 as they became due.

The redemptions and repurchases were paid for with available cash and other short-term borrowings.

On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on September 15, 2021 at an expected redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.


72			Cardinal Health \| Fiscal 2021 Form 10-K


Notes to Financial Statements

If we undergo a change of control, as defined in the notes, and if the notes receive specified ratings below investment grade by each of Standard & Poors Ratings Services, Moody’s Investors Services and Fitch Ratings, any holder of the notes, excluding the debentures, can require with respect to the notes owned by such holder, or we can offer, to repurchase the notes at 101% of the principal amount plus accrued and unpaid interest.

Other Financing Arrangements

In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility.

In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors.

At June 30, 2021 and 2020, we had no amounts outstanding under the revolving credit facility; however, availability was reduced by outstanding letters of credit of $1 million at both June 30, 2021 and 2020.

Under our committed receivables sales facility program, we had a maximum amount outstanding of $200 million and an immaterial daily amount outstanding during fiscal 2021. We had no amounts outstanding as of June 30, 2021 under the committed receivables sales facility program; however, availability was reduced by outstanding standby letters of credit of $31 million and $29 million at June 30, 2021 and 2020, respectively.

We had no amounts outstanding under the commercial paper program as of June 30, 2021 and 2020.

We also maintain other short-term credit facilities and an unsecured line of credit that allowed for borrowings up to $6 million at both June 30, 2021 and 2020. The $67 million and $35 million balance of other obligations at June 30, 2021 and 2020, respectively, consisted of finance leases and short-term borrowings.


			Cardinal Health \| Fiscal 2021 Form 10-K			73


Notes to Financial Statements

7. Commitments, Contingent Liabilities and Litigation

Commitments

Generic Sourcing Venture with CVS Health Corporation ("CVS Health")

In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement. These payments are included as purchase obligations and other payments in the Contractual Obligations section of MD&A.

Contingencies

New York Opioid Stewardship Act

In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.

The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. If the U.S. Supreme Court declines to take the case, or if it ultimately upholds the Second Circuit's ruling, New York State would likely seek to collect amounts allegedly owed under the OSA.

We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41 million for calendar years 2017 and 2018 in the fiscal year ended June 30, 2021 based on the probable estimated payment amount, which is our best estimate of the OSA payments probable at June 30, 2021.

Legal Proceedings

We become involved from time to time in disputes, litigation and regulatory matters.

From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions

have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.

From time to time, we become aware through employees, internal audits or other parties of possible product quality, regulatory or compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.

We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.

We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.

We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.

We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our consolidated statements of earnings/(loss).

Opioid Lawsuits and Investigations

Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,300 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well


74			Cardinal Health \| Fiscal 2021 Form 10-K


Notes to Financial Statements

as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.

States & Political Subdivisions

Approximately 2,900 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the “MDL”).

In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities.

In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). We continued to build out the Settlement Framework and to negotiate the terms of the settlement with the leadership group and other representatives of states and political subdivisions.

In July, 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement (the “Proposed Settlement Agreement”) and settlement process that, if all conditions are satisfied, would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups. The settlement process does not contemplate participation by any non-governmental or non-political entities or individuals. In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with the State of New York and its participating subdivisions. If the Proposed Settlement Agreement becomes effective, New York and its participating subdivisions will become a part of it.

The Proposed Settlement Agreement is subject to contingencies and will not become effective unless and until the three distributors each make separate independent determinations that (1) following a sign-on period, a sufficient number of states have agreed to the Proposed Settlement Agreement (the “Settling States”); and, subsequently, (2) following a notice period, that a sufficient number of states and political subdivisions, including those that have not sued, have agreed to the Agreement (or otherwise had their claims foreclosed) to proceed to effectiveness. Prior to the second determination, the Settling States will also have an opportunity to make a determination as to whether a sufficient number of political subdivisions have agreed to the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed with the

Proposed Settlement Agreement. This process is currently contemplated to end in February 2022, although it may be extended by agreement. It is possible that a sufficient number of states and subdivisions will not agree to the Proposed Settlement Agreement or that other required contingencies will not be satisfied.

If these conditions are satisfied, the Proposed Settlement Agreement would become effective sixty (60) days after the distributors determine that there is sufficient participation among political subdivisions. During this 60-day period, the Settling States and the distributors would cooperate to obtain consent judgments in each participating state embodying the terms of the Settlement.

The Proposed Settlement Agreement includes a cash component, pursuant to which the Company would pay up to approximately $6.37 billion, the majority of which would be paid over 18 years. The exact payment amount will depend on several factors, including the participation rate of states and political subdivisions, the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which political subdivisions in Settling States file additional opioid lawsuits against the Company after the Proposed Settlement Agreement becomes effective.

The Proposed Settlement Agreement also includes injunctive relief terms related to settling distributors’ controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.

In total, we have recorded total pre-tax charges of $1.17 billion and $5.63 billion in litigation charges/(recoveries), net in the years ended June 30, 2021 and 2020, respectively. In total, we have $6.73 billion accrued at June 30, 2021, of which $405 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in the consolidated balance sheets.

Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.


			Cardinal Health \| Fiscal 2021 Form 10-K			75


Notes to Financial Statements

Private Plaintiffs

The Proposed Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 442 lawsuits as of August 10, 2021. Of these, 128 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. A trial in one case is currently scheduled to begin in October 2021. We are vigorously defending ourselves in these matters.

Insurance Litigation

We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (“National Union”) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January, 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of June 30, 2021.

Department of Justice Investigations

Cordis Product Liability Lawsuits

As of August 10, 2021, we are named as a defendant in 419 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,427 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another 32 lawsuits involving similar claims by approximately 37 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 claims. This agreement is subject to certain contingencies. We continue to vigorously defend ourselves in these lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.

At June 30, 2021, we had a total of $524 million net of estimated insurance recoveries, accrued for losses and legal defense costs, net of expected insurance recoveries, related to the Cordis IVC filter lawsuits in the consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.03 billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.

SEC Investigation

In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. We are cooperating with this inquiry and cannot predict its outcome or duration.

Shareholder Securities Litigation

In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In November 2020, we filed a motion to dismiss the amended complaint. We believe that the claims asserted in this


76			Cardinal Health \| Fiscal 2021 Form 10-K


Notes to Financial Statements

complaint are without merit and intend to vigorously defend against them.

Specialty Solutions DOJ Investigation

In November 2018, the United States Attorney’s Office for the District of Massachusetts (the "USAO") commenced an investigation pertaining to the U.S. federal healthcare fraud and abuse laws. These requests sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with these requests and are engaged in resolution discussions with the USAO and Department of Health and Human Services, Office of Inspector General. In connection with these discussions, we recorded $13 million of expense within litigation charges/(recoveries) on our consolidated statements of earnings/(loss) during the fiscal year ended June 30, 2021. We cannot predict the outcome of the discussions and it is possible that we may incur additional losses or agree to other remedial measures; however, we are not currently able to estimate a range of reasonably possible additional losses.

Other Civil Litigation

Generic Pharmaceutical Pricing Antitrust Litigation

In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves.

Active Pharmaceutical Ingredient Impurity Litigation

Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product.

In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the “Sartan MDL”) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.

Antitrust Litigation Proceeds

We received and recognized income resulting from settlements of lawsuits in which we were a class member or plaintiff of $112 million, $16 million and $94 million during fiscal 2021, 2020, and 2019, respectively.

8. Income Taxes

Earnings/(Loss) before Income Taxes and Provision for/(Benefit From) Income Taxes

The following table summarizes earnings/(loss) before income taxes:


(in millions)	2021		2020		2019
U.S. operations	$	(47)	$	(4,056)	$	1,478
Non-U.S. operations	370		284		273
Earnings/(loss) before income taxes	$	323	$	(3,772)	$	1,751

The following table summarizes the components of provision for/(benefit from) income taxes:


(in millions)	2021		2020		2019
Current:
Federal	$	(989)	$	659	$	295
State and local	92		154		89
Non-U.S.	112		69		85
Total current	$	(785)	$	882	$	469

Deferred:
Federal	$	539	$	(822)	$	(28)
State and local	(28)		(127)		(37)
Non-U.S.	(15)		(12)		(18)
Total deferred	496		(961)		(83)
Provision for/(benefit from) income taxes	$	(289)	$	(79)	$	386

Tax Effects of Self-Insurance Pre-Tax Loss

During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.


			Cardinal Health \| Fiscal 2021 Form 10-K			77


Notes to Financial Statements

liability by approximately $700 million during fiscal 2021 related to this matter.

We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change. The actual amount of the tax benefit may differ materially from these estimates.

Tax Effects of Opioid Litigation Charges

In connection with the $1.17 billion and $5.63 billion pre-tax charges for the opioid litigation, during fiscal 2021 and 2020, we recorded a tax benefit of $228 million and $488 million, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.

We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the U.S. tax law governing deductibility was changed by the U.S. Tax Cuts and Jobs Act ("Tax Act"). Further, it is possible Congress or the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit may differ materially from these estimates.

Effective Tax Rate

The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate:


	2021 (1)		2020 (1)		2019 (1)
Provision at Federal statutory rate	21.0	%	21.0	%	21.0	%
State and local income taxes, net of federal benefit	3.2		2.5		0.9
Tax effect of foreign operations	0.7		—		(0.7)
Nondeductible/nontaxable items (2)	1.6		0.2		0.8
Cordis Disposition	7.0		—		—
Withholding Taxes (2)	9.0		(0.3)		0.7
Change in Valuation Allowances	(1.4)		1.5		4.5
US Taxes on International Income (2)(3)	(6.7)		0.2		0.7

Impact of Resolutions with IRS and other related matters (2)	(13.6)		(0.4)		(0.1)
Legal Entity Reorganization	—		—		(3.6)

Opioid litigation	17.7		(23.2)		—
Loss Carryback Claims	(129.9)		—		—
Other (2)	1.7		0.6		(2.1)
Effective income tax rate	(89.7)	%	2.1	%	22.1	%

(1) The table represents the following: fiscal 2021 is pretax income with tax benefit, fiscal 2020 is pretax loss with tax benefit, and fiscal 2019 is pretax income with tax expense.

(2) Certain prior year amounts have been reclassified to conform to current year presentation.

(3) Includes the tax impact of Global Intangible Low-Taxed Income ("GILTI") tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code.

The income tax benefit rate was 89.7% and 2.1% in fiscal 2021 and fiscal 2020 compared to an income tax expense rate of 22.1% in fiscal 2019. Fluctuations in the effective tax rates are primarily due to the impact of opioid litigation in fiscal 2021 and 2020, as well as the impact of the carryback claim filed in accordance with the CARES Act provision in fiscal year 2021.

Our effective tax rate has benefits from negotiated lower than statutory tax rates in select foreign jurisdictions which individually are not material to our effective tax rate but in aggregate have a favorable tax impact of approximately $20 million during fiscal 2021.

Deferred Income Taxes

Deferred income taxes arise from temporary differences between financial reporting and tax reporting bases of assets and liabilities and operating loss and tax credit carryforwards for tax purposes.

The following table presents the components of the deferred income tax assets and liabilities at June 30:


(in millions)	2021		2020
Deferred income tax assets:
Receivable basis difference	$	40	$	39
Accrued liabilities	874		607
Share-based compensation	38		38
Loss and tax credit carryforwards	805		589
Deferred tax assets related to uncertain tax positions	35		52
Other	16		87
Total deferred income tax assets	1,808		1,412
Valuation allowance for deferred income tax assets	(515)		(470)
Net deferred income tax assets	$	1,293	$	942

Deferred income tax liabilities:
Inventory basis differences	$	(1,119)	$	(1,083)
Property-related	(375)		(327)
Goodwill and other intangibles	(733)		(751)
Self-Insurance	(975)		—
Other	(23)		—
Total deferred income tax liabilities	$	(3,225)	$	(2,161)
Net deferred income tax liability	$	(1,932)	$	(1,219)


78			Cardinal Health \| Fiscal 2021 Form 10-K


Notes to Financial Statements

Deferred income tax assets and liabilities in the preceding table, after netting by taxing jurisdiction and for uncertain tax positions, are in the following captions in the consolidated balance sheets at June 30:


(in millions)	2021		2020
Noncurrent deferred income tax asset (1)	52		39
Noncurrent deferred income tax liability (2)	(1,981)		(1,258)
Noncurrent deferred income tax liability transferred to held for sale	(3)		—
Net deferred income tax liability	$	(1,932)	$	(1,219)

(1)Included in other assets in the consolidated balance sheets.

(2)Included in deferred income taxes and other liabilities in the consolidated balance sheets.

At June 30, 2021 we had gross federal, state and international loss and credit carryforwards of $272 million, $3.9 billion and $2.3 billion, respectively, the tax effect of which is an aggregate deferred tax asset of $805 million. Substantially all of these carryforwards are available for at least three years. Approximately $477 million of the valuation allowance at June 30, 2021 applies to certain federal, state and international loss carryforwards that, in our opinion, are more likely than not to expire unutilized. However, to the extent that tax benefits related to these carryforwards are realized in the future, the reduction in the valuation allowance would reduce income tax expense.

Unrecognized Tax Benefits

We had $932 million, $998 million and $456 million of unrecognized tax benefits at June 30, 2021, 2020 and 2019, respectively. The June 30, 2021, 2020 and 2019 balances include $849 million, $753 million and $303 million, respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate. The remaining unrecognized tax benefits relate to tax positions for which ultimate deductibility is highly certain but for which there is uncertainty as to the timing of such deductibility. Recognition of these tax benefits would not affect our effective tax rate. We include the full amount of unrecognized tax benefits in deferred income taxes and other liabilities in the consolidated balance sheets. The following table presents a reconciliation of the beginning and ending amounts of unrecognized tax benefits:


(in millions)	2021		2020		2019
Balance at beginning of fiscal year	$	998	$	456	$	423
Additions for tax positions of the current year	121		500		24
Additions for tax positions of prior years	223		78		39
Reductions for tax positions of prior years	(138)		(27)		(5)
Settlements with tax authorities	(271)		(6)		(25)
Expiration of the statute of limitations	(1)		(3)		—
Balance at end of fiscal year	$	932	$	998	$	456

It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues,

reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is a net decrease of $0 million to $20 million, exclusive of penalties and interest.

We recognize accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes. At June 30, 2021, 2020 and 2019, we had $49 million, $146 million and $122 million, respectively, accrued for the payment of interest and penalties. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the consolidated balance sheets. As a result of our IRS audit settlements and carryback claim, an immaterial amount of interest was recorded in fiscal 2021. During fiscal 2020 and 2019, we recognized $16 million and $8 million of expense for interest and penalties in income tax expense, respectively.

Other Tax Matters

We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.

We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $72 million and $176 million at June 30, 2021 and 2020, respectively, and is included in other assets in the consolidated balance sheets.

As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $12 million and $19 million at June 30, 2021 and 2020, respectively, and is included in other assets in the consolidated balance sheets.

9. Fair Value Measurements

The following tables present the fair values for assets and (liabilities) measured on a recurring basis at June 30:


	2021
(in millions)	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	1,883	$	—	$	—	$	1,883

Other investments (1)	126		—		—		126
Forward contracts (2)	—		42		—		42


	2020
(in millions)	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	721	$	—	$	—	$	721

Other investments (1)	114		—		—		114
Forward contracts (2)	—		53		—		53


			Cardinal Health \| Fiscal 2021 Form 10-K			79


Notes to Financial Statements

(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high-quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.

(2)The fair value of interest rate swaps, foreign currency contracts, net investment hedges and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the consolidated balance sheets.

Assets and (Liabilities) Measured on a Nonrecurring Basis

Assets and liabilities held for sale of $1.1 billion and $96 million, respectively, at June 30, 2021 are primarily related to the divestiture of our Cordis business. These estimated fair values utilized Level 3 unobservable inputs based on expected sales proceeds following a competitive bidding process. See Note 2 for additional information regarding assets and liabilities held for sale.

10. Financial Instruments

We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.

Interest Rate Risk Management

We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.

Currency Exchange Risk Management

We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange

rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.

Commodity Price Risk Management

We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.

The following table summarizes the fair value of our assets and liabilities related to derivatives designated as hedging instruments and the respective line items in which they were recorded in the consolidated balance sheets at June 30:


(in millions)	2021		2020
Assets:
Pay-floating interest rate swaps (1)	$	1	$	27
Cross-currency swap (1)	6		47
Cross-currency swap (2)	34		—
Foreign currency contracts (2)	5		—



Total assets	$	46	$	74

Liabilities:

Foreign currency contracts (4)	$	4	$	4
Forward interest rate swaps (3)	—		16

Commodity contracts (4)	—		1
Total liabilities	$	4	$	21

(1) Included in other assets in the consolidated balance sheets.

(2) Included in prepaid expenses and other in the consolidated balance sheets.

(3) Included in deferred income taxes and other liabilities in the consolidated balance sheets.

(4) Included in other accrued liabilities in the consolidated balance sheets.

Fair Value Hedges

We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the consolidated statements of earnings/(loss). During fiscal 2021, 2020 and 2019 there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.

During fiscal 2021, we unwound certain interest rate swap contracts with the notional amount of $550 million. In connection with the unwind of these contracts, we received cash proceeds of


80			Cardinal Health \| Fiscal 2021 Form 10-K


Notes to Financial Statements

$18 million. The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the debt agreement, which matures in March 2023.

During fiscal 2021, we entered into a pay-floating interest rate swap with total notional amounts of $200 million. This swap has been designated as fair value hedges of our fixed rate debt and is included in deferred income taxes and other liabilities in the consolidated balance sheets.

In May 2020, we unwound certain interest rate swap contracts. In connection with the unwind of these contracts, we received cash proceeds of $112 million. The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the related debt agreements, which ranged from 48 months to 63 months at June 30, 2020.

In connection with the debt repayment as described in Note 6, two pay-floating interest rate swaps with notional amounts of $200 million matured in the second quarter of fiscal 2020.

During fiscal 2019, we terminated notional amounts of $163 million of pay-floating interest rate swaps in connection with the debt repurchases in fiscal 2019 described in Note 6. These swaps were previously designated as fair value hedges.

The following tables summarize the outstanding interest rate swaps designated as fair value hedges at June 30:

2021

(in millions)

Notional Amount

Maturity Date

Pay-floating interest rate swaps

200

Mar 2028

2020

(in millions)

Notional Amount

Maturity Date

Pay-floating interest rate swaps

550

Mar 2023

The following table summarizes the gain/(loss) recognized in earnings for interest rate swaps designated as fair value hedges:


(in millions)	2021		2020		2019
Pay-floating interest rate swaps (1)	$	(8)	$	106	$	9
Fixed-rate debt (1)	8		(106)		(9)

(1) Included in interest expense, net in the consolidated statements of earnings/(loss).

Cash Flow Hedges

We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.

During fiscal 2020, we entered into forward interest rate swaps with a total notional amount of $200 million to hedge probable, but

not firmly committed, future transactions associated with our debt. During fiscal 2021, we terminated these swaps and reclassified an immaterial deferred gain from accumulated other comprehensive loss into interest expense, net in our consolidated statements of earnings/(loss) because the forecasted transactions were probable of not occurring.

All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges that are expected to be reclassified into net earnings within the next 12 months are immaterial.

We enter into foreign currency contracts to protect the value of anticipated foreign currency revenues and expenses. At June 30, 2021 and 2020, we held contracts to hedge probable, but not firmly committed, revenue and expenses. The principal currencies hedged are the Chinese renminbi, Canadian dollar, euro, Thai baht and Mexican peso.

We enter into commodity contracts to manage the price risk associated with forecasted purchases of certain commodities used in our Medical segment.

The following tables summarize the outstanding cash flow hedges at June 30:


	2021
(in millions)	Notional Amount		Maturity Date

Foreign currency contracts	$	436	Jul 2021	-	Jun 2022

2020

(in millions)

Notional Amount

Maturity Date

Forward interest rate swaps

200

Jun 2022

Foreign currency contracts

328

Jul 2020

Jun 2021

Commodity contracts

Jul 2020

Jun 2021

The following table summarizes the pre-tax gain/(loss) included in OCI for derivative instruments designated as cash flow hedges:


(in millions)	2021		2020		2019
Forward interest rate swaps	$	16	$	(16)	$	—
Commodity contracts	1		1		(5)
Foreign currency contracts	5		(8)		5

The following table summarizes the pre-tax gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges:


(in millions)	2021		2020		2019
Foreign currency contracts (1)	$	(12)	$	7	$	2
Foreign currency contracts (2)	(2)		1		—
Foreign currency contracts (3)	4		—		1
Forward interest rate swaps (4)	2		2		2
Commodity contracts (3)	6		(5)		—

(1) Included in revenue in the consolidated statements of earnings/(loss).

(2) Included in cost of products sold in the consolidated statements of earnings/(loss).

(3) Included in SG&A expenses in the consolidated statements of earnings/(loss).

(4) Included in interest expense, net in the consolidated statements of earnings/(loss).


			Cardinal Health \| Fiscal 2021 Form 10-K			81


Notes to Financial Statements

Net Investment Hedges

We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.

In August 2019, we entered into a ¥64 billion ($600 million) cross-currency swap maturing in 2022.

In September 2018, we entered into a €200 million ($233 million) cross-currency swap maturing in 2023.

Cross-currency swaps designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.

Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $7 million loss and a $35 million gain during fiscal 2021 and 2020, respectively. Gains recognized in interest expense, net in the consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $19 million and $17 million during fiscal 2021 and 2020, respectively.

Economic (Non-Designated) Hedges

We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. The principal currency managed through foreign currency contracts is the Chinese renminbi, Canadian dollar, euro, Mexican Peso, and Brazilian Real.

The following tables summarize the outstanding economic (non-designated) derivative instruments at June 30:

2021

(in millions)

Notional Amount

Maturity Date

Foreign currency contracts

254

July 2021

2020

(in millions)

Notional Amount

Maturity Date

Foreign currency contracts

325

Jul 2020

The following table summarizes the gain/(loss) recognized in earnings for economic (non-designated) derivative instruments:


(in millions)	2021		2020		2019
Foreign currency contracts (1)	$	(8)	$	(11)	$	(13)

(1) Included in other income, net in the consolidated statements of earnings/(loss).

Fair Value of Financial Instruments

The carrying amounts of cash and equivalents, trade receivables, net, accounts payable, and other accrued liabilities at June 30, 2021 and 2020 approximate fair value due to their short-term maturities.

The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at June 30:


(in millions)	2021		2020
Estimated fair value	$	6,751	$	7,273
Carrying amount	6,236		6,775

The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.

The following table is a summary of the fair value gain/(loss) of our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:


	2021				2020
(in millions)	Notional Amount		Fair Value Gain/(Loss)		Notional Amount		Fair Value Gain/(Loss)
Pay-floating interest rate swaps	$	200	$	1	$	550	$	27
Foreign currency contracts	690		1		653		(4)
Forward interest rate swaps	—		—		200		(16)
Cross-currency swap	833		40		833		47
Commodity contracts	—		—		16		(1)

11. Shareholders' Equity

At June 30, 2021 and 2020, authorized capital shares consisted of the following: 750 million Class A common shares, without par value; 5 million Class B common shares, without par value; and 500 thousand non-voting preferred shares, without par value. The Class A common shares and Class B common shares are collectively referred to below as “common shares”. Holders of common shares are entitled to share equally in any dividends declared by the Board of Directors and to participate equally in all distributions of assets upon liquidation. Generally, the holders of Class A common shares are entitled to one vote per share, and the holders of Class B common shares are entitled to one-fifth of one vote per share on proposals presented to shareholders for vote. Under certain circumstances, the holders of Class B common


82			Cardinal Health \| Fiscal 2021 Form 10-K


Notes to Financial Statements

shares are entitled to vote as a separate class. Only Class A common shares were outstanding at June 30, 2021 and 2020.

We repurchased $1.15 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2021, 2020 and 2019, as described below. We funded the repurchases with available cash and short term borrowings. The common shares repurchased are held in treasury to be used for general corporate purposes.

During fiscal 2021, we repurchased 3.7 million common shares having an aggregate cost of $200 million. The average price paid per common share was $54.40. These repurchases were made under an accelerated share repurchase ("ASR") program, which began on February 9, 2021 and was completed on March 31, 2021.

During fiscal 2020, we repurchased 7.3 million common shares having an aggregate cost of $350 million. The average price paid per common share was $48.00. These repurchases were made under an ASR program, which began on August 20, 2019 and was completed on December 4, 2019.

During fiscal 2019, we repurchased 11.5 million common shares having an aggregate cost of $600 million. The average price paid per common share was $52.32. These repurchases were made under an ASR program, which began on August 16, 2018 and was completed on October 25, 2018.

Accumulated Other Comprehensive Loss

The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:


(in millions)	Foreign Currency Translation Adjustments and other		Unrealized Gain/(Loss) on Derivatives, net of tax		Accumulated Other Comprehensive Loss
Balance at June 30, 2019	$	(95)	$	16	$	(79)
Other comprehensive income/(loss), net before reclassifications	3		(23)		(20)
Amounts reclassified to earnings	—		(5)		(5)
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax of $4 million	3		(28)		(25)
Balance at June 30, 2020	(92)		(12)		(104)
Other comprehensive income, before reclassifications	46		22		68
Amounts reclassified to earnings	—		2		2
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax of $4 million	46		24		70
Balance at June 30, 2021	$	(46)	$	12	$	(34)

12. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.

The following table reconciles the computation of basic and diluted earnings per share attributable to Cardinal Health, Inc.:


(in millions, except per share amounts)	2021		2020		2019
Net earnings/(loss)	$	612	$	(3,693)	$	1,365
Net earnings attributable to noncontrolling interest	(1)		(3)		(2)


Net earnings/(loss) attributable to Cardinal Health, Inc.	$	611	$	(3,696)	$	1,363
Weighted-average common shares–basic	292		293		300
Effect of dilutive securities:
Employee stock options, restricted share units, and performance share units	2		—		1
Weighted-average common shares–diluted	294		293		301
Basic earnings/(loss) per common share attributable to Cardinal Health, Inc.:	$	2.09	$	(12.61)	$	4.55




Diluted earnings/(loss) per common share attributable to Cardinal Health, Inc.:	2.08		(12.61)		4.53

The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for fiscal 2021, 2020 and 2019 were 3 million, 6 million and 7 million, respectively. During fiscal 2020, there were 2 million potentially dilutive employee stock options, restricted share units and performance share units not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would be anti-dilutive as a result of the net loss for the fiscal year.

13. Segment Information

Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.

Revenue

Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates pharmacies, including pharmacies in community health centers, nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products.


			Cardinal Health \| Fiscal 2021 Form 10-K			83


Notes to Financial Statements

products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.

The following table presents revenue for each reportable segment and Corporate:


(in millions)	2021		2020		2019
Pharmaceutical	$	145,796	$	137,495	$	129,917
Medical	16,687		15,444		15,633
Total segment revenue	162,483		152,939		145,550
Corporate (1)	(16)		(17)		(16)
Total revenue	$	162,467	$	152,922	$	145,534

(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:


(in millions)	2021		2020		2019
Pharmaceutical Distribution and Specialty Solutions (1) (2)	$	144,988	$	136,693	$	129,067
Nuclear and Precision Health Solutions	808		802		850
Pharmaceutical segment revenue	145,796		137,495		129,917
Medical distribution and products (3)	14,485		13,429		13,833
Cardinal Health at-Home Solutions	2,202		2,015		1,800
Medical segment revenue	16,687		15,444		15,633
Total segment revenue	162,483		152,939		145,550
Corporate (4)	(16)		(17)		(16)
Total revenue	$	162,467	$	152,922	$	145,534

(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services"

(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.

(3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division

(4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

The following table presents revenue by geographic area:


(in millions)	2021		2020		2019
United States	$	157,756	$	148,707	$	141,479
International	4,727		4,232		4,071
Total segment revenue	162,483		152,939		145,550
Corporate (1)	(16)		(17)		(16)
Total revenue	$	162,467	$	152,922	$	145,534

(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Segment Profit

We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general, and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.

We do not allocate the following items to our segments:

•last-in first-out, or ("LIFO"), inventory charges/(credits);

•surgical gown recall costs/(income); in connection with a voluntary recall for certain surgical gowns and a voluntary recall and field actions for surgical procedure packs containing affected gowns, we recognized a pre-tax charge of $85 million during fiscal 2020;

•restructuring and employee severance;

•amortization and other acquisition-related costs;

•impairments and (gain)/loss on disposal of assets; in connection with the divestiture of the Cordis business, we recognized a $60 million pre-tax write-down of the net assets held for sale during fiscal 2021; in connection with the naviHealth divestiture discussed in Note 2, we recognized a pre-tax gain of $508 million during fiscal 2019;

•litigation (recoveries)/charges, net; in connection with the opioid litigation as discussed further in Note 7, we recognized pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively;

•state opioid assessment related to prior fiscal years; in connection with the New York Opioid Stewardship Act as discussed further in Note 7, we recognized a pre-tax charge of $41 million during fiscal 2021, related to calendar years 2017 and 2018 assessments;

•other (income)/expense, net;

•interest expense, net;

•loss on early extinguishment of debt;

•(gain)/loss on sale of equity interest in naviHealth; in connection with the sale of our remaining equity interest in a partnership that owned naviHealth as discussed in Note 2, we recognized a $579 million pre-tax gain ($493 million after tax) during fiscal 2020;

•provision for/(benefit from) income taxes

In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally


84			Cardinal Health \| Fiscal 2021 Form 10-K


Notes to Financial Statements

includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $27 million, $69 million and $55 million for fiscal 2021, 2020 and 2019, respectively.

The following tables present segment profit by reportable segment and Corporate:


(in millions)	2021		2020		2019
Pharmaceutical	$	1,684	$	1,753	$	1,834
Medical	577		663		576
Total segment profit	2,261		2,416		2,410
Corporate	(1,789)		(6,514)		(350)
Total operating earnings	$	472	$	(4,098)	$	2,060

The following tables present depreciation and amortization and additions to property and equipment by reportable segment and Corporate:


(in millions)	2021		2020		2019
Pharmaceutical	$	151	$	135	$	147
Medical	226		243		288
Corporate	406		535		565
Total depreciation and amortization	$	783	$	913	$	1,000


(in millions)	2021		2020		2019
Pharmaceutical	$	55	$	47	$	35
Medical	97		86		74
Corporate	248		242		219
Total additions to property and equipment	$	400	$	375	$	328

The following table presents total assets for each reportable segment and Corporate at June 30:


(in millions)	2021		2020		2019
Pharmaceutical	$	23,624	$	22,398	$	22,446
Medical (1)	15,408		14,691		15,284
Corporate	5,421		3,677		3,233
Total assets	$	44,453	$	40,766	$	40,963

(1) Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021.

The following tables present property and equipment, net by geographic area:


(in millions)	2021		2020		2019
United States	$	1,958	$	1,880	$	1,846
International	402		486		510
Property and equipment, net	$	2,360	$	2,366	$	2,356

14. Share-Based Compensation

We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. At June 30, 2021, 9 million shares remain available for future grants under the Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan ("2011 LTIP"). Under the 2011 LTIP's fungible share counting provisions, stock options are counted against the plan as one share for every share issued; awards other than stock options are counted against the plan as two and one-half shares for every share issued. This means that only 3 million shares could be issued under awards other than stock options while 9 million shares could be issued under stock options. Shares are issued out of treasury shares when stock options are exercised and when restricted share units and performance share units vest.

The following table provides total share-based compensation expense by type of award:


(in millions)	2021		2020		2019
Restricted share unit expense	$	73	$	70	$	63
Employee stock option expense	—		3		10
Performance share unit expense	16		17		9
Total share-based compensation expense	$	89	$	90	$	82

The total tax benefit related to share-based compensation was $12 million, $16 million and $16 million for fiscal 2021, 2020 and 2019, respectively.

Restricted Share Units

Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.

The following table summarizes all transactions related to restricted share units under the Plans:


(in millions, except per share amounts)	Restricted Share Units	Weighted-Average Grant Date Fair Value per Share
Nonvested at June 30, 2019	2	$	51.65
Granted	2	42.71
Vested	(1)	60.21
Canceled and forfeited	—	—
Nonvested at June 30, 2020	3	45.92
Granted	2	53.76
Vested	(1)	49.37
Canceled and forfeited	(1)	48.74
Nonvested at June 30, 2021	3	$	49.05


			Cardinal Health \| Fiscal 2021 Form 10-K			85


Notes to Financial Statements

The following table provides additional data related to restricted share unit activity:


(in millions)	2021		2020		2019
Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax	$	73	$	77	$	75
Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years)	2		2		2
Total fair value of shares vested during the year	$	70	$	57	$	68

Stock Options

Until the end of fiscal 2018, stock options were granted to our officers and certain employees. There were no stock options granted to employees during fiscal year 2021, 2020 or 2019. Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for a period up to ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.

The following table summarizes all stock option transactions under the Plans:


(in millions, except per share amounts)	Stock Options	Weighted-Average Exercise Price per Common Share
Outstanding at June 30, 2019	6	$	63.78
Granted	—	—
Exercised	(1)	42.36
Canceled and forfeited	—	—
Outstanding at June 30, 2020	5	65.15
Granted	—	—
Exercised	(1)	43.08
Canceled and forfeited	—	—
Outstanding at June 30, 2021	4	$	68.46
Exercisable at June 30, 2021	4	$	68.62

The following table provides additional detail related to stock options:


(in millions, except per share amounts)	2021		2020		2019
Aggregate intrinsic value of outstanding options at period end	$	11	$	12	$	10
Aggregate intrinsic value of exercisable options at period end	11		12		10
Aggregate intrinsic value of exercised options	10		8		1
Net proceeds/(withholding) from share-based compensation	32		26		3
Excess tax benefits from share based compensation	(5)		6		7
Total compensation cost, net of estimated forfeitures, related to unvested stock options not yet recognized, pre-tax	—		1		5
Total fair value of shares vested during the year	3		8		20
Weighted-average grant date fair value per stock option	$	12.94	$	8.26	$	8.34


(in years)	2021	2020	2019
Weighted-average remaining contractual life of outstanding options	4	5	5
Weighted-average remaining contractual life of exercisable options	4	5	5
Weighted-average period over which stock option compensation cost is expected to be recognized	2	1	1

The fair values were estimated on the grant date using a lattice valuation model. We believe the lattice model provides reasonable estimates because it has the ability to take into account individual exercise patterns based on changes in our stock price and other variables, and it provides for a range of input assumptions, which are disclosed in the table below. The risk-free rate is based on the U.S. Treasury yield curve at the time of the grant. We analyzed historical data to estimate option exercise behaviors and employee terminations to be used within the lattice model. The expected life of the options granted was calculated from the option valuation model and represents the length of time in years that the options granted are expected to be outstanding. Expected volatilities are based on implied volatility from traded options on our common shares and historical volatility over a period of time commensurate with the contractual term of the option grant (up to ten years).

Performance Share Units

Performance share units generally vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.


86			Cardinal Health \| Fiscal 2021 Form 10-K


Notes to Financial Statements

The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):


(in millions, except per share amounts)	Performance Share Units	Weighted-Average Grant Date Fair Value per Share
Nonvested at June 30, 2019	0.9	$	51.45
Granted	0.7	44.03
Vested	(0.1)	48.40
Canceled and forfeited	(0.2)	50.92
Nonvested at June 30, 2020	1.3	54.24
Granted	0.4	55.45
Vested	(0.1)	42.72
Canceled and forfeited	(0.4)	53.71
Nonvested at June 30, 2021	1.2	$	54.89

The following table provides additional data related to performance share unit activity:


(in millions)	2021		2020		2019
Total compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized, pre-tax	$	26	$	29	$	12
Weighted-average period over which performance share unit cost is expected to be recognized (in years)	2		2		2
Total fair value of shares vested during the year	$	1	$	5	$	—

Employee Retirement Savings Plans

Substantially all of our domestic non-union employees are eligible to be enrolled in our company-sponsored contributory retirement savings plans, which include features under Section 401(k) of the Internal Revenue Code of 1986, and provide for matching and discretionary contributions by us. The total expense for our employee retirement savings plans was $55 million, $66 million and $99 million for fiscal 2021, 2020 and 2019, respectively.


			Cardinal Health \| Fiscal 2021 Form 10-K			87


Schedule II			Valuation and Qualifying Accounts

Cardinal Health, Inc. and Subsidiaries

Schedule II - Valuation and Qualifying Accounts


(in millions)	Balance at Beginning of Period		Charged to Costs and Expenses (1)		Charged to Other Accounts (2)		Deductions (3)		Balance at End of Period
Fiscal 2021
Accounts receivable	$	206	$	129	$	1	$	(94)	$	242
Finance notes receivable	27		5		—		(20)		12
Sales returns and allowances	495		2,568		—		(2,374)		689
Other	1		—		—		—		1
	$	729	$	2,702	$	1	$	(2,488)	$	944

Fiscal 2020
Accounts receivable	$	193	$	139	$	1	$	(127)	$	206
Finance notes receivable	14		15		—		(2)		27
Sales returns and allowances	479		2,253		—		(2,237)		495
Other	1		—		—		—		1
	$	687	$	2,407	$	1	$	(2,366)	$	729

Fiscal 2019
Accounts receivable	$	139	$	140	$	1	$	(87)	$	193
Finance notes receivable	7		8		—		(1)		14
Sales returns and allowances	479		2,205		—		(2,205)		479
Other	1		—		—		—		1
	$	626	$	2,353	$	1	$	(2,293)	$	687

(1)Fiscal 2021, 2020 and 2019 include $70 million, $49 million and $60 million, respectively, for reserves related to service charges and customer pricing disputes, excluded from provision for bad debts on the consolidated statements of cash flows and classified as a reduction in revenue in the consolidated statements of earnings/(loss).

(2)Recoveries of amounts provided for or written off in prior years was $1 million in each fiscal year 2021, 2020 and 2019.

(3)Write-off of uncollectible accounts or actual sales returns.

The sum of the components may not equal the total due to rounding.


88			Cardinal Health \| Fiscal 2021 Form 10-K


Directors, Executive Officers, and Corporate Governance

Directors, Executive Officers and Corporate Governance

Information About Our Executive Officers

The following is a list of our executive officers:


Name	Age	Position
Michael C. Kaufmann	58	Chief Executive Officer
Jason M. Hollar	48	Chief Financial Officer
Victor L. Crawford	60	Chief Executive Officer, Pharmaceutical segment
Stephen M. Mason	50	Chief Executive Officer, Medical segment
Michele A. M. Holcomb	53	Executive Vice President, Strategy and Corporate Development
Ola M. Snow	54	Chief Human Resources Officer
Jessica L. Mayer	52	Chief Legal and Compliance Officer
Brian S. Rice	58	Executive Vice President, Chief Information Officer and Customer Support Services

The business experience summaries provided below for our executive officers describe positions held during the last five years (unless otherwise indicated).

Mr. Kaufmann has served as Chief Executive Officer since January 2018. From November 2014 through December 2017, Mr. Kaufmann served as Chief Financial Officer.

Mr. Hollar has served as Chief Financial Officer since May 2020. Prior to that, Mr. Hollar served as the Executive Vice President and Chief Financial Officer of Tenneco Inc. ("Tenneco") from July 2018. From June 2017 to June 2018, Mr. Hollar was Senior Vice President Finance at Tenneco. Prior to that, Mr. Hollar served as Chief Financial Officer of Sears Holding Corporation ("Sears") from October 2016 to April 2017 and was Senior Vice President, Finance, at Sears beginning in October 2014. Sears filed for Chapter 11 bankruptcy in October 2018.

Mr. Crawford has served as Chief Executive Officer, Pharmaceutical segment since November 2018. From September 2012 until November 2018, Mr. Crawford served as the Chief Operating Officer, Healthcare, Education, Business Dining for Aramark Corporation.

Mr. Mason has served as Chief Executive Officer, Medical segment since August 2019. From September 2016 through August 2019, he served as President of our Cardinal Health at-Home Solutions within our Medical segment.

Ms. Holcomb has served as Executive Vice President, Strategy and Corporate Development since January 2017. She joined us from Teva Pharmaceutical Industries Ltd., where she served as Senior Vice President, Strategy, Portfolio, Search, and Partnerships and Chief Operating Officer, Global R&D from October 2015 to December 2016.

Ms. Snow has served as Chief Human Resources Officer since October 2018. From January 2016 through September 2018, Ms. Snow served as Senior Vice President, Human Resources, Total Rewards, Talent Acquisition and Corporate Business Partner.

Ms. Mayer has served as Chief Legal and Compliance Officer since March 2019. Ms. Mayer served as Executive Vice President, Deputy General Counsel and Secretary from September 2017 through March 2019 and was Senior Vice President, Deputy General Counsel from December 2015 through September 2017.

Mr. Rice has served as Executive Vice President, Chief Information Officer and Customer Support Services since February 2019. From 2009 until the beginning of 2019, Mr. Rice served as Senior Vice President, Chief Information Officer & Global and Business Services for Kellogg Company.

Directors and Corporate Governance

We have adopted Standards of Business Conduct that apply to all of our directors, officers and employees. The Standards of Business Conduct outline our corporate values and standards of integrity and behavior and are designed to protect and promote our reputation. The full text of the Standards of Business Conduct is posted on our website at www.cardinalhealth.com under “About Us — Ethics and Compliance.”

Any waiver of the Standards of Business Conduct for directors or executive officers must be approved by the Risk Oversight Committee. As required under SEC and New York Stock Exchange rules, we will disclose future amendments to our Standards of Business Conduct and waivers from the Standards of Business Conduct for our principal executive officer, principal financial officer, and principal accounting officer, or persons performing similar functions, and our other executive officers and directors on our website within four business days following the date of the amendment or waiver.


			Cardinal Health \| Fiscal 2021 Form 10-K			89


Directors, Executive Officers, and Corporate Governance

The other information called for by Item 10 of Form 10-K is incorporated by reference to our Definitive Proxy Statement (which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act) relating to our 2021 Annual Meeting of Shareholders (our “2021 Proxy Statement”) under the captions “Corporate Governance” and “Share Ownership Information.”

The other information called for by Item 12 of Form 10-K is incorporated by reference to our 2021 Proxy Statement under the caption "Share Ownership Information."


90			Cardinal Health \| Fiscal 2021 Form 10-K


Exhibits

Exhibits, Financial Statement Schedules

(a)(1) The following financial statements are included in the "Financial Statements" section of this report:


			Page

Consolidated Financial Statements and Schedule:			56
Consolidated Statements of Earnings/(Loss) for the Fiscal Years Ended June 30, 202 1 , 20 20 and 201 9			57
Consolidated Statements of Comprehensive Income/(Loss) for the Fiscal Years Ended June 30, 2021, 2020 and 2019			58
Consolidated Balance Sheets at June 30, 2021 and 2020			59
Consolidated Statements of Shareholders’ Equity for the Fiscal Years Ended June 30, 202 1 , 20 20 and 201 9			60
Consolidated Statements of Cash Flows for the Fiscal Years Ended June 30, 202 1 , 20 20 and 201 9			61
Notes to Consolidated Financial Statements			62

(a)(2) The following Supplemental Schedule is included in this report:


			Page
Schedule II - Valuation and Qualifying Accounts			88

All other schedules not listed above have been omitted as not applicable or because the required information is included in the Consolidated Financial Statements or in the Notes thereto.


Exhibit Number			Exhibit Description
2.1.1			Stock and Asset Purchase Agreement, dated April 18, 2017, between Cardinal Health, Inc. and Medtronic plc (incorporated by reference to Exhibit 2.1 to Cardinal Health's Current Report on Form 8-K filed on April 18, 2017, File No. 1-11373)
2.1.2			Amendment No. 1, dated as of July 28, 2017, to Stock and Asset Purchase Agreement, dated April 18, 2017, between Cardinal Health, Inc. and Medtronic plc (incorporated by reference to Exhibit 2.2.2 to Cardinal Health's Annual Report on Form 10-K for the year ended June 30, 2017, File No. 1-11373)
3.1			Amended and Restated Articles of Incorporation of Cardinal Health, Inc., as amended (incorporated by reference to Exhibit 3.1 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, File No. 1-11373)
3.2			Cardinal Health, Inc. Restated Code of Regulations (incorporated by reference to Exhibit 3.2 to Cardinal Health’s Current Report on Form 8-K filed on November 12, 2019, File No. 1-11373)
4.1			Specimen Certificate for Common Shares of Cardinal Health, Inc. (incorporated by reference to Exhibit 4.01 to Cardinal Health’s Annual Report on Form 10-K for the fiscal year ended June 30, 2001, File No. 1-11373)
4.2.1			Indenture, dated as of June 2, 2008, between Cardinal Health, Inc. and The Bank of New York Trust Company, N.A. (incorporated by reference to Exhibit 4.1 to Cardinal Health’s Current Report on Form 8-K filed on June 2, 2008, File No. 1-11373)
4.2.2			Form of 3.200% Notes due 2022 (incorporated by reference to Exhibit 4.2 to Cardinal Health's Current Report on Form 8-K filed on May 21, 2012, File No. 1-11373)
4.2.3			Form of 3.200% Notes due 2023 (incorporated by reference to Exhibit 4.2 to Cardinal Health's Current Report on Form 8-K filed on February 22, 2013, File No. 1-11373)
4.2.4			Form of 4.600% Notes due 2043 (incorporated by reference to Exhibit 4.3 to Cardinal Health's Current Report on Form 8-K filed on February 22, 2013, File No. 1-11373)
4.2.5			Form of 2.400% Notes due 2019 (incorporated by reference to Exhibit 4.1 to Cardinal Health’s Current Report on Form 8-K filed on November 19, 2014, File No. 1-11373)
4.2.6			Form of 3.500% Notes due 2024 (incorporated by reference to Exhibit 4.2 to Cardinal Health’s Current Report on Form 8-K filed on November 19, 2014, File No. 1-11373)
4.2.7			Form of 4.500% Notes due 2044 (incorporated by reference to Exhibit 4.3 to Cardinal Health’s Current Report on Form 8-K filed on November 19, 2014, File No. 1-11373)
4.2.8			Form of 3.750% Notes due 2025 (incorporated by reference to Exhibit 4.2 to Cardinal Health’s Current Report on Form 8-K filed on June 23, 2015, File No. 1-11373)
4.2.9			Form of 4.900% Notes due 2045 (incorporated by reference to Exhibit 4.3 to Cardinal Health’s Current Report on Form 8-K filed on June 23, 2015, File No. 1-11373)
4.2.10			Form of 2.616% notes due 2022 (incorporated by reference to Exhibit 4.2 to Cardinal Health's Current Report on Form 8-K filed on June 12, 2017, File No. 1-11373)
4.2.11			Form of Floating rate notes due 2022 (incorporated by reference to Exhibit 4.3 to Cardinal Health's Current Report on Form 8-K filed on June 12, 2017, File No. 1-11373)
4.2.12			Form of 3.079% notes due 2024 (incorporated by reference to Exhibit 4.4 to Cardinal Health's Current Report on Form 8-K filed on June 12, 2017, File No. 1-11373)
4.2.13			Form of 3.410% notes due 2027 (incorporated by reference to Exhibit 4.5 to Cardinal Health's Current Report on Form 8-K filed on June 12, 2017, File No. 1-11373)


			Cardinal Health \| Fiscal 2021 Form 10-K			91


Exhibits


4.2.14			Form of 4.368% notes due 2047 (incorporated by reference to Exhibit 4.6 to Cardinal Health's Current Report on Form 8-K filed on June 12, 2017, File No. 1-11373)
4.3			Agreement to furnish to the Securities and Exchange Commission upon request a copy of instruments defining the rights of holders of certain long-term debt of Cardinal Health, Inc. and consolidated subsidiaries (incorporated by reference to Exhibit 4.07 to Cardinal Health’s Annual Report on Form 10-K for the fiscal year ended June 30, 2005, File No. 1-11373)
4.4			Description of Securities (incorporated by reference to Exhibit 4.4 to Cardinal Health's Annual Report on Form 10-K for the fiscal year ended June 30, 2019, File No. 1-11373)
10.1.1			Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to Cardinal Health’s Current Report on Form 8-K/A filed on November 4, 2011, File No. 1-11373)*
10.1.2			First Amendment to Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1.2 to Cardinal Health's Annual Report on Form 10-K for the fiscal year ended June 30, 2014)*
10.1.3			Form of Nonqualified Stock Option Agreement under the Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.2 to Cardinal Health’s Current Report on Form 8-K/A filed on November 4, 2011, File No. 1-11373)*
10.1.4			Form of Nonqualified Stock Option Agreement under the Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1.3 to Cardinal Health’s Annual Report on Form 10-K for the fiscal year ended June 30, 2012, File No. 1-11373)*
10.1.5			Form of Restricted Share Units Agreement under the Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1.8 to Cardinal Health's Annual Report on Form 10-K for the fiscal year ended June 30, 2014)*
10.1.6			Form of Performance Share Units Agreement under the Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.4 to Cardinal Health's Current Report on Form 8-K/A filed on November 4, 2011, File No. 1-11373)*
10.1.7			Form of Amendment to Stock Option and Restricted Share Units Agreements under the Cardinal Health, Inc. 2011 Long-Term Incentive Plan, the Cardinal Health, Inc. 2005 Long-Term Incentive Plan and the Cardinal Health, Inc. 2007 Nonemployee Directors Equity Incentive Plan (incorporated by reference to Exhibit 10.1.9 to Cardinal Health's Annual Report on Form 10-K for the fiscal year ended June 30, 2013, File No. 1-11373)*
10.2.1			Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to Cardinal Health's Current Report on Form 8-K filed on November 7, 2016, File No. 1-11373)*
10.2.2			First Amendment to Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.2.2 to Cardinal Health's Annual Report on Form 10-K for the fiscal year end June 30, 2017, File No. 1-11373)*
10.2.3			Second Amendment to the Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.2 to Cardinal Health's Quarterly Report on Form 10-Q for the quarter ended December 31, 3019, File No. 1-11373)*
10.2.4			Form of Nonqualified Stock Option Agreement under the Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.2.3 to Cardinal Health's Annual Report on Form 10-K for the fiscal year end June 30, 2017, File No. 1-11373)*
10.2.5			Form of Restricted Share Units Agreement under the Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.2.4 to Cardinal Health's Annual Report on Form 10-K for the fiscal year end June 30, 2017, File No. 1-11373)*
10.2.6			Form of Restricted Share Units Agreement under the Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporate by reference to Exhibit 10.3 to Cardinal Health's Quarterly Report on Form 10-Q for the quarter ended December 31, 2019, File No. 1-11373)*
10.2.7			Form of Performance Share Units Agreement under the Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.2.5 to Cardinal Health's Annual Report on Form 10-K for the fiscal year end June 30, 2017, File No. 1-11373)*
10.2.8			Form of Directors Restricted Share Units Agreement under the Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.4 to Cardinal Health's Quarterly Report on Form 10-Q for the quarter ended December 31, 2018, File No. 1-11373)
10.3.1			Cardinal Health, Inc. 2005 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, File No. 1-11373)*
10.3.2			First Amendment to Cardinal Health, Inc. 2005 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1.1 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, File No. 1-11373)*
10.3.3			Second Amendment to Cardinal Health, Inc. 2005 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1.2 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, File No. 1-11373)*
10.3.4			Third Amendment to Cardinal Health, Inc. 2005 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.2.4 to Cardinal Health's Annual Report on Form 10-K for the fiscal year ended June 30, 2014)*
10.3.5			Form of Nonqualified Stock Option Agreement under the Cardinal Health, Inc. 2005 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1.11 to Cardinal Health's Annual Report on Form 10-K for the fiscal year ended June 30, 2010, File No. 1-11373)*
10.4.1			Cardinal Health, Inc. 2007 Nonemployee Directors Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2007, File No. 1-11373)*
10.4.2			First Amendment to Cardinal Health, Inc. 2007 Nonemployee Directors Equity Incentive Plan (incorporated by reference to Exhibit 10.2.1 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, File No. 1-11373)*
10.4.3			Second Amendment to the Cardinal Health, Inc. 2007 Nonemployee Directors Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to Cardinal Health's Quarterly Report on Form 10-Q for the Quarter ended December 31, 2011, File No. 1-11373)*
10.5			Cardinal Health Deferred Compensation Plan, Amended and Restated effective January 1, 2020 (incorporated by reference to Exhibit 10.4 to Cardinal Health's Quarterly Report on Form 10-Q for the quarter ended December 31, 2019, File No. 1-11373)*
10.6.1			Cardinal Health, Inc. Senior Executive Severance Plan (incorporated by reference to Exhibit 10.1 to Cardinal Health's Current Report on Form 8-K filed on September 26, 2018, File No. 1-11373)
10.6.2			First Amendment to the Cardinal Health, Inc. Senior Executive Severance Plan (incorporated by reference to Exhibit 10.1 to Cardinal Health's Quarterly Report on Form 10-Q for the quarter ended December 31, 2019, File No. 1-11373)
10.7			Cardinal Health, Inc. Policy Regarding Shareholder Approval of Severance Agreements (incorporated by reference to Exhibit 10.09 to Cardinal Health’s Current Report on Form 8-K filed on August 7, 2006, File No. 1-11373)*


92			Cardinal Health \| Fiscal 2021 Form 10-K


Exhibits


10.8.1			Confidentiality and Business Protection Agreement, effective as of February 15, 2010, between Cardinal Health, Inc. and Michael C. Kaufmann (incorporated by reference to Exhibit 10.15 to Cardinal Health’s Annual Report on Form 10-K for the fiscal year ended June 30, 2010, File No. 1-11373)*
10.8.2			Aircraft Time Sharing Agreement, effective as of February 8, 2018, by and between Cardinal Health, Inc. and Michael C. Kaufmann (incorporated by reference to Exhibit 10.2 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, File No. 1-11373)
10.9.1			Confidentiality and Business Protection Agreement, effective as of November 1, 2018, between Cardinal Health, Inc. and Victor L. Crawford (incorporated by reference to Exhibit 10.13.1 to Cardinal Health's Annual Report on Form 10-K for the fiscal year ended June 30, 2019, File No. 1-11373)*
10.9.2			Letter Agreement, dated October 30, 2018, between Cardinal Health, Inc. and Victor L. Crawford (incorporated by reference to Exhibit 10.13.2 to Cardinal Health's Annual Report on Form 10-K for the fiscal year ended June 30, 2019, File No. 1-11373) *
10.9.3			Letter Agreement, dated March 9, 2020, between Cardinal Health, Inc. and Jason Hollar (incorporated by reference to Exhibit 10.1 to Cardinal Health's Current Report on Form 8-K filed on March 19, 2020, File No. 1-11373)*
10.9.4			Confidentiality and Business Protection Agreement, effective as of April 27, 2020, between Cardinal Health, Inc. and Jason Hollar (incorporated by reference to Exhibit 10.2 to Cardinal Health's Current Report on Form 8-K filed on March 19, 2020, File No. 1-11373)*
10.10			Form of Indemnification Agreement between Cardinal Health, Inc. and certain individual directors (incorporated by reference to Exhibit 10.38 to Cardinal Health’s Annual Report on Form 10-K for the fiscal year ended June 30, 2004, File No. 1-11373)
10.11.1			Issuing and Paying Agency Agreement, dated August 9, 2006, between Cardinal Health, Inc. and The Bank of New York (incorporated by reference to Exhibit 10.01 to Cardinal Health’s Annual Report on Form 10-K for the fiscal year ended June 30, 2006, File No. 1-11373)
10.11.2			First Amendment to Issuing and Paying Agency Agreement, dated February 28, 2007, between Cardinal Health, Inc. and The Bank of New York (incorporated by reference to Exhibit 10.01 to Cardinal Health’s Current Report on Form 8-K filed on March 6, 2007, File No. 1-11373)
10.11.3			Second Amendment to Issuing and Paying Agency Agreement, effective as of December 1, 2016, between Cardinal Health, Inc. and The Bank of New York (incorporated by reference to Exhibit 10.2 to Cardinal Health's Quarterly Report on Form 10-Q for the quarter ended December 31, 2016, File No. 1-11373)
10.11.4			Third Amendment to Issuing and Paying Agency Agreement, dated September 15, 2017, between Cardinal Health, Inc. and The Bank of New York (incorporated by reference to Exhibit 10.2 to Cardinal Health's Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, File No. 1-11373)
10.11.5			Commercial Paper Dealer Agreement, dated August 9, 2006, between Cardinal Health, Inc. and J.P. Morgan Securities Inc. (incorporated by reference to Exhibit 10.02 to Cardinal Health’s Annual Report on Form 10-K for the fiscal year ended June 30, 2006, File No. 1-11373)
10.11.6			First Amendment to Commercial Paper Dealer Agreement, dated February 28, 2007, between Cardinal Health, Inc. and J.P. Morgan Securities Inc. (incorporated by reference to Exhibit 10.02 to Cardinal Health’s Current Report on Form 8-K filed on March 6, 2007, File No. 1-11373)
10.11.7			Second Amendment to Commercial Paper Dealer Agreement, effective as of December 31, 2012, between Cardinal Health, Inc. and J.P. Morgan Securities LLC (formerly known as J.P. Morgan Securities Inc.) (incorporated by reference to Exhibit 10.4 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2012, File No. 1-11373)
10.11.8			Commercial Paper Dealer Agreement between Cardinal Health, Inc. and J.P. Morgan Securities LLC, effective as of December 1, 2016 (incorporated by reference to Exhibit 10.6 to Cardinal Health's Quarterly Report on Form 10-Q for the quarter ended December 31, 2016, File No. 1-11373)
10.11.9			Commercial Paper Dealer Agreement, dated August 9, 2006, between Cardinal Health, Inc. and Banc of America Securities LLC (incorporated by reference to Exhibit 10.03 to Cardinal Health’s Annual Report on Form 10-K for the fiscal year ended June 30, 2006, File No. 1-11373)
10.11.10			First Amendment to Commercial Paper Dealer Agreement, dated February 28, 2007, between Cardinal Health, Inc. and Banc of America Securities LLC (incorporated by reference to Exhibit 10.03 to Cardinal Health’s Current Report on Form 8-K filed on March 6, 2007, File No. 1-11373)
10.11.11			Second Amendment to Commercial Paper Dealer Agreement, effective as of December 31, 2012, between Cardinal Health, Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, f/k/a Banc of America Securities LLC (incorporated by reference to Exhibit 10.5 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2012, File No. 1-11373)
10.11.12			Commercial Paper Dealer Agreement between Cardinal Health, Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, effective as of December 1, 2016 (incorporated by reference to Exhibit 10.3 to Cardinal Health's Quarterly Report on Form 10-Q for the quarter ended December 31, 2016, File No. 1-11373)
10.11.13			Commercial Paper Dealer Agreement, dated August 9, 2006, between Cardinal Health, Inc. and Wachovia Capital Markets, LLC (incorporated by reference to Exhibit 10.04 to Cardinal Health’s Annual Report on Form 10-K for the fiscal year ended June 30, 2006, File No. 1-11373)
10.11.14			First Amendment to Commercial Paper Dealer Agreement, dated February 28, 2007, between Cardinal Health, Inc. and Wachovia Capital Markets, LLC (incorporated by reference to Exhibit 10.04 to Cardinal Health’s Current Report on Form 8-K filed on March 6, 2007, File No. 1-11373)
10.11.15			Second Amendment to Commercial Paper Dealer Agreement, effective as of December 31, 2012, between Cardinal Health, Inc. and Wells Fargo Securities, LLC, as successor in interest to Wachovia Capital Markets, LLC (incorporated by reference to Exhibit 10.6 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2012, File No. 1-11373)
10.11.16			Commercial Paper Dealer Agreement between Cardinal Health, Inc. and Wells Fargo Securities, LLC, effective as of December 1, 2016 (incorporated by reference to Exhibit 10.5 to Cardinal Health's Quarterly Report on Form 10-Q for the quarter ended December 31, 2016, File No. 1-11373)
10.11.17			Commercial Paper Dealer Agreement, dated August 9, 2006, between Cardinal Health, Inc. and Goldman, Sachs & Co. (incorporated by reference to Exhibit 10.05 to Cardinal Health’s Annual Report on Form 10-K for the fiscal year ended June 30, 2006, File No. 1-11373)
10.11.18			First Amendment to Commercial Paper Dealer Agreement, dated February 28, 2007, between Cardinal Health, Inc. and Goldman, Sachs & Co. (incorporated by reference to Exhibit 10.05 to Cardinal Health’s Current Report on Form 8-K filed on March 6, 2007, File No. 1-11373)
10.11.19			Second Amendment to Commercial Paper Dealer Agreement, effective as of December 31, 2012, between Cardinal Health, Inc. and Goldman, Sachs & Co. (incorporated by reference to Exhibit 10.7 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2012, File No. 1-11373)
10.11.20			Commercial Paper Dealer Agreement between Cardinal Health, Inc. and Goldman Sachs & Co., effective as of December 1, 2016 (incorporated by reference to Exhibit 10.4 to Cardinal Health's Quarterly Report on Form 10-Q for the quarter ended December 31, 2016, File No. 1-11373)
10.11.21			Form of Commercial Paper Dealer Agreement between Cardinal Health, Inc. and SunTrust Robinson Humphrey, Inc. (incorporated by reference to Exhibit 10.2 to Cardinal Health’s Current Report on Form 8-K filed on April 21, 2009, File No. 1-11373)
10.11.22			Form of First Amendment to Commercial Paper Dealer Agreement between Cardinal Health, Inc. and SunTrust Robinson Humphrey, Inc. (incorporated by reference to Exhibit 10.8 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2012, File No. 1-11373)
10.11.23			Commercial Paper Dealer Agreement between Cardinal Health, Inc. and SunTrust Robinson Humphrey, Inc., effective as of December 1, 2016 (incorporated by reference to Exhibit 10.7 to Cardinal Health's Quarterly Report on Form 10-Q for the quarter ended December 31, 2016, File No. 1-11373)


			Cardinal Health \| Fiscal 2021 Form 10-K			93


Exhibits


10.12			Second Amended and Restated Five-Year Credit Agreement, dated as of June 27, 2019, among JPMorgan Chase Bank, N.A. as Administrative Agent, Joint Lead Arranger and Joint Book Manager, Bank of America, N.A. as Syndication Agent, MUFG Bank, Ltd. as Syndication Agent, Joint Lead Arranger and Joint Book Manager, Barclays Bank PLC, Deutsche Bank AG New York Branch, Goldman Sachs Bank USA, HSBC Bank USA, N.A. and Wells Fargo Bank, N.A., as Documentation Agents, and BOFA Securities, Inc., as Joint Lead Arranger and Joint Book Manager (incorporated by reference to Exhibit 10.1 to Cardinal Health's Current Report on Form 8-K filed on June 28, 2019, File No. 1-11373)
10.13.1			Fourth Amended and Restated Receivables Purchase Agreement, dated as of November 1, 2013, among Cardinal Health Funding, LLC, as Seller, Griffin Capital, LLC, as Servicer, the Conduits party thereto, the Financial Institutions Party thereto, the Managing Agents party thereto, and LC Banks party thereto and the Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as the Agent (incorporated by reference to Exhibit 10.1 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, File No. 1-11373)
10.13.2			First Amendment and Joinder, dated as of November 3, 2014, to the Fourth Amended and Restated Receivables Purchase Agreement, dated as of November 1, 2013 (incorporated by reference to Exhibit 10.3 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, File No. 1-11373)
10.13.3			Second Amendment, dated as of November 14, 2016, to the Fourth Amended and Restated Receivables Purchase Agreement, dated as of November 1, 2013 (incorporated by reference to Exhibit 10.4.3 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, File No. 1-11373)
10.13.4			Third Amendment, dated as of August 30, 2017, to the Fourth Amended and Receivables Purchase Agreement, dated as of November 1, 2013 (incorporated by reference to Exhibit 10.1 to Cardinal Health's Current Report on Form 8-K filed on August 31, 2017, File No. 1-11373)
10.13.5			Fourth Amendment and Joinder, dated September 30, 2019, to the Fourth Amended and Restated Receivables Purchase Agreement (incorporated by reference to Exhibit 10.1 to Cardinal Health's Current Report on Form 8-K filed on October 2, 2019, File No. 1-11373)
10.14.1			Seventh Amended and Restated Performance Guaranty, dated as of November 14, 2016, executed by Cardinal Health, Inc. in favor of Cardinal Health Funding, LLC (incorporated by reference to Exhibit 10.5.1 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, File No. 1-11373)
10.14.2			Amendment No. 1 to Seventh Amended and Restated Performance Guaranty, dated as of November 14, 2016 (incorporated by reference to Exhibit 10.5.2 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, File No. 1-11373
10.14.3			Amendment No. 2 to Seventh Amended and Restated Performance Guaranty, dated as of November 6, 2018 (incorporated by reference to Exhibit 10.4 to Cardinal Health's Quarterly Report on Form 10-Q for the Quarter ended September 30, 2018, File No. 1-11373)
10.14.4			Amendment No. 3 to Seventh Amended and Restated Performance Guaranty (incorporated by reference to Exhibit 10.2 to Cardinal Health's Current Report on Form 8-K filed October 2, 2019, File No. 1-11373)
10.15.1			Tax Matters Agreement, dated as of August 31, 2009, by and between Cardinal Health, Inc. and CareFusion Corporation (incorporated by reference to Exhibit 10.3 to Cardinal Health’s Current Report on Form 8-K filed on September 4, 2009, File No. 1-11373)
10.15.2			First Amendment to Tax Matters Agreement, dated as of May 28, 2012, by and between Cardinal Health, Inc. and CareFusion Corporation (incorporated by reference to Exhibit 10.20.2 to Cardinal Health’s Annual Report on Form 10-K for the fiscal year ended June 30, 2012, File No. 1-11373)
21.1			List of Subsidiaries of Cardinal Health, Inc.
23.1			Consent of Independent Registered Public Accounting Firm
31.1			Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2			Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1			Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
99.1			Statement Regarding Forward-Looking Information
101.INS			Inline XBRL Instance Document
101.SCH			Inline XBRL Taxonomy Extension Schema Document
101.CAL			Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF			Inline XBRL Taxonomy Definition Linkbase Document
101.LAB			Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE			Inline XBRL Taxonomy Extension Presentation Linkbase Document
104			Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)
			* Management contract or compensatory plan or arrangement.


94			Cardinal Health \| Fiscal 2021 Form 10-K


Form 10-K Cross Reference Index

Form 10-K Cross Reference Index


Item		Page(s)

	Part 1
1	Business	32
1A	Risk Factors	40
1B	Unresolved Staff Comments	N/A
2	Properties	47
3	Legal Proceedings	48
4	Mine Safety Disclosures	N/A


	Part II
5	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	49
6	Reserved	N/A
7	Management's Discussion and Analysis of Financial Condition and Results of Operations	3
7A	Quantitative and Qualitative Disclosures about Market Risk	30
8	Financial Statements and Supplementary Data	56
9	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	N/A
9A	Controls and Procedures	51
9B	Other Information	N/A

	Part III
10	Directors, Executive Officers and Corporate Governance	89
11	Executive Compensation	(a)
12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	(b)
13	Certain Relationships and Related Transactions, and Director Independence	(c)
14	Principal Accounting Fees and Services	(d)

	Part IV
15	Exhibits, Financial Statement Schedules	91
16	Form 10-K Summary	N/A
	Signatures	96


N/A			Not applicable
(a)			The information called for by Item 11 of Form 10-K is incorporated by reference to our 2021 Proxy Statement under the captions “Corporate Governance” and “Executive Compensation.”
(b)			The information called for by Item 12 of Form 10-K is incorporated by reference to our 2021 Proxy Statement under the caption "Executive Compensation."
(c)			The information called for by Item 13 of Form 10-K is incorporated by reference to our 2021 Proxy Statement under the caption "Corporate Governance."
(d)			The information called for by Item 14 of Form 10-K is incorporated by reference to our 2021 Proxy Statement under the caption “Audit Committee Matters.”


			Cardinal Health \| Fiscal 2021 Form 10-K			95


Signatures

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on August 16, 2021.


			Cardinal Health, Inc.

			By:			/s/ MICHAEL C. KAUFMANN
						Michael C. Kaufmann
						Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed below by the following persons on behalf of the registrant and in the capacities indicated on August 16, 2021.


Name						Title
/s/ MICHAEL C. KAUFMANN						Chief Executive Officer and Director (principal executive officer)
Michael C. Kaufmann

/s/ JASON M. HOLLAR						Chief Financial Officer (principal financial officer)
Jason M. Hollar

/s/ PATRICIA M. ENGLISH						Senior Vice President and Chief Accounting Officer (principal accounting officer)
Patricia M. English

/s/ CARRIE S. COX						Director
Carrie S. Cox

/s/ BRUCE L. DOWNEY						Director
Bruce L. Downey

/s/ SHERI H. EDISON						Director
Sheri H. Edison

/s/ DAVID C. EVANS						Director
David C. Evans

/s/ PATRICIA A. HEMINGWAY HALL						Director
Patricia A. Hemingway Hall

/s/ AKHIL JOHRI						Director
Akhil Johri

/s/ GREGORY B. KENNY						Director
Gregory B. Kenny

/s/ NANCY KILLEFER						Director
Nancy Killefer

/s/ J. MICHAEL LOSH						Director
J. Michael Losh

/s/ DEAN A. SCARBOROUGH						Director
Dean A. Scarborough

/s/ JOHN H. WEILAND						Director
John H. Weiland


96			Cardinal Health \| Fiscal 2021 Form 10-K

EX-21.1 2 a21q4_10kx63021xexhibit211.htm EX-21.1 Document

Exhibit 21.1

Subsidiaries of the Registrant

Listed below are majority-owned subsidiaries of Cardinal Health, Inc. as of June 30, 2021. Subsidiaries excluded from the list below would not, considered in the aggregate as a single subsidiary, constitute a “significant subsidiary” of Cardinal Health, Inc. as that term is defined in Rule 1-02(w) of SEC Regulation S-X.


Subsidiary Name						State/Jurisdiction of Incorporation
A+ Secure Packaging, LLC						Tennessee
Access Closure, Inc.						California
Aero-Med, Ltd.						Connecticut
Allegiance Corporation						Delaware
AssuraMed, Inc.						Delaware
Cardinal Health 2, LLC						Nevada
Cardinal Health 3, LLC						Delaware
Cardinal Health 5, LLC						Delaware
Cardinal Health 6, Inc.						Nevada
Cardinal Health 7, LLC						Delaware
Cardinal Health 100, Inc.						Indiana
Cardinal Health 104 LP						Ohio
Cardinal Health 105, Inc.						Ohio
Cardinal Health 107, LLC						Ohio
Cardinal Health 108, LLC						Delaware
Cardinal Health 110, LLC						Delaware
Cardinal Health 112, LLC						Delaware
Cardinal Health 113, LLC						Wisconsin
Cardinal Health 114, Inc.						Delaware
Cardinal Health 115, LLC						Ohio
Cardinal Health 116, LLC						Delaware
Cardinal Health 118, LLC						Delaware
Cardinal Health 119, LLC						Delaware
Cardinal Health 121, LLC						Delaware
Cardinal Health 122, LLC						Delaware
Cardinal Health 123, LLC						Delaware
Cardinal Health 124, LLC						Delaware
Cardinal Health 126, LLC						Delaware
Cardinal Health 127, Inc.						Kansas
Cardinal Health 132, LLC						Delaware
Cardinal Health 200, LLC						Delaware
Cardinal Health 201, Inc.						Delaware
Cardinal Health 222 (Thailand) Ltd.						Thailand
Cardinal Health 247, Inc.						Colorado
Cardinal Health 249, LLC						Delaware
Cardinal Health 414, LLC						Delaware
Cardinal Health Australia 503 Pty. Ltd.						Australia
Cardinal Health Austria 504 GmbH						Austria
Cardinal Health Belgium 505 BVBA						Belgium
Cardinal Health Canada Inc.						Canada
Cardinal Health Canada Holdings Cooperative U.A.						Netherlands
Cardinal Health Chile Limitada						Chile
Cardinal Health Colombia S.A.S.						Colombia
Cardinal Health do Brasil Ltd.						Brazil
Cardinal Health D.R. 203 II Ltd.						Bermuda
Cardinal Health Denmark ApS						Denmark
Cardinal Health Finland Oy						Finland


Subsidiary Name						State/Jurisdiction of Incorporation
Cardinal Health Foundation						Ohio
Cardinal Health France 506 SAS						France
Cardinal Health Funding, LLC						Nevada
Cardinal Health Germany 507 GmbH						Germany
Cardinal Health Germany Manufacturing GmbH						Germany
Cardinal Health International India Private Limited						India
Cardinal Health International Philippines, Inc.						Philippines
Cardinal Health IPS, LLC						Delaware
Cardinal Health Ireland 419 Designated Activity Company						Ireland
Cardinal Health Ireland 508 Limited						Ireland
Cardinal Health Ireland Unlimited Company						Ireland
Cardinal Health Italy 509 Srl						Italy
Cardinal Health Japan G.K.						Japan
Cardinal Health Korea Limited						Korea
Cardinal Health Malaysia 211 Sdn. Bhd.						Malaysia
Cardinal Health Malta 212 Limited						Malta
Cardinal Health Managed Care Services, LLC						Delaware
Cardinal Health Medical Products India Private Limited						India
Cardinal Health Mexico 244 S. de R.L. de C.V.						Mexico
Cardinal Health Mexico 514 S. de R.L. de C.V.						Mexico
Cardinal Health Middle East FZ-LLC						United Arab Emirates
Cardinal Health Netherlands 502 B.V.						Netherlands
Cardinal Health Norway AS						Norway
Cardinal Health Pharmaceutical Contracting, LLC						Delaware
Cardinal Health Pharmacy Services, LLC						Delaware
Cardinal Health Poland Spółlka z ograniczonąa odpowiedzialnośsciąa						Poland
Cardinal Health Portugal 513 Unipessoal Lda.						Portugal
Cardinal Health P.R. 120, Inc.						Puerto Rico
Cardinal Health P.R. 218, Inc.						Puerto Rico
Cardinal Health P.R. 220, LLC						Puerto Rico
Cardinal Health Singapore 225 Pte. Ltd.						Singapore
Cardinal Health Spain 511 S.L.						Spain
Cardinal Health Specialty Pharmacy, LLC						Delaware
Cardinal Health Sweden 512 A.B.						Sweden
Cardinal Health Switzerland 515 GmbH						Switzerland
Cardinal Health Systems, Inc.						Ohio
Cardinal Health Technologies, LLC						Nevada
Cardinal Health Technologies Switzerland GmbH						Switzerland
Cardinal Health U.K. 432 Limited						United Kingdom
Cardinal Health Medical Equipment Consulting (Shanghai) Co., Ltd.						China
Cirpro de Delicias S.A. de C.V.						Mexico
Convertors de Mexico S.A. de C.V.						Mexico
Cordis Cashel Company Unlimited						Ireland
Cordis Corporation						Florida
Cordis (Shanghai) Medical Devices Co., Ltd.						China
Cornerstone Rheumatology, L.P.						Tennessee


Subsidiary Name						State/Jurisdiction of Incorporation
Covidien Manufacturing Solutions, S.A.						Costa Rica
Curaspan Health Group, Inc.						Delaware
EPIC Insurance Company						Vermont
Especialidades Medicas Kenmex S.A. de C.V.						Mexico
GetOutcomes, LLC						Delaware
Griffin Capital, LLC						Nevada
Innovative Therapies, Inc.						Delaware
Instant Diagnostic Systems, Inc.						Alabama
Kendall Patient Recovery BVBA						Belgiuum
Kendall-Gammatron Limited						Thailand
KPR Australia Pty. Ltd.						Australia
KPR Italia S.r.l.						Italy
KPR Switzerland Sales Gmbh						Switzerland
KPR U.S., LLC						Delaware
Leader Drugstores, Inc.						Delaware
Limited Liability Company "Cardinal Health Russia"						Russian Federation
Ludlow Technical Products Canada, Ltd.						Canada
Marin Apothecaries						California
Medicine Shoppe International, Inc.						Delaware
Mediquip Sdn. Bhd.						Malaysia
Mirixa Corporation						Delaware
MosaicGPO, LLC						Delaware
mscripts, LLC						Delaware
Nippon Covidien Ltd.						Japan
One Cloverleaf, LLC						Delaware
Outcomes Incorporated						Iowa
Pinnacle Intellectual Property Services, Inc.						Nevada
Pinnacle Intellectual Property Services-International, Inc.						Nevada
Quiroproductos de Cuauhtemoc S. de R.L. de C.V.						Mexico
RainTree GPO, LLC						Delaware
Renal Purchasing Group, LLC						Tennessee
RGH Enterprises, Inc.						Ohio
Rxealtime, Inc.						Nevada
Sonexus Health, LLC						Texas
TelePharm, LLC						Iowa
The Harvard Drug Group, L.L.C.						Michigan
Traverse GPO, LLC						Delaware
WaveMark, Inc.						Delaware

EX-23.1 3 a21q4_10kx63021xexhibit231.htm EX-23.1 Document


						Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1) Registration Statement on Form S-3 No. 333-233377 of Cardinal Health, Inc.,

(2) Registration Statements on Form S-4 No. 333-62938 and No. 333-74761 of Cardinal Health, Inc., and

(3) Registration Statements on Form S-8 No. 33-42357, No. 333-90423, No. 333-38192, No. 333-38198, No. 333-56010, No. 333-129725, No. 333-149107, No. 333-155156, No. 333-163128, No. 333-164736, No. 333-177728, No. 333-183471, No. 333-206339, No. 333-206340, No. 333-214412, No. 333-219892, and 333-233380 of Cardinal Health, Inc.;

of our reports dated August 16, 2021, with respect to the consolidated financial statements and schedule of Cardinal Health, Inc. and subsidiaries and the effectiveness of internal control over financial reporting of Cardinal Health, Inc. and subsidiaries, included in this Annual Report (Form 10-K) of Cardinal Health, Inc. and subsidiaries for the year ended June 30, 2021.


/s/ Ernst & Young LLP

Grandview Heights, Ohio
August 16, 2021

EX-31.1 4 a21q4_10kx063021xexhibit311.htm EX-31.1 Document


						Exhibit 31.1

I, Michael C. Kaufmann, certify that:

1.I have reviewed this Form 10-K of Cardinal Health, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 16, 2021


/s/ MICHAEL C. KAUFMANN
Michael C. Kaufmann
Chief Executive Officer

EX-31.2 5 a21q4_10kx063021xexhibit312.htm EX-31.2 Document


						Exhibit 31.2

I, Jason M. Hollar, certify that:

1.I have reviewed this Form 10-K of Cardinal Health, Inc.;

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 16, 2021


/s/ JASON M. HOLLAR
Jason M. Hollar
Chief Financial Officer

EX-32.1 6 a21q4_10kx063021xexhibit321.htm EX-32.1 Document


						Exhibit 32.1

Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Michael C. Kaufmann, Chief Executive Officer of Cardinal Health, Inc. (the “Company”) and Jason M. Hollar, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that:

(1)the Periodic Report on Form 10-K for the fiscal year ended June 30, 2021 containing the financial statements of the Company (the “Periodic Report”), which this statement accompanies, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2)the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 16, 2021


			/s/ MICHAEL C. KAUFMANN
			Michael C. Kaufmann
			Chief Executive Officer


			/s/ JASON M. HOLLAR
			Jason M. Hollar
			Chief Financial Officer

EX-99.1 7 a21q4_10kx063021xexhibit991.htm EX-99.1 Document


						Exhibit 99.1

Statement Regarding Forward-Looking Information

As used in this exhibit, “we,” “our,” “us” and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including this Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the “2021 Form 10-K”), our quarterly reports on Form 10-Q and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include:

•risks arising from the COVID-19 pandemic, including the possibility that we will experience additional inventory reserves as a result of future decreases in demand or selling price; the risk that we may not be able to offset significant cost increases for certain personal protective equipment (PPE) products or that and price increases for these products could result in lost sales or customer losses or disputes; and the possibility that sustained reduced demand for generic pharmaceutical product may continue to advsersely impact our pharmaceutical generics program;

•competitive pressures in the markets in which we operate, including pricing pressures;

•uncertainties relating to the pricing of and demand for generic pharmaceuticals;

•uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches or other components of our pharmaceutical generics program;

•our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation;

•changes in manufacturer approaches to pricing branded pharmaceutical products and risks related to our compensation under contractual arrangements with manufacturers being set as a percentage of the wholesale acquisition cost of branded pharmaceuticals and where a part of our compensation is based on branded pharmaceutical price appreciation, changes in the magnitude of such price appreciation;

•changes in the timing or frequency of the introduction of branded pharmaceuticals;

•risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including risks associated with the proposed settlement agreement and process designed to resolve lawsuits and claims brought by states and local governmental entities, including the risk that we could fail to reach a final resolution and that any injunctive or non-monetary relief that we may agree to could have unintended consequences; and the risk that the outcome of other opioid-related lawsuits and investigations could have a material adverse effect on our results of operations, financial condition, cash flows or liquidity or the operations of our business;

•potential damage to our reputation, adverse operational impacts or other effects that may result from the national opioid epidemic, the allegations that have been made about our role in such epidemic and the ongoing unfavorable publicity surrounding the lawsuits and investigations against us;

•risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S. House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act; the possibility that we may receive additional negative or unfavorable publicity or that the IRS may not agree with our underlying assumptions and judgments;

•potential adverse impact to our financial results from enacted and proposed state taxes or other assessments on the sale or distribution of opioid medications;

•our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx;

•costs or claims resulting from quality issues, whether related to the manufacture of some of our sterile surgical gowns or pre-filled syringes, or other potential errors or defects in our manufacturing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits;

•actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions;

•any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption;

•uncertainties related to our Medical segment's Cardinal Health Brand products, including our ability to manage cost, infrastructure and to retain margin or improve its performance;

•risks associated with the realignment of our Medical segment's supply chain and other businesses, including our ability to achieve the expected benefits from such realignment;

•uncertainties with respect to our cost-savings initiatives or IT infrastructure activities, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel;

•difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties', or approvals associated with those activities;

•manufacturing disruptions, whether due to regulatory action, including regulatory action to reduce Ethylene Oxide emissions, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities;

•the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased;

•risks arising from possible violations of healthcare fraud and abuse laws;

•risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws;

•risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;

•risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements;

•risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations;

•changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications;

•material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers;

•unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix;

•risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments;

•uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All;

•reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services;

•changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices;

•changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits;

•changes in hospital buying groups or hospital buying practices;

•changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution;

•changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid;

•continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers;

•disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks;

•risks to our business and information and controls systems in the event that business process improvements, infrastructure modernizations or initiatives to use third-party service providers for key systems and processes are not effectively implemented;

•the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, qui tam actions, government investigations, shareholder lawsuits or other legal proceedings;

•possible losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products;

•our ability to maintain adequate intellectual property protections;

•the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions;

•risks associated with the divestiture of the Cordis business, including the risk that the costs associated with exit or disposal activities could ultimately be greater than we currently expect or that we could incur greater stranded costs than expected, and the risk that the impairment of the transferred assets could ultimately be greater than we currently expect;

•our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives;

•increased costs for commodities and other materials used in the Medical segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities;

•shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes;

•the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available;

•bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount;

•risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations;

•uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business;

•risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures;

•our ability to introduce and market new products and our ability to keep pace with advances in technology;

•significant charges to earnings if goodwill or intangible assets become impaired;

•uncertainties relating to general political, business, industry, regulatory and market conditions; and

•other factors described in the “Risk Factors” section of the 2021 Form 10-K.

The words “expect,” “anticipate,” “intend,” “plan,” “believe,” “will,” “should,” “could,” “would,” “project,” “continue,” “likely,” and similar expressions generally identify “forward-looking statements,” which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.

EX-101.SCH 8 cah-20210630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000010001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 100010002 - Statement - Consolidated Statements of Earnings link:presentationLink link:calculationLink link:definitionLink 100020003 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 100030004 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100040005 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100050006 - Statement - Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 100060007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 210011001 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 220022001 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 230033001 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 240044001 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Receivables) (Details) link:presentationLink link:calculationLink link:definitionLink 240054002 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Revenue and Gross Trade Receivables Percentage by Major Customers) (Details) link:presentationLink link:calculationLink link:definitionLink 240064003 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Major Customers) (Details) link:presentationLink link:calculationLink link:definitionLink 240074004 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Inventories) (Details) link:presentationLink link:calculationLink link:definitionLink 240084005 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Property and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 240094006 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Components of Property and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 240104007 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Goodwill and Other Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 240114008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Investments) (Details) link:presentationLink link:calculationLink link:definitionLink 240124009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Vendor Reserves) (Details) link:presentationLink link:calculationLink link:definitionLink 240134010 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Dividends) (Details) link:presentationLink link:calculationLink link:definitionLink 240144011 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Sales Returns and Allowances) (Details) link:presentationLink link:calculationLink link:definitionLink 240154012 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Shipping and Handling) (Details) link:presentationLink link:calculationLink link:definitionLink 240164013 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Loss Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 210171002 - Disclosure - Divestitures and Acquisitions link:presentationLink link:calculationLink link:definitionLink 230183002 - Disclosure - Divestitures and Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 240194014 - Disclosure - Divestitures and Acquisitions (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 210201003 - Disclosure - Restructuring and Employee Severance link:presentationLink link:calculationLink link:definitionLink 230213003 - Disclosure - Restructuring and Employee Severance (Tables) link:presentationLink link:calculationLink link:definitionLink 240224015 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 240234016 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) link:presentationLink link:calculationLink link:definitionLink 210241004 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 230253004 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 240264017 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 240274018 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 240284019 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 210291005 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 230303005 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 240314020 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 240324021 - Disclosure - Leases Schedule of Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 240334022 - Disclosure - Leases Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 240344023 - Disclosure - Leases Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 240354024 - Disclosure - Leases Schedule of Future Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 210361006 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings link:presentationLink link:calculationLink link:definitionLink 230373006 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 240384025 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 240394026 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240404027 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 240414028 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Other Financing Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 210421007 - Disclosure - Commitments, Contingent Liabilities and Litigation link:presentationLink link:calculationLink link:definitionLink 240434029 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 210441008 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 230453007 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 240464030 - Disclosure - Income Taxes (Schedule of Income before Income Tax, Domestic and Foreign) (Details) link:presentationLink link:calculationLink link:definitionLink 240474031 - Disclosure - Income Taxes (Schedule of Components of Income Tax Expense (Benefit), Current and Deferred) (Details) link:presentationLink link:calculationLink link:definitionLink 240484032 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details) link:presentationLink link:calculationLink link:definitionLink 240494033 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240504034 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 240514035 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities After Netting by Tax Jurisdiction) (Details) link:presentationLink link:calculationLink link:definitionLink 240524036 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits Roll Forward) (Details) link:presentationLink link:calculationLink link:definitionLink 210531009 - Disclosure - Guarantees link:presentationLink link:calculationLink link:definitionLink 210541010 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 230553008 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 240564037 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) link:presentationLink link:calculationLink link:definitionLink 240574038 - Disclosure - Fair Value Measurements (Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis Using Unobservable Inputs (Level 3)) (Details) link:presentationLink link:calculationLink link:definitionLink 240584039 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 210591011 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 230603009 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 240614040 - Disclosure - Financial Instruments (Schedule of the Fair Value of Assets and Liabilities Related to Derivatives Designated as Hedging Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 240624041 - Disclosure - Financial Instruments (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240634042 - Disclosure - Financial Instruments (Schedule of Outstanding Instruments, Fair Value Hedges) (Details) link:presentationLink link:calculationLink link:definitionLink 240644043 - Disclosure - Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Interest Rate Contracts Designated as Fair Value Hedges) (Details) link:presentationLink link:calculationLink link:definitionLink 240654044 - Disclosure - Financial Instruments (Schedule of Outstanding Instruments, Cash Flow Hedges) (Details) link:presentationLink link:calculationLink link:definitionLink 240664045 - Disclosure - Financial Instruments (Schedule of Gain/(Loss) Included in AOCI for Derivative Instruments Designated as Cash Flow Hedges) (Details) link:presentationLink link:calculationLink link:definitionLink 240674046 - Disclosure - Financial Instruments (Schedule of Gain/(Loss) Reclassified from AOCI into Earnings for Derivative Instruments Designated as Cash Flow Hedges) (Details) link:presentationLink link:calculationLink link:definitionLink 240684047 - Disclosure - Financial Instruments (Schedule of Outstanding Instruments, Economic Hedges) (Details) link:presentationLink link:calculationLink link:definitionLink 240694048 - Disclosure - Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Derivatives Not Designated as Hedging Instrument) (Details) link:presentationLink link:calculationLink link:definitionLink 240704049 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) link:presentationLink link:calculationLink link:definitionLink 240714050 - Disclosure - Financial Instruments (Schedule of Fair Value Gain Loss Derivative Instrument) (Details) link:presentationLink link:calculationLink link:definitionLink 210721012 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 230733010 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 240744051 - Disclosure - Shareholders' Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240754052 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 210761013 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. link:presentationLink link:calculationLink link:definitionLink 230773011 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 240784053 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) link:presentationLink link:calculationLink link:definitionLink 240794054 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 210801014 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 230813012 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 240824055 - Disclosure - Segment Information (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240834056 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 240844057 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 240854058 - Disclosure - Segment Information (Depreciation and Amortization and Additions to Property and Equipment by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 240864059 - Disclosure - Segment Information (Assets by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 240874060 - Disclosure - Segment Information Property and Equipment, net by Geographic Area) (Details) link:presentationLink link:calculationLink link:definitionLink 210881015 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 230893013 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 240904061 - Disclosure - Share-Based Compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 240914062 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) link:presentationLink link:calculationLink link:definitionLink 240924063 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 240934064 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) link:presentationLink link:calculationLink link:definitionLink 240944065 - Disclosure - Share-Based Compensation Schedule of Remaining Stock Option Plan Data (Details) link:presentationLink link:calculationLink link:definitionLink 240954066 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 240964067 - Disclosure - Share-Based Compensation (Additional Data Related to Restricted Share Unit Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 240974068 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 240984069 - Disclosure - Share-Based Compensation (Additional Data Related to Performance Share Unit Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 210991016 - Disclosure - Schedule II - Valuations and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 241004070 - Disclosure - Schedule II - Valuations and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 cah-20210630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 cah-20210630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 cah-20210630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Interest Rate, Currency and Commodity Risk Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block] Supplemental Information: Supplemental Cash Flow Information [Abstract] Customer [Domain] Customer [Domain] 4.9% Notes due 2045 4.9% Notes due 2045 [Member] 4.9% Notes due 2045 Letter of Credit Letter of Credit [Member] Net Operating Loss Carryback [Domain] Net Operating Loss Carryback [Domain] Net Operating Loss Carryback [Domain] Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period State and local Current State and Local Tax Expense (Benefit) Current State and Local Tax Expense (Benefit) Receivable Type [Axis] Receivable Type [Axis] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Less: leases not yet commenced (1) Lessee Operating Lease Liability Not Yet Commenced, Amount Lessee Operating Lease Liability Not Yet Commenced, Amount Canceled and forfeited (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Goodwill and Intangible Assets [Table] Goodwill and Intangible Assets [Table] Goodwill and Intangible Assets [Table] Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Translation of Foreign Currencies Foreign Currency Transactions and Translations Policy [Policy Text Block] Finance notes and related accrued interest, net, current Financing Receivable, after Allowance for Credit Loss, Current Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Number of shares available for grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Maturities of existing long-term obligations and other short-term borrowings-2021 Long-Term Debt, Maturity, Year Two Class Action Lawsuits [Member] Class Action Lawsuits [Member] Class Action Lawsuits [Member] Aggregate intrinsic value of exercised options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Income Taxes Tax Credit Carryforward [Line Items] Fair Value Hedging Fair Value Hedging [Member] Document Fiscal Year Focus Document Fiscal Year Focus SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Additional Restricted Shares and Restricted Share Units Activity Additional Restricted Shares And Restricted Share Units Data [Table Text Block] Additional Restricted Shares And Restricted Share Units Data [Table Text Block] Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Foreign Currency Translation Adjustments and other Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Amortization of Intangible Assets Amortization of Intangible Assets Entity Well-Known Seasoned Issuer Entity Well-known Seasoned Issuer Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Additions for tax positions of prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Deferred Tax Assets, Net Deferred Tax Assets, Net Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Write-down of assets held for sale Write-down of assets held for sale Write-down of assets held for sale Business Combination and Asset Acquisition [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Cash Flow Hedging Cash Flow Hedging [Member] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Schedule of Indefinite-Lived Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Award Type [Domain] Award Type [Domain] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Gain (Loss) on Sale of Investments Gain (Loss) on Sale of Investments Effective Income Tax Reconciliation, Opioid Litigation Effective Income Tax Reconciliation, Opioid Litigation Effective Income Tax Reconciliation, Opioid Litigation Fair Value, Nonrecurring Fair Value, Nonrecurring [Member] Exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Goodwill and Other Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Estimated range of decrease in unrecognized tax benefits within the next 12 months Decrease in Unrecognized Tax Benefits is Reasonably Possible Authorized—500 thousand shares, Issued—none Preferred Stock, Value, Issued Forward contracts Derivative Assets (Liabilities), at Fair Value, Net Retained Earnings Retained Earnings [Member] Project costs on investment and other spending Project Costs On Investment And Other Spending Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses. Estimated fair value Debt Instrument, Fair Value Disclosure Common Stock, Voting Rights, Votes Common Stock, Voting Rights, Votes Common Stock, Voting Rights, Votes Amount CareFusion is liable under tax matters agreement in the event amount must be paid to the taxing authority Indemnification Receivable Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes. 2.4% Notes due 2019 2.4% Notes due 2019 [Member] 2.4% Notes due 2019 Inventory basis differences Deferred Tax Liabilities, Inventory Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Goodwill and Intangible Assets [Line Items] Goodwill and Intangible Assets [Line Items] Goodwill and Intangible Assets [Line Items] Total comprehensive income/(loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Tax Period [Domain] Tax Period [Domain] Other Short-term Borrowings Other Short-term Borrowings Finance Lease, Principal Payments Finance Lease, Principal Payments Other Income, Net Other Nonoperating Income (Expense) [Member] Earnings Per Share, Basic Earnings Per Share, Basic Nonvested at beginning of period (in shares) Nonvested at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Document Type Document Type Maturities of existing long-term obligations and other short-term borrowings - 2020 Long-Term Debt, Maturity, Year One Less: leases not yet commenced (1) Total Lease Liability Not Yet Commenced, Amount Total Lease Liability Not Yet Commenced, Amount Diluted earnings per common share attributable to Cardinal Health, Inc.: Earnings Per Share, Diluted [Abstract] SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Entity Current Reporting Status Entity Current Reporting Status 4.368% Notes due fiscal 2047 4.368% Notes due 2047 [Member] 4.368% Notes due 2047 1.948% Notes due 2019 1.948% Notes due 2019 [Member] 1.948% Notes due 2019 Machinery and equipment Machinery and Equipment [Member] Commercial paper Commercial Paper Commercial Paper [Member] Net deferred income tax liability Deferred Tax Liabilities, Net Total assets Derivative Asset, Fair Value, Gross Asset Number of plaintiffs Loss Contingency, Number of Plaintiffs 2.616% Notes due fiscal 2022 2.616% Notes due 2022 [Member] 2.616% Notes due 2022 Total Lease Liability Total Lease Liability Total Lease Liability Property-related Deferred Tax Liabilities, Property, Plant and Equipment Trade receivables, net Receivables, Net, Current Discount Rate, fair value inputs Discount Rate, fair value inputs Discount Rate, fair value inputs Current portion of long-term obligations and other short-term borrowings Less: current portion of long-term obligations and other short-term borrowings Long-term Debt and Lease Obligation, Current Total fair value of shares vested during the year Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation Plan Name [Axis] Plan Name [Axis] Assets: Assets, Fair Value Disclosure [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill, Impairment Loss Goodwill, Impairment Loss Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Facility Exit and Other Costs Facility Exit and Other Costs Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services. Additions for tax positions of the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Effective Income Tax Rate Reconciliation, Withholding Taxes Effective Income Tax Rate Reconciliation, Withholding Taxes Effective Income Tax Rate Reconciliation, Withholding Taxes Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Net Operating Loss Carryback Net Operating Loss Carryback [Member] Net Operating Loss Carryback Increase/(decrease) in accounts payable Increase (Decrease) in Accounts Payable Interest Rate Swaps Interest Rate Swaps Interest Rate Swap [Member] Hedging Relationship [Domain] Hedging Relationship [Domain] ASC 842 ASC 842 [Member] ASC 842 SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Amortization and other acquisition-related costs Amortization and other acquisition-related costs The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Schedule of Gain/(Loss) Reclassified from AOCI into Earnings for Derivative Instruments Designated as Cash Flow Hedges Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Maturities of existing long-term obligations and other short-term borrowings-Thereafter Long-Term Debt, Maturity, after Year Five Estimated annual amortization of intangible assets - 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Four Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Settlements with tax authorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Assets by Reportable Segment Reconciliation of Assets from Segment to Consolidated [Table Text Block] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Unrecognized tax benefits Balance at beginning of fiscal year Balance at end of fiscal year Unrecognized Tax Benefits Total deferred income tax assets Deferred Tax Assets, Gross Income Tax Authority Income Tax Authority [Domain] Other obligations Other Borrowings Other Borrowings Beginning Balance Ending Balance Restructuring Reserve Trading Symbol Trading Symbol Vendor Reserves Cost of Sales, Vendor Reserves, Policy [Policy Text Block] Disclosure of accounting policy for allowances received from a vendor. The disclosure differentiates between those allowances that are recorded as a reduction in the price of the vendors' products or services (that is, the entity's inventory) and which ultimately will be recorded as a reduction in the entity's cost of sales and those that are not. Current liabilities: Liabilities, Current [Abstract] Receivable [Domain] Receivable [Domain] Valuation allowance on operating loss carryforwards Operating Loss Carryforwards, Valuation Allowance Exercisable at end of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Deferred tax assets related to uncertain tax positions Deferred Tax Assets, Related to uncertain tax positions Deferred tax assets related to uncertain tax positions Unrecognized tax benefits, interest and penalties accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Accounting Policies [Abstract] Accounting Policies [Abstract] Weighted-average remaining contractual life of outstanding options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Derivative Instrument [Axis] Derivative Instrument [Axis] Federal Current Federal Tax Expense (Benefit) Current Federal Tax Expense (Benefit) Total operating lease liabilities Total lease liabilities Operating Lease, Liability Redeemable Noncontrolling Interest, Equity, Carrying Amount Redeemable Noncontrolling Interest, Equity, Carrying Amount Short Term Credit Facilities Short Term Credit Facilities Member Other short-term credit facilities and an unsecured line of credit Authorized—755 million shares, Issued— 327 million shares at June 30, 2021 and 2020 Common Stock, Value, Issued Finance Lease, Weighted Average Discount Rate, Percent Finance Lease, Weighted Average Discount Rate, Percent Disposal Group, Including Discontinued Operation, Liabilities Disposal Group, Including Discontinued Operation, Liabilities Weighted-average period over which stock option compensation cost is expected to be recognized Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years) Weighted-average period over which performance share unit cost is expected to be recognized (in years) Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Nonvested at beginning of period (in usd per share) Nonvested at end of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Business Combination Disclosure Business Combination Disclosure [Text Block] Schedule of Range of Assumptions Used to Estimate Fair Value of Stock Options Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Non-U.S. Deferred Foreign Income Tax Expense (Benefit) Deferred Foreign Income Tax Expense (Benefit) 2024 Lessee Lease Liability Payments Due Year Three Lessee Lease Liability Payments Due Year Three Additional Data Related to Performance Share Units Activity Additional Performance Share Units Data [Table Text Block] Additional Performance Share Units Data [Table Text Block] Goodwill [Line Items] Goodwill [Line Items] Revenue from External Customers by Geographic Areas [Table Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Class of Stock [Axis] Class of Stock [Axis] Accrued liabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities 4.6% Notes due 2043 4.6% Notes due 2043 [Member] 4.6% Notes due 2043 Land, building and improvements Land, Buildings and Improvements [Member] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Income Tax Authority Income Tax Authority [Axis] Excess tax benefits from share based compensation Excess Tax Benefit from Share-based Compensation, Financing Activities Thereafter Finance Lease, Liability, to be Paid, after Year Five Line of Credit Facility, Maximum Amount Outstanding During Period Line of Credit Facility, Maximum Amount Outstanding During Period SG&A Expenses Selling, General and Administrative Expenses [Member] Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Notes Payable Repurchased Notes Payable Repurchased Principal Amount of Notes Payable Repurchased during the year Trademarks and patents IPR&D,TrademarksandOther [Member] Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style. Stock Options Stock Options Share-based Payment Arrangement, Option [Member] Consolidation Items [Domain] Consolidation Items [Domain] Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Effect of exchange rates changes on cash and equivalents Effect of Exchange Rate on Cash and Cash Equivalents Deferred Tax Liabilities, Deferred Expense, Reserves and Accruals Deferred Tax Liabilities, Deferred Expense, Reserves and Accruals Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Segment Information Segment Reporting Disclosure [Text Block] Finance Lease, Weighted Average Remaining Lease Term Finance Lease, Weighted Average Remaining Lease Term Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Income from Settlements of Class Action Lawsuits Income from Settlements of Class Action Lawsuits Income from Settlements of Class Action Lawsuits Increase (Decrease) in Shareholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] 4.5% Notes due 2044 4.5% Notes due 2044 [Member] 4.5% Notes due 2044 Leases Supplemental Balance Sheet Information LeasesSupplementalBalanceSheetInformation [Table Text Block] [Table Text Block] for LeasesSupplementalBalanceSheetInformation [Table] Tax Matter [Domain] Tax Matter [Domain] [Domain] for Tax Matter [Axis] Cash dividends per common share (in usd per share) Common Stock, Dividends, Per Share, Cash Paid Goodwill, Transfers Goodwill, Transfers Other Assets [Member] Other Assets [Member] Finance notes and related accrued interest, net, total Financing Receivable, after Allowance for Credit Loss Other (income)/expense, net Other Nonoperating Income (Expense) Gown Recall [Axis] Gown Recall [Axis] Gown Recall [Axis] Inventory Recall Expense Inventory Recall Expense Cash Discounts Cash Discounts [Policy Text Block] Cash Discounts [Policy Text Block] Facility Exit and Other Costs Facility Closing [Member] Business Combinations [Abstract] Business Combinations [Abstract] Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] EX-101.PRE 12 cah-20210630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 cah-20210630_g1.jpg begin 644 cah-20210630_g1.jpg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end GRAPHIC 14 cah-20210630_g2.jpg begin 644 cah-20210630_g2.jpg M_]C_X 02D9)1@ ! @$ 8 !@ #_[@ .061O8F4 90 !_]L 0P " 0$! M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D* M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\ $0@! MX ', P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! @,$!08'" D* M"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D*"__$ +41 (! M @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "OR._X.]/VI?VE/V5OV2_A5XH_9H^/?B_P!J6I_$6:UU&_\'^( M;C3IKF 6$KB*1X'4NFX!MIXR :_7&OQ1_P"#W#_DR[X.?]E0G_\ 3=-0![)_ MP:K_ +D?M6_%O7/$GC/X9_$6]M-7UGQ?K$MW>QZ=+;0SQ& M::9F?"2+>( 3A5B '3C\EOV"/^"M7_!1#]I'_@LU\,=0UK]L'XJ#X??$#]H& M/RO!\WC6^_LK[!/J0D-@+8R>7Y"131Q^5MVA<+C Q7KVF?M##_@E3^UC_P % M//V>Y+]=+B\:_"^XU[PJI;:L=[J,L*V*Q?[2IXE+ #M!SG%>+_L@_ 8? G]L MS_@F+]KL_)U#QE]A\4:A\N/,^U^*[[[.WOFTCM>?:@#^IOXH?%_X2_!#PLWC MCXT?%'P[X0T1)5B?6/%&MP:?:K(V=J&6=U0,<' SDX-3?#KXG?#7XP>%+?QW M\)?B%H?BC0[LD6NL^'=6AOK28CKLFA9D;'L:_G4_X*G_ !J_9D_;^_X.%]=_ M9X_X*6?M+WO@']GWX,Z8^G:=:Q7$L0N;Q+6!YHT*1R>7-/=3-NEV%C!:J@8$ M*PZ7_@B7\;/V>/V*_P#@O_J'[%G_ 3X_:3N_B#^SS\8_#]P^FK<7,DB66I6 M^G2WR%M\<>Z:)K6XMQ)L!:*X0-N*A@ ?O?\ %;]H[]GGX$76G6/QP^//@SP; M/K$ACTF'Q7XHM-.>]<$ K"+B1#(5P[-RX>W_ ,$H/V5=0_8B_P"#KS7/V5+OQ[J_B:U\%^'=1LM" MU?7KCS;MM);0()=.AE; !,5E);0_*%7$0"JJX4 'Z8?\$Z?@I^WUX'_X*M_M M#_$;]H+]MC2?''PNUNYU@^ /AS:?%&?59_#:OJZ20+)ISC98^7;AH2%^X3L' M!K[3^+O[3G[-G[/L]G;?'K]H3P/X(DU$$Z?'XO\ %EGIK70!P?+%Q(F_GCC- M?BS_ ,$2O$>G^#O^#B_]OOQ=JV[[+I7_ E]Y<[!D^7%XEB=L>^%->)?\$; :2.3$-M M$T$4,0 0 -N#8 H _I!T/7=$\3Z/;>(O#6LVNHZ?>PK-9WUC<+-#/&PRKHZ$ MJRD<@@D&O.]?_;8_8T\*^/W^%'BC]K?X8Z;XICN/L[^&K_Q[IT.H++G'EFW> M82!L\;=N:^&O^"5?_!(;]OC_ ()^?L._'#]C?QS^V_X?L]+\61WG_"I_$VAV MMU>3>"3/%/%/>%)_LX5F4V\PBC<)%,DC!VWEC^.?[97[%7_!!G]D?]B3Q-X' M@_X*!7WQ?_:A@GGETO5OA^TUQHD\WVOY8I"L%]7FL;N..2\19$66 M%E8*RG! /(KWO_@D=X]\;_%+_@F'\!OB/\2O%VHZ_P"(-;^%NCWFL:UJ]X]Q M=7MQ);(SRRRN2TCL226)))K\>/VDOB7XV^+7_!E5\.O&'Q"\07.J:DFM6NF_ M;+N9I)#;67BF\LK9"S$D[(+>)![(*_7'_@BE_P HC_V-4N;*X9%9XXY1'"WF*K%7@3Y2"PK M\?'_ &NO^#G[_@A#;6;_ +16A^(O%7PPT6>*V,GC**/Q)H;0[@D48U2!VN+, M,,+'&\T>,@>6<;: /W\_X)G?M;:S^W5^PA\-/VJ_$_A(Z%K'BS0"^NZ2(7C2 MVU"WFDM;I463YEC,\$I0,2=A7)/4]MX%_:L_9=^*'CNZ^%OPS_:2\ ^(O$]B M7^V^'-"\8V5W?V^S._?;Q2M(FW!SE1C'-?D?_P %K?\ @MMT+PMHMUXD\3ZU::=IUC T]]?W]RL, M-O$HRTCNY"HH ))) KB_"W[5_[+7CGP7/\ $GP3^TKX UCP[;7HL[G7]*\9 M6-Q917!&1"T\&9(6P"BUYS_P<,?\$'?@3_P2 MG_8E\,?&?]D+XE^-O[*UKQ38>&OB-H7B#65N(=8D^SW%S:Z@42-%1XY+>52H M! ^T#8$&_> ?T:ZW\6_A3X932)/$GQ-\/:>OB Z"U]K4$0U('9C[/N<>=_K M(_N9^^O]X5F:7^TC^SOKGQ5N?@3HGQ[\%WGC>S5S=^#;7Q3:2:K %&6+VBR& M9<#DY7@5_/E_POCM^QC\7?'B>/\ 6]5U'^V_%6IZ M[OO+C5[06H0LBJ8)'DGF++N8'*#LQ8 _I.T_]I+]G;5OBO/\ ?2OCWX+ MN?'-JK-<^#+?Q3:/JT(5=S%K02>,O"'P]\-7GC3Q]XKTW0 M]'TZ$RZAJVL7T=M;6T8ZO)+(0B+SU) K^9G_ (+P?\$F/AY_P1-\-?L\_M8? MLP_%;QC>][K=ND%VE_%A5:(M+]HRI+95DRO@9\?]$G\2_ ?XT>$_&VG6LWDW.H>$?$=KJ4 M$4F,[&>W=U5O8G-7YOBE\,K?Q=+\/[CXBZ#'KT-N9YM$?5X1>1Q!-YD:$MO" MA/FW$8QSTK^:[X8_$[]@/_@F)_P6P^ 'B_\ X([_ +6=_P",OAI\2M2LO"_Q M/\.S7\\ZVR75[':.)&DAB,J8GBN8U(9DEMF^;:P4=]_P40_97G_;@_X.T;W] MDF[^)&M^%M"\<^%["T\7ZCX=NQ!=S:1#X:6[NK1'((7STM_).0PQ*=RLN5(! M^_GPI_:1_9V^/%WJ.G_ [X]^"_&<^D.$U:#PIXIM-1>R;.,3+;R.8SD$8;%? MGQ\=?^"UWC'0O^"__P *O^";'AOQCX-T3X40Z7J-_P#$#Q1+J4$DFHW0T+4Y MHK.2=SY=FD5S#!E%/F-(J@N%)C/P/<_L7>!/^"+'_!T-^S[\%_V/_%/B"W\* M?$#1=/GO-.U;5#.XM=1FU#3KBTD<*OG1[[,3J'!*OL./(O!GQ4CU3Q;XAU.UU.R75+>]N-+U/5WCMY&M&B2$7 M$"*%>)V\LL"Q;#@ _IMM+NTO[6*_L+F.>">-9(9H7#)(A&0RD<$$'((J2L?X M>^"M*^&O@'0_ASH5Q<2V.@:/;:;9RW;JTKQ01+$C.5506*J"2 !G. .E;% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %?BC_P>X?\F7?!S_LJ$_\ Z;IJ_:ZB@#^7_P#X.\_V=M:\ M._\ !0[X:_$OP?I4S_\ "U/A5IEHT'_@F]\ ]%V?9/!'@SP=H-L4'!2SU6:W4CZB/-?OG10!_.I_P M5&\ _#S_ ()1?\%_-8_;H_;1_8SL/B_^SU\9-/+R1ZMX3L]7AM+N2V@2X$4= MZIMQ>PW%MYJJS(6M[@A6&6Q]$?\ !$W]J_X7_M__ /!2OQ-XY_8V_P""/?P/ M^'/P'\#VDLFB?%:/X0V.E>*+*[>U$"VR7EH3")YFDE9HHAF.W+*[L67=^S&N M:#H?B;2Y=#\2:+::A93@">SOK998I #D;D<$'D \CM1H>@Z'X9TN+0_#>BVF MGV4 (@L[&V6**,$Y.U$ Y)/ [T ?S@_LX?MAZQ_P:^?\%7?VA/A3^U'\"/% M.L_#7XJ:A_:/AK4_#5O$;BZM(;JZGTVZM_M$D<4ZB.]F@F42 QR@C)*%6T_^ M"47QL^,?[3?_ =47?[37QO^$VH^!]4^(/A'4M:TOPQJX(NK+1WT2./31*" M=S645NW09W9 (K^B77O"/A/Q4UJ_BCPQIVI&RG$]D;^RCF-O*.CIO!V-[C! MK1H _"7_ ((@:%IOBC_@XY_;W\,ZS!YMGJ,GBZUNX\_?BD\2Q(P_$$U\\_\ M!.G_ (*-^*?^#7SX]?'+]A/]M/\ 9V\5>(-+U'74U+PGJF@B*%KTQ"2&&\3S MV5);2ZA\EO,1BT31,I1FW*G],%97BCP)X'\;K GC3P;I6KK;,6MAJFG17 B8 M]2OF*=I.!T]* /PR^#GQR_X+6_\ !2__ ((C?M>_';XN7FL3Z7XNT]1\%?"] MEXTQ65021S\6_ +]N+]B1?^")?B?] MA;]FS_@GUJ^M?M+:MX5U8^/_ !Q9^$+:X-MI-O7>J2ZAN:Y6&.Q38(=J( MC@CI@R?U9QQI$@BB0*J@!548 'I6;HO@OP=X;U"\U?P[X3TRPN]1DWZA=65A M'%)IH _G2\6^+=$\1_P#!DQX7T?2KU)9] ^(4EAJ:(V3# M.WBR[N@C>A\JYB;'HP]:_:'_ ((I?\HC_P!G+_LC^A_^DB5]/T4 ?CG_ ,'7 M/[/'[9NE6_P@_P""B_['U]XDO/\ A4.K>;XLT;199Y4M5BN8;RRU*2VC.)(H MIHI5E8@[5DC)PH9A\E?MU?\ !V//^WS^PWK_ .QC\+/V'=3L?'?Q-T5- U6X M;6AJ%M#YQ59OL4$<(EGE?E8PVTHSAOG*@-_2#7/:'\)/A3X8\1S>,/#7PR\/ M:=J]R3]HU2QT6"&YESUW2H@9L^YH _!O]HO_ ((>_M5:=_P; > ?A2OP_OKK MXK>!/&DWQ'UCP7:P&2^CL[I;F.:Q2->6N([::WF>,?-O@EC4,VT'Q2R_X+%_ ML$>/_P!GKX5? ;]C?_@@Y\'?%?[2=Y=:?I'BK2_%7P'T:]TN_DCB,<[VOV4I M=333R!7'F*@B!DWF3:"W].%9.G> ? NC^(+CQ;I'@K2;75;O/VK4[;38DN)L MD$[Y%4,V2!G)[4 ?B;_PO@5H.E>(_V?K.V7QEX M*^'6C9TS0#FTNXY;.VB _P!!MKR"9#M'"3(YPJNP^-_^"W'_ 6T^.?_ 6! M_8)\*W/A#]CO5_ 7PO\ "OCFQD\8^+-0U/[3;:AXDDLKQ;>PM'$<8:-(A>2- M]YN8]XCPOF?L?_P7[^#/_!63QI$_!/Q@_X)+?&#Q#I/BCP3J%__ ,)/X.T# M4H8'\065RD&R41W'[FXDMWMSMC;YBMS+LR?E;\VOVO;#_@XC_P""\GA?P!^Q M'\=/^">,]2T2ZTZW,\4$ML;N1[N8[HT2XG?[/ KN[,N, M[10!7_X.#O\ D@?_ 2T_P"Q/7_TE$U[!_P>O?\BK^S'_V.&N_^@:=7[8?" MWX?:)\)/AEX<^%7AHN=.\,Z#9Z3IYDQN,%M"D,><<9VH*WJ /Q!_X/>?^36/ M@?\ ]E U'_TA%<7_ ,'(?[/&M?LU_M^? +_@KGXG_9ML_BI\)-,T'3-$^)WA MG5-'BO[+=;RS?+=1S(\2K/;W6V)Y%*+-;#."R _OE4=Y9VFH6DMA?VL<\$T9 M2:&9 R2*1@JP/!!'!!H _!3]C7]O+]DS_@HA_P %1O 7P<_X)A_\$/\ X%VW MPOTZ.TU#Q]XW\;_ S2K75_#[12M++>P3V#/#:E55(X Y=Y)\$; *Z'6?^5WK M2?\ L3V_]0J:OV\\,>#O"/@FP;2_!OA;3=(M7D,CVVF6,=O&SD %BJ G '/ MM6E0!^&/_!8/_E;._8X_[$_PS_Z?M=KSC_@LS^U /^"8?_!S[\.?V^_BM\,M M:U?PG8?#R.6TATI$$FHQRZ7J.ERB%Y&6,O').&92P(&TG[RY_H5K,\2>"_!W MC)((O%_A/3-56UE\VU74K".<0O\ WEW@[3[CF@#.^#GQ*TOXS_"+PK\8=#LY M;>R\6>&['6;.WF8%XHKJW2=%8C@D*X!QZ5TE P!10 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110!X_XK_P""A7[ O@3Q-J'@KQQ^W#\']&UG2;R2TU72 M-5^)>E6]U9W$;%9(98I+@/&ZL"K*P!!!!%;_ ,*/VM/V5OCSJC:)\#?VF/A] MXSO4C:1K/PIXSL=1E"#JQ2WE)+6Z\%:A:VUT]U#XEM;54=KJVN$,12\E) 0-N5#N !! MI_\ !=#_ ((X_#3_ (()ZK\'?VKOV&/VF_'2:W>^*YTL8_%%_:2:C975K&D\ M=U;RVL$"M&,E)$:,C]X@)(8K0!_4317SQ^T9_P %*/V7NH7%LLWV.U@'SR2#Y^N JH6=E4%AY%_P3K_ .#A MG_@G#_P4P^*[? GX)>*_$GA_QG+!+-I7ASQUHT=E-JL<:EY3;/#--%(RH"YC M+B3:K,%*JQ !]R45\U? S_@K!^R)^T#^W!XX_P"">/@O6->M/B?X AO)M;TK M6M#>UAECMIH8G>WE8D3 ^?%(N.6C;>!@'#_CM_P5:_9'_9Z_;<\"?\$]O&^K MZ]=?$[XAP6DVA:5HNAO=0QQ7$\T*/<2J0(0/(E=L\K&F\C!&0#Z2HKX:_P"" MB?\ P<._\$X?^":'Q:7X#?&OQ3XE\0^,XH(YM6\/>!=&CO9=(CD4/&;IYIH8 MHV9"'$8=I-K*Q4*ZD^^_L4_\% OV6/\ @H-\ A^TA^RW\15U[P]%+)!J<,EN MT%YIEU&@=[:Y@?YHI K*P'*LK*RLRL&(![117YP:]_P=6?\ !(?1/@&/C[#\ M1_%=]#-XCGT:Q\+6?A@C6+N:&"":698))$1(%6YB'FR2(K,65=Q5@/I;]@G_ M (*D_LA?\%(O@#JO[1'[,WC"^NM-\/RR0^)=&U:P^S:EI$JQF4)/"&8?,@W* MZ,Z-A@&)5@H!]$T5\\_\$[/^"GW[*O\ P5%^'VO_ !-_91U;6[S2O#6LKI>J M/K>C-9.MPT2R@*K$[AM8<^M1?L3?\%2OV3_^"@'Q.^)GPB_9VU?7+G6?A+JD M>G^,$U;17M8XYGGNH5$3,3YHWVDW([ 'O0!]%T5^$?$UB+O1-:T]F\NXCR5/# ,CJRLC(X#HZ MLK ,I .NHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH _E@^'O[%'[6O[>'_!P7^UQ\(_V,OVL;[X.^+-,\3^--9N?$EAK-_8M M>6#M9-IX7T+Q)XBEU+3M?OXCYZV4UY=.\B6US&$EB6-5%RK!=Z,Z*_ MZ<_\$I/^"87["5_P!Y&FW;M;:Q -7_ (.3/^")_P"TG^V1\2_AO^W3 M_P $YO!WVSXQ>%KZ"QURULMM3PW M-A#'&K,\DT.G0PX52V'XZUYK^W-XJ_:B_:=_;5_9Z_:N_8^_X(%?'CX&>(?A M9XHMIM=OK'X2:A%!JUK%=VLMLCI;6$2 1*ERA+?>CGV'Y5 'VU_P5S_X)@_\ M%$OV_O@7^SS_ ,%#/@_\/[?P3^UA\'K"UG\0>!Y=;L'^T7,,R7 -K_\ !RU_P4-_;P^&OQ8_;.6]_9O^&'PZ:-O$ MVE^!O$,FGP^*$61)9;=[-+VX:ZDG*)&7EQ##'N*?/E9 #F?^"OFG2?\ !-C_ M (.1/V;/^"C^DP&R\+_%EK?0/&UT.(VF0+I-Y))VPMC=V,J@\EK8D*;'7O!>GMJ%O9M M=L&-M=0>?<21QQ@V\\DGSNH+P1C.<4S_ (-Q/^":_P 3?^":?_!/E? O[0?A M"/1?B7XQ\5WVN^,]/&H6]X]H_#']I_X1_M\_M0WFJ_L'?%3X'?!WXB>& M+O7O#/A_QSX,O].L].N(;\?9;"*:X@CC=XX+VY557YO+BZ$*2&^/OV ?^"T? M_!&3_@HC\5OVD_\ @DC\"M ^*WPQ^,MY+>WGAG4I(W3397FEN(X)K?[5;3!K M>6>X6&6-V0Q28?#' ^OO^"'?[)?_ 5>^&O@7XG_ !T_X*E_'OQ)JOBGXCW< MT_ASX8W_ (K_ +0M/#22/+-*ZJLCP6S222*J6\#>7#%& <%RD8!\'_\ !F7^ MR!^S7\8_A5\;_B_\8O@MX:\6ZS%K6GZ#9R>)M%@ODM;)K>66:.-)E95\UG4. M0,L(U'08JY_P:W>'[#X;?M$_M\_";PFK6VA:.R6EE8AB52.VN];AAZ]U0D9] MZ^KO^#63_@G#^V=_P3B^ 7Q4\$_MF_!O_A#=3\2>,+.^T6V_X2+3M1^T01VI MC=]UC<3*F&XPQ!/88K-_X(&_\$R?VR_V-_VS?VM/B7^U;\$1X=\+?%+7Q-X0 MO3XCTZ]&J6YU'4I6/EVES+)#^ZN(CB54/SXZ@@ 'F'_!D']4U?0KR#(:& MXA;Q-+#,.XVLJO\ \!K2_89_8*_X./?^"0?QJ^)G[)G[#WP*\&^(?!7Q UF- M=.^)OBJ>WETZPBC\R.'5DQ=1R0S"%_WD$L,WS1J%BD &_P"D?^" '_!%_P#: MN_8U\4?M=_";]NCX?R2>#?BO;6V@Z+XF;7;"X;Q78!]7AN;KRK>XFEMC+#=1 M2;9PK#SL8)5@ #\\?^"+?QL\'?#;]@GQO\,=<_X(+_%+]H__ (6#KE];Z]\2 M_"W@B;4H1;FWBB2QAN%L9O)> EY1L<,LDV_@A2/TN_X-$OAY^UY\#/V*_B%\ M!_VJO@/X_P# D>C_ !!&H>%+/Q[X4O=*>2WN[2,3+;K=QH7C66 N=N0'F8GE MJ^5/@U^R3_P/4GMFETU[B); M?[;;[[V V5P8DB+QW"21)+'N3>NYI/UB_P"",G[*_P"V5^R7^Q3IG@?]O;]H MS7_B-\2M4U&74M6N-=\23:M_8D3I&D6FQ7,S%I1&L>]VR1YDL@4LBJQ /K"B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BOG+]OK_@ MI=\'?V -?^%?@'QGX1U[Q3XM^,?CF#PQX)\*>&5A-U<3.\:/<-YTB*L$;S6Z MNV209TP",D8WQ(_X*[_LP?"W_@I/X4_X)8^(_#?C.3XC^,=.CO=*U"TTJV;2 M4C>"XG DF:Y$JMMMI.!$W)7GDD 'U-1110 445\L_LA?\%=_V8/VUOVPOBU^ MQ'\)/#?C.U\7_!K4;^R\5W>NZ5;0V$\EGJ#6$IMI([F1Y%,RDJ7C3*\D \4 M?4U%%?+/[,?_ 5W_9@_:P_;M^)W_!//X:>&_&=MXY^$\-])XEO=8TJVBTV8 M6E[#9R_9Y4N7D//BQ\._@1 MX:\:6-]\'+R*V\5/XFTFVMXIGDENXE-L8KF4R#=9RYWA."GJ<8?[%_\ P7%_ M8_\ V[/V6OBO^UU\&_"?CVT\,?!S3KJ]\56WB#1K2"]FC@L9+UQ;)%=2)(?* MB8 .Z?-@9 YH ^R**\!_X)O?\%'?@/\ \%1_V>YOVE?V==$\3:?X?@\17.BO M!XLT^"VNOM$$<,CL$AFF79B9,'=G(/ [^_4 %%%% !1110 45\Y?\%"/^"EG MP>_X)LCX:Z_\??".O/X7^(GCJ'PM-XNTU8#9^'KF9=\D_;L_X/ +/P=JLGVWPW^S#\,Y;JPLS\T)O#:1%Y\=I$N]8A4MPO\ Q4N;RTCDDL_"KS6KNN3%(?"^ MFQEE]#L=U^C&G_MBV\$/_!YQ\"Y(H55I?"5F\K*N"[?V5JRY/J< #Z 4 ?NC M7\Q'[)O[=_QZ_8D_X+B?MJVO[)W[*^J?%_XH^/\ XH>+M(\'^%[%'-O$T?B2 MZN9[JY\OYS%''&<@%02>70#-?T[U^"?_ 0*UOP+I_\ PBF@#ZK_X(U_\%^_BA^VS^U%XG_X) M]_MY_LW6_P */C5H-O<7-EI]E%<06]^( &GM6M[IGE@N$C83+\[I+$'8%-HW MU/\ @F/^VC\(_C%_P7:_:;_9J\*?L,_#?P3XA\'6>N-JOQ2\.VI76O$@AUFR M@=;MBH#"1I%E;D_/&M?-'[0LNEZ[_P 'J_PSB^%+Q2:G8Z);+XL>T&2DJ^&[ MYIA(0>OV)H5Y[%1[5J_\$3?^5I/]MC_L'^)__4CTV@#/_P"#4G_DZ?\ ;T_[ M&"R_]+M?KC_^#63QEI/PY_X)#?MG?$+7_!&G>)K'0=/O]1O?#>L+NM-6A@T" MXE>TG'>*55,;#^ZYKL/^#4G_ ).G_;T_[&"R_P#2[7Z\O_X-N_\ E!I^WG_V M)^M_^HS=T ??_P#P1%_X*-_LUW__ 2$\;_MNZQ^S?X(^!'@3P3XJUF;7/#O MP_M2MF1;VMH[3K&0I>XE\Q(@HY=EC4/='UW]JO]GS_@ ME-#?_L_>&]3:'4_$>H6.JW,L42$;C-J-N1;0/@J6_&O/,$7QY@DUI8.]H+S1A\V.JB4PD_0'M7Z]?\$?O%'[-B?\&] M'P\U:]O-&3P)I_P:U"/QQYS)]FB=$N?[6$XZ#,OVDN&Y.XD]: -/4?\ @MI\ M//B/_P $8?$__!6;]FCP=#J#->NRK:?JD=Q##<6-P\7/R^:'5P! MOC>-\ /@?"/B#_@Z7_X*/_%7]EFV_::_9 _X)B0ZQX;\(6+2?&#QQJUGJ%UH MNFW8G^,X?^#9+]N74]028>'I M]1W3V=RRBW(?C3?16?C?Q'J]O:6^E: MA#::/=6K[KF2-)/WL(S%O4R(9%!4G\.'3+B2(VKK8WX6XMHI#+$=UHH52^1+_ !$ _5S_ M (+D:)X$_P""A_\ P;_>.OC+X-TJ\2UE\"Z=\0O#2ZG9F&ZL?LK17DBR1MS' M*+;[3"X_AWM7KO\ P0H_:AU;]L#_ ()-_!7XS>)=1:ZUD>%?[%URXE?=)-=Z M;-)I[S2'^_)]F$I/?S<]ZX/4_P!M&S_X*!?\&Z/Q"_;'\2>%(=";QG^S=XQE MUK289&:&"Y@T[4+2Y6(D[C&9H)"@)+;64$D\UYU_P:,VVH0?\$9?#;3$O\;8?[1BM$ MA:W]W:XTRP8@?Q7J'N:^JOC+_P $7/\ A;?_ 6;\!_\%=/^&D_[/_X0G1X; M#_A7W_"'>;]MV6MW!O\ M_VQ?+S]JW8\AO\ 5XS\V1[E^VO_ ,$\/V??V\;[ MX<^(/C$^N:?KGPI\:V_BGP/XB\,Z@EM>V%[$RMM#O'(IB9XX69-O)AC.1MY] MUH ^&/AU_P $7/\ A /^"UGB_P#X+"?\-)_:_P#A*M'-A_PKO_A#O+^RYTVU ML=_V_P"V'?\ \>WF8^SK]_;GC<3XR_\ !%S_ (6W_P %F_ ?_!73_AI/^S_^ M$)T>&P_X5]_PAWF_;=EK=P;_ +?]L7R\_:MV/(;_ %>,_-D?<]% !7X]_%+_ M (-/4\:?M'_&;]L#P7_P4+\2^%/B-X]^(6H>+_A[KOA?PU+IT_A"YN[V[N9K M9YXM0+W<;)="(R(+=P8@XX+1-^PE% 'YO_\ !&?_ (-\_#O_ 3.^,'B?]K/ MXZ_M WGQ=^+_ (F@FMAXFO;*2*/3X9G#W#J9I999[F9E7?<.P.W* #<[/W/[ M$W_!%S_ACK_@J5\;/^"E?_#2?_"1_P#"XK?5(O\ A"_^$.^Q_P!D?;-2MKW/ MVS[9)]HV?9]G^ICW;]W&-I^YZ* /A#_@E)_P1._X=B_%3X]?$S_AIC_A-_\ MA=VH077V+_A#/[-_L7RY[^7;O^V3_:<_;L9VQX\K./FPO+_\$W?^" W_ [X M_8:^/7[%_P#PUC_PEW_"[M'OK'_A)/\ A!/L']B_:-,FL=_V?[=-]IV^;YF/ M,CSMVY&=P_1>B@#XH_X)K_\ !%WX;_L,_P#!.SQ9_P $Y?C!\2(?BSX7\::O MJESKMU<>&CI*S6U[;P0/;B(74Y5E$.Y95D#!B" I4&O@'Q#_ ,&15(VB>&&\BM;R50J 3-&G0'8-H!_= M6B@#X[\3_P#!&OX&Z3_P23UW_@DO^SWXKG\&>']9T'["WBR^TQ=2NY+IKF.X MFOKB-9(!<2R.AR \:J"JJ%5%4:O['O\ P3!_X9/_ ."2X_X)?\_E9W)NPOU?10!^=7[)G_ M ;M_!;X)_\ !*[QW_P2P^/GQHNOB)H'C?QA<>(1XIT_PXNC7>E730V:0/!& MUQ=#S(9+-7#EMKAV1D*E@WRK;?\ !J)^VMJ/@6V_90\8_P#!:+Q==_ 6UOUD M7P+#H]Z(S;K+YJQ+:/?M;1G?\P^\BO\ O!&3Q7[?T4 ?FK_P6\LO@[_P3"_X M-Y_&7[.?P8M3IFC1^%;#P%X2L[B8-+=&\N$CN&=\#?*]O]LG=L#/HO M_@B_^RUJG[&?_!+CX+?L_>(M,:RUG3?!T5_K]G*N'M]1OY'O[J%_]J.:Y>,_ M[GIBNJ_;9_X)X?L_?\% ;GX=Q?M%R:[>:5\-O&L'BG2_#MAJ"16&I7\(Q%]M MC:-C-&JF1=@9,K-("3NX]UH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKG9OBOX MYG@EU_#HQ5A M]EEX(X/\--_X6Y\//^A@_P#)2;_XB@#I**YO_A;GP\_Z&#_R4F_^(H_X6Y\/ M/^A@_P#)2;_XB@#I**YO_A;GP\_Z&#_R4F_^(H_X6Y\//^A@_P#)2;_XB@#I M**YO_A;GP\_Z&#_R4F_^(H_X6Y\//^A@_P#)2;_XB@#I**PM-^)?@G5[Z+3= M.UKS)YFVQI]FD&3]2H%;M !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% 'SQK'_ "%KK_KY?_T(U6JSK'_(6NO^ MOE__ $(U6H **** "BBB@ HHHH W/AO_ ,CSIG_7R/Y&O=*\+^&__(\Z9_U\ MC^1KW2@ HHHH **** "BBB@ HHHH **** "BL3XD?\B-J?\ U['^8KPJ@#Z0 MHKYOHH ^D**^;Z* /I"BOF^B@#Z0HKYOKT#X _\ (6U#_KV3_P!"H ]0HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** /GC6/^0M=?]?+_ /H1JM5G6/\ D+77_7R__H1JM0 4444 %%%% M !1110!N?#?_ )'G3/\ KY'\C7NE>%_#?_D>=,_Z^1_(U[I0 4444 %%%% ! M1110 4444 %%%% &)\2/^1&U/_KV/\Q7A5>Z_$C_ )$;4_\ KV/\Q7A5 !11 M10 4444 %%%% !7H'P!_Y"VH?]>R?^A5Y_7H'P!_Y"VH?]>R?^A4 >H4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% 'SQK'_(6NO^OE__ $(U6JSK'_(6NO\ KY?_ -"-5J "BBB@ HHH MH **** -SX;_ /(\Z9_U\C^1KW2O"_AO_P CSIG_ %\C^1KW2@ HHHH **** M "BBB@ HHHH **** ,3XD?\ (C:G_P!>Q_F*\*KW7XD?\B-J?_7L?YBO"J " MBBB@ HHHH **** "O0/@#_R%M0_Z]D_]"KS^O0/@#_R%M0_Z]D_]"H ]0HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** /GC6/^0M=?]?+_P#H1KS/XW?M8_LX?LW:SX8\._'3XQ:+X9OO M&6M)I7ARVU*X(>ZN721QD*#Y4>(F!FDVQ!BJEPSH&],UC_D+77_7R_\ Z$:_ MG%_:N\$? C]I?_@KS\4?A=^W-X_O]&\4:E^T%I^@:)>:KJ+6EIIO@TZ=JRK, MDCLL2%7_ +%D4.0&\S*AA)+0!_1A'(DJ++$X96 *LIR"/45E:1X]\#>(/$6I M>#]!\9Z3?:OHVS^U]+L]1BEN;'>,IYT2L6BW#D;@,]J^0=6\*?M=_P#!,+_@ MESX<^"_[+<-[^T)\0](N8="\(WM]IK0*(;F>1HII8TED'V>UC8*-TR((T3=( MJK7R;_P;@:#\;/"_[>O[7'A_]I+Q0FM>/[34--C\8ZI'<>:EQJ(N[_SRK;5! M4/D#"A0 H % 'ZV>,?B3\._AVMJ_Q \?:+H2WTWDV)UG58;47$G'R)YC+O M;D<#)YK:!# ,IR#T(K^>SXE^-OV!_P!O3]M?]I;XN_\ !5']J2^\*6.A^(YO M!7P0TVVENYOL2Q2742W8MK6*5Q''Y,$C[E$3274A(I'B\/\ B.POFB , MBV=XDI0'H3M)Q7P%_P %4/\ @BK^P!^T9XM\:?\ !0+]J_XO?$W0!HOA076O M)X7UC3HK6.TL+8_ZN.>QEQ: MI8_\+;O-GA/1-2N$EEM- M9Y1;R3.L<8DFE=G)8*JE$C=57S" ?K+\-_P#D M>=,_Z^1_(U[I7A?PW_Y'G3/^OD?R->Z4 %%%% !1110 4444 %%%% !1110! MB?$C_D1M3_Z]C_,5X57NOQ(_Y$;4_P#KV/\ ,5\U?%KXF>&/@M\*O$WQC\;3 M/'HWA/P]>ZSJ\D2Y9;6U@>>4@=R$1N* .@HK\F[3_@JC_P %9/#?B^S_ &LO M'/P#\#7GPHO_ (>Z'XLN_A;X>FNY]>L/#>I:G-;6]]'+C;-?[0CR1X\ORC'\ MD;"0K^B'[57[9?P$_8X^ ]Y^T'\;/&,=CH\5J&TNS7'VS6+AEW16EK"V&EGD MX 4?=&68JJLP /5**\/_ ."?'[6NI?MB_L1>#/VMO&WAZQ\/3>)M-N[V\T^T MG9X+..&[GB'SOR?DA!)/)4-QHNK77QHL+62:V$K1^889E61?N$X(&>HR"#0!^B-%%?+O_ 5H_P"" ME/AK_@F3^S-_PMO_ (1ZW\0>*]8U%;#PCX8GN&C%[*/GGED* LL,,(9V8#[Q MC4D;P: /J*O0/@#_ ,A;4/\ KV3_ -"KS?2KQM0TNVOW0*T]NDA4= 64''ZU MZ1\ ?^0MJ'_7LG_H5 'J%%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110!\\:Q_R%KK_KY?_P!"-?B'_P % M/OC-_P $U/\ @H[^T?8?!?XO^!W^&/CSP'\=X?!OCOQ?K%W:V.HW7AQ-.U@S M7DK?7=J_B/0XK6>-K1A;.H\_P PVN)_E<1Q M%-^-H !R'_!L[XK^(OB?_@F'86GC?7+S4],T7QOJVF>"[^]#9FTB)HO+V[^0 MBS- -)^%?P MI\'V&@>'="LUM=(T?3(!'!;1+T55'J222*'YY9#B)4'S8Q@# !^/ M?_!/'X=?L*_"W]L7]NKX7?\ !0G3_!=OJ]IJE^VAMXY2W5GTEKG49+F6R,_( MD=)+&4&/]X0T97H:^BO^" _[57PV_91_X(W^&_B+^U]\5[+PAX5N?B1JNE># M]3UZ1UAE1RTPAC(!ZS17[>F8WKZQ_;!_X(]_\$^_VZ?B1:?%[]HGX'+J'B2W MAC@N-7TO6+K3Y;^%!A([@V\B>< %#'YU4!0P KK?C=_P $X_V*OVB?V>O# M?[*7Q8^!-E>?#WPA>V]YX<\,:=J5YIL-C-!!-!&RM9S12'$=Q,"&8AC(68%L M$ 'RU_P"+LQZK\8OB9I/AK:&(+6X9KENG.#-#;*1W#D M5]Z_"SX<^&?@]\,O#OPE\%V8M]'\,:'::3I4 'EV]O"L,:\>BH*Y#]H?]CG M]G']JW5_!NN_'WX>-KUU\/\ Q FN>$I/[9O+46-^C(RS;;::-9<&-/ED#KP> M.3GTV@#<^&__ "/.F?\ 7R/Y&O=*\+^&_P#R/.F?]?(_D:]TH **** "BBB@ M HHHH **** "BBB@#$^)'_(C:G_U['^8KYJ^+7PS\,?&GX5>)O@YXVADDT7Q M9X?O=&U>.)MKM:W4#P2A20<$H[8.*^E?B1_R(VI_]>Q_F*^5_P!HSX6ZK\;_ M (!>-/@[H/C.^\.7_B?PO?:98>(--G>*?39YH'CCN49"&!1V5^""=N.] 'Y8 M>'OB;^W9_P $:?VB9=.^.7@W3/CA\,O 'P=T;2[GQ;X3D-CK.B>$(]4O([2Z MN+67*SRPMYD;)&2/*2,M*/GE?\%7?B_XBUK_ ()^ M^+/V3;6U\?:S^S[I'P^\3_$:]\86T^D+H::E>QR>(>#YLIGA9T$('FB4.Q48 M$=?K?X#^&EA\+O@EHWP<\,S2W%KX=\*V^C:?),0'ECM[98(RQZ9(09]S0!\9 M?\$J/"WC_P *]&^$GAS3H_%GP*A\$VL&F'1 MXO+BGCM]2&;B2Y0%I6G8+N;>0-JK&_TA^PU^QU^T-X"_X(U:!^QKXSUS4OAG M\2H_!.JZ:FJ:1K*/<:%?S75U);SI<6DZOHT&J6T]R0FVWEB656?)PN M$8$\X%?CM_P4 ^*OPT_;6_8Y_:3_ &^_$OQ%T*2W;0HO!GP"\+S:O#]J@T.# M6+0WVK"W+;UFO[B(LIVAUMH(P"/@)I^H?!63P1 M=6/B;Q7<:W$D^ER0P^3:V:VYD$DJR( "ZH0OJM;R"874)DVR7=RL*_N1+]\@=ASB@#[_\ AMXH M\,^,? VF:[X1\16&JV,EHBQWNFW:3Q,RJ%8!T)!(((//!%>N? '_ )"VH?\ M7LG_ *%7@W[.'[/?PE_9=^$&E?!KX)^ ;3PSH&G*\D.D63NT<4TK&28@NS$E MI&9CSC)XKWGX _\ (6U#_KV3_P!"H ]0HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /GC6/^0M=?]?+_ M /H1JM5G6/\ D+77_7R__H1JM0 4444 %%%% !1110!N?#?_ )'G3/\ KY'\ MC7NE>%_#?_D>=,_Z^1_(U[I0 4444 %%%% !1110 4444 %%%% &)\2/^1&U M/_KV/\Q7A5>Z_$C_ )$;4_\ KV/\Q7A5 %1?#^@IKS^*DT2S&J26:VDFI"V3 M[0UNKLZQ&3&XH&9F"YP"Q.,DU;HHH **** "BBB@ KT#X _\A;4/^O9/_0J\ M_KT#X _\A;4/^O9/_0J /4**** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#YXUC_D+77_7R_\ Z$:K59UC M_D+77_7R_P#Z$:K4 %%%% !1110 4444 ;GPW_Y'G3/^OD?R->Z5X7\-_P#D M>=,_Z^1_(U[I0 4444 %%%% !1110 4444 %%%% &)\2/^1&U/\ Z]C_ #%> M%5[K\2/^1&U/_KV/\Q7A5 !1110 4444 %%%% !7H'P!_P"0MJ'_ %[)_P"A M5Y_7H'P!_P"0MJ'_ %[)_P"A4 >H4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SQK'_ "%KK_KY?_T( MU6JSK'_(6NO^OE__ $(U6H **** "BBB@ HHHH W/AO_ ,CSIG_7R/Y&O=*\ M+^&__(\Z9_U\C^1KW2@ HHHH **** "BBB@ HHHH **** ,3XD?\B-J?_7L? MYBO"J]U^)'_(C:G_ ->Q_F*\*H **** "BBB@ HHHH *] ^ /_(6U#_KV3_T M*O/Z] ^ /_(6U#_KV3_T*@#U"BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH \2U3]@CX-:OJ=SJUSXJ\;K)=3O-(L7B^Y50S, M6( !X&3P.U0?\.]_@G_T-OCO_P +*Y_QKW2B@#PO_AWO\$_^AM\=_P#A97/^ M-'_#O?X)_P#0V^.__"RN?\:]THH \+_X=[_!/_H;?'?_ (65S_C1_P .]_@G M_P!#;X[_ /"RN?\ &O=** /"_P#AWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^ M._\ PLKG_&O=** /"_\ AWO\$_\ H;?'?_A97/\ C1_P[W^"?_0V^.__ LK MG_&O=** /"_^'>_P3_Z&WQW_ .%E<_XT?\.]_@G_ -#;X[_\+*Y_QKW2B@#P MO_AWO\$_^AM\=_\ A97/^-'_ [W^"?_ $-OCO\ \+*Y_P :]THH \+_ .'> M_P $_P#H;?'?_A97/^-'_#O?X)_]#;X[_P#"RN?\:]THH \+_P"'>_P3_P"A MM\=_^%E<_P"-'_#O?X)_]#;X[_\ "RN?\:]THH \+_X=[_!/_H;?'?\ X65S M_C1_P[W^"?\ T-OCO_PLKG_&O=** /"_^'>_P3_Z&WQW_P"%E<_XT?\ #O?X M)_\ 0V^._P#PLKG_ !KW2B@#PO\ X=[_ 3_ .AM\=_^%E<_XT?\.]_@G_T- MOCO_ ,+*Y_QKW2B@#PO_ (=[_!/_ *&WQW_X65S_ (T?\.]_@G_T-OCO_P + M*Y_QKW2B@#PO_AWO\$_^AM\=_P#A97/^-'_#O?X)_P#0V^.__"RN?\:]THH M\+_X=[_!/_H;?'?_ (65S_C1_P .]_@G_P!#;X[_ /"RN?\ &O=** /"_P#A MWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^._\ PLKG_&O=** /"_\ AWO\$_\ MH;?'?_A97/\ C1_P[W^"?_0V^.__ LKG_&O=** /"_^'>_P3_Z&WQW_ .%E M<_XT?\.]_@G_ -#;X[_\+*Y_QKW2B@#PO_AWO\$_^AM\=_\ A97/^-'_ [W M^"?_ $-OCO\ \+*Y_P :]THH \+_ .'>_P $_P#H;?'?_A97/^-'_#O?X)_] M#;X[_P#"RN?\:]THH \+_P"'>_P3_P"AM\=_^%E<_P"-=G\&?V:_ 7P,U.]U M;PAK/B&ZDOX%BF76MFNL(B)#+'\^UI<+NY!/'% 'Z5Z7^ MTM^SEK;3IHOQ_P#!-X;6U>YN1:^*K.3R84&7E;;(=J*.2QX'>NMT76M&\2:3 M;:_X>U:VO["\A6:SO;*=989XV&5='4E64CD$'!KX[_95_P"":/\ P1#\/>*M M;UO]D/X+_"J_U6Y\.7>C^(/^$6\2_P!I,VF7T;07$$T:W,@$-/!VJ^);_P9I?BS3+G6-+2-]3TFWOXWN;1 M9%#(98@=T88$$%@,@@BJ'A+XP?"7Q]KVH>%? GQ1\.:UJFDG&JZ;I.MP7-Q9 MG.,2QQN6CYX^8#FOSF^!/_!+W]M#7?\ @E5\4##\2]/\(_M0?M5:I#XC^*WC M'5)9[=M'M;JXC9](A:%))(A;ZT\ ?%Y/C_X;\+^&G\.3R_;?%.EW+M'J=MJ&6)NX6M^99I,E M,@;U#X(!^LVLZSI'AW2+OQ!X@U6VL+"PMI+B^OKR=8H;>%%+/)([$*B*H)+$ M@ DU)8WUEJ=E#J6FWD5Q;W$2RV]Q!('25&&596'# @@@C@@U^87_!R3X=_X M*%_%3]E?XF^#?A5K>B^!?@+X5^%DOB'QUXI2[\[6?%U\KS8T""%2/LUJ!'!) M/,V/,641J642HWZ!_LG_ /)K/PT_[)_HW_I##0!W]%%% !1110 4444 %%%% M !1110 4444 %%%% '$ZW^TK^SGX:U>Y\/\ B/X_>"=/O[.9H;RRO?%5G%-! M(IPR.C2!E8'@@C(J?3/VA/@'K5O#>:-\-_%:Z?<+8>7"^(T-Q%N3S6D^;!YR,\8KZN^,?_ 1D_P""=WQ\_P""<_CW M]G3]@3PMX0\+1^)+Z/7O"7BKP;K374%EXIL%;[%>+<++)L*MNAD*$,(Y9 ,$ M@T ??9( R36#I_Q2^&6K>#IOB+I?Q&T&Y\/VZNUQKMOJ\+V<00X.]?E#XG_X*X?'3]L/_ ()E>!OV0?AW$%UXRU-;=1I\\ZPILF07;7%U.K.@=YCPW0 'V]X'^(/@'XG M: GBKX;>-]'\0Z7)(R1ZEH>IQ7=NS+U421,RDC(R,\5#=_%3X8:?XZM_A??_ M !'T&#Q-=P^=:^'9M8@6^FCP3O2W+>8RX!.0N.*_,_X;>!/@%_P3D_X+B>,/ MAW^Q3X4B\-^ [C]EJ^\9?&;P#X>++I&GW]G? :?>+$"4MKF2'S$\M< QOOV? M.6KRCX-?\$N?@E^U/_P1%\1?\%%/BUHDEY^TOX\\+:S\5[7XOQZC-'JNEZU$ M9[W38[68/FWMHHX;>+R5^4*&( (4J ?M+17C_P#P3Z_: U;]JK]ACX0_M'^( MC'_:OC7XP4 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^7 M/[<_[(O[-_[:O_!P_P##;X._M2_"?3O&7AF+]E/4M1CTC4WE6-;J/72J2YB= M6R%D<=5I,M MP+B2V^SB7R&S* WF&,R#H& XH X[]DG_ ()K_L-?L(ZSK/B']D;]G/1? ][X MAM8K?6KC2IKAC=11,S1JWFR.,!F8\8ZU\=_\%N_@U\*_B#_P4G_8!U?QKX$T M[4KF7XQW]G/-
WBA@NXX9/\ GI&L\22!6R =W&'8']-:\[^,7[*7P"^/ MWQ%^'_Q9^+?@+^UO$'PMUR76/ FH?VI=0?V9>R1B-Y=D,J)-E !ME5U'4 'F M@"/]KW]JOX1?L1?LV^+OVI_CKK#V?ACP=I37E\8%#37#EECAMH5) :665XXD M!(!>1- M-'^(?@S]BO[%K&@ZI;ZCI-Y_PL?Q))Y%S!(LL4FR3461MKJIVL"IQ@@CB@#O M/^"Z7_*'[]HG_LE^H_\ H KW#]D__DUGX:?]D_T;_P!(8:T_CI\#_A=^TK\' M_$7P$^-GAC^VO"?BS2Y-.\0:3]MGMOM5M(,/'YL#I*F?[R,K#L:W/"?A;0O MWA73/!7A:Q^RZ9H^GPV.G6WFL_DP1((XTW.2S850,L23CDDT :%%%% !1110 M 4444 %%%% !1110 4444 %%%% 'Y"_\$]?^"7W[ W[<_P"U3^VG\0OVL_V9 M]"\;ZUI'[5FNZ=INH:K-<*\%KY,$OE#RI4&-\CMR,_-7Z>_LU_LO? /]C[X5 M6OP0_9I^&=CX1\*65U-<6NBZ<\C11RS.7D8&1F;+,23S3/@A^RY\"?V<=>\< M^)O@SX&_L:^^)/C"?Q3XUG_M.ZN/[1U:9426YQ/*XARJ*/+B"1C'"C)KT"@# M\R_V3/@U\+-&_P"#G/\ :>\;:5X$TZ#58_@YX]@ 6PQ)^=MWT7_ ,%3?^"A6O\ [%/@3PM\,_@-X%M_&?QQ^+FL2:%$_!M MS.([>:Z5 UQJ%X^1LLK5&625LC.57 OL MWQ$\9Z'9Z/XE\0_VI=/]LLK7_41>0\I@CVX^\D:L?XB:\S_;>_X)'?\ !/?_ M (*.^+-#\;_MG? )_&>I>&].DL=%G/B_5]/6U@>3S'41V-W"C$M@EF4MP!G M H \\_8]_P"":>E?L_\ [*7Q4\,^-/BS;?$;XZ_'#0]0N/BS\1KB=3)K&I3V MDL,=O",@PV-N)?+AC&T*N6VIN"+XC^Q7^TQ\,/"?_!K7+\0O$FO6]E'X'^!6 MO^&O$%G=3".:TUBUBN;$6$BM@QSR3F%$1@"3/'CA@3]+?L>?\$2/^"8?[ OQ M@'Q[_9+_ &9?^$3\6#2Y].&K?$IK5__ *-,5,D?E7EY-%SL7YMNX8X(YJAX M^_X(6_\ !,;XF_M&77[3?C']G?[3K6I>($U[6M$3Q!?1Z'JFK( GRAPHIC 15 cah-20210630_g3.jpg begin 644 cah-20210630_g3.jpg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end GRAPHIC 16 cah-20210630_g4.jpg begin 644 cah-20210630_g4.jpg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end GRAPHIC 17 cah-20210630_g5.jpg begin 644 cah-20210630_g5.jpg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end GRAPHIC 18 cah-20210630_g6.jpg begin 644 cah-20210630_g6.jpg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end GRAPHIC 19 cah-20210630_g7.jpg begin 644 cah-20210630_g7.jpg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�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end XML 20 cah-20210630_htm.xml IDEA: XBRL DOCUMENT 0000721371 2020-07-01 2021-06-30 0000721371 2020-12-31 0000721371 2021-07-31 0000721371 2019-07-01 2020-06-30 0000721371 2018-07-01 2019-06-30 0000721371 2021-06-30 0000721371 2020-06-30 0000721371 us-gaap:CommonStockMember 2018-06-30 0000721371 us-gaap:RetainedEarningsMember 2018-06-30 0000721371 us-gaap:TreasuryStockMember 2018-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2018-06-30 0000721371 2018-06-30 0000721371 us-gaap:RetainedEarningsMember 2018-07-01 2019-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2018-07-01 2019-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2019-06-30 0000721371 us-gaap:CommonStockMember 2018-07-01 2019-06-30 0000721371 us-gaap:TreasuryStockMember 2018-07-01 2019-06-30 0000721371 us-gaap:CommonStockMember 2019-06-30 0000721371 us-gaap:RetainedEarningsMember 2019-06-30 0000721371 us-gaap:TreasuryStockMember 2019-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2019-06-30 0000721371 2019-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2019-07-01 2020-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2020-06-30 0000721371 us-gaap:CommonStockMember 2019-07-01 2020-06-30 0000721371 us-gaap:TreasuryStockMember 2019-07-01 2020-06-30 0000721371 us-gaap:RetainedEarningsMember 2019-07-01 2020-06-30 0000721371 us-gaap:CommonStockMember 2020-06-30 0000721371 us-gaap:RetainedEarningsMember 2020-06-30 0000721371 us-gaap:TreasuryStockMember 2020-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2020-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2020-07-01 2021-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2021-06-30 0000721371 us-gaap:CommonStockMember 2020-07-01 2021-06-30 0000721371 us-gaap:TreasuryStockMember 2020-07-01 2021-06-30 0000721371 us-gaap:RetainedEarningsMember 2020-07-01 2021-06-30 0000721371 us-gaap:CommonStockMember 2021-06-30 0000721371 us-gaap:RetainedEarningsMember 2021-06-30 0000721371 us-gaap:TreasuryStockMember 2021-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2021-06-30 0000721371 us-gaap:AllowanceForCreditLossMember 2021-06-30 0000721371 us-gaap:AllowanceForCreditLossMember 2020-06-30 0000721371 srt:MinimumMember 2020-07-01 2021-06-30 0000721371 srt:MaximumMember 2020-07-01 2021-06-30 0000721371 us-gaap:AllowanceForLossesOnFinanceReceivablesMember 2021-06-30 0000721371 us-gaap:AllowanceForLossesOnFinanceReceivablesMember 2020-06-30 0000721371 cah:CVSCaremarkCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember cah:PharmaceuticalMember 2020-07-01 2021-06-30 0000721371 cah:CVSCaremarkCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember cah:PharmaceuticalMember 2019-07-01 2020-06-30 0000721371 cah:CVSCaremarkCorporationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember cah:PharmaceuticalMember 2018-07-01 2019-06-30 0000721371 cah:CVSCaremarkCorporationMember cah:PharmaceuticalMember 2021-06-30 0000721371 cah:CVSCaremarkCorporationMember cah:PharmaceuticalMember 2020-06-30 0000721371 cah:OptumRxMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember cah:PharmaceuticalMember 2020-07-01 2021-06-30 0000721371 cah:OptumRxMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember cah:PharmaceuticalMember 2019-07-01 2020-06-30 0000721371 cah:OptumRxMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember cah:PharmaceuticalMember 2018-07-01 2019-06-30 0000721371 cah:OptumRxMember cah:PharmaceuticalMember 2021-06-30 0000721371 cah:OptumRxMember cah:PharmaceuticalMember 2020-06-30 0000721371 cah:GroupPurchasingOrganizationsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2021-06-30 0000721371 cah:GroupPurchasingOrganizationsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2020-06-30 0000721371 cah:GroupPurchasingOrganizationsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2019-06-30 0000721371 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2020-07-01 2021-06-30 0000721371 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2020-07-01 2021-06-30 0000721371 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2020-07-01 2021-06-30 0000721371 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2020-07-01 2021-06-30 0000721371 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2020-07-01 2021-06-30 0000721371 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2020-07-01 2021-06-30 0000721371 us-gaap:LandBuildingsAndImprovementsMember 2021-06-30 0000721371 us-gaap:LandBuildingsAndImprovementsMember 2020-06-30 0000721371 us-gaap:MachineryAndEquipmentMember 2021-06-30 0000721371 us-gaap:MachineryAndEquipmentMember 2020-06-30 0000721371 us-gaap:FurnitureAndFixturesMember 2021-06-30 0000721371 us-gaap:FurnitureAndFixturesMember 2020-06-30 0000721371 cah:CordisDivestitureMember 2021-06-30 0000721371 cah:TotalOpioidLitigationMember 2020-07-01 2021-06-30 0000721371 cah:TotalOpioidLitigationMember 2019-07-01 2020-06-30 0000721371 us-gaap:ShippingAndHandlingMember 2020-07-01 2021-06-30 0000721371 us-gaap:ShippingAndHandlingMember 2019-07-01 2020-06-30 0000721371 us-gaap:ShippingAndHandlingMember 2018-07-01 2019-06-30 0000721371 us-gaap:SubsequentEventMember cah:CordisDivestitureMember 2021-08-02 2021-08-02 0000721371 cah:CordisDivestitureMember 2020-07-01 2021-06-30 0000721371 cah:NaviHealthMember 2018-08-01 2018-08-31 0000721371 cah:NaviHealthMember 2018-07-01 2019-06-30 0000721371 cah:NaviHealthMember 2018-08-01 0000721371 cah:NaviHealthMember 2019-07-01 2020-06-30 0000721371 us-gaap:EmployeeSeveranceMember 2019-06-30 0000721371 us-gaap:FacilityClosingMember 2019-06-30 0000721371 us-gaap:EmployeeSeveranceMember 2019-07-01 2020-06-30 0000721371 us-gaap:FacilityClosingMember 2019-07-01 2020-06-30 0000721371 us-gaap:EmployeeSeveranceMember 2020-06-30 0000721371 us-gaap:FacilityClosingMember 2020-06-30 0000721371 us-gaap:EmployeeSeveranceMember 2020-07-01 2021-06-30 0000721371 us-gaap:FacilityClosingMember 2020-07-01 2021-06-30 0000721371 us-gaap:EmployeeSeveranceMember 2021-06-30 0000721371 us-gaap:FacilityClosingMember 2021-06-30 0000721371 cah:PharmaceuticalMember 2019-06-30 0000721371 cah:MedicalMemberMember 2019-06-30 0000721371 cah:PharmaceuticalMember 2019-07-01 2020-06-30 0000721371 cah:MedicalMemberMember 2019-07-01 2020-06-30 0000721371 cah:PharmaceuticalMember 2020-06-30 0000721371 cah:MedicalMemberMember 2020-06-30 0000721371 cah:PharmaceuticalMember 2020-07-01 2021-06-30 0000721371 cah:MedicalMemberMember 2020-07-01 2021-06-30 0000721371 cah:PharmaceuticalMember cah:CordisDivestitureMember 2021-06-30 0000721371 cah:MedicalMemberMember cah:CordisDivestitureMember 2021-06-30 0000721371 cah:PharmaceuticalMember 2021-06-30 0000721371 cah:MedicalMemberMember 2021-06-30 0000721371 cah:IPRDTrademarksandOtherMember 2021-06-30 0000721371 us-gaap:CustomerRelationshipsMember 2021-06-30 0000721371 us-gaap:CustomerRelationshipsMember 2020-07-01 2021-06-30 0000721371 cah:TrademarksAndPatentsMember 2021-06-30 0000721371 cah:TrademarksAndPatentsMember 2020-07-01 2021-06-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2021-06-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2020-07-01 2021-06-30 0000721371 cah:IPRDTrademarksandOtherMember 2020-06-30 0000721371 us-gaap:CustomerRelationshipsMember 2020-06-30 0000721371 cah:TrademarksAndPatentsMember 2020-06-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2020-06-30 0000721371 srt:MinimumMember 2021-06-30 0000721371 srt:MaximumMember 2021-06-30 0000721371 us-gaap:OtherAssetsMember 2021-06-30 0000721371 us-gaap:OtherAssetsMember 2020-06-30 0000721371 us-gaap:AccruedLiabilitiesMember 2021-06-30 0000721371 us-gaap:AccruedLiabilitiesMember 2020-06-30 0000721371 us-gaap:OtherLiabilitiesMember 2021-06-30 0000721371 us-gaap:OtherLiabilitiesMember 2020-06-30 0000721371 us-gaap:PropertyPlantAndEquipmentMember 2021-06-30 0000721371 us-gaap:PropertyPlantAndEquipmentMember 2020-06-30 0000721371 cah:ASC842Member 2020-07-01 2021-06-30 0000721371 cah:ASC842Member 2019-07-01 2019-07-01 0000721371 2019-07-01 2019-07-01 0000721371 cah:OperatingLeaseMember 2021-06-30 0000721371 cah:FinanceLeaseMember 2021-06-30 0000721371 cah:A2.616Notesdue2022Member 2021-06-30 0000721371 cah:A2.616Notesdue2022Member 2020-06-30 0000721371 cah:A3.2Notesdue2022Member 2021-06-30 0000721371 cah:A3.2Notesdue2022Member 2020-06-30 0000721371 cah:FloatingRateNotesdue2022Member 2021-06-30 0000721371 cah:FloatingRateNotesdue2022Member 2020-06-30 0000721371 cah:A3.2Notesdue2023Member 2021-06-30 0000721371 cah:A3.2Notesdue2023Member 2020-06-30 0000721371 cah:A3.079Notesdue2024Member 2021-06-30 0000721371 cah:A3.079Notesdue2024Member 2020-06-30 0000721371 cah:A3.5Notesdue2025Member 2021-06-30 0000721371 cah:A3.5Notesdue2025Member 2020-06-30 0000721371 cah:A3.75Notesdue2026Member 2021-06-30 0000721371 cah:A3.75Notesdue2026Member 2020-06-30 0000721371 cah:A3.41Notesdue2027Member 2021-06-30 0000721371 cah:A3.41Notesdue2027Member 2020-06-30 0000721371 cah:A4.6Notesdue2043Member 2021-06-30 0000721371 cah:A4.6Notesdue2043Member 2020-06-30 0000721371 cah:A4.5Notesdue2044Member 2021-06-30 0000721371 cah:A4.5Notesdue2044Member 2020-06-30 0000721371 cah:A4.9Notesdue2045Member 2021-06-30 0000721371 cah:A4.9Notesdue2045Member 2020-06-30 0000721371 cah:A4.368Notesdue2047Member 2021-06-30 0000721371 cah:A4.368Notesdue2047Member 2020-06-30 0000721371 cah:A7.0Debenturesduefiscal2027Member 2021-06-30 0000721371 cah:A7.0Debenturesduefiscal2027Member 2020-06-30 0000721371 cah:A7.0Debenturesduefiscal2027Member cah:AllegianceCorporationMember 2021-06-30 0000721371 cah:A3.2Notesdue2022Member 2020-07-01 2021-06-30 0000721371 cah:A2.616Notesdue2022Member 2021-04-01 2021-06-30 0000721371 cah:A32Notes2616NotesMember 2020-07-01 2021-06-30 0000721371 cah:FloatingRateNotesdue2022Member 2020-07-01 2021-06-30 0000721371 cah:A2.616Notesdue2022Member 2020-07-01 2021-06-30 0000721371 cah:FloatingRateNotes2616NotesMember 2020-07-01 2021-06-30 0000721371 cah:A4.625Notesdue2021Member 2019-07-01 2020-06-30 0000721371 cah:A2.616Notesdue2022Member 2019-07-01 2020-06-30 0000721371 cah:A3.2Notesdue2022Member 2019-07-01 2020-06-30 0000721371 cah:FloatingRateNotesdue2022Member 2019-07-01 2020-06-30 0000721371 cah:A3.41Notesdue2027Member 2019-07-01 2020-06-30 0000721371 cah:A4.6Notesdue2043Member 2019-07-01 2020-06-30 0000721371 cah:A4.9Notesdue2045Member 2019-07-01 2020-06-30 0000721371 cah:A4.368Notesdue2047Member 2019-07-01 2020-06-30 0000721371 cah:A2.616Notes3.2Notes3.41Notes4.6Notes4.9Notesand4.368NotesMember 2019-07-01 2020-06-30 0000721371 cah:A24NotesDue2019Member 2019-07-01 2020-06-30 0000721371 cah:A2.616Notesdue2022Member 2018-07-01 2019-06-30 0000721371 cah:A3.2Notesdue2022Member 2018-07-01 2019-06-30 0000721371 cah:FloatingRateNotesdue2022Member 2018-07-01 2019-06-30 0000721371 cah:A3.41Notesdue2027Member 2018-07-01 2019-06-30 0000721371 cah:A1.948Notesdue2019Member 2018-07-01 2019-06-30 0000721371 us-gaap:CommercialPaperMember 2021-06-30 0000721371 us-gaap:RevolvingCreditFacilityMember 2021-06-30 0000721371 cah:ShortTermCreditFacilitiesMember cah:CommittedReceivablesSalesFacilityProgramMember 2021-06-30 0000721371 us-gaap:LetterOfCreditMember 2021-06-30 0000721371 us-gaap:LetterOfCreditMember 2020-06-30 0000721371 cah:CommittedReceivablesSalesFacilityProgramMember 2020-07-01 2021-06-30 0000721371 cah:CommittedReceivablesSalesFacilityProgramMember 2020-06-30 0000721371 cah:CommittedReceivablesSalesFacilityProgramMember 2021-06-30 0000721371 us-gaap:LetterOfCreditMember cah:CommittedReceivablesSalesFacilityProgramMember 2021-06-30 0000721371 us-gaap:LetterOfCreditMember cah:CommittedReceivablesSalesFacilityProgramMember 2020-06-30 0000721371 us-gaap:CommercialPaperMember 2020-06-30 0000721371 cah:ShortTermCreditFacilitiesMember 2020-06-30 0000721371 cah:NewYorkOpioidStewardshipActMember 2021-06-30 0000721371 cah:NewYorkOpioidStewardshipActMember 2020-07-01 2021-06-30 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2021-08-10 0000721371 cah:OpioidLawsuitsStateDomain us-gaap:SubsequentEventMember 2021-08-10 0000721371 cah:TotalOpioidLitigationMember 2021-06-30 0000721371 us-gaap:AccruedLiabilitiesMember cah:TotalOpioidLitigationMember 2021-06-30 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember cah:PrivatePartiesMember 2021-08-10 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember cah:ClassActionLawsuitsMember cah:PrivatePartiesMember 2021-08-10 0000721371 cah:ProductLiabilityLawsuitsMember us-gaap:SubsequentEventMember 2021-08-10 2021-08-10 0000721371 cah:ProductLiabilityLawsuitsMember cah:AlamedaCountyMember us-gaap:SubsequentEventMember 2021-08-10 2021-08-10 0000721371 cah:ProductLiabilityLawsuitsMember us-gaap:SubsequentEventMember 2021-08-10 2021-08-10 0000721371 cah:ProductLiabilityLawsuitsMember cah:OtherJurisdictionsMember us-gaap:SubsequentEventMember 2021-08-10 2021-08-10 0000721371 cah:ProductLiabilityLawsuitsMember us-gaap:SubsequentEventMember 2021-07-01 2021-07-31 0000721371 cah:DOJInvestigationMember 2020-07-01 2021-06-30 0000721371 cah:NetOperatingLossCarrybackMember 2020-07-01 2021-06-30 0000721371 cah:NetOperatingLossCarrybackMember 2021-06-30 0000721371 cah:TotalOpioidLitigationMember 2020-06-30 0000721371 us-gaap:InternalRevenueServiceIRSMember 2021-06-30 0000721371 us-gaap:StateAndLocalJurisdictionMember 2021-06-30 0000721371 us-gaap:ForeignCountryMember 2021-06-30 0000721371 2019-04-01 2019-06-30 0000721371 cah:CareFusionMember 2021-06-30 0000721371 cah:CareFusionMember 2020-06-30 0000721371 cah:PatientRecoveryBusinessMember 2021-06-30 0000721371 cah:PatientRecoveryBusinessMember 2020-06-30 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000721371 us-gaap:FairValueMeasurementsNonrecurringMember 2021-06-30 0000721371 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000721371 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-06-30 0000721371 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000721371 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-06-30 0000721371 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000721371 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-06-30 0000721371 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000721371 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-06-30 0000721371 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000721371 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-06-30 0000721371 cah:DeferredIncomeTaxesandOtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000721371 cah:DeferredIncomeTaxesandOtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-06-30 0000721371 us-gaap:AccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000721371 us-gaap:AccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-06-30 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-06-30 0000721371 us-gaap:InterestRateSwapMember 2021-06-30 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-06-30 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000721371 us-gaap:FairValueHedgingMember 2020-07-01 2021-06-30 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2021-06-30 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember 2020-06-30 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2020-07-01 2021-06-30 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2019-07-01 2020-06-30 0000721371 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2018-07-01 2019-06-30 0000721371 cah:FixedRateDebtMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2020-07-01 2021-06-30 0000721371 cah:FixedRateDebtMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2019-07-01 2020-06-30 0000721371 cah:FixedRateDebtMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2018-07-01 2019-06-30 0000721371 us-gaap:CashFlowHedgingMember 2020-06-30 0000721371 us-gaap:CashFlowHedgingMember 2021-06-30 0000721371 us-gaap:CashFlowHedgingMember 2020-07-01 2021-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2021-06-30 0000721371 us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember 2020-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2020-06-30 0000721371 us-gaap:CommodityContractMember us-gaap:CashFlowHedgingMember 2020-06-30 0000721371 us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember 2020-07-01 2021-06-30 0000721371 us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember 2019-07-01 2020-06-30 0000721371 us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember 2018-07-01 2019-06-30 0000721371 us-gaap:CommodityContractMember us-gaap:CashFlowHedgingMember 2020-07-01 2021-06-30 0000721371 us-gaap:CommodityContractMember us-gaap:CashFlowHedgingMember 2019-07-01 2020-06-30 0000721371 us-gaap:CommodityContractMember us-gaap:CashFlowHedgingMember 2018-07-01 2019-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2020-07-01 2021-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2019-07-01 2020-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2018-07-01 2019-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2020-07-01 2021-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2019-07-01 2020-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2018-07-01 2019-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2020-07-01 2021-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2019-07-01 2020-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2018-07-01 2019-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2021-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2020-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2019-06-30 0000721371 us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2020-07-01 2021-06-30 0000721371 us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-07-01 2020-06-30 0000721371 us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2018-07-01 2019-06-30 0000721371 us-gaap:CommodityContractMember us-gaap:CashFlowHedgingMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2021-06-30 0000721371 us-gaap:CommodityContractMember us-gaap:CashFlowHedgingMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2020-06-30 0000721371 us-gaap:CommodityContractMember us-gaap:CashFlowHedgingMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2019-06-30 0000721371 us-gaap:CurrencySwapMember 2020-06-30 0000721371 us-gaap:CurrencySwapMember 2019-09-30 0000721371 us-gaap:ForeignExchangeContractMember 2020-07-01 2021-06-30 0000721371 us-gaap:ForeignExchangeContractMember 2019-07-01 2020-06-30 0000721371 us-gaap:NondesignatedMember 2020-07-01 2021-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-07-01 2021-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2020-06-30 0000721371 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-07-01 2019-06-30 0000721371 us-gaap:FairValueInputsLevel2Member 2021-06-30 0000721371 us-gaap:FairValueInputsLevel2Member 2020-06-30 0000721371 us-gaap:ForwardContractsMember us-gaap:CashFlowHedgingMember 2021-06-30 0000721371 us-gaap:CurrencySwapMember us-gaap:CashFlowHedgingMember 2021-06-30 0000721371 us-gaap:CurrencySwapMember us-gaap:CashFlowHedgingMember 2020-06-30 0000721371 us-gaap:CommodityContractMember us-gaap:CashFlowHedgingMember 2021-06-30 0000721371 us-gaap:CommonClassAMember 2021-06-30 0000721371 us-gaap:CommonClassBMember 2021-06-30 0000721371 us-gaap:CommonClassAMember 2020-07-01 2021-06-30 0000721371 us-gaap:TreasuryStockMember 2017-07-01 2020-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2020-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2020-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2020-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2020-06-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2020-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2020-07-01 2021-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2020-07-01 2021-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2020-07-01 2021-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-07-01 2020-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2018-07-01 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMemberMember 2020-07-01 2021-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMemberMember 2019-07-01 2020-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMemberMember 2018-07-01 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember 2020-07-01 2021-06-30 0000721371 us-gaap:OperatingSegmentsMember 2019-07-01 2020-06-30 0000721371 us-gaap:OperatingSegmentsMember 2018-07-01 2019-06-30 0000721371 us-gaap:CorporateNonSegmentMember 2020-07-01 2021-06-30 0000721371 us-gaap:CorporateNonSegmentMember 2019-07-01 2020-06-30 0000721371 us-gaap:CorporateNonSegmentMember 2018-07-01 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2020-07-01 2021-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2019-07-01 2020-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2018-07-01 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2020-07-01 2021-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2019-07-01 2020-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2018-07-01 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMemberMember cah:MedicaldistributionandproductsMember 2020-07-01 2021-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMemberMember cah:MedicaldistributionandproductsMember 2019-07-01 2020-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMemberMember cah:MedicaldistributionandproductsMember 2018-07-01 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMemberMember cah:CardinalHealthAtHomeSolutionsMember 2020-07-01 2021-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMemberMember cah:CardinalHealthAtHomeSolutionsMember 2019-07-01 2020-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMemberMember cah:CardinalHealthAtHomeSolutionsMember 2018-07-01 2019-06-30 0000721371 country:US 2020-07-01 2021-06-30 0000721371 country:US 2019-07-01 2020-06-30 0000721371 country:US 2018-07-01 2019-06-30 0000721371 us-gaap:NonUsMember 2020-07-01 2021-06-30 0000721371 us-gaap:NonUsMember 2019-07-01 2020-06-30 0000721371 us-gaap:NonUsMember 2018-07-01 2019-06-30 0000721371 cah:SterileSurgicalGownRecallMemberDomain 2019-07-01 2020-06-30 0000721371 cah:NaviHealthMember 2019-07-01 2020-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2021-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2020-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMemberMember 2021-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMemberMember 2020-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMemberMember 2019-06-30 0000721371 us-gaap:CorporateNonSegmentMember 2021-06-30 0000721371 us-gaap:CorporateNonSegmentMember 2020-06-30 0000721371 us-gaap:CorporateNonSegmentMember 2019-06-30 0000721371 country:US 2021-06-30 0000721371 country:US 2020-06-30 0000721371 country:US 2019-06-30 0000721371 us-gaap:NonUsMember 2021-06-30 0000721371 us-gaap:NonUsMember 2020-06-30 0000721371 us-gaap:NonUsMember 2019-06-30 0000721371 cah:A2011LtipMember 2021-06-30 0000721371 cah:AwardsOtherThanStockOptionsMember cah:A2011LtipMember 2021-06-30 0000721371 us-gaap:EmployeeStockOptionMember cah:A2011LtipMember 2021-06-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2021-06-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2020-06-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2019-06-30 0000721371 us-gaap:EmployeeStockOptionMember 2020-07-01 2021-06-30 0000721371 us-gaap:EmployeeStockOptionMember 2019-07-01 2020-06-30 0000721371 us-gaap:EmployeeStockOptionMember 2018-07-01 2019-06-30 0000721371 us-gaap:PerformanceSharesMember 2020-07-01 2021-06-30 0000721371 us-gaap:PerformanceSharesMember 2019-07-01 2020-06-30 0000721371 us-gaap:PerformanceSharesMember 2018-07-01 2019-06-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2021-06-30 0000721371 us-gaap:EmployeeStockOptionMember 2021-06-30 0000721371 us-gaap:EmployeeStockOptionMember 2020-06-30 0000721371 us-gaap:EmployeeStockOptionMember 2019-06-30 0000721371 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-07-01 2021-06-30 0000721371 srt:MinimumMember us-gaap:PerformanceSharesMember 2020-07-01 2021-06-30 0000721371 srt:MaximumMember us-gaap:PerformanceSharesMember 2020-07-01 2021-06-30 0000721371 us-gaap:PerformanceSharesMember 2019-06-30 0000721371 us-gaap:PerformanceSharesMember 2020-06-30 0000721371 us-gaap:PerformanceSharesMember 2021-06-30 0000721371 us-gaap:AllowanceForCreditLossMember 2020-07-01 2021-06-30 0000721371 us-gaap:AllowanceForLossesOnFinanceReceivablesMember 2020-07-01 2021-06-30 0000721371 us-gaap:SalesReturnsAndAllowancesMember 2020-06-30 0000721371 us-gaap:SalesReturnsAndAllowancesMember 2020-07-01 2021-06-30 0000721371 us-gaap:SalesReturnsAndAllowancesMember 2021-06-30 0000721371 us-gaap:AllowanceForLoanAndLeaseLossesMember 2020-06-30 0000721371 us-gaap:AllowanceForLoanAndLeaseLossesMember 2020-07-01 2021-06-30 0000721371 us-gaap:AllowanceForLoanAndLeaseLossesMember 2021-06-30 0000721371 us-gaap:AllowanceForCreditLossMember 2019-06-30 0000721371 us-gaap:AllowanceForCreditLossMember 2019-07-01 2020-06-30 0000721371 us-gaap:AllowanceForLossesOnFinanceReceivablesMember 2019-06-30 0000721371 us-gaap:AllowanceForLossesOnFinanceReceivablesMember 2019-07-01 2020-06-30 0000721371 us-gaap:SalesReturnsAndAllowancesMember 2019-06-30 0000721371 us-gaap:SalesReturnsAndAllowancesMember 2019-07-01 2020-06-30 0000721371 us-gaap:AllowanceForLoanAndLeaseLossesMember 2019-06-30 0000721371 us-gaap:AllowanceForLoanAndLeaseLossesMember 2019-07-01 2020-06-30 0000721371 us-gaap:AllowanceForCreditLossMember 2018-06-30 0000721371 us-gaap:AllowanceForCreditLossMember 2018-07-01 2019-06-30 0000721371 us-gaap:AllowanceForLossesOnFinanceReceivablesMember 2018-06-30 0000721371 us-gaap:AllowanceForLossesOnFinanceReceivablesMember 2018-07-01 2019-06-30 0000721371 us-gaap:SalesReturnsAndAllowancesMember 2018-06-30 0000721371 us-gaap:SalesReturnsAndAllowancesMember 2018-07-01 2019-06-30 0000721371 us-gaap:AllowanceForLoanAndLeaseLossesMember 2018-06-30 0000721371 us-gaap:AllowanceForLoanAndLeaseLossesMember 2018-07-01 2019-06-30 0000721371 cah:PricingDisputesMember 2020-07-01 2021-06-30 0000721371 cah:PricingDisputesMember 2019-07-01 2020-06-30 0000721371 cah:PricingDisputesMember 2018-07-01 2019-06-30 0000721371 cah:PriorYearRecoveriesMember 2020-07-01 2021-06-30 0000721371 cah:PriorYearRecoveriesMember 2019-07-01 2020-06-30 0000721371 cah:PriorYearRecoveriesMember 2018-07-01 2019-06-30 iso4217:USD shares iso4217:USD shares pure cah:organization cah:segment cah:StateAG cah:lawsuit cah:plaintiff iso4217:JPY iso4217:EUR cah:vestingPeriods false 2021-06-30 2021 FY 0000721371 --06-30 10-K true false 1-11373 Cardinal Health, Inc. OH 31-0958666 7000 Cardinal Place Dublin OH 43017 (614) 757-5000 Common shares (without par value) CAH NYSE Yes No Yes Yes Large Accelerated Filer false false true false 15693865917 290441408 <div style="text-align:center">Documents Incorporated by Reference: </div><div style="text-align:justify">Portions of the registrant’s Definitive Proxy Statement to be filed for its 2021 Annual Meeting of Shareholders are incorporated by reference into the sections of this Form 10-K addressing the requirements of Part III of Form 10-K.</div> 162467000000 152922000000 145534000000 155689000000 146054000000 138700000000 6778000000 6868000000 6834000000 4533000000 4572000000 4480000000 114000000 122000000 125000000 451000000 524000000 621000000 -79000000 -7000000 488000000 -1129000000 -5741000000 -36000000 472000000 -4098000000 2060000000 47000000 1000000 -15000000 180000000 238000000 294000000 -14000000 -16000000 0 -2000000 579000000 0 323000000 -3772000000 1751000000 -289000000 -79000000 386000000 612000000 -3693000000 1365000000 1000000 3000000 2000000 611000000 -3696000000 1363000000 2.09 -12.61 4.55 2.08 -12.61 4.53 292000000 293000000 300000000 294000000 293000000 301000000 612000000 -3693000000 1365000000 46000000 3000000 18000000 24000000 -28000000 -5000000 70000000 -25000000 13000000 682000000 -3718000000 1378000000 1000000 3000000 2000000 681000000 -3721000000 1376000000 3407000000 2771000000 9103000000 8264000000 14594000000 13198000000 2843000000 1707000000 1101000000 0 31048000000 25940000000 2360000000 2366000000 10094000000 11275000000 951000000 1185000000 44453000000 40766000000 23700000000 21374000000 871000000 10000000 2957000000 2231000000 96000000 0 27624000000 23615000000 5365000000 6765000000 9670000000 8594000000 500000 500000 0 0 0 0 755000000 755000000 327000000 327000000 2806000000 2789000000 1205000000 1170000000 36000000 34000000 2186000000 2066000000 -34000000 -104000000 1791000000 1789000000 3000000 3000000 1794000000 1792000000 44453000000 40766000000 327000000 2730000000 4645000000 18000000 1224000000 -92000000 0 6059000000 1363000000 2000000 1365000000 13000000 13000000 0 33000000 1000000 34000000 67000000 11000000 600000000 600000000 575000000 575000000 0 -1000000 0 0 -1000000 327000000 2763000000 5434000000 28000000 1790000000 -79000000 2000000 6330000000 -3696000000 3000000 -3693000000 -25000000 -25000000 0 26000000 0 74000000 100000000 7000000 350000000 350000000 570000000 570000000 0 -2000000 0 -2000000 0 327000000 2789000000 1170000000 35000000 2066000000 -104000000 3000000 1792000000 611000000 1000000 612000000 70000000 70000000 0 17000000 3000000 80000000 97000000 4000000 200000000 200000000 576000000 576000000 -1000000 -1000000 327000000 2806000000 1205000000 36000000 2186000000 -34000000 3000000 1794000000 612000000 -3693000000 1365000000 783000000 913000000 1000000000 0 0 -3000000 -2000000 579000000 0 -79000000 -7000000 488000000 -14000000 -16000000 0 89000000 90000000 82000000 496000000 -961000000 -83000000 65000000 106000000 88000000 904000000 -82000000 751000000 1584000000 409000000 551000000 2325000000 -162000000 1864000000 -452000000 -6550000000 -193000000 2429000000 1960000000 2722000000 3000000 0 82000000 400000000 375000000 328000000 22000000 20000000 18000000 47000000 886000000 3000000 0 2000000 763000000 -378000000 493000000 338000000 0 -2000000 0 -18000000 -112000000 0 570000000 1399000000 1102000000 8000000 8000000 -14000000 573000000 569000000 577000000 200000000 350000000 600000000 -1317000000 -2200000000 -2293000000 11000000 -13000000 1000000 -109000000 0 0 636000000 240000000 768000000 2771000000 2531000000 1763000000 3407000000 2771000000 2531000000 182000000 226000000 285000000 273000000 368000000 311000000 <div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify">1. Basis of Presentation and Summary of Significant Accounting Policies </div><div style="margin-bottom:3pt;text-align:justify">Cardinal Health, Inc. is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. References to “we”, “our” and similar pronouns in these consolidated financial statements are to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context otherwise requires.</div><div style="margin-bottom:3pt;text-align:justify">Our fiscal year ends on June 30. References to fiscal 2021, 2020 and 2019 in these consolidated financial statements are to the fiscal years ended June 30, 2021, 2020 and 2019, respectively.</div><div>Basis of Presentation</div><div style="margin-bottom:3pt;text-align:justify">Our consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</div><div>Use of Estimates</div><div style="margin-bottom:3pt;text-align:justify">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates, judgments and assumptions are used in the accounting and disclosure related to, among other items, allowance for doubtful accounts, inventory valuation and reserves, goodwill and other intangible asset impairment, loss contingencies (including product liability and self-insurance accruals), and income taxes. Actual amounts could ultimately differ from these estimated amounts.</div><div style="margin-bottom:3pt;text-align:justify">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.</div><div>Cash Equivalents</div><div style="margin-bottom:3pt;text-align:justify">We consider liquid investments purchased with an initial maturity of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.</div><div>Receivables and Allowance for Doubtful Accounts</div><div style="margin-bottom:3pt;text-align:justify">Trade receivables are presented net of an allowance for doubtful accounts of $242 million and $206 million at June 30, 2021 and 2020, respectively. An account is considered past due on the first </div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify">day after its due date. In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account is considered past due. We regularly monitor past due accounts and establish appropriate reserves to cover potential losses, and consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts.</div><div style="margin-bottom:3pt;text-align:justify">We provide financing to various customers. Such financing arrangements range from 1 year to 5 years at interest rates that are generally subject to fluctuation. Interest income on these arrangements is recognized as it is earned. The financings may be collateralized, guaranteed by third parties or unsecured. Finance notes, net and related accrued interest were $63 million (current portion $7 million) and $104 million (current portion $12 million) at June 30, 2021 and 2020, respectively, and are included in other assets (current portion is included in prepaid expenses and other) in the consolidated balance sheets. Finance notes receivable allowance for doubtful accounts were $12 million and $27 million at June 30, 2021 and 2020, respectively. We estimate an allowance for these financing receivables based on historical collection rates and the credit worthiness of the customer. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts.</div><div>Concentrations of Credit Risk</div><div style="margin-bottom:3pt;text-align:justify">We maintain cash depository accounts with major banks, and we invest in high quality, short-term liquid instruments, and in marketable securities. Our short-term liquid instruments mature within three months and we have not historically incurred any related losses.</div><div style="margin-bottom:3pt;text-align:justify">Our trade receivables and finance notes and related accrued interest are exposed to a concentration of credit risk with certain large customers and with customers in the retail and healthcare sectors. Credit risk can be affected by changes in reimbursement and other economic pressures impacting the healthcare industry. With respect to customers in the retail and healthcare sectors, such credit risk is limited due to supporting collateral and the diversity of the customer base, including its wide geographic dispersion. We perform regular credit evaluations of our customers’ financial conditions and maintain reserves for losses through the established allowance for doubtful accounts. Historically, such losses have been within our expectations. Refer to the "Receivables and Allowance for Doubtful Accounts" section within this Note for additional information on the accounting treatment of reserves for allowance for doubtful accounts. </div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div>Major Customers</div><div style="margin-bottom:3pt;text-align:justify">CVS Health Corporation ("CVS") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables. These customers are primarily serviced through our Pharmaceutical segment.</div><div style="margin-bottom:3pt;text-align:justify">In August 2021, we extended our pharmaceutical distribution agreements with CVS through June 2027. </div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes historical percent of revenue and gross trade receivables from CVS and OptumRx:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:35.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Percent of Revenue</td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Percent of Gross Trade Receivables at June 30</td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">CVS</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">OptumRx</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div><div style="margin-bottom:3pt;text-align:justify">We have entered into agreements with group purchasing organizations (“GPOs”) which act as purchasing agents that negotiate vendor contracts on behalf of their members. Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue. Sales to members of these two GPOs collectively accounted for 15 percent, 16 percent and 22 percent of revenue for fiscal 2021, 2020 and 2019, respectively. Our trade receivable balances are with individual members of the GPO, and therefore no significant concentration of credit risk exists with these types of arrangements.</div><div>Inventories</div><div style="margin-bottom:3pt;text-align:justify">A portion of our inventories (50 percent and 56 percent at June 30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These inventories are included within the core pharmaceutical distribution facilities of our Pharmaceutical segment (“distribution facilities”) and are primarily merchandise inventories. The LIFO method presumes that the most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue. We believe that the average cost method of inventory valuation provides a reasonable approximation of the current cost of replacing inventory within the distribution facilities. As such, the LIFO reserve is the difference between (a) inventory at the lower of LIFO cost or market and (b) inventory at replacement cost determined using the average cost method of inventory valuation.</div><div style="margin-bottom:3pt;text-align:justify">At June 30, 2021 and 2020, respectively, inventories valued at LIFO cost were $565 million and $411 million higher than the average cost value. We do not record inventories in excess of replacement cost. As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020. </div><div style="margin-bottom:3pt;text-align:justify">Our remaining inventory, including inventory in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value. Net realizable value is defined as the estimated selling prices and estimated sales demand in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Due to the unprecedented demand for </div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify">certain personal protective equipment as a result of COVID-19, our Medical segment manufactured and sourced inventory at higher costs than in periods prior to COVID-19. Personal protective equipment ("PPE") refers to protective clothing, medical and non-medical grade gloves, face shields, face masks and other equipment designed to protect the wearer from injury or the spread of infection or illness. As selling prices and customer demand have decreased compared to the peak of COVID-19, we recorded a reserve of $197 million, primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value.</div><div style="margin-bottom:3pt;text-align:justify">We reserve for inventory obsolescence using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, age and expiration dates of on-hand inventory and manufacturer return policies. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory which were $185 million and $155 million at June 30, 2021 and 2020, respectively.</div><div>Cash Discounts</div><div style="margin-bottom:3pt;text-align:justify">Manufacturer cash discounts are recorded as a component of inventory cost and recognized as a reduction of cost of products sold as inventory is sold.</div><div>Property and Equipment</div><div style="text-align:justify">Property and equipment are carried at cost less accumulated depreciation. Property and equipment held for sale are recorded at the lower of cost less accumulated depreciation before the decision to dispose of the asset was made or fair value less cost to sell. When certain events or changes in operating conditions occur, an impairment assessment may be performed on the recoverability of the carrying amounts.</div><div style="margin-top:3pt;text-align:justify">Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which are depreciated over the terms of their respective leases. We generally use the following range of useful lives for our property and equipment categories: buildings and improvements—3 to 39 years; machinery and equipment—3 to 20 years; and furniture and fixtures—3 to 7 years. We recorded depreciation and amortization expense of $377 million, $405 million and $455 million for fiscal 2021, 2020 and 2019, respectively.</div><div style="margin-top:3pt;text-align:justify">The following table presents the components of property and equipment, net at June 30:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Land, building and improvements</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,359 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,185 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Machinery and equipment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,093 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,008 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Furniture and fixtures</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total property and equipment, at cost</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,588 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,331 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Accumulated depreciation and amortization</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,228)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,965)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Property and equipment, net</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,360 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,366 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify">Repairs and maintenance expenditures are expensed as incurred. Interest on long-term projects is capitalized using a rate that approximates the weighted-average interest rate on long-term </div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify">obligations, which was 3 percent at June 30, 2021. The amount of capitalized interest was immaterial for all periods presented.</div><div>Goodwill and Other Intangible Assets</div><div style="margin-bottom:3pt;text-align:justify">Purchased goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment annually or when indicators of impairment exist.</div><div style="margin-bottom:3pt;text-align:justify">Purchased goodwill is tested for impairment at least annually. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. There is an option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the quantitative goodwill impairment test. We have elected to bypass the qualitative assessment for our annual goodwill impairment test in the current year. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. </div><div style="margin-bottom:3pt;text-align:justify">Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. </div><div style="margin-bottom:3pt;text-align:justify">We have two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. These operating segments are comprised of divisions (components), for which discrete financial information is available. Components are aggregated into reporting units for purposes of goodwill impairment testing to the extent that they share similar economic characteristics. Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (“Medical Unit”); and Cardinal Health at-Home Solutions division.</div><div style="margin-bottom:3pt;text-align:justify">Fair value can be determined using market, income or cost-based approaches. Our determination of estimated fair value of the reporting units is based on a combination of the income-based and market-based approaches. Under the income-based approach, we use a discounted cash flow model in which cash flows anticipated over several future periods, plus a terminal value at the end of that time horizon, are discounted to their present value using an appropriate risk-adjusted rate of return. We use our internal forecasts to estimate future cash flows, which we believe are consistent with those of a market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit. Actual results may differ materially from those used in our forecasts. We use discount rates that are commensurate with the risks and uncertainty inherent in the respective reporting units and in our internally-developed forecasts. Discount rates used in our reporting unit valuations ranged from 8.5 percent to 11.5 percent. Under the market-based guideline public company method, we determine fair value by comparing our reporting units to similar businesses or guideline companies whose securities are actively traded in public markets. We also use the guideline transaction method to </div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify">determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units. To further confirm fair value, we compare the aggregate fair value of our reporting units to our total market capitalization. Estimating the fair value of reporting units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results. The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment.</div><div style="margin-bottom:3pt;text-align:justify">We performed annual impairment testing in fiscal 2021, 2020 and 2019 and concluded that there were no impairments of goodwill as the estimated fair value of each reporting unit exceeded its carrying value.</div><div style="margin-bottom:3pt;text-align:justify">The impairment test for indefinite-lived intangibles other than goodwill involves first assessing qualitative factors to determine if it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount. If so, then a quantitative test is performed to compare the estimated fair value of the indefinite-lived intangible asset to the respective asset's carrying amount. Our qualitative evaluation requires the use of estimates and significant judgments and considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.</div><div style="margin-bottom:3pt;text-align:justify">Intangible assets with finite lives, primarily customer relationships; trademarks, trade names and patents; and developed technology, are amortized using a combination of straight-line and accelerated methods based on the expected cash flows from the asset over their estimated useful lives. We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group. Actual results may differ materially from those used in our forecasts.</div><div>Assets Held for Sale</div><div style="margin-bottom:3pt;text-align:justify">We classify assets and liabilities (the “disposal group”) as held for sale when management commits to a plan to sell the disposal group in its present condition and at a price that is reasonable in relation to its current fair value. We also consider whether an active program to locate a buyer has been initiated and if it is probable that the sale will occur within one year without significant changes to the plan to sell. Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization.</div><div style="margin-bottom:3pt;text-align:justify">On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman & Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and certain liabilities, including product liability for </div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify">lawsuits related to inferior vena cava filters in the U.S. and Canada as described in <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_130" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a> of the “Notes to Consolidated Financial Statements.” The transaction closed on August 2, 2021. See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_106" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a> for additional information.</div><div>Investments</div><div style="margin-bottom:3pt;text-align:justify">Investments in non-marketable equity securities are accounted for under the fair value, equity or net asset value method of accounting and are included in other assets in the consolidated balance sheets. For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which we can exercise significant influence but do not control, we use the equity method of accounting. Our share of the earnings and losses are recorded in other (income)/expense, net in the consolidated statements of earnings/(loss). We monitor our investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.</div><div>Vendor Reserves</div><div style="margin-bottom:3pt;text-align:justify">In the ordinary course of business, our vendors may dispute deductions taken against payments otherwise due to them or assert other disputes. These disputes are researched and resolved based upon the findings of the research performed. At any given time, there are outstanding items in various stages of research and resolution. In determining appropriate reserves for areas of exposure with our vendors, we assess historical experience and current outstanding claims. We have established various levels of reserves based on the type of claim and status of review. Though the claim types are relatively consistent, we periodically refine our methodology by updating the reserve estimate percentages to reflect actual historical experience. The ultimate outcome of certain claims may be different than our original estimate and may require an adjustment. Adjustments to vendor reserves are included in cost of products sold. In addition, the reserve balance will fluctuate due to variations of outstanding claims from period-to-period, timing of settlements and specific vendor issues, such as bankruptcies. Vendor reserves were $77 million at both June 30, 2021 and 2020, excluding third-party returns. See Third-Party Returns section within this Note for a description of third-party returns.</div><div>Distribution Services Agreement and Other Vendor Fees</div><div style="margin-bottom:3pt;text-align:justify">Our Pharmaceutical segment recognizes fees received from distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors’ inventory when those fees have been earned and we are entitled to payment. Since the benefit provided to a vendor is related to the purchase and distribution of the vendor’s inventory, we recognize the fees as a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold.</div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div>Loss Contingencies and Self-Insurance</div><div style="margin-bottom:3pt;text-align:justify">Loss Contingencies</div><div style="margin-bottom:3pt;text-align:justify">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. </div><div style="margin-bottom:3pt;text-align:justify">In connection with the opioid litigation as described further in the <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_130" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a>, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020 respectively which were retained at Corporate. In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement, subject to certain conditions and contingencies. There is no assurance that the contingencies to the proposed settlement agreement will be satisfied. </div><div style="margin-bottom:3pt;text-align:justify">We develop and periodically update reserve estimates for the Cordis inferior vena cava ("Cordis IVC") claims, including those received to date and expected to be received in the future and related costs. To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated indemnity severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs.</div><div style="margin-bottom:3pt;text-align:justify">Self-Insurance</div><div style="margin-bottom:3pt;text-align:justify">We also self-insure for employee healthcare, general liability, certain product liability matters, auto liability, property and workers' compensation. Self-insurance accruals include an estimate for expected settlements or pending claims, defense costs, administrative fees, claim adjustment costs and an estimate for claims incurred but not reported. </div><div style="margin-bottom:3pt;text-align:justify">Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies and other liabilities is highly subjective and requires judgments about future events. We regularly review contingencies and our self-insurance accruals to determine whether our accruals and related disclosures are adequate. Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.</div><div style="margin-bottom:3pt;text-align:justify">The amount of ultimate loss may differ materially from these estimates. We recognize these estimated loss contingencies, income from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss). See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_130" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a> for additional information regarding loss contingencies and product liability lawsuits.</div><div>Guarantees</div><div style="margin-bottom:3pt;text-align:justify">In the ordinary course of business, we agree to indemnify certain other parties under acquisition and disposition agreements, customer agreements, intellectual property licensing agreements, and other agreements. Such indemnification obligations vary in scope and, when defined, in duration. In many cases, a maximum obligation is not explicitly stated, and therefore the overall maximum amount of the liability under such indemnification obligations cannot be reasonably estimated. Where appropriate, such indemnification obligations are recorded as a liability. Historically, we have not, individually or in the aggregate, made </div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify">payments under these indemnification obligations in any material amounts. In certain circumstances, we believe that existing insurance arrangements, subject to the general deduction and exclusion provisions, would cover portions of the liability that may arise from these indemnification obligations. In addition, we believe that the likelihood of a material liability being triggered under these indemnification obligations is not probable.</div><div style="margin-bottom:3pt;text-align:justify">From time to time we enter into agreements that obligate us to make fixed payments upon the occurrence of certain events. Such obligations primarily relate to obligations arising under acquisition transactions, where we have agreed to make payments based upon the achievement of certain financial performance measures by the acquired business. Generally, the obligation is capped at an explicit amount. There were no material obligations at June 30, 2021. </div><div>Income Taxes</div><div style="margin-bottom:3pt;text-align:justify">We account for income taxes using the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in the respective jurisdictions in which we operate. We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized. The realizability of deferred tax assets depends on our ability to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence.</div><div style="margin-bottom:3pt;text-align:justify">Deferred taxes for non-U.S. liabilities are not provided on the unremitted earnings of subsidiaries outside of the United States when it is expected that these earnings are indefinitely reinvested.</div><div style="margin-bottom:3pt;text-align:justify">We operate in a complex multinational tax environment and are subject to tax treaty arrangements and transfer pricing guidelines for intercompany transactions that are subject to interpretation. Uncertainty in a tax position may arise as tax laws are subject to interpretation. </div><div style="margin-bottom:3pt;text-align:justify">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits. </div><div style="margin-bottom:3pt;text-align:justify">See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_133" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 8</a> for additional information regarding income taxes.</div><div>Other Accrued Liabilities</div><div style="margin-bottom:6pt;text-align:justify">Other accrued liabilities represent various current obligations, including certain accrued operating expenses and taxes payable.</div><div>Noncontrolling Interests</div><div style="margin-bottom:3pt;text-align:justify">Noncontrolling interests represent the portion of net earnings, comprehensive income and net assets that is not attributable to Cardinal Health, Inc. </div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div>Share-Based Compensation</div><div style="margin-bottom:3pt;text-align:justify">Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value of the awards. The fair value of restricted share units and performance share units is determined by the grant date market price of our common shares. The fair value of stock options is determined on the grant date using a lattice valuation model. The compensation expense associated with nonvested performance share units is dependent on our periodic assessment of the probability of the targets being achieved and our estimate, which may vary over time, of the number of shares that ultimately will be issued. The compensation expense recognized for share-based awards is net of estimated forfeitures and is recognized ratably over the service period of the awards. All income tax effects of share-based awards are recognized in the consolidated statements of earnings/(loss) as awards vest or are settled. We classify share-based compensation expense in distribution, selling, general and administrative ("SG&A") expenses to correspond with the same line item as the majority of the cash compensation paid to employees. If awards are modified in connection with a restructuring activity, the incremental share-based compensation expense is classified in restructuring and employee severance. See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_160" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 14</a> for additional information regarding share-based compensation.</div><div>Dividends</div><div style="margin-bottom:3pt;text-align:justify">We paid cash dividends per common share of $1.94, $1.92 and $1.91 in fiscal 2021, 2020 and 2019, respectively.</div><div>Revenue Recognition</div><div style="margin-bottom:3pt;text-align:justify">We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers.</div><div style="margin-bottom:3pt;text-align:justify">Revenue in both segments is primarily related to the distribution of pharmaceutical and medical products, which include both manufactured and sourced products, and we recognize at a point in time when title transfers to customers and we have no further obligation to provide services related to such merchandise. Service revenues are recognized over the period that services are provided to the customer. Revenues derived from services are not material for either segment for all periods presented.</div><div style="margin-bottom:3pt;text-align:justify">We are generally the principal in a transaction, therefore our revenue is primarily recorded on a gross basis. When we are a principal in a transaction, we have determined that we control the ability to direct the use of the product or service prior to transfer to a customer, are primarily responsible for fulfilling the promise to provide the product or service to our customer, have discretion in establishing prices, and ultimately control the transfer of the product or services provided to the customer. </div><div>Sales Returns and Allowances</div><div style="margin-bottom:3pt;text-align:justify">Revenue is recorded net of sales returns and allowances. Revenues are measured based on the amount of consideration that we expect to receive, reduced by estimates for return allowances, discounts, rebates and other variable consideration. Sales returns are recorded based on estimates using historical </div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify">data. Our customer return policies generally require that the product be physically returned, subject to restocking fees. We only allow customers to return products for credit in a condition suitable to be added back to inventory and resold at full value (“merchantable product”) or returned to vendors for credit. Product returns are generally consistent throughout the year and typically are not specific to any particular product or customer.</div><div style="margin-bottom:3pt;text-align:justify">We accrue for estimated sales returns and allowances at the time of sale based upon historical customer return trends, margin rates and processing costs. Our accrual for sales returns is reflected as a reduction of revenue and cost of products sold for the sales price and cost, respectively. At June 30, 2021 and 2020, the accrual for estimated sales returns and allowances was $689 million and $495 million, respectively, which is reflected in trade receivables, net and inventories, net in the consolidated balance sheets. Sales returns and allowances were $2.6 billion, $2.3 billion and $2.2 billion, for fiscal 2021, 2020 and 2019, respectively, and the net impact on net earnings/(loss) in the consolidated statements of earnings/(loss) was immaterial in fiscal 2021, 2020 and 2019. </div><div>Third-Party Returns</div><div style="margin-bottom:3pt;text-align:justify">We generally do not accept non-merchantable pharmaceutical product returns from our customers, so many of our customers return non-merchantable pharmaceutical products to the manufacturer through third parties. Since our customers generally do not have a direct relationship with manufacturers, our vendors pass the value of such returns to us (usually in the form of an accounts payable deduction). We, in turn, pass the value received to our customer. In certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor. Although we believe we have satisfactory protections, we could be subject to claims from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict with our contractual terms with our customers. We have maintained reserves for some of these situations based on their nature and our historical experience with their resolution.</div><div>Shipping and Handling</div><div style="margin-bottom:3pt;text-align:justify">Shipping and handling costs are primarily included in SG&A expenses in our consolidated statements of earnings/(loss) and include all delivery expenses as well as all costs to prepare the product for shipment to the end customer. Shipping and handling costs were $634 million, $620 million and $622 million, for fiscal 2021, 2020 and 2019, respectively. </div><div>Restructuring and Employee Severance</div><div style="margin-bottom:3pt;text-align:justify">Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance (including rationalizing headcount or other significant changes in personnel) and realigning operations (including realignment of the management structure in response to changing market conditions). Also included within restructuring and employee severance are </div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify">employee severance costs that are not incurred in connection with a restructuring activity. See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_109" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a> for additional information regarding our restructuring activities.</div><div>Amortization and Other Acquisition-Related Costs</div><div style="margin-bottom:3pt;text-align:justify">We classify certain costs incurred in connection with acquisitions as amortization and other acquisition-related costs in our consolidated statements of earnings/(loss). These costs consist of amortization of acquisition-related intangible assets, transaction costs, integration costs and changes in the fair value of contingent consideration obligations. Transaction costs are incurred during the initial evaluation of a potential acquisition and primarily relate to costs to analyze, negotiate and consummate the transaction as well as due diligence activities. Integration costs relate to activities required to combine the operations of an acquired enterprise into our operations and, in the case of the Cordis and Patient Recovery businesses, to stand-up the systems and processes needed to support an expanded geographic footprint. We record changes in the fair value of contingent consideration obligations relating to acquisitions as income or expense in amortization and other acquisition-related costs. See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_112" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a> for additional information regarding amortization of acquisition-related intangible assets. </div><div>Translation of Foreign Currencies</div><div style="margin-bottom:3pt;text-align:justify">Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign subsidiaries into U.S. dollars are accumulated in shareholders’ equity through accumulated and other comprehensive loss ("AOCI") utilizing period-end exchange rates. Revenues and expenses of these foreign subsidiaries are translated using average exchange rates during the year.</div><div style="margin-bottom:3pt;text-align:justify">The foreign currency translation gains/(losses) included in AOCI at June 30, 2021 and 2020 are presented in <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_145" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 11</a>. Foreign currency transaction gains and losses for the period are included in the consolidated statements of earnings/(loss) in the respective financial statement line item.</div><div>Interest Rate, Currency and Commodity Risk</div><div style="margin-bottom:3pt;text-align:justify">All derivative instruments are recognized at fair value on the consolidated balance sheets and all changes in fair value are recognized in net earnings or shareholders’ equity through AOCI, net of tax.</div><div style="margin-bottom:3pt;text-align:justify">For contracts that qualify for hedge accounting treatment, the hedge contracts must be effective at reducing the risk associated with the exposure being hedged and must be designated as a hedge at the inception of the contract. Hedge effectiveness is assessed periodically. Any contract not designated as a hedge, or so designated but ineffective, is adjusted to fair value and recognized immediately in net earnings. If a fair value or cash flow hedge ceases to qualify for hedge accounting treatment, the contract continues to be carried on the balance sheet at fair value until settled and future adjustments to the contract’s fair value are recognized immediately in net earnings. If a forecasted transaction is probable not to occur, amounts previously deferred in AOCI are recognized immediately in net earnings. Interest payments </div></div><div style="margin-bottom:3pt;text-align:justify">received from the cross currency swap are excluded from the net investment hedge effectiveness assessment and are recorded in interest expense, net in the consolidated statements of earnings/(loss).</div><div style="margin-bottom:3pt;text-align:justify">See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_139" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 10</a> for additional information regarding our derivative instruments, including the accounting treatment for instruments designated as fair value, cash flow, net investment and economic hedges.</div><div>Fair Value Measurements</div><div style="margin-bottom:3pt;text-align:justify">Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are:</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt">Level 1 - Observable prices in active markets for identical assets and liabilities.</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt">Level 2 - Observable inputs other than quoted prices in active markets for identical assets and liabilities.</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.</div><div style="margin-bottom:3pt;text-align:justify">See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_136" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 9</a> for additional information regarding fair value measurements.</div><div>Recently Adopted Financial Accounting Standards</div><div style="margin-bottom:3pt">Financial Instruments - Credit Losses</div><div style="margin-bottom:3pt;text-align:justify">In June 2016, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our consolidated financial statements.</div><div>Recently Issued Financial Accounting Standards Not Yet Adopted </div><div style="margin-bottom:3pt;text-align:justify">We address the adoption impacts of recently issued accounting standards by the FASB on the our consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2020 Form 10-K. There were no accounting </div>standards issued in fiscal 2021 that will have a material impact on our consolidated financial statements. <div>Basis of Presentation</div><div style="margin-bottom:3pt;text-align:justify">Our consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</div> <div>Use of Estimates</div><div style="margin-bottom:3pt;text-align:justify">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates, judgments and assumptions are used in the accounting and disclosure related to, among other items, allowance for doubtful accounts, inventory valuation and reserves, goodwill and other intangible asset impairment, loss contingencies (including product liability and self-insurance accruals), and income taxes. Actual amounts could ultimately differ from these estimated amounts.</div><div style="margin-bottom:3pt;text-align:justify">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.</div> <div>Cash Equivalents</div><div style="margin-bottom:3pt;text-align:justify">We consider liquid investments purchased with an initial maturity of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.</div> <div>Receivables and Allowance for Doubtful Accounts</div><div style="margin-bottom:3pt;text-align:justify">Trade receivables are presented net of an allowance for doubtful accounts of $242 million and $206 million at June 30, 2021 and 2020, respectively. An account is considered past due on the first </div><div style="margin-bottom:3pt;text-align:justify">day after its due date. In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account is considered past due. We regularly monitor past due accounts and establish appropriate reserves to cover potential losses, and consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts.</div><div style="margin-bottom:3pt;text-align:justify">We provide financing to various customers. Such financing arrangements range from 1 year to 5 years at interest rates that are generally subject to fluctuation. Interest income on these arrangements is recognized as it is earned. The financings may be collateralized, guaranteed by third parties or unsecured. Finance notes, net and related accrued interest were $63 million (current portion $7 million) and $104 million (current portion $12 million) at June 30, 2021 and 2020, respectively, and are included in other assets (current portion is included in prepaid expenses and other) in the consolidated balance sheets. Finance notes receivable allowance for doubtful accounts were $12 million and $27 million at June 30, 2021 and 2020, respectively. We estimate an allowance for these financing receivables based on historical collection rates and the credit worthiness of the customer. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts.</div> 242000000 206000000 P1Y P5Y 63000000 7000000 104000000 12000000 12000000 27000000 <div>Concentrations of Credit Risk</div><div style="margin-bottom:3pt;text-align:justify">We maintain cash depository accounts with major banks, and we invest in high quality, short-term liquid instruments, and in marketable securities. Our short-term liquid instruments mature within three months and we have not historically incurred any related losses.</div>Our trade receivables and finance notes and related accrued interest are exposed to a concentration of credit risk with certain large customers and with customers in the retail and healthcare sectors. Credit risk can be affected by changes in reimbursement and other economic pressures impacting the healthcare industry. With respect to customers in the retail and healthcare sectors, such credit risk is limited due to supporting collateral and the diversity of the customer base, including its wide geographic dispersion. We perform regular credit evaluations of our customers’ financial conditions and maintain reserves for losses through the established allowance for doubtful accounts. Historically, such losses have been within our expectations. Refer to the "Receivables and Allowance for Doubtful Accounts" section within this Note for additional information on the accounting treatment of reserves for allowance for doubtful accounts. <div>Major Customers</div><div style="margin-bottom:3pt;text-align:justify">CVS Health Corporation ("CVS") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables. These customers are primarily serviced through our Pharmaceutical segment.</div><div style="margin-bottom:3pt;text-align:justify">In August 2021, we extended our pharmaceutical distribution agreements with CVS through June 2027. </div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes historical percent of revenue and gross trade receivables from CVS and OptumRx:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:35.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Percent of Revenue</td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Percent of Gross Trade Receivables at June 30</td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">CVS</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">OptumRx</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div>We have entered into agreements with group purchasing organizations (“GPOs”) which act as purchasing agents that negotiate vendor contracts on behalf of their members. Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue. Sales to members of these two GPOs collectively accounted for 15 percent, 16 percent and 22 percent of revenue for fiscal 2021, 2020 and 2019, respectively. Our trade receivable balances are with individual members of the GPO, and therefore no significant concentration of credit risk exists with these types of arrangements <div style="margin-bottom:3pt;text-align:justify">The following table summarizes historical percent of revenue and gross trade receivables from CVS and OptumRx:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:35.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Percent of Revenue</td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Percent of Gross Trade Receivables at June 30</td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">CVS</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">OptumRx</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div> 0.26 0.26 0.26 0.24 0.26 0.15 0.14 0.13 0.03 0.06 2 2 0.15 0.16 0.22 <div>Inventories</div><div style="margin-bottom:3pt;text-align:justify">A portion of our inventories (50 percent and 56 percent at June 30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These inventories are included within the core pharmaceutical distribution facilities of our Pharmaceutical segment (“distribution facilities”) and are primarily merchandise inventories. The LIFO method presumes that the most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue. We believe that the average cost method of inventory valuation provides a reasonable approximation of the current cost of replacing inventory within the distribution facilities. As such, the LIFO reserve is the difference between (a) inventory at the lower of LIFO cost or market and (b) inventory at replacement cost determined using the average cost method of inventory valuation.</div><div style="margin-bottom:3pt;text-align:justify">At June 30, 2021 and 2020, respectively, inventories valued at LIFO cost were $565 million and $411 million higher than the average cost value. We do not record inventories in excess of replacement cost. As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020. </div><div style="margin-bottom:3pt;text-align:justify">Our remaining inventory, including inventory in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value. Net realizable value is defined as the estimated selling prices and estimated sales demand in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Due to the unprecedented demand for </div><div style="margin-bottom:3pt;text-align:justify">certain personal protective equipment as a result of COVID-19, our Medical segment manufactured and sourced inventory at higher costs than in periods prior to COVID-19. Personal protective equipment ("PPE") refers to protective clothing, medical and non-medical grade gloves, face shields, face masks and other equipment designed to protect the wearer from injury or the spread of infection or illness. As selling prices and customer demand have decreased compared to the peak of COVID-19, we recorded a reserve of $197 million, primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value.</div><div style="margin-bottom:3pt;text-align:justify">We reserve for inventory obsolescence using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, age and expiration dates of on-hand inventory and manufacturer return policies. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory which were $185 million and $155 million at June 30, 2021 and 2020, respectively.</div> 0.50 0.56 565000000 411000000 197000000 185000000 155000000 <div>Cash Discounts</div><div style="margin-bottom:3pt;text-align:justify">Manufacturer cash discounts are recorded as a component of inventory cost and recognized as a reduction of cost of products sold as inventory is sold.</div> <div>Property and Equipment</div><div style="text-align:justify">Property and equipment are carried at cost less accumulated depreciation. Property and equipment held for sale are recorded at the lower of cost less accumulated depreciation before the decision to dispose of the asset was made or fair value less cost to sell. When certain events or changes in operating conditions occur, an impairment assessment may be performed on the recoverability of the carrying amounts.</div><div style="margin-top:3pt;text-align:justify">Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which are depreciated over the terms of their respective leases. We generally use the following range of useful lives for our property and equipment categories: buildings and improvements—3 to 39 years; machinery and equipment—3 to 20 years; and furniture and fixtures—3 to 7 years. We recorded depreciation and amortization expense of $377 million, $405 million and $455 million for fiscal 2021, 2020 and 2019, respectively.</div><div style="margin-top:3pt;text-align:justify">The following table presents the components of property and equipment, net at June 30:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Land, building and improvements</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,359 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,185 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Machinery and equipment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,093 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,008 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Furniture and fixtures</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total property and equipment, at cost</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,588 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,331 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Accumulated depreciation and amortization</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,228)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,965)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Property and equipment, net</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,360 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,366 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify">Repairs and maintenance expenditures are expensed as incurred. Interest on long-term projects is capitalized using a rate that approximates the weighted-average interest rate on long-term </div>obligations, which was 3 percent at June 30, 2021. The amount of capitalized interest was immaterial for all periods presented. P3Y P39Y P3Y P20Y P3Y P7Y 377000000 405000000 455000000 <div style="margin-top:3pt;text-align:justify">The following table presents the components of property and equipment, net at June 30:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Land, building and improvements</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,359 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,185 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Machinery and equipment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,093 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,008 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Furniture and fixtures</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total property and equipment, at cost</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,588 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,331 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Accumulated depreciation and amortization</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,228)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,965)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Property and equipment, net</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,360 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,366 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2359000000 2185000000 3093000000 3008000000 136000000 138000000 5588000000 5331000000 3228000000 2965000000 2360000000 2366000000 0.03 <div>Goodwill and Other Intangible Assets</div><div style="margin-bottom:3pt;text-align:justify">Purchased goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment annually or when indicators of impairment exist.</div><div style="margin-bottom:3pt;text-align:justify">Purchased goodwill is tested for impairment at least annually. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. There is an option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the quantitative goodwill impairment test. We have elected to bypass the qualitative assessment for our annual goodwill impairment test in the current year. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. </div><div style="margin-bottom:3pt;text-align:justify">Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. </div><div style="margin-bottom:3pt;text-align:justify">We have two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. These operating segments are comprised of divisions (components), for which discrete financial information is available. Components are aggregated into reporting units for purposes of goodwill impairment testing to the extent that they share similar economic characteristics. Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (“Medical Unit”); and Cardinal Health at-Home Solutions division.</div><div style="margin-bottom:3pt;text-align:justify">Fair value can be determined using market, income or cost-based approaches. Our determination of estimated fair value of the reporting units is based on a combination of the income-based and market-based approaches. Under the income-based approach, we use a discounted cash flow model in which cash flows anticipated over several future periods, plus a terminal value at the end of that time horizon, are discounted to their present value using an appropriate risk-adjusted rate of return. We use our internal forecasts to estimate future cash flows, which we believe are consistent with those of a market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit. Actual results may differ materially from those used in our forecasts. We use discount rates that are commensurate with the risks and uncertainty inherent in the respective reporting units and in our internally-developed forecasts. Discount rates used in our reporting unit valuations ranged from 8.5 percent to 11.5 percent. Under the market-based guideline public company method, we determine fair value by comparing our reporting units to similar businesses or guideline companies whose securities are actively traded in public markets. We also use the guideline transaction method to </div><div style="margin-bottom:3pt;text-align:justify">determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units. To further confirm fair value, we compare the aggregate fair value of our reporting units to our total market capitalization. Estimating the fair value of reporting units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results. The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment.</div><div style="margin-bottom:3pt;text-align:justify">We performed annual impairment testing in fiscal 2021, 2020 and 2019 and concluded that there were no impairments of goodwill as the estimated fair value of each reporting unit exceeded its carrying value.</div><div style="margin-bottom:3pt;text-align:justify">The impairment test for indefinite-lived intangibles other than goodwill involves first assessing qualitative factors to determine if it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount. If so, then a quantitative test is performed to compare the estimated fair value of the indefinite-lived intangible asset to the respective asset's carrying amount. Our qualitative evaluation requires the use of estimates and significant judgments and considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.</div><div style="margin-bottom:3pt;text-align:justify">Intangible assets with finite lives, primarily customer relationships; trademarks, trade names and patents; and developed technology, are amortized using a combination of straight-line and accelerated methods based on the expected cash flows from the asset over their estimated useful lives. We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group. Actual results may differ materially from those used in our forecasts.</div> 2 2 0.085 0.115 0 0 0 <div>Assets Held for Sale</div><div style="margin-bottom:3pt;text-align:justify">We classify assets and liabilities (the “disposal group”) as held for sale when management commits to a plan to sell the disposal group in its present condition and at a price that is reasonable in relation to its current fair value. We also consider whether an active program to locate a buyer has been initiated and if it is probable that the sale will occur within one year without significant changes to the plan to sell. Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization.</div><div style="margin-bottom:3pt;text-align:justify">On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman & Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and certain liabilities, including product liability for </div>lawsuits related to inferior vena cava filters in the U.S. and Canada as described in <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_130" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a> of the “Notes to Consolidated Financial Statements.” The transaction closed on August 2, 2021. See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_106" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a> for additional information. 927000000 <div>Investments</div><div style="margin-bottom:3pt;text-align:justify">Investments in non-marketable equity securities are accounted for under the fair value, equity or net asset value method of accounting and are included in other assets in the consolidated balance sheets. For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which we can exercise significant influence but do not control, we use the equity method of accounting. Our share of the earnings and losses are recorded in other (income)/expense, net in the consolidated statements of earnings/(loss). We monitor our investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.</div> <div>Vendor Reserves</div><div style="margin-bottom:3pt;text-align:justify">In the ordinary course of business, our vendors may dispute deductions taken against payments otherwise due to them or assert other disputes. These disputes are researched and resolved based upon the findings of the research performed. At any given time, there are outstanding items in various stages of research and resolution. In determining appropriate reserves for areas of exposure with our vendors, we assess historical experience and current outstanding claims. We have established various levels of reserves based on the type of claim and status of review. Though the claim types are relatively consistent, we periodically refine our methodology by updating the reserve estimate percentages to reflect actual historical experience. The ultimate outcome of certain claims may be different than our original estimate and may require an adjustment. Adjustments to vendor reserves are included in cost of products sold. In addition, the reserve balance will fluctuate due to variations of outstanding claims from period-to-period, timing of settlements and specific vendor issues, such as bankruptcies. Vendor reserves were $77 million at both June 30, 2021 and 2020, excluding third-party returns. See Third-Party Returns section within this Note for a description of third-party returns.</div> 77000000 77000000 <div>Distribution Services Agreement and Other Vendor Fees</div><div style="margin-bottom:3pt;text-align:justify">Our Pharmaceutical segment recognizes fees received from distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors’ inventory when those fees have been earned and we are entitled to payment. Since the benefit provided to a vendor is related to the purchase and distribution of the vendor’s inventory, we recognize the fees as a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold.</div> <div>Loss Contingencies and Self-Insurance</div><div style="margin-bottom:3pt;text-align:justify">Loss Contingencies</div><div style="margin-bottom:3pt;text-align:justify">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. </div><div style="margin-bottom:3pt;text-align:justify">In connection with the opioid litigation as described further in the <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_130" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a>, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020 respectively which were retained at Corporate. In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement, subject to certain conditions and contingencies. There is no assurance that the contingencies to the proposed settlement agreement will be satisfied. </div><div style="margin-bottom:3pt;text-align:justify">We develop and periodically update reserve estimates for the Cordis inferior vena cava ("Cordis IVC") claims, including those received to date and expected to be received in the future and related costs. To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated indemnity severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs.</div><div style="margin-bottom:3pt;text-align:justify">Self-Insurance</div><div style="margin-bottom:3pt;text-align:justify">We also self-insure for employee healthcare, general liability, certain product liability matters, auto liability, property and workers' compensation. Self-insurance accruals include an estimate for expected settlements or pending claims, defense costs, administrative fees, claim adjustment costs and an estimate for claims incurred but not reported. </div><div style="margin-bottom:3pt;text-align:justify">Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies and other liabilities is highly subjective and requires judgments about future events. We regularly review contingencies and our self-insurance accruals to determine whether our accruals and related disclosures are adequate. Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.</div><div style="margin-bottom:3pt;text-align:justify">The amount of ultimate loss may differ materially from these estimates. We recognize these estimated loss contingencies, income from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss). See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_130" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a> for additional information regarding loss contingencies and product liability lawsuits.</div> 1170000000 5630000000 <div>Guarantees</div><div style="margin-bottom:3pt;text-align:justify">In the ordinary course of business, we agree to indemnify certain other parties under acquisition and disposition agreements, customer agreements, intellectual property licensing agreements, and other agreements. Such indemnification obligations vary in scope and, when defined, in duration. In many cases, a maximum obligation is not explicitly stated, and therefore the overall maximum amount of the liability under such indemnification obligations cannot be reasonably estimated. Where appropriate, such indemnification obligations are recorded as a liability. Historically, we have not, individually or in the aggregate, made </div>payments under these indemnification obligations in any material amounts. In certain circumstances, we believe that existing insurance arrangements, subject to the general deduction and exclusion provisions, would cover portions of the liability that may arise from these indemnification obligations. In addition, we believe that the likelihood of a material liability being triggered under these indemnification obligations is not probable.From time to time we enter into agreements that obligate us to make fixed payments upon the occurrence of certain events. Such obligations primarily relate to obligations arising under acquisition transactions, where we have agreed to make payments based upon the achievement of certain financial performance measures by the acquired business. Generally, the obligation is capped at an explicit amount. There were no material obligations at June 30, 2021. <div>Income Taxes</div><div style="margin-bottom:3pt;text-align:justify">We account for income taxes using the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in the respective jurisdictions in which we operate. We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized. The realizability of deferred tax assets depends on our ability to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence.</div><div style="margin-bottom:3pt;text-align:justify">Deferred taxes for non-U.S. liabilities are not provided on the unremitted earnings of subsidiaries outside of the United States when it is expected that these earnings are indefinitely reinvested.</div><div style="margin-bottom:3pt;text-align:justify">We operate in a complex multinational tax environment and are subject to tax treaty arrangements and transfer pricing guidelines for intercompany transactions that are subject to interpretation. Uncertainty in a tax position may arise as tax laws are subject to interpretation. </div><div style="margin-bottom:3pt;text-align:justify">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits. </div><div style="margin-bottom:3pt;text-align:justify">See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_133" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 8</a> for additional information regarding income taxes.</div> <div>Other Accrued Liabilities</div><div style="margin-bottom:6pt;text-align:justify">Other accrued liabilities represent various current obligations, including certain accrued operating expenses and taxes payable.</div> Noncontrolling InterestsNoncontrolling interests represent the portion of net earnings, comprehensive income and net assets that is not attributable to Cardinal Health, Inc. <div>Share-Based Compensation</div><div style="margin-bottom:3pt;text-align:justify">Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value of the awards. The fair value of restricted share units and performance share units is determined by the grant date market price of our common shares. The fair value of stock options is determined on the grant date using a lattice valuation model. The compensation expense associated with nonvested performance share units is dependent on our periodic assessment of the probability of the targets being achieved and our estimate, which may vary over time, of the number of shares that ultimately will be issued. The compensation expense recognized for share-based awards is net of estimated forfeitures and is recognized ratably over the service period of the awards. All income tax effects of share-based awards are recognized in the consolidated statements of earnings/(loss) as awards vest or are settled. We classify share-based compensation expense in distribution, selling, general and administrative ("SG&A") expenses to correspond with the same line item as the majority of the cash compensation paid to employees. If awards are modified in connection with a restructuring activity, the incremental share-based compensation expense is classified in restructuring and employee severance. See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_160" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 14</a> for additional information regarding share-based compensation.</div> <div>Dividends</div><div style="margin-bottom:3pt;text-align:justify">We paid cash dividends per common share of $1.94, $1.92 and $1.91 in fiscal 2021, 2020 and 2019, respectively.</div> 1.94 1.92 1.91 <div>Revenue Recognition</div><div style="margin-bottom:3pt;text-align:justify">We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers.</div><div style="margin-bottom:3pt;text-align:justify">Revenue in both segments is primarily related to the distribution of pharmaceutical and medical products, which include both manufactured and sourced products, and we recognize at a point in time when title transfers to customers and we have no further obligation to provide services related to such merchandise. Service revenues are recognized over the period that services are provided to the customer. Revenues derived from services are not material for either segment for all periods presented.</div>We are generally the principal in a transaction, therefore our revenue is primarily recorded on a gross basis. When we are a principal in a transaction, we have determined that we control the ability to direct the use of the product or service prior to transfer to a customer, are primarily responsible for fulfilling the promise to provide the product or service to our customer, have discretion in establishing prices, and ultimately control the transfer of the product or services provided to the customer. <div>Sales Returns and Allowances</div><div style="margin-bottom:3pt;text-align:justify">Revenue is recorded net of sales returns and allowances. Revenues are measured based on the amount of consideration that we expect to receive, reduced by estimates for return allowances, discounts, rebates and other variable consideration. Sales returns are recorded based on estimates using historical </div><div style="margin-bottom:3pt;text-align:justify">data. Our customer return policies generally require that the product be physically returned, subject to restocking fees. We only allow customers to return products for credit in a condition suitable to be added back to inventory and resold at full value (“merchantable product”) or returned to vendors for credit. Product returns are generally consistent throughout the year and typically are not specific to any particular product or customer.</div><div style="margin-bottom:3pt;text-align:justify">We accrue for estimated sales returns and allowances at the time of sale based upon historical customer return trends, margin rates and processing costs. Our accrual for sales returns is reflected as a reduction of revenue and cost of products sold for the sales price and cost, respectively. At June 30, 2021 and 2020, the accrual for estimated sales returns and allowances was $689 million and $495 million, respectively, which is reflected in trade receivables, net and inventories, net in the consolidated balance sheets. Sales returns and allowances were $2.6 billion, $2.3 billion and $2.2 billion, for fiscal 2021, 2020 and 2019, respectively, and the net impact on net earnings/(loss) in the consolidated statements of earnings/(loss) was immaterial in fiscal 2021, 2020 and 2019. </div><div>Third-Party Returns</div><div style="margin-bottom:3pt;text-align:justify">We generally do not accept non-merchantable pharmaceutical product returns from our customers, so many of our customers return non-merchantable pharmaceutical products to the manufacturer through third parties. Since our customers generally do not have a direct relationship with manufacturers, our vendors pass the value of such returns to us (usually in the form of an accounts payable deduction). We, in turn, pass the value received to our customer. In certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor. Although we believe we have satisfactory protections, we could be subject to claims from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict with our contractual terms with our customers. We have maintained reserves for some of these situations based on their nature and our historical experience with their resolution.</div> 689000000 495000000 2600000000 2300000000 2200000000 Shipping and HandlingShipping and handling costs are primarily included in SG&A expenses in our consolidated statements of earnings/(loss) and include all delivery expenses as well as all costs to prepare the product for shipment to the end customer. Shipping and handling costs were $634 million, $620 million and $622 million, for fiscal 2021, 2020 and 2019, respectively. 634000000 620000000 622000000 <div>Restructuring and Employee Severance</div><div style="margin-bottom:3pt;text-align:justify">Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance (including rationalizing headcount or other significant changes in personnel) and realigning operations (including realignment of the management structure in response to changing market conditions). Also included within restructuring and employee severance are </div>employee severance costs that are not incurred in connection with a restructuring activity. See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_109" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a> for additional information regarding our restructuring activities. Amortization and Other Acquisition-Related CostsWe classify certain costs incurred in connection with acquisitions as amortization and other acquisition-related costs in our consolidated statements of earnings/(loss). These costs consist of amortization of acquisition-related intangible assets, transaction costs, integration costs and changes in the fair value of contingent consideration obligations. Transaction costs are incurred during the initial evaluation of a potential acquisition and primarily relate to costs to analyze, negotiate and consummate the transaction as well as due diligence activities. Integration costs relate to activities required to combine the operations of an acquired enterprise into our operations and, in the case of the Cordis and Patient Recovery businesses, to stand-up the systems and processes needed to support an expanded geographic footprint. We record changes in the fair value of contingent consideration obligations relating to acquisitions as income or expense in amortization and other acquisition-related costs. See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_112" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a> for additional information regarding amortization of acquisition-related intangible assets. <div>Translation of Foreign Currencies</div><div style="margin-bottom:3pt;text-align:justify">Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign subsidiaries into U.S. dollars are accumulated in shareholders’ equity through accumulated and other comprehensive loss ("AOCI") utilizing period-end exchange rates. Revenues and expenses of these foreign subsidiaries are translated using average exchange rates during the year.</div><div style="margin-bottom:3pt;text-align:justify">The foreign currency translation gains/(losses) included in AOCI at June 30, 2021 and 2020 are presented in <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_145" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 11</a>. Foreign currency transaction gains and losses for the period are included in the consolidated statements of earnings/(loss) in the respective financial statement line item.</div> <div>Interest Rate, Currency and Commodity Risk</div><div style="margin-bottom:3pt;text-align:justify">All derivative instruments are recognized at fair value on the consolidated balance sheets and all changes in fair value are recognized in net earnings or shareholders’ equity through AOCI, net of tax.</div><div style="margin-bottom:3pt;text-align:justify">For contracts that qualify for hedge accounting treatment, the hedge contracts must be effective at reducing the risk associated with the exposure being hedged and must be designated as a hedge at the inception of the contract. Hedge effectiveness is assessed periodically. Any contract not designated as a hedge, or so designated but ineffective, is adjusted to fair value and recognized immediately in net earnings. If a fair value or cash flow hedge ceases to qualify for hedge accounting treatment, the contract continues to be carried on the balance sheet at fair value until settled and future adjustments to the contract’s fair value are recognized immediately in net earnings. If a forecasted transaction is probable not to occur, amounts previously deferred in AOCI are recognized immediately in net earnings. Interest payments </div><div style="margin-bottom:3pt;text-align:justify">received from the cross currency swap are excluded from the net investment hedge effectiveness assessment and are recorded in interest expense, net in the consolidated statements of earnings/(loss).</div><div style="margin-bottom:3pt;text-align:justify">See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_139" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 10</a> for additional information regarding our derivative instruments, including the accounting treatment for instruments designated as fair value, cash flow, net investment and economic hedges.</div> <div>Fair Value Measurements</div><div style="margin-bottom:3pt;text-align:justify">Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are:</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt">Level 1 - Observable prices in active markets for identical assets and liabilities.</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt">Level 2 - Observable inputs other than quoted prices in active markets for identical assets and liabilities.</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.</div><div style="margin-bottom:3pt;text-align:justify">See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_136" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 9</a> for additional information regarding fair value measurements.</div> <div>Recently Adopted Financial Accounting Standards</div><div style="margin-bottom:3pt">Financial Instruments - Credit Losses</div><div style="margin-bottom:3pt;text-align:justify">In June 2016, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our consolidated financial statements.</div><div>Recently Issued Financial Accounting Standards Not Yet Adopted </div><div style="margin-bottom:3pt;text-align:justify">We address the adoption impacts of recently issued accounting standards by the FASB on the our consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2020 Form 10-K. There were no accounting </div>standards issued in fiscal 2021 that will have a material impact on our consolidated financial statements. <div style="margin-bottom:6pt;text-align:justify">2. Divestitures and Acquisitions</div><div>Divestitures</div><div>Cordis Assets Held for Sale</div><div style="margin-bottom:3pt;text-align:justify">On March 12, 2021, we signed a definitive agreement with Hellman & Friedman to sell our Cordis business for gross proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and certain liabilities. The transaction closed on August 2, 2021 and we received proceeds of $927 million, net of cash transferred. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_130" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a>.</div><div style="margin-bottom:3pt;text-align:justify">Upon signing the agreement, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale. In connection with the divestiture, we allocated $388 million of goodwill from the Medical Unit (within our Medical Segment) to the Cordis disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained. We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations. </div><div style="margin-bottom:3pt;text-align:justify">At June 30, 2021, the book value of the disposal group exceeded its fair value less costs to sell. Accordingly, we recognized a $60 million pre-tax write-down on the disposal group in impairments and (gain)/loss on disposal of assets in our consolidated statement of earnings/(loss). This write-down includes a $3 million loss related to currency translation adjustments in accumulated other comprehensive loss. We recorded a net tax expense of $9 million associated with the impact of the write-down and the required tax adjustments related to held for sale accounting.</div><div style="margin-bottom:3pt;text-align:justify">The following table presents information related to the assets and liabilities that were classified as held for sale at June 30, 2021 related to the Cordis divestiture in the consolidated balance sheets:</div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2021</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and equivalents</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">109 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Inventories, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">164 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Property and equipment, net</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Goodwill and other intangibles, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">778 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other assets</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Write-down of assets held for sale</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(60)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total assets held for sale</td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,091 </td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Other accrued liabilities</td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Deferred income taxes and other liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total liabilities related to assets held for sale</td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">95 </td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div>naviHealth</div><div style="margin-bottom:3pt;text-align:justify">In August 2018, we sold our majority ownership interest in naviHealth, which operated within our Medical segment in exchange for cash proceeds of $737 million (after adjusting for certain fees and expenses) and a noncontrolling equity interest in a partnership that owned naviHealth. We also had certain call rights to reacquire naviHealth. </div><div style="margin-bottom:3pt;text-align:justify">As a result of this divestiture, during the fiscal year ended June 30, 2019, we recognized a pre-tax gain of $508 million in impairments and (gain)/loss on disposal of assets in our consolidated statements of earnings/(loss). This gain included our initial recognition of an equity method investment for $358 million and the derecognition of redeemable noncontrolling interests of $12 million. The fiscal 2019 tax expense as a result of this transaction was $130 million. We determined that the sale of the naviHealth business did not meet the criteria to be classified as discontinued operations.</div><div style="margin-bottom:3pt;text-align:justify">In May 2020 we sold the remainder of our noncontrolling equity interest in a partnership that owned naviHealth. We recognized a pre-tax gain of $579 million from this disposal in gain on sale of equity interest in naviHealth in our consolidated statements of earnings/(loss) during fiscal year 2020.</div><div style="margin-bottom:3pt;text-align:justify">Our proportionate share of naviHealth’s results, which was recorded in other (income)/expense, net in the consolidated statements of earnings/(loss), was income of $2 million and a loss of $10 million during fiscal 2020 and 2019, respectively. </div><div>Acquisitions</div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify">We did not complete any acquisitions during fiscal 2020. While we completed several small acquisitions during fiscal 2021 and 2019, the pro forma results of operations and the results of operations for acquired businesses since the acquisition dates have not been separately disclosed because the effects were not significant compared to the consolidated financial statements, individually or in the aggregate. The cash paid for these acquisitions, net of cash acquired was $3 million and $82 million for fiscal 2021 and 2019, respectively.</div> 927000000 927000000 388000000 -60000000 -3000000 9000000 <div style="margin-bottom:3pt;text-align:justify">The following table presents information related to the assets and liabilities that were classified as held for sale at June 30, 2021 related to the Cordis divestiture in the consolidated balance sheets:</div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2021</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and equivalents</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">109 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Inventories, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">164 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Property and equipment, net</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Goodwill and other intangibles, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">778 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other assets</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Write-down of assets held for sale</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(60)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total assets held for sale</td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,091 </td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Other accrued liabilities</td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Deferred income taxes and other liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total liabilities related to assets held for sale</td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">95 </td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 109000000 164000000 90000000 778000000 10000000 -60000000 1091000000 61000000 34000000 95000000 737000000 508000000 358000000 12000000 130000000 579000000 2000000 10000000 3000000 82000000 <div style="margin-bottom:6pt;text-align:justify">3. Restructuring and Employee Severance </div><div style="margin-bottom:3pt;text-align:justify">The following tables summarize restructuring and employee severance costs:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:57.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee-related costs </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">66 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">95 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Facility exit and other costs </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total restructuring and employee severance</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">114 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">122 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">125 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of professional, project management and other service fees to support divestitures, vendor transition fees, accelerated depreciation, lease costs associated with vacant facilities, equipment relocation costs, project consulting fees, costs </div><div style="margin-bottom:3pt;text-align:justify">associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.</div><div style="margin-bottom:3pt;text-align:justify">In fiscal 2021, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of our Cordis business. In fiscal 2020 and 2019, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures.</div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Employee- Related Costs</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Facility Exit and Other Costs</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at June 30, 2019</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">64 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">72 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Additions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">109 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Payments and other adjustments</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(81)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(85)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at June 30, 2020</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Additions</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Payments and other adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(64)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(28)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(92)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Balance at June 30, 2021</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">79 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:3pt;text-align:justify">The following tables summarize restructuring and employee severance costs:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:57.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee-related costs </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">66 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">95 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Facility exit and other costs </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total restructuring and employee severance</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">114 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">122 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">125 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 53000000 66000000 95000000 61000000 56000000 30000000 114000000 122000000 125000000 <div style="margin-bottom:3pt;text-align:justify">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Employee- Related Costs</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Facility Exit and Other Costs</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at June 30, 2019</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">64 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">72 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Additions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">109 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Payments and other adjustments</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(81)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(85)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at June 30, 2020</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Additions</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Payments and other adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(64)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(28)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(92)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Balance at June 30, 2021</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">79 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 64000000 8000000 72000000 85000000 24000000 109000000 81000000 4000000 85000000 68000000 28000000 96000000 49000000 26000000 75000000 64000000 28000000 92000000 53000000 26000000 79000000 <div style="margin-bottom:6pt;text-align:justify">4. Goodwill and Other Intangible Assets </div><div>Goodwill</div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Pharmaceutical (1)</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Medical (2)</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total </td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Balance at June 30, 2019</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,663 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,715 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,378 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Goodwill acquired, net of purchase price adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency translation adjustments and other</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom">Balance at June 30, 2020</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,657 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,700 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,357 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Goodwill acquired, net of purchase price adjustments</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency translation adjustments and other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Cordis goodwill reclassified to assets held for sale</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(388)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(388)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Balance at June 30, 2021</td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,659 </td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,330 </td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,989 </td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1) At June 30, 2021 and 2020, the Pharmaceutical segment accumulated goodwill impairment loss was $829 million.</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2) At June 30, 2021 and 2020, the Medical segment accumulated goodwill impairment loss was $1.4 billion. </div><div style="margin-bottom:6pt;text-align:justify">In connection with the divestiture of our Cordis business, during fiscal 2021 we allocated and reclassified $388 million of goodwill from the Medical Unit (within our Medical Segment) to the Cordis disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained, discussed further in <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_106" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a>.</div><div>Other Intangible Assets</div><div style="margin-bottom:3pt;text-align:justify">The following tables summarize other intangible assets by class at June 30:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.653%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Intangible</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Intangible</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted- Average Remaining Amortization Period (Years)</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Indefinite-life intangibles:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks and patents</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">N/A</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total indefinite-life intangibles</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">N/A</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Definite-life intangibles:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer relationships</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,330 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,989 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,341 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom">11</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks, trade names and patents</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">551 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">328 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">223 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">9</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technology and other</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,035 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">506 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">529 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom">10</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total definite-life intangibles</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,916 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,823 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,093 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">10</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total other intangible assets</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,928 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,823 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,105 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">N/A</td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Intangible</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Intangible</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Indefinite-life intangibles:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">IPR&D, trademarks and other</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total indefinite-life intangibles</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Definite-life intangibles:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer relationships</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,554 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,828 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,726 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks, trade names and patents</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">673 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">341 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">332 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technology and other</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,604 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">767 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">837 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total definite-life intangibles</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,831 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,936 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,895 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total other intangible assets</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,854 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,936 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,918 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Total amortization of intangible assets was $428 million, $512 million and $531 million for fiscal 2021, 2020 and 2019, respectively. The estimated annual amortization for intangible assets for fiscal 2022 through 2026 is as follows: $315 million, $287 million, $264 million, $238 million and $212 million. <div style="margin-bottom:3pt;text-align:justify">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Pharmaceutical (1)</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Medical (2)</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total </td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Balance at June 30, 2019</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,663 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,715 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,378 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Goodwill acquired, net of purchase price adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency translation adjustments and other</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom">Balance at June 30, 2020</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,657 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,700 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,357 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Goodwill acquired, net of purchase price adjustments</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency translation adjustments and other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Cordis goodwill reclassified to assets held for sale</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(388)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(388)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Balance at June 30, 2021</td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,659 </td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,330 </td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,989 </td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1) At June 30, 2021 and 2020, the Pharmaceutical segment accumulated goodwill impairment loss was $829 million.</div>(2) At June 30, 2021 and 2020, the Medical segment accumulated goodwill impairment loss was $1.4 billion. 2663000000 5715000000 8378000000 -5000000 0 -5000000 -1000000 -15000000 -16000000 2657000000 5700000000 8357000000 2000000 0 2000000 0 18000000 18000000 0 388000000 388000000 2659000000 5330000000 7989000000 829000000 829000000 1400000000 1400000000 388000000 <div style="margin-bottom:3pt;text-align:justify">The following tables summarize other intangible assets by class at June 30:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.653%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Intangible</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Intangible</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted- Average Remaining Amortization Period (Years)</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Indefinite-life intangibles:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks and patents</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">N/A</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total indefinite-life intangibles</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">N/A</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Definite-life intangibles:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer relationships</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,330 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,989 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,341 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom">11</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks, trade names and patents</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">551 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">328 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">223 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">9</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technology and other</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,035 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">506 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">529 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom">10</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total definite-life intangibles</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,916 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,823 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,093 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">10</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total other intangible assets</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,928 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,823 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,105 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">N/A</td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Intangible</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Intangible</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Indefinite-life intangibles:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">IPR&D, trademarks and other</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total indefinite-life intangibles</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Definite-life intangibles:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer relationships</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,554 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,828 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,726 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks, trade names and patents</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">673 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">341 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">332 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technology and other</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,604 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">767 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">837 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total definite-life intangibles</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,831 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,936 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,895 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total other intangible assets</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,854 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,936 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,918 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:3pt;text-align:justify">The following tables summarize other intangible assets by class at June 30:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.653%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Intangible</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Intangible</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted- Average Remaining Amortization Period (Years)</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Indefinite-life intangibles:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks and patents</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">N/A</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total indefinite-life intangibles</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">N/A</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Definite-life intangibles:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer relationships</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,330 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,989 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,341 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom">11</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks, trade names and patents</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">551 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">328 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">223 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">9</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technology and other</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,035 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">506 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">529 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom">10</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total definite-life intangibles</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,916 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,823 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,093 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">10</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total other intangible assets</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,928 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,823 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,105 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">N/A</td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Intangible</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net Intangible</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Indefinite-life intangibles:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">IPR&D, trademarks and other</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total indefinite-life intangibles</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Definite-life intangibles:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer relationships</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,554 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,828 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,726 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks, trade names and patents</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">673 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">341 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">332 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technology and other</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,604 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">767 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">837 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total definite-life intangibles</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,831 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,936 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,895 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total other intangible assets</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,854 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,936 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,918 </td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12000000 12000000 12000000 12000000 3330000000 1989000000 1341000000 P11Y 551000000 328000000 223000000 P9Y 1035000000 506000000 529000000 P10Y 4916000000 2823000000 2093000000 P10Y 4928000000 2823000000 2105000000 23000000 23000000 23000000 23000000 3554000000 1828000000 1726000000 673000000 341000000 332000000 1604000000 767000000 837000000 5831000000 2936000000 2895000000 5854000000 2936000000 2918000000 428000000 512000000 531000000 315000000 287000000 264000000 238000000 212000000 <div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify">5. Leases </div><div style="margin-bottom:3pt;text-align:justify">Our operating leases are primarily for corporate offices, distribution facilities, vehicles, and equipment. We determine if an arrangement is a lease at its inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of the asset. Our lease agreements generally do not contain any material residual value guarantees or material restrictive covenants. </div><div style="margin-bottom:3pt;text-align:justify">Beginning July 1, 2019, operating lease right-of-use assets and corresponding operating lease liabilities are recognized in our consolidated balance sheets at lease commencement date based on the present value of lease payments over the lease term. Operating lease expense for operating lease assets is recognized on a straight-line basis over the lease term. As most of our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. We use the implicit rate if it is readily determinable. </div><div style="margin-bottom:3pt;text-align:justify">Our lease agreements contain lease components and non-lease components. For all asset classes, we have elected to account for both of these components as a single lease component. We also, from time to time, sublease portions of our real estate property, resulting in sublease income. Sublease income and the related assets and cash flows are not material to the consolidated financial statements at or for the fiscal years ended June 30, 2021 and 2020.</div><div style="margin-bottom:3pt;text-align:justify">We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. Short-term lease expense recognized in fiscal 2021 and 2020 was not material. In addition, upon adoption of the new lease standard, we elected the package of three practical expedients permitted under the transition guidance, which include the carry forward of our leases without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs. </div><div style="margin-bottom:3pt;text-align:justify">Our leases have remaining lease terms from less than 1 year up to approximately 21 years. Our lease terms may include options to extend or terminate the lease when it is reasonably certain and there is a significant economic incentive to exercise that option. </div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes the components of lease cost: </div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.185%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease cost</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">119 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">134 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease cost</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Variable lease cost</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total lease cost</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">159 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">164 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify">Variable lease cost primarily includes payments for property taxes, maintenance and insurance. Our rental expense relating to operating leases was $153 million in fiscal 2019. </div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify">The following table summarizes supplemental balance sheet and other information related to leases at June 30:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating Leases</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease right-of-use assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">460 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">426 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Current portion of operating lease liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Long-term operating lease liabilities</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">374 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">341 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total operating lease liabilities</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">479 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">445 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance Leases</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease right-of-use assets</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current portion of finance lease liabilities</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Long-term finance lease liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total finance lease liabilities</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">64 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted-average remaining lease term (years)</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating leases</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">6.5 years</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">6.4 years</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom">4.2 years</td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom">4.3 years</td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted-average discount rate</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating leases</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.4 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table>Operating leases are included in other assets, other accrued liabilities, and deferred income taxes and other liabilities in our consolidated balance sheet. Finance leases are included in property and equipment, net, current portion of long-term obligations and other short-term borrowings, and long-term obligations, less current portion in our consolidated balance sheet. </div><div style="margin-bottom:3pt;text-align:justify">The following tables summarizes supplemental cash flow information related to leases:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.220%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.222%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for lease liabilities:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Operating cash flows paid for operating leases</td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">115 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">125 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Financing cash flows paid for finance leases</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-cash right-of-use assets obtained in exchange for lease obligations:</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">New operating leases</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">New finance leases</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt">Amended lease standard adoption impact as of July 1, 2019 (1) </div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">400 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Includes the effect of $22 million from reclassifying deferred rent as an offset to the lease right-of-use asset in accordance with the transition guidance. </div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"> </div><div style="margin-bottom:3pt;text-align:justify"> </div><div style="margin-bottom:3pt;text-align:justify"> </div></div><div style="margin-bottom:3pt">Future lease payments under non-cancellable leases as of June 30, 2021 were as follows: </div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:50.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.120%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Operating Leases</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Finance Leases</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">2022</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">136 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2023</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">93 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">2024</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">86 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">141 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">146 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total future lease payments</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">537 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">607 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Less: leases not yet commenced (1) </div></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: imputed interest</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease liabilities</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">479 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">64 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">543 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>(1)As of June 30, 2021, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the consolidated balance sheet. P1Y P21Y <div style="margin-bottom:3pt;text-align:justify">The following table summarizes the components of lease cost: </div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.185%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease cost</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">119 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">134 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease cost</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Variable lease cost</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total lease cost</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">159 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">164 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Variable lease cost primarily includes payments for property taxes, maintenance and insurance. 119000000 134000000 16000000 13000000 24000000 17000000 159000000 164000000 153000000 The following table summarizes supplemental balance sheet and other information related to leases at June 30:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating Leases</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease right-of-use assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">460 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">426 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Current portion of operating lease liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"> Long-term operating lease liabilities</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">374 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">341 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total operating lease liabilities</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">479 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">445 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance Leases</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance lease right-of-use assets</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Current portion of finance lease liabilities</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Long-term finance lease liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total finance lease liabilities</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">64 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted-average remaining lease term (years)</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating leases</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">6.5 years</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">6.4 years</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom">4.2 years</td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom">4.3 years</td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted-average discount rate</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating leases</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance leases</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.4 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> 460000000 426000000 105000000 104000000 374000000 341000000 479000000 445000000 63000000 33000000 19000000 9000000 45000000 25000000 64000000 34000000 P6Y6M P6Y4M24D P4Y2M12D P4Y3M18D 0.029 0.029 0.015 0.024 <div style="margin-bottom:3pt;text-align:justify">The following tables summarizes supplemental cash flow information related to leases:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.220%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.222%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for lease liabilities:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Operating cash flows paid for operating leases</td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">115 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">125 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Financing cash flows paid for finance leases</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-cash right-of-use assets obtained in exchange for lease obligations:</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">New operating leases</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">New finance leases</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt">Amended lease standard adoption impact as of July 1, 2019 (1) </div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">400 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Includes the effect of $22 million from reclassifying deferred rent as an offset to the lease right-of-use asset in accordance with the transition guidance. 115000000 125000000 15000000 7000000 138000000 150000000 45000000 40000000 0 400000000 22000000 <div style="margin-bottom:3pt">Future lease payments under non-cancellable leases as of June 30, 2021 were as follows: </div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:50.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.120%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Operating Leases</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Finance Leases</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">2022</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">136 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2023</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">93 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">2024</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">86 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">141 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">146 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total future lease payments</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">537 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">607 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Less: leases not yet commenced (1) </div></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: imputed interest</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease liabilities</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">479 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">64 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">543 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>(1)As of June 30, 2021, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the consolidated balance sheet. 116000000 20000000 136000000 93000000 20000000 113000000 72000000 14000000 86000000 65000000 8000000 73000000 50000000 3000000 53000000 141000000 5000000 146000000 537000000 70000000 607000000 3000000 0 3000000 55000000 6000000 61000000 479000000 64000000 543000000 <div style="margin-bottom:6pt;text-align:justify">6. Long-Term Obligations and Other Short-Term Borrowings </div><div style="margin-bottom:3pt">The following table summarizes long-term obligations and other short-term borrowings at June 30:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:57.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.026%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">(in millions) (1)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle">2020</td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle">2.616% Notes due 2022</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">572 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">834 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">3.2% Notes due 2022</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">236 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle">Floating Rate Notes due 2022</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">281 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">321 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">3.2% Notes due 2023</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">564 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">576 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle">3.079% Notes due 2024</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">794 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">809 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">3.5% Notes due 2024</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">410 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">413 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle">3.75% Notes due 2025</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">524 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">529 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">3.41% Notes due 2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,216 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,215 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle">4.6% Notes due 2043</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">341 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">340 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">4.5% Notes due 2044</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">342 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">342 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle">4.9% Notes due 2045</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">441 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">441 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">4.368% Notes due 2047</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">560 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">560 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle">7.0% Debentures due 2026</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">124 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">124 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">Other Obligations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">67 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">35 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle">Total</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6,236 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6,775 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">Less: current portion of long-term obligations and other short-term borrowings</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">871 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"> Long-term obligations, less current portion</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">5,365 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">6,765 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify">(1) Maturities are presented on a calendar year basis. </div><div style="margin-bottom:3pt;text-align:justify">Maturities of existing long-term obligations and other short-term borrowings for fiscal 2022 through 2026 and thereafter are as follows: $872 million, $584 million, $808 million, $418 million, $525 million and $3.0 billion.</div><div>Long-Term Debt</div><div style="margin-bottom:3pt;text-align:justify">All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. The 7.0% Debentures represent unsecured obligations of Allegiance Corporation (a wholly-owned subsidiary), which Cardinal Health, Inc. has guaranteed. None of these obligations are subject to a sinking fund and the Allegiance obligations are not redeemable prior to maturity. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $23.7 billion and $21.4 billion at June 30, 2021 and 2020, respectively.</div><div style="margin-bottom:3pt;text-align:justify">In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt. </div><div style="margin-bottom:3pt;text-align:justify">During fiscal 2021, we also early repurchased $40 million of the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022 with available cash. In connection with the early debt repurchases, we recorded a $1 million loss on early extinguishment of debt.</div><div style="margin-bottom:3pt;text-align:justify">During fiscal 2020, we redeemed $500 million aggregate principle amount of 4.625% Notes due December 2020 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with the redemption, we recorded a $7 million loss on early extinguishment of debt. We also early repurchased $247 million of the 2.616% Notes due 2022, $11 million of the 3.2% Notes due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the 3.41% Notes due 2027, $6 million of the 4.6% Notes due 2043, $5 million of the 4.9% Notes due 2045, and $35 million of the 4.368% Notes due 2047. In connection with the early debt repurchases, we recognized a $9 million loss on early extinguishment of debt. We also repaid the full principal of the $450 million 2.4% Notes due 2019 as they became due. </div><div style="margin-bottom:3pt;text-align:justify">During fiscal 2019, we repurchased $67 million of the 2.616% Notes due 2022, $1 million of the 3.2% Notes due 2022, 8 million of the Floating Rate Notes due 2022, and $24 million of the 3.41% Notes due 2027 for a total of $100 million. The loss on early extinguishment of debt in connection with these early repurchases was immaterial. We also repaid the full principal of the $1.0 billion 1.948% Notes due 2019 as they became due.</div><div style="margin-bottom:3pt;text-align:justify">The redemptions and repurchases were paid for with available cash and other short-term borrowings.</div><div style="margin-bottom:3pt;text-align:justify">On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on September 15, 2021 at an expected redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.</div><div style="margin-bottom:3pt;text-align:justify">If we undergo a change of control, as defined in the notes, and if the notes receive specified ratings below investment grade by each of Standard & Poors Ratings Services, Moody’s Investors Services and Fitch Ratings, any holder of the notes, excluding the debentures, can require with respect to the notes owned by such holder, or we can offer, to repurchase the notes at 101% of the principal amount plus accrued and unpaid interest.</div><div>Other Financing Arrangements</div><div style="margin-bottom:3pt;text-align:justify">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility.</div><div style="margin-bottom:3pt;text-align:justify">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </div><div style="margin-bottom:3pt;text-align:justify">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of June 30, 2021, we were in compliance with this financial covenant.</div><div style="margin-bottom:3pt;text-align:justify">At June 30, 2021 and 2020, we had no amounts outstanding under the revolving credit facility; however, availability was reduced by outstanding letters of credit of $1 million at both June 30, 2021 and 2020.</div><div style="margin-bottom:3pt;text-align:justify">Under our committed receivables sales facility program, we had a maximum amount outstanding of $200 million and an immaterial daily amount outstanding during fiscal 2021. We had no amounts outstanding as of June 30, 2021 under the committed receivables sales facility program; however, availability was reduced by outstanding standby letters of credit of $31 million and $29 million at June 30, 2021 and 2020, respectively. </div><div style="margin-bottom:3pt;text-align:justify">We had no amounts outstanding under the commercial paper program as of June 30, 2021 and 2020. </div><div style="margin-bottom:3pt;text-align:justify">We also maintain other short-term credit facilities and an unsecured line of credit that allowed for borrowings up to $6 million at both June 30, 2021 and 2020. The $67 million and $35 million balance of other obligations at June 30, 2021 and 2020, respectively, consisted of finance leases and short-term borrowings.</div> <div style="margin-bottom:3pt">The following table summarizes long-term obligations and other short-term borrowings at June 30:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:57.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.026%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">(in millions) (1)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle">2020</td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle">2.616% Notes due 2022</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">572 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">834 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">3.2% Notes due 2022</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">236 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle">Floating Rate Notes due 2022</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">281 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">321 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">3.2% Notes due 2023</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">564 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">576 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle">3.079% Notes due 2024</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">794 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">809 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">3.5% Notes due 2024</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">410 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">413 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle">3.75% Notes due 2025</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">524 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">529 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">3.41% Notes due 2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,216 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,215 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle">4.6% Notes due 2043</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">341 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">340 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">4.5% Notes due 2044</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">342 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">342 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle">4.9% Notes due 2045</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">441 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">441 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">4.368% Notes due 2047</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">560 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">560 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle">7.0% Debentures due 2026</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">124 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">124 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">Other Obligations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">67 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">35 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle">Total</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6,236 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6,775 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">Less: current portion of long-term obligations and other short-term borrowings</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">871 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"> Long-term obligations, less current portion</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">5,365 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">6,765 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div>(1) Maturities are presented on a calendar year basis. 572000000 834000000 0 236000000 281000000 321000000 564000000 576000000 794000000 809000000 410000000 413000000 524000000 529000000 1216000000 1215000000 341000000 340000000 342000000 342000000 441000000 441000000 560000000 560000000 124000000 124000000 67000000 35000000 6236000000 6775000000 871000000 10000000 5365000000 6765000000 872000000 584000000 808000000 418000000 525000000 3000000000.0 0.070 23700000000 21400000000 238000000 262000000 13000000 40000000 2000000 1000000 500000000 7000000 247000000 11000000 20000000 104000000 6000000 5000000 35000000 9000000 450000000 67000000 1000000 8000000 24000000 100000000 1000000000.0 1.01 2000000000.0 2000000000.0 1000000000.0 0 0 1000000 200000000 0 0 31000000 29000000 0 0 6000000 67000000 35000000 <div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify">7. Commitments, Contingent Liabilities and Litigation </div><div>Commitments</div><div>Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</div><div style="margin-bottom:3pt;text-align:justify">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement. These payments are included as purchase obligations and other payments in the Contractual Obligations section of MD&A. </div><div>Contingencies</div><div>New York Opioid Stewardship Act</div><div style="margin-bottom:3pt;text-align:justify">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</div><div style="margin-bottom:3pt;text-align:justify">The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. If the U.S. Supreme Court declines to take the case, or if it ultimately upholds the Second Circuit's ruling, New York State would likely seek to collect amounts allegedly owed under the OSA. </div><div style="margin-bottom:3pt;text-align:justify">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41 million for calendar years 2017 and 2018 in the fiscal year ended June 30, 2021 based on the probable estimated payment amount, which is our best estimate of the OSA payments probable at June 30, 2021.</div><div>Legal Proceedings</div><div style="margin-bottom:3pt;text-align:justify">We become involved from time to time in disputes, litigation and regulatory matters.</div><div style="margin-bottom:3pt;text-align:justify">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions </div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify">have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</div><div style="margin-bottom:3pt;text-align:justify">From time to time, we become aware through employees, internal audits or other parties of possible product quality, regulatory or compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</div><div style="margin-bottom:3pt;text-align:justify">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</div><div style="margin-bottom:3pt;text-align:justify">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</div><div style="margin-bottom:3pt;text-align:justify">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</div><div style="margin-bottom:3pt;text-align:justify">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our consolidated statements of earnings/(loss).</div><div style="text-align:justify">Opioid Lawsuits and Investigations</div><div style="margin-bottom:3pt;text-align:justify">Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,300 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well </div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify">as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</div><div style="margin-bottom:3pt;text-align:justify">States & Political Subdivisions</div><div style="margin-bottom:3pt;text-align:justify">Approximately 2,900 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the “MDL”).</div><div style="margin-bottom:3pt;text-align:justify">In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. </div><div style="margin-bottom:3pt;text-align:justify">In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). We continued to build out the Settlement Framework and to negotiate the terms of the settlement with the leadership group and other representatives of states and political subdivisions. </div><div style="margin-bottom:3pt;text-align:justify">In July, 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement (the “Proposed Settlement Agreement”) and settlement process that, if all conditions are satisfied, would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups. The settlement process does not contemplate participation by any non-governmental or non-political entities or individuals. In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with the State of New York and its participating subdivisions. If the Proposed Settlement Agreement becomes effective, New York and its participating subdivisions will become a part of it. </div><div style="text-align:justify">The Proposed Settlement Agreement is subject to contingencies and will not become effective unless and until the three distributors each make separate independent determinations that (1) following a sign-on period, a sufficient number of states have agreed to the Proposed Settlement Agreement (the “Settling States”); and, subsequently, (2) following a notice period, that a sufficient number of states and political subdivisions, including those that have not sued, have agreed to the Agreement (or otherwise had their claims foreclosed) to proceed to effectiveness. Prior to the second determination, the Settling States will also have an opportunity to make a determination as to whether a sufficient number of political subdivisions have agreed to the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed with the </div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify">Proposed Settlement Agreement. This process is currently contemplated to end in February 2022, although it may be extended by agreement. It is possible that a sufficient number of states and subdivisions will not agree to the Proposed Settlement Agreement or that other required contingencies will not be satisfied.</div><div style="margin-bottom:3pt;text-align:justify">If these conditions are satisfied, the Proposed Settlement Agreement would become effective sixty (60) days after the distributors determine that there is sufficient participation among political subdivisions. During this 60-day period, the Settling States and the distributors would cooperate to obtain consent judgments in each participating state embodying the terms of the Settlement. </div><div style="margin-bottom:3pt;text-align:justify">The Proposed Settlement Agreement includes a cash component, pursuant to which the Company would pay up to approximately $6.37 billion, the majority of which would be paid over 18 years. The exact payment amount will depend on several factors, including the participation rate of states and political subdivisions, the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which political subdivisions in Settling States file additional opioid lawsuits against the Company after the Proposed Settlement Agreement becomes effective. </div><div style="margin-bottom:3pt;text-align:justify">The Proposed Settlement Agreement also includes injunctive relief terms related to settling distributors’ controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.</div><div style="margin-bottom:3pt;text-align:justify">In total, we have recorded total pre-tax charges of $1.17 billion and $5.63 billion in litigation charges/(recoveries), net in the years ended June 30, 2021 and 2020, respectively. In total, we have $6.73 billion accrued at June 30, 2021, of which $405 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in the consolidated balance sheets. </div><div style="margin-bottom:3pt;text-align:justify">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.</div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify">Additionally, a trial before a judge in West Virginia in the Cabell County and City of Huntington cases concluded in July 2021 and the judge has not yet issued a decision. In addition, a trial in the case brought by the Ohio Attorney General is scheduled to begin in September 2021 and a trial in the case brought by the Washington Attorney General is scheduled to begin in November 2021. The Ohio Attorney General has issued a press release indicating support for the Proposed Settlement Agreement; however, the Washington Attorney General has issued a press release stating that Washington will not agree to the Proposed Settlement Agreement. These public announcements are not binding and there is no assurance that any state that has made a public announcement of support for the Proposed Settlement Agreement will ultimately execute the Proposed Settlement Agreement.</div><div style="margin-bottom:3pt;text-align:justify">Private Plaintiffs</div><div style="margin-bottom:3pt;text-align:justify">The Proposed Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 442 lawsuits as of August 10, 2021. Of these, 128 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. A trial in one case is currently scheduled to begin in October 2021. We are vigorously defending ourselves in these matters.</div><div style="text-align:justify">Insurance Litigation</div><div style="margin-bottom:3pt;text-align:justify">We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (“National Union”) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January, 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of June 30, 2021.</div><div style="margin-bottom:3pt;text-align:justify">Department of Justice Investigations</div><div style="margin-bottom:3pt;text-align:justify">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these requests. We are unable to predict the outcome of any of these investigations. </div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div>Cordis Product Liability Lawsuits</div><div style="margin-bottom:3pt;text-align:justify">As of August 10, 2021, we are named as a defendant in 419 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,427 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another 32 lawsuits involving similar claims by approximately 37 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 claims. This agreement is subject to certain contingencies. We continue to vigorously defend ourselves in these lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs. </div><div style="margin-bottom:3pt;text-align:justify">At June 30, 2021, we had a total of $524 million net of estimated insurance recoveries, accrued for losses and legal defense costs, net of expected insurance recoveries, related to the Cordis IVC filter lawsuits in the consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.03 billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained. </div><div style="margin-bottom:3pt;text-align:justify">SEC Investigation</div><div style="margin-bottom:3pt;text-align:justify">In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. We are cooperating with this inquiry and cannot predict its outcome or duration. </div><div style="margin-bottom:3pt;text-align:justify">Shareholder Securities Litigation</div><div style="margin-bottom:3pt;text-align:justify">In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In November 2020, we filed a motion to dismiss the amended complaint. We believe that the claims asserted in this </div></div><div style="margin-bottom:3pt;text-align:justify">complaint are without merit and intend to vigorously defend against them.</div><div style="text-align:justify">Specialty Solutions DOJ Investigation</div><div style="margin-bottom:3pt;text-align:justify">In November 2018, the United States Attorney’s Office for the District of Massachusetts (the "USAO") commenced an investigation pertaining to the U.S. federal healthcare fraud and abuse laws. These requests sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with these requests and are engaged in resolution discussions with the USAO and Department of Health and Human Services, Office of Inspector General. In connection with these discussions, we recorded $13 million of expense within litigation charges/(recoveries) on our consolidated statements of earnings/(loss) during the fiscal year ended June 30, 2021. We cannot predict the outcome of the discussions and it is possible that we may incur additional losses or agree to other remedial measures; however, we are not currently able to estimate a range of reasonably possible additional losses.</div><div style="text-align:justify">Other Civil Litigation </div><div style="text-align:justify">Generic Pharmaceutical Pricing Antitrust Litigation </div><div style="margin-bottom:3pt;text-align:justify">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. </div><div style="margin-bottom:3pt;text-align:justify">Active Pharmaceutical Ingredient Impurity Litigation</div><div style="margin-bottom:3pt;text-align:justify">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. </div><div style="margin-bottom:3pt;text-align:justify">In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the “Sartan MDL”) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter. </div><div>Antitrust Litigation Proceeds</div><div style="text-align:justify">We received and recognized income resulting from settlements of lawsuits in which we were a class member or plaintiff of $112 million, $16 million and $94 million during fiscal 2021, 2020, and 2019, respectively.</div> 100000000 41000000 3300 2900 25 6370000000 1170000000 5630000000 6730000000 405000000 442 128 419 5427 32 37 1300 524000000 1030000000.00 13000000 112000000 16000000 94000000 <div style="margin-bottom:6pt;text-align:justify">8. Income Taxes </div><div>Earnings/(Loss) before Income Taxes and Provision for/(Benefit From) Income Taxes</div><div style="margin-bottom:3pt">The following table summarizes earnings/(loss) before income taxes:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:53.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. operations</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(47)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(4,056)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,478 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-U.S. operations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">370 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">284 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">273 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Earnings/(loss) before income taxes</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">323 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,772)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,751 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes the components of provision for/(benefit from) income taxes:</div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.220%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Current:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Federal</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(989)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">659 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">295 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">State and local</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">154 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-U.S.</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total current</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(785)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">882 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">469 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred:</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Federal</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">539 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(822)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(28)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">State and local</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(28)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(127)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(37)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-U.S.</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(18)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total deferred</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">496 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(961)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(83)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Provision for/(benefit from) income taxes</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(289)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(79)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">386 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div> </div><div>Tax Effects of Self-Insurance Pre-Tax Loss</div><div style="margin-bottom:3pt;text-align:justify">During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.</div><div style="margin-bottom:3pt;text-align:justify">Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.</div><div style="margin-bottom:3pt;text-align:justify">We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021. We also increased our non-current deferred tax </div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify">liability by approximately $700 million during fiscal 2021 related to this matter.</div><div style="margin-bottom:3pt;text-align:justify">We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change. The actual amount of the tax benefit may differ materially from these estimates.</div><div style="margin-bottom:3pt;text-align:justify">Tax Effects of Opioid Litigation Charges</div><div style="margin-bottom:3pt;text-align:justify">In connection with the $1.17 billion and $5.63 billion pre-tax charges for the opioid litigation, during fiscal 2021 and 2020, we recorded a tax benefit of $228 million and $488 million, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively. </div><div style="margin-bottom:3pt;text-align:justify">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the U.S. tax law governing deductibility was changed by the U.S. Tax Cuts and Jobs Act ("Tax Act"). Further, it is possible Congress or the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit may differ materially from these estimates.</div><div>Effective Tax Rate</div><div style="margin-top:3pt;text-align:justify">The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.220%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">2021 (1)</div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">2020 (1)</div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">2019 (1)</div></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Provision at Federal statutory rate</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.0 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.0 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.0 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">State and local income taxes, net of federal benefit</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Tax effect of foreign operations</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.7)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Nondeductible/nontaxable items (2)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Cordis Disposition</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Withholding Taxes (2)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Change in Valuation Allowances</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.4)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.5 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>US Taxes on International Income (2)(3)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Impact of Resolutions with IRS and other related matters (2)</div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13.6)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Legal Entity Reorganization</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Opioid litigation</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.7 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23.2)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss Carryback Claims</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(129.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Other (2)</div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.7 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Effective income tax rate</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(89.7)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.1 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22.1 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1) The table represents the following: fiscal 2021 is pretax income with tax benefit, fiscal 2020 is pretax loss with tax benefit, and fiscal 2019 is pretax income with tax expense.</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2) Certain prior year amounts have been reclassified to conform to current year presentation.</div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(3) Includes the tax impact of Global Intangible Low-Taxed Income ("GILTI") tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. </div><div style="margin-bottom:3pt;text-align:justify">The income tax benefit rate was 89.7% and 2.1% in fiscal 2021 and fiscal 2020 compared to an income tax expense rate of 22.1% in fiscal 2019. Fluctuations in the effective tax rates are primarily due to the impact of opioid litigation in fiscal 2021 and 2020, as well as the impact of the carryback claim filed in accordance with the CARES Act provision in fiscal year 2021.</div><div style="margin-bottom:3pt;text-align:justify">Our effective tax rate has benefits from negotiated lower than statutory tax rates in select foreign jurisdictions which individually are not material to our effective tax rate but in aggregate have a favorable tax impact of approximately $20 million during fiscal 2021.</div><div style="margin-bottom:3pt;text-align:justify">As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment needs. The computation of tax required if those earnings are repatriated is not practicable. For amounts not considered indefinitely reinvested, we have recorded an immaterial amount of income tax expense in our financial statements in fiscal 2021. </div><div>Deferred Income Taxes</div><div style="margin-bottom:3pt;text-align:justify">Deferred income taxes arise from temporary differences between financial reporting and tax reporting bases of assets and liabilities and operating loss and tax credit carryforwards for tax purposes. </div><div style="margin-bottom:3pt;text-align:justify">The following table presents the components of the deferred income tax assets and liabilities at June 30:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.937%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred income tax assets:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Receivable basis difference</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">40 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">39 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued liabilities</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">874 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">607 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Share-based compensation</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss and tax credit carryforwards</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">805 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">589 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred tax assets related to uncertain tax positions</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total deferred income tax assets</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,808 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,412 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Valuation allowance for deferred income tax assets</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(515)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(470)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net deferred income tax assets</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,293 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">942 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred income tax liabilities:</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Inventory basis differences</td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">(1,119)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">(1,083)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Property-related</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(375)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(327)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Goodwill and other intangibles</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(733)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(751)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Self-Insurance</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(975)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total deferred income tax liabilities</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,225)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,161)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:6.75pt">Net deferred income tax liability</div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,932)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,219)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify">Deferred income tax assets and liabilities in the preceding table, after netting by taxing jurisdiction and for uncertain tax positions, are in the following captions in the consolidated balance sheets at June 30:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.937%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Noncurrent deferred income tax asset (1)</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Noncurrent deferred income tax liability (2)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,981)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,258)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Noncurrent deferred income tax liability transferred to held for sale</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net deferred income tax liability</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,932)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,219)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Included in other assets in the consolidated balance sheets.</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2)Included in deferred income taxes and other liabilities in the consolidated balance sheets.</div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify">At June 30, 2021 we had gross federal, state and international loss and credit carryforwards of $272 million, $3.9 billion and $2.3 billion, respectively, the tax effect of which is an aggregate deferred tax asset of $805 million. Substantially all of these carryforwards are available for at least three years. Approximately $477 million of the valuation allowance at June 30, 2021 applies to certain federal, state and international loss carryforwards that, in our opinion, are more likely than not to expire unutilized. However, to the extent that tax benefits related to these carryforwards are realized in the future, the reduction in the valuation allowance would reduce income tax expense.</div><div>Unrecognized Tax Benefits</div><div style="margin-bottom:3pt;text-align:justify">We had $932 million, $998 million and $456 million of unrecognized tax benefits at June 30, 2021, 2020 and 2019, respectively. The June 30, 2021, 2020 and 2019 balances include $849 million, $753 million and $303 million, respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate. The remaining unrecognized tax benefits relate to tax positions for which ultimate deductibility is highly certain but for which there is uncertainty as to the timing of such deductibility. Recognition of these tax benefits would not affect our effective tax rate. We include the full amount of unrecognized tax benefits in deferred income taxes and other liabilities in the consolidated balance sheets. The following table presents a reconciliation of the beginning and ending amounts of unrecognized tax benefits:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:53.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at beginning of fiscal year</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">998 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">456 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">423 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Additions for tax positions of the current year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">121 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Additions for tax positions of prior years</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">223 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Reductions for tax positions of prior years</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(138)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(27)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Settlements with tax authorities </td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(271)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(25)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expiration of the statute of limitations </td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt">Balance at end of fiscal year</div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">932 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">998 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">456 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"> </div><div style="margin-bottom:3pt;text-align:justify">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, </div><div style="margin-bottom:3pt;text-align:justify">reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is a net decrease of $0 million to $20 million, exclusive of penalties and interest.</div><div style="margin-bottom:3pt;text-align:justify">We recognize accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes. At June 30, 2021, 2020 and 2019, we had $49 million, $146 million and $122 million, respectively, accrued for the payment of interest and penalties. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the consolidated balance sheets. As a result of our IRS audit settlements and carryback claim, an immaterial amount of interest was recorded in fiscal 2021. During fiscal 2020 and 2019, we recognized $16 million and $8 million of expense for interest and penalties in income tax expense, respectively. </div><div style="margin-bottom:3pt;text-align:justify">Other Tax Matters</div><div style="margin-bottom:3pt;text-align:justify">We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year. </div><div style="margin-bottom:3pt;text-align:justify">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $72 million and $176 million at June 30, 2021 and 2020, respectively, and is included in other assets in the consolidated balance sheets.</div><div style="margin-bottom:3pt;text-align:justify">As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $12 million and $19 million at June 30, 2021 and 2020, respectively, and is included in other assets in the consolidated balance sheets.</div> <div style="margin-bottom:3pt">The following table summarizes earnings/(loss) before income taxes:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:53.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. operations</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(47)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(4,056)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,478 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-U.S. operations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">370 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">284 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">273 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Earnings/(loss) before income taxes</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">323 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,772)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,751 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -47000000 -4056000000 1478000000 370000000 284000000 273000000 323000000 -3772000000 1751000000 <div style="margin-bottom:3pt;text-align:justify">The following table summarizes the components of provision for/(benefit from) income taxes:</div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.220%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.174%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Current:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Federal</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(989)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">659 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">295 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">State and local</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">92 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">154 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-U.S.</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total current</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(785)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">882 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">469 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred:</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Federal</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">539 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(822)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(28)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">State and local</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(28)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(127)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(37)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-U.S.</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(18)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total deferred</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">496 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(961)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(83)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Provision for/(benefit from) income taxes</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(289)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(79)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">386 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -989000000 659000000 295000000 92000000 154000000 89000000 112000000 69000000 85000000 -785000000 882000000 469000000 539000000 -822000000 -28000000 -28000000 -127000000 -37000000 -15000000 -12000000 -18000000 496000000 -961000000 -83000000 -289000000 -79000000 386000000 -424000000 974000000 700000000 1170000000 5630000000 228000000 488000000 219000000 469000000 <div style="margin-top:3pt;text-align:justify">The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.220%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">2021 (1)</div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">2020 (1)</div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">2019 (1)</div></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Provision at Federal statutory rate</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.0 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.0 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.0 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">State and local income taxes, net of federal benefit</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Tax effect of foreign operations</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.7)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Nondeductible/nontaxable items (2)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Cordis Disposition</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.0 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Withholding Taxes (2)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Change in Valuation Allowances</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.4)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.5 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.5 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>US Taxes on International Income (2)(3)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Impact of Resolutions with IRS and other related matters (2)</div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13.6)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Legal Entity Reorganization</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Opioid litigation</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.7 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23.2)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss Carryback Claims</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(129.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Other (2)</div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.7 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2.1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Effective income tax rate</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(89.7)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.1 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22.1 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1) The table represents the following: fiscal 2021 is pretax income with tax benefit, fiscal 2020 is pretax loss with tax benefit, and fiscal 2019 is pretax income with tax expense.</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2) Certain prior year amounts have been reclassified to conform to current year presentation.</div> 0.210 0.210 0.210 0.032 0.025 0.009 0.007 0 -0.007 0.016 0.002 0.008 0.070 0 0 0.090 -0.003 0.007 -0.014 0.015 0.045 -0.067 0.002 0.007 -0.136 -0.004 -0.001 0 0 -0.036 0.177 -0.232 0 -1.299 0 0 0.017 0.006 -0.021 -0.897 0.021 0.221 -0.897 0.021 0.221 20000000 825000000 <div style="margin-bottom:3pt;text-align:justify">The following table presents the components of the deferred income tax assets and liabilities at June 30:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.937%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred income tax assets:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Receivable basis difference</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">40 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">39 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued liabilities</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">874 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">607 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Share-based compensation</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss and tax credit carryforwards</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">805 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">589 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred tax assets related to uncertain tax positions</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total deferred income tax assets</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,808 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,412 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Valuation allowance for deferred income tax assets</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(515)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(470)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net deferred income tax assets</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,293 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">942 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred income tax liabilities:</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Inventory basis differences</td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">(1,119)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">(1,083)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Property-related</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(375)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(327)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Goodwill and other intangibles</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(733)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(751)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Self-Insurance</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(975)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total deferred income tax liabilities</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,225)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,161)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:6.75pt">Net deferred income tax liability</div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,932)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,219)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 40000000 39000000 874000000 607000000 38000000 38000000 805000000 589000000 35000000 52000000 16000000 87000000 1808000000 1412000000 515000000 470000000 1293000000 942000000 1119000000 1083000000 375000000 327000000 733000000 751000000 975000000 0 23000000 0 3225000000 2161000000 1932000000 1219000000 <div style="margin-bottom:3pt;text-align:justify">Deferred income tax assets and liabilities in the preceding table, after netting by taxing jurisdiction and for uncertain tax positions, are in the following captions in the consolidated balance sheets at June 30:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.937%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Noncurrent deferred income tax asset (1)</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">52 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Noncurrent deferred income tax liability (2)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,981)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,258)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Noncurrent deferred income tax liability transferred to held for sale</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net deferred income tax liability</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,932)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,219)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Included in other assets in the consolidated balance sheets.</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2)Included in deferred income taxes and other liabilities in the consolidated balance sheets.</div> 52000000 39000000 1981000000 1258000000 3000000 0 1932000000 1219000000 272000000 3900000000 2300000000 805000000 477000000 932000000 998000000 456000000 849000000 753000000 303000000 The following table presents a reconciliation of the beginning and ending amounts of unrecognized tax benefits:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:53.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at beginning of fiscal year</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">998 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">456 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">423 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Additions for tax positions of the current year</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">121 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Additions for tax positions of prior years</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">223 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Reductions for tax positions of prior years</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(138)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(27)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Settlements with tax authorities </td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(271)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(25)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expiration of the statute of limitations </td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt">Balance at end of fiscal year</div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">932 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">998 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">456 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 998000000 456000000 423000000 121000000 500000000 24000000 223000000 78000000 39000000 138000000 27000000 5000000 271000000 6000000 25000000 1000000 3000000 0 932000000 998000000 456000000 0 20000000 49000000 146000000 122000000 16000000 8000000 72000000 176000000 12000000 19000000 <div style="margin-bottom:6pt;text-align:justify">9. Fair Value Measurements </div><div style="margin-bottom:3pt;text-align:justify">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at June 30:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash equivalents</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,883 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,883 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other investments (1)</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">126 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">126 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward contracts (2)</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash equivalents</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">721 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">721 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other investments (1)</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">114 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">114 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward contracts (2)</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high-quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.(2)The fair value of interest rate swaps, foreign currency contracts, net investment hedges and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the consolidated balance sheets. <div style="margin-bottom:6pt;text-align:justify">9. Fair Value Measurements </div><div style="margin-bottom:3pt;text-align:justify">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at June 30:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash equivalents</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,883 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,883 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other investments (1)</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">126 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">126 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward contracts (2)</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash equivalents</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">721 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">721 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other investments (1)</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">114 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">114 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward contracts (2)</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high-quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2)The fair value of interest rate swaps, foreign currency contracts, net investment hedges and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the consolidated balance sheets. </div><div style="margin-bottom:3pt;text-align:justify"> </div><div style="margin-bottom:3pt;text-align:justify">Assets and (Liabilities) Measured on a Nonrecurring Basis</div><div style="margin-bottom:6pt;text-align:justify">Assets and liabilities held for sale of $1.1 billion and $96 million, respectively, at June 30, 2021 are primarily related to the divestiture of our Cordis business. These estimated fair values utilized Level 3 unobservable inputs based on expected sales proceeds following a competitive bidding process. See <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_106" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a> for additional information regarding assets and liabilities held for sale.</div> <div style="margin-bottom:3pt;text-align:justify">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at June 30:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash equivalents</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,883 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,883 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other investments (1)</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">126 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">126 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward contracts (2)</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash equivalents</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">721 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">721 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other investments (1)</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">114 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">114 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward contracts (2)</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high-quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.(2)The fair value of interest rate swaps, foreign currency contracts, net investment hedges and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the consolidated balance sheets. 1883000000 0 0 1883000000 126000000 0 0 126000000 0 42000000 0 42000000 721000000 0 0 721000000 114000000 0 0 114000000 0 53000000 0 53000000 1100000000 96000000 <div style="margin-bottom:6pt;text-align:justify">10. Financial Instruments </div><div style="margin-bottom:3pt;text-align:justify">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</div><div>Interest Rate Risk Management</div><div style="margin-bottom:3pt;text-align:justify">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</div><div>Currency Exchange Risk Management</div><div style="margin-bottom:3pt;text-align:justify">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange </div><div style="margin-bottom:3pt;text-align:justify">rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</div><div>Commodity Price Risk Management</div><div style="margin-bottom:3pt;text-align:justify">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes the fair value of our assets and liabilities related to derivatives designated as hedging instruments and the respective line items in which they were recorded in the consolidated balance sheets at June 30:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:69.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.834%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-floating interest rate swaps (1)</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap (1) </td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap (2)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts (2)</td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total assets</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">46 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">74 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts (4)</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward interest rate swaps (3)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Commodity contracts (4)</td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total liabilities</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">21 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt">(1) Included in other assets in the consolidated balance sheets.</div><div style="padding-left:18pt;text-indent:-18pt">(2) Included in prepaid expenses and other in the consolidated balance sheets.</div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt">(3) Included in deferred income taxes and other liabilities in the consolidated balance sheets.</div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt">(4) Included in other accrued liabilities in the consolidated balance sheets.</div><div>Fair Value Hedges</div><div style="margin-bottom:3pt;text-align:justify">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the consolidated statements of earnings/(loss). During fiscal 2021, 2020 and 2019 there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</div><div style="margin-bottom:3pt;text-align:justify">During fiscal 2021, we unwound certain interest rate swap contracts with the notional amount of $550 million. In connection with the unwind of these contracts, we received cash proceeds of </div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify">$18 million. The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the debt agreement, which matures in March 2023.</div><div style="margin-bottom:3pt;text-align:justify">During fiscal 2021, we entered into a pay-floating interest rate swap with total notional amounts of $200 million. This swap has been designated as fair value hedges of our fixed rate debt and is included in deferred income taxes and other liabilities in the consolidated balance sheets.</div><div style="margin-bottom:3pt;text-align:justify">In May 2020, we unwound certain interest rate swap contracts. In connection with the unwind of these contracts, we received cash proceeds of $112 million. The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the related debt agreements, which ranged from 48 months to 63 months at June 30, 2020.</div><div style="margin-bottom:3pt;text-align:justify">In connection with the debt repayment as described in <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_124" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a>, two pay-floating interest rate swaps with notional amounts of $200 million matured in the second quarter of fiscal 2020. </div><div style="margin-bottom:3pt;text-align:justify">During fiscal 2019, we terminated notional amounts of $163 million of pay-floating interest rate swaps in connection with the debt repurchases in fiscal 2019 described in <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_124" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a>. These swaps were previously designated as fair value hedges.</div><div style="margin-bottom:3pt;text-align:justify">The following tables summarize the outstanding interest rate swaps designated as fair value hedges at June 30:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Maturity Date</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-floating interest rate swaps</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">200 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Mar 2028</td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Maturity Date</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-floating interest rate swaps</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">550 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Mar 2023</td></tr></table></div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes the gain/(loss) recognized in earnings for interest rate swaps designated as fair value hedges:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-floating interest rate swaps (1)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">106 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Fixed-rate debt (1)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(106)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt">(1) Included in interest expense, net in the consolidated statements of earnings/(loss).</div><div>Cash Flow Hedges</div><div style="margin-bottom:3pt;text-align:justify">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings. </div><div style="margin-bottom:3pt;text-align:justify">During fiscal 2020, we entered into forward interest rate swaps with a total notional amount of $200 million to hedge probable, but </div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify">not firmly committed, future transactions associated with our debt. During fiscal 2021, we terminated these swaps and reclassified an immaterial deferred gain from accumulated other comprehensive loss into interest expense, net in our consolidated statements of earnings/(loss) because the forecasted transactions were probable of not occurring. </div><div style="margin-bottom:3pt;text-align:justify">All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges that are expected to be reclassified into net earnings within the next 12 months are immaterial.</div><div style="margin-bottom:3pt;text-align:justify">We enter into foreign currency contracts to protect the value of anticipated foreign currency revenues and expenses. At June 30, 2021 and 2020, we held contracts to hedge probable, but not firmly committed, revenue and expenses. The principal currencies hedged are the Chinese renminbi, Canadian dollar, euro, Thai baht and Mexican peso.</div><div style="margin-bottom:3pt;text-align:justify">We enter into commodity contracts to manage the price risk associated with forecasted purchases of certain commodities used in our Medical segment.</div><div style="margin-bottom:3pt;text-align:justify">The following tables summarize the outstanding cash flow hedges at June 30:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Maturity Date</td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Foreign currency contracts</td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">436 </td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Jul 2021</td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">-</td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Jun 2022</td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Maturity Date</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward interest rate swaps</td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">200 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="9" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Jun 2022</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">328 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Jul 2020</div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">-</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Jun 2021</div></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Commodity contracts</td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Jul 2020</div></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">-</td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Jun 2021</div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes the pre-tax gain/(loss) included in OCI for derivative instruments designated as cash flow hedges:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.643%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:top">Forward interest rate swaps</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Commodity contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes the pre-tax gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:46.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts (1)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(12)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts (2)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts (3)</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward interest rate swaps (4)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Commodity contracts (3)</td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1) Included in revenue in the consolidated statements of earnings/(loss).</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2) Included in cost of products sold in the consolidated statements of earnings/(loss).</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(3) Included in SG&A expenses in the consolidated statements of earnings/(loss).</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(4) Included in interest expense, net in the consolidated statements of earnings/(loss).</div></div><div>Net Investment Hedges</div><div style="margin-bottom:3pt;text-align:justify">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</div><div style="margin-bottom:3pt;text-align:justify">In August 2019, we entered into a ¥64 billion ($600 million) cross-currency swap maturing in 2022.</div><div style="margin-bottom:3pt;text-align:justify">In September 2018, we entered into a €200 million ($233 million) cross-currency swap maturing in 2023.</div><div style="margin-bottom:3pt;text-align:justify">Cross-currency swaps designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. </div><div style="margin-bottom:3pt;text-align:justify">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $7 million loss and a $35 million gain during fiscal 2021 and 2020, respectively. Gains recognized in interest expense, net in the consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $19 million and $17 million during fiscal 2021 and 2020, respectively.</div><div>Economic (Non-Designated) Hedges</div><div style="margin-bottom:3pt;text-align:justify">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. The principal currency managed through foreign currency contracts is the Chinese renminbi, Canadian dollar, euro, Mexican Peso, and Brazilian Real. </div><div style="margin-bottom:3pt;text-align:justify">The following tables summarize the outstanding economic (non-designated) derivative instruments at June 30:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Maturity Date</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">254 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 2021</td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Maturity Date</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">325 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Jul 2020</td></tr></table></div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes the gain/(loss) recognized in earnings for economic (non-designated) derivative instruments:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:46.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts (1)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(11)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(13)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1) Included in other income, net in the consolidated statements of earnings/(loss).</div><div>Fair Value of Financial Instruments</div><div style="margin-bottom:3pt;text-align:justify">The carrying amounts of cash and equivalents, trade receivables, net, accounts payable, and other accrued liabilities at June 30, 2021 and 2020 approximate fair value due to their short-term maturities.</div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at June 30:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Estimated fair value</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,751 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,273 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Carrying amount</td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,236 </td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,775 </td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify">The following table is a summary of the fair value gain/(loss) of our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:31.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value Gain/(Loss)</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value Gain/(Loss)</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-floating interest rate swaps</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">200 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">550 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">690 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">653 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward interest rate swaps</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">200 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">833 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">833 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Commodity contracts</td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:3pt;text-align:justify">The following table summarizes the fair value of our assets and liabilities related to derivatives designated as hedging instruments and the respective line items in which they were recorded in the consolidated balance sheets at June 30:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:69.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.834%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-floating interest rate swaps (1)</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap (1) </td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap (2)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts (2)</td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total assets</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">46 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">74 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts (4)</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward interest rate swaps (3)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Commodity contracts (4)</td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total liabilities</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">21 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt">(1) Included in other assets in the consolidated balance sheets.</div><div style="padding-left:18pt;text-indent:-18pt">(2) Included in prepaid expenses and other in the consolidated balance sheets.</div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt">(3) Included in deferred income taxes and other liabilities in the consolidated balance sheets.</div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt">(4) Included in other accrued liabilities in the consolidated balance sheets.</div> 1000000 27000000 6000000 47000000 34000000 0 5000000 0 46000000 74000000 4000000 4000000 0 16000000 0 1000000 4000000 21000000 0 0 550000000 18000000 200000000 112000000 200000000 163000000 <div style="margin-bottom:3pt;text-align:justify">The following tables summarize the outstanding interest rate swaps designated as fair value hedges at June 30:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Maturity Date</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-floating interest rate swaps</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">200 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Mar 2028</td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Maturity Date</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-floating interest rate swaps</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">550 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Mar 2023</td></tr></table></div> 200000000 550000000 <div style="margin-bottom:3pt;text-align:justify">The following table summarizes the gain/(loss) recognized in earnings for interest rate swaps designated as fair value hedges:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-floating interest rate swaps (1)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">106 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Fixed-rate debt (1)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(106)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt">(1) Included in interest expense, net in the consolidated statements of earnings/(loss).</div> -8000000 106000000 9000000 8000000 -106000000 -9000000 200000000 200000000 <div style="margin-bottom:3pt;text-align:justify">The following tables summarize the outstanding cash flow hedges at June 30:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Maturity Date</td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Foreign currency contracts</td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">436 </td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Jul 2021</td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">-</td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Jun 2022</td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Maturity Date</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward interest rate swaps</td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">200 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="9" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Jun 2022</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">328 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Jul 2020</div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">-</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Jun 2021</div></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Commodity contracts</td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Jul 2020</div></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">-</td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Jun 2021</div></td></tr></table></div> 436000000 200000000 328000000 16000000 <div style="margin-bottom:3pt;text-align:justify">The following table summarizes the pre-tax gain/(loss) included in OCI for derivative instruments designated as cash flow hedges:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.643%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:top">Forward interest rate swaps</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Commodity contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 16000000 -16000000 0 1000000 1000000 -5000000 5000000 -8000000 5000000 <div style="margin-bottom:3pt;text-align:justify">The following table summarizes the pre-tax gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:46.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts (1)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(12)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts (2)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts (3)</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward interest rate swaps (4)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Commodity contracts (3)</td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1) Included in revenue in the consolidated statements of earnings/(loss).</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2) Included in cost of products sold in the consolidated statements of earnings/(loss).</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(3) Included in SG&A expenses in the consolidated statements of earnings/(loss).</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(4) Included in interest expense, net in the consolidated statements of earnings/(loss).</div> -12000000 7000000 2000000 -2000000 1000000 0 4000000 0 1000000 2000000 2000000 2000000 6000000 -5000000 0 64000000000 600000000 200000000 233000000 7000000 35000000 19000000 17000000 <div style="margin-bottom:3pt;text-align:justify">The following tables summarize the outstanding economic (non-designated) derivative instruments at June 30:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Maturity Date</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">254 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">July 2021</td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Maturity Date</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">325 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Jul 2020</td></tr></table></div> 254000000 325000000 <div style="margin-bottom:3pt;text-align:justify">The following table summarizes the gain/(loss) recognized in earnings for economic (non-designated) derivative instruments:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:46.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts (1)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(11)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(13)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1) Included in other income, net in the consolidated statements of earnings/(loss).</div> -8000000 -11000000 -13000000 <div style="margin-bottom:3pt;text-align:justify">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at June 30:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Estimated fair value</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,751 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,273 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Carrying amount</td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,236 </td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,775 </td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6751000000 7273000000 6236000000 6775000000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify">The following table is a summary of the fair value gain/(loss) of our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:31.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value Gain/(Loss)</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value Gain/(Loss)</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Pay-floating interest rate swaps</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">200 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">550 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">690 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">653 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Forward interest rate swaps</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">200 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">833 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">833 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Commodity contracts</td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 200000000 1000000 550000000 27000000 690000000 1000000 653000000 -4000000 0 0 200000000 -16000000 833000000 40000000 833000000 47000000 0 0 16000000 -1000000 <div style="margin-bottom:6pt;text-align:justify">11. Shareholders' Equity </div><div style="margin-bottom:3pt;text-align:justify">At June 30, 2021 and 2020, authorized capital shares consisted of the following: 750 million Class A common shares, without par value; 5 million Class B common shares, without par value; and 500 thousand non-voting preferred shares, without par value. The Class A common shares and Class B common shares are collectively referred to below as “common shares”. Holders of common shares are entitled to share equally in any dividends declared by the Board of Directors and to participate equally in all distributions of assets upon liquidation. Generally, the holders of Class A common shares are entitled to one vote per share, and the holders of Class B common shares are entitled to one-fifth of one vote per share on proposals presented to shareholders for vote. Under certain circumstances, the holders of Class B common </div><div style="margin-bottom:3pt;text-align:justify">shares are entitled to vote as a separate class. Only Class A common shares were outstanding at June 30, 2021 and 2020.</div><div style="margin-bottom:3pt;text-align:justify">We repurchased $1.15 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2021, 2020 and 2019, as described below. We funded the repurchases with available cash and short term borrowings. The common shares repurchased are held in treasury to be used for general corporate purposes.</div><div style="margin-bottom:3pt;text-align:justify">During fiscal 2021, we repurchased 3.7 million common shares having an aggregate cost of $200 million. The average price paid per common share was $54.40. These repurchases were made under an accelerated share repurchase ("ASR") program, which began on February 9, 2021 and was completed on March 31, 2021. </div><div style="margin-bottom:3pt;text-align:justify">During fiscal 2020, we repurchased 7.3 million common shares having an aggregate cost of $350 million. The average price paid per common share was $48.00. These repurchases were made under an ASR program, which began on August 20, 2019 and was completed on December 4, 2019. </div><div style="margin-bottom:3pt;text-align:justify">During fiscal 2019, we repurchased 11.5 million common shares having an aggregate cost of $600 million. The average price paid per common share was $52.32. These repurchases were made under an ASR program, which began on August 16, 2018 and was completed on October 25, 2018.</div><div>Accumulated Other Comprehensive Loss</div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign Currency Translation Adjustments and other</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gain/(Loss) on Derivatives, net of tax</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Other Comprehensive Loss</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at June 30, 2019</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(95)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(79)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive income/(loss), net before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(20)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Amounts reclassified to earnings</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax of $4 million</td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(28)</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(25)</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at June 30, 2020</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(92)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(104)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive income, before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Amounts reclassified to earnings</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax of $4 million</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Balance at June 30, 2021</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(46)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(34)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 750000000 5000000 500000 1 1150000000 3700000 200000000 54.40 7300000 350000000 48.00 11500000 600000000 52.32 <div style="margin-bottom:3pt;text-align:justify">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign Currency Translation Adjustments and other</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gain/(Loss) on Derivatives, net of tax</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Other Comprehensive Loss</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at June 30, 2019</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(95)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(79)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive income/(loss), net before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(20)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Amounts reclassified to earnings</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax of $4 million</td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(28)</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(25)</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at June 30, 2020</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(92)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(104)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive income, before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Amounts reclassified to earnings</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax of $4 million</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">70 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Balance at June 30, 2021</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(46)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(34)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -95000000 16000000 -79000000 3000000 -23000000 -20000000 0 5000000 5000000 3000000 -28000000 -25000000 -92000000 -12000000 -104000000 46000000 22000000 68000000 0 -2000000 -2000000 46000000 24000000 70000000 -46000000 12000000 -34000000 <div style="margin-bottom:6pt;text-align:justify">12. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc. </div><div style="margin-bottom:3pt;text-align:justify">The following table reconciles the computation of basic and diluted earnings per share attributable to Cardinal Health, Inc.:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:61.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions, except per share amounts)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Net earnings/(loss)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">612 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,693)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,365 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Net earnings attributable to noncontrolling interest</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt">Net earnings/(loss) attributable to Cardinal Health, Inc.</div></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">611 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,696)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,363 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted-average common shares–basic</td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">292 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">293 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">300 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Effect of dilutive securities:</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Employee stock options, restricted share units, and performance share units</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Weighted-average common shares–diluted</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">294 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">293 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">301 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic earnings/(loss) per common share attributable to Cardinal Health, Inc.:</td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.09 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(12.61)</td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4.55 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Diluted earnings/(loss) per common share attributable to Cardinal Health, Inc.:</td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.08 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12.61)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.53 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for fiscal 2021, 2020 and 2019 were 3 million, 6 million and 7 million, respectively. During fiscal 2020, there were 2 million potentially dilutive employee stock options, restricted share units and performance share units not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would be anti-dilutive as a result of the net loss for the fiscal year.</div> <div style="margin-bottom:3pt;text-align:justify">The following table reconciles the computation of basic and diluted earnings per share attributable to Cardinal Health, Inc.:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:61.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions, except per share amounts)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Net earnings/(loss)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">612 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,693)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,365 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Net earnings attributable to noncontrolling interest</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt">Net earnings/(loss) attributable to Cardinal Health, Inc.</div></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">611 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,696)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,363 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted-average common shares–basic</td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">292 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">293 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">300 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Effect of dilutive securities:</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Employee stock options, restricted share units, and performance share units</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Weighted-average common shares–diluted</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">294 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">293 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">301 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic earnings/(loss) per common share attributable to Cardinal Health, Inc.:</td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.09 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(12.61)</td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4.55 </td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Diluted earnings/(loss) per common share attributable to Cardinal Health, Inc.:</td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.08 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12.61)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.53 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 612000000 -3693000000 1365000000 1000000 3000000 2000000 611000000 -3696000000 1363000000 292000000 293000000 300000000 2000000 0 1000000 294000000 293000000 301000000 2.09 -12.61 4.55 2.08 -12.61 4.53 3000000 6000000 7000000 2000000 <div style="margin-bottom:6pt;text-align:justify">13. Segment Information </div><div style="margin-bottom:3pt;text-align:justify">Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</div><div style="margin-bottom:3pt;text-align:justify">Revenue</div><div style="margin-bottom:3pt;text-align:justify">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates pharmacies, including pharmacies in community health centers, nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </div><div style="margin-bottom:6pt;text-align:justify">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded </div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify">products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</div><div style="margin-bottom:3pt;text-align:justify">The following table presents revenue for each reportable segment and Corporate:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.690%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharmaceutical</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">145,796 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">137,495 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">129,917 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medical</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,687 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,444 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,633 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total segment revenue</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">162,483 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">152,939 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145,550 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate (1)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">162,467 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">152,922 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">145,534 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</div><div style="margin-bottom:3pt;text-align:justify"> </div><div style="margin-bottom:3pt;text-align:justify">The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharmaceutical Distribution and Specialty Solutions (1) (2)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">144,988 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">136,693 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">129,067 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Nuclear and Precision Health Solutions</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">808 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">802 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">850 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt">Pharmaceutical segment revenue</div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145,796 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">137,495 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">129,917 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Medical distribution and products (3)</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,485 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,429 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,833 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cardinal Health at-Home Solutions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,202 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,015 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,800 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt">Medical segment revenue</div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,687 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,444 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,633 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"> Total segment revenue</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">162,483 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">152,939 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145,550 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate (4)</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">162,467 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">152,922 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">145,534 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services"</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</div><div style="margin-bottom:3pt;text-align:justify">The following table presents revenue by geographic area:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">157,756 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">148,707 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">141,479 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">International</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,727 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,232 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,071 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total segment revenue</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">162,483 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">152,939 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145,550 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate (1)</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">162,467 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">152,922 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">145,534 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify">Segment Profit</div><div style="margin-bottom:3pt;text-align:justify">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general, and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</div><div style="margin-bottom:3pt;text-align:justify">We do not allocate the following items to our segments: </div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt">•last-in first-out, or ("LIFO"), inventory charges/(credits);</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt">•surgical gown recall costs/(income); in connection with a voluntary recall for certain surgical gowns and a voluntary recall and field actions for surgical procedure packs containing affected gowns, we recognized a pre-tax charge of $85 million during fiscal 2020;</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt">•restructuring and employee severance;</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt">•amortization and other acquisition-related costs;</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt">•impairments and (gain)/loss on disposal of assets; in connection with the divestiture of the Cordis business, we recognized a $60 million pre-tax write-down of the net assets held for sale during fiscal 2021; in connection with the naviHealth divestiture discussed in <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_106" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a>, we recognized a pre-tax gain of $508 million during fiscal 2019;</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt">•litigation (recoveries)/charges, net; in connection with the opioid litigation as discussed further in <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_130" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a>, we recognized pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively;</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt">•state opioid assessment related to prior fiscal years; in connection with the New York Opioid Stewardship Act as discussed further in <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_130" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a>, we recognized a pre-tax charge of $41 million during fiscal 2021, related to calendar years 2017 and 2018 assessments;</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt">•other (income)/expense, net;</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt">•interest expense, net;</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt">•loss on early extinguishment of debt;</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt">•(gain)/loss on sale of equity interest in naviHealth; in connection with the sale of our remaining equity interest in a partnership that owned naviHealth as discussed in <a href="#i4f0ec56b9c604f1782a65ea4a19c284d_106" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a>, we recognized a $579 million pre-tax gain ($493 million after tax) during fiscal 2020;</div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt">•provision for/(benefit from) income taxes </div><div style="margin-bottom:3pt;text-align:justify">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally </div></div><div style="margin-bottom:3pt;text-align:justify">includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $27 million, $69 million and $55 million for fiscal 2021, 2020 and 2019, respectively. </div><div style="margin-bottom:3pt;text-align:justify">The following tables present segment profit by reportable segment and Corporate:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.760%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharmaceutical</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,684 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,753 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,834 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medical</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">577 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">663 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">576 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total segment profit</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,261 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,416 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,410 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,789)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6,514)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(350)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total operating earnings</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">472 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(4,098)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,060 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify">The following tables present depreciation and amortization and additions to property and equipment by reportable segment and Corporate:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:47.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.002%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharmaceutical</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">151 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">135 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">147 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Medical</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">226 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">243 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">288 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">406 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">535 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">565 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total depreciation and amortization</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">783 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">913 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:47.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.002%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharmaceutical</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">55 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">47 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Medical</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">97 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">86 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">248 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">242 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">219 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total additions to property and equipment</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">400 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">375 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">328 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify">The following table presents total assets for each reportable segment and Corporate at June 30:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:46.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharmaceutical</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">23,624 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">22,398 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">22,446 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medical (1)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,408 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,691 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,284 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,421 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,677 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,233 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total assets</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">44,453 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">40,766 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">40,963 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt">(1) Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021.</div><div style="margin-bottom:3pt;text-align:justify"> </div><div style="margin-bottom:3pt;text-align:justify">The following tables present property and equipment, net by geographic area:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:46.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,958 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,880 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,846 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">International</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">402 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">486 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">510 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Property and equipment, net</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,360 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,366 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,356 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2 2 <div style="margin-bottom:3pt;text-align:justify">The following table presents revenue for each reportable segment and Corporate:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.690%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharmaceutical</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">145,796 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">137,495 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">129,917 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medical</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,687 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,444 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,633 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total segment revenue</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">162,483 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">152,939 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145,550 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate (1)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">162,467 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">152,922 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">145,534 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</div> 145796000000 137495000000 129917000000 16687000000 15444000000 15633000000 162483000000 152939000000 145550000000 -16000000 -17000000 -16000000 162467000000 152922000000 145534000000 <div style="margin-bottom:3pt;text-align:justify">The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharmaceutical Distribution and Specialty Solutions (1) (2)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">144,988 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">136,693 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">129,067 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Nuclear and Precision Health Solutions</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">808 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">802 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">850 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt">Pharmaceutical segment revenue</div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145,796 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">137,495 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">129,917 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Medical distribution and products (3)</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,485 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,429 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,833 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cardinal Health at-Home Solutions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,202 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,015 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,800 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt">Medical segment revenue</div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,687 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,444 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,633 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"> Total segment revenue</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">162,483 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">152,939 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145,550 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate (4)</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">162,467 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">152,922 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">145,534 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services"</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</div> <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharmaceutical Distribution and Specialty Solutions (1) (2)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">144,988 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">136,693 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">129,067 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Nuclear and Precision Health Solutions</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">808 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">802 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">850 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt">Pharmaceutical segment revenue</div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145,796 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">137,495 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">129,917 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Medical distribution and products (3)</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,485 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,429 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,833 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cardinal Health at-Home Solutions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,202 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,015 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,800 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt">Medical segment revenue</div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,687 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,444 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,633 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"> Total segment revenue</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">162,483 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">152,939 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145,550 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate (4)</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">162,467 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">152,922 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">145,534 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services"</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</div> 144988000000 136693000000 129067000000 808000000 802000000 850000000 145796000000 137495000000 129917000000 14485000000 13429000000 13833000000 2202000000 2015000000 1800000000 16687000000 15444000000 15633000000 162483000000 152939000000 145550000000 -16000000 -17000000 -16000000 162467000000 152922000000 145534000000 <div style="margin-bottom:3pt;text-align:justify">The following table presents revenue by geographic area:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">157,756 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">148,707 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">141,479 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">International</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,727 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,232 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,071 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total segment revenue</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">162,483 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">152,939 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145,550 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate (1)</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">162,467 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">152,922 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">145,534 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</div> 157756000000 148707000000 141479000000 4727000000 4232000000 4071000000 162483000000 152939000000 145550000000 -16000000 -17000000 -16000000 162467000000 152922000000 145534000000 85000000 -60000000 508000000 1170000000 5630000000 41000000 579000000 493000000 27000000 69000000 55000000 <div style="margin-bottom:3pt;text-align:justify">The following tables present segment profit by reportable segment and Corporate:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.760%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharmaceutical</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,684 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,753 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,834 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medical</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">577 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">663 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">576 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total segment profit</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,261 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,416 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,410 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,789)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6,514)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(350)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total operating earnings</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">472 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(4,098)</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,060 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1684000000 1753000000 1834000000 577000000 663000000 576000000 2261000000 2416000000 2410000000 -1789000000 -6514000000 -350000000 472000000 -4098000000 2060000000 <div style="margin-bottom:3pt;text-align:justify">The following tables present depreciation and amortization and additions to property and equipment by reportable segment and Corporate:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:47.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.002%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharmaceutical</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">151 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">135 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">147 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Medical</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">226 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">243 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">288 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">406 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">535 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">565 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total depreciation and amortization</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">783 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">913 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:47.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.002%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharmaceutical</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">55 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">47 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Medical</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">97 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">86 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">248 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">242 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">219 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total additions to property and equipment</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">400 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">375 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">328 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 151000000 135000000 147000000 226000000 243000000 288000000 406000000 535000000 565000000 783000000 913000000 1000000000 55000000 47000000 35000000 97000000 86000000 74000000 248000000 242000000 219000000 400000000 375000000 328000000 <div style="margin-bottom:3pt;text-align:justify">The following table presents total assets for each reportable segment and Corporate at June 30:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:46.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Pharmaceutical</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">23,624 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">22,398 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">22,446 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Medical (1)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,408 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,691 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,284 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,421 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,677 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,233 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total assets</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">44,453 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">40,766 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">40,963 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt">(1) Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021.</div> 23624000000 22398000000 22446000000 15408000000 14691000000 15284000000 5421000000 3677000000 3233000000 44453000000 40766000000 40963000000 1100000000 <div style="margin-bottom:3pt;text-align:justify">The following tables present property and equipment, net by geographic area:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:46.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,958 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,880 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,846 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">International</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">402 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">486 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">510 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Property and equipment, net</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,360 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,366 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,356 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1958000000 1880000000 1846000000 402000000 486000000 510000000 2360000000 2366000000 2356000000 <div style="margin-bottom:6pt;text-align:justify">14. Share-Based Compensation </div><div style="margin-bottom:3pt;text-align:justify">We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. At June 30, 2021, 9 million shares remain available for future grants under the Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan ("2011 LTIP"). Under the 2011 LTIP's fungible share counting provisions, stock options are counted against the plan as one share for every share issued; awards other than stock options are counted against the plan as two and one-half shares for every share issued. This means that only 3 million shares could be issued under awards other than stock options while 9 million shares could be issued under stock options. Shares are issued out of treasury shares when stock options are exercised and when restricted share units and performance share units vest. </div><div style="margin-bottom:3pt;text-align:justify">The following table provides total share-based compensation expense by type of award:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:58.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted share unit expense</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">73 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">70 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">63 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee stock option expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Performance share unit expense</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt">Total share-based compensation expense</div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">89 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">90 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">82 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify">The total tax benefit related to share-based compensation was $12 million, $16 million and $16 million for fiscal 2021, 2020 and 2019, respectively.</div><div>Restricted Share Units</div><div style="margin-bottom:3pt;text-align:justify">Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes all transactions related to restricted share units under the Plans:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions, except per share amounts)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Restricted Share Units</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average Grant Date Fair Value per Share</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at June 30, 2019</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">51.65 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42.71 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60.21 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Canceled and forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at June 30, 2020</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45.92 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53.76 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49.37 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Canceled and forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48.74 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at June 30, 2021</td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">49.05 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:4pt;text-align:justify">The following table provides additional data related to restricted share unit activity:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:53.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.835%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">73 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">77 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">75 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom">Total fair value of shares vested during the year</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">70 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">57 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">68 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div>Stock Options</div><div style="margin-bottom:3pt;text-align:justify">Until the end of fiscal 2018, stock options were granted to our officers and certain employees. There were no stock options granted to employees during fiscal year 2021, 2020 or 2019. Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for a period up to ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes all stock option transactions under the Plans:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions, except per share amounts)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Stock Options</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average Exercise Price per Common Share</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at June 30, 2019</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">63.78 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42.36 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Canceled and forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at June 30, 2020</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65.15 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43.08 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Canceled and forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at June 30, 2021</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">68.46 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercisable at June 30, 2021</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">68.62 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify">The following table provides additional detail related to stock options:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:53.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.835%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions, except per share amounts)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Aggregate intrinsic value of outstanding options at period end</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Aggregate intrinsic value of exercisable options at period end</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Aggregate intrinsic value of exercised options</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Net proceeds/(withholding) from share-based compensation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Excess tax benefits from share based compensation</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Total compensation cost, net of estimated forfeitures, related to unvested stock options not yet recognized, pre-tax</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Total fair value of shares vested during the year</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom">Weighted-average grant date fair value per stock option</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12.94 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8.26 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8.34 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:65.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.151%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in years)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Weighted-average remaining contractual life of outstanding options</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">4</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">5</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">5</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Weighted-average remaining contractual life of exercisable options</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">4</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">5</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">5</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom">Weighted-average period over which stock option compensation cost is expected to be recognized</td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2</td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">1</td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">1</td></tr></table></div><div style="margin-bottom:3pt;text-align:justify">The fair values were estimated on the grant date using a lattice valuation model. We believe the lattice model provides reasonable estimates because it has the ability to take into account individual exercise patterns based on changes in our stock price and other variables, and it provides for a range of input assumptions, which are disclosed in the table below. The risk-free rate is based on the U.S. Treasury yield curve at the time of the grant. We analyzed historical data to estimate option exercise behaviors and employee terminations to be used within the lattice model. The expected life of the options granted was calculated from the option valuation model and represents the length of time in years that the options granted are expected to be outstanding. Expected volatilities are based on implied volatility from traded options on our common shares and historical volatility over a period of time commensurate with the contractual term of the option grant (up to ten years). </div><div>Performance Share Units</div><div style="margin-bottom:3pt;text-align:justify">Performance share units generally vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</div></div><div style="margin-bottom:3pt;text-align:justify">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions, except per share amounts)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Performance Share Units</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average Grant Date Fair Value per Share</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at June 30, 2019</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">51.45 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">44.03 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48.40 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Canceled and forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50.92 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at June 30, 2020</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.3 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">54.24 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55.45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42.72 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Canceled and forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53.71 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at June 30, 2021</td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">54.89 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"> </div><div style="margin-bottom:6pt;text-align:justify">The following table provides additional data related to performance share unit activity:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:58.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Total compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized, pre-tax</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">29 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Weighted-average period over which performance share unit cost is expected to be recognized (in years)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom">Total fair value of shares vested during the year</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div>Employee Retirement Savings Plans</div><div style="margin-bottom:6pt;text-align:justify">Substantially all of our domestic non-union employees are eligible to be enrolled in our company-sponsored contributory retirement savings plans, which include features under Section 401(k) of the Internal Revenue Code of 1986, and provide for matching and discretionary contributions by us. The total expense for our employee retirement savings plans was $55 million, $66 million and $99 million for fiscal 2021, 2020 and 2019, respectively.</div> 9000000 3000000 9000000 <div style="margin-bottom:3pt;text-align:justify">The following table provides total share-based compensation expense by type of award:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:58.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted share unit expense</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">73 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">70 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">63 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee stock option expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Performance share unit expense</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt">Total share-based compensation expense</div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">89 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">90 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">82 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 73000000 70000000 63000000 0 3000000 10000000 16000000 17000000 9000000 89000000 90000000 82000000 12000000 16000000 16000000 P3Y <div style="margin-bottom:3pt;text-align:justify">The following table summarizes all transactions related to restricted share units under the Plans:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions, except per share amounts)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Restricted Share Units</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average Grant Date Fair Value per Share</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at June 30, 2019</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">51.65 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42.71 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60.21 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Canceled and forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at June 30, 2020</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45.92 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53.76 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49.37 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Canceled and forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48.74 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at June 30, 2021</td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">49.05 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2000000 51.65 2000000 42.71 1000000 60.21 0 0 3000000 45.92 2000000 53.76 1000000 49.37 1000000 48.74 3000000 49.05 <div style="margin-bottom:4pt;text-align:justify">The following table provides additional data related to restricted share unit activity:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:53.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.835%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">73 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">77 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">75 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom">Total fair value of shares vested during the year</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">70 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">57 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">68 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 73000000 77000000 75000000 P2Y P2Y P2Y 70000000 57000000 68000000 0 0 0 P3Y P10Y <div style="margin-bottom:3pt;text-align:justify">The following table summarizes all stock option transactions under the Plans:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions, except per share amounts)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Stock Options</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average Exercise Price per Common Share</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at June 30, 2019</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">63.78 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42.36 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Canceled and forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at June 30, 2020</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65.15 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43.08 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Canceled and forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Outstanding at June 30, 2021</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">68.46 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercisable at June 30, 2021</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">68.62 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6000000 63.78 0 0 1000000 42.36 0 0 5000000 65.15 0 0 1000000 43.08 0 0 4000000 68.46 4000000 68.62 <div style="margin-bottom:3pt;text-align:justify">The following table provides additional detail related to stock options:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:53.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.835%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions, except per share amounts)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Aggregate intrinsic value of outstanding options at period end</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Aggregate intrinsic value of exercisable options at period end</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Aggregate intrinsic value of exercised options</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Net proceeds/(withholding) from share-based compensation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Excess tax benefits from share based compensation</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Total compensation cost, net of estimated forfeitures, related to unvested stock options not yet recognized, pre-tax</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Total fair value of shares vested during the year</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom">Weighted-average grant date fair value per stock option</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12.94 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8.26 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8.34 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 11000000 12000000 10000000 11000000 12000000 10000000 10000000 8000000 1000000 32000000 26000000 3000000 -5000000 6000000 7000000 0 1000000 5000000 3000000 8000000 20000000 12.94 8.26 8.34 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:65.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.151%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in years)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Weighted-average remaining contractual life of outstanding options</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">4</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">5</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">5</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Weighted-average remaining contractual life of exercisable options</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">4</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">5</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">5</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom">Weighted-average period over which stock option compensation cost is expected to be recognized</td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2</td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">1</td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">1</td></tr></table> P4Y P5Y P5Y P4Y P5Y P5Y P2Y P1Y P1Y P10Y 3 0 2.40 <div style="margin-bottom:3pt;text-align:justify">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions, except per share amounts)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Performance Share Units</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average Grant Date Fair Value per Share</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at June 30, 2019</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">51.45 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">44.03 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48.40 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Canceled and forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50.92 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at June 30, 2020</td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.3 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">54.24 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55.45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42.72 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Canceled and forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53.71 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Nonvested at June 30, 2021</td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">54.89 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 900000 51.45 700000 44.03 100000 48.40 200000 50.92 1300000 54.24 400000 55.45 100000 42.72 400000 53.71 1200000 54.89 <div style="margin-bottom:6pt;text-align:justify">The following table provides additional data related to performance share unit activity:</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:58.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2021</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2020</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2019</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom">Total compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized, pre-tax</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">26 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">29 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom">Weighted-average period over which performance share unit cost is expected to be recognized (in years)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2</td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom">Total fair value of shares vested during the year</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 26000000 29000000 12000000 P2Y P2Y P2Y 1000000 5000000 0 55000000 66000000 99000000 <div style="margin-bottom:3pt;text-align:center">Cardinal Health, Inc. and Subsidiaries</div><div style="margin-bottom:3pt;text-align:center">Schedule II - Valuation and Qualifying Accounts</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.594%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Balance at Beginning of Period</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Charged to Costs and Expenses (1)</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Charged to Other Accounts (2)</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Deductions (3)</td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Balance at End of Period</td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Fiscal 2021</td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts receivable</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">206 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">129 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(94)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">242 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance notes receivable</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(20)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales returns and allowances</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">495 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,568 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,374)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">689 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">729 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,702 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,488)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">944 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Fiscal 2020</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts receivable</td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">193 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">139 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">(127)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom">206 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance notes receivable</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales returns and allowances</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">479 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,253 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,237)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">495 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">687 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,407 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,366)</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">729 </td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Fiscal 2019</td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts receivable</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">139 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">140 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(87)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">193 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finance notes receivable</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales returns and allowances</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">479 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,205 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,205)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">479 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">626 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,353 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,293)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">687 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Fiscal 2021, 2020 and 2019 include $70 million, $49 million and $60 million, respectively, for reserves related to service charges and customer pricing disputes, excluded from provision for bad debts on the consolidated statements of cash flows and classified as a reduction in revenue in the consolidated statements of earnings/(loss).</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2)Recoveries of amounts provided for or written off in prior years was $1 million in each fiscal year 2021, 2020 and 2019.</div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(3)Write-off of uncollectible accounts or actual sales returns.</div>The sum of the components may not equal the total due to rounding. 206000000 129000000 1000000 94000000 242000000 27000000 5000000 0 20000000 12000000 495000000 2568000000 0 2374000000 689000000 1000000 0 0 0 1000000 729000000 2702000000 1000000 2488000000 944000000 193000000 139000000 1000000 127000000 206000000 14000000 15000000 0 2000000 27000000 479000000 2253000000 0 2237000000 495000000 1000000 0 0 0 1000000 687000000 2407000000 1000000 2366000000 729000000 139000000 140000000 1000000 87000000 193000000 7000000 8000000 0 1000000 14000000 479000000 2205000000 0 2205000000 479000000 1000000 0 0 0 1000000 626000000 2353000000 1000000 2293000000 687000000 70000000 49000000 60000000 1000000 1000000 1000000 XML 21 R1.htm IDEA: XBRL DOCUMENT v3.21.2

Cover Page - USD ($)
12 Months Ended

Jun. 30, 2021

Jul. 31, 2021

Dec. 31, 2020

Cover [Abstract]

Document Type 10-K

Document Annual Report true

Document Transition Report false

Entity File Number 1-11373

Entity Registrant Name Cardinal Health, Inc.

Entity Incorporation, State or Country Code OH

Entity Tax Identification Number 31-0958666

Entity Address, Address Line One 7000 Cardinal Place

Entity Address, City or Town Dublin

Entity Address, State or Province OH

Entity Address, Postal Zip Code 43017

City Area Code (614)

Local Phone Number 757-5000

Title of 12(b) Security Common shares (without par value)

Trading Symbol CAH

Security Exchange Name NYSE

Entity Well-Known Seasoned Issuer Yes

Entity Voluntary Filers No

Entity Current Reporting Status Yes

Entity Interactive Data Current Yes

Entity Filer Category Large Accelerated Filer

Entity Small Business false

Entity Emerging Growth Company false

ICFR Auditor Attestation Flag true

Entity Shell Company false

Entity Public Float $ 15,693,865,917

Entity Common Stock, Shares Outstanding 290,441,408

Amendment Flag false

Document Period End Date Jun. 30, 2021

Document Fiscal Year Focus 2021

Document Fiscal Period Focus FY

Entity Central Index Key 0000721371

Current Fiscal Year End Date --06-30

Documents Incorporated by Reference
Documents Incorporated by Reference:
Portions of the registrant’s Definitive Proxy Statement to be filed for its 2021 Annual Meeting of Shareholders are incorporated by reference into the sections of this Form 10-K addressing the requirements of Part III of Form 10-K.

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as an annual report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_DocumentAnnualReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as a transition report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 10-Q, 20-F
-Number 240
-Section 13
-Subsection a-1
+ Details

Name: dei_DocumentTransitionReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Documents incorporated by reference.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-23
+ Details

Name: dei_DocumentsIncorporatedByReferenceTextBlock

Namespace Prefix: dei_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_IcfrAuditorAttestationFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 22 R2.htm IDEA: XBRL DOCUMENT v3.21.2

Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Income Statement [Abstract]

Revenue $ 162,467 $ 152,922 $ 145,534

Cost of products sold 155,689 146,054 138,700

Gross margin 6,778 6,868 6,834

Operating expenses:

Distribution, selling, general and administrative expenses 4,533 4,572 4,480

Restructuring and employee severance 114 122 125

Amortization and other acquisition-related costs 451 524 621

Impairments and (gain)/loss on disposal of assets, net 79 7 (488)

Litigation (recoveries)/charges, net 1,129 5,741 36

Operating earnings/(loss) 472 (4,098) 2,060

Other (income)/expense, net (47) (1) 15

Interest expense, net 180 238 294

Loss on early extinguishment of debt 14 16 0

Gain (Loss) on Sale of Investments (2) 579 0

Earnings/(loss) before income taxes 323 (3,772) 1,751

Provision for/(benefit from) income taxes (289) (79) 386

Net earnings 612 (3,693) 1,365

Less: Net earnings attributable to noncontrolling interests (1) (3) (2)

Net earnings/(loss) attributable to Cardinal Health, Inc. $ 611 $ (3,696) $ 1,363

Earnings/(loss) per common share attributable to Cardinal Health, Inc.

Earnings Per Share, Basic $ 2.09 $ (12.61) $ 4.55

Earnings Per Share, Diluted $ 2.08 $ (12.61) $ 4.53

Weighted-average number of common shares outstanding:

Basic (in shares) 292 293 300

Diluted (in shares) 294 293 301

X

- Definition
The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.
+ References
No definition available.
+ Details

Name: cah_Amortizationandotheracquisitionrelatedcosts

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349
+ Details

Name: us-gaap_GainLossRelatedToLitigationSettlement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067
+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b)(1))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R3.htm IDEA: XBRL DOCUMENT v3.21.2

Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Statement of Comprehensive Income [Abstract]

Net earnings $ 612 $ (3,693) $ 1,365

Other comprehensive income/(loss):

Foreign currency translation adjustments and other 46 3 18

Net unrealized gain/(loss) on derivative instruments, net of tax 24 (28) (5)

Total other comprehensive income/(loss), net of tax 70 (25) 13

Total comprehensive income/(loss) 682 (3,718) 1,378

Net Income (Loss) Attributable to Noncontrolling Interest 1 3 2

Total comprehensive income attributable to Cardinal Health, Inc. $ 681 $ (3,721) $ 1,376

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(20))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(22))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(24))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067
+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R4.htm IDEA: XBRL DOCUMENT v3.21.2

Consolidated Balance Sheets - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Current assets:

Cash and equivalents $ 3,407 $ 2,771

Trade receivables, net 9,103 8,264

Inventories, net 14,594 13,198

Prepaid expenses and other 2,843 1,707

Disposal Group, Including Discontinued Operation, Assets 1,101 0

Total current assets 31,048 25,940

Property and equipment, net 2,360 2,366

Goodwill and other intangibles, net 10,094 11,275

Other assets 951 1,185

Total assets 44,453 40,766

Current liabilities:

Accounts payable 23,700 21,374

Current portion of long-term obligations and other short-term borrowings 871 10

Other accrued liabilities 2,957 2,231

Disposal Group, Including Discontinued Operation, Liabilities 96 0

Total current liabilities 27,624 23,615

Long-term obligations, less current portion 5,365 6,765

Deferred income taxes and other liabilities 9,670 8,594

Preferred shares, without par value:

Authorized—500 thousand shares, Issued—none 0 0

Common shares, without par value:

Authorized—755 million shares, Issued— 327 million shares at June 30, 2021 and 2020 2,806 2,789

Retained earnings $ 1,205 $ 1,170

Common shares in treasury 36,000,000 34,000,000

Common shares in treasury, at cost: 36 million shares and 34 million shares at June 30, 2021 and 2020, respectively $ (2,186) $ (2,066)

Accumulated other comprehensive loss (34) (104)

Total Cardinal Health, Inc. shareholders' equity 1,791 1,789

Noncontrolling interests 3 3

Total shareholders’ equity 1,794 1,792

Total liabilities and shareholders’ equity $ 44,453 $ 40,766

Preferred shares, authorized 500,000 500,000

Preferred shares, issued 0 0

Common shares, authorized 755,000,000 755,000,000

Common shares, issued 327,000,000 327,000,000

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as assets attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760
+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.
+ References
No definition available.
+ Details

Name: us-gaap_IntangibleAssetsNetIncludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt and lease obligation, classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtAndCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt and lease obligation, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(24))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(22))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756
+ Details

Name: us-gaap_MinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of current assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 360
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-06(3))
-URI http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)(3)(iii)(03)
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 25 R5.htm IDEA: XBRL DOCUMENT v3.21.2

Consolidated Statements of Shareholders' Equity - USD ($)
shares in Thousands, $ in Millions

Total

Common Shares

Retained Earnings

Treasury Shares

Accumulated Other Comprehensive Loss

Noncontrolling Interests

Net Income (Loss) Attributable to Parent $ 1,363 $ 1,363

Balance at beginning of period (in shares) at Jun. 30, 2018 327,000

Balance at beginning of period at Jun. 30, 2018 6,059 $ 2,730 4,645 $ (92) $ 0

Treasury, balance at beginning of period (in shares) at Jun. 30, 2018 (18,000)

Treasury, balance at beginning of period at Jun. 30, 2018 $ (1,224)

Increase (Decrease) in Shareholders' Equity

Net earnings 1,365 2

Net Earnings Including Portion Attributable to Noncontrolling Interest Excluding Redeemable Noncontrolling Interest 1,365

Other comprehensive loss, net of tax 13 13

Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 67 $ 33 $ 34

Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture 0 1,000

Treasury shares acquired (in shares) (11,500)

Share repurchase program activity (600) $ (600)

Dividends declared (575) (575)

Stockholders' Equity, Other Shares 0

Other 1 $ 0 1 0

Balance at end of period (in shares) at Jun. 30, 2019 327,000

Balance at end of period at Jun. 30, 2019 6,330 $ 2,763 5,434 (79) 2

Treasury, balance at end of period (in shares) at Jun. 30, 2019 (28,000)

Treasury, balance at end of period at Jun. 30, 2019 $ (1,790)

Net Income (Loss) Attributable to Parent (3,696)

Increase (Decrease) in Shareholders' Equity

Net earnings (3,693) 3

Other comprehensive loss, net of tax (25) (25)

Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 100 $ 26 $ 74

Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture 0 0

Treasury shares acquired (in shares) (7,000)

Share repurchase program activity (350) $ (350)

Dividends declared (570) (570)

Stockholders' Equity, Other Shares 0

Other $ 0 $ 0 2 2

Balance at end of period (in shares) at Jun. 30, 2020 327,000 327,000

Balance at end of period at Jun. 30, 2020 $ 1,792 $ 2,789 1,170 (104) 3

Treasury, balance at end of period (in shares) at Jun. 30, 2020 (34,000) (35,000)

Treasury, balance at end of period at Jun. 30, 2020 $ (2,066) $ (2,066)

Net Income (Loss) Attributable to Parent 611

Increase (Decrease) in Shareholders' Equity

Net earnings 612 1

Other comprehensive loss, net of tax 70 70

Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture 97 $ 17 $ 80

Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture 0 3,000

Treasury shares acquired (in shares) (3,700)

Share repurchase program activity (200) $ (200)

Dividends declared (576) (576)

Stockholders' Equity, Other Shares

Other $ 1 1

Balance at end of period (in shares) at Jun. 30, 2021 327,000 327,000

Balance at end of period at Jun. 30, 2021 $ 1,794 $ 2,806 $ 1,205 $ (34) $ 3

Treasury, balance at end of period (in shares) at Jun. 30, 2021 (36,000) (36,000)

Treasury, balance at end of period at Jun. 30, 2021 $ (2,186) $ (2,186)

X

- Definition
Net Earnings Including Portion Attributable to Noncontrolling Interest Excluding Redeemable Noncontrolling Interest
+ References
No definition available.
+ Details

Name: cah_NetEarningsIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 405
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817
+ Details

Name: us-gaap_Dividends

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)(3)(iii)(03)
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.
+ References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of increase (decrease) in shares of stock classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityOtherShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares that have been repurchased during the period and are being held in treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_TreasuryStockSharesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_TreasuryStockValueAcquiredCostMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 26 R6.htm IDEA: XBRL DOCUMENT v3.21.2

Consolidated Statements of Cash Flows - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Cash flows from operating activities:

Net earnings $ 612 $ (3,693) $ 1,365

Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:

Depreciation and amortization 783 913 1,000

Loss on Sale of Investments 0 0 3

Gain (Loss) on Sale of Investments (2) 579 0

Impairments and (gain)/loss on disposal of assets, net 79 7 (488)

Loss on early extinguishment of debt 14 16 0

Share-based compensation 89 90 82

Provision for/(benefit from) deferred income taxes 496 (961) (83)

Provision for bad debts 65 106 88

Change in operating assets and liabilities, net of effects from acquisitions and divestitures:

(Increase)/decrease in trade receivables (904) 82 (751)

Increase in inventories (1,584) (409) (551)

Increase/(decrease) in accounts payable 2,325 (162) 1,864

Other accrued liabilities and operating items, net 452 6,550 193

Net cash provided by operating activities 2,429 1,960 2,722

Cash flows from investing activities:

Acquisition of subsidiaries, net of cash acquired (3) 0 (82)

Additions to property and equipment (400) (375) (328)

Purchase of other investments (22) (20) (18)

Proceeds from sale of investments 47 886 3

Proceeds from divestitures, net of cash sold, and disposal of property and equipment 0 2 763

Net cash provided by/(used in) investing activities (378) 493 338

Cash flows from financing activities:

Net change in short-term borrowings 0 (2) 0

Proceeds from interest rate swap terminations 18 112 0

Reduction of long-term obligations (570) (1,399) (1,102)

Net tax proceeds/(withholding) from share-based compensation 8 8 (14)

Dividends on common shares (573) (569) (577)

Purchase of treasury shares (200) (350) (600)

Net cash used in financing activities (1,317) (2,200) (2,293)

Effect of exchange rates changes on cash and equivalents 11 (13) 1

Cash reclassified to assets held for sale (109) 0 0

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 636 240 768

Cash and equivalents at beginning of period 2,771 2,531 1,763

Cash and equivalents at end of period 3,407 2,771 2,531

Supplemental Information:

Cash payments for interest 182 226 285

Cash payments for income taxes $ 273 $ 368 $ 311

X

- Definition
CashReclassifiedtoAssetsHeldforSale
+ References
No definition available.
+ Details

Name: cah_CashReclassifiedtoAssetsHeldforSale

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
No definition available.
+ Details

Name: cah_Netproceedstaxwithholdingsfromsharebasedcompensation

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from divestitures and disposal of property and equipment and held for sale assets
+ References
No definition available.
+ Details

Name: cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from sales of available-for-sale securities and other investments.
+ References
No definition available.
+ Details

Name: cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow from purchases of available-for-sale securities and other investments.
+ References
No definition available.
+ Details

Name: cah_Purchaseofavailableforsalesecuritiesandotherinvestments

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.2)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) included in earnings for investments classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfOtherInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net cash outflow or inflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.
+ References
No definition available.
+ Details

Name: us-gaap_PaymentsForProceedsFromHedgeFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfDividendsCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfShortTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense (reversal of expense) for expected credit loss on accounts receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(5))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R7.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies
12 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies
1. Basis of Presentation and Summary of Significant Accounting Policies
Cardinal Health, Inc. is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. References to “we”, “our” and similar pronouns in these consolidated financial statements are to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context otherwise requires.
Our fiscal year ends on June 30. References to fiscal 2021, 2020 and 2019 in these consolidated financial statements are to the fiscal years ended June 30, 2021, 2020 and 2019, respectively.
Basis of Presentation
Our consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.
Use of Estimates
Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates, judgments and assumptions are used in the accounting and disclosure related to, among other items, allowance for doubtful accounts, inventory valuation and reserves, goodwill and other intangible asset impairment, loss contingencies (including product liability and self-insurance accruals), and income taxes. Actual amounts could ultimately differ from these estimated amounts.
The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.
Cash Equivalents
We consider liquid investments purchased with an initial maturity of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.
Receivables and Allowance for Doubtful Accounts
Trade receivables are presented net of an allowance for doubtful accounts of $242 million and $206 million at June 30, 2021 and 2020, respectively. An account is considered past due on the first
day after its due date. In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account is considered past due. We regularly monitor past due accounts and establish appropriate reserves to cover potential losses, and consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts.
We provide financing to various customers. Such financing arrangements range from 1 year to 5 years at interest rates that are generally subject to fluctuation. Interest income on these arrangements is recognized as it is earned. The financings may be collateralized, guaranteed by third parties or unsecured. Finance notes, net and related accrued interest were $63 million (current portion $7 million) and $104 million (current portion $12 million) at June 30, 2021 and 2020, respectively, and are included in other assets (current portion is included in prepaid expenses and other) in the consolidated balance sheets. Finance notes receivable allowance for doubtful accounts were $12 million and $27 million at June 30, 2021 and 2020, respectively. We estimate an allowance for these financing receivables based on historical collection rates and the credit worthiness of the customer. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts.
Concentrations of Credit Risk
We maintain cash depository accounts with major banks, and we invest in high quality, short-term liquid instruments, and in marketable securities. Our short-term liquid instruments mature within three months and we have not historically incurred any related losses.
Our trade receivables and finance notes and related accrued interest are exposed to a concentration of credit risk with certain large customers and with customers in the retail and healthcare sectors. Credit risk can be affected by changes in reimbursement and other economic pressures impacting the healthcare industry. With respect to customers in the retail and healthcare sectors, such credit risk is limited due to supporting collateral and the diversity of the customer base, including its wide geographic dispersion. We perform regular credit evaluations of our customers’ financial conditions and maintain reserves for losses through the established allowance for doubtful accounts. Historically, such losses have been within our expectations. Refer to the "Receivables and Allowance for Doubtful Accounts" section within this Note for additional information on the accounting treatment of reserves for allowance for doubtful accounts.
Major Customers
CVS Health Corporation ("CVS") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables. These customers are primarily serviced through our Pharmaceutical segment.
In August 2021, we extended our pharmaceutical distribution agreements with CVS through June 2027.
The following table summarizes historical percent of revenue and gross trade receivables from CVS and OptumRx:
Percent of Revenue Percent of Gross Trade Receivables at June 30
2021 2020 2019 2021 2020
CVS 26 % 26 % 26 % 24 % 26 %
OptumRx 15 % 14 % 13 % 3 % 6 %
We have entered into agreements with group purchasing organizations (“GPOs”) which act as purchasing agents that negotiate vendor contracts on behalf of their members. Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue. Sales to members of these two GPOs collectively accounted for 15 percent, 16 percent and 22 percent of revenue for fiscal 2021, 2020 and 2019, respectively. Our trade receivable balances are with individual members of the GPO, and therefore no significant concentration of credit risk exists with these types of arrangements.
Inventories
A portion of our inventories (50 percent and 56 percent at June 30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These inventories are included within the core pharmaceutical distribution facilities of our Pharmaceutical segment (“distribution facilities”) and are primarily merchandise inventories. The LIFO method presumes that the most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue. We believe that the average cost method of inventory valuation provides a reasonable approximation of the current cost of replacing inventory within the distribution facilities. As such, the LIFO reserve is the difference between (a) inventory at the lower of LIFO cost or market and (b) inventory at replacement cost determined using the average cost method of inventory valuation.
At June 30, 2021 and 2020, respectively, inventories valued at LIFO cost were $565 million and $411 million higher than the average cost value. We do not record inventories in excess of replacement cost. As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.
Our remaining inventory, including inventory in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value. Net realizable value is defined as the estimated selling prices and estimated sales demand in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Due to the unprecedented demand for
certain personal protective equipment as a result of COVID-19, our Medical segment manufactured and sourced inventory at higher costs than in periods prior to COVID-19. Personal protective equipment ("PPE") refers to protective clothing, medical and non-medical grade gloves, face shields, face masks and other equipment designed to protect the wearer from injury or the spread of infection or illness. As selling prices and customer demand have decreased compared to the peak of COVID-19, we recorded a reserve of $197 million, primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value.
We reserve for inventory obsolescence using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, age and expiration dates of on-hand inventory and manufacturer return policies. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory which were $185 million and $155 million at June 30, 2021 and 2020, respectively.
Cash Discounts
Manufacturer cash discounts are recorded as a component of inventory cost and recognized as a reduction of cost of products sold as inventory is sold.
Property and Equipment
Property and equipment are carried at cost less accumulated depreciation. Property and equipment held for sale are recorded at the lower of cost less accumulated depreciation before the decision to dispose of the asset was made or fair value less cost to sell. When certain events or changes in operating conditions occur, an impairment assessment may be performed on the recoverability of the carrying amounts.
Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which are depreciated over the terms of their respective leases. We generally use the following range of useful lives for our property and equipment categories: buildings and improvements—3 to 39 years; machinery and equipment—3 to 20 years; and furniture and fixtures—3 to 7 years. We recorded depreciation and amortization expense of $377 million, $405 million and $455 million for fiscal 2021, 2020 and 2019, respectively.
The following table presents the components of property and equipment, net at June 30:
(in millions) 2021 2020
Land, building and improvements $ 2,359 $ 2,185
Machinery and equipment 3,093 3,008
Furniture and fixtures 136 138
Total property and equipment, at cost 5,588 5,331
Accumulated depreciation and amortization (3,228) (2,965)
Property and equipment, net $ 2,360 $ 2,366
Repairs and maintenance expenditures are expensed as incurred. Interest on long-term projects is capitalized using a rate that approximates the weighted-average interest rate on long-term
obligations, which was 3 percent at June 30, 2021. The amount of capitalized interest was immaterial for all periods presented.
Goodwill and Other Intangible Assets
Purchased goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment annually or when indicators of impairment exist.
Purchased goodwill is tested for impairment at least annually. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. There is an option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the quantitative goodwill impairment test. We have elected to bypass the qualitative assessment for our annual goodwill impairment test in the current year. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount.
Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit.
We have two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. These operating segments are comprised of divisions (components), for which discrete financial information is available. Components are aggregated into reporting units for purposes of goodwill impairment testing to the extent that they share similar economic characteristics. Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (“Medical Unit”); and Cardinal Health at-Home Solutions division.
Fair value can be determined using market, income or cost-based approaches. Our determination of estimated fair value of the reporting units is based on a combination of the income-based and market-based approaches. Under the income-based approach, we use a discounted cash flow model in which cash flows anticipated over several future periods, plus a terminal value at the end of that time horizon, are discounted to their present value using an appropriate risk-adjusted rate of return. We use our internal forecasts to estimate future cash flows, which we believe are consistent with those of a market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit. Actual results may differ materially from those used in our forecasts. We use discount rates that are commensurate with the risks and uncertainty inherent in the respective reporting units and in our internally-developed forecasts. Discount rates used in our reporting unit valuations ranged from 8.5 percent to 11.5 percent. Under the market-based guideline public company method, we determine fair value by comparing our reporting units to similar businesses or guideline companies whose securities are actively traded in public markets. We also use the guideline transaction method to
determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units. To further confirm fair value, we compare the aggregate fair value of our reporting units to our total market capitalization. Estimating the fair value of reporting units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results. The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment.
We performed annual impairment testing in fiscal 2021, 2020 and 2019 and concluded that there were no impairments of goodwill as the estimated fair value of each reporting unit exceeded its carrying value.
The impairment test for indefinite-lived intangibles other than goodwill involves first assessing qualitative factors to determine if it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount. If so, then a quantitative test is performed to compare the estimated fair value of the indefinite-lived intangible asset to the respective asset's carrying amount. Our qualitative evaluation requires the use of estimates and significant judgments and considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.
Intangible assets with finite lives, primarily customer relationships; trademarks, trade names and patents; and developed technology, are amortized using a combination of straight-line and accelerated methods based on the expected cash flows from the asset over their estimated useful lives. We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group. Actual results may differ materially from those used in our forecasts.
Assets Held for Sale
We classify assets and liabilities (the “disposal group”) as held for sale when management commits to a plan to sell the disposal group in its present condition and at a price that is reasonable in relation to its current fair value. We also consider whether an active program to locate a buyer has been initiated and if it is probable that the sale will occur within one year without significant changes to the plan to sell. Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization.
On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman & Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and certain liabilities, including product liability for
lawsuits related to inferior vena cava filters in the U.S. and Canada as described in Note 7 of the “Notes to Consolidated Financial Statements.” The transaction closed on August 2, 2021. See Note 2 for additional information.
Investments
Investments in non-marketable equity securities are accounted for under the fair value, equity or net asset value method of accounting and are included in other assets in the consolidated balance sheets. For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which we can exercise significant influence but do not control, we use the equity method of accounting. Our share of the earnings and losses are recorded in other (income)/expense, net in the consolidated statements of earnings/(loss). We monitor our investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.
Vendor Reserves
In the ordinary course of business, our vendors may dispute deductions taken against payments otherwise due to them or assert other disputes. These disputes are researched and resolved based upon the findings of the research performed. At any given time, there are outstanding items in various stages of research and resolution. In determining appropriate reserves for areas of exposure with our vendors, we assess historical experience and current outstanding claims. We have established various levels of reserves based on the type of claim and status of review. Though the claim types are relatively consistent, we periodically refine our methodology by updating the reserve estimate percentages to reflect actual historical experience. The ultimate outcome of certain claims may be different than our original estimate and may require an adjustment. Adjustments to vendor reserves are included in cost of products sold. In addition, the reserve balance will fluctuate due to variations of outstanding claims from period-to-period, timing of settlements and specific vendor issues, such as bankruptcies. Vendor reserves were $77 million at both June 30, 2021 and 2020, excluding third-party returns. See Third-Party Returns section within this Note for a description of third-party returns.
Distribution Services Agreement and Other Vendor Fees
Our Pharmaceutical segment recognizes fees received from distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors’ inventory when those fees have been earned and we are entitled to payment. Since the benefit provided to a vendor is related to the purchase and distribution of the vendor’s inventory, we recognize the fees as a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold.
Loss Contingencies and Self-Insurance
Loss Contingencies
We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
In connection with the opioid litigation as described further in the Note 7, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020 respectively which were retained at Corporate. In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement, subject to certain conditions and contingencies. There is no assurance that the contingencies to the proposed settlement agreement will be satisfied.
We develop and periodically update reserve estimates for the Cordis inferior vena cava ("Cordis IVC") claims, including those received to date and expected to be received in the future and related costs. To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated indemnity severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs.
Self-Insurance
We also self-insure for employee healthcare, general liability, certain product liability matters, auto liability, property and workers' compensation. Self-insurance accruals include an estimate for expected settlements or pending claims, defense costs, administrative fees, claim adjustment costs and an estimate for claims incurred but not reported.
Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies and other liabilities is highly subjective and requires judgments about future events. We regularly review contingencies and our self-insurance accruals to determine whether our accruals and related disclosures are adequate. Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.
The amount of ultimate loss may differ materially from these estimates. We recognize these estimated loss contingencies, income from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss). See Note 7 for additional information regarding loss contingencies and product liability lawsuits.
Guarantees
In the ordinary course of business, we agree to indemnify certain other parties under acquisition and disposition agreements, customer agreements, intellectual property licensing agreements, and other agreements. Such indemnification obligations vary in scope and, when defined, in duration. In many cases, a maximum obligation is not explicitly stated, and therefore the overall maximum amount of the liability under such indemnification obligations cannot be reasonably estimated. Where appropriate, such indemnification obligations are recorded as a liability. Historically, we have not, individually or in the aggregate, made
payments under these indemnification obligations in any material amounts. In certain circumstances, we believe that existing insurance arrangements, subject to the general deduction and exclusion provisions, would cover portions of the liability that may arise from these indemnification obligations. In addition, we believe that the likelihood of a material liability being triggered under these indemnification obligations is not probable.
From time to time we enter into agreements that obligate us to make fixed payments upon the occurrence of certain events. Such obligations primarily relate to obligations arising under acquisition transactions, where we have agreed to make payments based upon the achievement of certain financial performance measures by the acquired business. Generally, the obligation is capped at an explicit amount. There were no material obligations at June 30, 2021.
Income Taxes
We account for income taxes using the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in the respective jurisdictions in which we operate. We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized. The realizability of deferred tax assets depends on our ability to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence.
Deferred taxes for non-U.S. liabilities are not provided on the unremitted earnings of subsidiaries outside of the United States when it is expected that these earnings are indefinitely reinvested.
We operate in a complex multinational tax environment and are subject to tax treaty arrangements and transfer pricing guidelines for intercompany transactions that are subject to interpretation. Uncertainty in a tax position may arise as tax laws are subject to interpretation.
Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.
See Note 8 for additional information regarding income taxes.
Other Accrued Liabilities
Other accrued liabilities represent various current obligations, including certain accrued operating expenses and taxes payable.
Noncontrolling Interests
Noncontrolling interests represent the portion of net earnings, comprehensive income and net assets that is not attributable to Cardinal Health, Inc.
Share-Based Compensation
Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value of the awards. The fair value of restricted share units and performance share units is determined by the grant date market price of our common shares. The fair value of stock options is determined on the grant date using a lattice valuation model. The compensation expense associated with nonvested performance share units is dependent on our periodic assessment of the probability of the targets being achieved and our estimate, which may vary over time, of the number of shares that ultimately will be issued. The compensation expense recognized for share-based awards is net of estimated forfeitures and is recognized ratably over the service period of the awards. All income tax effects of share-based awards are recognized in the consolidated statements of earnings/(loss) as awards vest or are settled. We classify share-based compensation expense in distribution, selling, general and administrative ("SG&A") expenses to correspond with the same line item as the majority of the cash compensation paid to employees. If awards are modified in connection with a restructuring activity, the incremental share-based compensation expense is classified in restructuring and employee severance. See Note 14 for additional information regarding share-based compensation.
Dividends
We paid cash dividends per common share of $1.94, $1.92 and $1.91 in fiscal 2021, 2020 and 2019, respectively.
Revenue Recognition
We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers.
Revenue in both segments is primarily related to the distribution of pharmaceutical and medical products, which include both manufactured and sourced products, and we recognize at a point in time when title transfers to customers and we have no further obligation to provide services related to such merchandise. Service revenues are recognized over the period that services are provided to the customer. Revenues derived from services are not material for either segment for all periods presented.
We are generally the principal in a transaction, therefore our revenue is primarily recorded on a gross basis. When we are a principal in a transaction, we have determined that we control the ability to direct the use of the product or service prior to transfer to a customer, are primarily responsible for fulfilling the promise to provide the product or service to our customer, have discretion in establishing prices, and ultimately control the transfer of the product or services provided to the customer.
Sales Returns and Allowances
Revenue is recorded net of sales returns and allowances. Revenues are measured based on the amount of consideration that we expect to receive, reduced by estimates for return allowances, discounts, rebates and other variable consideration. Sales returns are recorded based on estimates using historical
data. Our customer return policies generally require that the product be physically returned, subject to restocking fees. We only allow customers to return products for credit in a condition suitable to be added back to inventory and resold at full value (“merchantable product”) or returned to vendors for credit. Product returns are generally consistent throughout the year and typically are not specific to any particular product or customer.
We accrue for estimated sales returns and allowances at the time of sale based upon historical customer return trends, margin rates and processing costs. Our accrual for sales returns is reflected as a reduction of revenue and cost of products sold for the sales price and cost, respectively. At June 30, 2021 and 2020, the accrual for estimated sales returns and allowances was $689 million and $495 million, respectively, which is reflected in trade receivables, net and inventories, net in the consolidated balance sheets. Sales returns and allowances were $2.6 billion, $2.3 billion and $2.2 billion, for fiscal 2021, 2020 and 2019, respectively, and the net impact on net earnings/(loss) in the consolidated statements of earnings/(loss) was immaterial in fiscal 2021, 2020 and 2019.
Third-Party Returns
We generally do not accept non-merchantable pharmaceutical product returns from our customers, so many of our customers return non-merchantable pharmaceutical products to the manufacturer through third parties. Since our customers generally do not have a direct relationship with manufacturers, our vendors pass the value of such returns to us (usually in the form of an accounts payable deduction). We, in turn, pass the value received to our customer. In certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor. Although we believe we have satisfactory protections, we could be subject to claims from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict with our contractual terms with our customers. We have maintained reserves for some of these situations based on their nature and our historical experience with their resolution.
Shipping and Handling
Shipping and handling costs are primarily included in SG&A expenses in our consolidated statements of earnings/(loss) and include all delivery expenses as well as all costs to prepare the product for shipment to the end customer. Shipping and handling costs were $634 million, $620 million and $622 million, for fiscal 2021, 2020 and 2019, respectively.
Restructuring and Employee Severance
Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance (including rationalizing headcount or other significant changes in personnel) and realigning operations (including realignment of the management structure in response to changing market conditions). Also included within restructuring and employee severance are
employee severance costs that are not incurred in connection with a restructuring activity. See Note 3 for additional information regarding our restructuring activities.
Amortization and Other Acquisition-Related Costs
We classify certain costs incurred in connection with acquisitions as amortization and other acquisition-related costs in our consolidated statements of earnings/(loss). These costs consist of amortization of acquisition-related intangible assets, transaction costs, integration costs and changes in the fair value of contingent consideration obligations. Transaction costs are incurred during the initial evaluation of a potential acquisition and primarily relate to costs to analyze, negotiate and consummate the transaction as well as due diligence activities. Integration costs relate to activities required to combine the operations of an acquired enterprise into our operations and, in the case of the Cordis and Patient Recovery businesses, to stand-up the systems and processes needed to support an expanded geographic footprint. We record changes in the fair value of contingent consideration obligations relating to acquisitions as income or expense in amortization and other acquisition-related costs. See Note 4 for additional information regarding amortization of acquisition-related intangible assets.
Translation of Foreign Currencies
Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign subsidiaries into U.S. dollars are accumulated in shareholders’ equity through accumulated and other comprehensive loss ("AOCI") utilizing period-end exchange rates. Revenues and expenses of these foreign subsidiaries are translated using average exchange rates during the year.
The foreign currency translation gains/(losses) included in AOCI at June 30, 2021 and 2020 are presented in Note 11. Foreign currency transaction gains and losses for the period are included in the consolidated statements of earnings/(loss) in the respective financial statement line item.
Interest Rate, Currency and Commodity Risk
All derivative instruments are recognized at fair value on the consolidated balance sheets and all changes in fair value are recognized in net earnings or shareholders’ equity through AOCI, net of tax.
For contracts that qualify for hedge accounting treatment, the hedge contracts must be effective at reducing the risk associated with the exposure being hedged and must be designated as a hedge at the inception of the contract. Hedge effectiveness is assessed periodically. Any contract not designated as a hedge, or so designated but ineffective, is adjusted to fair value and recognized immediately in net earnings. If a fair value or cash flow hedge ceases to qualify for hedge accounting treatment, the contract continues to be carried on the balance sheet at fair value until settled and future adjustments to the contract’s fair value are recognized immediately in net earnings. If a forecasted transaction is probable not to occur, amounts previously deferred in AOCI are recognized immediately in net earnings. Interest payments
received from the cross currency swap are excluded from the net investment hedge effectiveness assessment and are recorded in interest expense, net in the consolidated statements of earnings/(loss).
See Note 10 for additional information regarding our derivative instruments, including the accounting treatment for instruments designated as fair value, cash flow, net investment and economic hedges.
Fair Value Measurements
Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are:
Level 1 - Observable prices in active markets for identical assets and liabilities.
Level 2 - Observable inputs other than quoted prices in active markets for identical assets and liabilities.
Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
See Note 9 for additional information regarding fair value measurements.
Recently Adopted Financial Accounting Standards
Financial Instruments - Credit Losses
In June 2016, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our consolidated financial statements.
Recently Issued Financial Accounting Standards Not Yet Adopted
We address the adoption impacts of recently issued accounting standards by the FASB on the our consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2020 Form 10-K. There were no accounting
standards issued in fiscal 2021 that will have a material impact on our consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R8.htm IDEA: XBRL DOCUMENT v3.21.2

Divestitures and Acquisitions
12 Months Ended

Jun. 30, 2021

Business Combination and Asset Acquisition [Abstract]

Business Combination Disclosure
2. Divestitures and Acquisitions
Divestitures
Cordis Assets Held for Sale
On March 12, 2021, we signed a definitive agreement with Hellman & Friedman to sell our Cordis business for gross proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and certain liabilities. The transaction closed on August 2, 2021 and we received proceeds of $927 million, net of cash transferred. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in Note 7.
Upon signing the agreement, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale. In connection with the divestiture, we allocated $388 million of goodwill from the Medical Unit (within our Medical Segment) to the Cordis disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained. We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations.
At June 30, 2021, the book value of the disposal group exceeded its fair value less costs to sell. Accordingly, we recognized a $60 million pre-tax write-down on the disposal group in impairments and (gain)/loss on disposal of assets in our consolidated statement of earnings/(loss). This write-down includes a $3 million loss related to currency translation adjustments in accumulated other comprehensive loss. We recorded a net tax expense of $9 million associated with the impact of the write-down and the required tax adjustments related to held for sale accounting.
The following table presents information related to the assets and liabilities that were classified as held for sale at June 30, 2021 related to the Cordis divestiture in the consolidated balance sheets:
(in millions) June 30, 2021
Cash and equivalents $ 109
Inventories, net 164
Property and equipment, net 90
Goodwill and other intangibles, net 778
Other assets 10
Write-down of assets held for sale (60)
Total assets held for sale $ 1,091
Other accrued liabilities $ 61
Deferred income taxes and other liabilities 34
Total liabilities related to assets held for sale $ 95
naviHealth
In August 2018, we sold our majority ownership interest in naviHealth, which operated within our Medical segment in exchange for cash proceeds of $737 million (after adjusting for certain fees and expenses) and a noncontrolling equity interest in a partnership that owned naviHealth. We also had certain call rights to reacquire naviHealth.
As a result of this divestiture, during the fiscal year ended June 30, 2019, we recognized a pre-tax gain of $508 million in impairments and (gain)/loss on disposal of assets in our consolidated statements of earnings/(loss). This gain included our initial recognition of an equity method investment for $358 million and the derecognition of redeemable noncontrolling interests of $12 million. The fiscal 2019 tax expense as a result of this transaction was $130 million. We determined that the sale of the naviHealth business did not meet the criteria to be classified as discontinued operations.
In May 2020 we sold the remainder of our noncontrolling equity interest in a partnership that owned naviHealth. We recognized a pre-tax gain of $579 million from this disposal in gain on sale of equity interest in naviHealth in our consolidated statements of earnings/(loss) during fiscal year 2020.
Our proportionate share of naviHealth’s results, which was recorded in other (income)/expense, net in the consolidated statements of earnings/(loss), was income of $2 million and a loss of $10 million during fiscal 2020 and 2019, respectively.
Acquisitions
We did not complete any acquisitions during fiscal 2020. While we completed several small acquisitions during fiscal 2021 and 2019, the pro forma results of operations and the results of operations for acquired businesses since the acquisition dates have not been separately disclosed because the effects were not significant compared to the consolidated financial statements, individually or in the aggregate. The cash paid for these acquisitions, net of cash acquired was $3 million and $82 million for fiscal 2021 and 2019, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-URI http://asc.fasb.org/topic&trid=2303972
+ Details

Name: us-gaap_BusinessCombinationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R9.htm IDEA: XBRL DOCUMENT v3.21.2

Restructuring and Employee Severance
12 Months Ended

Jun. 30, 2021

Restructuring Charges [Abstract]

Restructuring and Employee Severance
3. Restructuring and Employee Severance
The following tables summarize restructuring and employee severance costs:
(in millions) 2021 2020 2019
Employee-related costs $ 53 $ 66 $ 95
Facility exit and other costs 61 56 30
Total restructuring and employee severance $ 114 $ 122 $ 125
Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of professional, project management and other service fees to support divestitures, vendor transition fees, accelerated depreciation, lease costs associated with vacant facilities, equipment relocation costs, project consulting fees, costs
associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.
In fiscal 2021, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of our Cordis business. In fiscal 2020 and 2019, restructuring costs were primarily related to the implementation of certain enterprise-wide cost-savings measures.
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions) Employee-
Related Costs Facility Exit
and Other Costs Total
Balance at June 30, 2019 $ 64 $ 8 $ 72
Additions 85 24 109
Payments and other adjustments (81) (4) (85)
Balance at June 30, 2020 68 28 96
Additions 49 26 75
Payments and other adjustments (64) (28) (92)
Balance at June 30, 2021 $ 53 $ 26 $ 79

X

- Definition
The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(e))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-URI http://asc.fasb.org/topic&trid=2175745

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RestructuringChargesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R10.htm IDEA: XBRL DOCUMENT v3.21.2

Goodwill and Other Intangible Assets
12 Months Ended

Jun. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets
4. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions) Pharmaceutical (1) Medical (2) Total
Balance at June 30, 2019 $ 2,663 $ 5,715 $ 8,378
Goodwill acquired, net of purchase price adjustments (5) — (5)
Foreign currency translation adjustments and other (1) (15) (16)
Balance at June 30, 2020 2,657 5,700 8,357
Goodwill acquired, net of purchase price adjustments 2 — 2
Foreign currency translation adjustments and other — 18 18
Cordis goodwill reclassified to assets held for sale — (388) (388)
Balance at June 30, 2021 $ 2,659 $ 5,330 $ 7,989
(1) At June 30, 2021 and 2020, the Pharmaceutical segment accumulated goodwill impairment loss was $829 million.
(2) At June 30, 2021 and 2020, the Medical segment accumulated goodwill impairment loss was $1.4 billion.
In connection with the divestiture of our Cordis business, during fiscal 2021 we allocated and reclassified $388 million of goodwill from the Medical Unit (within our Medical Segment) to the Cordis disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained, discussed further in Note 2.
Other Intangible Assets
The following tables summarize other intangible assets by class at June 30:
2021
(in millions) Gross
Intangible Accumulated
Amortization Net
Intangible Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents $ 12 $ — $ 12 N/A
Total indefinite-life intangibles 12 — 12 N/A
Definite-life intangibles:
Customer relationships 3,330 1,989 1,341 11
Trademarks, trade names and patents 551 328 223 9
Developed technology and other 1,035 506 529 10
Total definite-life intangibles 4,916 2,823 2,093 10
Total other intangible assets $ 4,928 $ 2,823 $ 2,105 N/A
2020
(in millions) Gross
Intangible Accumulated
Amortization Net
Intangible
Indefinite-life intangibles:
IPR&D, trademarks and other $ 23 $ — $ 23
Total indefinite-life intangibles 23 — 23
Definite-life intangibles:
Customer relationships 3,554 1,828 1,726
Trademarks, trade names and patents 673 341 332
Developed technology and other 1,604 767 837
Total definite-life intangibles 5,831 2,936 2,895
Total other intangible assets $ 5,854 $ 2,936 $ 2,918
Total amortization of intangible assets was $428 million, $512 million and $531 million for fiscal 2021, 2020 and 2019, respectively. The estimated annual amortization for intangible assets for fiscal 2022 through 2026 is as follows: $315 million, $287 million, $264 million, $238 million and $212 million.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R11.htm IDEA: XBRL DOCUMENT v3.21.2

Leases
12 Months Ended

Jun. 30, 2021

Leases [Abstract]

Leases
5. Leases
Our operating leases are primarily for corporate offices, distribution facilities, vehicles, and equipment. We determine if an arrangement is a lease at its inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of the asset. Our lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.
Beginning July 1, 2019, operating lease right-of-use assets and corresponding operating lease liabilities are recognized in our consolidated balance sheets at lease commencement date based on the present value of lease payments over the lease term. Operating lease expense for operating lease assets is recognized on a straight-line basis over the lease term. As most of our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. We use the implicit rate if it is readily determinable.
Our lease agreements contain lease components and non-lease components. For all asset classes, we have elected to account for both of these components as a single lease component. We also, from time to time, sublease portions of our real estate property, resulting in sublease income. Sublease income and the related assets and cash flows are not material to the consolidated financial statements at or for the fiscal years ended June 30, 2021 and 2020.
We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. Short-term lease expense recognized in fiscal 2021 and 2020 was not material. In addition, upon adoption of the new lease standard, we elected the package of three practical expedients permitted under the transition guidance, which include the carry forward of our leases without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs.
Our leases have remaining lease terms from less than 1 year up to approximately 21 years. Our lease terms may include options to extend or terminate the lease when it is reasonably certain and there is a significant economic incentive to exercise that option.
The following table summarizes the components of lease cost:
(in millions) 2021 2020
Operating lease cost $ 119 $ 134
Finance lease cost 16 13
Variable lease cost 24 17
Total lease cost $ 159 $ 164
Variable lease cost primarily includes payments for property taxes, maintenance and insurance. Our rental expense relating to operating leases was $153 million in fiscal 2019.
The following table summarizes supplemental balance sheet and other information related to leases at June 30:
(in millions) 2021 2020
Operating Leases
Operating lease right-of-use assets $ 460 $ 426
 Current portion of operating lease liabilities 105 104
 Long-term operating lease liabilities 374 341
Total operating lease liabilities 479 445
Finance Leases
Finance lease right-of-use assets 63 33
Current portion of finance lease liabilities 19 9
Long-term finance lease liabilities 45 25
Total finance lease liabilities $ 64 $ 34
Weighted-average remaining lease term (years)
Operating leases 6.5 years 6.4 years
Finance leases 4.2 years 4.3 years
Weighted-average discount rate
Operating leases 2.9 % 2.9 %
Finance leases 1.5 % 2.4 %
Operating leases are included in other assets, other accrued liabilities, and deferred income taxes and other liabilities in our consolidated balance sheet. Finance leases are included in property and equipment, net, current portion of long-term obligations and other short-term borrowings, and long-term obligations, less current portion in our consolidated balance sheet.
The following tables summarizes supplemental cash flow information related to leases:
(in millions) 2021 2020
Cash paid for lease liabilities:
Operating cash flows paid for operating leases $ 115 $ 125
Financing cash flows paid for finance leases 15 7
Non-cash right-of-use assets obtained in exchange for lease obligations:
New operating leases 138 150
New finance leases 45 40
Amended lease standard adoption impact as of July 1, 2019 (1)
— 400
(1)Includes the effect of $22 million from reclassifying deferred rent as an offset to the lease right-of-use asset in accordance with the transition guidance.

Future lease payments under non-cancellable leases as of June 30, 2021 were as follows:
(in millions) Operating Leases Finance Leases Total
2022 $ 116 $ 20 $ 136
2023 93 20 113
2024 72 14 86
2025 65 8 73
2026 50 3 53
Thereafter 141 5 146
Total future lease payments 537 70 607
Less: leases not yet commenced (1)
3 — 3
Less: imputed interest 55 6 61
Total lease liabilities $ 479 $ 64 $ 543
(1)As of June 30, 2021, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the consolidated balance sheet.

X

- Definition
Leases [Text Block]
+ References
No definition available.
+ Details

Name: cah_LeasesTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R12.htm IDEA: XBRL DOCUMENT v3.21.2

Long-Term Obligations and Other Short-Term Borrowings
12 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Long-Term Obligations and Other Short-Term Borrowings
6. Long-Term Obligations and Other Short-Term Borrowings
The following table summarizes long-term obligations and other short-term borrowings at June 30:
(in millions) (1) 2021 2020
2.616% Notes due 2022 $ 572 $ 834
3.2% Notes due 2022 — 236
Floating Rate Notes due 2022 281 321
3.2% Notes due 2023 564 576
3.079% Notes due 2024 794 809
3.5% Notes due 2024 410 413
3.75% Notes due 2025 524 529
3.41% Notes due 2027 1,216 1,215
4.6% Notes due 2043 341 340
4.5% Notes due 2044 342 342
4.9% Notes due 2045 441 441
4.368% Notes due 2047 560 560
7.0% Debentures due 2026 124 124
Other Obligations 67 35
Total 6,236 6,775
Less: current portion of long-term obligations and other short-term borrowings 871 10
 Long-term obligations, less current portion $ 5,365 $ 6,765
(1) Maturities are presented on a calendar year basis.
Maturities of existing long-term obligations and other short-term borrowings for fiscal 2022 through 2026 and thereafter are as follows: $872 million, $584 million, $808 million, $418 million, $525 million and $3.0 billion.
Long-Term Debt
All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. The 7.0% Debentures represent unsecured obligations of Allegiance Corporation (a wholly-owned subsidiary), which Cardinal Health, Inc. has guaranteed. None of these obligations are subject to a sinking fund and the Allegiance obligations are not redeemable prior to maturity. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $23.7 billion and $21.4 billion at June 30, 2021 and 2020, respectively.
In June 2021, we redeemed all outstanding 3.2% Notes due June 2022 for $238 million and $262 million aggregate principle amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with these redemptions, we recorded a $13 million loss on early extinguishment of debt.
During fiscal 2021, we also early repurchased $40 million of the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022 with available cash. In connection with the early debt repurchases, we recorded a $1 million loss on early extinguishment of debt.
During fiscal 2020, we redeemed $500 million aggregate principle amount of 4.625% Notes due December 2020 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with the redemption, we recorded a $7 million loss on early extinguishment of debt. We also early repurchased $247 million of the 2.616% Notes due 2022, $11 million of the 3.2% Notes due 2022, $20 million of the Floating Rate Notes due 2022, $104 million of the 3.41% Notes due 2027, $6 million of the 4.6% Notes due 2043, $5 million of the 4.9% Notes due 2045, and $35 million of the 4.368% Notes due 2047. In connection with the early debt repurchases, we recognized a $9 million loss on early extinguishment of debt. We also repaid the full principal of the $450 million 2.4% Notes due 2019 as they became due.
During fiscal 2019, we repurchased $67 million of the 2.616% Notes due 2022, $1 million of the 3.2% Notes due 2022, 8 million of the Floating Rate Notes due 2022, and $24 million of the 3.41% Notes due 2027 for a total of $100 million. The loss on early extinguishment of debt in connection with these early repurchases was immaterial. We also repaid the full principal of the $1.0 billion 1.948% Notes due 2019 as they became due.
The redemptions and repurchases were paid for with available cash and other short-term borrowings.
On August 13, 2021, we announced our intention to early redeem all remaining outstanding 2.616% Notes due June 2022 on September 15, 2021 at an expected redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes.
If we undergo a change of control, as defined in the notes, and if the notes receive specified ratings below investment grade by each of Standard & Poors Ratings Services, Moody’s Investors Services and Fitch Ratings, any holder of the notes, excluding the debentures, can require with respect to the notes owned by such holder, or we can offer, to repurchase the notes at 101% of the principal amount plus accrued and unpaid interest.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility.
In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors.
Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of June 30, 2021, we were in compliance with this financial covenant.
At June 30, 2021 and 2020, we had no amounts outstanding under the revolving credit facility; however, availability was reduced by outstanding letters of credit of $1 million at both June 30, 2021 and 2020.
Under our committed receivables sales facility program, we had a maximum amount outstanding of $200 million and an immaterial daily amount outstanding during fiscal 2021. We had no amounts outstanding as of June 30, 2021 under the committed receivables sales facility program; however, availability was reduced by outstanding standby letters of credit of $31 million and $29 million at June 30, 2021 and 2020, respectively.
We had no amounts outstanding under the commercial paper program as of June 30, 2021 and 2020.
We also maintain other short-term credit facilities and an unsecured line of credit that allowed for borrowings up to $6 million at both June 30, 2021 and 2020. The $67 million and $35 million balance of other obligations at June 30, 2021 and 2020, respectively, consisted of finance leases and short-term borrowings.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R13.htm IDEA: XBRL DOCUMENT v3.21.2

Commitments, Contingent Liabilities and Litigation
12 Months Ended

Jun. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments, Contingent Liabilities and Litigation
7. Commitments, Contingent Liabilities and Litigation
Commitments
Generic Sourcing Venture with CVS Health Corporation ("CVS Health")
In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement. These payments are included as purchase obligations and other payments in the Contractual Obligations section of MD&A.
Contingencies
New York Opioid Stewardship Act
In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.
The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. If the U.S. Supreme Court declines to take the case, or if it ultimately upholds the Second Circuit's ruling, New York State would likely seek to collect amounts allegedly owed under the OSA.
We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41 million for calendar years 2017 and 2018 in the fiscal year ended June 30, 2021 based on the probable estimated payment amount, which is our best estimate of the OSA payments probable at June 30, 2021.
Legal Proceedings
We become involved from time to time in disputes, litigation and regulatory matters.
From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions
have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.
From time to time, we become aware through employees, internal audits or other parties of possible product quality, regulatory or compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.
We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.
We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.
We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our consolidated statements of earnings/(loss).
Opioid Lawsuits and Investigations
Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,300 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well
as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.
States & Political Subdivisions
Approximately 2,900 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the “MDL”).
In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities.
In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). We continued to build out the Settlement Framework and to negotiate the terms of the settlement with the leadership group and other representatives of states and political subdivisions.
In July, 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement (the “Proposed Settlement Agreement”) and settlement process that, if all conditions are satisfied, would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups. The settlement process does not contemplate participation by any non-governmental or non-political entities or individuals. In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with the State of New York and its participating subdivisions. If the Proposed Settlement Agreement becomes effective, New York and its participating subdivisions will become a part of it.
The Proposed Settlement Agreement is subject to contingencies and will not become effective unless and until the three distributors each make separate independent determinations that (1) following a sign-on period, a sufficient number of states have agreed to the Proposed Settlement Agreement (the “Settling States”); and, subsequently, (2) following a notice period, that a sufficient number of states and political subdivisions, including those that have not sued, have agreed to the Agreement (or otherwise had their claims foreclosed) to proceed to effectiveness. Prior to the second determination, the Settling States will also have an opportunity to make a determination as to whether a sufficient number of political subdivisions have agreed to the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed with the
Proposed Settlement Agreement. This process is currently contemplated to end in February 2022, although it may be extended by agreement. It is possible that a sufficient number of states and subdivisions will not agree to the Proposed Settlement Agreement or that other required contingencies will not be satisfied.
If these conditions are satisfied, the Proposed Settlement Agreement would become effective sixty (60) days after the distributors determine that there is sufficient participation among political subdivisions. During this 60-day period, the Settling States and the distributors would cooperate to obtain consent judgments in each participating state embodying the terms of the Settlement.
The Proposed Settlement Agreement includes a cash component, pursuant to which the Company would pay up to approximately $6.37 billion, the majority of which would be paid over 18 years. The exact payment amount will depend on several factors, including the participation rate of states and political subdivisions, the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which political subdivisions in Settling States file additional opioid lawsuits against the Company after the Proposed Settlement Agreement becomes effective.
The Proposed Settlement Agreement also includes injunctive relief terms related to settling distributors’ controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating our controlled substances monitoring program; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting; distributors will fund the clearinghouse for ten years.
In total, we have recorded total pre-tax charges of $1.17 billion and $5.63 billion in litigation charges/(recoveries), net in the years ended June 30, 2021 and 2020, respectively. In total, we have $6.73 billion accrued at June 30, 2021, of which $405 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in the consolidated balance sheets.
Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.
Additionally, a trial before a judge in West Virginia in the Cabell County and City of Huntington cases concluded in July 2021 and the judge has not yet issued a decision. In addition, a trial in the case brought by the Ohio Attorney General is scheduled to begin in September 2021 and a trial in the case brought by the Washington Attorney General is scheduled to begin in November 2021. The Ohio Attorney General has issued a press release indicating support for the Proposed Settlement Agreement; however, the Washington Attorney General has issued a press release stating that Washington will not agree to the Proposed Settlement Agreement. These public announcements are not binding and there is no assurance that any state that has made a public announcement of support for the Proposed Settlement Agreement will ultimately execute the Proposed Settlement Agreement.
Private Plaintiffs
The Proposed Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 442 lawsuits as of August 10, 2021. Of these, 128 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. A trial in one case is currently scheduled to begin in October 2021. We are vigorously defending ourselves in these matters.
Insurance Litigation
We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (“National Union”) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January, 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of June 30, 2021.
Department of Justice Investigations
We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these requests. We are unable to predict the outcome of any of these investigations.
Cordis Product Liability Lawsuits
As of August 10, 2021, we are named as a defendant in 419 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,427 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another 32 lawsuits involving similar claims by approximately 37 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 claims. This agreement is subject to certain contingencies. We continue to vigorously defend ourselves in these lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.
At June 30, 2021, we had a total of $524 million net of estimated insurance recoveries, accrued for losses and legal defense costs, net of expected insurance recoveries, related to the Cordis IVC filter lawsuits in the consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.03 billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.
SEC Investigation
In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. We are cooperating with this inquiry and cannot predict its outcome or duration.
Shareholder Securities Litigation
In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In November 2020, we filed a motion to dismiss the amended complaint. We believe that the claims asserted in this
complaint are without merit and intend to vigorously defend against them.
Specialty Solutions DOJ Investigation
In November 2018, the United States Attorney’s Office for the District of Massachusetts (the "USAO") commenced an investigation pertaining to the U.S. federal healthcare fraud and abuse laws. These requests sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with these requests and are engaged in resolution discussions with the USAO and Department of Health and Human Services, Office of Inspector General. In connection with these discussions, we recorded $13 million of expense within litigation charges/(recoveries) on our consolidated statements of earnings/(loss) during the fiscal year ended June 30, 2021. We cannot predict the outcome of the discussions and it is possible that we may incur additional losses or agree to other remedial measures; however, we are not currently able to estimate a range of reasonably possible additional losses.
Other Civil Litigation
Generic Pharmaceutical Pricing Antitrust Litigation
In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves.
Active Pharmaceutical Ingredient Impurity Litigation
Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product.
In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the “Sartan MDL”) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.
Antitrust Litigation Proceeds
We received and recognized income resulting from settlements of lawsuits in which we were a class member or plaintiff of $112 million, $16 million and $94 million during fiscal 2021, 2020, and 2019, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 440
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R14.htm IDEA: XBRL DOCUMENT v3.21.2

Income Taxes
12 Months Ended

Jun. 30, 2021

Income Tax Disclosure [Abstract]

Income Taxes
8. Income Taxes
Earnings/(Loss) before Income Taxes and Provision for/(Benefit From) Income Taxes
The following table summarizes earnings/(loss) before income taxes:
(in millions) 2021 2020 2019
U.S. operations $ (47) $ (4,056) $ 1,478
Non-U.S. operations 370 284 273
Earnings/(loss) before income taxes $ 323 $ (3,772) $ 1,751
The following table summarizes the components of provision for/(benefit from) income taxes:
(in millions) 2021 2020 2019
Current:
Federal $ (989) $ 659 $ 295
State and local 92 154 89
Non-U.S. 112 69 85
Total current $ (785) $ 882 $ 469
Deferred:
Federal $ 539 $ (822) $ (28)
State and local (28) (127) (37)
Non-U.S. (15) (12) (18)
Total deferred 496 (961) (83)
Provision for/(benefit from) income taxes $ (289) $ (79) $ 386

Tax Effects of Self-Insurance Pre-Tax Loss
During fiscal 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.
Accordingly, our provision for income taxes during fiscal 2021 included a $424 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.
We have filed for a U.S. federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our consolidated balance sheet at June 30, 2021. We also increased our non-current deferred tax
liability by approximately $700 million during fiscal 2021 related to this matter.
We have recorded these amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change. The actual amount of the tax benefit may differ materially from these estimates.
Tax Effects of Opioid Litigation Charges
In connection with the $1.17 billion and $5.63 billion pre-tax charges for the opioid litigation, during fiscal 2021 and 2020, we recorded a tax benefit of $228 million and $488 million, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $219 million and $469 million, respectively.
We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the U.S. tax law governing deductibility was changed by the U.S. Tax Cuts and Jobs Act ("Tax Act"). Further, it is possible Congress or the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit may differ materially from these estimates.
Effective Tax Rate
The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate:

2021 (1)
2020 (1)
2019 (1)
Provision at Federal statutory rate 21.0 % 21.0 % 21.0 %
State and local income taxes, net of federal benefit 3.2 2.5 0.9
Tax effect of foreign operations 0.7 — (0.7)
Nondeductible/nontaxable items (2)
1.6 0.2 0.8
Cordis Disposition 7.0 — —
Withholding Taxes (2)
9.0 (0.3) 0.7
Change in Valuation Allowances (1.4) 1.5 4.5
US Taxes on International Income (2)(3)
(6.7) 0.2 0.7
Impact of Resolutions with IRS and other related matters (2)
(13.6) (0.4) (0.1)
Legal Entity Reorganization — — (3.6)
Opioid litigation 17.7 (23.2) —
Loss Carryback Claims (129.9) — —
Other (2)
1.7 0.6 (2.1)
Effective income tax rate (89.7) % 2.1 % 22.1 %
(1) The table represents the following: fiscal 2021 is pretax income with tax benefit, fiscal 2020 is pretax loss with tax benefit, and fiscal 2019 is pretax income with tax expense.
(2) Certain prior year amounts have been reclassified to conform to current year presentation.
(3) Includes the tax impact of Global Intangible Low-Taxed Income ("GILTI") tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code.
The income tax benefit rate was 89.7% and 2.1% in fiscal 2021 and fiscal 2020 compared to an income tax expense rate of 22.1% in fiscal 2019. Fluctuations in the effective tax rates are primarily due to the impact of opioid litigation in fiscal 2021 and 2020, as well as the impact of the carryback claim filed in accordance with the CARES Act provision in fiscal year 2021.
Our effective tax rate has benefits from negotiated lower than statutory tax rates in select foreign jurisdictions which individually are not material to our effective tax rate but in aggregate have a favorable tax impact of approximately $20 million during fiscal 2021.
As of June 30, 2021, foreign earnings of approximately $825 million are considered indefinitely reinvested for working capital and other offshore investment needs. The computation of tax required if those earnings are repatriated is not practicable. For amounts not considered indefinitely reinvested, we have recorded an immaterial amount of income tax expense in our financial statements in fiscal 2021.
Deferred Income Taxes
Deferred income taxes arise from temporary differences between financial reporting and tax reporting bases of assets and liabilities and operating loss and tax credit carryforwards for tax purposes.
The following table presents the components of the deferred income tax assets and liabilities at June 30:
(in millions) 2021 2020
Deferred income tax assets:
Receivable basis difference $ 40 $ 39
Accrued liabilities 874 607
Share-based compensation 38 38
Loss and tax credit carryforwards 805 589
Deferred tax assets related to uncertain tax positions 35 52
Other 16 87
Total deferred income tax assets 1,808 1,412
Valuation allowance for deferred income tax assets (515) (470)
Net deferred income tax assets $ 1,293 $ 942
Deferred income tax liabilities:
Inventory basis differences $ (1,119) $ (1,083)
Property-related (375) (327)
Goodwill and other intangibles (733) (751)
Self-Insurance (975) —
Other (23) —
Total deferred income tax liabilities $ (3,225) $ (2,161)
Net deferred income tax liability
$ (1,932) $ (1,219)
Deferred income tax assets and liabilities in the preceding table, after netting by taxing jurisdiction and for uncertain tax positions, are in the following captions in the consolidated balance sheets at June 30:
(in millions) 2021 2020
Noncurrent deferred income tax asset (1) 52 39
Noncurrent deferred income tax liability (2) (1,981) (1,258)
Noncurrent deferred income tax liability transferred to held for sale (3) —
Net deferred income tax liability $ (1,932) $ (1,219)
(1)Included in other assets in the consolidated balance sheets.
(2)Included in deferred income taxes and other liabilities in the consolidated balance sheets.
At June 30, 2021 we had gross federal, state and international loss and credit carryforwards of $272 million, $3.9 billion and $2.3 billion, respectively, the tax effect of which is an aggregate deferred tax asset of $805 million. Substantially all of these carryforwards are available for at least three years. Approximately $477 million of the valuation allowance at June 30, 2021 applies to certain federal, state and international loss carryforwards that, in our opinion, are more likely than not to expire unutilized. However, to the extent that tax benefits related to these carryforwards are realized in the future, the reduction in the valuation allowance would reduce income tax expense.
Unrecognized Tax Benefits
We had $932 million, $998 million and $456 million of unrecognized tax benefits at June 30, 2021, 2020 and 2019, respectively. The June 30, 2021, 2020 and 2019 balances include $849 million, $753 million and $303 million, respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate. The remaining unrecognized tax benefits relate to tax positions for which ultimate deductibility is highly certain but for which there is uncertainty as to the timing of such deductibility. Recognition of these tax benefits would not affect our effective tax rate. We include the full amount of unrecognized tax benefits in deferred income taxes and other liabilities in the consolidated balance sheets. The following table presents a reconciliation of the beginning and ending amounts of unrecognized tax benefits:
(in millions) 2021 2020 2019
Balance at beginning of fiscal year $ 998 $ 456 $ 423
Additions for tax positions of the current year 121 500 24
Additions for tax positions of prior years 223 78 39
Reductions for tax positions of prior years (138) (27) (5)
Settlements with tax authorities (271) (6) (25)
Expiration of the statute of limitations (1) (3) —
Balance at end of fiscal year
$ 932 $ 998 $ 456

It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues,
reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is a net decrease of $0 million to $20 million, exclusive of penalties and interest.
We recognize accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes. At June 30, 2021, 2020 and 2019, we had $49 million, $146 million and $122 million, respectively, accrued for the payment of interest and penalties. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the consolidated balance sheets. As a result of our IRS audit settlements and carryback claim, an immaterial amount of interest was recorded in fiscal 2021. During fiscal 2020 and 2019, we recognized $16 million and $8 million of expense for interest and penalties in income tax expense, respectively.
Other Tax Matters
We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year.
We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $72 million and $176 million at June 30, 2021 and 2020, respectively, and is included in other assets in the consolidated balance sheets.
As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $12 million and $19 million at June 30, 2021 and 2020, respectively, and is included in other assets in the consolidated balance sheets.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R15.htm IDEA: XBRL DOCUMENT v3.21.2

Fair Value Measurements
12 Months Ended

Jun. 30, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements
9. Fair Value Measurements
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at June 30:
2021
(in millions) Level 1 Level 2 Level 3 Total
Assets:
Cash equivalents $ 1,883 $ — $ — $ 1,883
Other investments (1) 126 — — 126
Forward contracts (2) — 42 — 42
2020
(in millions) Level 1 Level 2 Level 3 Total
Assets:
Cash equivalents $ 721 $ — $ — $ 721
Other investments (1) 114 — — 114
Forward contracts (2) — 53 — 53
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high-quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.(2)The fair value of interest rate swaps, foreign currency contracts, net investment hedges and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the consolidated balance sheets.

Fair Value Disclosures
9. Fair Value Measurements
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at June 30:
2021
(in millions) Level 1 Level 2 Level 3 Total
Assets:
Cash equivalents $ 1,883 $ — $ — $ 1,883
Other investments (1) 126 — — 126
Forward contracts (2) — 42 — 42
2020
(in millions) Level 1 Level 2 Level 3 Total
Assets:
Cash equivalents $ 721 $ — $ — $ 721
Other investments (1) 114 — — 114
Forward contracts (2) — 53 — 53
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high-quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)The fair value of interest rate swaps, foreign currency contracts, net investment hedges and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the consolidated balance sheets.

Assets and (Liabilities) Measured on a Nonrecurring Basis
Assets and liabilities held for sale of $1.1 billion and $96 million, respectively, at June 30, 2021 are primarily related to the divestiture of our Cordis business. These estimated fair values utilized Level 3 unobservable inputs based on expected sales proceeds following a competitive bidding process. See Note 2 for additional information regarding assets and liabilities held for sale.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-URI http://asc.fasb.org/topic&trid=2155941
+ Details

Name: us-gaap_FairValueMeasurementInputsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R16.htm IDEA: XBRL DOCUMENT v3.21.2

Financial Instruments
12 Months Ended

Jun. 30, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Instruments
10. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.
Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange
rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.
Commodity Price Risk Management
We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.
The following table summarizes the fair value of our assets and liabilities related to derivatives designated as hedging instruments and the respective line items in which they were recorded in the consolidated balance sheets at June 30:
(in millions) 2021 2020
Assets:
Pay-floating interest rate swaps (1) $ 1 $ 27
Cross-currency swap (1) 6 47
Cross-currency swap (2) 34 —
Foreign currency contracts (2) 5 —
Total assets $ 46 $ 74
Liabilities:
Foreign currency contracts (4) $ 4 $ 4
Forward interest rate swaps (3) — 16
Commodity contracts (4) — 1
Total liabilities $ 4 $ 21
(1) Included in other assets in the consolidated balance sheets.
(2) Included in prepaid expenses and other in the consolidated balance sheets.
(3) Included in deferred income taxes and other liabilities in the consolidated balance sheets.
(4) Included in other accrued liabilities in the consolidated balance sheets.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the consolidated statements of earnings/(loss). During fiscal 2021, 2020 and 2019 there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
During fiscal 2021, we unwound certain interest rate swap contracts with the notional amount of $550 million. In connection with the unwind of these contracts, we received cash proceeds of
$18 million. The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the debt agreement, which matures in March 2023.
During fiscal 2021, we entered into a pay-floating interest rate swap with total notional amounts of $200 million. This swap has been designated as fair value hedges of our fixed rate debt and is included in deferred income taxes and other liabilities in the consolidated balance sheets.
In May 2020, we unwound certain interest rate swap contracts. In connection with the unwind of these contracts, we received cash proceeds of $112 million. The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the related debt agreements, which ranged from 48 months to 63 months at June 30, 2020.
In connection with the debt repayment as described in Note 6, two pay-floating interest rate swaps with notional amounts of $200 million matured in the second quarter of fiscal 2020.
During fiscal 2019, we terminated notional amounts of $163 million of pay-floating interest rate swaps in connection with the debt repurchases in fiscal 2019 described in Note 6. These swaps were previously designated as fair value hedges.
The following tables summarize the outstanding interest rate swaps designated as fair value hedges at June 30:
2021
(in millions) Notional Amount Maturity Date
Pay-floating interest rate swaps $ 200 Mar 2028
2020
(in millions) Notional Amount Maturity Date
Pay-floating interest rate swaps $ 550 Mar 2023
The following table summarizes the gain/(loss) recognized in earnings for interest rate swaps designated as fair value hedges:
(in millions) 2021 2020 2019
Pay-floating interest rate swaps (1) $ (8) $ 106 $ 9
Fixed-rate debt (1) 8 (106) (9)
(1) Included in interest expense, net in the consolidated statements of earnings/(loss).
Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
During fiscal 2020, we entered into forward interest rate swaps with a total notional amount of $200 million to hedge probable, but
not firmly committed, future transactions associated with our debt. During fiscal 2021, we terminated these swaps and reclassified an immaterial deferred gain from accumulated other comprehensive loss into interest expense, net in our consolidated statements of earnings/(loss) because the forecasted transactions were probable of not occurring.
All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges that are expected to be reclassified into net earnings within the next 12 months are immaterial.
We enter into foreign currency contracts to protect the value of anticipated foreign currency revenues and expenses. At June 30, 2021 and 2020, we held contracts to hedge probable, but not firmly committed, revenue and expenses. The principal currencies hedged are the Chinese renminbi, Canadian dollar, euro, Thai baht and Mexican peso.
We enter into commodity contracts to manage the price risk associated with forecasted purchases of certain commodities used in our Medical segment.
The following tables summarize the outstanding cash flow hedges at June 30:
2021
(in millions) Notional Amount Maturity Date
Foreign currency contracts $ 436 Jul 2021 - Jun 2022
2020
(in millions) Notional Amount Maturity Date
Forward interest rate swaps $ 200 Jun 2022
Foreign currency contracts 328
Jul 2020
-
Jun 2021
Commodity contracts 16
Jul 2020
-
Jun 2021
The following table summarizes the pre-tax gain/(loss) included in OCI for derivative instruments designated as cash flow hedges:
(in millions) 2021 2020 2019
Forward interest rate swaps $ 16 $ (16) $ —
Commodity contracts 1 1 (5)
Foreign currency contracts 5 (8) 5
The following table summarizes the pre-tax gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges:
(in millions) 2021 2020 2019
Foreign currency contracts (1) $ (12) $ 7 $ 2
Foreign currency contracts (2) (2) 1 —
Foreign currency contracts (3) 4 — 1
Forward interest rate swaps (4) 2 2 2
Commodity contracts (3) 6 (5) —
(1) Included in revenue in the consolidated statements of earnings/(loss).
(2) Included in cost of products sold in the consolidated statements of earnings/(loss).
(3) Included in SG&A expenses in the consolidated statements of earnings/(loss).
(4) Included in interest expense, net in the consolidated statements of earnings/(loss).
Net Investment Hedges
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
In August 2019, we entered into a ¥64 billion ($600 million) cross-currency swap maturing in 2022.
In September 2018, we entered into a €200 million ($233 million) cross-currency swap maturing in 2023.
Cross-currency swaps designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.
Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $7 million loss and a $35 million gain during fiscal 2021 and 2020, respectively. Gains recognized in interest expense, net in the consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $19 million and $17 million during fiscal 2021 and 2020, respectively.
Economic (Non-Designated) Hedges
We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. The principal currency managed through foreign currency contracts is the Chinese renminbi, Canadian dollar, euro, Mexican Peso, and Brazilian Real.
The following tables summarize the outstanding economic (non-designated) derivative instruments at June 30:
2021
(in millions) Notional Amount Maturity Date
Foreign currency contracts $ 254 July 2021
2020
(in millions) Notional Amount Maturity Date
Foreign currency contracts $ 325 Jul 2020
The following table summarizes the gain/(loss) recognized in earnings for economic (non-designated) derivative instruments:
(in millions) 2021 2020 2019
Foreign currency contracts (1) $ (8) $ (11) $ (13)
(1) Included in other income, net in the consolidated statements of earnings/(loss).
Fair Value of Financial Instruments
The carrying amounts of cash and equivalents, trade receivables, net, accounts payable, and other accrued liabilities at June 30, 2021 and 2020 approximate fair value due to their short-term maturities.
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at June 30:
(in millions) 2021 2020
Estimated fair value $ 6,751 $ 7,273
Carrying amount 6,236 6,775
The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.
The following table is a summary of the fair value gain/(loss) of our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:
2021 2020
(in millions) Notional
Amount Fair Value
Gain/(Loss) Notional
Amount Fair Value
Gain/(Loss)
Pay-floating interest rate swaps $ 200 $ 1 $ 550 $ 27
Foreign currency contracts 690 1 653 (4)
Forward interest rate swaps — — 200 (16)
Cross-currency swap 833 40 833 47
Commodity contracts — — 16 (1)

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.
+ References
No definition available.
+ Details

Name: us-gaap_FinancialInstrumentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R17.htm IDEA: XBRL DOCUMENT v3.21.2

Shareholders' Equity
12 Months Ended

Jun. 30, 2021

Equity [Abstract]

Shareholders' Equity
11. Shareholders' Equity
At June 30, 2021 and 2020, authorized capital shares consisted of the following: 750 million Class A common shares, without par value; 5 million Class B common shares, without par value; and 500 thousand non-voting preferred shares, without par value. The Class A common shares and Class B common shares are collectively referred to below as “common shares”. Holders of common shares are entitled to share equally in any dividends declared by the Board of Directors and to participate equally in all distributions of assets upon liquidation. Generally, the holders of Class A common shares are entitled to one vote per share, and the holders of Class B common shares are entitled to one-fifth of one vote per share on proposals presented to shareholders for vote. Under certain circumstances, the holders of Class B common
shares are entitled to vote as a separate class. Only Class A common shares were outstanding at June 30, 2021 and 2020.
We repurchased $1.15 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2021, 2020 and 2019, as described below. We funded the repurchases with available cash and short term borrowings. The common shares repurchased are held in treasury to be used for general corporate purposes.
During fiscal 2021, we repurchased 3.7 million common shares having an aggregate cost of $200 million. The average price paid per common share was $54.40. These repurchases were made under an accelerated share repurchase ("ASR") program, which began on February 9, 2021 and was completed on March 31, 2021.
During fiscal 2020, we repurchased 7.3 million common shares having an aggregate cost of $350 million. The average price paid per common share was $48.00. These repurchases were made under an ASR program, which began on August 20, 2019 and was completed on December 4, 2019.
During fiscal 2019, we repurchased 11.5 million common shares having an aggregate cost of $600 million. The average price paid per common share was $52.32. These repurchases were made under an ASR program, which began on August 16, 2018 and was completed on October 25, 2018.
Accumulated Other Comprehensive Loss
The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions) Foreign
Currency
Translation
Adjustments and other Unrealized
Gain/(Loss) on
Derivatives,
net of tax Accumulated Other
Comprehensive
Loss
Balance at June 30, 2019 $ (95) $ 16 $ (79)
Other comprehensive income/(loss), net before reclassifications 3 (23) (20)
Amounts reclassified to earnings — (5) (5)
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax of $4 million 3 (28) (25)
Balance at June 30, 2020 (92) (12) (104)
Other comprehensive income, before reclassifications 46 22 68
Amounts reclassified to earnings — 2 2
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax of $4 million 46 24 70
Balance at June 30, 2021 $ (46) $ 12 $ (34)

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R18.htm IDEA: XBRL DOCUMENT v3.21.2

Earnings Per Share Attributable to Cardinal Health, Inc.
12 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Earnings Per Share Attributable to Cardinal Health, Inc.
12. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.
The following table reconciles the computation of basic and diluted earnings per share attributable to Cardinal Health, Inc.:
(in millions, except per share amounts) 2021 2020 2019
Net earnings/(loss) $ 612 $ (3,693) $ 1,365
Net earnings attributable to noncontrolling interest (1) (3) (2)
Net earnings/(loss) attributable to Cardinal Health, Inc.
$ 611 $ (3,696) $ 1,363
Weighted-average common shares–basic 292 293 300
Effect of dilutive securities:
Employee stock options, restricted share units, and performance share units 2 — 1
Weighted-average common shares–diluted 294 293 301
Basic earnings/(loss) per common share attributable to Cardinal Health, Inc.: $ 2.09 $ (12.61) $ 4.55
Diluted earnings/(loss) per common share attributable to Cardinal Health, Inc.: 2.08 (12.61) 4.53
The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for fiscal 2021, 2020 and 2019 were 3 million, 6 million and 7 million, respectively. During fiscal 2020, there were 2 million potentially dilutive employee stock options, restricted share units and performance share units not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would be anti-dilutive as a result of the net loss for the fiscal year.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R19.htm IDEA: XBRL DOCUMENT v3.21.2

Segment Information
12 Months Ended

Jun. 30, 2021

Segment Reporting [Abstract]

Segment Information
13. Segment Information
Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.
Revenue
Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates pharmacies, including pharmacies in community health centers, nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products.
Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded
products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.
The following table presents revenue for each reportable segment and Corporate:
(in millions) 2021 2020 2019
Pharmaceutical $ 145,796 $ 137,495 $ 129,917
Medical 16,687 15,444 15,633
Total segment revenue 162,483 152,939 145,550
Corporate (1) (16) (17) (16)
Total revenue $ 162,467 $ 152,922 $ 145,534
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:
(in millions) 2021 2020 2019
Pharmaceutical Distribution and Specialty Solutions (1) (2) $ 144,988 $ 136,693 $ 129,067
Nuclear and Precision Health Solutions 808 802 850
Pharmaceutical segment revenue
145,796 137,495 129,917
Medical distribution and products (3) 14,485 13,429 13,833
Cardinal Health at-Home Solutions 2,202 2,015 1,800
Medical segment revenue
16,687 15,444 15,633
 Total segment revenue 162,483 152,939 145,550
Corporate (4) (16) (17) (16)
Total revenue $ 162,467 $ 152,922 $ 145,534
(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services"
(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division
(4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
The following table presents revenue by geographic area:
(in millions) 2021 2020 2019
United States $ 157,756 $ 148,707 $ 141,479
International 4,727 4,232 4,071
Total segment revenue 162,483 152,939 145,550
Corporate (1) (16) (17) (16)
Total revenue $ 162,467 $ 152,922 $ 145,534
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general, and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
We do not allocate the following items to our segments:
•last-in first-out, or ("LIFO"), inventory charges/(credits);
•surgical gown recall costs/(income); in connection with a voluntary recall for certain surgical gowns and a voluntary recall and field actions for surgical procedure packs containing affected gowns, we recognized a pre-tax charge of $85 million during fiscal 2020;
•restructuring and employee severance;
•amortization and other acquisition-related costs;
•impairments and (gain)/loss on disposal of assets; in connection with the divestiture of the Cordis business, we recognized a $60 million pre-tax write-down of the net assets held for sale during fiscal 2021; in connection with the naviHealth divestiture discussed in Note 2, we recognized a pre-tax gain of $508 million during fiscal 2019;
•litigation (recoveries)/charges, net; in connection with the opioid litigation as discussed further in Note 7, we recognized pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020, respectively;
•state opioid assessment related to prior fiscal years; in connection with the New York Opioid Stewardship Act as discussed further in Note 7, we recognized a pre-tax charge of $41 million during fiscal 2021, related to calendar years 2017 and 2018 assessments;
•other (income)/expense, net;
•interest expense, net;
•loss on early extinguishment of debt;
•(gain)/loss on sale of equity interest in naviHealth; in connection with the sale of our remaining equity interest in a partnership that owned naviHealth as discussed in Note 2, we recognized a $579 million pre-tax gain ($493 million after tax) during fiscal 2020;
•provision for/(benefit from) income taxes
In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally
includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $27 million, $69 million and $55 million for fiscal 2021, 2020 and 2019, respectively.
The following tables present segment profit by reportable segment and Corporate:
(in millions) 2021 2020 2019
Pharmaceutical $ 1,684 $ 1,753 $ 1,834
Medical 577 663 576
Total segment profit 2,261 2,416 2,410
Corporate (1,789) (6,514) (350)
Total operating earnings $ 472 $ (4,098) $ 2,060
The following tables present depreciation and amortization and additions to property and equipment by reportable segment and Corporate:
(in millions) 2021 2020 2019
Pharmaceutical $ 151 $ 135 $ 147
Medical 226 243 288
Corporate 406 535 565
Total depreciation and amortization $ 783 $ 913 $ 1,000
(in millions) 2021 2020 2019
Pharmaceutical $ 55 $ 47 $ 35
Medical 97 86 74
Corporate 248 242 219
Total additions to property and equipment $ 400 $ 375 $ 328
The following table presents total assets for each reportable segment and Corporate at June 30:
(in millions) 2021 2020 2019
Pharmaceutical $ 23,624 $ 22,398 $ 22,446
Medical (1) 15,408 14,691 15,284
Corporate 5,421 3,677 3,233
Total assets $ 44,453 $ 40,766 $ 40,963
(1) Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021.

The following tables present property and equipment, net by geographic area:
(in millions) 2021 2020 2019
United States $ 1,958 $ 1,880 $ 1,846
International 402 486 510
Property and equipment, net $ 2,360 $ 2,366 $ 2,356

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R20.htm IDEA: XBRL DOCUMENT v3.21.2

Share-Based Compensation
12 Months Ended

Jun. 30, 2021

Share-based Payment Arrangement [Abstract]

Share-Based Compensation
14. Share-Based Compensation
We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. At June 30, 2021, 9 million shares remain available for future grants under the Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan ("2011 LTIP"). Under the 2011 LTIP's fungible share counting provisions, stock options are counted against the plan as one share for every share issued; awards other than stock options are counted against the plan as two and one-half shares for every share issued. This means that only 3 million shares could be issued under awards other than stock options while 9 million shares could be issued under stock options. Shares are issued out of treasury shares when stock options are exercised and when restricted share units and performance share units vest.
The following table provides total share-based compensation expense by type of award:
(in millions) 2021 2020 2019
Restricted share unit expense $ 73 $ 70 $ 63
Employee stock option expense — 3 10
Performance share unit expense 16 17 9
Total share-based compensation expense
$ 89 $ 90 $ 82
The total tax benefit related to share-based compensation was $12 million, $16 million and $16 million for fiscal 2021, 2020 and 2019, respectively.
Restricted Share Units
Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts) Restricted Share Units Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019 2 $ 51.65
Granted 2 42.71
Vested (1) 60.21
Canceled and forfeited — —
Nonvested at June 30, 2020 3 45.92
Granted 2 53.76
Vested (1) 49.37
Canceled and forfeited (1) 48.74
Nonvested at June 30, 2021 3 $ 49.05
The following table provides additional data related to restricted share unit activity:
(in millions) 2021 2020 2019
Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax $ 73 $ 77 $ 75
Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years) 2 2 2
Total fair value of shares vested during the year $ 70 $ 57 $ 68
Stock Options
Until the end of fiscal 2018, stock options were granted to our officers and certain employees. There were no stock options granted to employees during fiscal year 2021, 2020 or 2019. Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for a period up to ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.
The following table summarizes all stock option transactions under the Plans:
(in millions, except per share amounts) Stock
Options Weighted-Average
Exercise Price per
Common Share
Outstanding at June 30, 2019 6 $ 63.78
Granted — —
Exercised (1) 42.36
Canceled and forfeited — —
Outstanding at June 30, 2020 5 65.15
Granted — —
Exercised (1) 43.08
Canceled and forfeited — —
Outstanding at June 30, 2021 4 $ 68.46
Exercisable at June 30, 2021 4 $ 68.62
The following table provides additional detail related to stock options:
(in millions, except per share amounts) 2021 2020 2019
Aggregate intrinsic value of outstanding options at period end $ 11 $ 12 $ 10
Aggregate intrinsic value of exercisable options at period end 11 12 10
Aggregate intrinsic value of exercised options 10 8 1
Net proceeds/(withholding) from share-based compensation 32 26 3
Excess tax benefits from share based compensation (5) 6 7
Total compensation cost, net of estimated forfeitures, related to unvested stock options not yet recognized, pre-tax — 1 5
Total fair value of shares vested during the year 3 8 20
Weighted-average grant date fair value per stock option $ 12.94 $ 8.26 $ 8.34
(in years) 2021 2020 2019
Weighted-average remaining contractual life of outstanding options 4 5 5
Weighted-average remaining contractual life of exercisable options 4 5 5
Weighted-average period over which stock option compensation cost is expected to be recognized 2 1 1
The fair values were estimated on the grant date using a lattice valuation model. We believe the lattice model provides reasonable estimates because it has the ability to take into account individual exercise patterns based on changes in our stock price and other variables, and it provides for a range of input assumptions, which are disclosed in the table below. The risk-free rate is based on the U.S. Treasury yield curve at the time of the grant. We analyzed historical data to estimate option exercise behaviors and employee terminations to be used within the lattice model. The expected life of the options granted was calculated from the option valuation model and represents the length of time in years that the options granted are expected to be outstanding. Expected volatilities are based on implied volatility from traded options on our common shares and historical volatility over a period of time commensurate with the contractual term of the option grant (up to ten years).
Performance Share Units
Performance share units generally vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts) Performance
Share Units Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019 0.9 $ 51.45
Granted 0.7 44.03
Vested (0.1) 48.40
Canceled and forfeited (0.2) 50.92
Nonvested at June 30, 2020 1.3 54.24
Granted 0.4 55.45
Vested (0.1) 42.72
Canceled and forfeited (0.4) 53.71
Nonvested at June 30, 2021 1.2 $ 54.89

The following table provides additional data related to performance share unit activity:
(in millions) 2021 2020 2019
Total compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized, pre-tax $ 26 $ 29 $ 12
Weighted-average period over which performance share unit cost is expected to be recognized (in years) 2 2 2
Total fair value of shares vested during the year $ 1 $ 5 $ —
Employee Retirement Savings Plans
Substantially all of our domestic non-union employees are eligible to be enrolled in our company-sponsored contributory retirement savings plans, which include features under Section 401(k) of the Internal Revenue Code of 1986, and provide for matching and discretionary contributions by us. The total expense for our employee retirement savings plans was $55 million, $66 million and $99 million for fiscal 2021, 2020 and 2019, respectively.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R21.htm IDEA: XBRL DOCUMENT v3.21.2

Schedule II - Valuations and Qualifying Accounts
12 Months Ended

Jun. 30, 2021

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]
Cardinal Health, Inc. and Subsidiaries
Schedule II - Valuation and Qualifying Accounts
(in millions) Balance at
Beginning of Period Charged to Costs
and Expenses (1) Charged to
Other Accounts (2) Deductions (3) Balance at
End of Period
Fiscal 2021
Accounts receivable $ 206 $ 129 $ 1 $ (94) $ 242
Finance notes receivable 27 5 — (20) 12
Sales returns and allowances 495 2,568 — (2,374) 689
Other 1 — — — 1
$ 729 $ 2,702 $ 1 $ (2,488) $ 944
Fiscal 2020
Accounts receivable $ 193 $ 139 $ 1 $ (127) $ 206
Finance notes receivable 14 15 — (2) 27
Sales returns and allowances 479 2,253 — (2,237) 495
Other 1 — — — 1
$ 687 $ 2,407 $ 1 $ (2,366) $ 729
Fiscal 2019
Accounts receivable $ 139 $ 140 $ 1 $ (87) $ 193
Finance notes receivable 7 8 — (1) 14
Sales returns and allowances 479 2,205 — (2,205) 479
Other 1 — — — 1
$ 626 $ 2,353 $ 1 $ (2,293) $ 687
(1)Fiscal 2021, 2020 and 2019 include $70 million, $49 million and $60 million, respectively, for reserves related to service charges and customer pricing disputes, excluded from provision for bad debts on the consolidated statements of cash flows and classified as a reduction in revenue in the consolidated statements of earnings/(loss).
(2)Recoveries of amounts provided for or written off in prior years was $1 million in each fiscal year 2021, 2020 and 2019.
(3)Write-off of uncollectible accounts or actual sales returns.
The sum of the components may not equal the total due to rounding.

X

- Definition
The entire disclosure for valuation and qualifying accounts and reserves.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 09

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690
+ Details

Name: srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock

Namespace Prefix: srt_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: srt_ValuationAndQualifyingAccountsAbstract

Namespace Prefix: srt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R22.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)
12 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Basis of Presentation
Basis of Presentation
Our consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.

Use of Estimates
Use of Estimates
Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in accordance with GAAP requires us to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates, judgments and assumptions are used in the accounting and disclosure related to, among other items, allowance for doubtful accounts, inventory valuation and reserves, goodwill and other intangible asset impairment, loss contingencies (including product liability and self-insurance accruals), and income taxes. Actual amounts could ultimately differ from these estimated amounts.
The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.

Cash Equivalents
Cash Equivalents
We consider liquid investments purchased with an initial maturity of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.

Receivables
Receivables and Allowance for Doubtful Accounts
Trade receivables are presented net of an allowance for doubtful accounts of $242 million and $206 million at June 30, 2021 and 2020, respectively. An account is considered past due on the first
day after its due date. In accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account is considered past due. We regularly monitor past due accounts and establish appropriate reserves to cover potential losses, and consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts.
We provide financing to various customers. Such financing arrangements range from 1 year to 5 years at interest rates that are generally subject to fluctuation. Interest income on these arrangements is recognized as it is earned. The financings may be collateralized, guaranteed by third parties or unsecured. Finance notes, net and related accrued interest were $63 million (current portion $7 million) and $104 million (current portion $12 million) at June 30, 2021 and 2020, respectively, and are included in other assets (current portion is included in prepaid expenses and other) in the consolidated balance sheets. Finance notes receivable allowance for doubtful accounts were $12 million and $27 million at June 30, 2021 and 2020, respectively. We estimate an allowance for these financing receivables based on historical collection rates and the credit worthiness of the customer. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts.

Concentrations of Credit Risk
Concentrations of Credit Risk
We maintain cash depository accounts with major banks, and we invest in high quality, short-term liquid instruments, and in marketable securities. Our short-term liquid instruments mature within three months and we have not historically incurred any related losses.
Our trade receivables and finance notes and related accrued interest are exposed to a concentration of credit risk with certain large customers and with customers in the retail and healthcare sectors. Credit risk can be affected by changes in reimbursement and other economic pressures impacting the healthcare industry. With respect to customers in the retail and healthcare sectors, such credit risk is limited due to supporting collateral and the diversity of the customer base, including its wide geographic dispersion. We perform regular credit evaluations of our customers’ financial conditions and maintain reserves for losses through the established allowance for doubtful accounts. Historically, such losses have been within our expectations. Refer to the "Receivables and Allowance for Doubtful Accounts" section within this Note for additional information on the accounting treatment of reserves for allowance for doubtful accounts.

Major Customers
Major Customers
CVS Health Corporation ("CVS") and OptumRx, are our only customers that individually account for at least 10 percent of revenue and gross trade receivables. These customers are primarily serviced through our Pharmaceutical segment.
In August 2021, we extended our pharmaceutical distribution agreements with CVS through June 2027.
The following table summarizes historical percent of revenue and gross trade receivables from CVS and OptumRx:
Percent of Revenue Percent of Gross Trade Receivables at June 30
2021 2020 2019 2021 2020
CVS 26 % 26 % 26 % 24 % 26 %
OptumRx 15 % 14 % 13 % 3 % 6 %
We have entered into agreements with group purchasing organizations (“GPOs”) which act as purchasing agents that negotiate vendor contracts on behalf of their members. Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue. Sales to members of these two GPOs collectively accounted for 15 percent, 16 percent and 22 percent of revenue for fiscal 2021, 2020 and 2019, respectively. Our trade receivable balances are with individual members of the GPO, and therefore no significant concentration of credit risk exists with these types of arrangements

Inventories
Inventories
A portion of our inventories (50 percent and 56 percent at June 30, 2021 and 2020, respectively) are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These inventories are included within the core pharmaceutical distribution facilities of our Pharmaceutical segment (“distribution facilities”) and are primarily merchandise inventories. The LIFO method presumes that the most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue. We believe that the average cost method of inventory valuation provides a reasonable approximation of the current cost of replacing inventory within the distribution facilities. As such, the LIFO reserve is the difference between (a) inventory at the lower of LIFO cost or market and (b) inventory at replacement cost determined using the average cost method of inventory valuation.
At June 30, 2021 and 2020, respectively, inventories valued at LIFO cost were $565 million and $411 million higher than the average cost value. We do not record inventories in excess of replacement cost. As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2021 or 2020.
Our remaining inventory, including inventory in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value. Net realizable value is defined as the estimated selling prices and estimated sales demand in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Due to the unprecedented demand for
certain personal protective equipment as a result of COVID-19, our Medical segment manufactured and sourced inventory at higher costs than in periods prior to COVID-19. Personal protective equipment ("PPE") refers to protective clothing, medical and non-medical grade gloves, face shields, face masks and other equipment designed to protect the wearer from injury or the spread of infection or illness. As selling prices and customer demand have decreased compared to the peak of COVID-19, we recorded a reserve of $197 million, primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value.
We reserve for inventory obsolescence using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, age and expiration dates of on-hand inventory and manufacturer return policies. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory which were $185 million and $155 million at June 30, 2021 and 2020, respectively.

Cash Discounts
Cash Discounts
Manufacturer cash discounts are recorded as a component of inventory cost and recognized as a reduction of cost of products sold as inventory is sold.

Property and Equipment
Property and Equipment
Property and equipment are carried at cost less accumulated depreciation. Property and equipment held for sale are recorded at the lower of cost less accumulated depreciation before the decision to dispose of the asset was made or fair value less cost to sell. When certain events or changes in operating conditions occur, an impairment assessment may be performed on the recoverability of the carrying amounts.
Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which are depreciated over the terms of their respective leases. We generally use the following range of useful lives for our property and equipment categories: buildings and improvements—3 to 39 years; machinery and equipment—3 to 20 years; and furniture and fixtures—3 to 7 years. We recorded depreciation and amortization expense of $377 million, $405 million and $455 million for fiscal 2021, 2020 and 2019, respectively.
The following table presents the components of property and equipment, net at June 30:
(in millions) 2021 2020
Land, building and improvements $ 2,359 $ 2,185
Machinery and equipment 3,093 3,008
Furniture and fixtures 136 138
Total property and equipment, at cost 5,588 5,331
Accumulated depreciation and amortization (3,228) (2,965)
Property and equipment, net $ 2,360 $ 2,366
Repairs and maintenance expenditures are expensed as incurred. Interest on long-term projects is capitalized using a rate that approximates the weighted-average interest rate on long-term
obligations, which was 3 percent at June 30, 2021. The amount of capitalized interest was immaterial for all periods presented.

Goodwill and Other Intangible Assets
Goodwill and Other Intangible Assets
Purchased goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment annually or when indicators of impairment exist.
Purchased goodwill is tested for impairment at least annually. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. There is an option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the quantitative goodwill impairment test. We have elected to bypass the qualitative assessment for our annual goodwill impairment test in the current year. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount.
Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit.
We have two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. These operating segments are comprised of divisions (components), for which discrete financial information is available. Components are aggregated into reporting units for purposes of goodwill impairment testing to the extent that they share similar economic characteristics. Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (“Medical Unit”); and Cardinal Health at-Home Solutions division.
Fair value can be determined using market, income or cost-based approaches. Our determination of estimated fair value of the reporting units is based on a combination of the income-based and market-based approaches. Under the income-based approach, we use a discounted cash flow model in which cash flows anticipated over several future periods, plus a terminal value at the end of that time horizon, are discounted to their present value using an appropriate risk-adjusted rate of return. We use our internal forecasts to estimate future cash flows, which we believe are consistent with those of a market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit. Actual results may differ materially from those used in our forecasts. We use discount rates that are commensurate with the risks and uncertainty inherent in the respective reporting units and in our internally-developed forecasts. Discount rates used in our reporting unit valuations ranged from 8.5 percent to 11.5 percent. Under the market-based guideline public company method, we determine fair value by comparing our reporting units to similar businesses or guideline companies whose securities are actively traded in public markets. We also use the guideline transaction method to
determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units. To further confirm fair value, we compare the aggregate fair value of our reporting units to our total market capitalization. Estimating the fair value of reporting units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results. The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment.
We performed annual impairment testing in fiscal 2021, 2020 and 2019 and concluded that there were no impairments of goodwill as the estimated fair value of each reporting unit exceeded its carrying value.
The impairment test for indefinite-lived intangibles other than goodwill involves first assessing qualitative factors to determine if it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount. If so, then a quantitative test is performed to compare the estimated fair value of the indefinite-lived intangible asset to the respective asset's carrying amount. Our qualitative evaluation requires the use of estimates and significant judgments and considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.
Intangible assets with finite lives, primarily customer relationships; trademarks, trade names and patents; and developed technology, are amortized using a combination of straight-line and accelerated methods based on the expected cash flows from the asset over their estimated useful lives. We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group. Actual results may differ materially from those used in our forecasts.

Assets Held for Sale, Policy [Policy Text Block]
Assets Held for Sale
We classify assets and liabilities (the “disposal group”) as held for sale when management commits to a plan to sell the disposal group in its present condition and at a price that is reasonable in relation to its current fair value. We also consider whether an active program to locate a buyer has been initiated and if it is probable that the sale will occur within one year without significant changes to the plan to sell. Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization.
On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman & Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we retained certain working capital accounts and certain liabilities, including product liability for
lawsuits related to inferior vena cava filters in the U.S. and Canada as described in Note 7 of the “Notes to Consolidated Financial Statements.” The transaction closed on August 2, 2021. See Note 2 for additional information.

Investments
Investments
Investments in non-marketable equity securities are accounted for under the fair value, equity or net asset value method of accounting and are included in other assets in the consolidated balance sheets. For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which we can exercise significant influence but do not control, we use the equity method of accounting. Our share of the earnings and losses are recorded in other (income)/expense, net in the consolidated statements of earnings/(loss). We monitor our investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.

Vendor Reserves
Vendor Reserves
In the ordinary course of business, our vendors may dispute deductions taken against payments otherwise due to them or assert other disputes. These disputes are researched and resolved based upon the findings of the research performed. At any given time, there are outstanding items in various stages of research and resolution. In determining appropriate reserves for areas of exposure with our vendors, we assess historical experience and current outstanding claims. We have established various levels of reserves based on the type of claim and status of review. Though the claim types are relatively consistent, we periodically refine our methodology by updating the reserve estimate percentages to reflect actual historical experience. The ultimate outcome of certain claims may be different than our original estimate and may require an adjustment. Adjustments to vendor reserves are included in cost of products sold. In addition, the reserve balance will fluctuate due to variations of outstanding claims from period-to-period, timing of settlements and specific vendor issues, such as bankruptcies. Vendor reserves were $77 million at both June 30, 2021 and 2020, excluding third-party returns. See Third-Party Returns section within this Note for a description of third-party returns.

Distribution Service Agreement and Other Vendor Fees
Distribution Services Agreement and Other Vendor Fees
Our Pharmaceutical segment recognizes fees received from distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors’ inventory when those fees have been earned and we are entitled to payment. Since the benefit provided to a vendor is related to the purchase and distribution of the vendor’s inventory, we recognize the fees as a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings/(loss) when the inventory is sold.

Loss Contingencies
Loss Contingencies and Self-Insurance
Loss Contingencies
We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
In connection with the opioid litigation as described further in the Note 7, we recorded pre-tax charges of $1.17 billion and $5.63 billion during fiscal 2021 and 2020 respectively which were retained at Corporate. In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement, subject to certain conditions and contingencies. There is no assurance that the contingencies to the proposed settlement agreement will be satisfied.
We develop and periodically update reserve estimates for the Cordis inferior vena cava ("Cordis IVC") claims, including those received to date and expected to be received in the future and related costs. To project future Cordis IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, estimated indemnity severity by claim type, sales data, implant and injury to report lag patterns and estimated defense costs.
Self-Insurance
We also self-insure for employee healthcare, general liability, certain product liability matters, auto liability, property and workers' compensation. Self-insurance accruals include an estimate for expected settlements or pending claims, defense costs, administrative fees, claim adjustment costs and an estimate for claims incurred but not reported.
Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies and other liabilities is highly subjective and requires judgments about future events. We regularly review contingencies and our self-insurance accruals to determine whether our accruals and related disclosures are adequate. Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.
The amount of ultimate loss may differ materially from these estimates. We recognize these estimated loss contingencies, income from favorable resolution of litigation and certain defense costs in litigation (recoveries)/charges in our consolidated statements of earnings/(loss). See Note 7 for additional information regarding loss contingencies and product liability lawsuits.

Income Taxes
Income Taxes
We account for income taxes using the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in the respective jurisdictions in which we operate. We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized. The realizability of deferred tax assets depends on our ability to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence.
Deferred taxes for non-U.S. liabilities are not provided on the unremitted earnings of subsidiaries outside of the United States when it is expected that these earnings are indefinitely reinvested.
We operate in a complex multinational tax environment and are subject to tax treaty arrangements and transfer pricing guidelines for intercompany transactions that are subject to interpretation. Uncertainty in a tax position may arise as tax laws are subject to interpretation.
Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.
See Note 8 for additional information regarding income taxes.

Other Accrued Liabilities, Policy [Policy Text Block]
Other Accrued Liabilities
Other accrued liabilities represent various current obligations, including certain accrued operating expenses and taxes payable.

Noncontrolling Interests and Redeemable Noncontrolling Interests Noncontrolling InterestsNoncontrolling interests represent the portion of net earnings, comprehensive income and net assets that is not attributable to Cardinal Health, Inc.

Share-Based Compensation
Share-Based Compensation
Share-based compensation provided to employees is recognized in the consolidated statements of earnings/(loss) based on the grant date fair value of the awards. The fair value of restricted share units and performance share units is determined by the grant date market price of our common shares. The fair value of stock options is determined on the grant date using a lattice valuation model. The compensation expense associated with nonvested performance share units is dependent on our periodic assessment of the probability of the targets being achieved and our estimate, which may vary over time, of the number of shares that ultimately will be issued. The compensation expense recognized for share-based awards is net of estimated forfeitures and is recognized ratably over the service period of the awards. All income tax effects of share-based awards are recognized in the consolidated statements of earnings/(loss) as awards vest or are settled. We classify share-based compensation expense in distribution, selling, general and administrative ("SG&A") expenses to correspond with the same line item as the majority of the cash compensation paid to employees. If awards are modified in connection with a restructuring activity, the incremental share-based compensation expense is classified in restructuring and employee severance. See Note 14 for additional information regarding share-based compensation.

Dividends, Policy [Policy Text Block]
Dividends
We paid cash dividends per common share of $1.94, $1.92 and $1.91 in fiscal 2021, 2020 and 2019, respectively.

Revenue Recognition
Revenue Recognition
We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers.
Revenue in both segments is primarily related to the distribution of pharmaceutical and medical products, which include both manufactured and sourced products, and we recognize at a point in time when title transfers to customers and we have no further obligation to provide services related to such merchandise. Service revenues are recognized over the period that services are provided to the customer. Revenues derived from services are not material for either segment for all periods presented.
We are generally the principal in a transaction, therefore our revenue is primarily recorded on a gross basis. When we are a principal in a transaction, we have determined that we control the ability to direct the use of the product or service prior to transfer to a customer, are primarily responsible for fulfilling the promise to provide the product or service to our customer, have discretion in establishing prices, and ultimately control the transfer of the product or services provided to the customer.

Sales Returns and Allowances
Sales Returns and Allowances
Revenue is recorded net of sales returns and allowances. Revenues are measured based on the amount of consideration that we expect to receive, reduced by estimates for return allowances, discounts, rebates and other variable consideration. Sales returns are recorded based on estimates using historical
data. Our customer return policies generally require that the product be physically returned, subject to restocking fees. We only allow customers to return products for credit in a condition suitable to be added back to inventory and resold at full value (“merchantable product”) or returned to vendors for credit. Product returns are generally consistent throughout the year and typically are not specific to any particular product or customer.
We accrue for estimated sales returns and allowances at the time of sale based upon historical customer return trends, margin rates and processing costs. Our accrual for sales returns is reflected as a reduction of revenue and cost of products sold for the sales price and cost, respectively. At June 30, 2021 and 2020, the accrual for estimated sales returns and allowances was $689 million and $495 million, respectively, which is reflected in trade receivables, net and inventories, net in the consolidated balance sheets. Sales returns and allowances were $2.6 billion, $2.3 billion and $2.2 billion, for fiscal 2021, 2020 and 2019, respectively, and the net impact on net earnings/(loss) in the consolidated statements of earnings/(loss) was immaterial in fiscal 2021, 2020 and 2019.
Third-Party Returns
We generally do not accept non-merchantable pharmaceutical product returns from our customers, so many of our customers return non-merchantable pharmaceutical products to the manufacturer through third parties. Since our customers generally do not have a direct relationship with manufacturers, our vendors pass the value of such returns to us (usually in the form of an accounts payable deduction). We, in turn, pass the value received to our customer. In certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor. Although we believe we have satisfactory protections, we could be subject to claims from customers or vendors if our administration of this overall process was deficient in some respect or our contractual terms with vendors are in conflict with our contractual terms with our customers. We have maintained reserves for some of these situations based on their nature and our historical experience with their resolution.

Shipping and Handling Shipping and HandlingShipping and handling costs are primarily included in SG&A expenses in our consolidated statements of earnings/(loss) and include all delivery expenses as well as all costs to prepare the product for shipment to the end customer. Shipping and handling costs were $634 million, $620 million and $622 million, for fiscal 2021, 2020 and 2019, respectively.

Restructuring and Employee Severance
Restructuring and Employee Severance
Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance (including rationalizing headcount or other significant changes in personnel) and realigning operations (including realignment of the management structure in response to changing market conditions). Also included within restructuring and employee severance are
employee severance costs that are not incurred in connection with a restructuring activity. See Note 3 for additional information regarding our restructuring activities.

Amortization and Other Acquisition-Related Costs Amortization and Other Acquisition-Related CostsWe classify certain costs incurred in connection with acquisitions as amortization and other acquisition-related costs in our consolidated statements of earnings/(loss). These costs consist of amortization of acquisition-related intangible assets, transaction costs, integration costs and changes in the fair value of contingent consideration obligations. Transaction costs are incurred during the initial evaluation of a potential acquisition and primarily relate to costs to analyze, negotiate and consummate the transaction as well as due diligence activities. Integration costs relate to activities required to combine the operations of an acquired enterprise into our operations and, in the case of the Cordis and Patient Recovery businesses, to stand-up the systems and processes needed to support an expanded geographic footprint. We record changes in the fair value of contingent consideration obligations relating to acquisitions as income or expense in amortization and other acquisition-related costs. See Note 4 for additional information regarding amortization of acquisition-related intangible assets.

Translation of Foreign Currencies
Translation of Foreign Currencies
Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign subsidiaries into U.S. dollars are accumulated in shareholders’ equity through accumulated and other comprehensive loss ("AOCI") utilizing period-end exchange rates. Revenues and expenses of these foreign subsidiaries are translated using average exchange rates during the year.
The foreign currency translation gains/(losses) included in AOCI at June 30, 2021 and 2020 are presented in Note 11. Foreign currency transaction gains and losses for the period are included in the consolidated statements of earnings/(loss) in the respective financial statement line item.

Interest Rate, Currency and Commodity Risk
Interest Rate, Currency and Commodity Risk
All derivative instruments are recognized at fair value on the consolidated balance sheets and all changes in fair value are recognized in net earnings or shareholders’ equity through AOCI, net of tax.
For contracts that qualify for hedge accounting treatment, the hedge contracts must be effective at reducing the risk associated with the exposure being hedged and must be designated as a hedge at the inception of the contract. Hedge effectiveness is assessed periodically. Any contract not designated as a hedge, or so designated but ineffective, is adjusted to fair value and recognized immediately in net earnings. If a fair value or cash flow hedge ceases to qualify for hedge accounting treatment, the contract continues to be carried on the balance sheet at fair value until settled and future adjustments to the contract’s fair value are recognized immediately in net earnings. If a forecasted transaction is probable not to occur, amounts previously deferred in AOCI are recognized immediately in net earnings. Interest payments
received from the cross currency swap are excluded from the net investment hedge effectiveness assessment and are recorded in interest expense, net in the consolidated statements of earnings/(loss).
See Note 10 for additional information regarding our derivative instruments, including the accounting treatment for instruments designated as fair value, cash flow, net investment and economic hedges.

Fair Value Measurements
Fair Value Measurements
Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are:
Level 1 - Observable prices in active markets for identical assets and liabilities.
Level 2 - Observable inputs other than quoted prices in active markets for identical assets and liabilities.
Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
See Note 9 for additional information regarding fair value measurements.

Recent Financial Accounting Standards
Recently Adopted Financial Accounting Standards
Financial Instruments - Credit Losses
In June 2016, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our consolidated financial statements.
Recently Issued Financial Accounting Standards Not Yet Adopted
We address the adoption impacts of recently issued accounting standards by the FASB on the our consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2020 Form 10-K. There were no accounting
standards issued in fiscal 2021 that will have a material impact on our consolidated financial statements.

Guarantees, Indemnifications and Warranties Policies [Policy Text Block]
Guarantees
In the ordinary course of business, we agree to indemnify certain other parties under acquisition and disposition agreements, customer agreements, intellectual property licensing agreements, and other agreements. Such indemnification obligations vary in scope and, when defined, in duration. In many cases, a maximum obligation is not explicitly stated, and therefore the overall maximum amount of the liability under such indemnification obligations cannot be reasonably estimated. Where appropriate, such indemnification obligations are recorded as a liability. Historically, we have not, individually or in the aggregate, made
payments under these indemnification obligations in any material amounts. In certain circumstances, we believe that existing insurance arrangements, subject to the general deduction and exclusion provisions, would cover portions of the liability that may arise from these indemnification obligations. In addition, we believe that the likelihood of a material liability being triggered under these indemnification obligations is not probable.From time to time we enter into agreements that obligate us to make fixed payments upon the occurrence of certain events. Such obligations primarily relate to obligations arising under acquisition transactions, where we have agreed to make payments based upon the achievement of certain financial performance measures by the acquired business. Generally, the obligation is capped at an explicit amount. There were no material obligations at June 30, 2021.

X

- Definition
Disclosure of accounting policy for the costs incurred during and relating to an acquisition. These costs specifically include transaction and integration costs; changes in fair value of contingent consideration obligations and amortization of acquisition-related intangible assets, and are recorded within amortization and other acquisition-related costs.
+ References
No definition available.
+ Details

Name: cah_AmortizationandOtherAcquisitionRelatedCostsPolicyPolicyTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Assets Held for Sale, Policy [Policy Text Block]
+ References
No definition available.
+ Details

Name: cah_AssetsHeldforSalePolicyPolicyTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash Discounts [Policy Text Block]
+ References
No definition available.
+ Details

Name: cah_CashDiscountsPolicyTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for allowances received from a vendor. The disclosure differentiates between those allowances that are recorded as a reduction in the price of the vendors' products or services (that is, the entity's inventory) and which ultimately will be recorded as a reduction in the entity's cost of sales and those that are not.
+ References
No definition available.
+ Details

Name: cah_CostofSalesVendorReservesPolicyPolicyTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Describes an entity's accounting policy for fees received from distribution service agreements and other fees received from vendors related to the purchase or distribution of the vendor's inventory. Such fees are recognized as a reduction of inventory when those fees have been earned and the entity is entitled to payment.
+ References
No definition available.
+ Details

Name: cah_DistributionServiceAgreementAndOtherVendorFeesPolicyTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Dividends, Policy [Policy Text Block]
+ References
No definition available.
+ Details

Name: cah_DividendsPolicyPolicyTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Other Accrued Liabilities, Policy [Policy Text Block]
+ References
No definition available.
+ Details

Name: cah_OtherAccruedLiabilitiesPolicyPolicyTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
sales returns [Policy Text Block]
+ References
No definition available.
+ Details

Name: cah_SalesreturnsPolicyTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
ShippingandHandlingCosts [Policy Text Block]
+ References
No definition available.
+ Details

Name: cah_ShippingandHandlingCostsPolicyTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 450
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624
+ Details

Name: us-gaap_CommitmentsAndContingenciesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747
+ Details

Name: us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for derivatives used in hedging relationships, which may include how gains or losses are recognized and presented in the financial statements, and amortization policies for deferred amounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4EEEE
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL109999725-113959
+ Details

Name: us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-URI http://asc.fasb.org/topic&trid=2175825
+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249
+ Details

Name: us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 330
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-URI http://asc.fasb.org/topic&trid=2126998

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investment in financial asset.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(b))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_InvestmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592
+ Details

Name: us-gaap_MajorCustomersPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534
+ Details

Name: us-gaap_ReceivablesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R23.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Tables)
12 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Schedule of Revenue and Gross Trade Receivables Percentage by Major Customers
The following table summarizes historical percent of revenue and gross trade receivables from CVS and OptumRx:
Percent of Revenue Percent of Gross Trade Receivables at June 30
2021 2020 2019 2021 2020
CVS 26 % 26 % 26 % 24 % 26 %
OptumRx 15 % 14 % 13 % 3 % 6 %

Components of Property and Equipment
The following table presents the components of property and equipment, net at June 30:
(in millions) 2021 2020
Land, building and improvements $ 2,359 $ 2,185
Machinery and equipment 3,093 3,008
Furniture and fixtures 136 138
Total property and equipment, at cost 5,588 5,331
Accumulated depreciation and amortization (3,228) (2,965)
Property and equipment, net $ 2,360 $ 2,366

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R24.htm IDEA: XBRL DOCUMENT v3.21.2

Divestitures and Acquisitions (Tables)
12 Months Ended

Jun. 30, 2021

Business Combination and Asset Acquisition [Abstract]

Disposal Groups, Including Discontinued Operations
The following table presents information related to the assets and liabilities that were classified as held for sale at June 30, 2021 related to the Cordis divestiture in the consolidated balance sheets:
(in millions) June 30, 2021
Cash and equivalents $ 109
Inventories, net 164
Property and equipment, net 90
Goodwill and other intangibles, net 778
Other assets 10
Write-down of assets held for sale (60)
Total assets held for sale $ 1,091
Other accrued liabilities $ 61
Deferred income taxes and other liabilities 34
Total liabilities related to assets held for sale $ 95

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760
+ Details

Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R25.htm IDEA: XBRL DOCUMENT v3.21.2

Restructuring and Employee Severance (Tables)
12 Months Ended

Jun. 30, 2021

Restructuring Charges [Abstract]

Summary of Restructuring and Employee Severance
The following tables summarize restructuring and employee severance costs:
(in millions) 2021 2020 2019
Employee-related costs $ 53 $ 66 $ 95
Facility exit and other costs 61 56 30
Total restructuring and employee severance $ 114 $ 122 $ 125

Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions) Employee-
Related Costs Facility Exit
and Other Costs Total
Balance at June 30, 2019 $ 64 $ 8 $ 72
Additions 85 24 109
Payments and other adjustments (81) (4) (85)
Balance at June 30, 2020 68 28 96
Additions 49 26 75
Payments and other adjustments (64) (28) (92)
Balance at June 30, 2021 $ 53 $ 26 $ 79

X

- References
No definition available.
+ Details

Name: us-gaap_RestructuringChargesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b)(2))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R26.htm IDEA: XBRL DOCUMENT v3.21.2

Goodwill and Other Intangible Assets (Tables)
12 Months Ended

Jun. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill by Reportable Segment
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions) Pharmaceutical (1) Medical (2) Total
Balance at June 30, 2019 $ 2,663 $ 5,715 $ 8,378
Goodwill acquired, net of purchase price adjustments (5) — (5)
Foreign currency translation adjustments and other (1) (15) (16)
Balance at June 30, 2020 2,657 5,700 8,357
Goodwill acquired, net of purchase price adjustments 2 — 2
Foreign currency translation adjustments and other — 18 18
Cordis goodwill reclassified to assets held for sale — (388) (388)
Balance at June 30, 2021 $ 2,659 $ 5,330 $ 7,989
(1) At June 30, 2021 and 2020, the Pharmaceutical segment accumulated goodwill impairment loss was $829 million.
(2) At June 30, 2021 and 2020, the Medical segment accumulated goodwill impairment loss was $1.4 billion.

Schedule of Finite-Lived Intangible Assets
The following tables summarize other intangible assets by class at June 30:
2021
(in millions) Gross
Intangible Accumulated
Amortization Net
Intangible Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents $ 12 $ — $ 12 N/A
Total indefinite-life intangibles 12 — 12 N/A
Definite-life intangibles:
Customer relationships 3,330 1,989 1,341 11
Trademarks, trade names and patents 551 328 223 9
Developed technology and other 1,035 506 529 10
Total definite-life intangibles 4,916 2,823 2,093 10
Total other intangible assets $ 4,928 $ 2,823 $ 2,105 N/A
2020
(in millions) Gross
Intangible Accumulated
Amortization Net
Intangible
Indefinite-life intangibles:
IPR&D, trademarks and other $ 23 $ — $ 23
Total indefinite-life intangibles 23 — 23
Definite-life intangibles:
Customer relationships 3,554 1,828 1,726
Trademarks, trade names and patents 673 341 332
Developed technology and other 1,604 767 837
Total definite-life intangibles 5,831 2,936 2,895
Total other intangible assets $ 5,854 $ 2,936 $ 2,918

Schedule of Indefinite-Lived Intangible Assets
The following tables summarize other intangible assets by class at June 30:
2021
(in millions) Gross
Intangible Accumulated
Amortization Net
Intangible Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents $ 12 $ — $ 12 N/A
Total indefinite-life intangibles 12 — 12 N/A
Definite-life intangibles:
Customer relationships 3,330 1,989 1,341 11
Trademarks, trade names and patents 551 328 223 9
Developed technology and other 1,035 506 529 10
Total definite-life intangibles 4,916 2,823 2,093 10
Total other intangible assets $ 4,928 $ 2,823 $ 2,105 N/A
2020
(in millions) Gross
Intangible Accumulated
Amortization Net
Intangible
Indefinite-life intangibles:
IPR&D, trademarks and other $ 23 $ — $ 23
Total indefinite-life intangibles 23 — 23
Definite-life intangibles:
Customer relationships 3,554 1,828 1,726
Trademarks, trade names and patents 673 341 332
Developed technology and other 1,604 767 837
Total definite-life intangibles 5,831 2,936 2,895
Total other intangible assets $ 5,854 $ 2,936 $ 2,918

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267
+ Details

Name: us-gaap_ScheduleOfGoodwillTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b),(d)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R27.htm IDEA: XBRL DOCUMENT v3.21.2

Leases (Tables)
12 Months Ended

Jun. 30, 2021

Leases [Abstract]

Schedule of Lease Costs
The following table summarizes the components of lease cost:
(in millions) 2021 2020
Operating lease cost $ 119 $ 134
Finance lease cost 16 13
Variable lease cost 24 17
Total lease cost $ 159 $ 164
Variable lease cost primarily includes payments for property taxes, maintenance and insurance.

Leases Supplemental Balance Sheet Information The following table summarizes supplemental balance sheet and other information related to leases at June 30:
(in millions) 2021 2020
Operating Leases
Operating lease right-of-use assets $ 460 $ 426
 Current portion of operating lease liabilities 105 104
 Long-term operating lease liabilities 374 341
Total operating lease liabilities 479 445
Finance Leases
Finance lease right-of-use assets 63 33
Current portion of finance lease liabilities 19 9
Long-term finance lease liabilities 45 25
Total finance lease liabilities $ 64 $ 34
Weighted-average remaining lease term (years)
Operating leases 6.5 years 6.4 years
Finance leases 4.2 years 4.3 years
Weighted-average discount rate
Operating leases 2.9 % 2.9 %
Finance leases 1.5 % 2.4 %

Leases Supplemental Cash Flow Information
The following tables summarizes supplemental cash flow information related to leases:
(in millions) 2021 2020
Cash paid for lease liabilities:
Operating cash flows paid for operating leases $ 115 $ 125
Financing cash flows paid for finance leases 15 7
Non-cash right-of-use assets obtained in exchange for lease obligations:
New operating leases 138 150
New finance leases 45 40
Amended lease standard adoption impact as of July 1, 2019 (1)
— 400
(1)Includes the effect of $22 million from reclassifying deferred rent as an offset to the lease right-of-use asset in accordance with the transition guidance.

Schedule of Future Lease Payments
Future lease payments under non-cancellable leases as of June 30, 2021 were as follows:
(in millions) Operating Leases Finance Leases Total
2022 $ 116 $ 20 $ 136
2023 93 20 113
2024 72 14 86
2025 65 8 73
2026 50 3 53
Thereafter 141 5 146
Total future lease payments 537 70 607
Less: leases not yet commenced (1)
3 — 3
Less: imputed interest 55 6 61
Total lease liabilities $ 479 $ 64 $ 543
(1)As of June 30, 2021, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the consolidated balance sheet.

X

- Definition
[Table Text Block] for Lease Payments [Table]
+ References
No definition available.
+ Details

Name: cah_LeasePaymentsTableTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
[Table Text Block] for LeasesSupplementalBalanceSheetInformation [Table]
+ References
No definition available.
+ Details

Name: cah_LeasesSupplementalBalanceSheetInformationTableTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980
+ Details

Name: us-gaap_LeaseCostTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717
+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R28.htm IDEA: XBRL DOCUMENT v3.21.2

Long-Term Obligations and Other Short-Term Borrowings (Tables)
12 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Schedule of Debt
The following table summarizes long-term obligations and other short-term borrowings at June 30:
(in millions) (1) 2021 2020
2.616% Notes due 2022 $ 572 $ 834
3.2% Notes due 2022 — 236
Floating Rate Notes due 2022 281 321
3.2% Notes due 2023 564 576
3.079% Notes due 2024 794 809
3.5% Notes due 2024 410 413
3.75% Notes due 2025 524 529
3.41% Notes due 2027 1,216 1,215
4.6% Notes due 2043 341 340
4.5% Notes due 2044 342 342
4.9% Notes due 2045 441 441
4.368% Notes due 2047 560 560
7.0% Debentures due 2026 124 124
Other Obligations 67 35
Total 6,236 6,775
Less: current portion of long-term obligations and other short-term borrowings 871 10
 Long-term obligations, less current portion $ 5,365 $ 6,765
(1) Maturities are presented on a calendar year basis.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R29.htm IDEA: XBRL DOCUMENT v3.21.2

Income Taxes (Tables)
12 Months Ended

Jun. 30, 2021

Income Tax Disclosure [Abstract]

Schedule of Income Before Income Tax, Domestic and Foreign
The following table summarizes earnings/(loss) before income taxes:
(in millions) 2021 2020 2019
U.S. operations $ (47) $ (4,056) $ 1,478
Non-U.S. operations 370 284 273
Earnings/(loss) before income taxes $ 323 $ (3,772) $ 1,751

Schedule of Components of Income Tax Expense (Benefit), Current and Deferred
The following table summarizes the components of provision for/(benefit from) income taxes:
(in millions) 2021 2020 2019
Current:
Federal $ (989) $ 659 $ 295
State and local 92 154 89
Non-U.S. 112 69 85
Total current $ (785) $ 882 $ 469
Deferred:
Federal $ 539 $ (822) $ (28)
State and local (28) (127) (37)
Non-U.S. (15) (12) (18)
Total deferred 496 (961) (83)
Provision for/(benefit from) income taxes $ (289) $ (79) $ 386

Schedule of Effective Income Tax Rate Reconciliation
The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate:

2021 (1)
2020 (1)
2019 (1)
Provision at Federal statutory rate 21.0 % 21.0 % 21.0 %
State and local income taxes, net of federal benefit 3.2 2.5 0.9
Tax effect of foreign operations 0.7 — (0.7)
Nondeductible/nontaxable items (2)
1.6 0.2 0.8
Cordis Disposition 7.0 — —
Withholding Taxes (2)
9.0 (0.3) 0.7
Change in Valuation Allowances (1.4) 1.5 4.5
US Taxes on International Income (2)(3)
(6.7) 0.2 0.7
Impact of Resolutions with IRS and other related matters (2)
(13.6) (0.4) (0.1)
Legal Entity Reorganization — — (3.6)
Opioid litigation 17.7 (23.2) —
Loss Carryback Claims (129.9) — —
Other (2)
1.7 0.6 (2.1)
Effective income tax rate (89.7) % 2.1 % 22.1 %
(1) The table represents the following: fiscal 2021 is pretax income with tax benefit, fiscal 2020 is pretax loss with tax benefit, and fiscal 2019 is pretax income with tax expense.
(2) Certain prior year amounts have been reclassified to conform to current year presentation.

Schedule of Deferred Tax Assets and Liabilities
The following table presents the components of the deferred income tax assets and liabilities at June 30:
(in millions) 2021 2020
Deferred income tax assets:
Receivable basis difference $ 40 $ 39
Accrued liabilities 874 607
Share-based compensation 38 38
Loss and tax credit carryforwards 805 589
Deferred tax assets related to uncertain tax positions 35 52
Other 16 87
Total deferred income tax assets 1,808 1,412
Valuation allowance for deferred income tax assets (515) (470)
Net deferred income tax assets $ 1,293 $ 942
Deferred income tax liabilities:
Inventory basis differences $ (1,119) $ (1,083)
Property-related (375) (327)
Goodwill and other intangibles (733) (751)
Self-Insurance (975) —
Other (23) —
Total deferred income tax liabilities $ (3,225) $ (2,161)
Net deferred income tax liability
$ (1,932) $ (1,219)

Schedule of Deferred Tax Assets and Liabilities after Netting by Tax Jurisdiction
Deferred income tax assets and liabilities in the preceding table, after netting by taxing jurisdiction and for uncertain tax positions, are in the following captions in the consolidated balance sheets at June 30:
(in millions) 2021 2020
Noncurrent deferred income tax asset (1) 52 39
Noncurrent deferred income tax liability (2) (1,981) (1,258)
Noncurrent deferred income tax liability transferred to held for sale (3) —
Net deferred income tax liability $ (1,932) $ (1,219)
(1)Included in other assets in the consolidated balance sheets.
(2)Included in deferred income taxes and other liabilities in the consolidated balance sheets.

Schedule of Unrecognized Tax Benefits Roll Forward The following table presents a reconciliation of the beginning and ending amounts of unrecognized tax benefits:
(in millions) 2021 2020 2019
Balance at beginning of fiscal year $ 998 $ 456 $ 423
Additions for tax positions of the current year 121 500 24
Additions for tax positions of prior years 223 78 39
Reductions for tax positions of prior years (138) (27) (5)
Settlements with tax authorities (271) (6) (25)
Expiration of the statute of limitations (1) (3) —
Balance at end of fiscal year
$ 932 $ 998 $ 456

X

- Definition
Schedule Of Deferred Tax Assets And Liabilities After Netting By Tax Jurisdiction [Table Text Block]
+ References
No definition available.
+ Details

Name: cah_ScheduleOfDeferredTaxAssetsAndLiabilitiesAfterNettingByTaxJurisdictionTableTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of income before income tax between domestic and foreign jurisdictions.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the change in unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 55
-Paragraph 217
-URI http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-URI http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R30.htm IDEA: XBRL DOCUMENT v3.21.2

Fair Value Measurements (Tables)
12 Months Ended

Jun. 30, 2021

Fair Value Disclosures [Abstract]

Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at June 30:
2021
(in millions) Level 1 Level 2 Level 3 Total
Assets:
Cash equivalents $ 1,883 $ — $ — $ 1,883
Other investments (1) 126 — — 126
Forward contracts (2) — 42 — 42
2020
(in millions) Level 1 Level 2 Level 3 Total
Assets:
Cash equivalents $ 721 $ — $ — $ 721
Other investments (1) 114 — — 114
Forward contracts (2) — 53 — 53
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high-quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.(2)The fair value of interest rate swaps, foreign currency contracts, net investment hedges and commodity contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the consolidated balance sheets.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258
+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R31.htm IDEA: XBRL DOCUMENT v3.21.2

Financial Instruments (Tables)
12 Months Ended

Jun. 30, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Fair Value of Assets and Liabilities Related to Derivatives Designated as Hedging Instruments
The following table summarizes the fair value of our assets and liabilities related to derivatives designated as hedging instruments and the respective line items in which they were recorded in the consolidated balance sheets at June 30:
(in millions) 2021 2020
Assets:
Pay-floating interest rate swaps (1) $ 1 $ 27
Cross-currency swap (1) 6 47
Cross-currency swap (2) 34 —
Foreign currency contracts (2) 5 —
Total assets $ 46 $ 74
Liabilities:
Foreign currency contracts (4) $ 4 $ 4
Forward interest rate swaps (3) — 16
Commodity contracts (4) — 1
Total liabilities $ 4 $ 21
(1) Included in other assets in the consolidated balance sheets.
(2) Included in prepaid expenses and other in the consolidated balance sheets.
(3) Included in deferred income taxes and other liabilities in the consolidated balance sheets.
(4) Included in other accrued liabilities in the consolidated balance sheets.

Derivative [Line Items]

Schedule of Gain/(Loss) Included in AOCI for Derivative Instruments
The following table summarizes the pre-tax gain/(loss) included in OCI for derivative instruments designated as cash flow hedges:
(in millions) 2021 2020 2019
Forward interest rate swaps $ 16 $ (16) $ —
Commodity contracts 1 1 (5)
Foreign currency contracts 5 (8) 5

Schedule of Gain/(Loss) Recognized in Earnings for Interest Rate Contracts Designated as Fair Value Hedges
The following table summarizes the gain/(loss) recognized in earnings for interest rate swaps designated as fair value hedges:
(in millions) 2021 2020 2019
Pay-floating interest rate swaps (1) $ (8) $ 106 $ 9
Fixed-rate debt (1) 8 (106) (9)
(1) Included in interest expense, net in the consolidated statements of earnings/(loss).

Schedule of Gain/(Loss) Reclassified from AOCI into Earnings for Derivative Instruments Designated as Cash Flow Hedges
The following table summarizes the pre-tax gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges:
(in millions) 2021 2020 2019
Foreign currency contracts (1) $ (12) $ 7 $ 2
Foreign currency contracts (2) (2) 1 —
Foreign currency contracts (3) 4 — 1
Forward interest rate swaps (4) 2 2 2
Commodity contracts (3) 6 (5) —
(1) Included in revenue in the consolidated statements of earnings/(loss).
(2) Included in cost of products sold in the consolidated statements of earnings/(loss).
(3) Included in SG&A expenses in the consolidated statements of earnings/(loss).
(4) Included in interest expense, net in the consolidated statements of earnings/(loss).

Schedule of Gain/(Loss) Recognized in Earnings for Economic (Non-designated) Derivative Instruments
The following table summarizes the gain/(loss) recognized in earnings for economic (non-designated) derivative instruments:
(in millions) 2021 2020 2019
Foreign currency contracts (1) $ (8) $ (11) $ (13)
(1) Included in other income, net in the consolidated statements of earnings/(loss).

Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at June 30:
(in millions) 2021 2020
Estimated fair value $ 6,751 $ 7,273
Carrying amount 6,236 6,775

Schedule of Fair Value Gain/(Loss) Derivative Instrument
The following table is a summary of the fair value gain/(loss) of our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:
2021 2020
(in millions) Notional
Amount Fair Value
Gain/(Loss) Notional
Amount Fair Value
Gain/(Loss)
Pay-floating interest rate swaps $ 200 $ 1 $ 550 $ 27
Foreign currency contracts 690 1 653 (4)
Forward interest rate swaps — — 200 (16)
Cross-currency swap 833 40 833 47
Commodity contracts — — 16 (1)

Not Designated as Hedging Instrument

Derivative [Line Items]

Schedule of Outstanding Instruments
The following tables summarize the outstanding economic (non-designated) derivative instruments at June 30:
2021
(in millions) Notional Amount Maturity Date
Foreign currency contracts $ 254 July 2021
2020
(in millions) Notional Amount Maturity Date
Foreign currency contracts $ 325 Jul 2020

Fair Value Hedging

Derivative [Line Items]

Schedule of Outstanding Instruments
The following tables summarize the outstanding interest rate swaps designated as fair value hedges at June 30:
2021
(in millions) Notional Amount Maturity Date
Pay-floating interest rate swaps $ 200 Mar 2028
2020
(in millions) Notional Amount Maturity Date
Pay-floating interest rate swaps $ 550 Mar 2023

Cash Flow Hedging

Derivative [Line Items]

Schedule of Outstanding Instruments
The following tables summarize the outstanding cash flow hedges at June 30:
2021
(in millions) Notional Amount Maturity Date
Foreign currency contracts $ 436 Jul 2021 - Jun 2022
2020
(in millions) Notional Amount Maturity Date
Forward interest rate swaps $ 200 Jun 2022
Foreign currency contracts 328
Jul 2020
-
Jun 2021
Commodity contracts 16
Jul 2020
-
Jun 2021

X

- Definition
Summarizes the fair value and notional amounts of derivative instruments held as of the balance sheet date.
+ References
No definition available.
+ Details

Name: cah_ScheduleOfFairValueGainLossDerivativeInstrumentTableTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959
+ Details

Name: us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959
+ Details

Name: us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959
+ Details

Name: us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959
+ Details

Name: us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959
+ Details

Name: us-gaap_ScheduleOfDerivativeInstrumentsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4CC
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959
+ Details

Name: us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R32.htm IDEA: XBRL DOCUMENT v3.21.2

Shareholders' Equity (Tables)
12 Months Ended

Jun. 30, 2021

Equity [Abstract]

Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total
The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions) Foreign
Currency
Translation
Adjustments and other Unrealized
Gain/(Loss) on
Derivatives,
net of tax Accumulated Other
Comprehensive
Loss
Balance at June 30, 2019 $ (95) $ 16 $ (79)
Other comprehensive income/(loss), net before reclassifications 3 (23) (20)
Amounts reclassified to earnings — (5) (5)
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax of $4 million 3 (28) (25)
Balance at June 30, 2020 (92) (12) (104)
Other comprehensive income, before reclassifications 46 22 68
Amounts reclassified to earnings — 2 2
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax of $4 million 46 24 70
Balance at June 30, 2021 $ (46) $ 12 $ (34)

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accumulated other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900
+ Details

Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R33.htm IDEA: XBRL DOCUMENT v3.21.2

Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)
12 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share
The following table reconciles the computation of basic and diluted earnings per share attributable to Cardinal Health, Inc.:
(in millions, except per share amounts) 2021 2020 2019
Net earnings/(loss) $ 612 $ (3,693) $ 1,365
Net earnings attributable to noncontrolling interest (1) (3) (2)
Net earnings/(loss) attributable to Cardinal Health, Inc.
$ 611 $ (3,696) $ 1,363
Weighted-average common shares–basic 292 293 300
Effect of dilutive securities:
Employee stock options, restricted share units, and performance share units 2 — 1
Weighted-average common shares–diluted 294 293 301
Basic earnings/(loss) per common share attributable to Cardinal Health, Inc.: $ 2.09 $ (12.61) $ 4.55
Diluted earnings/(loss) per common share attributable to Cardinal Health, Inc.: 2.08 (12.61) 4.53

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R34.htm IDEA: XBRL DOCUMENT v3.21.2

Segment Information (Tables)
12 Months Ended

Jun. 30, 2021

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]
The following table presents revenue for each reportable segment and Corporate:
(in millions) 2021 2020 2019
Pharmaceutical $ 145,796 $ 137,495 $ 129,917
Medical 16,687 15,444 15,633
Total segment revenue 162,483 152,939 145,550
Corporate (1) (16) (17) (16)
Total revenue $ 162,467 $ 152,922 $ 145,534
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Revenue by Reportable Segment
The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:
(in millions) 2021 2020 2019
Pharmaceutical Distribution and Specialty Solutions (1) (2) $ 144,988 $ 136,693 $ 129,067
Nuclear and Precision Health Solutions 808 802 850
Pharmaceutical segment revenue
145,796 137,495 129,917
Medical distribution and products (3) 14,485 13,429 13,833
Cardinal Health at-Home Solutions 2,202 2,015 1,800
Medical segment revenue
16,687 15,444 15,633
 Total segment revenue 162,483 152,939 145,550
Corporate (4) (16) (17) (16)
Total revenue $ 162,467 $ 152,922 $ 145,534
(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services"
(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division
(4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Disaggregation of Revenue [Table Text Block]
(in millions) 2021 2020 2019
Pharmaceutical Distribution and Specialty Solutions (1) (2) $ 144,988 $ 136,693 $ 129,067
Nuclear and Precision Health Solutions 808 802 850
Pharmaceutical segment revenue
145,796 137,495 129,917
Medical distribution and products (3) 14,485 13,429 13,833
Cardinal Health at-Home Solutions 2,202 2,015 1,800
Medical segment revenue
16,687 15,444 15,633
 Total segment revenue 162,483 152,939 145,550
Corporate (4) (16) (17) (16)
Total revenue $ 162,467 $ 152,922 $ 145,534
(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services"
(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division
(4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Revenue from External Customers by Geographic Areas [Table Text Block]
The following table presents revenue by geographic area:
(in millions) 2021 2020 2019
United States $ 157,756 $ 148,707 $ 141,479
International 4,727 4,232 4,071
Total segment revenue 162,483 152,939 145,550
Corporate (1) (16) (17) (16)
Total revenue $ 162,467 $ 152,922 $ 145,534
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Segment Profit by Reportable Segment
The following tables present segment profit by reportable segment and Corporate:
(in millions) 2021 2020 2019
Pharmaceutical $ 1,684 $ 1,753 $ 1,834
Medical 577 663 576
Total segment profit 2,261 2,416 2,410
Corporate (1,789) (6,514) (350)
Total operating earnings $ 472 $ (4,098) $ 2,060

Depreciation and Amortization and Additions to Property and Equipment by Reportable Segment
The following tables present depreciation and amortization and additions to property and equipment by reportable segment and Corporate:
(in millions) 2021 2020 2019
Pharmaceutical $ 151 $ 135 $ 147
Medical 226 243 288
Corporate 406 535 565
Total depreciation and amortization $ 783 $ 913 $ 1,000
(in millions) 2021 2020 2019
Pharmaceutical $ 55 $ 47 $ 35
Medical 97 86 74
Corporate 248 242 219
Total additions to property and equipment $ 400 $ 375 $ 328

Assets by Reportable Segment
The following table presents total assets for each reportable segment and Corporate at June 30:
(in millions) 2021 2020 2019
Pharmaceutical $ 23,624 $ 22,398 $ 22,446
Medical (1) 15,408 14,691 15,284
Corporate 5,421 3,677 3,233
Total assets $ 44,453 $ 40,766 $ 40,963
(1) Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021.

Property and Equipment, Net by Geographic Area
The following tables present property and equipment, net by geographic area:
(in millions) 2021 2020 2019
United States $ 1,958 $ 1,880 $ 1,846
International 402 486 510
Property and equipment, net $ 2,360 $ 2,366 $ 2,356

X

- Definition
Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045
+ Details

Name: us-gaap_DisaggregationOfRevenueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph b
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599
+ Details

Name: us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599
+ Details

Name: us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599
+ Details

Name: us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599
+ Details

Name: us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599
+ Details

Name: us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph a
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599
+ Details

Name: us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599
+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 55 R35.htm IDEA: XBRL DOCUMENT v3.21.2

Share-Based Compensation (Tables)
12 Months Ended

Jun. 30, 2021

Share-based Payment Arrangement [Abstract]

Schedule of Total Share-based Compensation Expense by Type of Award
The following table provides total share-based compensation expense by type of award:
(in millions) 2021 2020 2019
Restricted share unit expense $ 73 $ 70 $ 63
Employee stock option expense — 3 10
Performance share unit expense 16 17 9
Total share-based compensation expense
$ 89 $ 90 $ 82

Schedule of Stock Option Transactions Under the Plans
The following table summarizes all stock option transactions under the Plans:
(in millions, except per share amounts) Stock
Options Weighted-Average
Exercise Price per
Common Share
Outstanding at June 30, 2019 6 $ 63.78
Granted — —
Exercised (1) 42.36
Canceled and forfeited — —
Outstanding at June 30, 2020 5 65.15
Granted — —
Exercised (1) 43.08
Canceled and forfeited — —
Outstanding at June 30, 2021 4 $ 68.46
Exercisable at June 30, 2021 4 $ 68.62

Schedule of Additional Data Related to Stock Option Activity
The following table provides additional detail related to stock options:
(in millions, except per share amounts) 2021 2020 2019
Aggregate intrinsic value of outstanding options at period end $ 11 $ 12 $ 10
Aggregate intrinsic value of exercisable options at period end 11 12 10
Aggregate intrinsic value of exercised options 10 8 1
Net proceeds/(withholding) from share-based compensation 32 26 3
Excess tax benefits from share based compensation (5) 6 7
Total compensation cost, net of estimated forfeitures, related to unvested stock options not yet recognized, pre-tax — 1 5
Total fair value of shares vested during the year 3 8 20
Weighted-average grant date fair value per stock option $ 12.94 $ 8.26 $ 8.34

Schedule of Remaining Stock Option Plan Data
(in years) 2021 2020 2019
Weighted-average remaining contractual life of outstanding options 4 5 5
Weighted-average remaining contractual life of exercisable options 4 5 5
Weighted-average period over which stock option compensation cost is expected to be recognized 2 1 1

Schedule of Range of Assumptions Used to Estimate Fair Value of Stock Options

Schedule of Transactions Related to Restricted Share Units Under the Plans
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts) Restricted Share Units Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019 2 $ 51.65
Granted 2 42.71
Vested (1) 60.21
Canceled and forfeited — —
Nonvested at June 30, 2020 3 45.92
Granted 2 53.76
Vested (1) 49.37
Canceled and forfeited (1) 48.74
Nonvested at June 30, 2021 3 $ 49.05

Additional Restricted Shares and Restricted Share Units Activity
The following table provides additional data related to restricted share unit activity:
(in millions) 2021 2020 2019
Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax $ 73 $ 77 $ 75
Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years) 2 2 2
Total fair value of shares vested during the year $ 70 $ 57 $ 68

Schedule of Transactions Related to Performance Share Units Under the Plans
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts) Performance
Share Units Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019 0.9 $ 51.45
Granted 0.7 44.03
Vested (0.1) 48.40
Canceled and forfeited (0.2) 50.92
Nonvested at June 30, 2020 1.3 54.24
Granted 0.4 55.45
Vested (0.1) 42.72
Canceled and forfeited (0.4) 53.71
Nonvested at June 30, 2021 1.2 $ 54.89

Additional Data Related to Performance Share Units Activity
The following table provides additional data related to performance share unit activity:
(in millions) 2021 2020 2019
Total compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized, pre-tax $ 26 $ 29 $ 12
Weighted-average period over which performance share unit cost is expected to be recognized (in years) 2 2 2
Total fair value of shares vested during the year $ 1 $ 5 $ —

X

- Definition
Additional Performance Share Units Data [Table Text Block]
+ References
No definition available.
+ Details

Name: cah_AdditionalPerformanceShareUnitsDataTableTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional Restricted Shares And Restricted Share Units Data [Table Text Block]
+ References
No definition available.
+ Details

Name: cah_AdditionalRestrictedSharesAndRestrictedShareUnitsDataTableTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
A disclosure of additional data related to all stock option activity
+ References
No definition available.
+ Details

Name: cah_AdditionalStockOptionPlanDataTableTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
[Table Text Block] for Remaining Stock Option Plan Data [Table]
+ References
No definition available.
+ Details

Name: cah_RemainingStockOptionPlanDataTableTextBlock

Namespace Prefix: cah_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the changes in outstanding nonvested performance-based units.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R36.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Receivables) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2018

Accounts, Notes, Loans and Financing Receivable [Line Items]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount $ 944 $ 729 $ 687 $ 626

Finance notes and related accrued interest, net, total 63 104

Finance notes and related accrued interest, net, current $ 7 12

Minimum

Accounts, Notes, Loans and Financing Receivable [Line Items]

Receivable financing agreement term 1 year

Maximum

Accounts, Notes, Loans and Financing Receivable [Line Items]

Receivable financing agreement term 5 years

SEC Schedule, 12-09, Allowance, Credit Loss [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount $ 242 206 193 139

SEC Schedule, 12-09, Allowance, Loss on Finance Receivable [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount $ 12 $ 27 $ 14 $ 7

X

- Definition
Receivable Financing Agreement Term
+ References
No definition available.
+ Details

Name: cah_ReceivableFinancingAgreementTerm

Namespace Prefix: cah_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsNotesAndLoansReceivableLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(7))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765
+ Details

Name: us-gaap_NotesAndLoansReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522
+ Details

Name: us-gaap_NotesReceivableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation and qualifying accounts and reserves.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09(Column B))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09(Column E))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690
+ Details

Name: us-gaap_ValuationAllowancesAndReservesBalance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForLossesOnFinanceReceivablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R37.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Revenue and Gross Trade Receivables Percentage by Major Customers) (Details) - Pharmaceutical
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

CVS Health

Revenue, Major Customer [Line Items]

Percent of Gross Trade Receivables 24.00% 26.00%

CVS Health | Revenue Benchmark | Customer Concentration Risk

Revenue, Major Customer [Line Items]

Percent of Revenue 26.00% 26.00% 26.00%

OptumRx [Member]

Revenue, Major Customer [Line Items]

Percent of Gross Trade Receivables 3.00% 6.00%

OptumRx [Member] | Revenue Benchmark | Customer Concentration Risk

Revenue, Major Customer [Line Items]

Percent of Revenue 15.00% 14.00% 13.00%

X

- Definition
Gross Trade Receivables, Major Customer Percentage
+ References
No definition available.
+ Details

Name: cah_GrossTradeReceivablesMajorCustomerPercentage

Namespace Prefix: cah_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EntityWideRevenueMajorCustomerLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=cah_CVSCaremarkCorporationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=cah_OptumRxMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R38.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Major Customers) (Details) - organization
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Concentration Risk [Line Items]

Largest group purchasing organizations 2

Group Purchasing Organizations | Revenue Benchmark | Customer Concentration Risk

Concentration Risk [Line Items]

Revenue, major customer, percentage 15.00% 16.00% 22.00%

X

- Definition
Concentration Risk, Largest Group Purchasing Organizations
+ References
No definition available.
+ Details

Name: cah_ConcentrationRiskLargestGroupPurchasingOrganizations

Namespace Prefix: cah_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_MajorCustomersAxis=cah_GroupPurchasingOrganizationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R39.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Inventories) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Accounting Policies [Abstract]

Portion of inventories held at LIFO, percentage 50.00% 56.00%

Inventories valued at LIFO amount higher than average cost value $ 565 $ 411

Reserves for excess and obsolete inventory 185 $ 155

Inventory Write-down $ 197

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(c))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryLIFOReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314
+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The percentage of LIFO (last in first out) inventory to total inventory as of the balance sheet date if other than 100 percent.
+ References
No definition available.
+ Details

Name: us-gaap_PercentageOfLIFOInventory

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

XML 60 R40.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Property and Equipment) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Property, Plant and Equipment [Line Items]

Depreciation $ 377 $ 405 $ 455

Interest rate on long-term projects (approximates weighted-average on long-term obligations) 3.00%

Building and Improvements | Minimum

Property, Plant and Equipment [Line Items]

Useful life of property and equipment 3 years

Building and Improvements | Maximum

Property, Plant and Equipment [Line Items]

Useful life of property and equipment 39 years

Machinery and equipment | Minimum

Property, Plant and Equipment [Line Items]

Useful life of property and equipment 3 years

Machinery and equipment | Maximum

Property, Plant and Equipment [Line Items]

Useful life of property and equipment 20 years

Furniture and fixtures | Minimum

Property, Plant and Equipment [Line Items]

Useful life of property and equipment 3 years

Furniture and fixtures | Maximum

Property, Plant and Equipment [Line Items]

Useful life of property and equipment 7 years

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average interest rate of long-term debt outstanding calculated at point in time.
+ References
No definition available.
+ Details

Name: us-gaap_LongtermDebtWeightedAverageInterestRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R41.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Components of Property and Equipment) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Property, Plant and Equipment [Line Items]

Total property and equipment, at cost $ 5,588 $ 5,331

Accumulated depreciation and amortization (3,228) (2,965)

Property and equipment, net 2,360 2,366 $ 2,356

Land, building and improvements

Property, Plant and Equipment [Line Items]

Total property and equipment, at cost 2,359 2,185

Machinery and equipment

Property, Plant and Equipment [Line Items]

Total property and equipment, at cost 3,093 3,008

Furniture and fixtures

Property, Plant and Equipment [Line Items]

Total property and equipment, at cost $ 136 $ 138

Maximum | Building and Improvements

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 39 years

Maximum | Machinery and equipment

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 20 years

Maximum | Furniture and fixtures

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 7 years

Minimum | Building and Improvements

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 3 years

Minimum | Machinery and equipment

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 3 years

Minimum | Furniture and fixtures

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment, Useful Life 3 years

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 360
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandBuildingsAndImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 R42.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Goodwill and Other Intangible Assets) (Details)
$ in Millions
12 Months Ended

Jun. 30, 2021

USD ($)

segment

Jun. 30, 2020

USD ($)

Jun. 30, 2019

USD ($)

Goodwill and Intangible Assets [Line Items]

Number of Operating Segments | segment 2

Goodwill, Impairment Loss | $ $ 0 $ 0 $ 0

Minimum

Goodwill and Intangible Assets [Line Items]

Discount Rate, fair value inputs 8.50%

Maximum

Goodwill and Intangible Assets [Line Items]

Discount Rate, fair value inputs 11.50%

X

- Definition
Discount Rate, fair value inputs
+ References
No definition available.
+ Details

Name: cah_DiscountRatefairvalueinputs

Namespace Prefix: cah_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Goodwill and Intangible Assets [Line Items]
+ References
No definition available.
+ Details

Name: cah_GoodwillAndIntangibleAssetsLineItems

Namespace Prefix: cah_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266
+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R43.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Vendor Reserves) (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Accounting Policies [Abstract]

Vendor reserves $ 77 $ 77

X

- Definition
Total of reserves, relating to vendor disputes or deductions, that are netted against vendor liabilities in the ordinary course of business.
+ References
No definition available.
+ Details

Name: cah_VendorReserves

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 64 R44.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Dividends) (Details) - $ / shares
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Accounting Policies [Abstract]

Cash dividends per common share (in usd per share) $ 1.94 $ 1.92 $ 1.91

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate dividends paid during the period for each share of common stock outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_CommonStockDividendsPerShareCashPaid

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

XML 65 R45.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Sales Returns and Allowances) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Accounting Policies [Abstract]

Accrual for estimated sales returns and allowances $ 689 $ 495

Revenue Recognition, Sales Returns, Reserve for Sales Returns $ 2,600 $ 2,300 $ 2,200

X

- Definition
Revenue Recognition, Reserve for Sales Returns and Allowances
+ References
No definition available.
+ Details

Name: cah_RevenueRecognitionReserveforSalesReturnsandAllowances

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of estimated sales returns.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRecognitionSalesReturnsReserveForSalesReturns

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 66 R46.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Shipping and Handling) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Distribution, selling, general and administrative expenses [Line Items]

Distribution, selling, general and administrative expenses $ 4,533 $ 4,572 $ 4,480

Shipping and Handling [Member]

Distribution, selling, general and administrative expenses [Line Items]

Distribution, selling, general and administrative expenses $ 634 $ 620 $ 622

X

- Definition
[Line Items] for goods and services sold [Table]
+ References
No definition available.
+ Details

Name: cah_GoodsandservicessoldLineItems

Namespace Prefix: cah_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 67 R47.htm IDEA: XBRL DOCUMENT v3.21.2

Basis of Presentation and Summary of Significant Accounting Policies Loss Contingencies (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Loss Contingencies [Line Items]

Gain (Loss) Related to Litigation Settlement $ (1,129) $ (5,741) $ (36)

Total Opioid Litigation [Member]

Loss Contingencies [Line Items]

Gain (Loss) Related to Litigation Settlement $ 1,170 $ 5,630

X

- Definition
Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349
+ Details

Name: us-gaap_GainLossRelatedToLitigationSettlement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingenciesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 68 R48.htm IDEA: XBRL DOCUMENT v3.21.2

Divestitures and Acquisitions (Narrative) (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended

Aug. 02, 2021

Aug. 31, 2018

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Aug. 01, 2018

Business Acquisition

Payments to Acquire Businesses, Net of Cash Acquired $ 3 $ 0 $ 82

Pre-Tax Gain on Divestiture 508

Income (Loss) from Equity Method Investments 2 10

Disposal Group, Including Discontinued Operation, Assets 1,101 0

Disposal Group, Including Discontinued Operation, Liabilities 96 0

naviHealth [Member]

Business Acquisition

Proceeds from Divestiture of Businesses $ 737

Pre-Tax Gain on Divestiture $ 508

Equity Method Investments $ 358

Redeemable Noncontrolling Interest, Equity, Carrying Amount $ 12

Provisional tax benefit related to transaction $ 130

Gain on Sale of Investments 579

Cordis Divestiture

Business Acquisition

Disposal Group, Including Discontinued Operation, Consideration 927

Disposal Group, Including Discontinued Operation, Goodwill (388)

Write-down of assets held for sale (60)

Disposal Group, Including Discontinued Operation, Assets 1,091

Disposal Group, Including Discontinued Operation, Accrued Liabilities 61

Disposal Group, Including Discontinued Operation, Other Liabilities 34

Disposal Group, Including Discontinued Operation, Liabilities 95

Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses) (3)

Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation 9

Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents 109

Disposal Group, Including Discontinued Operation, Inventory 164

Disposal Group, Including Discontinued Operation, Property, Plant and Equipment 90

Disposal Group Including Discontinued Operations Goodwill and Other Intangibles, net 778

Disposal Group, Including Discontinued Operation, Other Assets $ 10

Cordis Divestiture | Subsequent Event

Business Acquisition

Proceeds from Divestiture of Businesses $ 927

naviHealth [Member]

Business Acquisition

Gain on Sale of Investments $ 579

X

- Definition
Disposal Group Including Discontinued Operations Goodwill and Other Intangibles, net
+ References
No definition available.
+ Details

Name: cah_DisposalGroupIncludingDiscontinuedOperationsGoodwillAndOtherIntangiblesNet

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Pre-Tax Gain on Divestiture
+ References
No definition available.
+ Details

Name: cah_PreTaxGainonDivestiture

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Provisional tax benefit related to transaction
+ References
No definition available.
+ Details

Name: cah_Provisionaltaxbenefitrelatedtotransaction

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Write-down of assets held for sale
+ References
No definition available.
+ Details

Name: cah_WriteDownOfAssetsHeldForSale

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount classified as assets attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760
+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324
+ Details

Name: us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.
+ References
No definition available.
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount classified as goodwill attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as inventory attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as other assets attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as other liabilities attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_EquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(a))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(9)(a))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(7)(c))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_GainOnSaleOfInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) for proportionate share of equity method investee's income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(12))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(10))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(f))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570
+ Details

Name: us-gaap_IncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromDivestitureOfBusinesses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph (16)(c)
-URI http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph 15
-URI http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph (12)(c)
-URI http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph 14
-URI http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764
+ Details

Name: us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: cah_NaviHealthAxis=cah_NaviHealthMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: cah_CordisDivestitureAxis=cah_CordisDivestitureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cah_NaviHealthMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 69 R49.htm IDEA: XBRL DOCUMENT v3.21.2

Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Restructuring Charges [Abstract]

Employee-related costs $ 53 $ 66 $ 95

Facility Exit and Other Costs 61 56 30

Total restructuring and employee severance $ 114 $ 122 $ 125

X

- Definition
Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.
+ References
No definition available.
+ Details

Name: cah_FacilityExitAndOtherCosts

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b)(1))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RestructuringChargesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_SeveranceCosts1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 70 R50.htm IDEA: XBRL DOCUMENT v3.21.2

Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Restructuring Reserve [Roll Forward]

Beginning Balance $ 96 $ 72

Additions 75 109

Payments and other adjustments (92) (85)

Ending Balance 79 96

Employee- Related Costs

Restructuring Reserve [Roll Forward]

Beginning Balance 68 64

Additions 49 85

Payments and other adjustments (64) (81)

Ending Balance 53 68

Facility Exit and Other Costs

Restructuring Reserve [Roll Forward]

Beginning Balance 28 8

Additions 26 24

Payments and other adjustments (28) (4)

Ending Balance $ 26 $ 28

X

- Definition
Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585
+ Details

Name: us-gaap_PaymentsForRestructuring

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_RestructuringCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4(b)(2))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringReserveRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 71 R51.htm IDEA: XBRL DOCUMENT v3.21.2

Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Goodwill [Line Items]

Goodwill, Transfers $ 2 $ (5)

Goodwill [Roll Forward]

Beginning balance 8,357 8,378

Foreign currency translation adjustments and other (18) 16

Ending balance 7,989 8,357

Cordis Divestiture

Goodwill [Roll Forward]

Disposal Group, Including Discontinued Operation, Goodwill (388)

Medical

Goodwill [Line Items]

Goodwill, Transfers 0 0

Goodwill [Roll Forward]

Beginning balance 5,700 5,715

Foreign currency translation adjustments and other (18) 15

Ending balance 5,330 5,700

Accumulated goodwill impairment loss 1,400 1,400

Medical | Cordis Divestiture

Goodwill [Roll Forward]

Disposal Group, Including Discontinued Operation, Goodwill (388)

Pharmaceutical

Goodwill [Line Items]

Goodwill, Transfers 2 (5)

Goodwill [Roll Forward]

Beginning balance 2,657 2,663

Foreign currency translation adjustments and other 0 1

Ending balance 2,659 2,657

Accumulated goodwill impairment loss 829 $ 829

Pharmaceutical | Cordis Divestiture

Goodwill [Roll Forward]

Disposal Group, Including Discontinued Operation, Goodwill $ 0

X

- Definition
Amount classified as goodwill attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillForeignCurrencyTranslationGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillImpairedAccumulatedImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillTransfers

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: cah_CordisDivestitureAxis=cah_CordisDivestitureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 72 R52.htm IDEA: XBRL DOCUMENT v3.21.2

Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Indefinite-lived Intangible Assets [Line Items]

Net Intangible $ 12 $ 23

Finite-Lived Intangible Assets [Line Items]

Amortization of Intangible Assets 428 512 $ 531

Gross Intangible 4,916 5,831

Accumulated Amortization 2,823 2,936

Net Intangible $ 2,093 2,895

Weighted- Average Remaining Amortization Period (Years) 10 years

Gross Intangible, Total other intangible assets $ 4,928 5,854

Net Intangible, Total other intangible assets 2,105 2,918

Trademarks and patents

Indefinite-lived Intangible Assets [Line Items]

Net Intangible 12 23

Customer relationships

Finite-Lived Intangible Assets [Line Items]

Gross Intangible 3,330 3,554

Accumulated Amortization 1,989 1,828

Net Intangible $ 1,341 1,726

Weighted- Average Remaining Amortization Period (Years) 11 years

Trademarks, trade names and patents

Finite-Lived Intangible Assets [Line Items]

Gross Intangible $ 551 673

Accumulated Amortization 328 341

Net Intangible $ 223 332

Weighted- Average Remaining Amortization Period (Years) 9 years

Developed technology and other

Finite-Lived Intangible Assets [Line Items]

Gross Intangible $ 1,035 1,604

Accumulated Amortization 506 767

Net Intangible $ 529 $ 837

Weighted- Average Remaining Amortization Period (Years) 10 years

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated amortization of intangible assets, excluding goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 73 R53.htm IDEA: XBRL DOCUMENT v3.21.2

Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Goodwill [Line Items]

Goodwill $ 7,989 $ 8,357 $ 8,378

Amortization of Intangible Assets 428 512 531

Estimated annual amortization of intangible assets - 2022 315

Estimated annual amortization of intangible assets - 2023 287

Estimated annual amortization of intangible assets - 2024 264

Estimated annual amortization of intangible assets - 2025 238

Estimated annual amortization of intangible assets - 2026 212

Medical

Goodwill [Line Items]

Goodwill 5,330 5,700 5,715

Accumulated goodwill impairment loss 1,400 1,400

Pharmaceutical

Goodwill [Line Items]

Goodwill 2,659 2,657 $ 2,663

Accumulated goodwill impairment loss $ 829 $ 829

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillImpairedAccumulatedImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 74 R54.htm IDEA: XBRL DOCUMENT v3.21.2

Leases (Details) - USD ($)
$ in Millions
12 Months Ended

Jul. 01, 2019

Jun. 30, 2019

Jun. 30, 2021

Jun. 30, 2020

Operating Leases, Rent Expense $ 153

Reclassification of deferred rent in accordance with ASC 842 $ 22

Operating Lease, Weighted Average Remaining Lease Term 6 years 6 months 6 years 4 months 24 days

Operating Lease, Weighted Average Discount Rate, Percent 2.90% 2.90%

Finance Lease, Weighted Average Remaining Lease Term 4 years 2 months 12 days 4 years 3 months 18 days

Finance Lease, Weighted Average Discount Rate, Percent 1.50% 2.40%

Minimum

Lessee, Operating Lease, Term of Contract 1 year

Maximum

Lessee, Operating Lease, Term of Contract 21 years

X

- Definition
Reclassification of deferred rent in accordance with ASC 842
+ References
No definition available.
+ Details

Name: cah_ReclassificationofdeferredrentinaccordancewithASC842

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average discount rate for finance lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseTermOfContract

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 75 R55.htm IDEA: XBRL DOCUMENT v3.21.2

Leases Schedule of Lease Costs (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Leases [Abstract]

Operating Lease, Cost $ 119 $ 134

Amortization of right-of-use assets 16 13

Variable lease cost 24 17

Total lease cost $ 159 $ 164

X

- Definition
Amount of amortization expense attributable to right-of-use asset from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of lease cost recognized by lessee for lease contract.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
+ Details

Name: us-gaap_LeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
+ Details

Name: us-gaap_VariableLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 76 R56.htm IDEA: XBRL DOCUMENT v3.21.2

Leases Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Leases [Abstract]

Total operating lease liabilities $ 479 $ 445

Total finance lease liabilities 64 34

Finance Lease, Liability, Current 19 9

Finance Lease, Liability, Noncurrent $ 45 $ 25

Operating Lease, Weighted Average Remaining Lease Term 6 years 6 months 6 years 4 months 24 days

Finance Lease, Weighted Average Remaining Lease Term 4 years 2 months 12 days 4 years 3 months 18 days

Operating Lease, Weighted Average Discount Rate, Percent 2.90% 2.90%

Finance Lease, Weighted Average Discount Rate, Percent 1.50% 2.40%

Total lease liabilities $ 479 $ 445

Finance Lease, Liability, Current 19 9

Other Assets [Member]

Leases [Abstract]

Operating Lease, Right-of-Use Asset 460 426

Operating Lease, Right-of-Use Asset 460 426

Other Liabilities

Leases [Abstract]

Operating Lease, Liability, Noncurrent 374 341

Operating Lease, Liability, Noncurrent 374 341

Other Accrued Liabilities

Leases [Abstract]

Operating Lease, Liability, Current 105 104

Operating Lease, Liability, Current 105 104

Property, Plant and Equipment

Leases [Abstract]

Finance Lease, Right-of-Use Asset, after Accumulated Amortization 63 33

Finance Lease, Right-of-Use Asset, after Accumulated Amortization $ 63 $ 33

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after accumulated amortization, of right-of-use asset from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average discount rate for finance lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_PropertyPlantAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 77 R57.htm IDEA: XBRL DOCUMENT v3.21.2

Leases Supplemental Cash Flow Information (Details) - USD ($)
$ in Millions
12 Months Ended

Jul. 01, 2019

Jun. 30, 2021

Jun. 30, 2020

Operating Lease, Payments $ 115 $ 125

Finance Lease, Principal Payments 15 7

Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 138 150

Right-of-Use Asset Obtained in Exchange for Finance Lease Liability 45 $ 40

Reclassification of deferred rent in accordance with ASC 842 $ 22

ASC 842

New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification (Deprecated 2020-01-31) $ 400 $ 0

X

- Definition
impact of adoption of new accounting standard
+ References
No definition available.
+ Details

Name: cah_Impactofadoptionofnewaccountingstandard

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Reclassification of deferred rent in accordance with ASC 842
+ References
No definition available.
+ Details

Name: cah_ReclassificationofdeferredrentinaccordancewithASC842

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for principal payment on finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980
+ Details

Name: us-gaap_FinanceLeasePrincipalPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeasePayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in right-of-use asset obtained in exchange for finance lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980
+ Details

Name: us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in right-of-use asset obtained in exchange for operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980
+ Details

Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=cah_ASC842Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 78 R58.htm IDEA: XBRL DOCUMENT v3.21.2

Leases Schedule of Future Lease Payments (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

2023 $ 113

2024 86

2025 73

2026 53

Thereafter 146

Total future lease payments 607

Less: leases not yet commenced (1) 3

Less: imputed interest 61

Total lease liabilities 479 $ 445

Total lease liabilities 64 $ 34

Total Lease Liability 543

2022 136

Operating Leases

2023 93

2024 72

2025 65

2026 50

Thereafter 141

Total future lease payments 537

Less: leases not yet commenced (1) 3

Less: imputed interest 55

Total lease liabilities 479

2022 116

Finance Leases

2023 20

2024 14

2025 8

2026 3

Thereafter 5

Total future lease payments 70

Less: leases not yet commenced (1) 0

Less: imputed interest 6

Total lease liabilities 64

2022 $ 20

X

- Definition
Finance Lease Imputed Interest
+ References
No definition available.
+ Details

Name: cah_FinanceLeaseImputedInterest

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Lessee Finance Lease Liability Not Yet Commenced, Amount
+ References
No definition available.
+ Details

Name: cah_LesseeFinanceLeaseLiabilityNotYetCommencedAmount

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee Lease Liability Payments Due After Year Five
+ References
No definition available.
+ Details

Name: cah_LesseeLeaseLiabilityPaymentsDueAfterYearFive

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee Lease Liability Payments Due Year Five
+ References
No definition available.
+ Details

Name: cah_LesseeLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee Lease Liability Payments Due Year Four
+ References
No definition available.
+ Details

Name: cah_LesseeLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee Lease Liability Payments Due Year One
+ References
No definition available.
+ Details

Name: cah_LesseeLeaseLiabilityPaymentsDueYearOne

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee Lease Liability Payments Due Year Three
+ References
No definition available.
+ Details

Name: cah_LesseeLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee Lease Liability Payments Due Year Two
+ References
No definition available.
+ Details

Name: cah_LesseeLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee Operating Lease Liability Not Yet Commenced, Amount
+ References
No definition available.
+ Details

Name: cah_LesseeOperatingLeaseLiabilityNotYetCommencedAmount

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Operating Lease Imputed Interest
+ References
No definition available.
+ Details

Name: cah_OperatingLeaseImputedInterest

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total Lease Liability
+ References
No definition available.
+ Details

Name: cah_TotalLeaseLiability

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total Lease Liability Not Yet Commenced, Amount
+ References
No definition available.
+ Details

Name: cah_TotalLeaseLiabilityNotYetCommencedAmount

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total undiscounted Lease Liability Payments Due for both operating and financing leases
+ References
No definition available.
+ Details

Name: cah_TotalLeaseLiabilityPaymentsDue

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total Lease Liability Undiscounted Excess Amount
+ References
No definition available.
+ Details

Name: cah_TotalLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=cah_OperatingLeaseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=cah_FinanceLeaseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 79 R59.htm IDEA: XBRL DOCUMENT v3.21.2

Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Debt Instrument [Line Items]

Accounts payable $ 23,700 $ 21,374

Other obligations 67 35

Total 6,236 6,775

Less: current portion of long-term obligations and other short-term borrowings 871 10

Long-term obligations, less current portion 5,365 6,765

2.616% Notes due fiscal 2022

Debt Instrument [Line Items]

Notes Payable 572 834

3.2% Notes due 2022

Debt Instrument [Line Items]

Notes Payable 0 236

Floating Rate Notes due fiscal 2022

Debt Instrument [Line Items]

Notes Payable 281 321

3.2% Notes due 2023

Debt Instrument [Line Items]

Notes Payable 564 576

3.079% Notes due fiscal 2024

Debt Instrument [Line Items]

Notes Payable 794 809

3.5% Notes due fiscal 2025

Debt Instrument [Line Items]

Notes Payable 410 413

3.75% Notes due 2025

Debt Instrument [Line Items]

Notes Payable 524 529

3.41% Notes due fiscal 2027

Debt Instrument [Line Items]

Notes Payable 1,216 1,215

4.6% Notes due 2043

Debt Instrument [Line Items]

Notes Payable 341 340

4.5% Notes due 2044

Debt Instrument [Line Items]

Notes Payable 342 342

4.9% Notes due 2045

Debt Instrument [Line Items]

Notes Payable 441 441

4.368% Notes due fiscal 2047

Debt Instrument [Line Items]

Notes Payable 560 560

7.0% Debentures due 2026

Debt Instrument [Line Items]

Notes Payable $ 124 $ 124

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of short-term and long-term debt and lease obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.13,16)
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.16)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910
+ Details

Name: us-gaap_DebtAndCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of long-term debt and lease obligation, classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtAndCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt and lease obligation, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.13,16)
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_OtherBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A3.2Notesdue2022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A3.2Notesdue2023Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A3.079Notesdue2024Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A3.5Notesdue2025Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A3.75Notesdue2026Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A3.41Notesdue2027Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A4.6Notesdue2043Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A4.5Notesdue2044Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A4.9Notesdue2045Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A4.368Notesdue2047Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A7.0Debenturesduefiscal2027Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 80 R60.htm IDEA: XBRL DOCUMENT v3.21.2

Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Jun. 30, 2021

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Line of Credit Facility [Line Items]

Document Fiscal Year Focus 2021

Accounts Payable, Current $ 23,700 $ 23,700 $ 21,374

Notes Payable Repurchased $ 100

Other Borrowings 67 67 35

Gain (Loss) on Extinguishment of Debt (14) (16) 0

Accounts Payable 23,700 23,700 21,400

Maturities of existing long-term obligations and other short-term borrowings - 2020 872 872

Maturities of existing long-term obligations and other short-term borrowings-2021 584 584

Maturities of existing long-term obligations and other short-term borrowings-2022 808 808

Maturities of existing long-term obligations and other short-term borrowings-2023 418 418

Maturities of existing long-term obligations and other short-term borrowings-2024 525 525

Maturities of existing long-term obligations and other short-term borrowings-Thereafter 3,000 3,000

Letter of Credit

Line of Credit Facility [Line Items]

Long-term Line of Credit 1 1

Committed Receivables Sales Facility Program

Line of Credit Facility [Line Items]

Line of Credit Facility, Maximum Amount Outstanding During Period 200

Revolving Credit Facility

Line of Credit Facility [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity 2,000 2,000

Commercial paper

Line of Credit Facility [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity 2,000 2,000

Short Term Credit Facilities

Line of Credit Facility [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity 6

2.616% Notes due fiscal 2022

Line of Credit Facility [Line Items]

Notes Payable Repurchased $ 262 2 247 67

Floating Rate Notes due fiscal 2022

Line of Credit Facility [Line Items]

Notes Payable Repurchased 40 20 8

3.41% Notes due fiscal 2027

Line of Credit Facility [Line Items]

Notes Payable Repurchased 104 24

4.6% Notes due 2043

Line of Credit Facility [Line Items]

Notes Payable Repurchased 6

4.9% Notes due 2045

Line of Credit Facility [Line Items]

Notes Payable Repurchased 5

4.368% Notes due fiscal 2047

Line of Credit Facility [Line Items]

Notes Payable Repurchased 35

2.616% Notes, 3.2% Notes, 3.41% Notes, 4.6% Notes, 4.9% Notes and 4.368% Notes [Member]

Line of Credit Facility [Line Items]

Gain (Loss) on Extinguishment of Debt 9

4.625% Notes due 2020

Line of Credit Facility [Line Items]

Notes Payable Repurchased 500

Gain (Loss) on Extinguishment of Debt 7

3.2% Notes due 2022

Line of Credit Facility [Line Items]

Notes Payable Repurchased 238 11 $ 1

Floating rate notes, 2.616% Notes

Line of Credit Facility [Line Items]

Gain (Loss) on Extinguishment of Debt 1

3.2% notes, 2.616% Notes

Line of Credit Facility [Line Items]

Gain (Loss) on Extinguishment of Debt $ 13

2.4% Notes due 2019

Line of Credit Facility [Line Items]

Notes Payable Repurchased $ 450

X

- Definition
Principal Amount of Notes Payable Repurchased during the year
+ References
No definition available.
+ Details

Name: cah_NotesPayableRepurchased

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_AccountsPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910
+ Details

Name: us-gaap_LineOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum amount borrowed under the credit facility at any time during the period.
+ References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601
+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.13,16)
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_OtherBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=cah_CommittedReceivablesSalesFacilityProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A3.41Notesdue2027Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A4.6Notesdue2043Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A4.9Notesdue2045Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A4.368Notesdue2047Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A2.616Notes3.2Notes3.41Notes4.6Notes4.9Notesand4.368NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A4.625Notesdue2021Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A3.2Notesdue2022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_FloatingRateNotes2616NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A32Notes2616NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A24NotesDue2019Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 81 R61.htm IDEA: XBRL DOCUMENT v3.21.2

Long-Term Obligations and Other Short-Term Borrowings Long-Term Debt (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Jun. 30, 2021

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Debt Instrument [Line Items]

Accounts payable $ 23,700 $ 23,700 $ 21,374

Offer as percentage of principal amount 101.00%

Gain (Loss) on Extinguishment of Debt $ (14) (16) $ 0

Notes Payable Repurchased 100

1.948% Notes due 2019

Debt Instrument [Line Items]

Notes Payable Repurchased 1,000

2.616% Notes due fiscal 2022

Debt Instrument [Line Items]

Notes Payable Repurchased $ 262 2 247 67

3.41% Notes due fiscal 2027

Debt Instrument [Line Items]

Notes Payable Repurchased 104 24

4.368% Notes due fiscal 2047

Debt Instrument [Line Items]

Notes Payable Repurchased 35

2.616% Notes, 3.2% Notes, 3.41% Notes, 4.6% Notes, 4.9% Notes and 4.368% Notes [Member]

Debt Instrument [Line Items]

Gain (Loss) on Extinguishment of Debt 9

Floating Rate Notes due fiscal 2022

Debt Instrument [Line Items]

Notes Payable Repurchased 40 20 8

2.4% Notes due 2019

Debt Instrument [Line Items]

Notes Payable Repurchased 450

3.2% Notes due 2022

Debt Instrument [Line Items]

Notes Payable Repurchased $ 238 11 $ 1

4.6% Notes due 2043

Debt Instrument [Line Items]

Notes Payable Repurchased 6

4.625% Notes due 2020

Debt Instrument [Line Items]

Gain (Loss) on Extinguishment of Debt 7

Notes Payable Repurchased 500

4.9% Notes due 2045

Debt Instrument [Line Items]

Notes Payable Repurchased $ 5

7.0% Debentures due 2026 | Allegiance Corporation

Debt Instrument [Line Items]

Stated interest rate 7.00% 7.00%

X

- Definition
Principal Amount of Notes Payable Repurchased during the year
+ References
No definition available.
+ Details

Name: cah_NotesPayableRepurchased

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage of principal amount that the company is required to offer to purchase certain notes, under certain circumstances.
+ References
No definition available.
+ Details

Name: cah_OfferAsPercentageOfPrincipalAmount

Namespace Prefix: cah_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A1.948Notesdue2019Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A3.41Notesdue2027Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A4.368Notesdue2047Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A2.616Notes3.2Notes3.41Notes4.6Notes4.9Notesand4.368NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A24NotesDue2019Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A3.2Notesdue2022Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A4.6Notesdue2043Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A4.625Notesdue2021Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A4.9Notesdue2045Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_A7.0Debenturesduefiscal2027Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=cah_AllegianceCorporationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 82 R62.htm IDEA: XBRL DOCUMENT v3.21.2

Long-Term Obligations and Other Short-Term Borrowings Other Financing Arrangements (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Debt Instrument [Line Items]

Other obligations $ 67 $ 35

Revolving Credit Facility

Debt Instrument [Line Items]

Maximum borrowing capacity 2,000

Letter of Credit

Debt Instrument [Line Items]

Line of credit 1

Other Short-term Borrowings 0 0

Letter of Credit | Committed Receivables Sales Facility Program

Debt Instrument [Line Items]

Line of credit 31 29

Short Term Credit Facilities

Debt Instrument [Line Items]

Maximum borrowing capacity 6

Short Term Credit Facilities | Committed Receivables Sales Facility Program

Debt Instrument [Line Items]

Maximum borrowing capacity 1,000

Commercial Paper

Debt Instrument [Line Items]

Maximum borrowing capacity 2,000

Other Short-term Borrowings 0 0

Committed Receivables Sales Facility Program

Debt Instrument [Line Items]

Other Short-term Borrowings $ 0 $ 0

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910
+ Details

Name: us-gaap_LineOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.13,16)
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_OtherBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a)(7))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=cah_CommittedReceivablesSalesFacilityProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 83 R63.htm IDEA: XBRL DOCUMENT v3.21.2

Commitments, Contingent Liabilities and Litigation (Details)
$ in Millions
1 Months Ended 12 Months Ended

Aug. 10, 2021

lawsuit

plaintiff

StateAG

Jul. 31, 2021

lawsuit

Jun. 30, 2021

USD ($)

Jun. 30, 2020

USD ($)

Jun. 30, 2019

USD ($)

Loss Contingencies [Line Items]

Income from Settlements of Class Action Lawsuits $ 112 $ 16 $ 94

Cost of Goods and Services Sold 155,689 146,054 138,700

Distribution, selling, general and administrative expenses 4,533 4,572 4,480

Gain (Loss) Related to Litigation Settlement (1,129) (5,741) $ (36)

Opioid Lawsuits | Subsequent Event

Loss Contingencies [Line Items]

Loss Contingency, Lawsuits, Number 3,300

Number of State Attorneys General filing lawsuits | StateAG 25

Opioid Lawsuits State [Domain] | Subsequent Event

Loss Contingencies [Line Items]

Loss Contingency, Lawsuits, Number 2,900

Product Liability Lawsuits | Subsequent Event

Loss Contingencies [Line Items]

Number of lawsuits filed | lawsuit 32

Loss Contingency, Claims Settled, Number | lawsuit 1,300

New York Opioid Stewardship Act

Loss Contingencies [Line Items]

Aggregate Annual Assessment 100

DOJ Investigation

Loss Contingencies [Line Items]

Gain (Loss) Related to Litigation Settlement 13

Alameda County [Member] | Product Liability Lawsuits | Subsequent Event

Loss Contingencies [Line Items]

Number of plaintiffs | plaintiff 5,427

Other Jurisdictions [Member] | Product Liability Lawsuits | Subsequent Event

Loss Contingencies [Line Items]

Number of plaintiffs | plaintiff 37

Product Liability Lawsuits | Subsequent Event

Loss Contingencies [Line Items]

Number of lawsuits filed | lawsuit 419

Minimum

Loss Contingencies [Line Items]

Loss Contingency Accrual 524

Maximum

Loss Contingencies [Line Items]

Loss Contingency, Estimate of Possible Loss 1,030

Total Opioid Litigation [Member]

Loss Contingencies [Line Items]

Estimated Litigation Liability 6,730

Loss Contingency, Estimate of Possible Loss 6,370

Gain (Loss) Related to Litigation Settlement 1,170 5,630

Litigation Settlement, Expense 1,170 $ 5,630

Total Opioid Litigation [Member] | Other Accrued Liabilities

Loss Contingencies [Line Items]

Estimated Litigation Liability $ 405

Private Parties [Member] | Opioid Lawsuits | Subsequent Event

Loss Contingencies [Line Items]

Loss Contingency, Lawsuits, Number | lawsuit 442

Class Action Lawsuits [Member] | Private Parties [Member] | Opioid Lawsuits | Subsequent Event

Loss Contingencies [Line Items]

Loss Contingency, Lawsuits, Number | lawsuit 128

X

- Definition
Aggregate Annual Assessment
+ References
No definition available.
+ Details

Name: cah_AggregateAnnualAssessment

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Income from Settlements of Class Action Lawsuits
+ References
No definition available.
+ Details

Name: cah_IncomefromSettlementsofClassActionLawsuits

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Loss Contingency, Lawsuits, Number
+ References
No definition available.
+ Details

Name: cah_LossContingencyLawsuitsNumber

Namespace Prefix: cah_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of State Attorneys General filing lawsuits
+ References
No definition available.
+ Details

Name: cah_NumberofStateAttorneysGeneralfilinglawsuits

Namespace Prefix: cah_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349
+ Details

Name: us-gaap_GainLossRelatedToLitigationSettlement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LitigationReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.
+ References
No definition available.
+ Details

Name: us-gaap_LitigationSettlementExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingenciesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of loss contingency liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349
+ Details

Name: us-gaap_LossContingencyAccrualAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of claims settled.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingencyClaimsSettledNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248
+ Details

Name: us-gaap_LossContingencyEstimateOfPossibleLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The total number of new claims filed pertaining to a loss contingency during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349
+ Details

Name: us-gaap_LossContingencyNewClaimsFiledNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of plaintiffs that have filed claims pertaining to a loss contingency.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingencyNumberOfPlaintiffs

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_LitigationCaseAxis=cah_OpioidLawsuitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_LitigationCaseAxis=cah_OpioidLawsuitsStateDomain

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_LitigationCaseAxis=cah_DOJInvestigationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=cah_AlamedaCountyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: cah_PlaintiffTypeAxis=cah_PrivatePartiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 84 R64.htm IDEA: XBRL DOCUMENT v3.21.2

Income Taxes (Schedule of Income before Income Tax, Domestic and Foreign) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Income Tax Disclosure [Abstract]

Document Fiscal Year Focus 2021

U.S. operations $ (47) $ (4,056) $ 1,478

Non-U.S. operations 370 284 273

Earnings/(loss) before income taxes $ 323 $ (3,772) $ 1,751

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.3)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.3)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 85 R65.htm IDEA: XBRL DOCUMENT v3.21.2

Income Taxes (Schedule of Components of Income Tax Expense (Benefit), Current and Deferred) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Current:

Federal $ (989) $ 659 $ 295

State and local 92 154 89

Non-U.S. 112 69 85

Total current (785) 882 469

Deferred:

Federal 539 (822) (28)

State and local (28) (127) (37)

Non-U.S. (15) (12) (18)

Total deferred 496 (961) (83)

Provision for/(benefit from) income taxes $ (289) $ (79) $ 386

X

- Definition
Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_CurrentFederalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_CurrentForeignTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.2)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817
+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredFederalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredForeignIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.2)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 86 R66.htm IDEA: XBRL DOCUMENT v3.21.2

Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Income Tax Disclosure [Abstract]

Provision at Federal statutory rate 21.00% 21.00% 21.00%

State and local income taxes, net of federal benefit 3.20% 2.50% 0.90%

Effective Income Tax Rate Reconciliation, Tax Effect of Foreign Operations 0.70% 0.00% (0.70%)

Nondeductible/nontaxable items (2) 1.60% 0.20% 0.80%

Goodwill impairment 7.00% 0.00% 0.00%

Effective Income Tax Rate Reconciliation, Withholding Taxes 9.00% (0.30%) 0.70%

Change in valuation allowances (1.40%) 1.50% 4.50%

China tax related to divestiture (13.60%) (0.40%) (0.10%)

Effective Income Tax Rate Reconciliation Legal Entity Reorganization Reconciling Items Percent 0.00% 0.00% (3.60%)

Effective Income Tax Reconciliation, Opioid Litigation 17.70% (23.20%) 0.00%

Effective Income Tax Rate Reconciliation, Loss Carryback Claims (129.90%) 0.00% 0.00%

Other (2) 1.70% 0.60% (2.10%)

US Taxes on International Income (6.70%) 0.20% 0.70%

Effective income tax rate (89.70%) 2.10% 22.10%

X

- Definition
Effective Income Tax Rate Reconciliation Legal Entity Reorganization Reconciling Items Percent
+ References
No definition available.
+ Details

Name: cah_EffectiveIncomeTaxRateReconciliationLegalEntityReorganizationReconcilingItemsPercent

Namespace Prefix: cah_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Effective Income Tax Rate Reconciliation, Loss Carryback Claims
+ References
No definition available.
+ Details

Name: cah_EffectiveIncomeTaxRateReconciliationLossCarrybackClaims

Namespace Prefix: cah_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Effective Income Tax Rate Reconciliation, Tax Effect of Foreign Operations
+ References
No definition available.
+ Details

Name: cah_EffectiveIncomeTaxRateReconciliationTaxEffectOfForeignOperations

Namespace Prefix: cah_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Effective Income Tax Rate Reconciliation, Withholding Taxes
+ References
No definition available.
+ Details

Name: cah_EffectiveIncomeTaxRateReconciliationWithholdingTaxes

Namespace Prefix: cah_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Effective Income Tax Reconciliation, Opioid Litigation
+ References
No definition available.
+ Details

Name: cah_EffectiveIncomeTaxReconciliationOpioidLitigation

Namespace Prefix: cah_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Effective Tax Rate Reconciliation, Impact of Resolutions with IRS and other related matters
+ References
No definition available.
+ Details

Name: cah_EffectiveTaxRateReconciliationImpactOfResolutionsWithIRSAndOtherRelatedMatters

Namespace Prefix: cah_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Effective Tax Rate Reconciliation, US Taxes on International Income
+ References
No definition available.
+ Details

Name: cah_EffectiveTaxRateReconciliationUSTaxesOnInternationalIncome

Namespace Prefix: cah_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.
+ References
No definition available.
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 87 R67.htm IDEA: XBRL DOCUMENT v3.21.2

Income Taxes (Narrative) (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Jun. 30, 2019

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2018

Income Taxes

Effective Income Tax Rate Reconciliation, Percent (89.70%) 2.10% 22.10%

Income Tax Expense (Benefit) $ (289) $ (79) $ 386

Effective Tax Rate Impact From Certain Foreign Jurisdictions $ 20

Provision at Federal statutory rate 21.00% 21.00% 21.00%

Federal $ (539) $ 822 $ 28

Deferred tax assets on tax credit carryforwards (805) (589)

Valuation allowance on operating loss carryforwards 477

Unrecognized tax benefits that would impact effective tax rate $ 303 849 753 303

Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions 223 78 39

Unrecognized tax benefits 456 932 998 456 $ 423

Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 271 6 25

Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 1 3 0

Unrecognized tax benefits, interest and penalties accrued 122 49 146 122

Unrecognized tax benefits, interest and penalties $ 16 $ 8

Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense 825

Deferred income taxes and other liabilities 9,670 8,594

Net Operating Loss Carryback

Income Taxes

Income Tax Expense (Benefit) (424)

Income Taxes Receivable 974

Deferred income taxes and other liabilities 700

Minimum

Income Taxes

Estimated range of decrease in unrecognized tax benefits within the next 12 months 0

Maximum

Income Taxes

Estimated range of decrease in unrecognized tax benefits within the next 12 months 20

Federal

Income Taxes

Tax credit carryforwards 272

State and Local

Income Taxes

Tax credit carryforwards 3,900

Foreign

Income Taxes

Tax credit carryforwards 2,300

Patient Recovery Business [Member]

Income Taxes

Amount CareFusion is liable under tax matters agreement in the event amount must be paid to the taxing authority 12 19

CareFusion [Member]

Income Taxes

Amount CareFusion is liable under tax matters agreement in the event amount must be paid to the taxing authority 72 176

Total Opioid Litigation [Member]

Income Taxes

Estimated Litigation Liability 6,730

Income Tax Expense (Benefit) 228 488

Unrecognized tax benefits that would impact effective tax rate 219 469

Litigation Settlement, Expense $ 1,170 $ 5,630

X

- Definition
Effective Tax Rate Impact From Certain Foreign Jurisdictions
+ References
No definition available.
+ Details

Name: cah_EffectiveTaxRateImpactFromCertainForeignJurisdictions

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.
+ References
No definition available.
+ Details

Name: cah_IndemnificationReceivable

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (d)(3)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319
+ Details

Name: us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredFederalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(10))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910
+ Details

Name: us-gaap_IncomeTaxReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LitigationReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.
+ References
No definition available.
+ Details

Name: us-gaap_LitigationSettlementExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_OperatingLossCarryforwardsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319
+ Details

Name: us-gaap_TaxCreditCarryforwardAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_TaxCreditCarryforwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income tax expense from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 10B
-URI http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(4)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: cah_NetOperatingLossCarrybackAxis=cah_NetOperatingLossCarrybackMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: cah_TaxMatterAxis=cah_CareFusionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 88 R68.htm IDEA: XBRL DOCUMENT v3.21.2

Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Deferred income tax assets:

Receivable basis difference $ 40 $ 39

Accrued liabilities 874 607

Share-based compensation 38 38

Loss and tax credit carryforwards 805 589

Deferred tax assets related to uncertain tax positions 35 52

Other 16 87

Total deferred income tax assets 1,808 1,412

Deferred Tax Assets, Valuation Allowance (515) (470)

Deferred Tax Assets, Net 1,293 942

Deferred income tax liabilities:

Inventory basis differences (1,119) (1,083)

Property-related (375) (327)

Other (733) (751)

Deferred Tax Liabilities, Deferred Expense, Reserves and Accruals (975) 0

Deferred Tax Liabilities, Other (23) 0

Total deferred income tax liabilities (3,225) (2,161)

Net deferred income tax liability $ (1,932) $ (1,219)

X

- Definition
Deferred tax assets related to uncertain tax positions
+ References
No definition available.
+ Details

Name: cah_DeferredTaxAssetsRelatedtouncertaintaxpositions

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ComponentsOfDeferredTaxAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(15)(b)(2))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(2))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredIncomeTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from reserves and accruals.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 89 R69.htm IDEA: XBRL DOCUMENT v3.21.2

Income Taxes (Schedule of Deferred Tax Assets and Liabilities After Netting by Tax Jurisdiction) (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Income Tax Disclosure [Abstract]

Deferred Income Taxes and Other Assets, Noncurrent $ 52 $ 39

Deferred Income Taxes and Other Tax Liabilities, Noncurrent 1,981 1,258

Deferred Income Taxes and Other Tax Liabilities, Transferred to Held for Sale, Noncurrent (3) 0

Net deferred income tax liability $ (1,932) $ (1,219)

X

- Definition
Deferred Income Taxes and Other Tax Liabilities, Transferred to Held for Sale, Noncurrent
+ References
No definition available.
+ Details

Name: cah_DeferredIncomeTaxesAndOtherTaxLiabilitiesTransferredToHeldForSaleNoncurrent

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other tax liabilities expected to be paid after one year or operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 90 R70.htm IDEA: XBRL DOCUMENT v3.21.2

Income Taxes (Schedule of Unrecognized Tax Benefits Roll Forward) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Income Tax Contingency [Line Items]

Current Federal Tax Expense (Benefit) $ (989) $ 659 $ 295

Current State and Local Tax Expense (Benefit) 92 154 89

Current Foreign Tax Expense (Benefit) 112 69 85

Current Income Tax Expense (Benefit) (785) 882 469

Deferred Federal Income Tax Expense (Benefit) 539 (822) (28)

Deferred State and Local Income Tax Expense (Benefit) (28) (127) (37)

Deferred Foreign Income Tax Expense (Benefit) (15) (12) (18)

Deferred Income Tax Expense (Benefit) 496 (961) (83)

Income Tax Expense (Benefit) (289) (79) 386

Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]

Balance at beginning of fiscal year 998 456 423

Additions for tax positions of the current year 121 500 24

Additions for tax positions of prior years 223 78 39

Reductions for tax positions of prior years (138) (27) (5)

Settlements with tax authorities (271) (6) (25)

Expiration of the statute of limitations (1) (3) 0

Balance at end of fiscal year $ 932 $ 998 $ 456

X

- Definition
Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_CurrentFederalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_CurrentForeignTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.2)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817
+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredFederalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredForeignIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.2)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeTaxContingencyLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 10B
-URI http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(4)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 91 R71.htm IDEA: XBRL DOCUMENT v3.21.2

Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Liabilities:

Disposal Group, Including Discontinued Operation, Assets $ 1,101 $ 0

Disposal Group, Including Discontinued Operation, Liabilities 96 0

Fair Value, Measurements, Recurring

Assets:

Cash equivalents 1,883 721

Other investments 126 114

Liabilities:

Forward contracts 42 53

Fair Value, Measurements, Recurring | Level 1

Assets:

Cash equivalents 1,883 721

Other investments 126 114

Liabilities:

Forward contracts 0 0

Fair Value, Measurements, Recurring | Level 2

Assets:

Cash equivalents 0 0

Other investments 0 0

Liabilities:

Forward contracts 42 53

Fair Value, Measurements, Recurring | Level 3

Assets:

Cash equivalents 0 0

Other investments 0 0

Liabilities:

Forward contracts 0 $ 0

Fair Value, Nonrecurring

Liabilities:

Disposal Group, Including Discontinued Operation, Assets $ 1,100

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as assets attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760
+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958
+ Details

Name: us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258
+ Details

Name: us-gaap_InvestmentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 92 R72.htm IDEA: XBRL DOCUMENT v3.21.2

Fair Value Measurements (Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis Using Unobservable Inputs (Level 3)) (Details) - Fair Value, Measurements, Recurring - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Forward contracts $ 42 $ 53

Level 1

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Forward contracts 0 0

Level 2

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Forward contracts 42 53

Level 3

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Forward contracts $ 0 $ 0

X

- Definition
Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958
+ Details

Name: us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 93 R73.htm IDEA: XBRL DOCUMENT v3.21.2

Fair Value Measurements (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Disposal Group, Including Discontinued Operation, Liabilities $ 96 $ 0

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 94 R74.htm IDEA: XBRL DOCUMENT v3.21.2

Financial Instruments (Schedule of the Fair Value of Assets and Liabilities Related to Derivatives Designated as Hedging Instruments) (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Derivatives, Fair Value [Line Items]

Total assets $ 46 $ 74

Total liabilities 4 21

Designated as Hedging Instrument | Cash Flow Hedging | Foreign Currency Contracts | Prepaid Expenses and Other

Derivatives, Fair Value [Line Items]

Total assets 5 0

Designated as Hedging Instrument | Cash Flow Hedging | Foreign Currency Contracts | Other Accrued Liabilities

Derivatives, Fair Value [Line Items]

Total liabilities 4 4

Designated as Hedging Instrument | Cash Flow Hedging | Interest Rate Swaps | Deferred Income Taxes and Other Liabilities

Derivatives, Fair Value [Line Items]

Total liabilities 0 16

Designated as Hedging Instrument | Cash Flow Hedging | Commodity Contracts | Other Accrued Liabilities

Derivatives, Fair Value [Line Items]

Total liabilities 0 1

Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swaps | Other Assets [Member]

Derivatives, Fair Value [Line Items]

Total assets 1 27

Designated as Hedging Instrument | Fair Value Hedging | Cross Currency Interest Rate Contract [Member] | Other Assets [Member]

Derivatives, Fair Value [Line Items]

Total assets 6 47

Designated as Hedging Instrument | Fair Value Hedging | Cross Currency Interest Rate Contract [Member] | Prepaid Expenses and Other

Derivatives, Fair Value [Line Items]

Total assets $ 34 $ 0

X

- Definition
Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 4D
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 4D
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativesFairValueLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=cah_DeferredIncomeTaxesandOtherLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CommodityContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 95 R75.htm IDEA: XBRL DOCUMENT v3.21.2

Financial Instruments (Narrative) (Details)
€ in Millions, ¥ in Millions, $ in Millions
12 Months Ended

Jun. 30, 2021

USD ($)

Jun. 30, 2020

USD ($)

Jun. 30, 2020

JPY (¥)

Sep. 30, 2019

USD ($)

Sep. 30, 2019

EUR (€)

Jun. 30, 2019

USD ($)

Derivative [Line Items]

Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments $ 0 $ 0

Interest Rate Swaps

Derivative [Line Items]

Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge 18

Currency Swap [Member]

Derivative [Line Items]

Derivative Liability, Notional Amount 600 ¥ 64,000 $ 233 € 200

Foreign Currency Contracts

Derivative [Line Items]

Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 7 35

Interest Income (Expense), Nonoperating, Net 19 17

Cash Flow Hedging

Derivative [Line Items]

Derivative Liability, Notional Amount 200

Derivates, Hedge Discontinuances, Hedging Instrument Terminated, Amount 200

Fair Value Hedging | Interest Rate Swaps

Derivative [Line Items]

Derivative, notional amount 200 550

Cash Flow Hedging | Foreign Currency Contracts

Derivative [Line Items]

Derivative, notional amount 436 328

Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swaps

Derivative [Line Items]

Derivative Liability, Notional Amount 200

Derivatives, matured notional amounts 200

Derivates, Hedge Discontinuances, Hedging Instrument Terminated, Amount $ 550

Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge $ 112

Derivatives, terminated notional amounts $ 163

X

- Definition
Derivates, Hedge Discontinuances, Hedging Instrument Terminated, Amount
+ References
No definition available.
+ Details

Name: cah_DerivatesHedgeDiscontinuancesHedgingInstrumentTerminatedAmount

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount
+ References
No definition available.
+ Details

Name: cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Amount
+ References
No definition available.
+ Details

Name: cah_DerivativesHedgeDiscontinuancesTerminationofHedgingInstrumentAmount

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986
+ Details

Name: us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount as of the balance sheet date of the unamortized adjustment to the carrying value of an interest-bearing hedged item made under an effective interest rate fair value hedge that is amortized upon discontinuation of the interest rate fair value hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 35
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124267147&loc=d3e75592-113984
+ Details

Name: us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Nominal or face amount used to calculate payments on the derivative asset.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959
+ Details

Name: us-gaap_DerivativeAssetNotionalAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Nominal or face amount used to calculate payments on the derivative liability.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959
+ Details

Name: us-gaap_DerivativeLiabilityNotionalAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net amount of nonoperating interest income (expense).
+ References
No definition available.
+ Details

Name: us-gaap_InterestIncomeExpenseNonoperatingNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4CCC
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 96 R76.htm IDEA: XBRL DOCUMENT v3.21.2

Financial Instruments (Schedule of Outstanding Instruments, Fair Value Hedges) (Details) - Interest Rate Swaps - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Derivative [Line Items]

Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge $ 18

Fair Value Hedging

Derivative [Line Items]

Notional Amount $ 200 $ 550

Designated as Hedging Instrument | Fair Value Hedging

Derivative [Line Items]

Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge 112

Derivatives, matured notional amounts $ 200

X

- Definition
Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount
+ References
No definition available.
+ Details

Name: cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount as of the balance sheet date of the unamortized adjustment to the carrying value of an interest-bearing hedged item made under an effective interest rate fair value hedge that is amortized upon discontinuation of the interest rate fair value hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 35
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124267147&loc=d3e75592-113984
+ Details

Name: us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Nominal or face amount used to calculate payments on the derivative asset.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959
+ Details

Name: us-gaap_DerivativeAssetNotionalAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 97 R77.htm IDEA: XBRL DOCUMENT v3.21.2

Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Interest Rate Contracts Designated as Fair Value Hedges) (Details) - Fair Value Hedging - Interest Expense, Net - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Interest Rate Swaps

Derivative [Line Items]

Gain/(loss) on derivative $ (8) $ 106 $ 9

Fixed-Rate Debt

Derivative [Line Items]

Gain/(loss) on derivative $ 8 $ (106) $ (9)

X

- Definition
Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959
+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=cah_FixedRateDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 98 R78.htm IDEA: XBRL DOCUMENT v3.21.2

Financial Instruments (Schedule of Outstanding Instruments, Cash Flow Hedges) (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Cash Flow Hedging

Derivative [Line Items]

Derivative Liability, Notional Amount $ 200

Fair Value Hedging | Interest Rate Swaps

Derivative [Line Items]

Notional Amount $ 200 550

Cash Flow Hedging | Foreign Currency Contracts

Derivative [Line Items]

Notional Amount 436 328

Cash Flow Hedging | Commodity Contracts

Derivative [Line Items]

Notional Amount 16

Cash Flow Hedging | Forward Contracts [Member]

Derivative [Line Items]

Notional Amount $ 200

Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swaps

Derivative [Line Items]

Derivative Liability, Notional Amount $ 200

X

- Definition
Nominal or face amount used to calculate payments on the derivative asset.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959
+ Details

Name: us-gaap_DerivativeAssetNotionalAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Nominal or face amount used to calculate payments on the derivative liability.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959
+ Details

Name: us-gaap_DerivativeLiabilityNotionalAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CommodityContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 99 R79.htm IDEA: XBRL DOCUMENT v3.21.2

Financial Instruments (Schedule of Gain/(Loss) Included in AOCI for Derivative Instruments Designated as Cash Flow Hedges) (Details) - Cash Flow Hedging - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Forward Contracts [Member]

Derivative [Line Items]

Gain/(loss) included in AOCI for derivative instruments designated as cash flow hedges $ 16 $ (16) $ 0

Commodity Contracts

Derivative [Line Items]

Gain/(loss) included in AOCI for derivative instruments designated as cash flow hedges 1 1 (5)

Foreign Currency Contracts

Derivative [Line Items]

Gain/(loss) included in AOCI for derivative instruments designated as cash flow hedges $ 5 $ (8) $ 5

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121558989&loc=d3e80720-113993

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CommodityContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 100 R80.htm IDEA: XBRL DOCUMENT v3.21.2

Financial Instruments (Schedule of Gain/(Loss) Reclassified from AOCI into Earnings for Derivative Instruments Designated as Cash Flow Hedges) (Details) - Cash Flow Hedging - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Foreign Currency Contracts | Revenue

Derivative [Line Items]

Gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges $ (12) $ 7 $ 2

Foreign Currency Contracts | Cost of Products Sold

Derivative [Line Items]

Gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges (2) 1 0

Foreign Currency Contracts | SG&A Expenses

Derivative [Line Items]

Gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges 4 0 1

Forward Contracts [Member] | Interest Expense, Net

Derivative [Line Items]

Gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges 2 2 2

Commodity Contracts | SG&A Expenses

Derivative [Line Items]

Gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges $ 6 $ (5) $ 0

X

- Definition
The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959
+ Details

Name: us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CommodityContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 101 R81.htm IDEA: XBRL DOCUMENT v3.21.2

Financial Instruments (Schedule of Outstanding Instruments, Economic Hedges) (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Foreign Currency Contracts | Not Designated as Hedging Instrument

Derivative [Line Items]

Notional Amount $ 254 $ 325

X

- Definition
Nominal or face amount used to calculate payments on the derivative asset.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959
+ Details

Name: us-gaap_DerivativeAssetNotionalAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 102 R82.htm IDEA: XBRL DOCUMENT v3.21.2

Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Derivatives Not Designated as Hedging Instrument) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Not Designated as Hedging Instrument | Foreign Currency Contracts | Other Income, Net

Derivative [Line Items]

Gain/(loss) recognized in earnings for economic (non-designated) derivative instruments $ (8) $ (11) $ (13)

X

- Definition
Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4CC
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959
+ Details

Name: us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 103 R83.htm IDEA: XBRL DOCUMENT v3.21.2

Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Carrying Amount of Long-Term and other Short-Term Borrowings $ 6,236 $ 6,775

Carrying amount 6,236 6,775

Level 2

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Estimated fair value $ 6,751 $ 7,273

X

- Definition
Carrying Amount of Long-Term and other Short-Term Borrowings
+ References
No definition available.
+ Details

Name: cah_CarryingAmountofLongTermandotherShortTermBorrowings

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of short-term and long-term debt and lease obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.13,16)
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.16)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910
+ Details

Name: us-gaap_DebtAndCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69C
-URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1D
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611
+ Details

Name: us-gaap_DebtInstrumentFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 104 R84.htm IDEA: XBRL DOCUMENT v3.21.2

Financial Instruments (Schedule of Fair Value Gain Loss Derivative Instrument) (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Fair Value Hedging | Interest Rate Swaps

Derivative [Line Items]

Notional Amount $ 200 $ 550

Fair Value Gain/(Loss) 1 27

Cash Flow Hedging | Foreign Currency Contracts

Derivative [Line Items]

Notional Amount 690 653

Fair Value Gain/(Loss) 1 (4)

Cash Flow Hedging | Forward Contracts [Member]

Derivative [Line Items]

Notional Amount 0 200

Fair Value Gain/(Loss) 0 (16)

Cash Flow Hedging | Currency Swap [Member]

Derivative [Line Items]

Notional Amount 833 833

Fair Value Gain/(Loss) 40 47

Cash Flow Hedging | Commodity Contracts

Derivative [Line Items]

Notional Amount 0 16

Fair Value Gain/(Loss) $ 0 $ (1)

X

- Definition
Fair value of the assets less the liabilities of a derivative or group of derivatives.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Nominal or face amount used to calculate payment on derivative.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959
+ Details

Name: us-gaap_DerivativeNotionalAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CommodityContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 105 R85.htm IDEA: XBRL DOCUMENT v3.21.2

Shareholders' Equity (Narrative) (Details)
$ / shares in Units, $ in Millions
12 Months Ended 36 Months Ended

Jun. 30, 2021

USD ($)

$ / shares

shares

Jun. 30, 2020

USD ($)

$ / shares

shares

Jun. 30, 2019

USD ($)

$ / shares

shares

Jun. 30, 2020

USD ($)

shares

Class of Stock [Line Items]

Treasury shares acquired | $ $ 200 $ 350 $ 600

Payments for Repurchase of Common Stock | $ 200 350 600

Retained earnings decrease | $ $ (1,205) $ (1,170) $ (1,170)

Common shares, authorized | shares 755,000,000 755,000,000 755,000,000

Common Class A

Class of Stock [Line Items]

Common shares, authorized | shares 750,000,000

Common Stock, Voting Rights, Votes 1

Common Class B

Class of Stock [Line Items]

Common shares, authorized | shares 5,000,000

Treasury Shares

Class of Stock [Line Items]

Treasury shares acquired | $ $ 200 $ 350 $ 600 $ 1,150

Treasury Stock, Shares, Acquired | shares 3,700,000 7,000,000 11,500,000

Payments for Repurchase of Common Stock | $ $ 200

Treasury shares acquired, average price per share (in usd per share) | $ / shares $ 54.40 $ 48.00 $ 52.32

Treasury Stock Acquired Shares | shares 7,300,000

X

- Definition
Common Stock, Voting Rights, Votes
+ References
No definition available.
+ Details

Name: cah_CommonStockVotingRightsVotes

Namespace Prefix: cah_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Treasury Stock Acquired Shares
+ References
No definition available.
+ Details

Name: cah_TreasuryStockAcquiredShares

Namespace Prefix: cah_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total cost of shares repurchased divided by the total number of shares repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockAcquiredAverageCostPerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares that have been repurchased during the period and are being held in treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_TreasuryStockSharesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_TreasuryStockValueAcquiredCostMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 106 R86.htm IDEA: XBRL DOCUMENT v3.21.2

Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

AOCI Attributable to Parent, Net of Tax [Roll Forward]

Balance at beginning of period $ 1,792 $ 6,330 $ 6,059

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 70 (25) 13

Balance at end of period 1,794 1,792 6,330

Foreign Currency Translation Adjustments and other

AOCI Attributable to Parent, Net of Tax [Roll Forward]

Balance at beginning of period (92) (95)

Other comprehensive income/(loss), net before reclassifications 46 3

Amounts reclassified to earnings 0 0

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 46 3

Balance at end of period (46) (92) (95)

Unrealized Gain/(Loss) on Derivatives, net of tax

AOCI Attributable to Parent, Net of Tax [Roll Forward]

Balance at beginning of period (12) 16

Other comprehensive income/(loss), net before reclassifications 22 (23)

Amounts reclassified to earnings 2 (5)

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 24 (28)

Balance at end of period 12 (12) 16

AOCI Including Portion Attributable to Noncontrolling Interest [Member]

AOCI Attributable to Parent, Net of Tax [Roll Forward]

Balance at beginning of period (104)

Balance at end of period (34) (104)

Accumulated Other Comprehensive Loss

AOCI Attributable to Parent, Net of Tax [Roll Forward]

Balance at beginning of period (104) (79) (92)

Other comprehensive income/(loss), net before reclassifications 68 (20)

Amounts reclassified to earnings 2 (5)

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 70 (25) 13

Balance at end of period $ (34) $ (104) $ (79)

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_AOCIAttributableToParentNetOfTaxRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067
+ Details

Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (a)(3)(iii)(03)
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 107 R87.htm IDEA: XBRL DOCUMENT v3.21.2

Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Earnings Per Share [Abstract]

Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $ 612 $ (3,693) $ 1,365

Net earnings attributable to noncontrolling interest (1) (3) (2)

Net Income (Loss) Attributable to Parent $ 611 $ (3,696) $ 1,363

Weighted-average common shares–basic (in shares) 292 293 300

Effect of dilutive securities:

Employee stock options, restricted share units, and performance share units (in shares) 2 0 1

Weighted-average common shares–diluted (in shares) 294 293 301

Diluted earnings per common share attributable to Cardinal Health, Inc.:

Earnings Per Share, Basic $ 2.09 $ (12.61) $ 4.55

Earnings Per Share, Diluted $ 2.08 $ (12.61) $ 4.53

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067
+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 108 R88.htm IDEA: XBRL DOCUMENT v3.21.2

Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) - shares
shares in Thousands
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Earnings Per Share [Abstract]

Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares) 3,000 6,000 7,000

shares that would be antidilutive as a result of net loss 2,000

X

- Definition
shares that would be antidilutive as a result of net loss
+ References
No definition available.
+ Details

Name: cah_Sharesthatwouldbeantidilutiveasaresultofnetloss

Namespace Prefix: cah_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 109 R89.htm IDEA: XBRL DOCUMENT v3.21.2

Segment Information (Narrative) (Details)
$ in Millions
12 Months Ended

Jun. 30, 2021

USD ($)

segment

Jun. 30, 2020

USD ($)

Jun. 30, 2019

USD ($)

Segment Reporting Information [Line Items]

Pre-Tax Gain on Divestiture $ 508

Gain (Loss) Related to Litigation Settlement $ (1,129) $ (5,741) (36)

Project costs on investment and other spending $ 27 69 $ 55

Number of Reportable Segments | segment 2

Sterile Surgical Gown Recall [Member] [Domain]

Segment Reporting Information [Line Items]

Inventory Recall Expense 85

New York Opioid Stewardship Act

Segment Reporting Information [Line Items]

Estimated Liability for New York Opioid Stewardship Act $ 41

naviHealth [Member]

Segment Reporting Information [Line Items]

Gain on Sale of Investments 579

Gain on Divestiture After Tax 493

Total Opioid Litigation [Member]

Segment Reporting Information [Line Items]

Gain (Loss) Related to Litigation Settlement $ 1,170 $ 5,630

X

- Definition
Estimated Liability for New York Opioid Stewardship Act
+ References
No definition available.
+ Details

Name: cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Gain on Divestiture After Tax
+ References
No definition available.
+ Details

Name: cah_GainonDivestitureAfterTax

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Pre-Tax Gain on Divestiture
+ References
No definition available.
+ Details

Name: cah_PreTaxGainonDivestiture

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.
+ References
No definition available.
+ Details

Name: cah_ProjectCostsOnInvestmentAndOtherSpending

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349
+ Details

Name: us-gaap_GainLossRelatedToLitigationSettlement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(a))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(9)(a))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(7)(c))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_GainOnSaleOfInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_InventoryRecallExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599
+ Details

Name: us-gaap_NumberOfReportableSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: cah_SterileSurgicalGownRecallAxis=cah_SterileSurgicalGownRecallMemberDomain

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cah_NaviHealthMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 110 R90.htm IDEA: XBRL DOCUMENT v3.21.2

Segment Information (Revenue by Reportable Segment) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Segment Reporting Information [Line Items]

Revenue $ 162,467 $ 152,922 $ 145,534

Non-US [Member]

Segment Reporting Information [Line Items]

Revenue 4,727 4,232 4,071

United States

Segment Reporting Information [Line Items]

Revenue 157,756 148,707 141,479

Operating Segments

Segment Reporting Information [Line Items]

Revenue 162,483 152,939 145,550

Operating Segments | Pharmaceutical

Segment Reporting Information [Line Items]

Revenue 145,796 137,495 129,917

Operating Segments | Pharmaceutical | Pharmaceutical Distribution and Specialty [Member]

Segment Reporting Information [Line Items]

Revenue 144,988 136,693 129,067

Operating Segments | Pharmaceutical | Nuclear Precision Health Services [Member]

Segment Reporting Information [Line Items]

Revenue 808 802 850

Operating Segments | Medical

Segment Reporting Information [Line Items]

Revenue 16,687 15,444 15,633

Operating Segments | Medical | Medical distribution and products [Member]

Segment Reporting Information [Line Items]

Revenue 14,485 13,429 13,833

Operating Segments | Medical | Cardinal Health At Home Solutions [Member]

Segment Reporting Information [Line Items]

Revenue 2,202 2,015 1,800

Corporate

Segment Reporting Information [Line Items]

Revenue $ (16) $ (17) $ (16)

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeSolutionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 111 R91.htm IDEA: XBRL DOCUMENT v3.21.2

Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]

Total operating earnings $ 472 $ (4,098) $ 2,060

Operating Segments

Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]

Total operating earnings 2,261 2,416 2,410

Operating Segments | Pharmaceutical

Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]

Total operating earnings 1,684 1,753 1,834

Operating Segments | Medical

Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]

Total operating earnings 577 663 576

Corporate

Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]

Total operating earnings $ (1,789) $ (6,514) $ (350)

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 112 R92.htm IDEA: XBRL DOCUMENT v3.21.2

Segment Information (Depreciation and Amortization and Additions to Property and Equipment by Reportable Segment) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Segment Reporting Information [Line Items]

Total depreciation and amortization $ 783 $ 913 $ 1,000

Total additions to property and equipment 400 375 328

Operating Segments | Pharmaceutical

Segment Reporting Information [Line Items]

Total depreciation and amortization 151 135 147

Total additions to property and equipment 55 47 35

Operating Segments | Medical

Segment Reporting Information [Line Items]

Total depreciation and amortization 226 243 288

Total additions to property and equipment 97 86 74

Corporate

Segment Reporting Information [Line Items]

Total depreciation and amortization 406 535 565

Total additions to property and equipment $ 248 $ 242 $ 219

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 113 R93.htm IDEA: XBRL DOCUMENT v3.21.2

Segment Information (Assets by Reportable Segment) (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Segment Reporting Information [Line Items]

Total assets $ 44,453 $ 40,766 $ 40,963

Disposal Group, Including Discontinued Operation, Assets 1,101 0

Cordis Divestiture

Segment Reporting Information [Line Items]

Disposal Group, Including Discontinued Operation, Assets 1,091

Medical | Cordis Divestiture

Segment Reporting Information [Line Items]

Disposal Group, Including Discontinued Operation, Assets 1,100

Operating Segments | Pharmaceutical

Segment Reporting Information [Line Items]

Total assets 23,624 22,398 22,446

Operating Segments | Medical

Segment Reporting Information [Line Items]

Total assets 15,408 14,691 15,284

Corporate

Segment Reporting Information [Line Items]

Total assets $ 5,421 $ 3,677 $ 3,233

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as assets attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760
+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: cah_CordisDivestitureAxis=cah_CordisDivestitureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 114 R94.htm IDEA: XBRL DOCUMENT v3.21.2

Segment Information Property and Equipment, net by Geographic Area) (Details) - USD ($)
$ in Millions

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Long-Lived Assets [Line Items]

Property and equipment, net $ 2,360 $ 2,366 $ 2,356

United States

Long-Lived Assets [Line Items]

Property and equipment, net 1,958 1,880 1,846

International

Long-Lived Assets [Line Items]

Property and equipment, net $ 402 $ 486 $ 510

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 360
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 115 R95.htm IDEA: XBRL DOCUMENT v3.21.2

Share-Based Compensation (Narrative) (Details) - USD ($)
shares in Millions, $ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Tax benefit related to share-based compensation $ 12 $ 16 $ 16

Total expense on employee retirement savings plans $ 55 $ 66 $ 99

Granted (in shares) 0 0 0

Performance Share Units | Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Target performance goal (as a percent) 240.00%

Stock Options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Award vesting period (in years) 3 years

Exercisable period of plans (in years) 10 years

Stock Options | Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercisable period of plans (in years) 10 years

2011 LTIP

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares available for grant 9

2011 LTIP | Awards Other than Stock Options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares available for grant 3

2011 LTIP | Stock Options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares available for grant 9

X

- Definition
The instrument's contractual term.
+ References
No definition available.
+ Details

Name: cah_ExercisablePeriodOfPlansInYears

Namespace Prefix: cah_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost for defined contribution plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942
+ Details

Name: us-gaap_DefinedContributionPlanCostRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of tax benefit for recognition of expense of award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of vesting of award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=cah_A2011LtipMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=cah_AwardsOtherThanStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 116 R96.htm IDEA: XBRL DOCUMENT v3.21.2

Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total share-based compensation expense $ 89 $ 90 $ 82

Restricted Share Unit

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total share-based compensation expense 73 70 63

Stock Options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total share-based compensation expense 0 3 10

Performance Share Units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total share-based compensation expense $ 16 $ 17 $ 9

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 117 R97.htm IDEA: XBRL DOCUMENT v3.21.2

Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) - $ / shares
shares in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Stock Options

Outstanding at beginning of period (in shares) 5 6

Granted (in shares) 0 0 0

Exercised (in shares) (1) (1)

Canceled and forfeited (in shares) 0 0

Outstanding at end of period (in shares) 4 5 6

Exercisable at end of period (in shares) 4

Weighted-Average Exercise Price per Common Share

Outstanding at beginning of period (in usd per share) $ 65.15 $ 63.78

Granted (in usd per share) 0 0

Exercised (in usd per share) 43.08 42.36

Canceled and forfeited (in usd per share) 0 0

Outstanding at end of period (in usd per share) 68.46 $ 65.15 $ 63.78

Exercisable at end of period (in usd per share) $ 68.62

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price of options that were either forfeited or expired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 118 R98.htm IDEA: XBRL DOCUMENT v3.21.2

Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Net proceeds/(withholding) from share-based compensation $ 8 $ 8 $ (14)

Stock Options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Aggregate intrinsic value of outstanding options at period end 11 12 10

Aggregate intrinsic value of exercisable options at period end 11 12 10

Aggregate intrinsic value of exercised options 10 8 1

Net proceeds/(withholding) from share-based compensation 32 26 3

Excess tax benefits from share based compensation (5) 6 7

Total compensation cost, net of estimated forfeitures, related to unvested stock options not yet recognized, pre-tax 0 1 5

Total fair value of shares vested during the year $ 3 $ 8 $ 20

Weighted-average grant date fair value per stock option (in usd per share) $ 12.94 $ 8.26 $ 8.34

Award vesting period (in years) 3 years

Exercisable period of plans (in years) 10 years

Stock Options | Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercisable period of plans (in years) 10 years

X

- Definition
The instrument's contractual term.
+ References
No definition available.
+ Details

Name: cah_ExercisablePeriodOfPlansInYears

Namespace Prefix: cah_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
No definition available.
+ Details

Name: cah_Netproceedstaxwithholdingsfromsharebasedcompensation

Namespace Prefix: cah_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=122142933&loc=d3e11374-113907
+ Details

Name: us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 119 R99.htm IDEA: XBRL DOCUMENT v3.21.2

Share-Based Compensation Schedule of Remaining Stock Option Plan Data (Details) - Stock Options
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted-average remaining contractual life of outstanding options 4 years 5 years 5 years

Weighted-average remaining contractual life of exercisable options 4 years 5 years 5 years

Weighted-average period over which stock option compensation cost is expected to be recognized 2 years 1 year 1 year

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 120 R100.htm IDEA: XBRL DOCUMENT v3.21.2

Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units - $ / shares
shares in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Restricted Share Units

Nonvested at beginning of period (in shares) 3 2

Granted (in shares) 2 2

Vested (in shares) (1) (1)

Canceled and forfeited (in shares) (1) 0

Nonvested at end of period (in shares) 3 3

Weighted-Average Grant Date Fair Value per Share

Nonvested at beginning of period (in usd per share) $ 45.92 $ 51.65

Granted (in usd per share) 53.76 42.71

Vested (in usd per share) 49.37 60.21

Canceled and forfeited (in usd per share) 48.74 0

Nonvested at end of period (in usd per share) $ 49.05 $ 45.92

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 121 R101.htm IDEA: XBRL DOCUMENT v3.21.2

Share-Based Compensation (Additional Data Related to Restricted Share Unit Activity) (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Restricted Share Units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax $ 73 $ 77 $ 75

Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years) 2 years 2 years 2 years

Total fair value of shares vested during the year $ 70 $ 57 $ 68

Award vesting period (in years) 3 years

Performance Share Units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax $ 26 $ 29 $ 12

Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years) 2 years 2 years 2 years

Total fair value of shares vested during the year $ 1 $ 5 $ 0

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 122 R102.htm IDEA: XBRL DOCUMENT v3.21.2

Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units - $ / shares
shares in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Performance Share Units

Nonvested at beginning of period (in shares) 1.3 0.9

Granted (in shares) 0.4 0.7

Vested (in shares) (0.1) (0.1)

Canceled and forfeited (in shares) (0.4) (0.2)

Nonvested at end of period (in shares) 1.2 1.3

Weighted-Average Grant Date Fair Value per Share

Nonvested at beginning of period (in usd per share) $ 54.24 $ 51.45

Granted (in usd per share) 55.45 44.03

Vested (in usd per share) 42.72 48.40

Canceled and forfeited (in usd per share) 53.71 50.92

Nonvested at end of period (in usd per share) $ 54.89 $ 54.24

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 123 R103.htm IDEA: XBRL DOCUMENT v3.21.2

Share-Based Compensation (Additional Data Related to Performance Share Unit Activity) (Details) - Performance Share Units
$ in Millions
12 Months Ended

Jun. 30, 2021

USD ($)

vestingPeriods

Jun. 30, 2020

USD ($)

Jun. 30, 2019

USD ($)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized, pre-tax $ 26 $ 29 $ 12

Weighted-average period over which performance share unit cost is expected to be recognized (in years) 2 years 2 years 2 years

Total fair value of shares vested during the year $ 1 $ 5 $ 0

Vesting Period in years for Shares | vestingPeriods 3

Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Target performance goal (as a percent) 0.00%

X

- Definition
Vesting Period in years for Shares
+ References
No definition available.
+ Details

Name: cah_VestingPeriodinyearsforShares

Namespace Prefix: cah_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of vesting of award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 124 R104.htm IDEA: XBRL DOCUMENT v3.21.2

Schedule II - Valuations and Qualifying Accounts (Details) - USD ($)
$ in Millions
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2018

SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount $ 944 $ 729 $ 687 $ 626

SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 2,702 2,407 2,353

SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 1 1 1

SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 2,488 2,366 2,293

Pricing Disputes [Member]

SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 70 49 60

SEC Schedule, 12-09, Allowance, Credit Loss [Member]

SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount 242 206 193 139

SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 129 139 140

SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 1 1 1

SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 94 127 87

Prior Year Recoveries

SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Addition, Recovery 1 1 1

SEC Schedule, 12-09, Allowance, Loss on Finance Receivable [Member]

SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount 12 27 14 7

SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 5 15 8

SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 0 0 0

SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 20 2 1

Sales Returns and Allowances [Member]

SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount 689 495 479 479

SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 2,568 2,253 2,205

SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 0 0 0

SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 2,374 2,237 2,205

SEC Schedule, 12-09, Allowance, Loan and Lease Loss [Member]

SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount 1 1 1 $ 1

SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]

SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 0 0 0

SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 0 0 0

SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction $ 0 $ 0 $ 0

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: srt_ValuationAndQualifyingAccountsDisclosureLineItems

Namespace Prefix: srt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_MovementInValuationAllowancesAndReservesRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of valuation and qualifying accounts and reserves.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09(Column B))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09(Column E))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690
+ Details

Name: us-gaap_ValuationAllowancesAndReservesBalance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09(Column C)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690
+ Details

Name: us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09(Column C)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690
+ Details

Name: us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of decrease in valuation and qualifying accounts and reserves.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09(Column D))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690
+ Details

Name: us-gaap_ValuationAllowancesAndReservesDeductions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in valuation and qualifying accounts and reserves from recovery of amount previously written off or reestablishment of reserve previously utilized.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09(Column C)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690
+ Details

Name: us-gaap_ValuationAllowancesAndReservesRecoveries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=cah_PricingDisputesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=cah_PriorYearRecoveriesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForLossesOnFinanceReceivablesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForLoanAndLeaseLossesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 125 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 127 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 128 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 420 562 1 false 128 0 false 12 false false R1.htm 000010001 - Document - Cover Page Sheet http://www.cardinal.com/role/CoverPage Cover Page Cover 1 false false R2.htm 100010002 - Statement - Consolidated Statements of Earnings Sheet http://www.cardinal.com/role/ConsolidatedStatementsofEarnings Consolidated Statements of Earnings Statements 2 false false R3.htm 100020003 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 100030004 - Statement - Consolidated Balance Sheets Sheet http://www.cardinal.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 4 false false R5.htm 100050006 - Statement - Consolidated Statements of Shareholders' Equity Sheet http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity Consolidated Statements of Shareholders' Equity Statements 5 false false R6.htm 100060007 - Statement - Consolidated Statements of Cash Flows Sheet http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 210011001 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 7 false false R8.htm 210171002 - Disclosure - Divestitures and Acquisitions Sheet http://www.cardinal.com/role/DivestituresandAcquisitions Divestitures and Acquisitions Notes 8 false false R9.htm 210201003 - Disclosure - Restructuring and Employee Severance Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeverance Restructuring and Employee Severance Notes 9 false false R10.htm 210241004 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 10 false false R11.htm 210291005 - Disclosure - Leases Sheet http://www.cardinal.com/role/Leases Leases Notes 11 false false R12.htm 210361006 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Sheet http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings Long-Term Obligations and Other Short-Term Borrowings Notes 12 false false R13.htm 210421007 - Disclosure - Commitments, Contingent Liabilities and Litigation Sheet http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation Commitments, Contingent Liabilities and Litigation Notes 13 false false R14.htm 210441008 - Disclosure - Income Taxes Sheet http://www.cardinal.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 210541010 - Disclosure - Fair Value Measurements Sheet http://www.cardinal.com/role/FairValueMeasurements Fair Value Measurements Notes 15 false false R16.htm 210591011 - Disclosure - Financial Instruments Sheet http://www.cardinal.com/role/FinancialInstruments Financial Instruments Notes 16 false false R17.htm 210721012 - Disclosure - Shareholders' Equity Sheet http://www.cardinal.com/role/ShareholdersEquity Shareholders' Equity Notes 17 false false R18.htm 210761013 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc Earnings Per Share Attributable to Cardinal Health, Inc. Notes 18 false false R19.htm 210801014 - Disclosure - Segment Information Sheet http://www.cardinal.com/role/SegmentInformation Segment Information Notes 19 false false R20.htm 210881015 - Disclosure - Share-Based Compensation Sheet http://www.cardinal.com/role/ShareBasedCompensation Share-Based Compensation Notes 20 false false R21.htm 210991016 - Disclosure - Schedule II - Valuations and Qualifying Accounts Sheet http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccounts Schedule II - Valuations and Qualifying Accounts Notes 21 false false R22.htm 220022001 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 22 false false R23.htm 230033001 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 23 false false R24.htm 230183002 - Disclosure - Divestitures and Acquisitions (Tables) Sheet http://www.cardinal.com/role/DivestituresandAcquisitionsTables Divestitures and Acquisitions (Tables) Tables http://www.cardinal.com/role/DivestituresandAcquisitions 24 false false R25.htm 230213003 - Disclosure - Restructuring and Employee Severance (Tables) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables Restructuring and Employee Severance (Tables) Tables http://www.cardinal.com/role/RestructuringandEmployeeSeverance 25 false false R26.htm 230253004 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets 26 false false R27.htm 230303005 - Disclosure - Leases (Tables) Sheet http://www.cardinal.com/role/LeasesTables Leases (Tables) Tables http://www.cardinal.com/role/Leases 27 false false R28.htm 230373006 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables) Sheet http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables Long-Term Obligations and Other Short-Term Borrowings (Tables) Tables http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings 28 false false R29.htm 230453007 - Disclosure - Income Taxes (Tables) Sheet http://www.cardinal.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.cardinal.com/role/IncomeTaxes 29 false false R30.htm 230553008 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.cardinal.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.cardinal.com/role/FairValueMeasurements 30 false false R31.htm 230603009 - Disclosure - Financial Instruments (Tables) Sheet http://www.cardinal.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.cardinal.com/role/FinancialInstruments 31 false false R32.htm 230733010 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.cardinal.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.cardinal.com/role/ShareholdersEquity 32 false false R33.htm 230773011 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) Tables http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc 33 false false R34.htm 230813012 - Disclosure - Segment Information (Tables) Sheet http://www.cardinal.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.cardinal.com/role/SegmentInformation 34 false false R35.htm 230893013 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.cardinal.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.cardinal.com/role/ShareBasedCompensation 35 false false R36.htm 240044001 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Receivables) (Details) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Receivables) (Details) Details http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 36 false false R37.htm 240054002 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Revenue and Gross Trade Receivables Percentage by Major Customers) (Details) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails Basis of Presentation and Summary of Significant Accounting Policies (Revenue and Gross Trade Receivables Percentage by Major Customers) (Details) Details http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 37 false false R38.htm 240064003 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Major Customers) (Details) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Major Customers) (Details) Details http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 38 false false R39.htm 240074004 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Inventories) (Details) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeInventoriesDetails Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Inventories) (Details) Details http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 39 false false R40.htm 240084005 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Property and Equipment) (Details) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Property and Equipment) (Details) Details http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 40 false false R41.htm 240094006 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Components of Property and Equipment) (Details) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails Basis of Presentation and Summary of Significant Accounting Policies (Components of Property and Equipment) (Details) Details http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 41 false false R42.htm 240104007 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Goodwill and Other Intangible Assets) (Details) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeGoodwillandOtherIntangibleAssetsDetails Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Goodwill and Other Intangible Assets) (Details) Details http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 42 false false R43.htm 240124009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Vendor Reserves) (Details) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeVendorReservesDetails Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Vendor Reserves) (Details) Details http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 43 false false R44.htm 240134010 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Dividends) (Details) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDividendsDetails Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Dividends) (Details) Details http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 44 false false R45.htm 240144011 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Sales Returns and Allowances) (Details) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeSalesReturnsandAllowancesDetails Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Sales Returns and Allowances) (Details) Details http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 45 false false R46.htm 240154012 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Shipping and Handling) (Details) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeShippingandHandlingDetails Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Shipping and Handling) (Details) Details http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 46 false false R47.htm 240164013 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Loss Contingencies (Details) Sheet http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLossContingenciesDetails Basis of Presentation and Summary of Significant Accounting Policies Loss Contingencies (Details) Details 47 false false R48.htm 240194014 - Disclosure - Divestitures and Acquisitions (Narrative) (Details) Sheet http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails Divestitures and Acquisitions (Narrative) (Details) Details http://www.cardinal.com/role/DivestituresandAcquisitionsTables 48 false false R49.htm 240224015 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) Details http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables 49 false false R50.htm 240234016 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) Sheet http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) Details http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables 50 false false R51.htm 240264017 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) Details http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables 51 false false R52.htm 240274018 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) Details http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables 52 false false R53.htm 240284019 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details) Sheet http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails Goodwill and Other Intangible Assets (Narrative) (Details) Details http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables 53 false false R54.htm 240314020 - Disclosure - Leases (Details) Sheet http://www.cardinal.com/role/LeasesDetails Leases (Details) Details http://www.cardinal.com/role/LeasesTables 54 false false R55.htm 240324021 - Disclosure - Leases Schedule of Lease Costs (Details) Sheet http://www.cardinal.com/role/LeasesScheduleofLeaseCostsDetails Leases Schedule of Lease Costs (Details) Details 55 false false R56.htm 240334022 - Disclosure - Leases Supplemental Balance Sheet Information (Details) Sheet http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails Leases Supplemental Balance Sheet Information (Details) Details 56 false false R57.htm 240344023 - Disclosure - Leases Supplemental Cash Flow Information (Details) Sheet http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails Leases Supplemental Cash Flow Information (Details) Details 57 false false R58.htm 240354024 - Disclosure - Leases Schedule of Future Lease Payments (Details) Sheet http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails Leases Schedule of Future Lease Payments (Details) Details 58 false false R59.htm 240384025 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) Sheet http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) Details 59 false false R60.htm 240394026 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) Sheet http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) Details http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables 60 false false R61.htm 240404027 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Long-Term Debt (Details) Sheet http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails Long-Term Obligations and Other Short-Term Borrowings Long-Term Debt (Details) Details 61 false false R62.htm 240414028 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Other Financing Arrangements (Details) Sheet http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails Long-Term Obligations and Other Short-Term Borrowings Other Financing Arrangements (Details) Details 62 false false R63.htm 240434029 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details) Sheet http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails Commitments, Contingent Liabilities and Litigation (Details) Details http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation 63 false false R64.htm 240464030 - Disclosure - Income Taxes (Schedule of Income before Income Tax, Domestic and Foreign) (Details) Sheet http://www.cardinal.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails Income Taxes (Schedule of Income before Income Tax, Domestic and Foreign) (Details) Details http://www.cardinal.com/role/IncomeTaxesTables 64 false false R65.htm 240474031 - Disclosure - Income Taxes (Schedule of Components of Income Tax Expense (Benefit), Current and Deferred) (Details) Sheet http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails Income Taxes (Schedule of Components of Income Tax Expense (Benefit), Current and Deferred) (Details) Details http://www.cardinal.com/role/IncomeTaxesTables 65 false false R66.htm 240484032 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details) Sheet http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details) Details http://www.cardinal.com/role/IncomeTaxesTables 66 false false R67.htm 240494033 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://www.cardinal.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details http://www.cardinal.com/role/IncomeTaxesTables 67 false false R68.htm 240504034 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) Sheet http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) Details http://www.cardinal.com/role/IncomeTaxesTables 68 false false R69.htm 240514035 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities After Netting by Tax Jurisdiction) (Details) Sheet http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesAfterNettingbyTaxJurisdictionDetails Income Taxes (Schedule of Deferred Tax Assets and Liabilities After Netting by Tax Jurisdiction) (Details) Details http://www.cardinal.com/role/IncomeTaxesTables 69 false false R70.htm 240524036 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits Roll Forward) (Details) Sheet http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails Income Taxes (Schedule of Unrecognized Tax Benefits Roll Forward) (Details) Details http://www.cardinal.com/role/IncomeTaxesTables 70 false false R71.htm 240564037 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) Sheet http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) Details http://www.cardinal.com/role/FairValueMeasurementsTables 71 false false R72.htm 240574038 - Disclosure - Fair Value Measurements (Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis Using Unobservable Inputs (Level 3)) (Details) Sheet http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details Fair Value Measurements (Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis Using Unobservable Inputs (Level 3)) (Details) Details http://www.cardinal.com/role/FairValueMeasurementsTables 72 false false R73.htm 240584039 - Disclosure - Fair Value Measurements (Details) Sheet http://www.cardinal.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.cardinal.com/role/FairValueMeasurementsTables 73 false false R74.htm 240614040 - Disclosure - Financial Instruments (Schedule of the Fair Value of Assets and Liabilities Related to Derivatives Designated as Hedging Instruments) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails Financial Instruments (Schedule of the Fair Value of Assets and Liabilities Related to Derivatives Designated as Hedging Instruments) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 74 false false R75.htm 240624041 - Disclosure - Financial Instruments (Narrative) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments (Narrative) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 75 false false R76.htm 240634042 - Disclosure - Financial Instruments (Schedule of Outstanding Instruments, Fair Value Hedges) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails Financial Instruments (Schedule of Outstanding Instruments, Fair Value Hedges) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 76 false false R77.htm 240644043 - Disclosure - Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Interest Rate Contracts Designated as Fair Value Hedges) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Interest Rate Contracts Designated as Fair Value Hedges) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 77 false false R78.htm 240654044 - Disclosure - Financial Instruments (Schedule of Outstanding Instruments, Cash Flow Hedges) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails Financial Instruments (Schedule of Outstanding Instruments, Cash Flow Hedges) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 78 false false R79.htm 240664045 - Disclosure - Financial Instruments (Schedule of Gain/(Loss) Included in AOCI for Derivative Instruments Designated as Cash Flow Hedges) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossIncludedinAOCIforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails Financial Instruments (Schedule of Gain/(Loss) Included in AOCI for Derivative Instruments Designated as Cash Flow Hedges) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 79 false false R80.htm 240674046 - Disclosure - Financial Instruments (Schedule of Gain/(Loss) Reclassified from AOCI into Earnings for Derivative Instruments Designated as Cash Flow Hedges) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails Financial Instruments (Schedule of Gain/(Loss) Reclassified from AOCI into Earnings for Derivative Instruments Designated as Cash Flow Hedges) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 80 false false R81.htm 240684047 - Disclosure - Financial Instruments (Schedule of Outstanding Instruments, Economic Hedges) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails Financial Instruments (Schedule of Outstanding Instruments, Economic Hedges) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 81 false false R82.htm 240694048 - Disclosure - Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Derivatives Not Designated as Hedging Instrument) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforDerivativesNotDesignatedasHedgingInstrumentDetails Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Derivatives Not Designated as Hedging Instrument) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 82 false false R83.htm 240704049 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 83 false false R84.htm 240714050 - Disclosure - Financial Instruments (Schedule of Fair Value Gain Loss Derivative Instrument) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails Financial Instruments (Schedule of Fair Value Gain Loss Derivative Instrument) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 84 false false R85.htm 240744051 - Disclosure - Shareholders' Equity (Narrative) (Details) Sheet http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails Shareholders' Equity (Narrative) (Details) Details http://www.cardinal.com/role/ShareholdersEquityTables 85 false false R86.htm 240754052 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) Sheet http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) Details http://www.cardinal.com/role/ShareholdersEquityTables 86 false false R87.htm 240784053 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) Details http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables 87 false false R88.htm 240794054 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) Sheet http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) Details http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables 88 false false R89.htm 240824055 - Disclosure - Segment Information (Narrative) (Details) Sheet http://www.cardinal.com/role/SegmentInformationNarrativeDetails Segment Information (Narrative) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 89 false false R90.htm 240834056 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails Segment Information (Revenue by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 90 false false R91.htm 240844057 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails Segment Information (Segment Profit by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 91 false false R92.htm 240854058 - Disclosure - Segment Information (Depreciation and Amortization and Additions to Property and Equipment by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationDepreciationandAmortizationandAdditionstoPropertyandEquipmentbyReportableSegmentDetails Segment Information (Depreciation and Amortization and Additions to Property and Equipment by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 92 false false R93.htm 240864059 - Disclosure - Segment Information (Assets by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails Segment Information (Assets by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 93 false false R94.htm 240874060 - Disclosure - Segment Information Property and Equipment, net by Geographic Area) (Details) Sheet http://www.cardinal.com/role/SegmentInformationPropertyandEquipmentnetbyGeographicAreaDetails Segment Information Property and Equipment, net by Geographic Area) (Details) Details 94 false false R95.htm 240904061 - Disclosure - Share-Based Compensation (Narrative) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails Share-Based Compensation (Narrative) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 95 false false R96.htm 240914062 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 96 false false R97.htm 240924063 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 97 false false R98.htm 240934064 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 98 false false R99.htm 240944065 - Disclosure - Share-Based Compensation Schedule of Remaining Stock Option Plan Data (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofRemainingStockOptionPlanDataDetails Share-Based Compensation Schedule of Remaining Stock Option Plan Data (Details) Details 99 false false R100.htm 240954066 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 100 false false R101.htm 240964067 - Disclosure - Share-Based Compensation (Additional Data Related to Restricted Share Unit Activity) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoRestrictedShareUnitActivityDetails Share-Based Compensation (Additional Data Related to Restricted Share Unit Activity) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 101 false false R102.htm 240974068 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 102 false false R103.htm 240984069 - Disclosure - Share-Based Compensation (Additional Data Related to Performance Share Unit Activity) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails Share-Based Compensation (Additional Data Related to Performance Share Unit Activity) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 103 false false R104.htm 241004070 - Disclosure - Schedule II - Valuations and Qualifying Accounts (Details) Sheet http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails Schedule II - Valuations and Qualifying Accounts (Details) Details http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccounts 104 false false All Reports Book All Reports cah-20210630.htm a21q4_10kx063021xexhibit311.htm a21q4_10kx063021xexhibit312.htm a21q4_10kx063021xexhibit321.htm a21q4_10kx063021xexhibit991.htm a21q4_10kx63021xexhibit211.htm a21q4_10kx63021xexhibit231.htm cah-20210630.xsd cah-20210630_cal.xml cah-20210630_def.xml cah-20210630_lab.xml cah-20210630_pre.xml cah-20210630_g1.jpg cah-20210630_g2.jpg cah-20210630_g3.jpg cah-20210630_g4.jpg cah-20210630_g5.jpg cah-20210630_g6.jpg cah-20210630_g7.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 http://xbrl.sec.gov/country/2021 http://fasb.org/srt/2021-01-31 true true JSON 131 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cah-20210630.htm": { "axisCustom": 8, "axisStandard": 34, "contextCount": 420, "dts": { "calculationLink": { "local": [ "cah-20210630_cal.xml" ] }, "definitionLink": { "local": [ "cah-20210630_def.xml" ] }, "inline": { "local": [ "cah-20210630.htm" ] }, "labelLink": { "local": [ "cah-20210630_lab.xml" ], "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml", "https://xbrl.fasb.org/srt/2021/elts/srt-doc-2021-01-31.xml" ] }, "presentationLink": { "local": [ "cah-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml", "https://xbrl.fasb.org/srt/2021/elts/srt-ref-2021-01-31.xml" ] }, "schema": { "local": [ "cah-20210630.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 840, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 6, "total": 6 }, "keyCustom": 81, "keyStandard": 481, "memberCustom": 58, "memberStandard": 66, "nsprefix": "cah", "nsuri": "http://www.cardinal.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000010001 - Document - Cover Page", "role": "http://www.cardinal.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210241004 - Disclosure - Goodwill and Other Intangible Assets", "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets", "shortName": "Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "ifb9b7ea1688a4fb4a266a5ac9179360e_I20200630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240954066 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "icf32a92391924ff7b30fe54e99e0979b_I20190630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cah:AdditionalRestrictedSharesAndRestrictedShareUnitsDataTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i401c6da5266c42ffb2f8a5466c3eba3c_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240964067 - Disclosure - Share-Based Compensation (Additional Data Related to Restricted Share Unit Activity) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoRestrictedShareUnitActivityDetails", "shortName": "Share-Based Compensation (Additional Data Related to Restricted Share Unit Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cah:AdditionalRestrictedSharesAndRestrictedShareUnitsDataTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i401c6da5266c42ffb2f8a5466c3eba3c_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "ib996ace534574f9da807e45a4e349efc_I20200630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240974068 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i837fa9d3c1f04fb6aa54fd33592f52b3_I20190630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cah:AdditionalPerformanceShareUnitsDataTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i09a66472ecae47489b82c3a6aade6b47_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240984069 - Disclosure - Share-Based Compensation (Additional Data Related to Performance Share Unit Activity) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails", "shortName": "Share-Based Compensation (Additional Data Related to Performance Share Unit Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i217c2671c6f84df1ab8278415bc34c16_D20200701-20210630", "decimals": "INF", "lang": "en-US", "name": "cah:VestingPeriodinyearsforShares", "reportCount": 1, "unique": true, "unitRef": "vestingperiods", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241004070 - Disclosure - Schedule II - Valuations and Qualifying Accounts (Details)", "role": "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails", "shortName": "Schedule II - Valuations and Qualifying Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "cah:LeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210291005 - Disclosure - Leases", "role": "http://www.cardinal.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "cah:LeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210361006 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings", "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings", "shortName": "Long-Term Obligations and Other Short-Term Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210421007 - Disclosure - Commitments, Contingent Liabilities and Litigation", "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation", "shortName": "Commitments, Contingent Liabilities and Litigation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210441008 - Disclosure - Income Taxes", "role": "http://www.cardinal.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210541010 - Disclosure - Fair Value Measurements", "role": "http://www.cardinal.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210591011 - Disclosure - Financial Instruments", "role": "http://www.cardinal.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210721012 - Disclosure - Shareholders' Equity", "role": "http://www.cardinal.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210761013 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.", "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210801014 - Disclosure - Segment Information", "role": "http://www.cardinal.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010002 - Statement - Consolidated Statements of Earnings", "role": "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "shortName": "Consolidated Statements of Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210881015 - Disclosure - Share-Based Compensation", "role": "http://www.cardinal.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210991016 - Disclosure - Schedule II - Valuations and Qualifying Accounts", "role": "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccounts", "shortName": "Schedule II - Valuations and Qualifying Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "220022001 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:MajorCustomersPolicyPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230033001 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:MajorCustomersPolicyPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230183002 - Disclosure - Divestitures and Acquisitions (Tables)", "role": "http://www.cardinal.com/role/DivestituresandAcquisitionsTables", "shortName": "Divestitures and Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230213003 - Disclosure - Restructuring and Employee Severance (Tables)", "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables", "shortName": "Restructuring and Employee Severance (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230253004 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables", "shortName": "Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "cah:LeasesTextBlock", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230303005 - Disclosure - Leases (Tables)", "role": "http://www.cardinal.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "cah:LeasesTextBlock", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230373006 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables)", "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables", "shortName": "Long-Term Obligations and Other Short-Term Borrowings (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230453007 - Disclosure - Income Taxes (Tables)", "role": "http://www.cardinal.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020003 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230553008 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.cardinal.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230603009 - Disclosure - Financial Instruments (Tables)", "role": "http://www.cardinal.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230733010 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.cardinal.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230773011 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)", "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230813012 - Disclosure - Segment Information (Tables)", "role": "http://www.cardinal.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230893013 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.cardinal.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240044001 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Receivables) (Details)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Receivables) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NotesReceivableNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "us-gaap:MajorCustomersPolicyPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8e11ba21ea4c434ca0730a61f91af07b_I20210630", "decimals": "2", "first": true, "lang": "en-US", "name": "cah:GrossTradeReceivablesMajorCustomerPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240054002 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Revenue and Gross Trade Receivables Percentage by Major Customers) (Details)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Revenue and Gross Trade Receivables Percentage by Major Customers) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "us-gaap:MajorCustomersPolicyPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8e11ba21ea4c434ca0730a61f91af07b_I20210630", "decimals": "2", "first": true, "lang": "en-US", "name": "cah:GrossTradeReceivablesMajorCustomerPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "cah:ConcentrationRiskLargestGroupPurchasingOrganizations", "reportCount": 1, "unique": true, "unitRef": "organization", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240064003 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Major Customers) (Details)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Major Customers) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "cah:ConcentrationRiskLargestGroupPurchasingOrganizations", "reportCount": 1, "unique": true, "unitRef": "organization", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:InventoryPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:PercentageOfLIFOInventory", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240074004 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Inventories) (Details)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeInventoriesDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Inventories) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:InventoryPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:PercentageOfLIFOInventory", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030004 - Statement - Consolidated Balance Sheets", "role": "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240084005 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Property and Equipment) (Details)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Property and Equipment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240094006 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Components of Property and Equipment) (Details)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Components of Property and Equipment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240104007 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Goodwill and Other Intangible Assets) (Details)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeGoodwillandOtherIntangibleAssetsDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Goodwill and Other Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "cah:CostofSalesVendorReservesPolicyPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:VendorReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240124009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Vendor Reserves) (Details)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeVendorReservesDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Vendor Reserves) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "cah:CostofSalesVendorReservesPolicyPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:VendorReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "cah:DividendsPolicyPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240134010 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Dividends) (Details)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDividendsDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Dividends) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "cah:DividendsPolicyPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:RevenueRecognitionReserveforSalesReturnsandAllowances", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240144011 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Sales Returns and Allowances) (Details)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeSalesReturnsandAllowancesDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Sales Returns and Allowances) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:RevenueRecognitionReserveforSalesReturnsandAllowances", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240154012 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Shipping and Handling) (Details)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeShippingandHandlingDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Shipping and Handling) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "ic3592f06406544abac446d0e612f00d3_D20200701-20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GainLossRelatedToLitigationSettlement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240164013 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Loss Contingencies (Details)", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLossContingenciesDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies Loss Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240194014 - Disclosure - Divestitures and Acquisitions (Narrative) (Details)", "role": "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "shortName": "Divestitures and Acquisitions (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "ia31e9a409b874bb19d0ff6f2f39ecc09_D20190701-20200630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240224015 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)", "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails", "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i00a6d666bf604826b24e68ddbd63eac4_D20180701-20190630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050006 - Statement - Consolidated Statements of Shareholders' Equity", "role": "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity", "shortName": "Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i368e27a25f8645faa683a133e4fd114e_D20180701-20190630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i299cea70f47b4fbe96772aaa8cc00b79_I20200630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240234016 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)", "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails", "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "if6dc09eec4e74751b47cdf037a5b1860_I20190630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillTransfers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240264017 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillTransfers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240274018 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)", "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240284019 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)", "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "shortName": "Goodwill and Other Intangible Assets (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "div", "cah:LeasesTextBlock", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i00a6d666bf604826b24e68ddbd63eac4_D20180701-20190630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240314020 - Disclosure - Leases (Details)", "role": "http://www.cardinal.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "cah:LeasesTextBlock", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i00a6d666bf604826b24e68ddbd63eac4_D20180701-20190630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "div", "cah:LeasesTextBlock", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240324021 - Disclosure - Leases Schedule of Lease Costs (Details)", "role": "http://www.cardinal.com/role/LeasesScheduleofLeaseCostsDetails", "shortName": "Leases Schedule of Lease Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "div", "cah:LeasesTextBlock", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "cah:LeasesTextBlock", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240334022 - Disclosure - Leases Supplemental Balance Sheet Information (Details)", "role": "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails", "shortName": "Leases Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "cah:LeasesTextBlock", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cah:LeasePaymentsTableTextBlock", "div", "cah:LeasesTextBlock", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240344023 - Disclosure - Leases Supplemental Cash Flow Information (Details)", "role": "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails", "shortName": "Leases Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cah:LeasePaymentsTableTextBlock", "div", "cah:LeasesTextBlock", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:LesseeLeaseLiabilityPaymentsDueYearTwo", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240354024 - Disclosure - Leases Schedule of Future Lease Payments (Details)", "role": "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails", "shortName": "Leases Schedule of Future Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:LesseeLeaseLiabilityPaymentsDueYearTwo", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240384025 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)", "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails", "shortName": "Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i6040899ecc9f44f893d3f559f74eb30e_I20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060007 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GainLossOnSaleOfOtherInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240394026 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)", "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "shortName": "Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i299cea70f47b4fbe96772aaa8cc00b79_I20200630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AccountsPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240404027 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Long-Term Debt (Details)", "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "shortName": "Long-Term Obligations and Other Short-Term Borrowings Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "INF", "lang": "en-US", "name": "cah:OfferAsPercentageOfPrincipalAmount", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherBorrowings", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240414028 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Other Financing Arrangements (Details)", "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails", "shortName": "Long-Term Obligations and Other Short-Term Borrowings Other Financing Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2085dadd50db412cae65d5356e28138c_I20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:IncomefromSettlementsofClassActionLawsuits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240434029 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)", "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "shortName": "Commitments, Contingent Liabilities and Litigation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:IncomefromSettlementsofClassActionLawsuits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240464030 - Disclosure - Income Taxes (Schedule of Income before Income Tax, Domestic and Foreign) (Details)", "role": "http://www.cardinal.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails", "shortName": "Income Taxes (Schedule of Income before Income Tax, Domestic and Foreign) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240474031 - Disclosure - Income Taxes (Schedule of Components of Income Tax Expense (Benefit), Current and Deferred) (Details)", "role": "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails", "shortName": "Income Taxes (Schedule of Components of Income Tax Expense (Benefit), Current and Deferred) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240484032 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)", "role": "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails", "shortName": "Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240494033 - Disclosure - Income Taxes (Narrative) (Details)", "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "lang": "en-US", "name": "cah:EffectiveTaxRateImpactFromCertainForeignJurisdictions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240504034 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)", "role": "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails", "shortName": "Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cah:ScheduleOfDeferredTaxAssetsAndLiabilitiesAfterNettingByTaxJurisdictionTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240514035 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities After Netting by Tax Jurisdiction) (Details)", "role": "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesAfterNettingbyTaxJurisdictionDetails", "shortName": "Income Taxes (Schedule of Deferred Tax Assets and Liabilities After Netting by Tax Jurisdiction) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cah:ScheduleOfDeferredTaxAssetsAndLiabilitiesAfterNettingByTaxJurisdictionTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210011001 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240524036 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits Roll Forward) (Details)", "role": "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails", "shortName": "Income Taxes (Schedule of Unrecognized Tax Benefits Roll Forward) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240564037 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)", "role": "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "shortName": "Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i53e687ceccba4bac9c2829e01e82f358_I20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i53e687ceccba4bac9c2829e01e82f358_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240574038 - Disclosure - Fair Value Measurements (Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis Using Unobservable Inputs (Level 3)) (Details)", "role": "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details", "shortName": "Fair Value Measurements (Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis Using Unobservable Inputs (Level 3)) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R73": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240584039 - Disclosure - Fair Value Measurements (Details)", "role": "http://www.cardinal.com/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240614040 - Disclosure - Financial Instruments (Schedule of the Fair Value of Assets and Liabilities Related to Derivatives Designated as Hedging Instruments) (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "shortName": "Financial Instruments (Schedule of the Fair Value of Assets and Liabilities Related to Derivatives Designated as Hedging Instruments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240624041 - Disclosure - Financial Instruments (Narrative) (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "shortName": "Financial Instruments (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i69a44d9974c04cc3abf8c7aeb68f22c6_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240634042 - Disclosure - Financial Instruments (Schedule of Outstanding Instruments, Fair Value Hedges) (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "shortName": "Financial Instruments (Schedule of Outstanding Instruments, Fair Value Hedges) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i17248417fcbc4d118aebc5dfbe183bfc_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240644043 - Disclosure - Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Interest Rate Contracts Designated as Fair Value Hedges) (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails", "shortName": "Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Interest Rate Contracts Designated as Fair Value Hedges) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i17248417fcbc4d118aebc5dfbe183bfc_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i58c9aa5163a64897b2ad19c7f47190d0_I20200630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeLiabilityNotionalAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240654044 - Disclosure - Financial Instruments (Schedule of Outstanding Instruments, Cash Flow Hedges) (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "shortName": "Financial Instruments (Schedule of Outstanding Instruments, Cash Flow Hedges) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i4de6f0288abd431bbc839b56b68b328b_I20200630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeAssetNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i405b6b2ebdbb4b00959f5be8d40c1adb_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240664045 - Disclosure - Financial Instruments (Schedule of Gain/(Loss) Included in AOCI for Derivative Instruments Designated as Cash Flow Hedges) (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossIncludedinAOCIforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "shortName": "Financial Instruments (Schedule of Gain/(Loss) Included in AOCI for Derivative Instruments Designated as Cash Flow Hedges) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i405b6b2ebdbb4b00959f5be8d40c1adb_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210171002 - Disclosure - Divestitures and Acquisitions", "role": "http://www.cardinal.com/role/DivestituresandAcquisitions", "shortName": "Divestitures and Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "ibb6fbf503d8d4b92b0852c5ea1309753_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240674046 - Disclosure - Financial Instruments (Schedule of Gain/(Loss) Reclassified from AOCI into Earnings for Derivative Instruments Designated as Cash Flow Hedges) (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "shortName": "Financial Instruments (Schedule of Gain/(Loss) Reclassified from AOCI into Earnings for Derivative Instruments Designated as Cash Flow Hedges) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "ibb6fbf503d8d4b92b0852c5ea1309753_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i6ca29000e9a8453b9f0281faeb2f2ed2_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssetNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240684047 - Disclosure - Financial Instruments (Schedule of Outstanding Instruments, Economic Hedges) (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails", "shortName": "Financial Instruments (Schedule of Outstanding Instruments, Economic Hedges) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i6ca29000e9a8453b9f0281faeb2f2ed2_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssetNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "ifca9e60bdc7a4338aa4de50477f141d8_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240694048 - Disclosure - Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Derivatives Not Designated as Hedging Instrument) (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforDerivativesNotDesignatedasHedgingInstrumentDetails", "shortName": "Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Derivatives Not Designated as Hedging Instrument) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "ifca9e60bdc7a4338aa4de50477f141d8_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240704049 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails", "shortName": "Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cah:ScheduleOfFairValueGainLossDerivativeInstrumentTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i04848fa4190a4546999fce3b74a1093a_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240714050 - Disclosure - Financial Instruments (Schedule of Fair Value Gain Loss Derivative Instrument) (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails", "shortName": "Financial Instruments (Schedule of Fair Value Gain Loss Derivative Instrument) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cah:ScheduleOfFairValueGainLossDerivativeInstrumentTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i04848fa4190a4546999fce3b74a1093a_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240744051 - Disclosure - Shareholders' Equity (Narrative) (Details)", "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails", "shortName": "Shareholders' Equity (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i0a081dfdf3e846b387ac5e60a2f4e8a5_I20210630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i299cea70f47b4fbe96772aaa8cc00b79_I20200630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240754052 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)", "role": "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i10ebef79cb324951a3c60cf340e5e0c7_D20200701-20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240784053 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)", "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240794054 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)", "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i00a6d666bf604826b24e68ddbd63eac4_D20180701-20190630", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:PreTaxGainonDivestiture", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240824055 - Disclosure - Segment Information (Narrative) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "shortName": "Segment Information (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "lang": "en-US", "name": "cah:ProjectCostsOnInvestmentAndOtherSpending", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210201003 - Disclosure - Restructuring and Employee Severance", "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance", "shortName": "Restructuring and Employee Severance", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240834056 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "shortName": "Segment Information (Revenue by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i3d4fc04fd3ba4fe9b28a1f419dbc6b15_D20200701-20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240844057 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails", "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "ie5f1ec6cee11430ab0571ee6201cd0f7_D20200701-20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240854058 - Disclosure - Segment Information (Depreciation and Amortization and Additions to Property and Equipment by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationDepreciationandAmortizationandAdditionstoPropertyandEquipmentbyReportableSegmentDetails", "shortName": "Segment Information (Depreciation and Amortization and Additions to Property and Equipment by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i76b6a114dfd6424fb4c07d91075a91ff_D20200701-20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240864059 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "shortName": "Segment Information (Assets by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "if6dc09eec4e74751b47cdf037a5b1860_I20190630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i2e87824102b34590a0208cc7da91b5f5_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240874060 - Disclosure - Segment Information Property and Equipment, net by Geographic Area) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationPropertyandEquipmentnetbyGeographicAreaDetails", "shortName": "Segment Information Property and Equipment, net by Geographic Area) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "ieb5c5f04a3584568a0813006020736e0_I20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240904061 - Disclosure - Share-Based Compensation (Narrative) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "shortName": "Share-Based Compensation (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240914062 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails", "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i299cea70f47b4fbe96772aaa8cc00b79_I20200630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240924063 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails", "shortName": "Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i8d202c3bdf6c4f3c8a5885a63cf6bb9c_D20200701-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "cah:Netproceedstaxwithholdingsfromsharebasedcompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240934064 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails", "shortName": "Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "cah:AdditionalStockOptionPlanDataTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "ib473c6ce356d4388a73564ce9f41c306_I20210630", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "cah:RemainingStockOptionPlanDataTableTextBlock", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i9fac2b1e8f484ef081a25d163aa2c3a6_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240944065 - Disclosure - Share-Based Compensation Schedule of Remaining Stock Option Plan Data (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofRemainingStockOptionPlanDataDetails", "shortName": "Share-Based Compensation Schedule of Remaining Stock Option Plan Data (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "cah:RemainingStockOptionPlanDataTableTextBlock", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "cah-20210630.htm", "contextRef": "i9fac2b1e8f484ef081a25d163aa2c3a6_D20200701-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 128, "tag": { "cah_A1.948Notesdue2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.948% Notes due 2019", "label": "1.948% Notes due 2019 [Member]", "terseLabel": "1.948% Notes due 2019" } } }, "localname": "A1.948Notesdue2019Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A2.616Notes3.2Notes3.41Notes4.6Notes4.9Notesand4.368NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.616% Notes, 3.2% Notes, 3.41% Notes, 4.6% Notes, 4.9% Notes and 4.368% Notes [Member]", "label": "2.616% Notes, 3.2% Notes, 3.41% Notes, 4.6% Notes, 4.9% Notes and 4.368% Notes [Member]", "terseLabel": "2.616% Notes, 3.2% Notes, 3.41% Notes, 4.6% Notes, 4.9% Notes and 4.368% Notes [Member]" } } }, "localname": "A2.616Notes3.2Notes3.41Notes4.6Notes4.9Notesand4.368NotesMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_A2.616Notesdue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.616% Notes due 2022", "label": "2.616% Notes due 2022 [Member]", "terseLabel": "2.616% Notes due fiscal 2022" } } }, "localname": "A2.616Notesdue2022Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A2011LtipMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2011 LTIP [Member]", "label": "2011 LTIP [Member]", "terseLabel": "2011 LTIP" } } }, "localname": "A2011LtipMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "domainItemType" }, "cah_A24NotesDue2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.4% Notes due 2019", "label": "2.4% Notes due 2019 [Member]", "terseLabel": "2.4% Notes due 2019" } } }, "localname": "A24NotesDue2019Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A3.079Notesdue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.079% Notes due 2024", "label": "3.079% Notes due 2024 [Member]", "terseLabel": "3.079% Notes due fiscal 2024" } } }, "localname": "A3.079Notesdue2024Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A3.2Notesdue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.2% Notes due 2022", "label": "3.2% Notes due 2022 [Member]", "terseLabel": "3.2% Notes due 2022" } } }, "localname": "A3.2Notesdue2022Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A3.2Notesdue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.2% Notes due 2023", "label": "3.2% Notes due 2023 [Member]", "terseLabel": "3.2% Notes due 2023" } } }, "localname": "A3.2Notesdue2023Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A3.41Notesdue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.41% Notes due 2027", "label": "3.41% Notes due 2027 [Member]", "terseLabel": "3.41% Notes due fiscal 2027" } } }, "localname": "A3.41Notesdue2027Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A3.5Notesdue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.5% Notes due 2025", "label": "3.5% Notes due 2025 [Member]", "terseLabel": "3.5% Notes due fiscal 2025" } } }, "localname": "A3.5Notesdue2025Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A3.75Notesdue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.75% Notes due 2026", "label": "3.75% Notes due 2026 [Member]", "terseLabel": "3.75% Notes due 2025" } } }, "localname": "A3.75Notesdue2026Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A32Notes2616NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.2% notes, 2.616% Notes", "label": "3.2% notes, 2.616% Notes [Member]", "terseLabel": "3.2% notes, 2.616% Notes" } } }, "localname": "A32Notes2616NotesMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_A4.368Notesdue2047Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.368% Notes due 2047", "label": "4.368% Notes due 2047 [Member]", "terseLabel": "4.368% Notes due fiscal 2047" } } }, "localname": "A4.368Notesdue2047Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A4.5Notesdue2044Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.5% Notes due 2044", "label": "4.5% Notes due 2044 [Member]", "terseLabel": "4.5% Notes due 2044" } } }, "localname": "A4.5Notesdue2044Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A4.625Notesdue2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.625% Notes due 2021", "label": "4.625% Notes due 2021 [Member]", "terseLabel": "4.625% Notes due 2020" } } }, "localname": "A4.625Notesdue2021Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A4.6Notesdue2043Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.6% Notes due 2043", "label": "4.6% Notes due 2043 [Member]", "terseLabel": "4.6% Notes due 2043" } } }, "localname": "A4.6Notesdue2043Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A4.9Notesdue2045Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.9% Notes due 2045", "label": "4.9% Notes due 2045 [Member]", "terseLabel": "4.9% Notes due 2045" } } }, "localname": "A4.9Notesdue2045Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_A7.0Debenturesduefiscal2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "7.0% Debentures due fiscal 2027", "label": "7.0% Debentures due fiscal 2027 [Member]", "terseLabel": "7.0%\u00a0Debentures due 2026" } } }, "localname": "A7.0Debenturesduefiscal2027Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_ASC842Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ASC 842", "label": "ASC 842 [Member]", "terseLabel": "ASC 842" } } }, "localname": "ASC842Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "domainItemType" }, "cah_AdditionalPerformanceShareUnitsDataTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Performance Share Units Data [Table Text Block]", "label": "Additional Performance Share Units Data [Table Text Block]", "terseLabel": "Additional Data Related to Performance Share Units Activity" } } }, "localname": "AdditionalPerformanceShareUnitsDataTableTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "cah_AdditionalRestrictedSharesAndRestrictedShareUnitsDataTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Restricted Shares And Restricted Share Units Data [Table Text Block]", "label": "Additional Restricted Shares And Restricted Share Units Data [Table Text Block]", "terseLabel": "Additional Restricted Shares and Restricted Share Units Activity" } } }, "localname": "AdditionalRestrictedSharesAndRestrictedShareUnitsDataTableTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "cah_AdditionalStockOptionPlanDataTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A disclosure of additional data related to all stock option activity", "label": "Additional Stock Option Plan Data [Table Text Block]", "terseLabel": "Schedule of Additional Data Related to Stock Option Activity" } } }, "localname": "AdditionalStockOptionPlanDataTableTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "cah_AggregateAnnualAssessment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate Annual Assessment", "label": "Aggregate Annual Assessment", "terseLabel": "Aggregate Annual Assessment" } } }, "localname": "AggregateAnnualAssessment", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "monetaryItemType" }, "cah_AlamedaCountyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alameda County [Member]", "label": "Alameda County [Member]", "terseLabel": "Alameda County [Member]" } } }, "localname": "AlamedaCountyMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_AllegianceCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allegiance Corporation [Member]", "label": "Allegiance Corporation [Member]", "terseLabel": "Allegiance Corporation" } } }, "localname": "AllegianceCorporationMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "cah_AmortizationandOtherAcquisitionRelatedCostsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the costs incurred during and relating to an acquisition. These costs specifically include transaction and integration costs; changes in fair value of contingent consideration obligations and amortization of acquisition-related intangible assets, and are recorded within amortization and other acquisition-related costs.", "label": "Amortization and Other Acquisition Related Costs Policy [Policy Text Block]", "terseLabel": "Amortization and Other Acquisition-Related Costs" } } }, "localname": "AmortizationandOtherAcquisitionRelatedCostsPolicyPolicyTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cah_Amortizationandotheracquisitionrelatedcosts": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Amortization and other acquisition-related costs", "terseLabel": "Amortization and other acquisition-related costs" } } }, "localname": "Amortizationandotheracquisitionrelatedcosts", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "cah_AssetsHeldforSalePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets Held for Sale, Policy [Policy Text Block]", "label": "Assets Held for Sale, Policy [Policy Text Block]", "terseLabel": "Assets Held for Sale, Policy [Policy Text Block]" } } }, "localname": "AssetsHeldforSalePolicyPolicyTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cah_AwardsOtherThanStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Awards Other than Stock Options [Member]", "label": "Awards Other than Stock Options [Member]", "terseLabel": "Awards Other than Stock Options" } } }, "localname": "AwardsOtherThanStockOptionsMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_CVSCaremarkCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CVS Caremark Corporation [Member]", "label": "CVS Caremark Corporation [Member]", "terseLabel": "CVS Health" } } }, "localname": "CVSCaremarkCorporationMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "cah_CardinalHealthAtHomeSolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cardinal Health At Home Solutions [Member]", "label": "Cardinal Health At Home Solutions [Member]", "terseLabel": "Cardinal Health At Home Solutions [Member]" } } }, "localname": "CardinalHealthAtHomeSolutionsMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_CareFusionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CareFusion [Member]", "label": "CareFusion [Member]", "terseLabel": "CareFusion [Member]" } } }, "localname": "CareFusionMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_CarryingAmountofLongTermandotherShortTermBorrowings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings", "label": "Carrying Amount of Long-Term and other Short-Term Borrowings", "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings" } } }, "localname": "CarryingAmountofLongTermandotherShortTermBorrowings", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "cah_CashDiscountsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Discounts [Policy Text Block]", "label": "Cash Discounts [Policy Text Block]", "terseLabel": "Cash Discounts" } } }, "localname": "CashDiscountsPolicyTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cah_CashReclassifiedtoAssetsHeldforSale": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "CashReclassifiedtoAssetsHeldforSale", "label": "CashReclassifiedtoAssetsHeldforSale", "terseLabel": "Cash reclassified to assets held for sale" } } }, "localname": "CashReclassifiedtoAssetsHeldforSale", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cah_ClassActionLawsuitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Action Lawsuits [Member]", "label": "Class Action Lawsuits [Member]", "terseLabel": "Class Action Lawsuits [Member]" } } }, "localname": "ClassActionLawsuitsMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_CommittedReceivablesSalesFacilityProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.", "label": "Committed Receivables Sales Facility Program [Member]", "terseLabel": "Committed Receivables Sales Facility Program" } } }, "localname": "CommittedReceivablesSalesFacilityProgramMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails" ], "xbrltype": "domainItemType" }, "cah_CommonStockVotingRightsVotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Voting Rights, Votes", "label": "Common Stock, Voting Rights, Votes", "terseLabel": "Common Stock, Voting Rights, Votes" } } }, "localname": "CommonStockVotingRightsVotes", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "pureItemType" }, "cah_ConcentrationRiskLargestGroupPurchasingOrganizations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration Risk, Largest Group Purchasing Organizations", "label": "Concentration Risk, Largest Group Purchasing Organizations", "terseLabel": "Largest group purchasing organizations" } } }, "localname": "ConcentrationRiskLargestGroupPurchasingOrganizations", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails" ], "xbrltype": "integerItemType" }, "cah_CordisDivestitureAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cordis Divestiture", "label": "Cordis Divestiture [Axis]", "terseLabel": "Cordis Divestiture [Axis]" } } }, "localname": "CordisDivestitureAxis", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "cah_CordisDivestitureDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cordis Divestiture [Domain]", "label": "Cordis Divestiture [Domain]", "terseLabel": "Cordis Divestiture [Domain]" } } }, "localname": "CordisDivestitureDomain", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_CordisDivestitureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cordis Divestiture", "label": "Cordis Divestiture [Member]", "terseLabel": "Cordis Divestiture" } } }, "localname": "CordisDivestitureMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_CostofSalesVendorReservesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for allowances received from a vendor. The disclosure differentiates between those allowances that are recorded as a reduction in the price of the vendors' products or services (that is, the entity's inventory) and which ultimately will be recorded as a reduction in the entity's cost of sales and those that are not.", "label": "Cost of Sales, Vendor Reserves, Policy [Policy Text Block]", "terseLabel": "Vendor Reserves" } } }, "localname": "CostofSalesVendorReservesPolicyPolicyTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cah_DOJInvestigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DOJ Investigation", "label": "DOJ Investigation [Member]", "terseLabel": "DOJ Investigation" } } }, "localname": "DOJInvestigationMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_DeferredIncomeTaxesAndOtherTaxLiabilitiesTransferredToHeldForSaleNoncurrent": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesAfterNettingbyTaxJurisdictionDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Income Taxes and Other Tax Liabilities, Transferred to Held for Sale, Noncurrent", "label": "Deferred Income Taxes and Other Tax Liabilities, Transferred to Held for Sale, Noncurrent", "negatedTerseLabel": "Deferred Income Taxes and Other Tax Liabilities, Transferred to Held for Sale, Noncurrent" } } }, "localname": "DeferredIncomeTaxesAndOtherTaxLiabilitiesTransferredToHeldForSaleNoncurrent", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesAfterNettingbyTaxJurisdictionDetails" ], "xbrltype": "monetaryItemType" }, "cah_DeferredIncomeTaxesandOtherLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Income Taxes and Other Liabilities [Member]", "label": "Deferred Income Taxes and Other Liabilities [Member]", "terseLabel": "Deferred Income Taxes and Other Liabilities" } } }, "localname": "DeferredIncomeTaxesandOtherLiabilitiesMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "cah_DeferredTaxAssetsRelatedtouncertaintaxpositions": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets related to uncertain tax positions", "label": "Deferred Tax Assets, Related to uncertain tax positions", "terseLabel": "Deferred tax assets related to uncertain tax positions" } } }, "localname": "DeferredTaxAssetsRelatedtouncertaintaxpositions", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cah_DerivatesHedgeDiscontinuancesHedgingInstrumentTerminatedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivates, Hedge Discontinuances, Hedging Instrument Terminated, Amount", "label": "Derivates, Hedge Discontinuances, Hedging Instrument Terminated, Amount", "terseLabel": "Derivates, Hedge Discontinuances, Hedging Instrument Terminated, Amount" } } }, "localname": "DerivatesHedgeDiscontinuancesHedgingInstrumentTerminatedAmount", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount", "label": "Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount", "terseLabel": "Derivatives, matured notional amounts" } } }, "localname": "DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails" ], "xbrltype": "monetaryItemType" }, "cah_DerivativesHedgeDiscontinuancesTerminationofHedgingInstrumentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Amount", "label": "Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Amount", "terseLabel": "Derivatives, terminated notional amounts" } } }, "localname": "DerivativesHedgeDiscontinuancesTerminationofHedgingInstrumentAmount", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_DiscountRatefairvalueinputs": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discount Rate, fair value inputs", "label": "Discount Rate, fair value inputs", "terseLabel": "Discount Rate, fair value inputs" } } }, "localname": "DiscountRatefairvalueinputs", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeGoodwillandOtherIntangibleAssetsDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "percentItemType" }, "cah_DisposalGroupIncludingDiscontinuedOperationsGoodwillAndOtherIntangiblesNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group Including Discontinued Operations Goodwill and Other Intangibles, net", "label": "Disposal Group Including Discontinued Operations Goodwill and Other Intangibles, net", "terseLabel": "Disposal Group Including Discontinued Operations Goodwill and Other Intangibles, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsGoodwillAndOtherIntangiblesNet", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_DistributionServiceAgreementAndOtherVendorFeesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Describes an entity's accounting policy for fees received from distribution service agreements and other fees received from vendors related to the purchase or distribution of the vendor's inventory. Such fees are recognized as a reduction of inventory when those fees have been earned and the entity is entitled to payment.", "label": "Distribution Service Agreement And Other Vendor Fees [Policy Text Block]", "terseLabel": "Distribution Service Agreement and Other Vendor Fees" } } }, "localname": "DistributionServiceAgreementAndOtherVendorFeesPolicyTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cah_DividendsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividends, Policy [Policy Text Block]", "label": "Dividends, Policy [Policy Text Block]", "terseLabel": "Dividends, Policy [Policy Text Block]" } } }, "localname": "DividendsPolicyPolicyTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cah_EffectiveIncomeTaxRateReconciliationLegalEntityReorganizationReconcilingItemsPercent": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation Legal Entity Reorganization Reconciling Items Percent", "label": "Effective Income Tax Rate Reconciliation Legal Entity Reorganization Reconciling Items Percent", "terseLabel": "Effective Income Tax Rate Reconciliation Legal Entity Reorganization Reconciling Items Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationLegalEntityReorganizationReconcilingItemsPercent", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "cah_EffectiveIncomeTaxRateReconciliationLossCarrybackClaims": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Loss Carryback Claims", "label": "Effective Income Tax Rate Reconciliation, Loss Carryback Claims", "terseLabel": "Effective Income Tax Rate Reconciliation, Loss Carryback Claims" } } }, "localname": "EffectiveIncomeTaxRateReconciliationLossCarrybackClaims", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "cah_EffectiveIncomeTaxRateReconciliationTaxEffectOfForeignOperations": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Tax Effect of Foreign Operations", "label": "Effective Income Tax Rate Reconciliation, Tax Effect of Foreign Operations", "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Effect of Foreign Operations" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxEffectOfForeignOperations", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "cah_EffectiveIncomeTaxRateReconciliationWithholdingTaxes": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Withholding Taxes", "label": "Effective Income Tax Rate Reconciliation, Withholding Taxes", "terseLabel": "Effective Income Tax Rate Reconciliation, Withholding Taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationWithholdingTaxes", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "cah_EffectiveIncomeTaxReconciliationOpioidLitigation": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 13.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Reconciliation, Opioid Litigation", "label": "Effective Income Tax Reconciliation, Opioid Litigation", "terseLabel": "Effective Income Tax Reconciliation, Opioid Litigation" } } }, "localname": "EffectiveIncomeTaxReconciliationOpioidLitigation", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "cah_EffectiveTaxRateImpactFromCertainForeignJurisdictions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Effective Tax Rate Impact From Certain Foreign Jurisdictions", "label": "Effective Tax Rate Impact From Certain Foreign Jurisdictions", "terseLabel": "Effective Tax Rate Impact From Certain Foreign Jurisdictions" } } }, "localname": "EffectiveTaxRateImpactFromCertainForeignJurisdictions", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_EffectiveTaxRateReconciliationImpactOfResolutionsWithIRSAndOtherRelatedMatters": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 10.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Tax Rate Reconciliation, Impact of Resolutions with IRS and other related matters", "label": "Effective Tax Rate Reconciliation, Impact of Resolutions with IRS and other related matters", "terseLabel": "China tax related to divestiture" } } }, "localname": "EffectiveTaxRateReconciliationImpactOfResolutionsWithIRSAndOtherRelatedMatters", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "cah_EffectiveTaxRateReconciliationUSTaxesOnInternationalIncome": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Tax Rate Reconciliation, US Taxes on International Income", "label": "Effective Tax Rate Reconciliation, US Taxes on International Income", "terseLabel": "US Taxes on International Income" } } }, "localname": "EffectiveTaxRateReconciliationUSTaxesOnInternationalIncome", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated Liability for New York Opioid Stewardship Act", "label": "Estimated Liability for New York Opioid Stewardship Act", "terseLabel": "Estimated Liability for New York Opioid Stewardship Act" } } }, "localname": "EstimatedLiabilityForNewYorkOpioidStewardshipAct", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_ExercisablePeriodOfPlansInYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The instrument's contractual term.", "label": "Exercisable period of plans, in years", "terseLabel": "Exercisable period of plans (in years)" } } }, "localname": "ExercisablePeriodOfPlansInYears", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" ], "xbrltype": "durationItemType" }, "cah_FacilityExitAndOtherCosts": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.", "label": "Facility Exit and Other Costs", "terseLabel": "Facility Exit and Other Costs" } } }, "localname": "FacilityExitAndOtherCosts", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" ], "xbrltype": "monetaryItemType" }, "cah_FinanceLeaseImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease Imputed Interest", "label": "Finance Lease Imputed Interest", "terseLabel": "Less: imputed interest" } } }, "localname": "FinanceLeaseImputedInterest", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_FinanceLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance Lease", "label": "Finance Lease [Member]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "cah_FixedRateDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed Rate Debt [Member]", "label": "Fixed Rate Debt [Member]", "terseLabel": "Fixed-Rate Debt" } } }, "localname": "FixedRateDebtMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails" ], "xbrltype": "domainItemType" }, "cah_FloatingRateNotes2616NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Floating rate notes, 2.616% Notes", "label": "Floating rate notes, 2.616% Notes [Member]", "terseLabel": "Floating rate notes, 2.616% Notes" } } }, "localname": "FloatingRateNotes2616NotesMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_FloatingRateNotesdue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Floating Rate Notes due 2022", "label": "Floating Rate Notes due 2022 [Member]", "terseLabel": "Floating Rate Notes due fiscal 2022" } } }, "localname": "FloatingRateNotesdue2022Member", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "cah_GainonDivestitureAfterTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on Divestiture After Tax", "label": "Gain on Divestiture After Tax", "terseLabel": "Gain on Divestiture After Tax" } } }, "localname": "GainonDivestitureAfterTax", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_GoodsandservicessoldLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for goods and services sold [Table]", "label": "goods and services sold [Line Items]", "terseLabel": "Distribution, selling, general and administrative expenses [Line Items]" } } }, "localname": "GoodsandservicessoldLineItems", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeShippingandHandlingDetails" ], "xbrltype": "stringItemType" }, "cah_GoodsandservicessoldTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "goods and services sold [Table]", "label": "goods and services sold [Table]", "terseLabel": "Distribution, selling, general and administrative expenses [Table]" } } }, "localname": "GoodsandservicessoldTable", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeShippingandHandlingDetails" ], "xbrltype": "stringItemType" }, "cah_GoodwillAndIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill and Intangible Assets [Line Items]", "label": "Goodwill and Intangible Assets [Line Items]", "terseLabel": "Goodwill and Intangible Assets [Line Items]" } } }, "localname": "GoodwillAndIntangibleAssetsLineItems", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "cah_GoodwillAndIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill and Intangible Assets [Table]", "label": "Goodwill and Intangible Assets [Table]", "terseLabel": "Goodwill and Intangible Assets [Table]" } } }, "localname": "GoodwillAndIntangibleAssetsTable", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "cah_GownRecallAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gown Recall [Axis]", "label": "Gown Recall [Axis]", "terseLabel": "Gown Recall [Axis]" } } }, "localname": "GownRecallAxis", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "stringItemType" }, "cah_GownRecallDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Gown Recall [Axis]", "label": "Gown Recall [Domain]", "terseLabel": "Gown Recall [Domain]" } } }, "localname": "GownRecallDomain", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_GrossTradeReceivablesMajorCustomerPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross Trade Receivables, Major Customer Percentage", "label": "Gross Trade Receivables, Major Customer Percentage", "terseLabel": "Percent\u00a0of\u00a0Gross Trade\u00a0Receivables" } } }, "localname": "GrossTradeReceivablesMajorCustomerPercentage", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails" ], "xbrltype": "percentItemType" }, "cah_GroupPurchasingOrganizationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Group Purchasing Organizations [Member]", "label": "Group Purchasing Organizations [Member]", "terseLabel": "Group Purchasing Organizations" } } }, "localname": "GroupPurchasingOrganizationsMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "cah_IPRDTrademarksandOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "IPR&D,TrademarksandOther [Member]", "terseLabel": "Trademarks and patents" } } }, "localname": "IPRDTrademarksandOtherMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cah_Impactofadoptionofnewaccountingstandard": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "impact of adoption of new accounting standard", "label": "impact of adoption of new accounting standard", "terseLabel": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification (Deprecated 2020-01-31)" } } }, "localname": "Impactofadoptionofnewaccountingstandard", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "cah_IncomefromSettlementsofClassActionLawsuits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income from Settlements of Class Action Lawsuits", "label": "Income from Settlements of Class Action Lawsuits", "terseLabel": "Income from Settlements of Class Action Lawsuits" } } }, "localname": "IncomefromSettlementsofClassActionLawsuits", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "monetaryItemType" }, "cah_IndemnificationReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.", "label": "Indemnification Receivable", "terseLabel": "Amount CareFusion is liable under tax matters agreement in the event amount must be paid to the taxing authority" } } }, "localname": "IndemnificationReceivable", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_LawsuitTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lawsuit Type [Axis]", "label": "Lawsuit Type [Axis]", "terseLabel": "Lawsuit Type [Axis]" } } }, "localname": "LawsuitTypeAxis", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "stringItemType" }, "cah_LawsuitTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Lawsuit Type [Axis]", "label": "Lawsuit Type [Domain]", "terseLabel": "Lawsuit Type [Domain]" } } }, "localname": "LawsuitTypeDomain", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_LeasePaymentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Table Text Block] for Lease Payments [Table]", "label": "Lease Payments [Table Text Block]", "terseLabel": "Leases Supplemental Cash Flow Information" } } }, "localname": "LeasePaymentsTableTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cah_LeasesSupplementalBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Table Text Block] for LeasesSupplementalBalanceSheetInformation [Table]", "label": "LeasesSupplementalBalanceSheetInformation [Table Text Block]", "terseLabel": "Leases Supplemental Balance Sheet Information" } } }, "localname": "LeasesSupplementalBalanceSheetInformationTableTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cah_LeasesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases [Text Block]", "label": "Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeasesTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "cah_LesseeFinanceLeaseLiabilityNotYetCommencedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee Finance Lease Liability Not Yet Commenced, Amount", "label": "Lessee Finance Lease Liability Not Yet Commenced, Amount", "terseLabel": "Less: leases not yet commenced (1)" } } }, "localname": "LesseeFinanceLeaseLiabilityNotYetCommencedAmount", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee Lease Liability Payments Due After Year Five", "label": "Lessee Lease Liability Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee Lease Liability Payments Due Year Five", "label": "Lessee Lease Liability Payments Due Year Five", "terseLabel": "2026" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee Lease Liability Payments Due Year Four", "label": "Lessee Lease Liability Payments Due Year Four", "terseLabel": "2025" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueYearOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee Lease Liability Payments Due Year One", "label": "Lessee Lease Liability Payments Due Year One", "terseLabel": "2022" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearOne", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee Lease Liability Payments Due Year Three", "label": "Lessee Lease Liability Payments Due Year Three", "terseLabel": "2024" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee Lease Liability Payments Due Year Two", "label": "Lessee Lease Liability Payments Due Year Two", "terseLabel": "2023" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeOperatingLeaseLiabilityNotYetCommencedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessee Operating Lease Liability Not Yet Commenced, Amount", "label": "Lessee Operating Lease Liability Not Yet Commenced, Amount", "terseLabel": "Less: leases not yet commenced (1)" } } }, "localname": "LesseeOperatingLeaseLiabilityNotYetCommencedAmount", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LitigationTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Litigation Type [Axis]", "label": "Litigation Type [Axis]", "terseLabel": "Litigation Type [Axis]" } } }, "localname": "LitigationTypeAxis", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "stringItemType" }, "cah_LitigationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Litigation Type [Axis]", "label": "Litigation Type [Domain]", "terseLabel": "Litigation Type [Domain]" } } }, "localname": "LitigationTypeDomain", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_LossContingencyLawsuitsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Lawsuits, Number", "label": "Loss Contingency, Lawsuits, Number", "terseLabel": "Loss Contingency, Lawsuits, Number" } } }, "localname": "LossContingencyLawsuitsNumber", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "integerItemType" }, "cah_MedicalMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical [Member]", "label": "Medical Member [Member]", "terseLabel": "Medical" } } }, "localname": "MedicalMemberMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDepreciationandAmortizationandAdditionstoPropertyandEquipmentbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_MedicaldistributionandproductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical distribution and products [Member]", "label": "Medical distribution and products [Member]", "terseLabel": "Medical distribution and products [Member]" } } }, "localname": "MedicaldistributionandproductsMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_NaviHealthAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "naviHealth", "label": "naviHealth [Axis]", "terseLabel": "naviHealth [Axis]" } } }, "localname": "NaviHealthAxis", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_NaviHealthDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "naviHealth [Domain]", "label": "naviHealth [Domain]", "terseLabel": "naviHealth [Domain]" } } }, "localname": "NaviHealthDomain", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_NaviHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "naviHealth [Member]", "label": "naviHealth [Member]", "terseLabel": "naviHealth [Member]" } } }, "localname": "NaviHealthMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_NetEarningsIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Earnings Including Portion Attributable to Noncontrolling Interest Excluding Redeemable Noncontrolling Interest", "label": "Net Earnings Including Portion Attributable to Noncontrolling Interest Excluding Redeemable Noncontrolling Interest", "terseLabel": "Net Earnings Including Portion Attributable to Noncontrolling Interest Excluding Redeemable Noncontrolling Interest" } } }, "localname": "NetEarningsIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "cah_NetOperatingLossCarrybackAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Operating Loss Carryback", "label": "Net Operating Loss Carryback [Axis]", "terseLabel": "Net Operating Loss Carryback [Axis]" } } }, "localname": "NetOperatingLossCarrybackAxis", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_NetOperatingLossCarrybackDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Operating Loss Carryback [Domain]", "label": "Net Operating Loss Carryback [Domain]", "terseLabel": "Net Operating Loss Carryback [Domain]" } } }, "localname": "NetOperatingLossCarrybackDomain", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_NetOperatingLossCarrybackMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Operating Loss Carryback", "label": "Net Operating Loss Carryback [Member]", "terseLabel": "Net Operating Loss Carryback" } } }, "localname": "NetOperatingLossCarrybackMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.", "label": "Net proceeds/(tax withholdings) from share-based compensation", "terseLabel": "Net tax proceeds/(withholding) from share-based compensation", "verboseLabel": "Net proceeds/(withholding) from share-based compensation" } } }, "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "cah_NewYorkOpioidStewardshipActMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New York Opioid Stewardship Act", "label": "New York Opioid Stewardship Act [Member]", "terseLabel": "New York Opioid Stewardship Act" } } }, "localname": "NewYorkOpioidStewardshipActMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_NotesPayableRepurchased": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Principal Amount of Notes Payable Repurchased during the year", "label": "Notes Payable Repurchased", "terseLabel": "Notes Payable Repurchased" } } }, "localname": "NotesPayableRepurchased", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_NuclearPrecisionHealthServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nuclear Precision Health Services [Member]", "label": "Nuclear Precision Health Services [Member]", "terseLabel": "Nuclear Precision Health Services [Member]" } } }, "localname": "NuclearPrecisionHealthServicesMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_NumberofStateAttorneysGeneralfilinglawsuits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of State Attorneys General filing lawsuits", "label": "Number of State Attorneys General filing lawsuits", "terseLabel": "Number of State Attorneys General filing lawsuits" } } }, "localname": "NumberofStateAttorneysGeneralfilinglawsuits", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "integerItemType" }, "cah_OfferAsPercentageOfPrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount that the company is required to offer to purchase certain notes, under certain circumstances.", "label": "Offer As Percentage Of Principal Amount", "terseLabel": "Offer as percentage of principal amount" } } }, "localname": "OfferAsPercentageOfPrincipalAmount", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "cah_OperatingLeaseImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease Imputed Interest", "label": "Operating Lease Imputed Interest", "terseLabel": "Less: imputed interest" } } }, "localname": "OperatingLeaseImputedInterest", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_OperatingLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease", "label": "Operating Lease [Member]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidLawsuitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Opioid Lawsuits [Member]", "label": "Opioid Lawsuits [Member]", "terseLabel": "Opioid Lawsuits" } } }, "localname": "OpioidLawsuitsMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidLawsuitsStateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Opioid Lawsuits State and Political Subdivisions [Domain]", "label": "Opioid Lawsuits State [Domain]", "terseLabel": "Opioid Lawsuits State [Domain]" } } }, "localname": "OpioidLawsuitsStateDomain", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidLitigationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Opioid Litigation", "label": "Opioid Litigation [Axis]", "terseLabel": "Opioid Litigation [Axis]" } } }, "localname": "OpioidLitigationAxis", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLossContingenciesDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_OpioidLitigationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Opioid Litigation [Domain]", "label": "Opioid Litigation [Domain]", "terseLabel": "Opioid Litigation [Domain]" } } }, "localname": "OpioidLitigationDomain", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLossContingenciesDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_OptumRxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OptumRx [Member]", "label": "OptumRx [Member]", "terseLabel": "OptumRx [Member]" } } }, "localname": "OptumRxMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "cah_OtherAccruedLiabilitiesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Accrued Liabilities, Policy [Policy Text Block]", "label": "Other Accrued Liabilities, Policy [Policy Text Block]", "terseLabel": "Other Accrued Liabilities, Policy [Policy Text Block]" } } }, "localname": "OtherAccruedLiabilitiesPolicyPolicyTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cah_OtherJurisdictionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Jurisdictions [Member]", "label": "Other Jurisdictions [Member]", "terseLabel": "Other Jurisdictions [Member]" } } }, "localname": "OtherJurisdictionsMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_PatientRecoveryBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patient Recovery Business [Member]", "label": "Patient Recovery Business [Member]", "terseLabel": "Patient Recovery Business [Member]" } } }, "localname": "PatientRecoveryBusinessMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "domainItemType" }, "cah_PharmaceuticalDistributionandSpecialtyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmaceutical Distribution and Specialty [Member]", "label": "Pharmaceutical Distribution and Specialty [Member]", "terseLabel": "Pharmaceutical Distribution and Specialty [Member]" } } }, "localname": "PharmaceuticalDistributionandSpecialtyMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_PharmaceuticalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmaceutical [Member]", "label": "Pharmaceutical Member", "terseLabel": "Pharmaceutical" } } }, "localname": "PharmaceuticalMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDepreciationandAmortizationandAdditionstoPropertyandEquipmentbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_PlaintiffTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plaintiff Type [Axis]", "label": "Plaintiff Type [Axis]", "terseLabel": "Plaintiff Type [Axis]" } } }, "localname": "PlaintiffTypeAxis", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "stringItemType" }, "cah_PlaintiffTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Plaintiff Type [Axis]", "label": "Plaintiff Type [Domain]", "terseLabel": "Plaintiff Type [Domain]" } } }, "localname": "PlaintiffTypeDomain", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_PreTaxGainonDivestiture": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Pre-Tax Gain on Divestiture", "label": "Pre-Tax Gain on Divestiture", "terseLabel": "Pre-Tax Gain on Divestiture" } } }, "localname": "PreTaxGainonDivestiture", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_PricingDisputesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expense related to pricing disputes, excluded from provision for bad debts in the consolidated statements of cash flows and recorded as a reduction in gross margin in the consolidated statements of earnings.", "label": "Pricing Disputes [Member]", "terseLabel": "Pricing Disputes [Member]" } } }, "localname": "PricingDisputesMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "cah_PriorYearRecoveriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prior Year Recoveries [Member]", "label": "Prior Year Recoveries [Member]", "terseLabel": "Prior Year Recoveries" } } }, "localname": "PriorYearRecoveriesMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "cah_PrivatePartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Parties [Member]", "label": "Private Parties [Member]", "terseLabel": "Private Parties [Member]" } } }, "localname": "PrivatePartiesMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from divestitures and disposal of property and equipment and held for sale assets", "label": "Proceeds from divestitures and disposal of property and equipment and held for sale assets", "terseLabel": "Proceeds from divestitures, net of cash sold, and disposal of property and equipment" } } }, "localname": "Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sales of available-for-sale securities and other investments.", "label": "Proceeds from sale of available-for-sale securities and other investments", "terseLabel": "Proceeds from sale of investments" } } }, "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cah_ProductLiabilityLawsuitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Liability Lawsuits [Member]", "label": "Product Liability Lawsuits [Member]", "terseLabel": "Product Liability Lawsuits" } } }, "localname": "ProductLiabilityLawsuitsMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "domainItemType" }, "cah_ProjectCostsOnInvestmentAndOtherSpending": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.", "label": "Project Costs On Investment And Other Spending", "terseLabel": "Project costs on investment and other spending" } } }, "localname": "ProjectCostsOnInvestmentAndOtherSpending", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_Provisionaltaxbenefitrelatedtotransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Provisional tax benefit related to transaction", "label": "Provisional tax benefit related to transaction", "terseLabel": "Provisional tax benefit related to transaction" } } }, "localname": "Provisionaltaxbenefitrelatedtotransaction", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_Purchaseofavailableforsalesecuritiesandotherinvestments": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from purchases of available-for-sale securities and other investments.", "label": "Purchase of available-for-sale securities and other investments", "negatedLabel": "Purchase of other investments" } } }, "localname": "Purchaseofavailableforsalesecuritiesandotherinvestments", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cah_ReceivableFinancingAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Receivable Financing Agreement Term", "label": "Receivable Financing Agreement Term", "terseLabel": "Receivable financing agreement term" } } }, "localname": "ReceivableFinancingAgreementTerm", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails" ], "xbrltype": "durationItemType" }, "cah_ReclassificationofdeferredrentinaccordancewithASC842": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reclassification of deferred rent in accordance with ASC 842", "label": "Reclassification of deferred rent in accordance with ASC 842", "terseLabel": "Reclassification of deferred rent in accordance with ASC 842" } } }, "localname": "ReclassificationofdeferredrentinaccordancewithASC842", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "cah_RemainingStockOptionPlanDataTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Table Text Block] for Remaining Stock Option Plan Data [Table]", "label": "Remaining Stock Option Plan Data [Table Text Block]", "terseLabel": "Schedule of Remaining Stock Option Plan Data" } } }, "localname": "RemainingStockOptionPlanDataTableTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "cah_RevenueRecognitionReserveforSalesReturnsandAllowances": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue Recognition, Reserve for Sales Returns and Allowances", "label": "Revenue Recognition, Reserve for Sales Returns and Allowances", "terseLabel": "Accrual for estimated sales returns and allowances" } } }, "localname": "RevenueRecognitionReserveforSalesReturnsandAllowances", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeSalesReturnsandAllowancesDetails" ], "xbrltype": "monetaryItemType" }, "cah_SalesreturnsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "sales returns [Policy Text Block]", "label": "sales returns [Policy Text Block]", "terseLabel": "Sales Returns and Allowances" } } }, "localname": "SalesreturnsPolicyTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cah_ScheduleOfDeferredTaxAssetsAndLiabilitiesAfterNettingByTaxJurisdictionTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Deferred Tax Assets And Liabilities After Netting By Tax Jurisdiction [Table Text Block]", "label": "Schedule Of Deferred Tax Assets And Liabilities After Netting By Tax Jurisdiction [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities after Netting by Tax Jurisdiction" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesAfterNettingByTaxJurisdictionTableTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "cah_ScheduleOfFairValueGainLossDerivativeInstrumentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summarizes the fair value and notional amounts of derivative instruments held as of the balance sheet date.", "label": "Schedule Of Fair Value Gain Loss Derivative Instrument [Table Text Block]", "terseLabel": "Schedule of Fair Value Gain/(Loss) Derivative Instrument" } } }, "localname": "ScheduleOfFairValueGainLossDerivativeInstrumentTableTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "cah_Sharesthatwouldbeantidilutiveasaresultofnetloss": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "shares that would be antidilutive as a result of net loss", "label": "shares that would be antidilutive as a result of net loss", "terseLabel": "shares that would be antidilutive as a result of net loss" } } }, "localname": "Sharesthatwouldbeantidilutiveasaresultofnetloss", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cah_ShippingandHandlingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ShippingandHandlingCosts [Policy Text Block]", "label": "ShippingandHandlingCosts [Policy Text Block]", "terseLabel": "Shipping and Handling" } } }, "localname": "ShippingandHandlingCostsPolicyTextBlock", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cah_ShortTermCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other short-term credit facilities and an unsecured line of credit", "label": "Short Term Credit Facilities Member", "terseLabel": "Short Term Credit Facilities" } } }, "localname": "ShortTermCreditFacilitiesMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails" ], "xbrltype": "domainItemType" }, "cah_SterileSurgicalGownRecallAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sterile Surgical Gown Recall", "label": "Sterile Surgical Gown Recall [Axis]", "terseLabel": "Sterile Surgical Gown Recall [Axis]" } } }, "localname": "SterileSurgicalGownRecallAxis", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_SterileSurgicalGownRecallDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sterile Surgical Gown Recall [Domain]", "label": "Sterile Surgical Gown Recall [Domain]", "terseLabel": "Sterile Surgical Gown Recall [Domain]" } } }, "localname": "SterileSurgicalGownRecallDomain", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_SterileSurgicalGownRecallMemberDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sterile Surgical Gown Recall [Member] [Domain]", "label": "Sterile Surgical Gown Recall [Member] [Domain]", "terseLabel": "Sterile Surgical Gown Recall [Member] [Domain]" } } }, "localname": "SterileSurgicalGownRecallMemberDomain", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_TaxMatterAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Matter [Axis]", "label": "Tax Matter [Axis]", "terseLabel": "Tax Matter [Axis]" } } }, "localname": "TaxMatterAxis", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_TaxMatterDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Tax Matter [Axis]", "label": "Tax Matter [Domain]", "terseLabel": "Tax Matter [Domain]" } } }, "localname": "TaxMatterDomain", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_TotalLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total Lease Liability", "label": "Total Lease Liability", "terseLabel": "Total Lease Liability" } } }, "localname": "TotalLeaseLiability", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalLeaseLiabilityNotYetCommencedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total Lease Liability Not Yet Commenced, Amount", "label": "Total Lease Liability Not Yet Commenced, Amount", "terseLabel": "Less: leases not yet commenced (1)" } } }, "localname": "TotalLeaseLiabilityNotYetCommencedAmount", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalLeaseLiabilityPaymentsDue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total undiscounted Lease Liability Payments Due for both operating and financing leases", "label": "Total Lease Liability Payments Due", "terseLabel": "Total future lease payments" } } }, "localname": "TotalLeaseLiabilityPaymentsDue", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total Lease Liability Undiscounted Excess Amount", "label": "Total Lease Liability Undiscounted Excess Amount", "terseLabel": "Less: imputed interest" } } }, "localname": "TotalLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalOpioidLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Opioid Litigation", "label": "Total Opioid Litigation [Member]", "terseLabel": "Total Opioid Litigation [Member]" } } }, "localname": "TotalOpioidLitigationMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLossContingenciesDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_TrademarksAndPatentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Trademarks And Patents Member", "terseLabel": "Trademarks, trade names and patents" } } }, "localname": "TrademarksAndPatentsMember", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cah_TreasuryStockAcquiredShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury Stock Acquired Shares", "label": "Treasury Stock Acquired Shares", "terseLabel": "Treasury Stock Acquired Shares" } } }, "localname": "TreasuryStockAcquiredShares", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cah_VendorReserves": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total of reserves, relating to vendor disputes or deductions, that are netted against vendor liabilities in the ordinary course of business.", "label": "Vendor Reserves", "terseLabel": "Vendor reserves" } } }, "localname": "VendorReserves", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeVendorReservesDetails" ], "xbrltype": "monetaryItemType" }, "cah_VestingPeriodinyearsforShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting Period in years for Shares", "label": "Vesting Period in years for Shares", "terseLabel": "Vesting Period in years for Shares" } } }, "localname": "VestingPeriodinyearsforShares", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails" ], "xbrltype": "integerItemType" }, "cah_WriteDownOfAssetsHeldForSale": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Write-down of assets held for sale", "label": "Write-down of assets held for sale", "terseLabel": "Write-down of assets held for sale" } } }, "localname": "WriteDownOfAssetsHeldForSale", "nsuri": "http://www.cardinal.com/20210630", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.cardinal.com/role/SegmentInformationPropertyandEquipmentnetbyGeographicAreaDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r776", "r777", "r778" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage", "http://www.cardinal.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r779" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r774" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r780" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r780" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r780" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r782" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r780" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r780" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r780" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r780" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-Known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r776", "r777", "r778" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r773" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r775" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r144", "r209", "r222", "r223", "r224", "r225", "r227", "r229", "r233", "r343", "r344", "r345", "r346", "r347", "r348", "r350", "r351", "r353", "r355", "r356", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804" ], "lang": { "en-us": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDepreciationandAmortizationandAdditionstoPropertyandEquipmentbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r144", "r209", "r222", "r223", "r224", "r225", "r227", "r229", "r233", "r343", "r344", "r345", "r346", "r347", "r348", "r350", "r351", "r353", "r355", "r356", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804" ], "lang": { "en-us": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDepreciationandAmortizationandAdditionstoPropertyandEquipmentbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case Type" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r242", "r427", "r430", "r740" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r361", "r402", "r442", "r444", "r676", "r677", "r678", "r679", "r680", "r681", "r683", "r737", "r741", "r771", "r772" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeGoodwillandOtherIntangibleAssetsDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r361", "r402", "r442", "r444", "r676", "r677", "r678", "r679", "r680", "r681", "r683", "r737", "r741", "r771", "r772" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeGoodwillandOtherIntangibleAssetsDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r242", "r427", "r430", "r740" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r236", "r427", "r428", "r685", "r736", "r738" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeShippingandHandlingDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r236", "r427", "r428", "r685", "r736", "r738" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeShippingandHandlingDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r361", "r402", "r431", "r442", "r444", "r676", "r677", "r678", "r679", "r680", "r681", "r683", "r737", "r741", "r771", "r772" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeGoodwillandOtherIntangibleAssetsDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails", "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r361", "r402", "r431", "r442", "r444", "r676", "r677", "r678", "r679", "r680", "r681", "r683", "r737", "r741", "r771", "r772" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeGoodwillandOtherIntangibleAssetsDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails", "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r152", "r793" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccounts" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r237", "r238", "r427", "r429", "r739", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r783", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/SegmentInformationPropertyandEquipmentnetbyGeographicAreaDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r237", "r238", "r427", "r429", "r739", "r756", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r783", "r784" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/SegmentInformationPropertyandEquipmentnetbyGeographicAreaDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2021-01-31", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r145", "r146", "r147", "r150", "r151", "r793" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]", "terseLabel": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails", "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r60", "r671" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "verboseLabel": "Accounts Payable, Current" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r700", "r725" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable", "terseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Other Accrued Liabilities" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r57", "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r81", "r86", "r94", "r95", "r96", "r554" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Foreign Currency Translation Adjustments and other" } } }, "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r82", "r86", "r554" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax" } } }, "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r47", "r84", "r85", "r86", "r719", "r749", "r753" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r83", "r86", "r94", "r95", "r96", "r154", "r155", "r156", "r554", "r744", "r745", "r809" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r157", "r158", "r159", "r160", "r169", "r251", "r252", "r256", "r257", "r258", "r259", "r260", "r261", "r342", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r521", "r522", "r523", "r524", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r668", "r687", "r688", "r689", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r805", "r806", "r807", "r808", "r809" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r446", "r473", "r484" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossMember": { "auth_ref": [ "r145", "r146", "r147", "r150", "r151" ], "lang": { "en-us": { "role": { "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]", "terseLabel": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]" } } }, "localname": "AllowanceForCreditLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails", "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForLoanAndLeaseLossesMember": { "auth_ref": [ "r145", "r146", "r147", "r150", "r151" ], "lang": { "en-us": { "role": { "documentation": "Allowance for portion expected to be uncollectible of receivable from loan and lease portfolio.", "label": "SEC Schedule, 12-09, Allowance, Loan and Lease Loss [Member]", "terseLabel": "SEC Schedule, 12-09, Allowance, Loan and Lease Loss [Member]" } } }, "localname": "AllowanceForLoanAndLeaseLossesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForLossesOnFinanceReceivablesMember": { "auth_ref": [ "r145", "r146", "r147", "r150", "r151" ], "lang": { "en-us": { "role": { "documentation": "Allowance for portion expected to be uncollectible of investment in contractual right to receive money on demand or on fixed or determinable date recognized as asset in creditor's statement of financial position.", "label": "SEC Schedule, 12-09, Allowance, Loss on Finance Receivable [Member]", "terseLabel": "SEC Schedule, 12-09, Allowance, Loss on Finance Receivable [Member]", "verboseLabel": "SEC Schedule, 12-09, Allowance, Loss on Finance Receivable [Member]" } } }, "localname": "AllowanceForLossesOnFinanceReceivablesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails", "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r126", "r281", "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r83", "r86", "r94", "r95", "r96", "r554" ], "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]" } } }, "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r139", "r217", "r224", "r231", "r255", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r352", "r354", "r356", "r357", "r547", "r555", "r626", "r669", "r671", "r692", "r717" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r27", "r28", "r76", "r139", "r255", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r352", "r354", "r356", "r357", "r547", "r555", "r626", "r669", "r671" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r5", "r6", "r16", "r18", "r22", "r300" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "terseLabel": "Disposal Group, Including Discontinued Operation, Assets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r448", "r475" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoRestrictedShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofRemainingStockOptionPlanDataDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r570", "r575" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and Improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r441", "r443" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]", "verboseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r441", "r443", "r538", "r539" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "verboseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination Disclosure" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r23", "r53", "r128" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and equivalents at end of period", "periodStartLabel": "Cash and equivalents at beginning of period", "terseLabel": "Cash and equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r33", "r129" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r122", "r635" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossIncludedinAOCIforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r596" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r136", "r139", "r172", "r173", "r174", "r176", "r178", "r188", "r189", "r190", "r255", "r343", "r348", "r349", "r350", "r356", "r357", "r400", "r401", "r405", "r409", "r626", "r781" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper", "verboseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r323", "r324", "r325", "r336", "r758" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments, Contingent Liabilities and Litigation" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r339", "r759" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Loss Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommodityContractMember": { "auth_ref": [ "r432", "r586" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to commodity prices.", "label": "Commodity Contract [Member]", "terseLabel": "Commodity Contracts" } } }, "localname": "CommodityContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossIncludedinAOCIforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Cash dividends per common share (in usd per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDividendsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r154", "r155", "r608" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Common shares, without par value:" } } }, "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common shares, authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "terseLabel": "Common shares, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r43", "r671" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Authorized\u2014755 million shares, Issued\u2014 327 million shares at June 30, 2021 and 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred income tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred income tax liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r89", "r91", "r92", "r104", "r706", "r731" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r89", "r91", "r103", "r545", "r559", "r705", "r730" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income/(loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r198", "r199", "r242", "r623", "r624", "r757" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r198", "r199", "r242", "r623", "r624", "r754", "r757" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r198", "r199", "r242", "r623", "r624", "r754", "r757" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r193", "r713" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r198", "r199", "r242", "r623", "r624" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Revenue, major customer, percentage", "verboseLabel": "Percent of Revenue" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r196", "r198", "r199", "r200", "r623", "r625", "r757" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r198", "r199", "r242", "r623", "r624", "r757" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r131", "r549" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Noncontrolling Interests and Redeemable Noncontrolling Interests" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r222", "r223", "r224", "r225", "r227", "r233", "r235" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDepreciationandAmortizationandAdditionstoPropertyandEquipmentbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r110", "r685" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Goods and Services Sold", "verboseLabel": "Cost of products sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Products Sold" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "auth_ref": [ "r313", "r314", "r321" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "terseLabel": "Restructuring and Employee Severance" } } }, "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CrossCurrencyInterestRateContractMember": { "auth_ref": [ "r432", "r587" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.", "label": "Cross Currency Interest Rate Contract [Member]", "terseLabel": "Cross Currency Interest Rate Contract [Member]" } } }, "localname": "CrossCurrencyInterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Currency Swap [Member]" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r140", "r517", "r527" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal", "verboseLabel": "Current Federal Tax Expense (Benefit)" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r140", "r517" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Non-U.S.", "verboseLabel": "Current Foreign Tax Expense (Benefit)" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r140", "r517", "r527", "r529" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "terseLabel": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r140", "r517", "r527" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State and local", "verboseLabel": "Current State and Local Tax Expense (Benefit)" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r197", "r242" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r699", "r726" ], "calculation": { "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term and long-term debt and lease obligation.", "label": "Debt and Lease Obligation", "totalLabel": "Total", "verboseLabel": "Carrying amount" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r135", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r375", "r382", "r383", "r385", "r392" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r36", "r37", "r38", "r138", "r144", "r358", "r359", "r360", "r361", "r362", "r363", "r365", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r386", "r387", "r388", "r389", "r649", "r693", "r695", "r716" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r373", "r386", "r387", "r622" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Estimated fair value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r64", "r359" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r65", "r138", "r144", "r358", "r359", "r360", "r361", "r362", "r363", "r365", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r386", "r387", "r388", "r389", "r649" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r65", "r138", "r144", "r358", "r359", "r360", "r361", "r362", "r363", "r365", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r384", "r386", "r387", "r388", "r389", "r417", "r420", "r421", "r422", "r646", "r647", "r649", "r650", "r712" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r495" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r140", "r518", "r527" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "negatedTerseLabel": "Federal", "terseLabel": "Federal", "verboseLabel": "Deferred Federal Income Tax Expense (Benefit)" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r140", "r518", "r527" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Non-U.S.", "verboseLabel": "Deferred Foreign Income Tax Expense (Benefit)" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge": { "auth_ref": [ "r595" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount as of the balance sheet date of the unamortized adjustment to the carrying value of an interest-bearing hedged item made under an effective interest rate fair value hedge that is amortized upon discontinuation of the interest rate fair value hedge.", "label": "Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge", "terseLabel": "Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge" } } }, "localname": "DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r126", "r140", "r518", "r527", "r528", "r529" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Provision for/(benefit from) deferred income taxes", "totalLabel": "Total deferred", "verboseLabel": "Deferred Income Tax Expense (Benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r39", "r40", "r507", "r694", "r715" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred income tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesAfterNettingbyTaxJurisdictionDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Deferred Income Taxes and Other Assets, Noncurrent", "terseLabel": "Deferred Income Taxes and Other Assets, Noncurrent" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesAfterNettingbyTaxJurisdictionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesAfterNettingbyTaxJurisdictionDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other tax liabilities expected to be paid after one year or operating cycle, if longer.", "label": "Deferred Income Taxes and Other Tax Liabilities, Noncurrent", "terseLabel": "Deferred Income Taxes and Other Tax Liabilities, Noncurrent" } } }, "localname": "DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesAfterNettingbyTaxJurisdictionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r140", "r518", "r527" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State and local", "verboseLabel": "Deferred State and Local Income Tax Expense (Benefit)" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.", "label": "Deferred Tax and Other Liabilities, Noncurrent", "terseLabel": "Deferred income taxes and other liabilities" } } }, "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r508" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred income tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r510" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Deferred Tax Assets, Net" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r515", "r516" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r513", "r515", "r516" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "negatedLabel": "Deferred tax assets on tax credit carryforwards", "terseLabel": "Loss and tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r515", "r516" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Share-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r515", "r516" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r515", "r516" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.", "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Receivable basis difference" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r509" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Deferred Tax Assets, Valuation Allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r490", "r510" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesAfterNettingbyTaxJurisdictionDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred income tax liability" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesAfterNettingbyTaxJurisdictionDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": { "auth_ref": [ "r515", "r516" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.", "label": "Deferred Tax Liabilities, Inventory", "negatedLabel": "Inventory basis differences" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from reserves and accruals.", "label": "Deferred Tax Liabilities, Deferred Expense, Reserves and Accruals", "negatedTerseLabel": "Deferred Tax Liabilities, Deferred Expense, Reserves and Accruals" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "auth_ref": [ "r515", "r516" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets", "negatedLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r515", "r516" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedTerseLabel": "Deferred Tax Liabilities, Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r515", "r516" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Property-related" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r440" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Total expense on employee retirement savings plans" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r126", "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r126", "r212" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "verboseLabel": "Total depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/SegmentInformationDepreciationandAmortizationandAdditionstoPropertyandEquipmentbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotionalAmount": { "auth_ref": [ "r562", "r563", "r565" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative asset.", "label": "Derivative Asset, Notional Amount", "terseLabel": "Notional Amount", "verboseLabel": "Derivative, notional amount" } } }, "localname": "DerivativeAssetNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r560" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "terseLabel": "Forward contracts" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative, Name [Domain]", "verboseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossIncludedinAOCIforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforDerivativesNotDesignatedasHedgingInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r77", "r78", "r79", "r573", "r682" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Total assets" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r77", "r78", "r79", "r573", "r682" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Total liabilities" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "auth_ref": [ "r622" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.", "label": "Derivative, Fair Value, Net", "terseLabel": "Fair\u00a0Value Gain/(Loss)" } } }, "localname": "DerivativeFairValueOfDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Gain/(loss) on derivative" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r78", "r571", "r574", "r580", "r589" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossIncludedinAOCIforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforDerivativesNotDesignatedasHedgingInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r568", "r571", "r580" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossIncludedinAOCIforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails", "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": { "auth_ref": [ "r578", "r588" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "terseLabel": "Gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges" } } }, "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r579", "r581" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Gain/(loss) recognized in earnings for economic (non-designated) derivative instruments" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforDerivativesNotDesignatedasHedgingInstrumentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotionalAmount": { "auth_ref": [ "r562", "r563", "r565" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative liability.", "label": "Derivative Liability, Notional Amount", "terseLabel": "Derivative Liability, Notional Amount" } } }, "localname": "DerivativeLiabilityNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossIncludedinAOCIforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforDerivativesNotDesignatedasHedgingInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r563", "r565" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r561", "r564", "r565", "r568", "r569", "r576", "r580", "r592", "r593", "r597", "r599" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossIncludedinAOCIforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforDerivativesNotDesignatedasHedgingInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for derivatives used in hedging relationships, which may include how gains or losses are recognized and presented in the financial statements, and amortization policies for deferred amounts.", "label": "Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block]", "terseLabel": "Interest Rate, Currency and Commodity Risk" } } }, "localname": "DerivativesMethodsOfAccountingHedgingDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "verboseLabel": "Developed technology and other" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation": { "auth_ref": [ "r7", "r8", "r19", "r534" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.", "label": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation", "terseLabel": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation" } } }, "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": { "auth_ref": [ "r5", "r6", "r16", "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities", "terseLabel": "Disposal Group, Including Discontinued Operation, Accrued Liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "auth_ref": [ "r5", "r6", "r16", "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Disposal Group, Including Discontinued Operation, Consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses": { "auth_ref": [ "r640" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.", "label": "Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses)", "terseLabel": "Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses)" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": { "auth_ref": [ "r5", "r6", "r16", "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Goodwill", "negatedTerseLabel": "Disposal Group, Including Discontinued Operation, Goodwill" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "auth_ref": [ "r5", "r6", "r16", "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Inventory", "terseLabel": "Disposal Group, Including Discontinued Operation, Inventory" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": { "auth_ref": [ "r5", "r6", "r16", "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Assets", "terseLabel": "Disposal Group, Including Discontinued Operation, Other Assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "auth_ref": [ "r5", "r6", "r16", "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities", "terseLabel": "Disposal Group, Including Discontinued Operation, Other Liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r5", "r6", "r16", "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "terseLabel": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r441", "r443" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r423", "r711" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedLabel": "Dividends declared" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r105", "r161", "r162", "r163", "r164", "r165", "r170", "r172", "r176", "r177", "r178", "r183", "r184", "r609", "r610", "r707", "r732" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Earnings Per Share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Earnings/(loss) per common share attributable to Cardinal Health, Inc." } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r105", "r161", "r162", "r163", "r164", "r165", "r172", "r176", "r177", "r178", "r183", "r184", "r609", "r610", "r707", "r732" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings Per Share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted earnings per common share attributable to Cardinal Health, Inc.:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r179", "r181", "r182", "r185" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Earnings Per Share Attributable to Cardinal Health, Inc." } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r635" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rates changes on cash and equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r492" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r142", "r492", "r531" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 11.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Provision at Federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r492", "r531" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowances" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r492", "r531" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Nondeductible/nontaxable items (2)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r492", "r531" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 12.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent", "verboseLabel": "Goodwill impairment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent", "terseLabel": "Other (2)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r492", "r531" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State and local income taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r474" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "netLabel": "Total compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized, pre-tax", "terseLabel": "Total compensation cost, net of estimated forfeitures, related to unvested stock options not yet recognized, pre-tax", "verboseLabel": "Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoRestrictedShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "netLabel": "Weighted-average period over which performance share unit cost is expected to be recognized (in years)", "terseLabel": "Weighted-average period over which stock option compensation cost is expected to be recognized", "verboseLabel": "Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoRestrictedShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofRemainingStockOptionPlanDataDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r473" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Tax benefit related to share-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee- Related Costs" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options", "verboseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofRemainingStockOptionPlanDataDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Major Customer [Line Items]", "terseLabel": "Revenue, Major Customer [Line Items]" } } }, "localname": "EntityWideRevenueMajorCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r94", "r95", "r96", "r154", "r155", "r156", "r158", "r166", "r168", "r187", "r259", "r416", "r423", "r480", "r481", "r482", "r523", "r524", "r608", "r636", "r637", "r638", "r639", "r640", "r642", "r744", "r745", "r746", "r809" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r54", "r218", "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities": { "auth_ref": [ "r485" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation, Financing Activities", "verboseLabel": "Excess tax benefits from share based compensation" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FacilityClosingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Facility Closing [Member]", "terseLabel": "Facility Exit and Other Costs" } } }, "localname": "FacilityClosingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r611", "r612", "r613", "r619" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r616", "r619" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r373", "r386", "r387", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r612", "r673", "r674", "r675" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r618", "r619" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r611", "r612", "r614", "r615", "r620" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Disclosures" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair Value Hedging" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails", "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r373", "r432", "r433", "r438", "r439", "r612", "r673" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r373", "r386", "r387", "r432", "r433", "r438", "r439", "r612", "r674" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r373", "r386", "r387", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r612", "r675" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r373", "r386", "r387", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r673", "r674", "r675" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "auth_ref": [ "r611", "r612", "r614", "r615", "r617", "r620" ], "lang": { "en-us": { "role": { "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.", "label": "Fair Value, Nonrecurring [Member]", "terseLabel": "Fair Value, Nonrecurring" } } }, "localname": "FairValueMeasurementsNonrecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r618", "r620" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "http://www.cardinal.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisUsingUnobservableInputsLevel3Details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r570", "r576", "r594" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r653", "r666" ], "calculation": { "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total lease liabilities", "totalLabel": "Total finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r653" ], "calculation": { "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance Lease, Liability, Current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r653" ], "calculation": { "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance Lease, Liability, Noncurrent" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "terseLabel": "Total future lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r655", "r661" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Finance Lease, Principal Payments" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r652" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r654", "r658", "r667" ], "calculation": { "http://www.cardinal.com/role/LeasesScheduleofLeaseCostsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r664", "r667" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r663", "r667" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r288" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Estimated annual amortization of intangible assets - 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "Estimated annual amortization of intangible assets - 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Estimated annual amortization of intangible assets - 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Estimated annual amortization of intangible assets - 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Estimated annual amortization of intangible assets - 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r282", "r284", "r288", "r292", "r686", "r690" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r288", "r690" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Intangible" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r282", "r287" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r288", "r686" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Net Intangible" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r686" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Weighted- Average Remaining Amortization Period (Years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r644" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Translation of Foreign Currencies" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r78", "r432", "r585" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Currency Contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossIncludedinAOCIforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforDerivativesNotDesignatedasHedgingInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts [Member]" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossIncludedinAOCIforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "verboseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r126" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "Gain (Loss) on Sale of Investments", "terseLabel": "Gain (Loss) on Sale of Investments" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfOtherInvestments": { "auth_ref": [ "r126" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) included in earnings for investments classified as other.", "label": "Gain (Loss) on Sale of Other Investments", "negatedTerseLabel": "Loss on Sale of Investments" } } }, "localname": "GainLossOnSaleOfOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "auth_ref": [ "r126" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net" } } }, "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r326" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "negatedTerseLabel": "Litigation (recoveries)/charges, net", "terseLabel": "Gain (Loss) Related to Litigation Settlement" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLossContingenciesDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainOnSaleOfInvestments": { "auth_ref": [ "r107", "r108", "r126", "r702", "r733" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.", "label": "Gain on Sale of Investments", "terseLabel": "Gain on Sale of Investments" } } }, "localname": "GainOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r126", "r390", "r391" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on early extinguishment of debt", "terseLabel": "Gain (Loss) on Extinguishment of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r269", "r271", "r671", "r691" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r277", "r285" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r274" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Foreign currency translation adjustments and other" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r272", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Accumulated goodwill impairment loss" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r126", "r270", "r273", "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill, Impairment Loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillTransfers": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Transfers", "terseLabel": "Goodwill, Transfers" } } }, "localname": "GoodwillTransfers", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r109", "r139", "r217", "r223", "r227", "r230", "r233", "r255", "r343", "r344", "r345", "r348", "r349", "r350", "r352", "r354", "r356", "r357", "r626" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.", "label": "Guarantees, Indemnifications and Warranties Policies [Policy Text Block]", "terseLabel": "Guarantees, Indemnifications and Warranties Policies [Policy Text Block]" } } }, "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r568", "r590" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforDerivativesNotDesignatedasHedgingInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails", "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforDerivativesNotDesignatedasHedgingInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails", "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossIncludedinAOCIforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails", "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r141", "r530" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S. operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r141", "r530" ], "calculation": { "http://www.cardinal.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Non-U.S. operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r217", "r223", "r227", "r230", "r233" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.cardinal.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Earnings/(loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r100", "r126", "r214", "r253", "r701", "r727" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "terseLabel": "Income (Loss) from Equity Method Investments" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r441", "r443" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r299", "r308" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforDerivativesNotDesignatedasHedgingInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforDerivativesNotDesignatedasHedgingInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r497", "r504", "r506", "r520" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r142", "r493", "r505", "r512", "r525", "r532", "r535", "r536", "r537" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r143", "r167", "r168", "r215", "r491", "r526", "r533", "r735" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income Tax Expense (Benefit)", "totalLabel": "Provision for/(benefit from) income taxes", "verboseLabel": "Provision for/(benefit from) income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitCurrentandDeferredDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r93", "r488", "r489", "r505", "r506", "r511", "r519" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReceivable": { "auth_ref": [ "r52", "r714" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.", "label": "Income Taxes Receivable", "terseLabel": "Income Taxes Receivable" } } }, "localname": "IncomeTaxReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash payments for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r125" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Increase/(decrease) in accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r125" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Increase in inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r125" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedTerseLabel": "Other accrued liabilities and operating items, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r125" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedTerseLabel": "(Increase)/decrease in trade receivables" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Shareholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r283", "r291" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Net Intangible" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r283", "r291" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Gross Intangible, Total other intangible assets" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r280", "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Net Intangible, Total other intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "Intangible Assets, Net (Including Goodwill)", "terseLabel": "Goodwill and other intangibles, net" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r98", "r211", "r645", "r648", "r708" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense, Net" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest Income (Expense), Nonoperating, Net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r119", "r123", "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash payments for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swaps", "verboseLabel": "Interest Rate Swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofFairValueGainLossDerivativeInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossIncludedinAOCIforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforInterestRateContractsDesignatedasFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsCashFlowHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsFairValueHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Federal" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "terseLabel": "Inventories valued at LIFO amount higher than average cost value" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r24", "r72", "r671" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r32", "r73", "r132", "r186", "r264", "r266", "r268", "r684" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRecallExpense": { "auth_ref": [ "r111" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise.", "label": "Inventory Recall Expense", "terseLabel": "Inventory Recall Expense" } } }, "localname": "InventoryRecallExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r72", "r267" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Reserves for excess and obsolete inventory" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r265" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory Write-down" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r254", "r734" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r611" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Other investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandBuildingsAndImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real estate held and additions or improvements to real estate held and structures used in the conduct of business.", "label": "Land, Buildings and Improvements [Member]", "terseLabel": "Land, building and improvements" } } }, "localname": "LandBuildingsAndImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Operating Leases, Rent Expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r665", "r667" ], "calculation": { "http://www.cardinal.com/role/LeasesScheduleofLeaseCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r665" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Costs" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Total future lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r657" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, Operating Lease, Term of Contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r50", "r139", "r255", "r626", "r671", "r697", "r722" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r63", "r139", "r255", "r343", "r344", "r345", "r348", "r349", "r350", "r352", "r354", "r356", "r357", "r548", "r555", "r556", "r626", "r669", "r670", "r671" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r5", "r6", "r16", "r18", "r22", "r300" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "terseLabel": "Disposal Group, Including Discontinued Operation, Liabilities" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails", "http://www.cardinal.com/role/FairValueMeasurementsDetails", "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r38", "r695", "r716" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Long-term Line of Credit", "verboseLabel": "Line of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r61", "r138" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r61", "r138" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum amount borrowed under the credit facility at any time during the period.", "label": "Line of Credit Facility, Maximum Amount Outstanding During Period", "terseLabel": "Line of Credit Facility, Maximum Amount Outstanding During Period" } } }, "localname": "LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity", "verboseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsLongTermDebtDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r61", "r138" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r66", "r326" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Estimated Litigation Liability" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Litigation Settlement, Expense" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-lived Assets by Geographic Areas [Table Text Block]", "terseLabel": "Property and Equipment, Net by Geographic Area" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r38" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term Debt and Lease Obligation", "terseLabel": "Long-term obligations, less current portion" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r62" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails": { "order": 1.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-term Debt and Lease Obligation, Current", "terseLabel": "Current portion of long-term obligations and other short-term borrowings", "verboseLabel": "Less: current portion of long-term obligations and other short-term borrowings" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r144", "r341", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Maturities of existing long-term obligations and other short-term borrowings-Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r144", "r341", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "Maturities of existing long-term obligations and other short-term borrowings - 2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r144", "r341", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "Maturities of existing long-term obligations and other short-term borrowings-2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r144", "r341", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "Maturities of existing long-term obligations and other short-term borrowings-2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r144", "r341", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "Maturities of existing long-term obligations and other short-term borrowings-2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r144", "r341", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "Maturities of existing long-term obligations and other short-term borrowings-2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.", "label": "Long-term Debt, Weighted Average Interest Rate, at Point in Time", "verboseLabel": "Interest rate on long-term projects (approximates weighted-average on long-term obligations)" } } }, "localname": "LongtermDebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r326", "r327", "r328", "r331", "r332", "r333", "r335", "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLossContingenciesDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r326", "r327", "r328", "r331", "r332", "r333", "r335", "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLossContingenciesDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r326" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Loss Contingency Accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyClaimsSettledNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of claims settled.", "label": "Loss Contingency, Claims Settled, Number", "terseLabel": "Loss Contingency, Claims Settled, Number" } } }, "localname": "LossContingencyClaimsSettledNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "auth_ref": [ "r330", "r334", "r337" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "label": "Loss Contingency, Estimate of Possible Loss", "terseLabel": "Loss Contingency, Estimate of Possible Loss" } } }, "localname": "LossContingencyEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r326", "r327", "r328", "r331", "r332", "r333", "r335", "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Number of lawsuits filed" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.", "label": "Loss Contingency, Number of Plaintiffs", "terseLabel": "Number of plaintiffs" } } }, "localname": "LossContingencyNumberOfPlaintiffs", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "verboseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MajorCustomersPolicyPolicyTextBlock": { "auth_ref": [ "r196", "r198", "r199", "r242" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.", "label": "Major Customers, Policy [Policy Text Block]", "terseLabel": "Major Customers" } } }, "localname": "MajorCustomersPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r71", "r139", "r255", "r343", "r348", "r349", "r350", "r356", "r357", "r626", "r696", "r721" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r122" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r122" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by/(used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r122", "r124", "r127" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r22", "r87", "r90", "r96", "r101", "r127", "r139", "r157", "r161", "r162", "r163", "r164", "r167", "r168", "r175", "r217", "r223", "r227", "r230", "r233", "r255", "r343", "r344", "r345", "r348", "r349", "r350", "r352", "r354", "r356", "r357", "r610", "r626", "r703", "r728" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net earnings/(loss) attributable to Cardinal Health, Inc.", "verboseLabel": "Net Income (Loss) Attributable to Parent" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r87", "r90", "r96", "r167", "r168", "r551", "r558" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 }, "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net earnings attributable to noncontrolling interest", "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests", "terseLabel": "Net Income (Loss) Attributable to Noncontrolling Interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Financial Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International", "verboseLabel": "Non-US [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationPropertyandEquipmentnetbyGeographicAreaDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r154", "r155", "r156", "r423", "r543" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforDerivativesNotDesignatedasHedgingInstrumentDetails", "http://www.cardinal.com/role/FinancialInstrumentsScheduleofOutstandingInstrumentsEconomicHedgesDetails", "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "domainItemType" }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r25", "r26", "r44", "r244", "r245", "r698" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Finance notes and related accrued interest, net, current" } } }, "localname": "NotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r38", "r695", "r718" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "terseLabel": "Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r45", "r244", "r263" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, after Allowance for Credit Loss", "terseLabel": "Finance notes and related accrued interest, net, total" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeGoodwillandOtherIntangibleAssetsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r217", "r223", "r227", "r230", "r233" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Total operating earnings", "totalLabel": "Operating earnings/(loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r659", "r667" ], "calculation": { "http://www.cardinal.com/role/LeasesScheduleofLeaseCostsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r653" ], "calculation": { "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r653" ], "calculation": { "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r653" ], "calculation": { "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating Lease, Liability, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r656", "r661" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r652" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r664", "r667" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r663", "r667" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "auth_ref": [ "r509" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.", "label": "Operating Loss Carryforwards, Valuation Allowance", "terseLabel": "Valuation allowance on operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwardsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r222", "r223", "r224", "r225", "r227", "r233" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDepreciationandAmortizationandAdditionstoPropertyandEquipmentbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r29", "r30", "r31", "r62" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r75", "r671" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r570", "r594" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets [Member]" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r58" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherBorrowings": { "auth_ref": [ "r699" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount as of the balance sheet date for the aggregate of other miscellaneous borrowings owed by the reporting entity.", "label": "Other Borrowings", "terseLabel": "Other obligations", "verboseLabel": "Other Borrowings" } } }, "localname": "OtherBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r86", "r94", "r95", "r97", "r636", "r638", "r642" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "verboseLabel": "Other comprehensive income/(loss), net before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": { "auth_ref": [ "r82" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax", "terseLabel": "Net unrealized gain/(loss) on derivative instruments, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r80" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments and other" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r582" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r88", "r91", "r94", "r95", "r97", "r102", "r416", "r636", "r641", "r642", "r704", "r729" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive income/(loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income/(loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r88", "r91", "r545", "r546", "r553" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive loss, net of tax", "verboseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r82", "r84", "r598" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax", "terseLabel": "Gain/(loss) included in AOCI for derivative instruments designated as cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossIncludedinAOCIforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r570", "r594" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]", "terseLabel": "Other Liabilities" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r113" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income)/expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Income, Net" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossRecognizedinEarningsforDerivativesNotDesignatedasHedgingInstrumentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherShortTermBorrowings": { "auth_ref": [ "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.", "label": "Other Short-term Borrowings", "terseLabel": "Other Short-term Borrowings" } } }, "localname": "OtherShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromHedgeFinancingActivities": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash outflow or inflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.", "label": "Payments for (Proceeds from) Hedge, Financing Activities", "negatedTerseLabel": "Proceeds from interest rate swap terminations" } } }, "localname": "PaymentsForProceedsFromHedgeFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r117" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchase of treasury shares", "terseLabel": "Payments for Repurchase of Common Stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r120", "r307" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Payments and other adjustments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r117" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends on common shares" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r115" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisition of subsidiaries, net of cash acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r116" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to property and equipment", "terseLabel": "Total additions to property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/SegmentInformationDepreciationandAmortizationandAdditionstoPropertyandEquipmentbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PercentageOfLIFOInventory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of LIFO (last in first out) inventory to total inventory as of the balance sheet date if other than 100 percent.", "label": "Percentage of LIFO Inventory", "terseLabel": "Portion of inventories held at LIFO, percentage" } } }, "localname": "PercentageOfLIFOInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeInventoriesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Share Units" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoRestrictedShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r448", "r475" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Preferred shares, without par value:" } } }, "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred shares, authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r42", "r400" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred shares, issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r42", "r671" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Authorized\u2014500 thousand shares, Issued\u2014none" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleoftheFairValueofAssetsandLiabilitiesRelatedtoDerivativesDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r114" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from Divestiture of Businesses" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-term Debt", "terseLabel": "Net change in short-term borrowings" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r22", "r87", "r90", "r96", "r121", "r139", "r157", "r167", "r168", "r217", "r223", "r227", "r230", "r233", "r255", "r343", "r344", "r345", "r348", "r349", "r350", "r352", "r354", "r356", "r357", "r545", "r550", "r552", "r558", "r559", "r610", "r626", "r709" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net earnings", "totalLabel": "Net earnings", "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows", "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r57", "r298" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails", "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r56", "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r34", "r35", "r298", "r671", "r710", "r724" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails", "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/SegmentInformationPropertyandEquipmentnetbyGeographicAreaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r55", "r298", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r34", "r298" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Components of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r34", "r296" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails", "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, Plant and Equipment, Useful Life", "verboseLabel": "Useful life of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r106", "r262" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for bad debts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]", "terseLabel": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails", "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r45", "r51", "r671", "r723", "r755" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "terseLabel": "Trade receivables, net" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r246", "r248", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Receivables" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r86", "r94", "r95", "r97", "r636", "r640", "r642" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified to earnings" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r224", "r227" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Assets by Reportable Segment" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r223", "r227" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r223", "r227" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Segment Profit by Reportable Segment" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r225", "r227" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.", "label": "Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]", "terseLabel": "Depreciation and Amortization and Additions to Property and Equipment by Reportable Segment" } } }, "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r222", "r227" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "terseLabel": "Revenue by Reportable Segment" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "auth_ref": [ "r394", "r395", "r396", "r397" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "terseLabel": "Redeemable Noncontrolling Interest, Equity, Carrying Amount" } } }, "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r118" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Reduction of long-term obligations" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Share Units", "verboseLabel": "Restricted Share Unit" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoRestrictedShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r305", "r307", "r310", "r320", "r322" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Employee Severance" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeverance" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r126", "r304", "r313", "r317" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "totalLabel": "Total restructuring and employee severance", "verboseLabel": "Restructuring and employee severance" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring Charges [Abstract]", "terseLabel": "Restructuring Charges [Abstract]" } } }, "localname": "RestructuringChargesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r306", "r307", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "terseLabel": "Additions" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r307", "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r46", "r423", "r483", "r671", "r720", "r748", "r753" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Retained earnings decrease", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r154", "r155", "r156", "r158", "r166", "r168", "r259", "r480", "r481", "r482", "r523", "r524", "r608", "r744", "r746" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r133", "r134" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionSalesReturnsReserveForSalesReturns": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of estimated sales returns.", "label": "Revenue Recognition, Sales Returns, Reserve for Sales Returns", "terseLabel": "Revenue Recognition, Sales Returns, Reserve for Sales Returns" } } }, "localname": "RevenueRecognitionSalesReturnsReserveForSalesReturns", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeSalesReturnsandAllowancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r99", "r139", "r208", "r209", "r222", "r228", "r229", "r236", "r237", "r242", "r255", "r343", "r344", "r345", "r348", "r349", "r350", "r352", "r354", "r356", "r357", "r626", "r709" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationPropertyandEquipmentnetbyGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsOtherFinancingArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r662", "r667" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r662", "r667" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesReturnsAndAllowancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.", "label": "Sales Returns and Allowances [Member]", "terseLabel": "Sales Returns and Allowances [Member]" } } }, "localname": "SalesReturnsAndAllowancesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r198", "r242" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeMajorCustomersDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r86", "r641", "r642" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r538", "r539" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount" } } }, "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Gain/(Loss) Reclassified from AOCI into Earnings for Derivative Instruments Designated as Cash Flow Hedges" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit), Current and Deferred" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.", "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Gain/(Loss) Included in AOCI for Derivative Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r571", "r580", "r590" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of Gain/(Loss) Recognized in Earnings for Interest Rate Contracts Designated as Fair Value Hedges" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of Fair Value of Assets and Liabilities Related to Derivatives Designated as Hedging Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r561", "r564", "r565", "r568", "r569", "r576", "r580", "r592", "r593" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Outstanding Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r6", "r10", "r11", "r12", "r13", "r14", "r15", "r17", "r20", "r21", "r22", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Disposal Groups, Including Discontinued Operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/DivestituresandAcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.", "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]" } } }, "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r611", "r612" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r282", "r287", "r686" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r282", "r287" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r651" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Lease Payments" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r277", "r279" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]", "verboseLabel": "Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r277", "r279" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill by Reportable Segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income Before Income Tax, Domestic and Foreign" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r291", "r293" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r291", "r293" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]", "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r579", "r581" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Schedule of Gain/(Loss) Recognized in Earnings for Economic (Non-designated) Derivative Instruments" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r57", "r298" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesComponentsofPropertyandEquipmentDetails", "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativePropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r306", "r307", "r308", "r309", "r317", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r311", "r312", "r316" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of Restructuring and Employee Severance" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r307", "r318" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "terseLabel": "Schedule of Revenue and Gross Trade Receivables Percentage by Major Customers" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r99", "r241" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationPropertyandEquipmentnetbyGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r217", "r220", "r226", "r277" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDepreciationandAmortizationandAdditionstoPropertyandEquipmentbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r217", "r220", "r226", "r277" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table Text Block]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r448", "r475" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoRestrictedShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofRemainingStockOptionPlanDataDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r453", "r465", "r468" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Transactions Under the Plans" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Range of Assumptions Used to Estimate Fair Value of Stock Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r67", "r136", "r188", "r189", "r393", "r398", "r399", "r400", "r401", "r402", "r403", "r405", "r409", "r414", "r417", "r418", "r419", "r420", "r421", "r422", "r423" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r504", "r520" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r204", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r222", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r233", "r242", "r309", "r319", "r736" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDepreciationandAmortizationandAdditionstoPropertyandEquipmentbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r204", "r206", "r207", "r217", "r221", "r227", "r231", "r232", "r233", "r234", "r236", "r241", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDepreciationandAmortizationandAdditionstoPropertyandEquipmentbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r112" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Distribution, selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeShippingandHandlingDetails", "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "SG&A Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsScheduleofGainLossReclassifiedfromAOCIintoEarningsforDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r126" ], "calculation": { "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "verboseLabel": "Employee-related costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r125" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoRestrictedShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Canceled and forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Canceled and forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested at end of period (in shares)", "periodStartLabel": "Nonvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Share Units", "verboseLabel": "Performance Share Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested at end of period (in usd per share)", "periodStartLabel": "Nonvested at beginning of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value per Share", "verboseLabel": "Weighted-Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r467" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Total fair value of shares vested during the year" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoRestrictedShareUnitActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoRestrictedShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofRemainingStockOptionPlanDataDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r467" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of exercised options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Canceled and forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Canceled and forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value per stock option (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of outstanding options at period end" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r455", "r475" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period (in usd per share)", "periodStartLabel": "Outstanding at beginning of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price per Common Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r445", "r450" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoRestrictedShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofRemainingStockOptionPlanDataDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r448", "r451" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Target performance goal (as a percent)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationAdditionalDataRelatedtoPerformanceShareUnitActivityDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of exercisable options at period end" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual life of exercisable options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofRemainingStockOptionPlanDataDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted-average remaining contractual life of outstanding options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofRemainingStockOptionPlanDataDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Total fair value of shares vested during the year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShippingAndHandlingMember": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Packing and transport of product.", "label": "Shipping and Handling [Member]", "terseLabel": "Shipping and Handling [Member]" } } }, "localname": "ShippingAndHandlingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeShippingandHandlingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r9", "r204", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r222", "r223", "r224", "r225", "r227", "r228", "r229", "r230", "r231", "r233", "r242", "r277", "r301", "r309", "r319", "r736" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "verboseLabel": "Operating and Reportable Segment" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenueandGrossTradeReceivablesPercentagebyMajorCustomersDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDepreciationandAmortizationandAdditionstoPropertyandEquipmentbyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r41", "r42", "r43", "r136", "r139", "r172", "r173", "r174", "r176", "r178", "r188", "r189", "r190", "r255", "r343", "r348", "r349", "r350", "r356", "r357", "r400", "r401", "r405", "r409", "r416", "r626", "r781" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r69", "r94", "r95", "r96", "r154", "r155", "r156", "r158", "r166", "r168", "r187", "r259", "r416", "r423", "r480", "r481", "r482", "r523", "r524", "r608", "r636", "r637", "r638", "r639", "r640", "r642", "r744", "r745", "r746", "r809" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails", "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r154", "r155", "r156", "r187", "r685" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/LeasesDetails", "http://www.cardinal.com/role/LeasesScheduleofFutureLeasePaymentsDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails", "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r42", "r43", "r416", "r423" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r42", "r43", "r416", "r423", "r457" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r42", "r43", "r423", "r447", "r466" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r43", "r48", "r49", "r139", "r247", "r255", "r626", "r671" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Cardinal Health, Inc. shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r95", "r139", "r154", "r155", "r156", "r158", "r166", "r255", "r259", "r423", "r480", "r481", "r482", "r523", "r524", "r543", "r544", "r557", "r608", "r626", "r636", "r637", "r642", "r745", "r746", "r809" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r137", "r401", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r415", "r423", "r426" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOtherShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of increase (decrease) in shares of stock classified as other.", "label": "Stockholders' Equity, Other Shares", "terseLabel": "Stockholders' Equity, Other Shares" } } }, "localname": "StockholdersEquityOtherShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsConsolidationItemsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.", "label": "Subsegments Consolidation Items [Axis]", "terseLabel": "Subsegments Consolidation Items [Axis]" } } }, "localname": "SubsegmentsConsolidationItemsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.", "label": "Subsegments Consolidation Items [Domain]", "terseLabel": "Subsegments Consolidation Items [Domain]" } } }, "localname": "SubsegmentsConsolidationItemsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r643", "r672" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r643", "r672" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r643", "r672" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails", "http://www.cardinal.com/role/DivestituresandAcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r513" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Tax Credit Carryforward [Line Items]", "terseLabel": "Income Taxes" } } }, "localname": "TaxCreditCarryforwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardTable": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Tax Credit Carryforward [Table]", "terseLabel": "Income Taxes" } } }, "localname": "TaxCreditCarryforwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense": { "auth_ref": [ "r519" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of income tax expense from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense", "terseLabel": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense" } } }, "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Treasury shares acquired, average price per share (in usd per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r68", "r424" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Shares" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r68", "r424" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)", "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)", "terseLabel": "Common shares in treasury" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r43", "r416", "r423" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedLabel": "Treasury shares acquired (in shares)", "terseLabel": "Treasury Stock, Shares, Acquired" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r68", "r424", "r425" ], "calculation": { "http://www.cardinal.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Common shares in treasury, at cost: 36 million shares and 34 million shares at June 30, 2021 and 2020, respectively", "negatedPeriodEndLabel": "Treasury, balance at end of period", "negatedPeriodStartLabel": "Treasury, balance at beginning of period" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedBalanceSheets", "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r416", "r423", "r424" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Share repurchase program activity", "terseLabel": "Treasury shares acquired" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r157", "r158", "r159", "r160", "r169", "r251", "r252", "r256", "r257", "r258", "r259", "r260", "r261", "r342", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r521", "r522", "r523", "r524", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r668", "r687", "r688", "r689", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r805", "r806", "r807", "r808", "r809" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r306", "r307", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r487", "r498" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance at end of fiscal year", "periodStartLabel": "Balance at beginning of fiscal year", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r499" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Reductions for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r501" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedLabel": "Settlements with tax authorities", "terseLabel": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r494" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits, interest and penalties accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r494" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Unrecognized tax benefits, interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r500" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions for tax positions of the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r499" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions for tax positions of prior years", "verboseLabel": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r502" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedTerseLabel": "Expiration of the statute of limitations", "terseLabel": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r503" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r191", "r192", "r194", "r195", "r201", "r202", "r203" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r145", "r151" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails", "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r148" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": { "auth_ref": [ "r149" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account" } } }, "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r150" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r145", "r146", "r147", "r150", "r151" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails", "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesRecoveries": { "auth_ref": [ "r149" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from recovery of amount previously written off or reestablishment of reserve previously utilized.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Addition, Recovery", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Addition, Recovery" } } }, "localname": "ValuationAllowancesAndReservesRecoveries", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r145", "r146", "r147", "r150", "r151" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeReceivablesDetails", "http://www.cardinal.com/role/ScheduleIIValuationsandQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r660", "r667" ], "calculation": { "http://www.cardinal.com/role/LeasesScheduleofLeaseCostsDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesScheduleofLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r178" ], "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Employee stock options, restricted share units, and performance share units (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r171", "r178" ], "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average common shares\u2013diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r170", "r178" ], "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares\u2013basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted-average number of common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cardinal.com/role/ConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" } }, "unitCount": 12 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r294": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r322": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r325": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r336": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r392": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r426": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11374-113907" }, "r486": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r537": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r542": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "4EEEE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109999725-113959" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "35", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=124267147&loc=d3e75592-113984" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121558989&loc=d3e80720-113993" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r621": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r644": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r773": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r774": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r775": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r776": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r777": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r778": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r779": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r780": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r781": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r782": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r783": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r784": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r785": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r786": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r787": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r788": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r789": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r790": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r791": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r792": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r793": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r794": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01" }, "r795": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "02" }, "r796": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(ii)", "Subsection": "01" }, "r797": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)", "Subsection": "01" }, "r798": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "01" }, "r799": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(A)", "Subsection": "02" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r800": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "01" }, "r801": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(B)", "Subsection": "02" }, "r802": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iii)(C)", "Subsection": "02" }, "r803": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01" }, "r804": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 132 0000721371-21-000080-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000721371-21-000080-xbrl.zip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�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
JS*]H-;JJ/]\BQ%"&5 2'V0VGU[OX:OGV_KG MR=*QE@DM94)+F="RG^"G5B:TE DM^4IH:;Q\0DMATE>ZM:ZV56LRK;EV.YI- MTU>ZO=VGK\!C>^MEQ;SZ])7 D;7#U)4=S'F_4NN<()Y3G'Q?N3LOFW"3;SMB M S;>7J[0%\GXR$4"U$$BA=A?:>=APO4: :X^WRO&V\V%S?:B+4135O)+]@?, MJR\Q,W$,?4C*S M._+Y[I##3T'4\)T.,T$DR7OG>-,J M'PQ$$EIL:A0?X?:(\FX\A-B9HP\57LAQ(/!Z?4ZOU!W;QEA+,*9*, BC,'2&!(CLF?E<^)9:,'7(E56^YUW).,?]E>MZ*3 M>'+VMV)9-HB')QNYYH!W]WJU=F^K"@&U6^NHZWFP-GILKU;7=N]O*]AH\;'M MG8I%M?7JY"+&V%(G5C(R3'&:NF;?QVR,OLLHM0=Y&65CF7I*.E1$CC&(KGGJ M&Q&%><#5'/$J95<"!XY).2%!;,\?2*U(H_6Z;R,TILX:B]"".@Q%2*$K* M"2^2P5,G/8*DH,#WQ5X?"AJ2($MG$0SLK>*0O@POLGW=PMR12#H+:<$,TUDZ M LI98)CSB('ZM]'XY1WSF%!*S"FF(C#,[[0L_"GDL0ALCV!(FWA!J\)S<]6,Y:&MJB$);A842KU"*. M0:8^PQY2U[>'RL?N[[&Y$ZKYR:6DE&9Y5@-9%1-!P&L],"4",RPN9].1J$#N M2JNK0A9?*%1#(V\>LM,@^Y"L1\(5-4R7)=J#.<5O\+=RJWX2+ T3+1B5C+$LE'#T\2#?D !>B- MK=,Y6GM)Y]"Z^TGGV$D!^@;UU&6*PJY3% Z'@;>;%(7=4(*+ SM$G+/QTH!4 M6Z9L]%X^9:.X&"3/L(;*+(XRB^-XLCA61Z7WG\61SUC_^WAYO%RB[?+7UV&+ M!PCN9X$6K!/;;Q6+5Q5@.@I,.$96$.-@6\3)FQBM;M/4#$>0P@*$'8S M4/SIEE1P(7++R"AW%,2(/!PB]8"[&:4O!]AR@GC H89X#Y+?VT/E@KDV5CK] M=/JKXWEG&W"ZXK*&=J?6JN\>]*U;ZW:V4PY7?]=J[CY.7+2Q[D2-/;QFUGTF M6O>I:2MCP>5B9W4K.UQH)P>8\Y)"&.#E&TSH>=ZH@\T]V]F"0!W'/_?L?7]/ MF$N)V6]LC.KTWZ:&U]@T#(L?8,HD@9U0 O-0 EL)"9QD=DMGG:V*R@G$EZ2N MY'UAWNQO[F_3[L3<3+K9T7;OY5V/[R1K'W>^Z/CMAHN_RNOPU+%/L\6C/#C9 M&WGD!R=[TJ?-2KW7W1^_/##Y;O*,3>:4APW-YH37M:O:)HK 2W4//.R5&VM# MTE&>/VTH^QC?!ODG0TPS<3FBI5"- RA$"((VYLL-'6VS9Z?WRK12KUS*M(J\,]ETVFUMJ"[E>'>V?<;Q6&9+>-&4D,HFIF,B*+?'/6\L M@)(L"@=A)A@YC^-@XEMQIXR%R=496)(/T2V6J9)'=:[(5)&]-XWCV9QMGW'L M2MH7[DU=/ZBH(4S/\<1RYARK<6&0HI7[J]'25+59$$:88R6DR&21O3>JIAW/ M]I0Z8O8FGX\1+O3OJ,I=5"(P_2_?%*GQU4!=)"OV%:F'S99:$+:88Q6DR&21 MO3,-.5*/_ %4^'S+3/?L*0)B(XHV?3\>!5SH ,ZRWY M8M[U@FR^V.D5A"WF6!TI,E5D[TWG>#:GU!6SM_A7T =E(X13;/D%XS*Y=_:3 M0+;W*HK-IZ](/U0KJE845IAC%:3(A+%$0ZQTFNKQ;-!+ZXC)@AQM(0-@V_2 M7"6'A;GKBYESFXK0G:U7GC*#GIM2M_.UR0.[69)K7-%:K8+(H3T<\9=0&7MC7.R#DE/+[T\ M_UQ,VER*CR&G5D5F^K.:@@N7U:7B(Y.ZCOYEI?(%JV(H3P.6B4BNK1C MA]Y-V?V1/O9E;U5J0BI[92I$$Q0K-W!6HCWJ.E76^4$K_J&S160540Z'DBD*VM>8"O%C:\G;A8 M,/HH.P.*)ZLUM1,^&I_SIE5K-Z):X.0#T0LSM D3/.BI'+3!-13+9'V$"L4> MF9ZCF_0A-;"WV,SSS6#S+6:.$:85T;ZF"D-/MS?%%GC]N>)%<&,3!V%'"9?. M[P=P7YY()L,%D TV$P7%,"-LR*J[YD3\+7+1)DAL$?JH5U-N.__YC:BSN7V]@[5S9_#YJ)QIOVKM4X:Q> '5G4 MN:I&\E\L'P-11L ,_GWRCW5:+M71OIURI?.OG]B[W5LF:YYXL:62XYW@@ C\ M+H&($;6XB/IOUTZ4IUA;-CQJ?IC=8HE\!LO+8%PS:E-M@"CV.#8L&$^8+CMV MO[_YX_)#5>TM<#&&!PH;:"/D(1QV[CYP8DRN(7),76[X.A=R!^8VQY<^,,L7 M75&EZ$EC7L)P/4)GG+BP<:(W /;LI4,>!SH(91=LWU *L)CAY;S@!YI>+W- M,>,5MN1O*NBG-]>4SZN>KYR>?/Y\<7(FVI0+R,3H,MUR@'W8PTJ(K8@K;<-* M!W\/76;P< P#A@T,1B:WC."O,0M:+XMTB^C-L*) .T%R+KV35FX&VP87$H2# M:?_P8:TEP_> PX)@@TF;]D!R.&QG8%G8@T"PUETR2VK$*H$]X;Y8 ]6:\H=C M^6/L'HU(EP)8TEF.$B[QGU$0.K!DXP72PND)&L3I111(()CYTD&,C+XP@*S45_"H\] MT)$9<^8)%-:HS;UH[Y%"Z0Y;5)@1O&:*Q$47VA&<6MA7['4>2DW:Y! 2-;5V M!.@Q-A_7[4*[R*->&)QI"4/Z8"+P?@R.>.+D9$=S3QA6^^HR(MYRA/3HD#$T7G5*W65DL8+24.3(D#\\R4@WJMWBF18'(I<.JULL[W^&LW2BR8U1RJ7E/KQ3)8\JC4 M%9DNEG''>EG*GU)5+"%A-F2, M:DUM%(0QYE@+*3)=+('*JC5*4)BCUQ)+4)B5*F-1T+)RK)(4F2Z6VL^E=_'8 MDE6VAXH%++7<+& MI3K+F6O-%1@D#!H,_Q&%BT"U-7A_.Y2OO"LPRQ3;>HF.72JVF71Q//N3<\7V M8+U,3S\E3'RLOJ,BP;]\K*LW,4F>>]B56['9@_E?SJSIZ!7Y0S$Z6A#FF&-- MI,ATL2R)M=;>O)=A'O1=+K2VN'+XD &Z]5/2 ,K)$!A[!/'^DN M:XZ?6>1W7 "7NRT"/!* R^Q%:=5:G8((SCTPII=0;U\6M_:8C_5N*Q2/Y%@O M@;^O-3=M+EP>K^W< J\)ME8K145>MZ:$S-T19*ZDEL8BKF1AEBUF#;SLJU-+ M5,?9!R!S >;E3Z?HR3^+X*P4-A6X>X0BA^B@S(6'P'B$+[^B7-IZ33D]B=EG M)PBO&'Y H8'P>2=G&VQQXKG$]");-RT\7^:4C^%,(LXCHH_: *PA]U#DR5$)-7N3$%=N9?/K.G!)X9(!+C=7R 6)L4"V+Z M:&% ?(EV?9 5J&=_R6X4+(,B0T9H&U.S:D%XS^Y>)Q8S(Y2\).WX6O#)T80 MME<2G7(5@*ULDCN60A@+XO> MV.O4-$W#@6X*WMC0:FJCL?3K;4$&X;'-_3Q6;:P'B;@G\,(=.].>ACW.T-3V M^/HE#8,W!FG++9[>F@N>DI:K/)><:QVMN:^E_[\].$W77(,X?O)'QQTK:KWZ MO\^#Z\O0H./_CMSH[B&O]EW.[JML #3P,[-F;.Z=_)1DQ< FY9 [Z =^'LL6 M$^N[\(ZU59T7Y_3/P.G5FK6.MAU*[:K'MNJU7K>W\\=J\-C>3G!J%RU9WE0' MC5;*DHT9J_+['8:L93!I3TPB@#!? \+V!>>\7YGTA7N^-25,_!O1 @"TSATN MP'I\ZTC,H$:.S*"/$5:+:#63"",FK=(UK5PT-- 8P1BD!,0G*'K\+#!D[,#L MB!Z>;8S!P'1?5 G['OE!%#%#^( AI,*0,NFT7B/LN:,[XS$FV>%3O: 9 !AK MLEN.,X7-%SC^-$WLQ0!VD^^"10+?AT,%&G% Y+$IK)#A<]F8QG05M..JX:W" M@L,&-GA"J!,&/B&TVM!BI&4,.NO C$W'J,4:)M2CY8C';\'H7'OVK=6SCWH% M9KMW$JU2=6;8(,2TP=A'8!+LQ^29ALFH_XI\&8.C80VJT45!LREZKFDK MV$HIQC\4[/3D4P^70>A0\,*>.+&&*[$Q!ZV9PN7!]ANFM^K5 6$;)K9,F8:- M-V!V83NL>(,><3KQ-N;!R39\ZD?C".]*?/R)NP8'#@L,E(UH4X1MPR$UOFP*Z)+F+D_\5! M^_08XL%R8(,X$U=;%?RW3?]V9!,QM:LPXN1C*6?E??GBGGLF,*+,,4 MQA"0;,A*5Y$DS?9-4VL&'.RM,G)FB)93H7D%JY5P5D6T%;52F8%\LBQ'IYU[ MT^CV0I8H7>_!L&"OK+5.HN2=7B \##&CD%E'[\8L%B*G*7D5A1M,86-0@Z?! MZU<=I%6'(>BLAOUI?#P4$^8B"!O>' \*B V(<8QH-61/M66W4L>X1B1"3"]@ M0@:EI*?GNXFDR$C,?[W<'\LEKN%;H/GNAII+PY;=0T]4RT_SM5 M.[56,Q&R0$N?2#!@GK:2UD&2C0)KZW;8R<_&?U@0EE+##7IM+6A=HM43^:EL>,.UH&H?N=/CMIUQ^F@C* M>"-A!0 =/P"AVS$DHA6]FEO+SGYA7/>];JU77\]U+YWAJ;"X#%6L\HBF$K9D M6&M==V@!&"\Z&O2 A'A$0F K6:3"D-W7J#6C-M53Y1??YN+8-.H5H9M@9A0P M7E*#WFBU[LK+Z\(* NO%!5L%?Q%CR.I1BXX H::A/D:735SGP30$ZX\4-(9J MG7 .HJ&D14.NQ#J!BO=P@GNE-JIO6IW()XGF!"KY!BI9%?RN+@:>N(#WT<\S M87/B W 9+&WB$3J;F&AA\\<)/,B<"NN3%%(M=6G@5 7[&2P?;Y75EH]DCD,Q MBEZOUFTUML[F:.TEFT/K[B>;H[/+;(YCZ/A7N R%@R4H*+O)4-@-)5#B\B$" MH:V,">],0&?E0Y09&V7&1IFQ469L'%_&1O:J;"D^M?4:R&_N$M,*RXM,!W%/0**$>!EQL<0[FG)\%G)V<4PC9M7SBFF*A%0&_5[[5; MD<Y9%XNN5XW*B(_);@37T^A!G#@S%^YHJ< M$_D.=(_V,:.%8PNIP#S'NZZ,5( M^D6&H.-.*54!UC'QR'K&(P5YSM8=5=8C@JEG#$Z-7"S%HXO/(^:.F\Q0OJL3+? M0'%;RYD%M&*A=/=D-SITN\L95%+4L'I=X#K7>1"Y'8RZV54Q6:2*OV'6AYE@ M7@,'0SG9W$NM*;#8ZB^0$%\H!A[M[(Y)81_#5FWKT7Z[D3&RC')+6@42.] MD_9]!E0%%U)@T[1_^.Y2=_(UYCV RPB)C=*[H(/ MX1@] !)WQMRE[%LS2,@ZQQQ.,5I*3_-$2I#C3Q74,F6YJ'AKF!^",)&]"M&"UP7:*H;4G=AP-$DI M<<*(MHH6B/7AL%"@!X9@F7^3(?3 +)]2=^!XR(Y]L?NP"MA]H/#^&[772:@E ME>PTG;":'SX8.JZ,& 4'5:03,@,3^1+R-$44O;"& M*@S^52XV*A6C9S?,M86)"ERX%5U.]=F31WKNN87(G#_@R*K&Y* M(KSEMI1[L2LNPD5A/ MQI,Z ^JH*?\5'##0Q*069L&Y>R U/RN9;MD>GX=;0&ET MW)O 4"5%XIS6. #!^).'$!D0I7X'63?$$2K+%F%&^G"P4J X\.#8+ HN <1 M9_!5_#G)F4GEDT=12&4<4C3(FG)IAQ1(S,(*]-D8/_6"?O"AC$C5G;B8VXY0 M%994)^!"^!L#Q<(BM(,#%].!ERQ"7"\T79B,C6QA#/0W2LOJ2C#(4&%>5ZE4 M @V!12IKF%DO5/>4VIVBF<(=3S":)0=%APAP*-V<)$S5!9M=>#<6?3F4 KQH M5H.,0F9K<5&B$1.4PC22])TT[A=*A8B8UY*&Z5.5TGQ6VCIQ:1^;8E WEJA. MT\*I!90"?"FH%9CAB;>Q%B1F^X?>(I)R26=1QG*Z42Z?D.GD!X./DVXPG=PG M(,K0B-C(N114]^!^S49<-,1$^A]QU&6!MP&;B5Y#\CG<8-2:36G@X3K@&\; MPE ;#WU=Z=%48K420:)&98GGRY$9.P-@.\".HF=*Z1WX8N ZHBTB)BR["&EX M)X=Q28SQ '[W&Y%?_ZO,[U\S^ZUTM+\R1SL([E]\X.62C>*!L!V?' Q"SQ7F MY73F2,DO$'G@[6%UA^-ZPFP#WN],16T)0PF'M4^HXDRG%F6'*@Q.H?CM%#F5 MK,?Z'%QY&UUY'EP9UFD);2F\@%0#<8Z130^P8BC.9="4\&"HW@ KT4XCUO4? MA[D&<8\/H,WK./K_$4T M ],2RA>5S=#HL:+)4H:H#-CX+&3*P'VFI$ 54!. %?C#Q,&9+%D'1 Y3H06< MC]'3B:$4E+%B6U#. 7V 0A7Z73(V5IK31%CDW05Y[E@/PD(.J\$"DI.2!:2E M\"Q@3L!$>G@R'FXX,!8GX4C$K( ]0+,H+?GY+M*;!D($/PL*H$* M]I!DF4V)DCZSA$X,C[>EU18,+CED24XKCT E/(088WKB(%+""RV2++T)GQ<. M@+*UJ221SY1OCGL?AIQB*P G);ZG,)LU1@H;A36=GBPL-]%(V> E@8I$=:$1 MA:!ME?/\SQ+,JP3S.CXPKW8)YE6">95@7F5J:)D:6J:&EJFAZX)YY<,^NWM2 M64>[R^__(/]E$* <BRW-)')%G*IGR@ 8JS,3:%*8#5!U; E* M5<%/_,$ PVF(8>./^\)?+W$KR) D!T08MUV]/'$7!5V ;R7;R0N<$F]Q"2H$ M/D0>U2D&?DZUY#!A!4V=AZ.DJ:P>ZG*(C;@/=CJ"L8O'">\+[)3G8R9CQE1C MTT)/,1J0,]/C%%81R& 2^V/@P-Y11N29S+/0Y6/"[1>Y$Y^#Y*186D1BUT0N M4&KE!%&!>>S(46(48.*X4]]&1PHE-MRC\9=X%$:_X*O0ZYR]>DM023;?^*U6 M*#2O5SY<1OL#/P3"I(7AE)@O0BRX3;Z.C[SO^@ALA5$$H'+02S$7 R,ATK<- M_$;$\]!G$;WIDHXXC,4S"?-N/<);-,C)7X./76_Y*$,#7B6\%&'4/,E?8KPE M*VLLF/ X+C#9=ETQ*(P]F$JXJP0##0Y(%'O#Y DOOK]) MAQ8;.QAHSCPDL>P9>$2[7H4WQSC6XC$.W%&)(8F)Z(X(RQ"Y.'W9(L)&6'KE MAV\,PYH%$@$I;Q"YIOBX[QCS,*L:IAE*DF@!"^@R74,D1_AY%,T*.VY4$$O, M0QA^P0@QVBD0T,83=%.*I9_ KOD3JC9OUQJ=J-0;+XU[J\4# L)#$"9#02>G MHG8IMBD]I_P1(VBRICN !*.C*R0U]8/&T"0L$":C 1$D)53:J>I*S^,:@HX MK)"QQ68L;YN2B)#= IR((2\XX3'W(5LHG/+:L%:A*Y4^PM7!<->^^ZP2TG]Z MA$M>AWA&J1.$ 8)XUD[Z[0'X5GR7(U:PH1NV>)SUZ;-"2D1X8##QTQ:,TQ4@ M@()OQ#')O& +XER+NM=VWHJ\#5#;.(E H#3$>9!PJ9AS@L0F\[63H7"4^Q)! M"U[R,ZFI(F* CWA+^F"DVNK2E>\RD1045']0SJW-K5C,7-8Z+(S*PS06$\/M ME#A$0X+7-,XHE=OH/9B 8/.9 +%XA"G'DY \N*-YII!51$A>YIC"5AGY MIZ3E*J>M,QB"-X'#[/B>N#$VD)IR'OP59CIXE,@CH0$I;T?T$+), :(1A6L( MO$(<%4IFD[)'I-O EDJ>E,PR6C\H0@/B]A A9YE(W*TB8YHKH,T:0HU%3D>9 M/)2E#C,"++#@%_(Z13N3"83 MW!C&] @Q$QDP_(G"G3(ODZ%!&4-]S_H<5N8]RI YK>![*8S^*S(=IPX!GG#, MKXTA.(;1Z7"WQ7NPZ@,5R#E'-1<-'[(:1%E!BE2"H)8XEQ@?8Q@*L-H0+EO"@E.!64V6& M6P@VA! [K5J[D?P82"L.U"H>\5,<4I:@9 -Z)IZE"#LS ^HH !]-HVY>VF*L MT1Q ->VDAL)TW27"R4)1JD0*ZYMF?2G2J^#_P9,"P%-1]NG%4_6DBT& )V-F M*+-MGQ)(HS0!J?%2$!WS YV9(DI')+.+CG\TRH ]15AZJ1$:6#$C8O,!)#./ M5[K$QAPRD7BI8P ^Y8TXQX*'_W"=H501()Q)]UTZD1XH!3B B%D(MUT &H@9 MRK%:<@=-=B^LQL+4#4?7?H'W$"M+X.G2B4BHP208R>+W8L8>ZV/= MB$S&YP^BPN0K+M70IZ(R!2MR0541VL BC/"83:>RVBBR>P-W$.XD[;O@HLR M 6 ^'['*",<8,XTIM9+6"UTGA@GZL1LO\97@B/@4\4"1N5]"&[YN[-"3C4HL M7C8J(JPE$ (783N^(/4S.C_O!7'QN(&Q5KAS520?/35+%1P#8E\470W)(K"EQ_ M4Z)TRZLD\R*]2?IZR543(> '? ]=(K;(5E^N:D2+0_JJ&[:$].T8JGABB@0: MJ/92B]<./TBOT=TH6?VY:]3>!7A]5ILC*5^/O""N);$0TEZ1]\0GF\ M$8\**K^$:1P66#&*%@O^GQQP8!)3"P29,A8(ND3KA$#FA=H EFAB&6P$IQ]; MC95"""5A.+92#NU0#C6D'.H>MQPJ=/E")-'H;-\BA/QE""'_&0P?O.)74.6" MT18F(:>L6]A3G:A3]@R#0.4M838:Z,+B9A;(PE>FANW7,.K(? M^2I2$]&Q1IDP?3Z=80DQ ;I(NR+2GF1]D.8 M)9F6*674H#>ZUXDHA450+8$W;26M9-B#@;&="!"[7.<8SI28G:HF@8,D@G!$ M]JFH/$MX_+,!:Q-1W.R(-\5&@_0V"3N'S\&Z\^ %83"9O 9A>T_, $\"OW9B MO756MU\FO[>(M"ZGIGS13I0/0>YRX67WHI:V8V:#NH?NF?_QDK[Y>'B&R )S MZXP@(P_7E,UBV2]F1B[]5/:L9?YTY,@.[+I(@1XQ"\%[ CS&9$C%3=X.+XIN M@WMDW#H9-X![S'$L7W!)%"$>.B!J9A*7MHP>E-Q0]>(\,VE,^ !.' 6* MM8P2O,8HP4W@QE6URBJ((PDLC FD ],60'X16!&ECEL6R0Q)62%B)'SW7_@. M!(U"EI+R$5W;^"[CR$ MF74Y!J2QKDJ&IF>.>T\)WK+-'A,0HK+(0J1RQQ0%'%U6[^^8/H"8R53D]\!M MK$=Y8,KIR>4?[T_.4&>C?"R9IA:V7'@/\M9@2;#*LC7L<>9/R=+8#7K#RK)9 MTF^F+@Q!UO"(:DK4U\[](49_M'A.I>AYC_JXL?0\58),%JJ:HF<+]7@I"A.^ MDX#*4?%/8B;=X>TBQ>.6NP\$S!JK#CVYNSV'(Q ^J>_/N2LK0;%)9I1A304I M634-HD8+;%)[.J\BPF@ 3!K5#4]EA^92=3NZWLIY5-T.'KL7ISS("F/*FW:J MF4H0^IZ!I<6KAC.SXR8_V=N(WV])K&%&@6.*G9MN:/6=8E'=V4_D%D![&-0\ MQ\/BNT'PA*S$ZS#&C]>E>JW(/.;0 1 DO%&76T]@SO:2,\G*7TRBY<;F&&65 M!^CC:'%&"D%<8"=GST(,\>,IFC BA;Z2V1@Y046B60*E,,;2/U.KSQ]-LJ]# M6HA:)HL>07&O$.QR4& ;:ZA#Y!.=3?':C%WV>.SAE42B8VHFU!4@Z) @$DU# M&C,Q\]";NCXV?Q#(_X:"N '.G'-9CHL.)C/#^13+5EE"RA&@,;Y=YM *>!#/ M](A"4PZF;B.^#@AL#7HQK01.T2'M-O+#Q.H=/"%G3(HDJQ=@VR!,H_;8#I@O%%_<[7G616LMH\PMW9A*[%U_!$#4Z9;O( M2F[9;UR6P:3QU%VLU_!YAF>Q&SL!8NW7:H:0^:2P-Q4IAZFQ9]E=2? :UPR: MQH2YNN2."S.G!XCBCO5!ZS9L^ @L@3^"16=Q4?H"6E^@P2W ;BRVEXA[WPB; MFAQ\Y+/T[1!_/P[%'140+>4?JWB5J!]#S=<(.9\>U/[ =S(C]%_4UDHY5*V'A$!#8BU)@OL)PW[%ZYQ?919(7_^NM[=#,1QS\]27\?F-OO M_[@-TLA 'DRD,8AM0<,O3L[(Y \<":'+;RPX+M621,@[J8=BM2P[H%/3G;I6[W03RYK)=[" MRP81H*/4MOF,65*J]*58H*ZHV6^)]1-S%_9-E+3&^S%)"&T!C+5N0T*96+RJ M>6>JY\>1":A V4A)IK(G0RF[4L;O].DN=LX3_2&CW $TK!!?;B2@N+RIMZ0' M'#E.T0:3 '[4(DL>V_'8,0*KF/H[(5=U,1)]'^\M]53+OYCY%[#25*^I6$*/ MY*QX037HR#6&J[ C5%PDRA8W$0\CEB)QT'13MA9,F+89+177M5_695'Y* XH MH>E+:/KC@Z;OEM#T)31]"4U?U@V4=0-EW4!9-_#LNH'\V,B7461;N>/ZR(:7 M#N?*I8TA 0I=E69S:39G)OLM]^\2$IO"E#&"@ G?;1":Q$0WC/*(X"3">EIP M?Q#M#QQ>HN"?I[J:>G-ORL=H$8M" 31X4T9C14DK;FQ:_2_6-=R&(&L(-R:R M_2GL!0^FP8JGRVRF,-LC$:1ED3D;'H^HP:IH8!A9NG+*8=PTC) RPNZ?N%PW M)4YSK"^\S">DBPV*R84(!0+ 47;\C>SF#+>>0#=<848+/R4%TO)N49?E]F6Y M?6DFEN7V^2ZW[QVRW!Z?:AK_/GDZ*5/33E[V$X9>&=6E8'\*PSEZ5+06LMA[FZ^I5.: %_T5D#.;53 >N MJJJMUVVEA_JI.08KUM6!,MBHB@I3O=VH_SE4:S\FPQ/L-;;DF^2\M&9]\KC- M7F@-N!'%^I)Q:$O'H>UG'$\0:QX"JUN3;P?L*G6]4.5&CZVU.]LYVU=_UVJ^ M[K&V:^WF1LQF:RM8U=8Q?@2]OX!6T%U3*4A*F6WB?KL/QN]O%;)LW57U>:>F M'235>V?K*TLI^2,'7QRR0 FQJ]FNX38JW*IENTP0Y;1FN7:^UY7\K,0V7O_9G]S?YMV'^9FTFJS5>GTVKOW M[*Y'?,F+(GK38ZE6:O==Q$'#Y# M>_H9SR/H?''&DB<>;.G_^3P%3+KKBZ* R?22I.G'KE5APY[Y2Q1**V*LUFL]RA/.S0$V4:K^+8%DSR;:L+=&J=5HXE MY!VU1D[!EVPE+X]03U7;6J79;13D6.;4^'F>&_1H*6Z9D-8JO4:OW/DCWOG2 M)L[9TK\NFSC @ME.RA=3LSY5VPM1W=+FR0,UGJJ=H]B9YS&(?)V6Z]I5;9?& MDDS8TA;DQ-I"1!A16=0L,^USLW;"GEIB1[W8>N4IJ+7;B/ .UB:_!X_LS791 MO+>[WIB7M4J>-]XMP]''=;)W&ZX^DI.]PJ[7M/*$;7W"MO +[.FTY4MF%--O M$Y5Y\+8,M\_9H]5 M68%>:S5Z_WR+!::R/D1\L#C"DW4?OGIR(I<_.=:=5FYI:U5NQ0NGWQ.VL<" MB#ZO/]E*HBSKVDM9U\N67:X!I_Y$P5D[-[ P<:)> @\3]#@8NGR&[0G>=&L- MI1\VGHG:=!!F-W97\>!:9S8=B>82*2QE(.FI:_8)W44@GTP06<6:SA4O!'T) M,)M#,)6I,^0$C!H!ML1Z+\"0U&!(BP I!Z".#;&,+93TOXM Y 1'( MGL 2_EQBY\0V/-C.[%U4:ZK0,OI!X[(%\A(]A!)-L .0]S0,O "T>8BC['[^ M?$%#&L%4(\SP %>> 'T9=9,..FGLF9C6[=$E^%IL("5&=_$PNK<1UR5N6(D;5N*&E;AA^W2)'\!@_T0VT!7Q MIB/PM9>>A=QX%IZ")FLLA01K9$*"-1I;0H+5)238FF?KSD0_VS6?*5^<,;.? MY^,0JOOBO\%16[(VS:5KT]S/VJRQM;D#4'L&3'^G"8K5[@&OV[6FL,-WC4JV M)HKV,8]UIW;_T@R.7@$!U-['.W%FRO,-S;02?:U$7RO1U_:'OG;,"[-W@+6G MLK2*P7("PVNP\A7G6ML94YX'GRG^Y?B&7.*P1>3:F.I>,R ;?;B*:U1]FN866OY!K6MI+Z7-N6SNAQ&_<#AIX[+ M38<%SHRO ML \FO 2S=6%"EODWT3H]'Q[ @%:9!0]P!@,/$WKG&^3D8N:$@H2!?B48FQEK MBNOR(:69#!C@U,34])0@7UY0_:+2X:[CAX:B79-(/N0VTHWN8G3ETV7AASW OLK:6&J". MF(&;FB2!FG)'+4Z#',T9=_FJY07*B[+O*7VZ[\),D=Y28Z8\_K'Y2 N! Q-) MUYBJ#T]!GFMZ\ P8)U&0[[HX1>H>:]J>[U)'6*0W&"[2!::&B[QLUW13GK^:5!^4*$9G'RAYWLG9^MF MN.:'#<5=) K"P@3$:P"?<7'N\43A,:Q'Q(%B*;^KBCID[G&*A/;&CY:QF9KR M=63"'RL)/#P/>($L&( )PR.3;!F%,1ROQ24BBIB+PPG+@ 4LL9(#P0[P"" ] M#M-K7S;S79&C53;S+9OY%B.?M&SF&UJNA\AD4]6,&;]8-]\RP;9,L"T3;,L$ MV_PGV#Z3Z65[LI;V]]UV<==+L?V0*"J^Y19<,JPHG]#"9L+R.S> U>)EI#,K MIR>WGP01GIPI%X\3;GM\L2-PZ:L[@*^.GI>9;%'F/Q8NI[!(8WV9_,="=I - MF.4BJRRS&PE6Z8Z'I*00O[,E_#G5YDT5>8[KKTHS4JK4? MK/4JCVZ9[[CVHL#1[938PNOI0F6^8YGON!\(WYCS:EF5]FZKHYMK)7@LYA^6 M"9IE@F;^G+ZYRXR*T^R"=?548F8L.2Y*X",V )=['-$[."RN!T-B#[!@GC*& MI_DN]RB#C_+FJI@G)!/CH@2[&?-$_M^ /3@NK.E>4]>5-18YED$OX MIJDF!JLP#Q;9HY0NRB#CGNZ:$WJ4,S$=H+@Q97Z)-+[IB$W%. C>TG&C!#28 M DP6>>DWQ[T' L(4-\I0M;AMP-+B^GHP,;5#HX%?NC7EEO.G0,%V$1S-(KQ5 MKL5_L7P,1!FY?/#ODW^8S4&=ZZUVOZ>WZ\V!VNEJK-WBK,G4GJYUF\:?:J-^ M\N[:@37O_.LG]NX0F3&"RG-%'1_]&TF4VG]18)A(CSA+)#E^05 M(TG#XT*ZNA%$>3OE,^8:WLB<*.?Z]"4 3TN8TERF2I8PI25,Z1'"E&HE3&D) M4UK"E)99E&4699E%6691[DG_/@Q,Z6U00^4Z S/5HZ;0%D'IQWL)/UX^O'9? MN<*QW _=/$%1(/ )LMRQ K5//CLPW\,OB=HK"AL[]E!QJ*E4Y(LK'4&[<@2U MFM(1I#:.S1.4)*4MG3Y/0?FVEL+5MC+A:IOU9\+5+AE'>^DXVOL91PF;NZOT MYB*E8A=IK&7:^/*T\81.21$6J;:#L+U@+J(KE*GD92IYF4I>II(7/96\&/PF MW:IXR_2O8B63[C8/O"#)HDM".)5VMUG(/._<)*$^,T^[6$=GMWG8!3DZV9-6 M*YU6X[A)>(L\Z>/(@VYNFP=]K'G.FRA ,LQ5% 5(@L8M5997T7[&5 M WJU. MIR B/YN4]LH24Z_5X FI5ZKULH=*+EM2Q%*.K:&?)2"@"I+/4Z2-Z_NGZM5_G8_3UVW3HZM;7S0KJ7K:;5%E-! ME545H 5#[%K2#]E=/!?;=8I&G6C"+NO4N=/6F\7K M+KED%P9AD9TKR[D-1[&=:=#Y5&""J36UH_0#0##;4-ZT:NU&^(F ,O,0*LR! M9^'^A4!F$B/,,J?F4)3I932S%'!?6KV"HY@@%AKV>A0UGSOL"HO7K 7;4A:2 M%@E13&SI;HM):\JE'7Y56<;#UCL]):)>2?]%H_^M8?4.H#H%G8>/2&=*-U.6 MRE($=6JAQ-VT WV$C[KC7O2YZ#V?8-AK ;S&U48871\6?,QL'^%4A8["!X@< MR^'@X,6BDW30BSK623I[MW)Q-A;#Z44Y#HB]&VMK'DXD4W]T>?PD!'BX("AU MW_.$F,0O;@A3!)TOCDTZ)!Z2.)M^L6U!V5#RS2LFU[V;:]Q-=\*D10MFV/XC;[)80EAV6[ZS#7<)-U<5V8W[G'1?NV/'-0&.;NG[@34=A MPL<3RYES1(2&02(.=(EZMH^YYS?_4U5+S+,2\ZS$/-MXTJKVO,[2^R/@HU#' M3MZ=CQT8R-\B_P&%E6A!P/2_?%-$?ZH4,.(&A9.7NQZRX:%S5>NZI'ZKE4\\ MC_UQV0T*FG.[E]D+VM*:>U_38]=?+\<39KI1@]S3(3/MLY_0D8%Y'^@W<#QX ME3.@I+ZI5\'4EN?@ ^66R+(91J>72WZQ+N$5!=\SMU21O3>=PVW.4QSIB1*[ MHC"F7Z-T^E/,UH-QF=P[^TEFXJ_-AC98CES1W3) ;57+*4/:C.YVR9?6?/,Z M[*FHU+)$0:IT@LS\ ^Y:;@K0%GUU%X&O[G;!5U>@*%OW"3.\*$29F"":#AD.!A.VT!Z:&+T4E@45 M2KYI:MT@+B3K\%0M_ "K.=:IJLO#)B]85I_(LOI56E8?8I;5N;2LKGGQ:CH^ M+.2J5^ $4X'%T(;G8$'!FW8]W,*)B^'G1V7FFE->-9R9'31)E%0PXI9!&XVE MJ*)6=5WN@G5?>.V."RK+6K*=U)+5V[*63#NFGIRY$"AQ8^E+S%AZ'QA+Q\%9 M8OP^R6("IA*4:<,6/U'1G908E87"[D"I",I5V124"Z^LU\XYCSGB>M7B 3)L M<(#?M-I)K4^M-X(/TD<5EA4U@3&M(CJJI0UB\2&\QN #3.&3MD067L/E'^]A M3!:<9RQC-,#Z4"R3 5\PIW-%MY@YWJ3LK7AK;=JZ,^:"1\9T:['L[66K#G2X MX7&Z,[&>%L("DP)Z1IALHI"YLNF*QF>>;0@2( M2F18HLI GW1G9#BG? M*R(>S[OR*'*9RM3R5Y]:?I1S+QN'RRD+)?54* =G/\G*K,RP_U&F!9?Y].&D M3YN=7+5'*E/:RY3VM9'EU:,EW4V><U-EE90M4K[XDN2Y M;CV7J7-E[O\6UD"C6Z[IKO4L;6D3N-?54+)@IE*04L29:\V!AR,HA6]Z(X&_ M/% ,WG]-%1M%J[[-HTI79*I84ENZ95_E/.[.\WA7OD[KQETNCZ2^)94.2LF. MF-GPEX]I"&:@D9NV8K,'4^!5OKYZEYPV6RQK77+'WT];G>7]I8N[7SMA?/DZ MT_EHCY>?M(I523JGES+^<1%X9A8R>0N-67[XU5^_JL%9'I&BM)4!>W!<2C+1 M8[T/,8%EXIJ.6\56-I/72I$ZXL RC_L08&U#IC6Z+J$RS'& M]XID;]@*T=W"FU+^:- &0W27@"%96%LEV^S(CA@B$Q+>L8AZB"F 9CQQ9^"[ M-&FXNLQ/WDE^HO4$+[L;& M#%I8LHND]^UFH'R(>]]*B9V#!'A9,T )\,UT_GNBD5TZ"1X3P!W;EL4\844! MR&4^GH35O,(/2^?%Y1/?!?Y&TA4D*S7"ZY>2=?>256M*R=HNFF2MG>18M&3S MO)3SZE8ZKRZ$Y+]<[;S*WR37Y"@+C(2%A8=#JA4$AM+J])*M,,,"YL##A]I\ MAI>/47,XF[O4>)!Z<#DS&UX2K6"E9"%E@?(2%K((>9 J53EP6[!#X=5W:IJV M%5X]]=G:?6,9[ JVG\>JC9U4(3RCP=,!NEFM53N]%SF8"C6_<..LLH7:N_\[ M2$EH/6U9;]]";;UF/&7'L&5%GV7'L+)C6-DQ[!5W#/OL.@^F%^""E:7J23Z0 MTO_+4G60VZD0!%I9?# 0_CTL0!=>:VJVO> %E^"#LO&\Q 6R(N ETU[B?&0( M:6A9^#/YC+#C/+)F@3R"P"2BF3?3L4,]0E)&?L;WYU\N;I5SG?JO2]*/7DOQ M17QW\=!+SLFK E:M98:8@2)P&DRS3[$*1^S9@ .YPJL],(#]J>/.8Q@"M(6X M7^1G"3"54]/VT&S'V&3QI91U6K M=1?/-FH!$N-#/7N>P^5(=G0Y5L:+[&@F-,LN=_38:[BWJJL\I MW7H>?$"^\H;!L,EG_>Y!*OD/6U)Y@'JS8I+R$OX,I/R:2"I[%9Y9I2N=R47A M]&18R:1)G:RI"/90))&#B19X-OKN14;S3M9+.&4M=;AMN?8E<\[]BA=I,1[9$*^\W0R0/L0"2 M+IHC0WO*-55D,;TD$:[6+@C[++6W%]R;>DW+K?;V4G#;.P/F+KRZ*?NUB;%P.!Y9#*Q=Z5O;9O5@&6+.#(N#G+V*NJ'R) MHM;M;1+XV!>9Y:+J<@^%O#M9J!U4 1\9+2^K?5.?521\9.2\=A'Q!KATS=".8'U,BZ?N-RCOCR$ MDT889KB9"6@ZTT/<>I0L4L@(@#GX6Y8=BWX]L98PT1W8.V/A^DT YXJSXMKR M%7\/Q(^(_]382P#OL3$<1%CW$0/AW>?<1D@[BWF>.3!%)S#=(?PL^M5W76P/ M(UJ"B2TC)^YQKF3C;-E"7HJ>9()79ZL9'4<1:_0 C?: KP]OE3;+23/9J$7'@H/0U4+JP M^P+0?%"&1L!O]/C?:[D,%.P&R1BA(E[:FKP=[+M5$VY##HW+L6L):C&^"CP M)4QYT]2B!E>!< \[TA#FB"CVASF09(_@:"/\VR!)!KM4*AZW!B!//-\E:-J@ M_PW>G!PG;-4HN2#*C+OBI3'5P8L_GH2 RQFU%@P0*R.IX 4?92UW!B*O/@*J MX9M"N.ZN2U(N>ADBQH/P*M#RW>+^78;[]UGN'\9W"H<:G-FDU7>5V0BX[+PJ MVB=%M.KY?<\T3(:P:@CJ:E 'IQ4$C62,%!K7A"-HMD$(F>J%D*G9IV:!,FO* MW0C4BQ6O#AJY&G"?[4Q#M@V]CDXDE%65F(%'1T$,@ #'"!)=36Q7\MTW_=BJ2$ZA=1&^&%X[-*8X\ MTMTB]&QN,UJ?_EPH=;:)?Q% DX>XN$-83MK]*^;JQ,7J!<34)@!Q6'1L7"@( M)PZ7'X>?4HQ%,19V"]Z1%(%]=?G 0JP9O,LP@2>!#:2CL32=H;VT'K*W'&I, M#* 1Y8GQ(%'@FX@,3ANM4, N(1Q),AWQ2W?)Y=TS^I[@VJ7A]O0X@==JH4 O M'O5\Y<*2%7CT! 0MC)],GC'PT90:*&]ZG5A#3=1 !&,*!/=*6LDXJ0$;G'%J M7(NT@V2D<]1]9!MK55/&,)V1;#/,(K(7,XCQ^F#WP"K'@0CNF."(8'$*63'B M< 58@;_X-A>F:J->$>CZ"JP-LSPG;-AMT'.P"W+P@K!;-_%SD_5-"_O] ;\! M-NU0?H)E82 KQ(UQTC<\^)Z=' ;-HX$&1\Z0B1MRJN$&TMX0,8,2!;T$F;& MQ2@<,->'@4_9/;>7=<1=7!PZFU+_AW?Y=JR/9F**R$8TM9=:O';X07J-[E(& M06KSZ/[E;R.;9*'7!Z[DX@KB6U'_4;#3=6B,?'8=5'= ?^#3J45ZH'(.&@3] M)K80'N6+_L">:! <[""L"+KOQ>%.#EB7+D;2J&3N \S\+]^$ <Q%9L+QV,"T V'NQ:BKEO>6D@=M)]#8QN5"71I; M.T?HQYZ2VNZ!_VFT.VD]=DP [(5KDWBP+HG*;MHD[H82*&BY7T)8DHW56H9J MOPMGYW+W?MDWT[!MYP+Z1^;$'L^W<&WOHH%E^[AM@+Q3. MG/TJ7#B++MZP 6+"J_/#=TW/,,F:JR@/8!0YOB<;F9/QTY+I@)W(M;R\+7 M)]Q\(V!*PU'2+1==54,8"\5B,V$TP^PG%G^D$<=>"X.?X^M,U!,IQ44..RNV M,$-G$I [YA6 V82>+#" P;;C,B5&&J9!*.L]O)/9; M["9I2Z\Z68K2PEWN$*Y(]R_MA!U$'\CW!G3X(/<$?5,B^P46#'L>ZB-8%FZC M#R3FN9+N!MIACPQ09@ ?]- !QJ0'*=&K,?*ARH "FU-T92=>U"WW6LQ\B?FX:_SYYNANOU@I%P8MY1C(9 M_0JQ? "/B-;>UB/2KN_>G=VJUSJMW3?=U=1:8\WVN*5'Y!5Z1'XU__)- \TS MM!'?LXDY)6O+ ^-D%?[I(7PCV>NSI4C1UG.$K+L^!?*,2+>!A6%NR^0/(O._ MHO1%4@?8S _,M(@;ZW*^;C!?Y51GW@@O&E%HFQ+FQC+I3':$;/#@(DRAL6%<8(TOO;;O>[!2GJ< @YN!!D/AZD?8&_03O!4Y M@3+ [/0M&=R'I\7M]+=1%D)BT@;OPY&0;@L9RJ8;*@IG+@P$Z (FY9O>* B[ MXRT5!:C)-&#HPN'DC="AX_()+,D(=@K>1^]QIG 34L=B\H$7A>:#06;F=#P1 MR[\\@$8K)CD[=B[*"C0X>9";L09F9P6G38*T?XVY!&1:S> M'-/' \7S=7B_"XO,],A#AIX2W%=RC^DZIV0IL9-PIN[Y5'AAD*E(A%:9DFH/ M7ZHR16W^,V[=[,@]T%%3[@'\8%_N 5$\L<845E5^+&7)V[*P]EHL^3WR#B2E M"Z"X!V8A7>>U4"5&2GYZY@NF]T6K=E9?71?97D(=)R6@XAHQ,2LJ+%\E=F"!&EY'_VQ!YX)% MEEYZ##Q0*EHTY I\,,#,4;A>O(=/+&?.1>IKJ]-(Y/>%0JN"W]63WZ$D! DF M91%.">C#&,@!P44%PPG; "PW+<:14SY4 0H^8HK]V= M)_]%Z7LA'E1?L9Y18K D.:"B>DC)0"QKDV JQ3-Z-*F":2TP2Z6)M(Q0\\&X M%Q"5X\J4Z3?=;CLDJ=3H=%0LHV1_#V:(E\3VLD*%-5-&NA=JDQ@9&P2)VVRA MP"MX!,5\8-&FL]7'38VQDNPCU8IR1I,'4DRZT7KJ'!6. M2$4'#XKLID@CH*.@CBC+_-!AM!@/C6>78DIL7($%BP:8@B$$Y@H%1S C%M(]TI! MEY+JP^SR^&$/1;O'*%2L5*9R=9=PI*I M-RVM$6>HF<\B>0O+%I8EDL;A3STT+F5N>:(RK7CK>&G3,L73)S#U!%=(U3H+ M*Q2L2)!)DE@9*3TP%Z)PZW!.JF262A9,E3/7AK-%UZ5*A+I:*ZJ%H$P6&TG$ M):7+X&#SFW0A/"A0QE"<+>@&(=@%2M41.BHB(2[.LM"F40/W11Y,4#P@?37P M0B1+!ZL$@O%*FER^1H728'0(QY+_S^'T._OXB5.&-0BXCJ/C/0O LG MOR[MT,M,Z%59Z@S)ERRS0@B=(( !'-N* DFKU"@L/(^;S7JTBA-<150QARX; M5PA#0)C0J5M<_N!8#S2>1$!F'M7PBH +FI/)-XDXCB@U1K+UR&[U8D]8XF0A MP86@#:'(0YT.S&,RH409I2@[7C:=I:-&ATMPZ]/CR\I@??KU8A^7OB01TOO)L^.($-5T M!)-NU#HM8.)5%6AYJ8(*^TS>0:KS'4\L4SASA7?)]&)*ENZ '<@P3%906_P M\N)7QQY6[]!'>A,%4PM'T:LYH> (%LZ4O,&QL'$\S3R>QC]QW!1 7\R;#-J' M2Z"6PC_?KFD!XUY1L9S7IR7@*1F-#91QHZW QO M- 4+N1!FT 0^"_GDR$B3J!RN3^D%4Q!"A"@0.'TKRL3RA2=QS.YY%=&;" QI M;()@(5@@LB,##X#M4''Z92;P@,=CH_3DBH;X'V_41G(]"('$L5>F'Q20JI84 MKY#"(Z8:N;D17*$>=\40BJ;E"#WN"])*1!!("QLFEMZ98[@9JT.^.&-F/V]B M!\EJI3>+\Y1>IX430X>%B#&>.N2-EM&KW(X@>!&YR-.$FZ#;U[D%:QW6PIW5 MF 2H)R7 FU8LTKN::7IL7OTE,:M@P>:,$C1> MBYNDOL)-(@SP-UJSDXQ=B%T4OPMW@/@]Z1.HR-O5I"&_^(B4FR]^KU9_XMY5 M7IMP /7FDR-HJJDA=(*[VT_<"U(T>6NS$=S:>O+67NK6%F6GRML;3]_?:'=3 M3^C4@BXS2WR%3WA?)& HDV/H)7?^2$_%78(K$#>*K8T$3$6&1%E&BZZNI[SV MQ7/1W-C*N3]$2'JU$0MN,-MV$*=5Q$N1/=M!A#S@'NC)(4\^<&=FVA0 C?GT M5SCBAW=!<[VN@%.UH_[)9*D8=(AEI@V@"G>1_/.(I2:V_#=&NZ07TK M\06Q^^7_9^]=F]S&D37AO\+P^NQ41:C4NI3JTMZ=B&K;/>,YW6VOW6?FW4]O M0!0DL4V1:EZJK(GSXSTSN-*A^>(IS0\6 M.,-*3TZ3EURCO.25"O)A=:/M=+OS; ]'QDB)U2]RO3".U0C1H1YLL1MY0^JV M$I$Q[ 7.%ZMMQSOY*/UP;JI2?BZT@_D]HE)5K2U1-:07.]J=?;);%DA;C5MV M_41VN67[ZI:].]4E2^RJ+]E7VU^OK5>F3FK_/ET[]=AJ.[FV6]03 M$/E6YZJ<3\^M36*\UF XE;JCWB+#Q6!78G$@06'4Z2[2+D3N)=GME7H0J=_6 M$S=VHF.DRB+)OM8 5,B2L:2\X,A11#%X7?#=W^&[&2R,;@CG9^ROB7_B&31( M#G3XK=I;!?C1LD'1N9!;6#7[R@^608@KY @NZ154H:$;5BT5GFK\$%+'U4,Y MM\+OU/;7H%\YZ#U@_#7E=NVULGN17?.2FKNO6E5+=QDCAPP-S;)AO>I_N#K+ MDV!!,;G?$4C&-GZZIJRQ,1^>*YI5WT<++N_G2,PDRH#:R>A_<;W*ZYOVK2H3 M,-A3RJM?7J]H*0Q:O"TA$!8K7=8"#1*PB38;,D-"Z6+X\W,P),[07:<=L+>5 M\-;M8$BT7Z&"K=5_BE#]@=U73%M0A@Z6HG[-^6X>N5 M6(.Z,R_G/>1@^AA%[':PHC%MS2V_DV]3M\=WLCHSI8"(.327GI)*NI_\\F9= M#_(?\/.9@Z\8IDBD.PU@F1-.I(2O(H&1"9<:&BE@XZ5&N96NIVE:S32M9LZP MU7*H*R8()Z2[ZOS)V2]WVU=,8Y95\&O*WL <4,%(IWRWQ5T8HZHO(*(DI$ M;V(6AXA97 ]TBO&)L\9W#UJ\*K:_LEQWF^ Y7]]>9PCMJM?\OU4"U5(C"+MZ M"X$6-50F)6W(;W,/79'PC0'=Z9=+J7KX@"OMOFS@@!HXH,8EM]$EU\ !G18. MZ/Z4<$"C[=MAWQEY?RS'9@5"3W?M^]N;/3V5UX/#QX@&8!8-MDMBV]%3>7M_ M$-'=>"K/T5-)O3%>T!]Y:.&V>^KCM%&98VD[9S M)3'A?T86H,F,0IR,X0*=2EY(C8*PY3(6@_I^^!3_N"W@RDW> 3>H1IK$?;M_ MMU^:1+]]?W_XN^J^?7MSO]>HZ]_8'_0./M=NI]V_W^]>;29[1I/MM7LW.]4( M'-H:.9R,O=O"Z%KGD+SP NWEBB^WN/O7K)@E8D76_.JO-A+]KCD>9[#V/GI( MX7^OOV,:#!0-;KY7&OP."KUD(_W\25!NU/R.\?+V;5WZOPK8<=MM^B^F MD8Z!ABIOCG/179+XFVA07@&GEF,3J.-4G4ROC[?V-T478V46?3?HYQ-Q#[YX M_'9'(JQS-6PZC$59U3#P>3-PM]4?W#TE16V"3E=ZEVA*[?WO7$/O%./MNO>K1$/N@UO;@ MNE-CUF"BW/16QV, M7)02H%'NO"M7MIQ)7R& \X]W9UUW5[,Z+7-'=9G>JNSN#9G.JL#GE6M5M MIR8JU0&Y8H-*I=-4@Y"J5=IKMJ?+V7.]JHS3;\X)J\*!_6Q,]N'$M;DW9 M3[HOBZU397VW3:WZ[OU@=1F>TY[C]_MF7G;;,^+ M1%%N]\SM;[;G)=2L;NOF9E 31>OE'(XKE;P\R$1O*>-MYW2XV_;MX"0*VVU[ ML'VEVBK( ^=B<.E9WK;J=U=U>7/,*J'.Q=L6#5.Z_P./S8O2M%+N6/O& D@^3'*WSH95WP M!&5J(2J][*L+).K@ZC_+>21CBO+.1))&7N+)6/==R1? KH@2E\-&R6\:>W6\ MLGXEZTD_E'[X=*Q^+%N1Y@7:L3QS'CMT8^E=JVXL-\=IQK(=G^M>+/_S?]SU M>ITWVW=DH1]TWU 7E7$:$9?935EVZ(]4'Z'0JZA0\ )OEL[6G&)&68:MQ.9+ M7N"X:11A0[DYB 5LBP-#I'LFQ!+& A]H-9]))Q#=IBQK[^49@- *C$1CE N.Z0@+CP9DO M)ZHZ'AH0H)9@Y]"8VK%.(DD[@[MG?C$)PU&,/5QA-H^>BWN+_?;@U[Z<"-]? M.!)52U=2AP;"P9U+UQN30/%])X:M@;]<@>."(I+K*S'VOL'K87 MR/Y,X3F6 M+C")H33S&+WAAUN9S(L*/2;JT=?OV?Q] FY^%# 2;N\\ @[ QHN/7HR7RQO: M<.I ^XT:A#B)-\.-53(AB>"EPN56D+]/92DCBEF84D<1+W;]$'N%'XI59<2O'?X:6IL&J;)&'N5P,4( M?!JZH ^WG2RE.Z+NM[0^U9A27:CVZ>"S$#R&/DPX"(%'0=7&=JM>,C-=H:6G MTL$C[$\.LV3C'OM[@'.&Q2 //AV5&= != MO'%]=,18?T6S#Q_+#385<%\-I0S67V;4)@SX!C_V FR4 :(PA>LJ M2H07P'6H^(Q/R8)D/[Q*MRDFQ7,H79&BN!^K87@:"QPW G,7&&R(:JA2$O2M MK]00$2SRUWTC9 \FI?I*R-Y5053MW++<^"5 [TSC6/E:;;_'>8JJFPJ)JO7I M^*,0=3^MPUF*&RF/8H&ZXTR,9)F^ABP1SKW00Q]7HH9L48O",G_4%\M,?2O@B60*]K#N9HK/J)AQV9$^%G6+1YHP3O91 MF4CQX 7L?K3:K]!\^4<* ID[3*)A%@0AROP1;]P3NPF2IU!=+FPUP#!P$A/8 MD30)P?*B&R:0$U#^Z6TXD4]@P)"%^$4FB<_.B@?CMB#G0_8%6#LNQCGPI2W' M&Y,[ MADI*X6M']B>'4\]M"O\!2F_@@NE#CU$]Y3:8^F2/$H8F2]/\ >Y-M+ M\YAXBE.X0\$"1$MLN("=Q\N(@S#(/A.X%*, QX(_I/)RL%6\?EG 6G$Z_ .X M#7= 79UT9N P2=@ =5,;4T?PA0=R; X\$,#BP<"*4\%6")LMN):W\ !>C[QR M.%U..LMO'U3;M_R^PPY!YV+;;L+"(H&YS&07M. $5PN4[WSEE($<$Z M_R5UP GOZF]SM9R9^"K)[@3+.<8M#% (V+O(AQ[?\OJZ,]!]]&"U:%'!"0Z? M$&N:] 20ZA)H. =>',++=9M3L*C'Q>W,G%VC$$B&8@;T#)3\ZKOZ[H;+YR-^/S<]$QONQYOW5%Y.:X. : MKR1EL/\825_@Y?G&]%DO!#W46>ED/Q%#6$*:K/[)VE-VJA;AM^U>;[\6X;TV M6,X'[[<,PUX?9]AN__J4;9R)[5[RP)4D_1[Q]2LJ#SN%V.9>76(WT54/47:< M7ISB;T':>&@%JGC,&MKOJ1)L2?O_WG1U'H\&MJ?AYQ"4LV[GZC]WYH1<>45) M&GA1E]]2I[LU.MTTREXYD5?#2(JOW #Y1^$_B47\ZH>\ ?AJM9YVP-";"WH M-U@Q:W[VPK?!7?N.[NF=;X/>=?NVM_KK?<7VH-.^O[L_^+ ]&/9^]4]WN V6 MZR;D=7?<'Q3J)JS2"/7] ;'A5*7&D<2(=@=NT1/\!==\W&OK+=8_N'DKZA,L MQ?BHOL@ M;Y':3_Q7J=W')!4V\G +63/BUJCAZ)?7>Q4LU[+\IB;]488RPMC M6?HM.3 NO$M6U# MAAS&(N(&)J.SSY:H=3J35&247 MGGX!9:-$'%Q4P4CTK_KR&[N=V4&+&Y,E*PTII26=PVOFZ#9&-V'D2?38X&]F M(A#LKD$CK7O[)G;^2$<3_*#M?.1<%AG.,:MN/N?8J EW2O.HCJ[&8B:=,24* MX>"N%[GI#*TX3-ESR3,[XK@&6('C,4=BS5S;SD\JRII-'^FO8[;^(HO:MAP5 MJM%TPT@,CTFY2^0U5<$1\O_K0 O/T]J>;*MA@1X[H.:1G M* EK*+<[V+S;V MK8X%:5)B*90'Z]3L(YU9"*0?R;FDL!OR@K5$S.Z*XW0VISUOH]*U(BY8QH-H M5'LPD5CG5MM+Y^CYV,Z"*!FC!8\WOIK&5[-G0G0UQ#C&L-Y^_.>'=U?=>Q!U ML'&:0RSC&-XN952",A>DP&:=& =E6I1BLXL67M<- !+0[G;T,,3#A[CO;&6+*M"GX M097=N4YK+11[*UUR6Y75(O[2:I^7F'Z]B\/UQ')&Y/AUI/E57:UQ%@6?R #S MH^V2!!=/I8P>)8=M1Y*3ECD O6G@X<)!L22QN#+[%'WHWB/7/DPH+1A4@"2, M2*M] ODAK$Q"!!*&6F98#(_M,!:B!'0,UJ8)T#E *++**?M1"26K"_=2()6 MX7#1%V?)B>!KE,X3UU.KB^0D]04F/,M'X:>8C# -GQQWBD%"RFM1@M>UDB+L MX@P4>N81K4FS+%P2]BU2 I4 UI/SXJ]'R[9K])OZZ3<;ZM+U14JJ\8*>^FQ. M%U^J&RZK79(HJB'1'ISI8HY94&P&PRV#90X4EH.#&'$Q)Z:JJ7^K"+T28U2X MI7\ !A#M3(1))I%-N,0I2P(HYCN)8.4KAV+$"!9HP09L_;Z^UZDX)&V4V96; MW0Q3? 57F,'FJ1^3S,3[D,R]L9U;%TG./9I'F/*U>CJ!2)?"DHR2COTABG M24J&>9XC-MU>)9P"MYD$];Q0;X2#K<^&<'X*X7^,SZ+F17C5X"6J$$SDM%[ MDH(HQ0TEUE#^I]AD#I+M QR S* N7+"3\'B!&&4AD*7OV^( S90)GO97G+8& M;[5^_\J9A2/IJV(SD.@>E<%92DWFQ6H9" D[JY)L'^.F8N?8'#$FZ&],T7-% M#!SY!"QIWV9$41MK8 M!)*JQ,QQB,>*JQ*X_E$5WMO7%BA:%+J<;*5&4EHDVY,Q"I!(2KTZRI3\<&S+>[;MYU>C>:Z76+(";IV MGCYBM@VVW#K[Y )$H5*PP"I3I;?9!1ZO[BBU%14XSZ,R"'\HV'=8T,J.)M5> M^XJ6,ATKV^>[6WOW?HNUOW"'WYJUH7LH53G8WLL,@,2J/ "-BJOI=VU6\UTB MK>Z\]NHBJ?8Z=>E3LBO13]Q3ZRP/3OE&GOG!6=&6[W[/OF\- S<,7(5%=_M[ M]I4\$0._L,I7WO6XLBS\=BJB"=>@NF&LG6[7M:3P,ZS;LLQREE-3*VX9!2>USX$_&8:02L75<?T_BB_OK[3O*-MVB7Y"M+[J]VV9KJKDU=U7:F=,8([M87I6] M.LJ=TX[MEY9<*+&C1WI7(E7)+W'8WE\U\4NL\$A?]^IEP57&H;?+?/;LN%>O M4_5<;U\M3]6JN.I-P]T-=Y\I=^\>C#DM=S?.A:TT1.4H )V0_Y5/5S:>!2N9 M]3OR(O3:MS71DPYCC;TT??]C&_")QD"W^'%P9GQ1OLZ&+W;EBST3)7J-7J!QZJM"Y"U5 U7)])RX]RY$J]0I++_-.NWNH";JPGY<6QWQ<$AU M8D=:/"=D7%N&+V&J_!/!U B?B+KAJ)99Q#*P_X4R^/7PA6N1]/=J)8+P;P* S 0PJY\E?/OS\T=&,N:@A.@C6S2L 0BPN][(S MYEP,.@8K!).K!C?9GV6('_00UAJV$*!CSG7W_N*24"<0(0CA!QBA#8PN+KO' MW.*60@R@+T2,_<BF3"Z!=YJL.\M MA3JC>B#9P#/4V"HFG*EY%&(&88S"#]MS(1 I80.:E]/XGKOT\OQ[\:TCZ>+I M*KXX!W)3^MX&OJJ!K]H?OLI2B4JUN!K!Y%3UBOPONIM0=%.+/]P4B2VM\F>[ M*#T9WH:$5 9G4Y1B);*ZI?&M$#,K$S.Z-5S^I0JIJ52N(!X3,@O\4T;6]&#F M4^G312S4-8R_;R-WPH;%$N7OL];%];-7.87=-,OZMT=8]AN?SL\H"W!8)Z'G-$TT]FKF<[) M>NDXAVFFG"3-52'D7;4U7[W9C#Z;_+)^1S.1/!,M\S) M'$*OK[M=0P5EC0*+!\L[1(3DU@$AA>X8R3I';,35_^;*.,Y8-^,"BR6?,N1: M+HM.Y_1">D?1W[]PQE$XRT\F":WM+/?X X]2:Y,*!S[*XS8_USMN\S'%+'6$ M/\])+;NY@N4,8;?AKW)DARY:+&5!3B&'K C/E$DC;$"5D ]S4S"'8SC%:,[/ M2]&<0"*C U'_33([.P1:F**K<^E-JWYI34#WX<)>.W#ZL"L6._<)S";[4B!L M]0CH&9@6]2&9MT ]T TB!J37_7=:CH^GS]PR%-P VK*BSV@YIGL;._7PV@YC MU2LDB6#G":^:Y>X[#L=3X[> XR1HUH_TC'#UJJ&/\^G3>T9:5]XS>(]NE=$J MVV4[-L0@^3$\Y#7$S]\Q)Y:&'1#+ [NS> "12@,:.X9FW?A6>QL57[B4:IE MK?.0[4NHH8BPJG<@-\_BR\UJO*==SP;_G9S*+;MW7G8@= \?2J 92@V-/^+N M??*;P(/=0L^RW5IC8*+CA7>ME$+<(*.PG?E?E JXI;M[N+ 478RVONYW,K6+ M-@LO;T??VT4W>*4.2?F%_9Y5'MS=C^A5!V6WQO=WX6[+=C*DM<4N60Q\D17; M?9(.6=HLP?H8Z00,\0>W7^ +3C> TKVJ=&-3^TQ;J@3J@0KTS>.HK#.B:2#[ M!5=3D4L:4/U&LSR$2,+_!J8-9=N.5>HV!])D M[JJ3.::#:%@BU"QA&7"4O9NA%)RA.$GZ0K%U7"'\B1V(^&^D6!QSQ^K_ M8SV'UPPN'XG&O7SX2:FRL73?1= $/3)99Z'5^@IE,UJ]QL^87ZTHK!=_3^*= M+2-8?V&UE-ZGTB6 EB3M<1[#Q5S$[ BT%YDMBG8:FW@57QC0IVR!Z9=?0J,C$3&[DSS80#)>5"F?H+:!4XFV'Z+556R=/.2$-\R3Z-Y&"NC>(WH55P)FTJ? M*N&S #T7WQ1[L'$BLIJFPL<@YF#3X.=NS/9Q\?WPRR62EC DZ,K*+XC[\EOJ M^G RB?:?,/>,>M"K3(XOF++$-K.B\>6;77_QQOBA-LYE52))XV0Z;/^_Y.KO M(9S,DMTU2>QZS_X+.$MGKK^A+2]NTNK1:BC?MM*6_DA'RFV>[U_LH:^66F?J M"&/AA+9R5ZK, I:8XO_(<@:=?%[DIK,X0<,WWEF'0;6DH 72L)3*&4BTDP7: M]-8U:L5#EZ]3,9^#V4Z".[^<&FXO2DU-S(SR*W2)L$3$>I;GA:[RH340\4 M'X*XH(?8$8*1$OT!>N:$.\6*&O;HX'V$2@AVU\9NM6@>P,<4@;MK9WY$X()N M-_O[DG2WE./1]@"FM2M, Q@@3O%CMC)("\(VV30OXR5-%L9Y:G7\U;K2TAW# M81'V.0(A S1&KD:H!8%X'V4M-]L@.D:J^V2.!MA+4Y)/=)X.?6H(#NP:+$P4 MZ,ENEFYM"9:7L"*HKHL22T1?G#H^(ZG59O9*?A?5\TSAFH:+"-13+O"A&U[Y M=KBG*:U439*7P,W.2:-#VJ]9&P5V!&%2ZUA[[B#;Z](,A:Y@7,T,JT;F'(>* MR-%![, :E2]U0(G7839<+QU>4T*<*H=ER\^JRK\Q <2U1JCI6$N1,X[19C$06II!S M_V%=VD2:)K1@Q@.I([+KYQ)>CVEH\YABHM:C3#$L!T< B,S9$W9>' MRSJ#ERC-[&DM#@%O\>G,P_"4*60Z#.MJ.5Q5C7+\3^2)O+]M]WJ]O5/\#]_K M%5/\CS-LM[]=#]DC]7LEMGOQU/0\7L3+YX3W3I0%W]1#_/6_3Y+G1J\^3#W$ M=OFR3?I_D_[?I/\WZ?]-^O^91$\S\\I8,F0(88)5](1@'D;YGTF9F!!3YM,' MR@1L/)GZ94K_T*84F@U@_=" SE>YR.6'I7&6C(+.O[A5%E=BDPA,0TSL*/7U M$^J#*EGF\%T-76;_LB.V*N17ZAS50!YXY5/B3$72U#-,8KQD.4(IMZI!C:9 MU^1;R5P^>0[3=K_%:K'V[NJI4:!>\[F?++C_V:)KSI?,P=?)';N^>0$R_ MOFYW#=%+\RAKR.;9#CIB1) HMC.VH#>TJ-B*DCPL94(,L=2%7+P*[6N6THYRKRZY0I2&3,5$NM!?7M2:@+6 M"^C%+*V$SGD^";_3-D>=8<^LWY:>WN4ANGJ 5ED]@Y6S;T120=*5'I MPW!/F>0LRI#\3:7WP"BL931N*[D8(1.[RYW58%V'2KXL'F*&:>9'33: MEZU++G ^MV14L3;'+UW*@"B,Q"_#Y 5ZX1"KHK/\RMSL.%NO>$24A- $&)6+ MAJXM";Q#T+9^ 54=N<[,N74):J,TTJ'79!I)Z8"43Z:QP^"*OXH(&+O?5142 M6LP5E-^\+DZJ+VUW3O?]O;10;,N?L^IQ#Y)^J*O6X,=\['(:"3ZGE\OOW)@X MBC^QA&VH3D.)UJD+7;?("%$)(.:N+TT/:5GA:%N5(#LD3WJ=;IR=GD!GF]H1 M[T*TN=3&*;VK5I!=/5JJH-?O9/RNM#/;A.%:+%-PXE,>1I:_'QN%1UCW[D56 M,DD9)+B[\666.6:GIR/#_%F2QO[\G'653[!JZEQZL$4B.]Q!<4@2.^#4_"QK MFZV\V)(E6!K*U:<;$[0WSVTY9YL^_TO))#&E:T56W;Y)(0BK4OHH+PS+UN$^ =L]0[#=5]M#[+[BBAN[##,K M!,!$_X@,[EP!E]:D"V5<.[=-6-608/O LAKE%*69OX0@!X"\J"J!+,S":/[X MZ@.EG(*4:]HR-*68E1#S5%\_27T149[AHR>?\'8O,&^,S.MIYG6$ZT:I\ O: MF+YCR?.MG\!?:WP,M#O]$ ;1^<0C[+>"]OP#&,9BA&1@'6.I#-1OL*E'*'?:,T+T;+*0BHZ*WG9^D*U1">RS-%)9P56QL(ZXAR$ .5 F M"N'B&4G0[N47$VNV+,,G3R*$Z 9JPCOB=/B'UOB)+DJ#MY1S\J>KJ#IKV%5F M^16Y[>S>)GV?@@8%>G 0#%1T./@I*-[B*4XYS=WPDG)S95B$A(OU'N)2?S10?L"U($$B.PIF2';6/ML3 PA#':UX"#H3I'+ \6!;QUA:Y1K$2=$.=R=.]UM]V]U6XV MU3D5854&[1O5JDZ[X)1'<5R812FR2N#\(P5QP-'C)ZHU#U-J)\ .*14L>]*^ M;7:YV>U[T)5"3C&PF,/$8Y Z%*8M/?$9*U%,(BFYGD^)GQS.E07MPGZ! M[*!:M?Y!2*XZUAZ,H9T_UCH#8MT<3') #"N*T8W0]"EH^A3D9]OT*:A[7G[3 MI^"T?0KZ39^"IE"A*51H"A6:0H6F4.%Y?A_E]^"*9G+4<>=*)YUCZ,%@>^;! M;"T#'(QLQ_6%-XOS>"((3X T!2.0^<1CJ9 .#.T+NN9')QMSBU)6,Y@K(0: M!U0_5)P"/ZDS83&SB7)!@923AHLH4 MM-%O@0'0AX6@#O1DLIC#[Q7\MDA$"R/ROE!)3%[P1QHM' .Z!-.8.'/R4P5% M".^1',,YD7K5%78.E?M#=XNC5/%,9,YT2AX*T\D44YZG(6*%A$\!,:LVEL'F MCKV1A_CJA!8 NQXNI'2FI*2[ J&9M3&N&OY9/E#EJVPY DS^[/,66=GP*T:C M?0JCK_#47RA% 9@C\[PB;CX-G4T(9X$N4V!$SO@A=E8S\+U9+=$TOJR(;VA7 MH[ ""0RHJX1,YJ3@=L,RR(XWD#UWV!#4%M,1XB12.2T2CST_:X4_%+@\9R_G MWZN>-1[M89JHYA=X[#7NMMX-%!K<(/G;G,,N"CZ&9;*=B**>XD4AP I]J%#N M0[5,+BAB@612L#1&AH'G@K>Y6'#&$GGR%&TV4)!3,/5)T<@W\ HWY24QLGJD[Q1@%;@E MB&O()YDUZ81OY)Q^@:@HQ*IS1*FC''28B4J*"RS93&*;2^$:+_+1BZLOW MM8DBU>X&_;[S" I2>JUGZ00I29^PXQOAD'(K= P].[^+;YMS"9H\I"8/Z05S M1$P)"Y<%8+6)C.TF?91LB[+ LG%40>8[T+5)I<,XK,*/MY_4NMQ,BIAZ/*FF M(0&7'IF2O1*81["NO1AS.RC0:23$DP9@5AUYLDF3+@V*/UL -"OKR_+)M532 M",JE20"DXSD-0:$<(F- EA'=0]_9-7%"5K>1R]F,P%=D?,A<> M*=@>W&-FJ;F>(AE,1&QNN]7W436XARI60.*$3\0I))A4YY0X=R=S?@S>+$A; M'=;5%;E.O_/C'A+Q5&'=9XC$VU[[YN;P<=UNM]V[WF_8]:_L7Q\>\HXFNUVT MN%STZWT,0E+"=WSR2#!ZASM[=UO$3-=9)1>86L79+?'E%N[W-2MFG>,$:UX1 M(>U8O=S7Q!.6XE J*G28[(*3$:4\>(Z92EL0Y:B'9IGB+OW?NBB7DMZ5H>/O M88*96JOUAHONTFG:M/QR)54MPZ9-QZF.O"D_>Z^/M_8WQ>R+RBRZV[KKW!W> M2;(=0^8A4@].=OQV1_+O)',+$J H<\_RZ)1OY)D?G?)%=UO7W5ZM6/A4:F75 M+L)_FE)EA#E[,M''=5=C;[6BV=M>+UMYG*MU*UP,NH/M58&2-1Y;]&ZK[M9Y M:\IY]^+ZME.AK3F-TKV+_*RR(.+;P_[O;S(Q8H@_85G$_\X$TE["Z""*1[4D M5;?5N^\W^NMS]->MYK.7A*TUOY5O^?UUH_+54>5;[?NP B7?DX;7;_5ZC8YW MZLU9H>/U6MV;'7QQYZWEJG\O9.L!5 MOV4Q+V88JG5<(9?_V+TKOZ?I(T1*#)(?K_"AE]WD'F_RY?(US?_=&%;U= .6 MUW>=@4Y<?*#3Q@EA Q$_$/4G8;S'<1@]B6@4ER/\K\+SV#+7MUX; MT5N]$5/I/):X]C-P6,[SI8PU!4#=XEPT5>S&_6,YX=KL1>D^8+@@R^8U=2V1 M!(K].^O(RFER)M/.B[/^S_7+Q'[_;>YQ$^@(EI'&E)*VGDP:]$@!2HW*]D>G M6N/*X(D_4Q'!/L!N/2$ [L:VZXGC2X'HOLLM8$R:Y:@D@Y, 7W"8H=XVK')Z M0#P ZKV^T*FA95/F0?H_PO*XW9RY:<*6:PGP*N6.W[D_,(.T$+L3H.2O4 M?#7##&Q(#,-'23VPF^J=H["VRK;EEAE8K.C+;]P/W,@#2KX-'KTH#&:F'4TD M;>PB?"0!7L+JQPA;RLL,V)@ZO6 ID.XV;IK Q"HO&1A/MX^QVL+8G<:S-]'3 MPY[O=51[;Y-A)J%B(! (0*XMCMB/%4[QIR-J)I]_MG&:JLC*R-D>. MK$A#)4-O)6<89E\1U(!%P6H9F#V=P\?8/:6 0I](=QI0(>$,"Z]-1RL]E%VZ M#0(+(:!81R&9 11F MU.(%PJ\FR+L:7'V0M2U2!(%?#25/E,4EKSJK5%6=G>Q]H*&5H"2X\#&7&ZOI MJG8=UG;DD!;'=-.LR%NO\@5:7BV#'/J>&KC3!N<+SIU/"ND-<3DKO+15G>:* M(',MNOHV%Y^;:BE1+.+2T'>D8GB,?IZ]H.-DO4/**@N6U#XJ&EY"]<-#Y,7K M7JW;R8P\;IBB^TFE40;.9YXR_L^>>+(U1#%$L- %F< M1H&!OR-X/5Z%R"'HHQJ1M>XD:HW5.9RG$6+>,6)>V8,X1U39$#/C\ M_HOS &3453*Z00]BX8^X')+0:4$F\>YS_PTD7)4/_HI^9E3+#43'9E+,.';= M7*XFJ02NT1B0PGE]W;LV%J.6WZ8)8\D&DSY..VOUR A-S0_#F6*-,G57&,KD M"9%M"=!$<62-8!!/5$%X?]ON]7I[HR >O@ %41"/,VRW?WU(%,0] .U.@-Z7 MC_B_I-K ]0_7)P(*;" C__K?FU 9CD>#PT!&;@ M">I!9AO;!B6Z.*T&D\K&6$@1*8\96G+4;Q-MMXO^H+Q!;F;M*3OOEO]QM^+Q MNTL3"- (6LO]/XOSQ)[>W5IW_208_+'GHW6/8#[YSJ0H;,4'Z-G"]#-RV/IY+@*,J[DNN^J%D+61PH"(,K_89JXAA\BYSO',]D#PY:+ZUW=W.78LMMGXF!:\ MY!B0,&!P^KAJ%PT=+^O,97@LA8:?'&QFCZ.GSHIZ2OG]R1N/T2"-UY))"X6' M!?/Z2IV-MNV)HJ)@))/&:T!FB%#=^X)P(VK=W*^EUN_9345[A*^RMV ]N UU MD\Y<7Z.4^DD3 M@2+0WB) *&F5#-)]TWY$O6-^1!]PTA,482AX MFK$/[42< 5)FJ#M_R?HM<=-#:^-IHPQ.I9H9B@*0[V^<:?B$P+ZM(JZ@CKN7 M-ER%#[EIBFK)K0*#SB2$H:BW:9Z5R%7,_;\1SB,R:][\4K- M[M5EV_F9F^6T=&LMN+(\TUK+.'G5<:4(>)I,PXBAE5SJ@@QO]GV)F&EA&A6" ME05ZZ('R.V!W=$YCY=TF%K#AF\M.3YQE<*B0&^)N^H5N7S9+-LB/!YO(+LB/ M?87\>%=)Y$?&'M^ _MA6\(^UN[W_Q:KNUJ#L MPY4,\DO&?!>K"S+C*DH;R5#;\.XDD-/JIET=[;+3'["_-8=6 MR3Q1@)J$"DY9"33]MO,;XG_JRR#7FD\C\.,.,_JN&&%W;]3@!&G,-!M)_Z1N MZL;65-%2AG6N=&9!^>G[R/J,N>!L9'[D2W3(K4R'6:N=AAJ9Q[>&HF'Z81E_,L9A<)T6T6 [C0F M50+^_VKTZ983-S?*]W&CG+=9A7)6]PA1G@Z-,6S#3ZL,L;AP91A]3#W$\A:S M^UPSW# *Q4@E&;+IHL^U(JYQ#KGA2*J$OIR[!3Y:F\7'#B5VM 7..^G*V1"& MZ/4X6_"0+K3]'&C*X8IIH)G%EC5XSKF:U K!%&JTUN]&QAQ :SV(1KIKPLS. M(VW72;5R>9]-^^NF_763R[@QE[%I?VU*XT^11=4;G++]-8[JC?[WJ\VW\77' M6+POEA%:FL5?CQS1^W:7;?M=[X!!IWUS=_@[H-=O=P='&+;7OKO9J=?1]YLC M^OX;MM#-,B0^@WH,*B-8;-KJ^BT,KO[V\/#)TB9_Y9K-HV5+OG#BY:JD[\-< M>;WMDJ4.LQ'U<1908 YQ$/(]K:7SRKZ!/SYB2$\^ 1-8&3Y88Z=RFUM4<(A> M9:NT4M446P7I6 UI-3 M:5J*E*UA*?F'P%AQ%#/&'K#_)K]!&CE#;.^%:2/& M_Y#1R Y3S&$G1+2:+J;=-T?# LV()117R"0^U^Y)C@)P)LQ<1O1*:@,N@XG@ MKH+9(.0(X6Q1LDGQ0&!V3TLUG-7-$3$9**"P:*Y9\U"Z B?Y5(A/\*3-#"G$ MB^ZAS/B%=QH #CY^R)0@7F8R'TW@YFE8>8_-%S&( ,3*HHHMW411KU,[P=C3 ML*"UA,$DQ W2FT-.)3VIS00F_(-'&9/[6J ?:#[G5"]Z*HD\-U8)0UZ,(4^! MWB3:64HATL=,9HF9W >- K&/NHLS5P"7[ Q7_V/9,)&*8MU7Z#:[HMQ$X#35 M@9@2\V; 5YH;;;J0PTXDFCZTCXF':VH[?[=2Q-:3 D=0G*E2!:TSKFM%$Y7/ MU-*9W9'$O SZA0)5X7F2+H:;&'MP2JF))TP)@;B)K[G7.H$$Q\<0:#6?4*-&E,H!*4EO-I:4CR>QFA_DBFI$M]Y'ETM4&[:WBXW(/_RX>?/YHT M]@Q<*SZ=8YPRU+\I& *M$Q!/JY@O [U@]WK'%S'N.(BP"/Z!;3$O7N&*7ET2 MIP94[J-7AWV4>7%P1:3NE ),\-U,N#+EHC.XW%)\#1P,AD_BI 7I:BV>.K?X MF99/MZ>DVU*_SH?#Z44_&(EX4WF\%L5:X#%M&,]$UL9=GARR];1#1"WD'PG-2ZEX,D"OG^AYFH MZTI@^VB&,4(*HBG%(<["B%DZ8_'Z M4IE[('B ?+0+R\_0Y:79_:V&T]$/2S32:B@7\$RSRJ\M8PRY: MXV[:EH3- MTGOU3?\/D&6(>D0 0(I*, I8/1AV?HCC4$LU?5$_C!YQ6'V9_XJB /7P\.L'$+&_H*1S^C!Q:T-4!G7HI_ \ 29)?^1HA+D+84\%[;.Y M<+^JL@DVQMB,XQ]P[AF)/5BG+U#WX9@Z:_#TXTM:P"?,_$HC0K<*059B?NXG M&ELY&"CQEXPFH"'-M*T3>8AF\6JV H4H:\2\3/RL>$-O+?TLRS8PUYEZB@:E ME^HZQ)PD1>L/UVT9BM3X&K/A)PC^- M.,@K4B6. :W^LJD7@7P(K5I1"SPM%CZG72UOCW+F:,7NB>SX%G<6Z*#WC)\.^."+TB<6$K#G6); QYR\7Y+@]/#$E7 /"%+S#MCMO81^H]C"2WFR8 M1LHO95LOC42MA$3]+%%WPBWANJ.1@RP8+B2<"F0(TB1('ZB>P;TPD1=0$8Q[ M1Y],X^@O$0R6/&B8\/1,^#!#T?GOS-)@Y5FX((4Y*>Y*B['3LJ+&(U VE U. MK6TAC$]->(GZ([*ILD(.=A5Y$56P4 0')3_0"Z\*[:E7[IRAK] %XM8QC\'I M%>^_E*G<^;M:62685FKS"]U6RXP"^P 4I])Z7?\3L7?9%?%4)T[K#<7OL*A6 MH;KJ>A[R*J,R( -WD<&<9\6!Z"RC0LTLX1ON:RU*D;4*\T/7'FEGL/^9,VNU M:RJC:2M#OF!?-W =0DH=RH1GHSVN&\X3S851AY:N'FD8*QDS7X+7&-PK&=2 M,G"JBRX$H)]27*PJJU"EVKNJ[0'ZV).L0-=#Y&N8>PXHASR?%C//P6Z>BEAJ MER<8GVZ&^VTL5JKAPG5OLT,MG>2/I3>K=FO-_5"-=-\&YK6!>3U#F->;!N:U M@7D])YC7)JFW2>IMDGK/.JFW\0\H% M4YV-F 8J;4*;LY9-RI9M2V=0DNTF^$U>1N;6"FOY!6S7QB%W^@-G0:C:4>1( MYZ-0R+^*#N$05+= N2XX/YR$A@'[I&@W'3Z5C1S7G M4MOY7*X$0=/!N@+FJNVDL9"/40Z68".WG2^4T:# 80L^L$)C)NKI(HB0.2*41LQ4 $QH.Y72;GJ\!S\ M./7BJ4[ &0?4MS2!.R-.D&<#\>BQ M3^AT1PWQCLT-M (06R\!+\%(SE1"V]H%.1D@)S6SXQ3?PB_PW0@YXP6KWZV# M"/8<9N(/!#-=^>XB+G[WGN(F69%"_O"QT:'E#,',:1-$TA9R+IS*$1EK8'UL M[(G#*65B+YG$,2(U$+8G7?DY2X@200180S@1CQXB16")$KDN"+SY>T_[:0>G1J6)ANPJ:&15%635[WA[Z%)&2W4[L160ZV(A M5V"OKU 2=%3:)"/K3"O3TA0/#M@]BYP,X"A^*8HS$&X>$H*N@=*E,D\%T$@2 MTAI)W]:4_JK)J12/>$?- P]ILF*/LG1O^_AJ-#$-S1R3=I)8>,5V==25.HZ9 MVE<.KFFCL%G+CAA'/LN,6T&W8M<;G4&,M<-)I%R+^"W\#W"GE0"I8;!!3\5+ M9S>Q48WZN=^55:20(9'X4H"(5B3C(CG?(Z>)&()%WE)!?6I0G:SE /AM"P^" M*7 >.:DIT\V16PV)VYHHZL8:)(^+5\ULS/;8V.,7\64^W92>I,Q0!JQ3-TI$ M9B6]!T9!0S4[=K1L?@.UJ]#%?W39XRU!-T02VK=5KG"T4KN_767H.]@H[@"^ M;>5G^?5VBB8\?X,1$(>=DH8R>,:3W0L_(GOI&<7%FE%*<RY5-K6=SV3G\)HOAHO2S[<%O:O.QIH03N9$T@+VA)N[/)D?+E#[O53W M/'YST;W,E<_]<*&*YRY;SD7OUNN\C79H X3H')K_Y_K+X]JU< M,G4^)JAVF:.B]3VMYA72D5I8;-(^X>&Q)ZL/T%9S;HY4S8Y4BRT 55,,8E%= M7-W.Y4H;9[$JU!U6_1/>_ M^NW=UQ3@M\G1E<"3-9%,A1CQ771W@9WTH[Q?^FXW!_[.>/#G\[9J5*(TP/,- M\'Q37;&QNJ(!GC\M\/QM38#G^PWP?%.CTM2H-#4J^]2H;-'8Z$7CFSID:RB> MWXR-0<\DG),@.'WA,_!6N\.B= ]ULW_7VU8FE+")7@.8<7*O)[>>ZFV[<[== MU?/I1[UI=ZZWINJ9CMJ]7_W+:LUUT+Z[/P8/=.\/:AH=X';;4Z+>;:',KTTL M]@('7N8SUHC\YLHYY2Y@;=8,G83LJ>+2C\LM[KEG2YW=R,QR_02$+MM]O.E25=Z>QR+IRHF-M^;<#]6+1SY_JS3>7JG0HOO/WVIVSEJ]QK) M>!X[65&)N+-'=S3$_[>+(_)PME[O=O/$U#' /:FM)%=!M?^+..086:.%OBI'7RJSX^K9W M?&F[#<3E82F.7^U(^77JPK,G4UT&^*W]:_M(7-\<]\KM=K_7;XZ[WUQMWP.O M7_3N[I>B! V_-?QVI!7?=%_ <*V5;&U4*/Q0)2H]^M0AQ<7??OJV.Z'WI MY?]'HT]_+S*_U^[<-4*_$?K/\3EN<325^AN.X#>5(95;:$V#4X2_V[_4S8$QBJSQ*# MS>X<2V6I)V7O&\(>A["]BE#V$ *E$4IE.]QI=SOUWN/G)I%679'ZO 4 7&7T MIA+:UN 0=+O7.YZ!]ARBD8L MV:K3SNIQQ?;XW'U0#SLBXE9&C:JG+7$]Z-;;E&BVI_&3[*FA-KZ]8WE-^_UJ MD+;Q01WM]+2[-=_C<_=!?=BU24!E-*EZFA:W-3Q- M15RHC3OJB.ZH7>V[BNWQ2[NC#HP]!N*^* ;CQH*]2^ M+;I@-DZS9Y9OW_6ZO3?UMH'.>XN:1*ZCA>#4VY_P( MVZ3HG3=A&Q_8$=6XFN_Q!C7N&&T+FR>K].3!D>Y*6?NV?3NHA+*_ O]/=50^ M:1N.G0A[3CBBNRV\"K?!"AS15F\PJ(GELM M>NW;XR8W\J[V\J[;JTOCH9>2=PVWGRNW7]_5I>M.P^L-KS]OQ=W63?^VX?9& MDVVN]XIHT=\G]_7:=6G,;6C-.,!R7W :NQ-S"RN0V_,P] M$OZO%)'3Z_0Z!^F/5I?LSR88?%AZGK-6O:+'S'6KT$!=W-_4SV.:[2*<_<9KJC) M:>]9JEI#[UTY!;Z#0$DC?)7P[?;:-P?L1=L(W\,(WWU+D7=IZ%K98_@EC28X M#V<2/@5.).&?/G>6^.'""]QP)I<8]KB^S@/2O087X-VNZ+%[\-Y+%(<=KW]T ML^FGV?3O;$]Z>Y:'-WMRO#VYV1,$\+R$8R-]#PXZ78>S?I1M/_>XZY=$)-() MYUX(E,"V'G%,:(6Z95H2.O/("R-GS-'IA111T_CC+&#<&J"P"F_.^1&V(A![ MYT?87>_F"HN31B0="/2F8GM\[MB%GV6<1*F;I!',EIJGR=G<#Q=2.K&$28K ME951FNJ)_-3=UP:I"O!3LST-J-U^]WO3C^1(E+UO>F:<^0YWVOWSQ@NLO0/J M81;"1/[-S=)0MRG[$K[HBC(6ADUJIZVQ*!7.#.E[SL7[-]_C4/[E1$$QFWG$":EF.'F]N@W=MB M=F] @R.7V(_D$O,>Y1M,9;OJM7%M!3(.12QQ ##/#,,114^N[]73 AJT;J]K M'H9O-JAQ\>Q+W*:K[_'XMM?;U5ZIL&!IA%.I_^RV?5>1$]0XT-8WH)4B\A<. M3!(FG7KQE/+AP[$SDL.FV>QS@4>IV6R]S:#SWJ+N335VY_PHNZOX;PB[=>YA M-2C;^,Z.Z#NKR.FIB^_LI7?H;\(+4'F*A2]169)_IEZR<#Q$V)5Q O]P O'H M_5T*/YG"7X_P(2I6E5&HZFE6[*=05$TVDO5N=U2^AJH; MJ7I]WS\Y61LOU/$ U=HWNT-D5V5_-^A0U6OUWCQYV"=?V@-YD@#T[Q'\EJ*\ M,%XBOCE#&&KB(/O_ A[L4/OA@H+E$8H ME6XN H?4=G_W]9CNC#EWV[X=5-BS^EL87%6^.U:1MM\3FOK2VJLK$7JM_KY9 M*)6!;3T(*U9K6P[=TN$ 6_+2)#A<5X=&%-5$%'6O]\QZ? E1U+#?>;/?H+\K MJE+#? WS'>J^;]UT=JWW.X4:=F!KJ\(;XBSI']\?$7J#=@D=&EETWK)HT+ZN M@RCZSBS"/5'(S]Q/G7N=D3C;$Q@(\29"SIK]T&_;X/]NO?[5IIW#!? MPWP'DWW]G7NE-@K("RL@WQ\5>KW&!?_]":/K]J"1117:CR59M&_=T;[DJ-21 MK&-ONW,*!75[>T(#5T8X[#*?IN=ZG7;].]N4_IYU2,V>'&]/]NWA=U[2L1&_ M5>D;6'^^.O<@9M-Q\$7)?=.K""AW PE3Z>TY/])VK^\:TA[)97:[I\>LBD*E M$4SE'0<'-4?%_R[@BO9N.WBXB1X5PFC00!@=!%?P;@?JV.9'5X-;&37I$C7_/M->J[/'!T=UKXT2M M!9[[=ULV6)>:P5ZK?_"BP4J!]M5-).^BR!Q[(UYZ[8>K6&[D3L6WNM?J7!^Z M@\3)03L:KJLXUUU7]JYK>.Y<>:[;&MP=ND= I3 9GN,\UV\MSOP4^V0!IFSR M11^62-7BUP-CQS3RJ>+R:=#N[5E>5'_Q5*V=N'$:K/(J8U\WX]1K'#H_/R1B MZ,NM#_/OWDS&SF_RR?DP+M[?W423%Q2Z MM$D;O\-MR M?Y"C\])L\G,8.6.&[.]U>IV6@Z$79^3Y*>([4)7B7,)5/161=,0V/$55CLE4 M.N\_?7&\V5RXB3..PAE]1J/#+P,5Y+$&QX3YP/5\1%'S$CF+'?P4)N:F##:1 MQ@2PYO!ZX .!Z&H3B:63O?N^ Y3Q,?7>#6)K",$TLWC8"-X'LS56#K< :K2X!"HY36"Q][$:PO\:[,3^5X M+-TDANG'J9_@#&F$,(UXL8%,F(QC& ?'A15[X:CM_&Q3W=!#4YZ(%V^__,'Z MY7O!VN73LZ'<"T%!\LTT MV\[O\#'.RDH9C+&8.G0]^N63ETS+?VOFC:+F=:]W9TX1S?OZ+OM@G!.4JZ:[ M^D9=9ES%IG_]7\/HA[\^ZPB\K$VW-9NT,CX1]N9D+#!BT$R;KM9V"]K5$ 2F M(,%*8M2%N2_06FX['T'&/DU#$&57X5- '!6GA+?IQ.DP]D:>B!;9RP2(>7]\ ME3VDF9?&!6Y$MK'N0B"G2%(0_POX-(!?(.GP,\G5_//(FXD(R&K/N90]09"O M>;66T2/X71 F^L[$&\0PC<-_DS$<$N-4A<_A8W 7]CSS_UJ+,'* M@&]@2\*9I.V(9))&S.KP*%_MFO(QL)%! MG"-NF0<#XZ[1V\0(&17.67?0PO_>T']OU9GKWL'AQFMTYB5T M,8+HYZOU;1B%@7CTHC1V'KQ1R_D,4E:.Z7?O88EPG[O.%[[K%\X%IB[V.F_> M/GQ^_X7^W7USZ3RX"2\F"1.8@V99HQ:L8TE:[>OKWK66&F^<:?B$(+ M6I>F M%HI)G>9B\=9,"N /NK1!U_+]T*6=>]V_NS=B"'Z)L]#3@KWRMSJ)2@V(M2(T MXA49O2-[-]Y-Q$[X'GV9.6(6IL *ZO7K#M*ZP^"XOO! LX,YQBD>BKD 0C(W M,E/0T5(;8$F,C!KJ&ECU4[J!^H/5*H628H-K$'/+=_:3-TJFRFUE_XK;:?W8 MR7XBAG"VX+RL_ G(AHD77*E?]O."FYMVH;^+>#_O"@#Y[8MY+'_4_WBCO5%> M0)*8?O0F_X(2+8/>QU^K6=[?MGN]'DY4I9:I%ZLUM&D-!3NMAMVR\=N6_GW3=NW !12;'3.=S+H\O.JX]/K;\A#+ MW=:1IF?0M42C,L?IQ2E>,(&=-;27LG?;NSX6[?][W:N/2X.?+?7MYS":.=W. MU7_NS FK79QJ".N_TRC[]41>#2,IOEZ),?# C\)_$HOXU0]Y60QR4DWY%KU* MSY/96VCM2P.]O*B_;W>[@WU$_:#3OKD;'%PF]] 4/L*PO?;=S>JO=Q#URR$X M>=T=]PH;T7AU/?[RK*2@ZI2PH\D(]Y_ ]8*,F#7S]KEQA_96NG/1BO] M56F&VW2?V9)0VT=%=AMJI=2HOCVM]7LOUD8S.4B6]/.*N^R/ZBN[KIJO[+,< M^^3\U89A8E>P+IF.D52[B)8*GC8T?T=R+*,(#1LT9 @!D,XF',JAY[-/&DP= MY;(-QV-XPADNU(!S 68[GU[\/5I8(IYR%Q(1!< /9!&!\0GS#C*W"(S:9MI] MD7*3YK"'0-J&?LR,(W3/T I^)$.>M_I_B4K,PYE&[@9GCO MWG2NQ]W;NYZX&4AQ+;KW;N_N>O3_@W&$I2M@D((.+/YZ*H[4!OHKG$I,,1K; M"91)]2_&C_6*7!,SX! 0./#/&;NMOF,Y,ZB:G'E7<)-V[\E%!/O*+K29^",D MEY:'&JJ,$[HZQ*.GC!(4!^@:F@3P3G2$:H<-8I&2QV30R3S=%Z_[MY8C'+5J M%"Z71V*) _B_C\QNVX6QT&45IS-] MUP-@\# _OJ K,AL?'C-*$C%L.^H>^8 M[A"'%$^*\%E^L/I3Y5_2$?,YW%R/(EK@\LCQ+% XC>1<\I*5LQ&COG^)@7&3 M%(/- =^)?P#SQR//I4ON:2I13B5*3TKQYEQ-I6KX^C*E\L4MP+M!?V]GW^%- M-73V]>Z.X^R[/:2S;PO[I/%?'=I_=3+WE7,8_]5A..'P50+;^F[O2U9<8E#O M+O567?)% ]T;_>]7FQ7MZ_M7!_ "7O?:MX-='($O+KUA3NT.SVM7\=WKMV^N M>P>7L[?7H#=O)[Z_>T_;.Q I?D@>&T<,PS1Q?A715[#AY\X.N_;=(]K"3=,V312UTN1O\%C55^P\ _ M1:_)03/VPZ>\EV;L8P]991@(S)CA/ ^T)[3Q,&-"@#[\E6/DLGA+Y7_,9N$(34@8PI59@R_Z";SL7_@F^"%.0SA3.9J@ MXCZ/PDDD9OB:F0@P&?$Q1.W:QY&L1( 8,SO8,,JF3#2A;58IFM0V-];9%>A# M:SE2I6WP-.%,>(_,)EG:A!=@ UZ._J,Y&U$Z",R(TPXDT:;M',?1M14;O(2G MZ[D3V<'5U>DH5U?W.*ZN+8\6<42SHP=Q7M[K'>V<=DN5\T1E9FWOQ%3I6YP] MED;4L! T,3>-8\XYG9"=,R%W61J3,+*$B25"EKT)!Z7#S587Y,]*9K]7,MOY MC'+LBZ3@PB,(UTWW(/HY!_726N_OVO>=G0*Y!3?/E@6$MC+%6LZVRI1%YJ75 M6M\5:#GT0_?K$N7"N:+8]5V[U[W>SY_TXN?S)XX[*0^=BF!-_'"(#:STM:WR M%W?7>@HE%$7%A=05]"-Z6=YW+"TU E])$3CAJA <^1#Q$U\I%.P8Q]ESCN$8 M#D#X1*]4;R.?(H@7B?.9P[ 8JZ.ZC>H9_>B\!:5H MY,$FC?"@1:#.I%'8@C<+SQF*:=)R?I7?,,G6FBWG M 38[@GVWQO@)*U6 FG,TH&B)_Q# "/B[A5P3N*DJ4QD7L7#^*?Q47CTD5ZCK M.Q>O_OGP^=6E,Y/)-(35AY,%995BTO"&;39,P=L,XSB@WTH?_<:"%$('%&!O MID*G84@0T*5WR6_YTCU7A&F=ER27X;>7SCS7FQ7;/ M0>"!@:/B=PN0?B@A05YBN!7F9*YUF*/P%Y0ASC,I\YAMNFIFXMN5\HRW![?= M_WB#?B_E&>(/EB^C5]L.OOX>&]3D'D.1#3<26:?E?*6K]=*YBU6 $WOS],UC M-DME[/"&LUC!]!U5Q\'<43"9K8S\D<1B"Y8VQF8MGQ:P%4I*+@0DH;9)-&8' M!<4;S9.B+)V96IGL!E]#**HW,/2 ^8%L?-V]T;%E MBP:FZ$# ?^05_7@:1MZ_5:::<.X'>& P4(+%*F-O)+'RP)>/TJ^.F#7W3VW% M+%S&4_&8Z3#%\COKFJ7$HK+"J()>E"F&>+&&SG^UOZC<(]9H0%]<(72W9O>E M>_]X[#LX./>6"OEUAMU*K^UQC=(/VFW8&*.-,5H-454T,ME;3;6)#Q .05&\'T^&< M4I"DRK<.0F;DJ5@"SH_TVS$L*(QB+IR= ]>![NK%EO,^,Z7ALP(%-?S S/O& M@O^;9.,3C'JNA23SG-9!=:DPHQ$:=E$X1XM=8M(JOP>G2A&%%",%_Y;Y5SGQ MDYCGG/JV7H1$-'=3<99@XSW*#9E35>7F!T[SU8Q")FI&+DMMS P'@;=+@#;I ML@GA&1/"TG57$F[]/:A*F,W (H[3&15U3Q=S9"T2)LZ@@Q>AAQ@3'MYS[ Q9 M.HMD&OTC#23K /U.BS(OBCD^K=G5FS&Q,,2P%>Z"C@_T=R1 MH2]S4U9S?-*&^^N>OMW;C>5U3*$M_#BT);<5Q61;?K4HM^N+@;U-OCO] V7A M(UC]) L+T"?\#M9 ,KP7\MPPT@Q7J<.?EF/'"U0VIQ6 & J?00:F4NIB9>LG MZ@2OG!C*W#@=_H%9G^;26GU#69105"H0)+NT2%(0#0M:NPUDT#5&9.0MZ8RX!Y'K MVR0CY;4YG2[4%(SOEI79%(PW!>/KTJ3ZG:9@O"D8KW;!>),JVJ2*?E>IHFO+ MLD[@=WQK2DQ70POM&?K1D,4>B MPDQ,^#L23PX:3[CF&&U:Z9$/T)Y?C,:<^E?B:>2W+!482P>_L:.2D-F\P .3 M=Z3#Z684GC>LC1U806X0I@0-M0;HLZH[O8=7;DM?'#./1:@M0\\?MQU&E-GU MQHY7KMEO9&$#X[R^SI NT?^R]--.N:>@0VN?BA$%D+FX.(QT>)#SO5?.,78N MXB8KN\GAW2:']Y+\;,#73_B? )U_29P(+B#.6(N +(6K2@&6\QK*CT7C[3T. M+VPKK#;'X5]?7QL03/:X9J$"1#'X@2+[$^]1+GD8NQT3>[?231WK+E:W%%RZ M%-I@=O%:!AHA77DT@8=A8V1DAO4" M@@T.,7)!/EK0'_3P0 F*USUYY&)%P)?6%O3)$, 5BSN&NXE>.9KPL!2VR]* M2(+3\H"1I@JHG"%9 CMUGNHNKZ")N< 8: MG('&[=G@#%0;9Z#?K0?.P*!W")R![P5M]#DNZ.OVS=WA7="#3ON^N_JG>\.- M=MO=SD$N@?/W;/^D4M3JB1QZ: %4-1"&I=TYH8O_;S+ YA1;NO,KD!?QO3CX MJ^I8*.\\1L5]JAP5LY F$3F;IO2,BY:YJ?]":WT>A=@\)290/A&@%R!\]-BA M1 8[H26224:9M&B#@Z$^]Q+AQZW;[2F(7$ MB7AA=K\%YN?]H0N%MFT/>]?KW;Q$5EDYZJ]-IIMVE[@^F8*J/9E2CZ_"3KSS M8NY]A;Y3V O]CC@$=17/+P$46#F;9RYF]C).*[NM1E$Z DF$DOG!F8ACN"4P-AS NN!EEZWL*K-*1*P)J\LEBE7ZOZ;,WAR[%4SM MR5CV_N:Z5PV6';2O;Y *NN"(JY>D\PA< !H(^Y6!DZ;>7%W M1;U<+A+2T!K 5A-X&KDSN]HYGR!\@@]116!5AP+>Q)P9KZQG%1/GB%>W@FZ8 MY*!,HD@?9YHMB)2":)J)(,7:KS0BW3.3,B-+\K6HAB @=37+< Q*!*L1J"@ M?C#!;G)/6GR!\IH&[I3T1?B:11QUG>-.?R.,&B%\"8[?<,0+<82^Z5 2?$P3 M;*IHN /-"AG1/L)=%%#O"FVRQ%@R,Q<+O(F6[0=E(WGJYAE)GS%P6 H4C"2X M?6(LQR;[B8T3QED!N2'F!?[R)B18E)$#1LA$9]<0K(OTI;[FSI2%JJ!PC/O"BV&HVZ[09&KAL:L^2'@TG M[LV)OZ6NCRE)N"^?(MA=PM]40?\RYC271J!^F5T4RG35VTU93\)53;%T>:_% M#BWL:S/7QK9249Q(C+RP*,R0^5(N*-?O]69BHC$@F%7)>!I1>AH\ES\42Y[: M@I7,%)57W+L_)01N.*W@O_K]P[$W"2V;NT!]Q@['?L&C7>9BA=(;W M4@1?HS?HP7GEYKP[ORQF<\PMDU];*UX[\L0D )L/)+ZAP 0!&FJ7J]T /!\J ME7APK5.)^_5/)2[WNX))"]9N2C(CI [CB-7"[?=R+>BQ%A[SW'7S^?NZY@J? M !-MC:.U=M+EX[(+O]1QC*S7O7T#>G2$&Q0IB32"K$M2!CMKC4W'?#\$EXHXD^K8XQN.1G$[%][0KA&5U)[#"KMT^D,J/IA'0*BWMMS M859EJ!C;KY-[)W->[D59P2&E7*CR"C'133Y -P]]2?"[POTS]3B_G6(+O.D( M@<-]; NO^@"3&C%T64MA.I5YDS+:M5;1;?D(Y3!7$77-0]15U4NWX"0G0815A F'XXKH=;7Y3S0^\HJBAGH@GC6NGH#5]LI.4OBBA4SNN_!>*VC$W&LJE M71DQ2J$6EB^XS>M<="AAE(VSV2-FOZ2M#1TL\%K[!ML'& 8N0>BVG&@JTYE( MU%]II/X1R/F4_VU[0U;,Y^+5QCF_4JX,>%=PI:\OL&/BF2CW.Z+/4E5.\ M.QYW;XO,1MN:]#T@)X4Z_6VM8(48##.8?# M.&M#OSMW66-BQR9*O\F[9)>>7V2L0[>Z:H6CY8L7\*YOWM(<&[XBA18[)PRY M\;&(= %D<>0T5D>"J.H%(^QOL> .]]A=8QF[N.M !\8CE:GOP["54,GY4"A'XHG4_OZH: MIZ;@IRGXJ9(C"*UHS9LZMIS/]B#\O#1"YT%1R]2N:Q4AX6>-Z:W*^EI4/FB* M3$S%X")OC(_DH\Y#0= U\YT.*45>AO,VT>1F&,:SR1\4EU*Q!R3=^!=8S_U<)X9L)*&8<+X"==:OM'N MJC>Z^PJV( G#F?+.LB=$XJ^ $H8>#NZ@)56KL[1W)=&SZ$J% MD+.X;.VPLTF_X.'+,>4JQ2(L),0MH!G><]G'Z M/CR 2*H^B\8@#*[TWR9%T/GJU?0HLCPKRD*17/T=05]-**%50BG[N"[5H*.C M7!6N_X5*ULOWHY8T6Q)?+<=.@OV7>)0HTJTT5Z*7.1O8N0FN"]584+I3Y1T' MP9 0B"R&[\OJL0Y#K2U0DJH& OZ0I1'PN7SG49LVTK$:8^ [,P9*K.[#"H+M M8MPV4]9.BNE.KY2@$Q%RQBY=%:U6FQ5*VDE8D6EO4CN2?I[941B$D50714(2+>?*H M.!"D"O=>).A6LG!2BF+.TRB&?^G,)/R]+8_4O39.41K5+W'^798:Z(LX<<:4 M0);AR\:4LX(&H"\Y4^R1K56+!I3F\H\4%+Y>IWO+22Z:L7#@3RKL#OP YL\[ M*>?./R70#?6/V3",/=3_8$]^LVS)#T&<9B7J%DM>X(BO])"?I8L\NG"T5_35 M)>?&P1T-ME^ 7.6[=*6^OFEWG:&"R<7:0Q%/:=M5M49QA?$,#"],0;-W>[29 M7*; $?^9Y9(C8?!G=DZM;5%;V#JW:+^,\Y+/4MX[-])ZO])73SF;HUSK[8AA:P M8KRV5]Y#IY_ANMT*QYRL4PZGN;1W-^>V=Y8-5.$=?/57ZAU6X1FNX[$+;,G M6FM\N0H^>Y=\")?^;]=\!W9H'X\LY5E)G=L?NK?;)#K4>I4KC1DT$(PATT)+ MYNQI\2O\=.Q)?]1R?GTX^]5NMHS7&\8K"73S+ *1!5H-"J'5GEOE!GFGC&D-$6.^I&U^!IF%'S,2H1;695PMDPJ$\R6J"O1WX81\*^)C&"XX._2]V
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

Cover Page - USD ($)	12 Months Ended
Cover Page - USD ($)	Jun. 30, 2021	Jul. 31, 2021	Dec. 31, 2020
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Entity File Number	1-11373
Entity Registrant Name	Cardinal Health, Inc.
Entity Incorporation, State or Country Code	OH
Entity Tax Identification Number	31-0958666
Entity Address, Address Line One	7000 Cardinal Place
Entity Address, City or Town	Dublin
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	43017
City Area Code	(614)
Local Phone Number	757-5000
Title of 12(b) Security	Common shares (without par value)
Trading Symbol	CAH
Security Exchange Name	NYSE
Entity Well-Known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 15,693,865,917
Entity Common Stock, Shares Outstanding		290,441,408
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Central Index Key	0000721371
Current Fiscal Year End Date	--06-30
Documents Incorporated by Reference	Documents Incorporated by Reference: Portions of the registrant’s Definitive Proxy Statement to be filed for its 2021 Annual Meeting of Shareholders are incorporated by reference into the sections of this Form 10-K addressing the requirements of Part III of Form 10-K.

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenue	$ 162,467	$ 152,922	$ 145,534
Cost of products sold	155,689	146,054	138,700
Gross margin	6,778	6,868	6,834
Operating expenses:
Distribution, selling, general and administrative expenses	4,533	4,572	4,480
Restructuring and employee severance	114	122	125
Amortization and other acquisition-related costs	451	524	621
Impairments and (gain)/loss on disposal of assets, net	79	7	(488)
Litigation (recoveries)/charges, net	1,129	5,741	36
Operating earnings/(loss)	472	(4,098)	2,060
Other (income)/expense, net	(47)	(1)	15
Interest expense, net	180	238	294
Loss on early extinguishment of debt	14	16	0
Gain (Loss) on Sale of Investments	(2)	579	0
Earnings/(loss) before income taxes	323	(3,772)	1,751
Provision for/(benefit from) income taxes	(289)	(79)	386
Net earnings	612	(3,693)	1,365
Less: Net earnings attributable to noncontrolling interests	(1)	(3)	(2)
Net earnings/(loss) attributable to Cardinal Health, Inc.	$ 611	$ (3,696)	$ 1,363
Earnings/(loss) per common share attributable to Cardinal Health, Inc.
Earnings Per Share, Basic	$ 2.09	$ (12.61)	$ 4.55
Earnings Per Share, Diluted	$ 2.08	$ (12.61)	$ 4.53
Weighted-average number of common shares outstanding:
Basic (in shares)	292	293	300
Diluted (in shares)	294	293	301

Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Current assets:
Cash and equivalents	$ 3,407	$ 2,771
Trade receivables, net	9,103	8,264
Inventories, net	14,594	13,198
Prepaid expenses and other	2,843	1,707
Disposal Group, Including Discontinued Operation, Assets	1,101	0
Total current assets	31,048	25,940
Property and equipment, net	2,360	2,366
Goodwill and other intangibles, net	10,094	11,275
Other assets	951	1,185
Total assets	44,453	40,766
Current liabilities:
Accounts payable	23,700	21,374
Current portion of long-term obligations and other short-term borrowings	871	10
Other accrued liabilities	2,957	2,231
Disposal Group, Including Discontinued Operation, Liabilities	96	0
Total current liabilities	27,624	23,615
Long-term obligations, less current portion	5,365	6,765
Deferred income taxes and other liabilities	9,670	8,594
Preferred shares, without par value:
Authorized—500 thousand shares, Issued—none	0	0
Common shares, without par value:
Authorized—755 million shares, Issued— 327 million shares at June 30, 2021 and 2020	2,806	2,789
Retained earnings	$ 1,205	$ 1,170
Common shares in treasury	36,000,000	34,000,000
Common shares in treasury, at cost: 36 million shares and 34 million shares at June 30, 2021 and 2020, respectively	$ (2,186)	$ (2,066)
Accumulated other comprehensive loss	(34)	(104)
Total Cardinal Health, Inc. shareholders' equity	1,791	1,789
Noncontrolling interests	3	3
Total shareholders’ equity	1,794	1,792
Total liabilities and shareholders’ equity	$ 44,453	$ 40,766
Preferred shares, authorized	500,000	500,000
Preferred shares, issued	0	0
Common shares, authorized	755,000,000	755,000,000
Common shares, issued	327,000,000	327,000,000

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Millions	Total	Common Shares	Retained Earnings	Treasury Shares	Accumulated Other Comprehensive Loss	Noncontrolling Interests
Net Income (Loss) Attributable to Parent	$ 1,363		$ 1,363
Balance at beginning of period (in shares) at Jun. 30, 2018		327,000
Balance at beginning of period at Jun. 30, 2018	6,059	$ 2,730	4,645		$ (92)	$ 0
Treasury, balance at beginning of period (in shares) at Jun. 30, 2018				(18,000)
Treasury, balance at beginning of period at Jun. 30, 2018				$ (1,224)
Increase (Decrease) in Shareholders' Equity
Net earnings	1,365					2
Net Earnings Including Portion Attributable to Noncontrolling Interest Excluding Redeemable Noncontrolling Interest	1,365
Other comprehensive loss, net of tax	13				13
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	67	$ 33		$ 34
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		0		1,000
Treasury shares acquired (in shares)				(11,500)
Share repurchase program activity	(600)			$ (600)
Dividends declared	(575)		(575)
Stockholders' Equity, Other Shares				0
Other	1	$ 0	1			0
Balance at end of period (in shares) at Jun. 30, 2019		327,000
Balance at end of period at Jun. 30, 2019	6,330	$ 2,763	5,434		(79)	2
Treasury, balance at end of period (in shares) at Jun. 30, 2019				(28,000)
Treasury, balance at end of period at Jun. 30, 2019				$ (1,790)
Net Income (Loss) Attributable to Parent	(3,696)
Increase (Decrease) in Shareholders' Equity
Net earnings	(3,693)					3
Other comprehensive loss, net of tax	(25)				(25)
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	100	$ 26		$ 74
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		0		0
Treasury shares acquired (in shares)				(7,000)
Share repurchase program activity	(350)			$ (350)
Dividends declared	(570)		(570)
Stockholders' Equity, Other Shares				0
Other	$ 0	$ 0	2			2
Balance at end of period (in shares) at Jun. 30, 2020	327,000	327,000
Balance at end of period at Jun. 30, 2020	$ 1,792	$ 2,789	1,170		(104)	3
Treasury, balance at end of period (in shares) at Jun. 30, 2020	(34,000)			(35,000)
Treasury, balance at end of period at Jun. 30, 2020	$ (2,066)			$ (2,066)
Net Income (Loss) Attributable to Parent	611
Increase (Decrease) in Shareholders' Equity
Net earnings	612					1
Other comprehensive loss, net of tax	70				70
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	97	$ 17		$ 80
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		0		3,000
Treasury shares acquired (in shares)				(3,700)
Share repurchase program activity	(200)			$ (200)
Dividends declared	(576)		(576)
Stockholders' Equity, Other Shares
Other	$ 1					1
Balance at end of period (in shares) at Jun. 30, 2021	327,000	327,000
Balance at end of period at Jun. 30, 2021	$ 1,794	$ 2,806	$ 1,205		$ (34)	$ 3
Treasury, balance at end of period (in shares) at Jun. 30, 2021	(36,000)			(36,000)
Treasury, balance at end of period at Jun. 30, 2021	$ (2,186)			$ (2,186)

Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Inventories) (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Accounting Policies [Abstract]
Portion of inventories held at LIFO, percentage	50.00%	56.00%
Inventories valued at LIFO amount higher than average cost value	$ 565	$ 411
Reserves for excess and obsolete inventory	185	$ 155
Inventory Write-down	$ 197

Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Goodwill and Other Intangible Assets) (Details) $ in Millions	12 Months Ended
	Jun. 30, 2021 USD ($) segment	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)
Goodwill and Intangible Assets [Line Items]
Number of Operating Segments \| segment	2
Goodwill, Impairment Loss \| $	$ 0	$ 0	$ 0
Minimum
Goodwill and Intangible Assets [Line Items]
Discount Rate, fair value inputs	8.50%
Maximum
Goodwill and Intangible Assets [Line Items]
Discount Rate, fair value inputs	11.50%

Divestitures and Acquisitions (Narrative) (Details) - USD ($) $ in Millions		1 Months Ended	12 Months Ended
	Aug. 02, 2021	Aug. 31, 2018	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Aug. 01, 2018
Business Acquisition
Payments to Acquire Businesses, Net of Cash Acquired			$ 3	$ 0	$ 82
Pre-Tax Gain on Divestiture					508
Income (Loss) from Equity Method Investments				2	10
Disposal Group, Including Discontinued Operation, Assets			1,101	0
Disposal Group, Including Discontinued Operation, Liabilities			96	0
naviHealth [Member]
Business Acquisition
Proceeds from Divestiture of Businesses		$ 737
Pre-Tax Gain on Divestiture					$ 508
Equity Method Investments						$ 358
Redeemable Noncontrolling Interest, Equity, Carrying Amount						$ 12
Provisional tax benefit related to transaction		$ 130
Gain on Sale of Investments				579
Cordis Divestiture
Business Acquisition
Disposal Group, Including Discontinued Operation, Consideration			927
Disposal Group, Including Discontinued Operation, Goodwill			(388)
Write-down of assets held for sale			(60)
Disposal Group, Including Discontinued Operation, Assets			1,091
Disposal Group, Including Discontinued Operation, Accrued Liabilities			61
Disposal Group, Including Discontinued Operation, Other Liabilities			34
Disposal Group, Including Discontinued Operation, Liabilities			95
Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses)			(3)
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation			9
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents			109
Disposal Group, Including Discontinued Operation, Inventory			164
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment			90
Disposal Group Including Discontinued Operations Goodwill and Other Intangibles, net			778
Disposal Group, Including Discontinued Operation, Other Assets			$ 10
Cordis Divestiture \| Subsequent Event
Business Acquisition
Proceeds from Divestiture of Businesses	$ 927
naviHealth [Member]
Business Acquisition
Gain on Sale of Investments				$ 579

Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 96	$ 72
Additions	75	109
Payments and other adjustments	(92)	(85)
Ending Balance	79	96
Employee- Related Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	68	64
Additions	49	85
Payments and other adjustments	(64)	(81)
Ending Balance	53	68
Facility Exit and Other Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	28	8
Additions	26	24
Payments and other adjustments	(28)	(4)
Ending Balance	$ 26	$ 28

Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Goodwill [Line Items]
Goodwill, Transfers	$ 2	$ (5)
Goodwill [Roll Forward]
Beginning balance	8,357	8,378
Foreign currency translation adjustments and other	(18)	16
Ending balance	7,989	8,357
Cordis Divestiture
Goodwill [Roll Forward]
Disposal Group, Including Discontinued Operation, Goodwill	(388)
Medical
Goodwill [Line Items]
Goodwill, Transfers	0	0
Goodwill [Roll Forward]
Beginning balance	5,700	5,715
Foreign currency translation adjustments and other	(18)	15
Ending balance	5,330	5,700
Accumulated goodwill impairment loss	1,400	1,400
Medical \| Cordis Divestiture
Goodwill [Roll Forward]
Disposal Group, Including Discontinued Operation, Goodwill	(388)
Pharmaceutical
Goodwill [Line Items]
Goodwill, Transfers	2	(5)
Goodwill [Roll Forward]
Beginning balance	2,657	2,663
Foreign currency translation adjustments and other	0	1
Ending balance	2,659	2,657
Accumulated goodwill impairment loss	829	$ 829
Pharmaceutical \| Cordis Divestiture
Goodwill [Roll Forward]
Disposal Group, Including Discontinued Operation, Goodwill	$ 0

Leases (Details) - USD ($) $ in Millions		12 Months Ended
Leases (Details) - USD ($) $ in Millions	Jul. 01, 2019	Jun. 30, 2019	Jun. 30, 2021	Jun. 30, 2020
Operating Leases, Rent Expense		$ 153
Reclassification of deferred rent in accordance with ASC 842	$ 22
Operating Lease, Weighted Average Remaining Lease Term			6 years 6 months	6 years 4 months 24 days
Operating Lease, Weighted Average Discount Rate, Percent			2.90%	2.90%
Finance Lease, Weighted Average Remaining Lease Term			4 years 2 months 12 days	4 years 3 months 18 days
Finance Lease, Weighted Average Discount Rate, Percent			1.50%	2.40%
Minimum
Lessee, Operating Lease, Term of Contract			1 year
Maximum
Lessee, Operating Lease, Term of Contract			21 years

Leases Schedule of Lease Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Leases [Abstract]
Operating Lease, Cost	$ 119	$ 134
Amortization of right-of-use assets	16	13
Variable lease cost	24	17
Total lease cost	$ 159	$ 164

Leases Supplemental Balance Sheet Information (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Leases [Abstract]
Total operating lease liabilities	$ 479	$ 445
Total finance lease liabilities	64	34
Finance Lease, Liability, Current	19	9
Finance Lease, Liability, Noncurrent	$ 45	$ 25
Operating Lease, Weighted Average Remaining Lease Term	6 years 6 months	6 years 4 months 24 days
Finance Lease, Weighted Average Remaining Lease Term	4 years 2 months 12 days	4 years 3 months 18 days
Operating Lease, Weighted Average Discount Rate, Percent	2.90%	2.90%
Finance Lease, Weighted Average Discount Rate, Percent	1.50%	2.40%
Total lease liabilities	$ 479	$ 445
Finance Lease, Liability, Current	19	9
Other Assets [Member]
Leases [Abstract]
Operating Lease, Right-of-Use Asset	460	426
Operating Lease, Right-of-Use Asset	460	426
Other Liabilities
Leases [Abstract]
Operating Lease, Liability, Noncurrent	374	341
Operating Lease, Liability, Noncurrent	374	341
Other Accrued Liabilities
Leases [Abstract]
Operating Lease, Liability, Current	105	104
Operating Lease, Liability, Current	105	104
Property, Plant and Equipment
Leases [Abstract]
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	63	33
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	$ 63	$ 33

Leases Schedule of Future Lease Payments (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
2023	$ 113
2024	86
2025	73
2026	53
Thereafter	146
Total future lease payments	607
Less: leases not yet commenced (1)	3
Less: imputed interest	61
Total lease liabilities	479	$ 445
Total lease liabilities	64	$ 34
Total Lease Liability	543
2022	136
Operating Leases
2023	93
2024	72
2025	65
2026	50
Thereafter	141
Total future lease payments	537
Less: leases not yet commenced (1)	3
Less: imputed interest	55
Total lease liabilities	479
2022	116
Finance Leases
2023	20
2024	14
2025	8
2026	3
Thereafter	5
Total future lease payments	70
Less: leases not yet commenced (1)	0
Less: imputed interest	6
Total lease liabilities	64
2022	$ 20

Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Debt Instrument [Line Items]
Accounts payable	$ 23,700	$ 21,374
Other obligations	67	35
Total	6,236	6,775
Less: current portion of long-term obligations and other short-term borrowings	871	10
Long-term obligations, less current portion	5,365	6,765
2.616% Notes due fiscal 2022
Debt Instrument [Line Items]
Notes Payable	572	834
3.2% Notes due 2022
Debt Instrument [Line Items]
Notes Payable	0	236
Floating Rate Notes due fiscal 2022
Debt Instrument [Line Items]
Notes Payable	281	321
3.2% Notes due 2023
Debt Instrument [Line Items]
Notes Payable	564	576
3.079% Notes due fiscal 2024
Debt Instrument [Line Items]
Notes Payable	794	809
3.5% Notes due fiscal 2025
Debt Instrument [Line Items]
Notes Payable	410	413
3.75% Notes due 2025
Debt Instrument [Line Items]
Notes Payable	524	529
3.41% Notes due fiscal 2027
Debt Instrument [Line Items]
Notes Payable	1,216	1,215
4.6% Notes due 2043
Debt Instrument [Line Items]
Notes Payable	341	340
4.5% Notes due 2044
Debt Instrument [Line Items]
Notes Payable	342	342
4.9% Notes due 2045
Debt Instrument [Line Items]
Notes Payable	441	441
4.368% Notes due fiscal 2047
Debt Instrument [Line Items]
Notes Payable	560	560
7.0% Debentures due 2026
Debt Instrument [Line Items]
Notes Payable	$ 124	$ 124

Long-Term Obligations and Other Short-Term Borrowings Other Financing Arrangements (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Debt Instrument [Line Items]
Other obligations	$ 67	$ 35
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	2,000
Letter of Credit
Debt Instrument [Line Items]
Line of credit	1
Other Short-term Borrowings	0	0
Letter of Credit \| Committed Receivables Sales Facility Program
Debt Instrument [Line Items]
Line of credit	31	29
Short Term Credit Facilities
Debt Instrument [Line Items]
Maximum borrowing capacity		6
Short Term Credit Facilities \| Committed Receivables Sales Facility Program
Debt Instrument [Line Items]
Maximum borrowing capacity	1,000
Commercial Paper
Debt Instrument [Line Items]
Maximum borrowing capacity	2,000
Other Short-term Borrowings	0	0
Committed Receivables Sales Facility Program
Debt Instrument [Line Items]
Other Short-term Borrowings	$ 0	$ 0

Commitments, Contingent Liabilities and Litigation (Details) $ in Millions		1 Months Ended	12 Months Ended
	Aug. 10, 2021 lawsuit plaintiff StateAG	Jul. 31, 2021 lawsuit	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)
Loss Contingencies [Line Items]
Income from Settlements of Class Action Lawsuits			$ 112	$ 16	$ 94
Cost of Goods and Services Sold			155,689	146,054	138,700
Distribution, selling, general and administrative expenses			4,533	4,572	4,480
Gain (Loss) Related to Litigation Settlement			(1,129)	(5,741)	$ (36)
Opioid Lawsuits \| Subsequent Event
Loss Contingencies [Line Items]
Loss Contingency, Lawsuits, Number	3,300
Number of State Attorneys General filing lawsuits \| StateAG	25
Opioid Lawsuits State [Domain] \| Subsequent Event
Loss Contingencies [Line Items]
Loss Contingency, Lawsuits, Number	2,900
Product Liability Lawsuits \| Subsequent Event
Loss Contingencies [Line Items]
Number of lawsuits filed \| lawsuit	32
Loss Contingency, Claims Settled, Number \| lawsuit		1,300
New York Opioid Stewardship Act
Loss Contingencies [Line Items]
Aggregate Annual Assessment			100
DOJ Investigation
Loss Contingencies [Line Items]
Gain (Loss) Related to Litigation Settlement			13
Alameda County [Member] \| Product Liability Lawsuits \| Subsequent Event
Loss Contingencies [Line Items]
Number of plaintiffs \| plaintiff	5,427
Other Jurisdictions [Member] \| Product Liability Lawsuits \| Subsequent Event
Loss Contingencies [Line Items]
Number of plaintiffs \| plaintiff	37
Product Liability Lawsuits \| Subsequent Event
Loss Contingencies [Line Items]
Number of lawsuits filed \| lawsuit	419
Minimum
Loss Contingencies [Line Items]
Loss Contingency Accrual			524
Maximum
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss			1,030
Total Opioid Litigation [Member]
Loss Contingencies [Line Items]
Estimated Litigation Liability			6,730
Loss Contingency, Estimate of Possible Loss			6,370
Gain (Loss) Related to Litigation Settlement			1,170	5,630
Litigation Settlement, Expense			1,170	$ 5,630
Total Opioid Litigation [Member] \| Other Accrued Liabilities
Loss Contingencies [Line Items]
Estimated Litigation Liability			$ 405
Private Parties [Member] \| Opioid Lawsuits \| Subsequent Event
Loss Contingencies [Line Items]
Loss Contingency, Lawsuits, Number \| lawsuit	442
Class Action Lawsuits [Member] \| Private Parties [Member] \| Opioid Lawsuits \| Subsequent Event
Loss Contingencies [Line Items]
Loss Contingency, Lawsuits, Number \| lawsuit	128

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Jun. 30, 2019	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Income Taxes
Effective Income Tax Rate Reconciliation, Percent		(89.70%)	2.10%	22.10%
Income Tax Expense (Benefit)		$ (289)	$ (79)	$ 386
Effective Tax Rate Impact From Certain Foreign Jurisdictions		$ 20
Provision at Federal statutory rate		21.00%	21.00%	21.00%
Federal		$ (539)	$ 822	$ 28
Deferred tax assets on tax credit carryforwards		(805)	(589)
Valuation allowance on operating loss carryforwards		477
Unrecognized tax benefits that would impact effective tax rate	$ 303	849	753	303
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions		223	78	39
Unrecognized tax benefits	456	932	998	456	$ 423
Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities		271	6	25
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations		1	3	0
Unrecognized tax benefits, interest and penalties accrued	122	49	146	122
Unrecognized tax benefits, interest and penalties	$ 16			$ 8
Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense		825
Deferred income taxes and other liabilities		9,670	8,594
Net Operating Loss Carryback
Income Taxes
Income Tax Expense (Benefit)		(424)
Income Taxes Receivable		974
Deferred income taxes and other liabilities		700
Minimum
Income Taxes
Estimated range of decrease in unrecognized tax benefits within the next 12 months		0
Maximum
Income Taxes
Estimated range of decrease in unrecognized tax benefits within the next 12 months		20
Federal
Income Taxes
Tax credit carryforwards		272
State and Local
Income Taxes
Tax credit carryforwards		3,900
Foreign
Income Taxes
Tax credit carryforwards		2,300
Patient Recovery Business [Member]
Income Taxes
Amount CareFusion is liable under tax matters agreement in the event amount must be paid to the taxing authority		12	19
CareFusion [Member]
Income Taxes
Amount CareFusion is liable under tax matters agreement in the event amount must be paid to the taxing authority		72	176
Total Opioid Litigation [Member]
Income Taxes
Estimated Litigation Liability		6,730
Income Tax Expense (Benefit)		228	488
Unrecognized tax benefits that would impact effective tax rate		219	469
Litigation Settlement, Expense		$ 1,170	$ 5,630

Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Deferred income tax assets:
Receivable basis difference	$ 40	$ 39
Accrued liabilities	874	607
Share-based compensation	38	38
Loss and tax credit carryforwards	805	589
Deferred tax assets related to uncertain tax positions	35	52
Other	16	87
Total deferred income tax assets	1,808	1,412
Deferred Tax Assets, Valuation Allowance	(515)	(470)
Deferred Tax Assets, Net	1,293	942
Deferred income tax liabilities:
Inventory basis differences	(1,119)	(1,083)
Property-related	(375)	(327)
Other	(733)	(751)
Deferred Tax Liabilities, Deferred Expense, Reserves and Accruals	(975)	0
Deferred Tax Liabilities, Other	(23)	0
Total deferred income tax liabilities	(3,225)	(2,161)
Net deferred income tax liability	$ (1,932)	$ (1,219)

Income Taxes (Schedule of Deferred Tax Assets and Liabilities After Netting by Tax Jurisdiction) (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Deferred Income Taxes and Other Assets, Noncurrent	$ 52	$ 39
Deferred Income Taxes and Other Tax Liabilities, Noncurrent	1,981	1,258
Deferred Income Taxes and Other Tax Liabilities, Transferred to Held for Sale, Noncurrent	(3)	0
Net deferred income tax liability	$ (1,932)	$ (1,219)

Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Liabilities:
Disposal Group, Including Discontinued Operation, Assets	$ 1,101	$ 0
Disposal Group, Including Discontinued Operation, Liabilities	96	0
Fair Value, Measurements, Recurring
Assets:
Cash equivalents	1,883	721
Other investments	126	114
Liabilities:
Forward contracts	42	53
Fair Value, Measurements, Recurring \| Level 1
Assets:
Cash equivalents	1,883	721
Other investments	126	114
Liabilities:
Forward contracts	0	0
Fair Value, Measurements, Recurring \| Level 2
Assets:
Cash equivalents	0	0
Other investments	0	0
Liabilities:
Forward contracts	42	53
Fair Value, Measurements, Recurring \| Level 3
Assets:
Cash equivalents	0	0
Other investments	0	0
Liabilities:
Forward contracts	0	$ 0
Fair Value, Nonrecurring
Liabilities:
Disposal Group, Including Discontinued Operation, Assets	$ 1,100

Fair Value Measurements (Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis Using Unobservable Inputs (Level 3)) (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Forward contracts	$ 42	$ 53
Level 1
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Forward contracts	0	0
Level 2
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Forward contracts	42	53
Level 3
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Forward contracts	$ 0	$ 0

Fair Value Measurements (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Disposal Group, Including Discontinued Operation, Liabilities	$ 96	$ 0

Financial Instruments (Schedule of the Fair Value of Assets and Liabilities Related to Derivatives Designated as Hedging Instruments) (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Derivatives, Fair Value [Line Items]
Total assets	$ 46	$ 74
Total liabilities	4	21
Designated as Hedging Instrument \| Cash Flow Hedging \| Foreign Currency Contracts \| Prepaid Expenses and Other
Derivatives, Fair Value [Line Items]
Total assets	5	0
Designated as Hedging Instrument \| Cash Flow Hedging \| Foreign Currency Contracts \| Other Accrued Liabilities
Derivatives, Fair Value [Line Items]
Total liabilities	4	4
Designated as Hedging Instrument \| Cash Flow Hedging \| Interest Rate Swaps \| Deferred Income Taxes and Other Liabilities
Derivatives, Fair Value [Line Items]
Total liabilities	0	16
Designated as Hedging Instrument \| Cash Flow Hedging \| Commodity Contracts \| Other Accrued Liabilities
Derivatives, Fair Value [Line Items]
Total liabilities	0	1
Designated as Hedging Instrument \| Fair Value Hedging \| Interest Rate Swaps \| Other Assets [Member]
Derivatives, Fair Value [Line Items]
Total assets	1	27
Designated as Hedging Instrument \| Fair Value Hedging \| Cross Currency Interest Rate Contract [Member] \| Other Assets [Member]
Derivatives, Fair Value [Line Items]
Total assets	6	47
Designated as Hedging Instrument \| Fair Value Hedging \| Cross Currency Interest Rate Contract [Member] \| Prepaid Expenses and Other
Derivatives, Fair Value [Line Items]
Total assets	$ 34	$ 0

Financial Instruments (Narrative) (Details) € in Millions, ¥ in Millions, $ in Millions	12 Months Ended
	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2020 JPY (¥)	Sep. 30, 2019 USD ($)	Sep. 30, 2019 EUR (€)	Jun. 30, 2019 USD ($)
Derivative [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	$ 0	$ 0
Interest Rate Swaps
Derivative [Line Items]
Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge	18
Currency Swap [Member]
Derivative [Line Items]
Derivative Liability, Notional Amount		600	¥ 64,000	$ 233	€ 200
Foreign Currency Contracts
Derivative [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax	7	35
Interest Income (Expense), Nonoperating, Net	19	17
Cash Flow Hedging
Derivative [Line Items]
Derivative Liability, Notional Amount		200
Derivates, Hedge Discontinuances, Hedging Instrument Terminated, Amount	200
Fair Value Hedging \| Interest Rate Swaps
Derivative [Line Items]
Derivative, notional amount	200	550
Cash Flow Hedging \| Foreign Currency Contracts
Derivative [Line Items]
Derivative, notional amount	436	328
Designated as Hedging Instrument \| Fair Value Hedging \| Interest Rate Swaps
Derivative [Line Items]
Derivative Liability, Notional Amount	200
Derivatives, matured notional amounts		200
Derivates, Hedge Discontinuances, Hedging Instrument Terminated, Amount	$ 550
Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge		$ 112
Derivatives, terminated notional amounts						$ 163

Financial Instruments (Schedule of Outstanding Instruments, Fair Value Hedges) (Details) - Interest Rate Swaps - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Derivative [Line Items]
Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge	$ 18
Fair Value Hedging
Derivative [Line Items]
Notional Amount	$ 200	$ 550
Designated as Hedging Instrument \| Fair Value Hedging
Derivative [Line Items]
Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge		112
Derivatives, matured notional amounts		$ 200

Financial Instruments (Schedule of Outstanding Instruments, Economic Hedges) (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Foreign Currency Contracts \| Not Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	$ 254	$ 325

Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Amount of Long-Term and other Short-Term Borrowings	$ 6,236	$ 6,775
Carrying amount	6,236	6,775
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value	$ 6,751	$ 7,273

Shareholders' Equity (Narrative) (Details) $ / shares in Units, $ in Millions	12 Months Ended			36 Months Ended
	Jun. 30, 2021 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2019 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) shares
Class of Stock [Line Items]
Treasury shares acquired \| $	$ 200	$ 350	$ 600
Payments for Repurchase of Common Stock \| $	200	350	600
Retained earnings decrease \| $	$ (1,205)	$ (1,170)		$ (1,170)
Common shares, authorized \| shares	755,000,000	755,000,000		755,000,000
Common Class A
Class of Stock [Line Items]
Common shares, authorized \| shares	750,000,000
Common Stock, Voting Rights, Votes	1
Common Class B
Class of Stock [Line Items]
Common shares, authorized \| shares	5,000,000
Treasury Shares
Class of Stock [Line Items]
Treasury shares acquired \| $	$ 200	$ 350	$ 600	$ 1,150
Treasury Stock, Shares, Acquired \| shares	3,700,000	7,000,000	11,500,000
Payments for Repurchase of Common Stock \| $	$ 200
Treasury shares acquired, average price per share (in usd per share) \| $ / shares	$ 54.40	$ 48.00	$ 52.32
Treasury Stock Acquired Shares \| shares		7,300,000

Segment Information (Narrative) (Details) $ in Millions	12 Months Ended
Segment Information (Narrative) (Details) $ in Millions	Jun. 30, 2021 USD ($) segment	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)
Segment Reporting Information [Line Items]
Pre-Tax Gain on Divestiture			$ 508
Gain (Loss) Related to Litigation Settlement	$ (1,129)	$ (5,741)	(36)
Project costs on investment and other spending	$ 27	69	$ 55
Number of Reportable Segments \| segment	2
Sterile Surgical Gown Recall [Member] [Domain]
Segment Reporting Information [Line Items]
Inventory Recall Expense		85
New York Opioid Stewardship Act
Segment Reporting Information [Line Items]
Estimated Liability for New York Opioid Stewardship Act	$ 41
naviHealth [Member]
Segment Reporting Information [Line Items]
Gain on Sale of Investments		579
Gain on Divestiture After Tax		493
Total Opioid Litigation [Member]
Segment Reporting Information [Line Items]
Gain (Loss) Related to Litigation Settlement	$ 1,170	$ 5,630

Segment Information Property and Equipment, net by Geographic Area) (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Long-Lived Assets [Line Items]
Property and equipment, net	$ 2,360	$ 2,366	$ 2,356
United States
Long-Lived Assets [Line Items]
Property and equipment, net	1,958	1,880	1,846
International
Long-Lived Assets [Line Items]
Property and equipment, net	$ 402	$ 486	$ 510